

UNITED STATES DISTRICT COURT  
NORTHERN DISTRICT OF NEW YORK

---

MICHELE BAKER; CHARLES CARR; ANGELA CORBETT; PAMELA FORREST; MICHAEL HICKEY, individually and as parent and natural guardian of O.H., infant; KATHLEEN MAIN-LINGENER; KRISTIN MILLER, as parent and natural guardian of K.M., infant; JENNIFER PLOUFFE; SILVIA POTTER, individually and as parent and natural guardian of C.P, infant; and DANIEL SCHUTTIG, individually and on behalf of all others similarly situated,

Plaintiffs,

CIV. No. 1:16-CV-917 (LEK/DJS)

v.

SAINT-GOBAIN PERFORMANCE PLASTICS CORP., HONEYWELL INTERNATIONAL INC. f/k/a ALLIED-SIGNAL INC. and/or ALLIEDSIGNAL LAMINATE SYSTEMS, INC., E.I. DUPONT DE NEMOURS AND COMPANY and 3M CO.,

Defendants.

---

**DECLARATION OF ALAN DUCATMAN, M.D.**

I, Alan Ducatman, declare and state as follows:

1. I prepared the Expert Report attached as Exhibit A to this Declaration.
2. Each of the opinions in the Expert Report is stated to a reasonable degree of medical and scientific certainty and was arrived at using reliable and generally accepted scientific methods.
3. If called as a witness, I will testify competently to the matters stated in this Expert Report.
4. I declare under penalty of perjury under the laws of the United States of America that the foregoing is true and correct.

A handwritten signature in blue ink, appearing to read "Alan Ducatman". The signature is fluid and cursive, with a long horizontal stroke at the end.

Dated: March 27, 2020

Alan Ducatman, M.D.

# EXHIBIT A

UNITED STATES DISTRICT COURT  
NORTHERN DISTRICT OF NEW YORK

---

IN RE HOOSICK FALLS PFOA CASES

**Case No. 1:19-mc-00018-LEK-DJS**

---

**EXPERT REPORT OF  
ALAN DUCATMAN, MD**

## **BACKGROUND AND QUALIFICATIONS**

I am board certified in Internal Medicine and Occupational Medicine, and have been licensed to practice medicine since 1982. I am a Professor Emeritus of Public Health at West Virginia University School of Public Health and was also a Professor of Medicine at West Virginia University School of Medicine. In the past, I was the Chair of the Department of Community Medicine in the West Virginia University School of Medicine for many years. I also have been a member of the American Board of Preventive Medicine, which determines credentials and qualifications for board certification, and Chair of the Residency Review Committee in Preventive Medicine, which accredits clinical residency training programs. I have participated on and chaired an external scientific advisory committee to the Agency for Toxic Substances and Disease Registry (ATSDR) and the National Center for Environmental Health (NEHC) of the US Centers for Disease Control and Prevention (CDC) and have a Director's Award for outstanding service to this federal agency. Before becoming a tenured professor at West Virginia University, I was Director of the Environmental Medical Service at Massachusetts Institute of Technology (1986-1992). Before that I was an active duty Lieutenant Commander in the U.S. Navy Medical Corps, responsible for national and international consultation concerning environmental exposures of active duty service personnel and employed civilians (1983-1986). A copy of my C.V. is attached as **Exhibit A**.

I have published numerous original papers, reviews, and book chapters and written extensively about the relationship of environmental chemicals to human disease, including, but not limited to, perfluoroalkyl substances (PFAS) such as perfluorooctanoic acid (PFOA). I also perform research and publish peer review articles concerning quality assurance in health care, notably in the setting of ordering and interpreting clinical testing, and increasing the value of clinical testing. I am the recipient of honors and recognitions in my field. I have been asked to

provide formal and informal health science advice to leaders of federal organizations such as the U.S. Centers for Disease Control and Prevention and the Environmental Protection Agency, state agencies with health and safety interests including the West Virginia Bureau for Public Health, nonprofit foundations, and industry. I have also been invited to provide summaries of the health effects of PFAS exposure in academic settings and for professional societies, for example at the 2019 PFAS meeting of the Society for Environmental Toxicology and Chemistry.

I have significant experience in evaluation and medical monitoring of humans exposed to PFOA. I am familiar with the C8 Health Project, which enrolled a large population and evaluated the health effects of PFOA and other PFAS among residents of PFOA-contaminated water districts in the mid-Ohio Valley. I advised the leaders of that Project and have published more than 25 peer-reviewed articles relating to the PFAS, including papers based upon analysis of the C8 Health Project data, and papers based on the national NHANES data set. This includes a summary article (published with members of the C8 Science Panel and with the leaders of the C8 Health Project design and the leaders of the enrollment effort), which describes the C8 Project's design, methods, and participants. (1) I led a team that analyzed data from the Project, and was responsible for a website that provided open access to summary data from the Project during its initial phase. I collaborate with scientists at many institutions regarding current PFAS knowledge. My work addresses the effects of PFOA and other PFAS on liver function and its biomarkers, thyroid function, kidney function, and on serum lipid levels (including total and LDL-cholesterol), among other subjects.

In my career, I have participated directly in the following medical monitoring projects in addition to the C8 Health Project mentioned above:

- the U.S. Navy Asbestos Medical Surveillance Program, which involved many thousands of Department of Defense employees, during my active duty as a Lieutenant Commander in the U.S. Navy Medical Corps from 1983-1986.
- Medical surveillance programs, including surveillance for lead poisoning, at the Massachusetts Institute of Technology, where I was Director of the Environmental Medical Service from 1986-1992.
- Multiple medical surveillance programs for workers at West Virginia University, from 1992-2018.
- And, I have advised the creation and direction of the state of West Virginia Lead Poisoning Prevention Program, and have been a consultant for decisions concerning the treatment of patients detected to have elevated blood lead concentrations.

My perspective is that of a clinician, with a career spanning more than three decades caring for patients and populations who have had exposures that can harm their health. I provide this report in support of plaintiffs' motion for class certification and specifically in support of class treatment for a medical monitoring program for individuals who meet the PFOA Invasion Injury Class definition. My rate for the expert work I perform in this case is \$450 per hour with an increase to \$600 per hour for deposition testimony and testimony in court. In the last four years, I have provided testimony in *Sullivan, et al. v. Saint-Gobain Performance Plastics, Co.*, Case No. 5:16-cv-00125.

#### **FACTS AND DATA CONSIDERED; MATERIALS REVIEWED**

To prepare this report, I reviewed certain data produced in this case pursuant to a subpoena by the New York State Department of Environmental Conservation (**Exhibit B**) and New York State Department of Health (**Exhibit C**), including PFOA blood testing results and data related to PFOA, testing of public and private wells and soils in and around the Village of Hoosick Falls and maps depicting these results produced by the agencies. I also reviewed the First Amended Master Consolidated Class Action Complaint in this action and the affidavits of the representative plaintiffs detailing their PFOA blood test results and the results of the PFOA

tests of their drinking water together with information about their water consumption. I reviewed the reports of Dr. David Savitz and Dr. Hyeong Moo Shin submitted in support of Plaintiffs' motion for class certification. I am familiar with the medical and scientific literature listed in **Exhibit D**, as well as the relevant papers listed in my CV, and am generally familiar with other medical and scientific literature concerning PFAS and their health effects, and concerning medical monitoring. The opinions that follow are based on my review of the specific case information listed above, my review of this literature and the report of Dr. Savitz, as well as on my decades of experience with medical monitoring programs, including the C8 Health Project, and are expressed to a reasonable degree of medical certainty.

#### **CRITERIA FOR ASSESSING THE NEED FOR COMMUNITY MEDICAL MONITORING**

The Agency for Toxic Substances and Disease Registry (ATSDR) is a lead agency in the Centers for Disease Control and Prevention tasked with conducting health surveillance assessments to evaluate exposure to hazardous agents in the environment and identify trends in adverse health outcomes resulting from chemical exposures. The ATSDR provides the following criteria for considering the establishment of medical monitoring programs in its Final Criteria for Determining the Appropriateness of a Medical Monitoring Program under the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA), published in the Federal Register, that have specific application to this case (quoted in part). (*See Exhibit E*)

#### **ATSDR Background for Considering Medical Monitoring**

- “Medical monitoring should be directed toward a target community identified as being at “significant increased risk for disease” on the basis of its exposure. Significant increased risk will vary for particular sites depending upon such factors as the underlying risk of the selected outcome, the risk attributable to the exposure, and the presence of sensitive subpopulations. These factors will be



considered when evaluating the appropriateness of medical monitoring in a community.”

#### **ATSDR Exposure Criteria for Considering Medical Monitoring**

- “There should be evidence of contaminant levels in environmental media that would suggest the high likelihood of environmental exposure to a hazardous substance and subsequent adverse health outcomes. “
- “An exposure will be considered to be a sufficient level if there is documentation of an increased opportunity for exposure to a level that meets or exceeds *some* health-based comparison value such as Minimum Risk Levels (MRLs) or Reference Doses (RfDs) *or* that meets a level reported in the peer-reviewed literature to result in some adverse health effect. Documentation is considered sufficient if it is from an exposure assessment, environmental exposure modeling or sampling from the general area . . . . *Documentation of individual levels of exposure is not required.*” (emphasis added)

#### **ATSDR Outcome Criteria for Considering Medical Monitoring**

- “There should be documented human health research that demonstrates a scientific basis for a *reasonable association* between an exposure to a hazardous substance and a specific adverse health effect (such as an illness or *change in a biological marker or effect*).” (emphasis added)
- “The monitoring should be directed at detecting adverse health effects that are consistent with the existing body of knowledge and amenable to prevention or intervention measures.”
- “In addition, the adverse health effects (disease process, illness, or biomarkers of effect) should be such that early detection and treatment or intervention interrupts the progress to symptomatic disease, improves the quality of life of the individual, or is amenable to primary prevention.”

#### **ATSDR System Criteria for Considering Medical Monitoring**

- “The monitoring aspect of a health surveillance program consists of the periodic medical testing to screen individuals who are at increased risk of disease. Monitoring serves to identify those individuals with an unrecognized adverse health effect. This is consistent with the definition of screening as the presumptive identification of unrecognized disease or defect by the application of tests, examinations or other procedures which can be applied rapidly. Screening tests sort out apparently well persons who probably have a disease

from those who probably do not. A screening test is not intended to be diagnostic. Persons with positive or suspicious findings must be referred to their physicians for diagnosis and necessary treatment.”

(See **Exhibit E**)

### **PFOA IS A HAZARDOUS SUBSTANCE THAT IS ASSOCIATED WITH ADVERSE HEALTH EFFECTS**

PFOA is a man-made toxic substance, also known as a "toxicant." There is “documented human health research that demonstrates a scientific basis for a reasonable association between an exposure to [PFOA] and a specific adverse health effect (such as an illness or change in a biological marker of effect).” (See ATSDR Criteria, **Exhibit E**, p. 38841). Based on numerous peer-reviewed publications (See **Exhibit D**) reporting results from exposed communities in the United States and around the world (including, but not limited to the well-known C8 study of exposed communities in West Virginia and Ohio), and from governmental publications and assessments, we know to a reasonable degree of medical certainty that human exposure to PFOA leads to alterations in the biomarkers for and function of the liver, the thyroid, the immune system, and other organs. (1, 3, 13-19, 21-26, 28-35, 39-43, 45, 47-52, 54-55, 57-58, 63, 68, 89, 91-95, 114, 123, 125, 127)<sup>1</sup> PFOA exposure is associated with excess risks of adverse health effects, as compared to the background population, and we now have clinical population outcome data on these and a variety of health effects. (Id., 27, 36, 38, 44, 59-64, 69-75, 78-88, 90, 97-100, 113, 124, 127-134). The epidemiological literature on the health effects of PFOA exposure is also summarized in the report of Dr. Savitz that has been submitted in support of this motion. The number of known epidemiologic associations, experimentally verified toxicities in

---

<sup>1</sup> Parenthetical references are to articles listed in **Exhibit D**. These specific references are merely examples of voluminous published articles supporting an association between PFOA exposure and adverse health effects, many additional articles are listed in Exhibit D.

vitro and in vivo, and accepted human health problems has increased over time as the scientific study of PFOA has advanced. The science is developing and the body of peer-reviewed literature finding new associations and providing further support of known associations continues to grow.

**THE VILLAGE OF HOOSICK FALLS AND THE SURROUNDING AREA IS A TARGET COMMUNITY AT SIGNIFICANT INCREASED RISK FOR DISEASE BASED UPON EXPOSURES TO PFOA AT LEVELS THAT EXCEED HEALTH BASED COMPARISON LEVELS**

PFOA is a manmade chemical that does not occur naturally in the environment and was identified by the United States Environmental Protection Agency (EPA) in 2009 as an emerging contaminant of concern. In 2013 the State of New Jersey established a preliminary health based guidance level of 40 ppt in drinking water. **See Exhibit F.** In May of 2016 EPA established drinking water health advisories of 70 ppt for the combined concentrations of PFOS and PFOA. (107) In March of 2017 the State of Vermont established a health advisory level for PFOA in water as 20 ppt. <http://www.healthvermont.gov/health-environment/drinking-water/perfluorooctanoic-acid-pfoa>. In October of 2017 the New Jersey Drinking Water Quality Institute developed a Health-based Maximum Contaminant Level (MCL) of 14 ng/L (ppt). **See Exhibit F.** This progressive lowering of the health-based MCL and health advisory contaminant levels for PFOA in drinking water by the federal government and the states has been driven by additional published research on PFOA and other PFAS health effects. New Jersey authors also note, correctly, as the EPA also recognized in its guidance, that PFOA exposure does not happen in a PFAS vacuum, and have made recommendations for total PFAS summed exposures, such as PFOA and PFOS. Nevertheless, experts affiliated with important research institutions have recommended in peer review settings that the New Jersey level is still too lenient, and have proposed that the PFOA health advisory level in drinking water should be reduced to 1 ppt. (108)

The State of New Jersey received publicly available communications from these scientists and from Environmental Groups pointing out that the 14 ppt standard could be lowered based on scientific evidence.<sup>2</sup> The New Jersey guidance is consistent with what could be accurately measured by commercial laboratories at that time, and the protective goal was achievable in contaminated systems with available technologies at that time. The conclusions found in numerous studies emphasize the need to consider fetal exposures (27, 36-37, 39, 53, 56-57, 62, 68-84, 86-87, 97-98, 100, 105, 115) and infant's exposure through breast milk (11, 65, 112, 116-117), when developing health-based toxicity values for exposure to PFOA and that current values may underestimate the potential risks for fetuses and nursing infants. (119, 122) This is an important consideration, it is based on excellent science, and targets a threshold effect that is deeply important to society.

An important factor in the human health hazard created by PFOA is that once ingested the chemical binds to proteins in blood serum and bioaccumulates in the body. While PFOA is typically detected in drinking water in units of ng/L (parts per trillion), it is typically measured in blood serum of those exposed to such PFOA-contaminated drinking water in ug/L (or ng/mL, parts per billion). As the New Jersey report states, the predicted ratio of PFOA drinking water: PFOA serum levels is ~ 114:1, meaning that an average level in the body is about 114 times higher than the level in the long-term ingested drinking water. (**Exhibit F**). An online serum PFOA calculator for adults consuming water at steady state, after starting or stopping consumption of PFOA-contaminated water, has recently been made publicly available by scientists from UC Irvine. (109).

When drinking water is contaminated with PFOA, we know from the contamination in the mid-Ohio Valley, as well as from other contaminated sites around the world, that the

contamination is long-lasting and that the drinking water is a primary source of exposure to PFOA for those who consume it. (Direct and indirect food contamination is most often the primary source when water is not contaminated.) The primacy of water contamination in populations exposed to PFOA-contaminated water has been shown by the work of Emmett, Holzer, Steenland, and others. (1, 2, 12, 104, 109, 110, 119) The population "half-life" of PFOA as measured in human serum has an arithmetic mean of about 3.8 years. (8, 9) We do not know the half-life of PFOA in other human organs, but we do know that PFOA is concentrated in the liver, lungs, bone, and in other organs (9-11). This means that those who drank PFOA-contaminated water in and around the Village of Hoosick Falls in the last 1-12 years likely have not excreted all of the PFOA that has bio-accumulated in their serum, with potentially longer time horizons for other organs in their bodies.

**REDACTED PURSUANT TO PROTECTIVE ORDER (ECF NOS. 131 & 132)**

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED].<sup>2</sup> New York's proposed MCL is among the most recent "health based comparison value" to be based on and thorough review of the most recent literature and established for PFOA health effects. (*See* ATSDR Criteria, **Exhibit E**, p.38841; **Exhibit F**).

---

<sup>2</sup> On March 13, 2019, the New Jersey Department of Environmental Protection established an interim specific ground water quality standard for PFOA of 10 ppt that became effective upon posting to the "Table of Interim Specific Ground Water Quality Criteria (ISGWQC), Interim PQLs (IPQLs), and Interim Specific Ground Water Quality Standards (ISGWQS) for Constituents in Class II-A Ground Water" on the NJDEP website at <https://www.nj.gov/dep/wms/bears/gwqs.htm>. See <https://www.nj.gov/dep/srp/emerging-contaminants/>.

The geometric mean background blood serum level in the United States adult population for 2013-14 was 1.86 µg/L.<sup>3</sup> (114). REDACTED PURSUANT TO PROTECTIVE ORDER (ECF NOS. 131 & 132)

[REDACTED]

It appears that the Department of Health continues to offer blood testing. See <https://www.health.ny.gov/environmental/investigations/hoosick/> (last visited March 17, 2020). Accordingly, it is possible that some current and former residents of the Village of Hoosick Falls and the surrounding area who ingested significant quantities of PFOA in the contaminated drinking water at home and who have not yet had their blood tested will be shown to have serum concentrations well above US adult population geometric mean serum concentrations if tested. Many of the exposed individuals, including three representative plaintiffs, are children. Children are considered a sensitive subpopulation because they have smaller body mass, greater liquid

---

<sup>3</sup> The geometric mean background level for 2015-2016 based on the US NHANES dataset is 1.56 µg/L. [https://www.cdc.gov/exposurereport/pdf/FourthReport\\_Updated\\_Tables\\_Volume1\\_Jan2019-508.pdf](https://www.cdc.gov/exposurereport/pdf/FourthReport_Updated_Tables_Volume1_Jan2019-508.pdf) (last visited April 10, 2019). This data was published in January 2019 and reflects the geometric mean background level at the time the Hoosick Falls PFOA blood testing was conducted. Therefore, the threshold level for eligibility here (1.86 µg/L) is a conservative number.

ingestion per unit of body weight, and potentially greater adverse impact at equal concentration of PFOA in their bodies. Further, young children will start their lives with a body burden from their mother because PFOA is delivered to the developing human trans placentally. (77, 115) And, breast-feeding is highly recommended for maternal and child health, yet it too delivers PFOA directly to the infant. (112, 116, 117).

Among the representative plaintiffs for the medical monitoring class, the blood serum PFOA concentration measured for Plaintiff Michael Hickey was 24.6 µg/L, for Plaintiff O.H. was 27.7 µg/L, for plaintiff Kathleen Main-Lingener was 95.4 µg/L, for another Plaintiff K.M. was 108 µg/L, for Plaintiff Silvia Potter was 120 µg/L, and for Plaintiff C.P. was 28.6 µg/L. These plaintiffs received their drinking water from the Village of Hoosick Falls three Municipal wells tested at ranges between 150 ppt to 662 ppt. *See*

<https://www.villageofhoosickfalls.com/Water/testing.html> (last visited March 17, 2020).

Plaintiff Charles Carr's serum tested at 186 µg/L and this private well tested at 390 ppt. Plaintiff Angela Corbett's serum tested at 22.2 µg/L and this private well tested at more than 500 ppt.

The U.S. Environmental Protection Agency (EPA) in late November of 2015 recommended residents, including the representative plaintiffs, stop drinking or cooking with their water and repeated this recommendation in mid-December 2015. *See*

<https://www.villageofhoosickfalls.com/Media/PDF/EPA-PFOA-letter-112515.pdf> (last visited March 17, 2020) and

<https://www.villageofhoosickfalls.com/Media/PDF/EPAStatementHoosickFallsWaterContamination.pdf> (last visited March 17, 2020). In mid-December, Saint-Gobain began providing bottled water to Village residents. In addition, the State began upon request testing private wells in area

in January 2016, and in late January 2016 the EPA advised individuals with private wells to use bottled water if there was more than 100 ppt of PFOA detected in their well. *See*

<https://www.villageofhoosickfalls.com/Water/Documents/DOH-PrivateWells-Redacted-011916.PDF> (last visited March 17, 2020) and

[https://www.villageofhoosickfalls.com/Water/Documents/EPASStatementPrivateWellsTownHoosick\\_012816.pdf](https://www.villageofhoosickfalls.com/Water/Documents/EPASStatementPrivateWellsTownHoosick_012816.pdf) (last visited March 17, 2020).

The PFAS that contaminate water, such as PFOA, can be encountered in straight (“n”) or a mixed variety of branched isomeric forms (“m”). The precise biological half-life in humans also depends on the isomers encountered. (120) Recent data for drinking water contamination (from Ronneby, Sweden) indicates that average decline in PFOA following the specific case of cessation of contaminated drinking water exposure is about 27% annually, with a mean half-life of 2.7 years. (121) Many factors influence the isomeric content of drinking water contamination, so it is uncertain that the experience in Hoosick Falls will be similar; this is simply the best available evidence to use for “scoping” predictions. Using the child plaintiff K.M. as an example (PFOA level from blood serum drawn in March of 2016 of 108 µg/L), assuming a 2.7 years as the future half-life of PFOA in the blood serum and no further exposure, K.M. who was 7 years of age when his blood was drawn, will still have a PFOA level of approximately around 27 µg/L when he turns 13 in 2022. K.M. will generally be predicted to continue to have a PFOA level in his blood serum of substantially more than 10 times the 2013-14 geometric mean for the United States population generally when he turns 13 years of age about two years from now. Similarly, plaintiff Main-Lingener (PFOA level from blood serum drawn in February of 2016 of 95.4 µg/L) is generally predicted to continue to have a PFOA serum level above the 2013-14 geometric mean serum concentration for the United States population for more than a decade



from now, with ongoing contamination of internal organs. Again, these data are presented to illustrate the scope of the problem, actual experience will be unique for both the population and the individuals within it. This acknowledged individual uniqueness is also why continued testing into the future is an important component of any medical monitoring plan that is implemented.

In Hoosick Falls there is not only “evidence of contaminant levels in environmental media that would suggest the high likelihood of environmental exposure to a hazardous substance” (See ATSDR Criteria, **Exhibit E**, p. 38841), but established exposure to PFOA via contaminated drinking water in both the public water system and more than 300 private wells above NY’s proposed MCL. In addition, the PFOA in the blood serum of the exposed population above geometric mean US background levels were measured months after they stopped consuming the water. **REDACTED PURSUANT TO PROTECTIVE ORDER (ECF NOS. 131 & 132)**

**REDACTED PURSUANT TO PROTECTIVE ORDER (ECF NOS. 131 & 132)**

**REDACTED PURSUANT TO PROTECTIVE ORDER (ECF NOS. 131 & 132)**

**REDACTED PURSUANT TO PROTECTIVE ORDER (ECF NOS. 131 & 132)** This finding and other less dramatic exceedances in biological burdens show that these above-threshold exposures have been consequential in the exposure population. Thus, in Hoosick Falls, we know exposures to PFOA above health-based comparison levels *have occurred* and that the exposed population has PFOA in their blood at levels in excess of background, which will remain for years due to the long half-life of this chemical in serum, and its propensity to concentrate in vital organs such as bone, liver, kidneys, and testicles.

Based upon the above analysis, it is my opinion that the target community in Hoosick Falls has been exposed to PFOA above health based comparison values set by state and federal

agencies and meets the criteria described by ATSDR for consideration of a medical monitoring program.

**MONITORING FOR EVIDENCE OF CONTINUED  
EXPOSURE IS WARRANTED IN HOOSICK FALLS**

As the ATSDR criteria states “[a]t sites with exposure in the community, the medical monitoring program might include biological markers of continuing exposure.” (See **Exhibit E**, p. 38842). It is my opinion to a reasonable degree of medical certainty that ongoing testing for PFOA blood levels in the likely exposed population should continue into the future because (1) PFOA can be readily detected in blood serum; (2) PFOA is extremely persistent in the environment; (3) PFOA has a protracted half-life in the blood serum (and other organs) that varies from individual to individual; and (4) the presumed primary mechanism of transport of PFOA to the community was through air emissions that traveled significant distances before depositing in the soil (See Shin report, submitted herewith), and from air and soil into water .

**MEDICAL TESTS AND SCREENING PROCEDURES ARE AVAILABLE TO DETECT  
ADVERSE HEALTH EFFECTS FROM PFOA**

As the ATSDR criteria discuss, “[t]he monitoring aspect of a health surveillance program consists of the periodic medical testing to screen individuals who are at increased risk of disease”. (See **Exhibit C**, p. 38842). Adverse instances of exposures and of health effects have been documented in multiple settings of PFOA-exposure community survey data, as well as from public health registries such as NHANES in the United States and from studies internationally. The report of David Savitz, Ph.D. submitted herewith, provides a summary of these health effects, although additional studies are being published weekly, and it is expected that additional adverse health effects may be identified. These increased risks of adverse health effects pertain to a wide variety of individuals, and, to a reasonable degree of medical certainty, require the

additional medical attention attained through medical monitoring for the relevant health condition and/or clinical biomarker measure. A medical monitoring program for the individuals in Hoosick Falls who have been exposed to PFOA through contaminated water should include monitoring for each of these health effects to the degree that useful testing exists.

A medical monitoring program for the population in Hoosick Falls exposed above background levels and at increased risk for developing one of the many conditions associated with PFOA ingestion should begin with a medical survey to be completed by each at-risk individual. Such a survey could be based on the C8 Health Survey but updated to include new scientific information, such as (but not limited to) diagnoses of gout and steatohepatitis (nonalcoholic fatty liver disease), as well as the birth weight and developmental weights/heights of children.<sup>4</sup> (13-32, 40, 41, 43) It should include a review of systems that addresses the frequency of infectious diseases and respiratory diseases, especially in children. (33-39, 132-133)

The medical monitoring program for Hoosick Falls should also include periodic and serial clinical laboratory testing of biomarkers pertinent to PFOA exposure. As shown below, these tests are related primarily to PFOA serum concentrations, as well as early detection of specific cancers to the degree feasible, liver function, uric acid status, and disease such as ulcerative colitis, kidney function, endocrine function, lipid status, and participant concerns about pregnancy and transfer of toxins to infants and young children in utero or by breast feeding. (11,28-32,39,42,57,63-85,91-94,116-117) These tests are above and beyond those that are part of standard, recommended preventive health screening. For example, they target specific outcomes such as altered lipid metabolism in children that are not covered by standard screening. And, because the anticipated internal exposures are anticipated to diminish over time, there is the

---

<sup>4</sup> This list of new information is meant to be illustrative, not exhaustive.

potential to consider cessation of lipid lowering agents, a very important and unique topic area that is seldom addressed by routine visits. The information can be tied to unique opportunities for targeted consideration of the underlying metabolic defects specifically worsened by PFOA exposure, as clinicians can use the data in risk calculators and help participants to make lifestyle adjustments that can diminish, mitigate, and postpone disease processes. These empowering data do not dispel the inherent risk of PFOA exposure per se, they prepare the at risk population to deal with and diminish the risk. By way of another example, urinalysis, which is no longer part of routine annual examinations<sup>5</sup>, screens for renal disease and renal cancer in this population. It also provides important data that allows more comprehensive interpretation of the meaning of the serum PFOA concentration. Individuals with kidney disease and notably kidney disease with albuminuria are shown to have lower serum PFAS concentrations than the rest of the population.

Compilation of the tests to be performed and other elements of this medical monitoring program should benefit from collaborative review and comment work, with input from peer expert reviewers from different disciplines, as well as feedback from regional clinicians. Such interdisciplinary peer collaboration leads to better clinical biomonitoring programs and the advancement of science. (4-7) The development of specific additional monitoring tests and evaluations, aside from blood testing, as well as the methodology to implement these tests, will be set forth in a future report. The testing protocol that is ultimately recommended should be applied to all individuals who are at increased risk of developing future disease as a result of their exposure to PFOA. The monitoring program for this exposed population would include, for example, regular blood tests to monitor for thyroid, liver function abnormality, non-alcoholic fatty liver disease, hyperlipidemia, uric acid abnormalities, gout, and PFOA blood level; serum

---

<sup>5</sup> <https://www.health.harvard.edu/diseases-and-conditions/urine-testing-no-longer-routine>

lipid screening; and urinalysis, with screens for renal disease and renal cancer. In addition, an appropriate monitoring program will also implement survey monitoring protocols consisting of diagnostic questions tailored to the human health conditions caused by exposure to PFOA.

Residents in and around Hoosick Falls, New York, who have been exposed to PFOA, primarily through consumption of contaminated drinking water, and have above-background levels of PFOA in their blood, have resulting increased risks of the developing the illnesses and adverse health conditions described at length in Dr. Savitz's report. To a reasonable degree of medical certainty, a medical monitoring program is clinically necessary for this population to detect known PFOA-related adverse health effects as early as possible in order to minimize disease and improve health outcomes. (5) The earlier these health conditions and precursors of adverse health conditions are detected, the more effectively they can be treated. Early diagnosis and treatment of virtually all cancers is beneficial, and this is certainly true of kidney cancer and testicular cancer that are associated with PFOA exposures. (59-61, 128) Similarly, thyroid disease can be treated effectively with medications and the sooner someone afflicted by this condition is treated the sooner the symptoms caused by this condition will diminish. Early detection of thyroid conditions is considered to be especially important in pregnancy. (111) High cholesterol and high uric acid levels can also be treated with medication once detected and risk can be lowered before conditions associated with these biomarkers can develop (e.g. higher uric acid is a risk factor for gout and cardiovascular disease; higher cholesterol levels mean that additional people will be recommended for lifestyle interventions and/or pharmacological treatment of elevated lipid levels to prevent coronary artery disease).

As is detailed in the report of Dr. Savitz, for all of the conditions associated with PFOA exposure, risk increases with exposure, although for some conditions, there appears to be a

plateau effect once PFOA blood levels reach a certain point. The presence of a dose plateau effect is not good news for the exposed population or for public health in general, since the implication is that the effects detected begin to operate at low serum concentrations. The epidemiological data does not provide a particular PFOA blood level in humans at which there is no increased risk of PFOA associated diseases other than zero. Because of this, it is my opinion that the proposed class definition for the medical monitoring program should include all of the exposed individuals in the Class Area whose blood serum was detected to contain PFOA at levels above the US (2013-4) geometric mean background level of 1.86 ug/L when the Hoosick Falls blood tests were done (circa 2016), months after these exposed residents stopped ingesting the contaminated water.

**A MEDICAL MONITORING PROGRAM IS MOST PRACTICALLY AND EFFICIENTLY ADMINISTERED TO A COMMUNITY AND NOT ON AN INDIVIDUAL BASIS**

I have been informed by the attorneys for the plaintiffs in this case that the Court on this motion must determine whether medical monitoring of an exposed population is best approached on a group or individual-by-individual basis. Based upon my background and experience, it is my opinion to a reasonable degree of medical certainty that establishing a program to provide appropriate medical surveillance for an entire exposed community is far superior in multiple ways compared to attempting to provide such surveillance on an individual basis. (3-7,110) The available criteria for medical monitoring programs (See **Exhibit E**) deal exclusively with programs administered on a community-wide basis. The reasons for this include simple feasibility to perform the needed tasks, lower cost due to economies of scale and centralized administration, increased capability to communicate with affected individuals and their treating clinicians, consistency of applying appropriate testing protocols and continuity into the future.

Moreover, requiring each adversely affected individual to bring a separate lawsuit seeking medical monitoring damages would delay the implementation of such a program for some or most of these individuals for many years defeating the important purpose of beginning monitoring as soon as practicable so that illnesses can be detected and treated as early as possible.

Adequate medical monitoring proposed for this exposed population would have two temporal components. Medical screening (initial testing) focuses on protecting the health of an exposed population, generally emphasizes early detection and response to clinical outcomes of exposure. This would include screening for the health effects and risks listed in Dr. Savitz's accompanying report. Medical surveillance collects prospective data on the exposed population (providing a means to follow the exposed individuals over time). Ongoing monitoring adds the potential to detect the presence of additional and cumulative hazards (risks to be deterred) in individuals and populations. The goal is untoward health outcomes detected earlier, and negative consequences prevented or mitigated over time. Throughout the process, central data collection with ongoing assessment of what is being learned has the potential to inform about the ongoing exposure status and to add an element of protection. For industrial chemicals, the Department of Labor, Occupational Safety and Health Administration provides support to industry and explains the role of medical monitoring for employers of workers, recognizing that industrial chemicals in the workplace can be hazardous and that one aspect of a mitigation strategy is medical monitoring. <https://www.osha.gov/SLTC/medicalsurance/> (last accessed March 17, 2020). These concepts translate to non-occupational settings when populations are exposed to industrial chemicals.

A typical medical surveillance program collects survey questionnaire demographic information describing the participants, survey questionnaire health information directed at the population diseases, symptoms, and needs, as well as laboratory and/or radiographic/imaging information pertinent to detection of outcomes of known exposure risks. Depending on the nature of exposure, the targeted health information collected from the participants can also inform the data collected in follow up efforts and can seamlessly be turned into de-identified community summary data that portrays the community experience and protects individual privacy. Medical surveillance may also collect simple physical examination information such as height, weight, and blood pressure. Such programs feature a centralized data base so that meaningful reporting of summary data and key findings can occur. This step, providing community feedback concerning summary key findings, is important for fairness, participation/engagement, and quality assurance purposes. An example is reporting of sequential serum PFOA concentrations. Such feedback reporting is obviously impossible at the individual level, and the testing is more expensive per capita.

A medical surveillance program relies upon uniform data storage to collect information in a reliable way on behalf of participants as individuals and as members of the affected community. Other important benefits of uniform data storage include the ability to provide personal materials back to properly-identified participants who have lost their original data. (In the C8 Health Project, participants were provided their personal data, and there is a means for participants to identify themselves and obtain their data again). It is also very helpful to the members of the affected community to have an accessible health communications strategy that provides information about processes, procedures, and summary findings. This summary information is also generally available to anyone with internet access and interest in the



monitoring. The featured information is accessible to anyone, and the featured information deliberately has no means to identify individuals. The point about identification is important. In the C8 Health Study, focus group interviews of potential participants repeatedly mentioned loss of privacy as their largest fear. Any process which threatens loss of privacy is problematic. In that regard, the federal government provides guidance about the public reporting findings of rare diseases in small populations, with helpful guidance for protecting privacy.

The truism that individuals are unique is an argument for an appropriate community-wide medical monitoring program for the exposed population, rather than against, or a determinant of who should be included. In general, the uniqueness of individuals is understood in the medical and public health communities to illustrate the need to monitor more of the exposed population inclusively. That people have varying medical histories, including medical co-morbidities, is well understood by experts and by the general public. These unique individual characteristics include but are not limited to our individually inherited genetics, personal health habits, and varying historical environmental experiences. Our individual uniqueness means that we are aware of excess risks to the exposed population, but generally are unable to predict in advance who in the population with demonstrable excess risk will get which disease known or suspected to be associated with exposure, or when. In addition, we cannot predict the severity of the health effects for any particular individual. There are no known medical comorbidities that mitigate the risks from PFOA exposure (i.e. no trait or pre-existing condition has been identified that reliably protects an individual against the adverse health effects of PFOA). Rather, we must work to identify behaviors, characteristics, and comorbidities that may further increase these risks, and we work to identify the attendant disease processes as early as possible. Consider the half-life established for PFOA, by Olsen and colleagues from 3M. (8) This useful data represents a

population mean, and it is understood by readers that individuals will not all have this precise half-life, for a wide variety of reasons related to inherited genetics, environment, habits, absorption, excretion, and body habitus, among many variables that are different among all of us. The data are valuable estimates of mean tendencies despite the differences among those who were tested. (Id.) In health care, health professionals in many organizations collect data and become increasingly expert at predicting average tendencies, including factors that bring increased risk (e.g. the relationship between high cholesterol and heart disease), yet we remain persistently mediocre or worse at predicting who among the high risk community specifically will be the one(s) to suffer the outcome(s), and when the outcomes will occur. This necessitates monitoring all of an exposed population, and is why children are monitored for lead exposure in communities where that exposure is merely possible for all, but the extent of exposure is not determined in advance for any. In the Class Area, based on blood testing data from NYSDOH more than 2,000 individuals have tested above PFOA background, clearly demonstrating that the class requires attention. Individual medical records and histories are irrelevant to whether a medical monitoring program, as described above, is clinically necessary for exposed class members in a demonstrably contaminated geography. A need for pre-review of individual medical records is not mentioned in the ATSDR document addressing the rationale and implementation of medical monitoring for environmental risks. While individualized factors, such as age, sex, height, weight, prior medical conditions, and a host of other differences /between/among all people, can and do inform data collection, this information can be collected most efficiently and effectively through an appropriate survey, as part of a medical monitoring program administered to an entire group of exposed individuals.

For example, we screen a small subset of adults for lead poisoning -- workers with potential lead exposure -- because we generally can target those as being most at risk. We screen many thousands of young children, including those who live in contiguous and potentially contaminated areas with different risks of lead poisoning, because the exposure is even more serious in children, and the specific behaviors and environmental and social circumstances that lead to childhood exposure are highly individualized. It is hard to predict the presence of safety in the absence of checking for the hazard. Further, we know that some conditions, such as inadequate diet, may increase the risk of childhood lead poisoning, but this does not dissuade us from monitoring, or limit those whom we monitor. In the case of Hoosick Falls, the existence of shared risk of exposure is certain. In all populations, the presence of some individuals with increased susceptibility due to age, co-morbidities or other factors, is also certain.

Similarly, the preventive health community does not limit monitoring based on more than one possible source of exposure of the offending toxin. We know that workers in a benzene monitoring program may have exposure from two (or more) sources, such as work and personal cigarette smoking, but that supports the need to include all workers, smoking and nonsmoking in the monitoring program, and to pair demographic data and environmental monitoring data collected in a worker survey, and to compare these to the laboratory results. We also know that some of the risks of asbestos exposure are potentiated by cigarette smoking (such as lung cancer and parenchymal asbestosis), whereas other diseases (such as malignant mesothelioma) are related to asbestos exposure and not potentiated by smoking. Smoking status is determined in surveys, but the status does not determine eligibility for monitoring in asbestos-affected workplaces and communities. It is also why demographic and independent risk data are collected

in the survey as part of the program which collects health and exposure data from the participants rather than trying to extract it from medical records.

In clinical care, if a risk is known to exist, we monitor and evaluate that risk to the degree possible and useful. In Hoosick Falls, multiple adverse health risks are present in the exposed population as a direct result of their exposure to PFOA, primarily in drinking water, and for this reason these risks and the population that has endured them should be monitored, irrespective of individual differences. The class is homogenous only in their a priori risk of exposure to PFOA, and therefore in their legitimate concern about health outcomes including increased risks of adverse health outcomes. These outcomes include ICD-codeable diseases, and markers for increased risks of diseases such as abnormal biomarkers of various body system functions. These risks determine the medical necessity of an appropriate medical monitoring program, as discussed by the ATSDR, just as exposure to asbestos or to lead determines the necessity of participation in an asbestos or lead medical monitoring program. Individualized predictions of outcomes are not possible, nor are they beneficial to the exposed population, and pretenses that we need to know outcomes before we search for evidence of disease turns the health care paradigm on its head. We can make assessments of increased risk in populations and in population subgroups, but we do not know enough to make such individualized assessments in order to determine outcomes before we find them. We know that every exposed person faces increased risks of related adverse health effects. The goal is early detection and mitigation of harm.

The literature establishes that drinking water that has been contaminated with PFOA is the primary source of exposure for those who consume it. Consistent with this literature, the data for the named representative plaintiffs supports that elevated PFOA in the drinking water leads to

elevated PFOA levels in the blood. (2, 12, 104, 119, 135) The consideration of an industrially contaminated residential population is also not unique to PFOA. (6,7) Possible subsidiary sources of PFOA - to the extent they exist - do not impact the clinical necessity of medical monitoring based on this primary exposure. Subsidiary sources are expected and documented in predecessor efforts for populations who have consumed contaminated water and do not negate the findings about primary sources in numerous studies including the population investigated in the C8 Health Study and other populations. (2, 10, 12, 104, 105-110, 119, 135) When drinking water is not contaminated, however, community exposures are from other sources, and, biological burdens are lower. (106, 119)

In my career, I have participated directly in multiple medical monitoring projects (see pages 3-4 above). In all of these projects and programs, admission to the program was based solely on exposure to the relevant toxic substance or hazard (PFOA, asbestos, lead, noise, etc.) and the risks resulting from that exposure, and was available to entire exposed and at-risk population. None of these projects and programs was based on individualized determinations of who among the exposed and at-risk population considered to be exposed should be excluded or participate. The programs were based on the opportunity for exposure that would place individuals at increased risk of developing illness. In this case, however, participation in the program would involve more than an opportunity for exposure because blood testing results are available and confirmatory. This testing has detected a population at risk and it can continue to demonstrate the ongoing quantity of PFOA in the blood of each participant. Existing PFOA serum testing provides a very high degree of capability to assess the degree to which the exposed population and its individuals did once and continue to carry a biological burden of exposure.

From a medical perspective, another consideration favoring administering the medical monitoring program on a class-wide basis is the protection of the participants' privacy and confidential medical information. In the C8 Health Project, focus groups of the exposed population, and speakers in town meetings, repeatedly expressed the concern that their confidential information would be available to the company that was responsible for their exposure, and many would not have participated in the monitoring program absent strong protocols protecting their privacy and confidential medical information.

For all of these reasons, any suggestion that individual variability within the exposed population is an argument against using the class action vehicle to resolve claims for medical monitoring damages and to create a unified medical monitoring program for the exposed population in Hoosick Falls is contrary to the published medical literature, prior PFOA medical monitoring experience, accepted medical monitoring standards including federally published standards, and common sense. Individual histories or records are not relevant to determining the clinical appropriateness of medical monitoring, or who among the exposed population should be included in the program. Doctors routinely reject the idea that individual uniqueness is an argument against the usefulness of evaluation in a clinical setting.

Finally, that some of the testing that would be contemplated in a medical monitoring program for this population might be duplicative of testing some of these individuals would routinely receive during physicals with their primary care physician is also not a valid argument against a community-wide program. Consider serum lipid testing. Even if serum lipid levels (including total and LDL-cholesterol) are evaluated for some of the exposed population, the intervals at which they are checked is variable and would not replace a regimented program of testing designed specifically for the risks associated with PFOA exposure. Moreover, serum

lipid levels (including total and LDL-cholesterol) are infrequently or never checked in healthy children, adolescents and young adults. Individuals in the C8 Health study reported acting on such data by bringing the survey-determined information to their treating clinician. There may also be class members who have no insurance or who are underinsured. Thus, while some of the exposed population may receive some of the testing that would be included in a medical monitoring program for PFOA, this would not duplicate or replace the benefit of a specifically designed medical monitoring program to test for early adverse health effects associated with PFOA exposure.

In summary, it is my opinion to a reasonable degree of medical certainty, that establishing a medical monitoring program for the benefit of the entire class of individuals sufficiently exposed to PFOA to elevate their risk of developing diseases and conditions associated with PFOA exposure is supported by the published medical literature, standards published by ATSDR as well as the experience of the C8 Health Project and such an approach is far superior to attempting to provide medical monitoring on an individual basis.



---

Alan Ducatman, M.D.

# EXHIBIT A



December 12, 2018

**CURRICULUM VITAE**  
**ALAN M. DUCATMAN, MD, MSc**  
Professor Emeritus, WVU School of Public Health  
Adjunct Professor, WVU School of Medicine

**PERSONAL DATA**

Citizenship: United States  
Family: Married, three children

**ADDRESS**

Alan Ducatman LLC  
910 Westchester Way  
Birmingham, Mi 48009  
Contact: 249 940-2950  
[Alan.ducatman@gmail.com](mailto:Alan.ducatman@gmail.com)

**Academic Affiliation**

Professor Emeritus  
WVU School of Public Health  
Once Medical Center Drive  
PO Box 9190  
Morgantown, WV 26506-9190  
[aducatman@hsc.wvu.edu](mailto:aducatman@hsc.wvu.edu)

Personal Statement: My current consultation work engages both environmental health and quality assurance. I have been a successful leader of occupational and environmental health enterprises in research, education, and clinical as well as consultation service. Previous settings for my work have included military service, compliance oversight in highly technical workplaces, and academic healthcare. I have been a successful consultant to government, industry, and labor entities. My work goal is simply to provide public health value to decision-making, whether the work is about clinical service, teaching, or research.

**EDUCATION**

1978	MD	Medicine, Wayne State University, Detroit, MI
1974	MSc	Environmental Health. City University of New York—Hunter College, and Mt. Sinai School of Medicine, New York, NY
1972	AB	Analytical Biology. Columbia College, New York, NY

**POSTGRADUATE TRAINING**

1982	Fellowship in Occupational Medicine, Mayo Clinic, Rochester, MN
1981	Medical Residency. Mayo Clinic, Rochester, MN
1979	Medical Internship. Brown University, Providence, RI

**ACADEMIC APPOINTMENTS**

June 2018-	Professor Emeritus, West Virginia University
2012-2018	Professor of Public Health, and Professor of Medicine, West Virginia University

- 1992- 2012 Professor of Medicine, West Virginia University School of Medicine
- 2012-2015 Professor, Department of Emergency Medicine, West Virginia University School of Medicine
- 2011-12 Professor and Interim Founding Dean, Professor of Public Health, West Virginia University School of Public Health
- 2002-present Adjunct Professor, Department of Animal and Nutritional Sciences, Davis College of Agriculture, Natural Resources, and Design, West Virginia University
- 1994-97 Adjunct Professor of Medicine. Medical University of South Carolina
- 1991-2004 Clinical Associate Professor of Preventive Medicine. University of Mississippi School of Medicine, Jackson, MS
- 1990-93 Adjunct Associate Professor of Public Health (Environmental Health). Boston University School of Medicine, Boston, MA
- 1990-93 Clinical Associate in Neurology, Massachusetts General Hospital, Boston, MA
- 1987-89 Lecturer on Medicine. Harvard Medical School, Boston, MA
- 1983-86 Assistant Professor of Community Medicine, Eastern Virginia Medical School, Norfolk, VA

### **PROFESSIONAL EXPERIENCE**

- June 2018- Professor Emeritus, WVU School of Public Health
- 2012- 2018 Tenured faculty in the School of Public Health, co-appointment in the School of Medicine, Department of Medicine. Responsible for clinical care, graduate teaching (including for-credit as a member of the graduate faculty), funded research, and external consultation to industry, labor, government, and non-profit organizations. More recent duties also include for-credit teaching of true undergraduates.
- 2011-2012 **Interim Founding Dean**, West Virginia University School of Public Health. The School of Public Health enrolls over 170 master's and PhD graduate students in the MPH, the PhD in Public Health Sciences, and the MS in School Health Education.
- 1997-2011 Appointment as **Chair**, Department of Community Medicine, West Virginia University School of Medicine
- The Department of Community Medicine has grown and evolved to become the WVU School of Public Health. This is the first fully new school at WVU in more than five decades. Faculty participate in and direct programs in a Prevention Research Center, an Injury Control Research Center, an Institute for Occupational and Environmental Health, a Health Services Research Center, and a Center on Aging, as well as the Mary Babb Randolph Cancer Center and other organ-based research centers. Faculty focus much of their research in population health, health services, community intervention, and community health in rural settings.
- 1996-97 **Interim Chair**, Department of Community Medicine, West Virginia University School of Medicine.
- 1992-97 **Director**, Institute of Occupational and Environmental Health (IOEH), West Virginia University School of Medicine
- The IOEH sponsors NIOSH-supported occupational medicine residency training program and participates in multidisciplinary research and teaching activities. Service and research are provided for clinical care and outcomes, environmental health, toxic exposure

assessment, health services research, ergonomics, and epidemiology. IOEH faculty provide clinical care, graduate and continuing medical education, grant-funded research with an emphasis on clinical outcomes, and workplace epidemiology consulting to government agencies, industry, and labor. A primary goal of the Institute is decreasing the frequency and severity of work-related injury in West Virginia.

- 1992 Faculty member, WVU Institute of Occupational and Environmental Health
- 1986-92 **Director**, Environmental Medical Service, Massachusetts Institute of Technology, Cambridge, MA
- Responsible for Occupational/Environmental Health at Massachusetts Institute of Technology and affiliated institutions with over 20,000 employees, as well as students and official visitors. Supervised 50 professionals and support staff, with a budget in excess of \$3 million. Provided service to MIT in biohazards, industrial hygiene, radiation protection, nuclear reactor safety, occupational health, and toxicology. In addition, provided selective research and consultation to governments, industry, and workers.
- 1983-86 **Director**, Professional Occupational Health Branch, United States Navy Environmental Health Center, Norfolk, VA (LCDR, Medical Corps).
- Responsible for worldwide consulting concerning occupational health problems of the Navy's 1.1 million employees. Reported to the Navy Inspector General concerning the status of occupational health care at Navy clinics. Provided quality assurance assessment for asbestos medical surveillance
- 1982-83 **Director**, Occupational Medical Services, Columbia Park and Brooklyn Park Medical Groups, Columbia Park and Brooklyn Park, MN. Founded a successful and rapidly expanding private occupational health practice within a multispecialty group.

### **PATIENT SERVICE**

**Outpatient Care** Devise and conduct medical surveillance programs for industry, labor, and government in West Virginia and surroundings. Conduct clinical referral evaluations of patients with known or suspected environmental exposure. .

**Environmental Health Consulting:** Evaluate and ameliorate environmental risks on behalf of government, industry, workers, and citizen groups.

### **CERTIFICATION AND LICENSURE**

**Certification:** American Board of Preventive Medicine (Occupational Medicine)  
January 24, 1983 - Certificate Number 21816

American Board of Internal Medicine  
September 16, 1981 - Certificate Number 79779

**Licensure:** West Virginia - July 13, 1992 - Perm. 16937

**Military Service:** LCDR, Medical Corps, USNR, 1983-86  
CDR (inactive) USNR, 1986-91

### **UNDERGRADUATE AND MEDICAL STUDENT TEACHING**

#### **Annual**

2016-17 PUBH 243 Global Occupational and Environmental Health (Required true undergraduate course in new public health program. Enrollment 2016, 29 students; 2017, 72 students)

2001-2005 MDS 124: Community Health and Disease (1 hour).

2000-2005 Pathology 751: Environmental Diseases (1 hour).

2000- CCMD 712 and CCMD 713: Public Health Topics in Disease Status and Disease Prevention.

1997-2001 Orientation 60 (undergraduate), 1 hour

1996-2001 **West Virginia School of Osteopathic Medicine.** MSI Lectures in Occupational and Environmental Health – 6- 8 hours per year

**Intermittent**

1996 Physical diagnosis for medical students

1994 **Medical University of South Carolina.** Summer M2 Lectures, Environmental Health

1994-95 **Uniformed Service University of Health Sciences (Bethesda, MD),** Occupational and Respiratory Disease (2 contact hours)

1993 Medical Aspects of Environmental Health, **West Virginia University,** 2.0 credits

1991-92 **Harvard University.** Principles of Occupational Health - 4.0 credits, undergraduate faculty

1987-1991 **University of Mississippi.** Occupational Hazards of Rural Areas, Toxic Hazards in the Workplace, Environmental Dust Diseases. University of Mississippi School, of Medicine, Jackson, MS (Visiting Associate Professor, undergraduate medical education)

1990 **University of Mississippi.** Undergraduate Medical School Course (1 day) Occupational Medicine: An Environmental and Workplace Imperative (Mississippi Physicians and Nurses also attended)

1987 **American Industrial Hygiene Association.** Toxicology. American Industrial Hygiene Association. ABIH Certification Exam Review Class. Faculty

1973-74 **Hunter/CUNY.** Physiology Laboratory. Hunter/CUNY- 2.0 lab credits instructor

**Graduate Teaching**

1997-2015 **West Virginia University** Master of Public Health Program, Ph. D program. OEHS 601 (previously PUBH 601, 610, and 650): Environmental Health (Core Curriculum) - 3 credits. Principle Instructor and/or co-principal instructor. Course is now provided online, and in the classroom. Currently, Dr. Ducatman is the primary instructor for the online section (20-50 enrollees).

1999- 2012 CMED 691A/PUBH 605: Introduction to International Public Health. Environmental influences on International Health (1 hour).

1997-2003 CMED 791C: Advanced Topics in Toxicology - 1 credit  
Special Projects and Independent Study – Variable Credit

1997-present Plan of Study Committee – IOEH Residents

1995 Critical Ethical and Legal Issues in Health Care, 3.0 credits

1987-92 **Harvard School of Public Health.** Organic Solvents. Fundamentals of Industrial Hygiene. (Twice annually; graduate visiting lecturer)

**Doctoral Committees**

2012-13 Member, PhD in Public Health Sciences Committee for Omayma Alshaarawy.  
 2011-12 Member, PhD in Public Health Sciences Committee for Sarah Geiger  
 2009-10 Member, PhD in Public Health Sciences Committee for Joseph Putila  
 2009-2011 Member, PhD in Public Health Sciences Committee for Loretta Cain

**Clinical Teaching**

2002-2017 Lectures to residents on selected topics  
 1993-2002 Residency Director, Occupational and Environmental Medicine, West Virginia University.  
 1992- Medical student and resident rotations in Occupational Environmental Medicine, West Virginia University. Classroom teaching in environmental health; Clinic teaching in introduction to clinical medicine.  
 1987 Resident Training Advisor, **Boston University School of Public Health.** Residency rotations  
 1989 Resident Training Advisor, **University of Kentucky**, Department of Preventive Medicine and Environmental Health. Resident 3 weeks at MIT. 40 hours/week.

**MEMBERSHIPS ON SUPERVISING COMMITTEES AND BOARDS OF TRUSTEES**

**West Virginia and Region**

2016-2018 Advisory Committee to West Virginia DHHS, Bureau for Public Health. WV Childhood Lead Poisoning Prevention Council  
 2013-2018 West Virginia Health Innovation Collaborative, member (for WV DHHR Cabinet Secretary)  
 2012 West Virginia Public Health Assessment Committee  
 2011-2014 Governor’s Advisory Council on Substance Abuse  
 2010 External advisory member for health communications, Marietta (OH)/Mid-Ohio Valley (WV) US EPA Workgroup  
 2009-present West Virginia Bureau for Public Health Cancer Cluster Work Group  
 2006 Monongalia County All-Hazards Advisory Committee  
 2006 ATSDR State Environmental Waste Site Planning Committee  
 2005 West Virginia Leadership Council on Public Health Threat Preparedness  
 2003 West Virginia Heart Disease Program Advisory Council, WV Bureau for Public Health  
 2003 ATSDR Cooperative Programs Partner, WV DHHR  
 2003 Ad Hoc Potassium Iodide Policy Review Committee, WV Bureau for Public Health  
 2003 Monongalia County Health Department Threat Preparedness Advisory Committee  
 1999 Technical Assistance and Training Subcommittee, WV Bureau for Public Health  
 1999-2003 Lead Poisoning Prevention Committee, WV Bureau for Public Health  
 1999 Healthy People 2010 Cancer Work Group  
 1999 Healthy People 2010 Occupational Safety and Health Work Group  
 1998 Executive Council, WV Public Health Association  
 1998 Steering Committee, Tri-State (Southeast) Public Health Leadership Institute  
 1997-98 WV Bureau for Public Health Medical Waste Advisory Committee  
 1997-2000 Chair, WV Public Health Association Committee for Continuing Education

1997 Steering Committee, WV Bureau for Public Health Transitions Project  
 1995-1998 Lead Abatement Advisory Committee, WV Bureau for Public Health and  
 WV Department of Environmental Health  
 1993-2009 WV Poison Control Center Advisory Board  
 1993-94 Grant Proposal Reviewer, WV University Injury Control Training and Demonstration Center.

**National**

2018 Science Advisory Board, PFAS “REACH” grant. Official title: Assessment of pediatric immunotoxicity, public education, and capacity-building in communities impacted by PFAS-contaminated drinking water. Project period 09/07/2018 – 06/30/2023 Grant number: 1R01ES028311-01A1 PI: Laurel Schaidler. Silent Spring Institute. CoPI Phil Brown, Northeastern University  
 2018 APC Program Steering Committee Annual Meeting Abstracts. Coronado, CA. July 15-19, 2018  
 2016 Ad hoc reviewer for Centers for Disease Control, Agency for Toxic Substances and Disease Agency for the work entitled “Health Consultation, Dimock Site.” Published May 24, 2016  
 2014-2015 Member, Health Effects Institute – Special Committee on Unconventional Oil and Gas Development  
 2008-present Accreditation Council for Graduate Medical Education (ACGME) – Board of Appeals Panel member).  
 2007-2008 Member, Program Peer Review Subcommittee, Board of Scientific Counselors, National Center for Environmental Health/Agency for Toxic Substances and Disease Registry.  
 2005-2008 Board of Scientific Counselors, National Center for Environmental Health/Agency for Toxic Substances and Disease Registry. Appointed Committee Chair, August 2007; term ended October 2008.  
 2004-2009 Wayne State University, External Peer Review for Internal Research Grants Committee  
 2002-2004 Strategic Medical Intelligence Section, Department of Justice and University of Pittsburgh  
 2002-2003 American Board of Preventive Medicine. Core Examination Committee.  
 2002-2007 University of Kentucky Prevention Research Center, Markey Cancer Center; Community Advising Committee through 2003, Scientific Advisory Committee from 2003.  
 1999-2004 Residency Review Committee; Accreditation Council on Graduate Medical Education-Preventive Medicine, Appointed Vice Chair, 2002; Appointed Chair, 2004.  
 1998-2004 Board of Regents, American College of Preventive Medicine  
 1993-2002 American Board of Preventive Medicine, Trustee  
 Chair: Client and External Relations Committee, 1992-99  
 Chair: Combined Preventive Medicine/Internal Medicine Residency Training Committee  
 1993-95 International Union of Operating Engineers. National HAZMAT Program Board of Scientific Advisors  
 1988-92 Residency Advisory Committee, Boston University Medical Center Occupational Health Program  
 1988-95 American Board of Preventive Medicine/National Board of Medical Examiners. Occupational Medicine Examination Committee.  
 1985-2003 American College of Occupational and Environmental Medicine. Practice Committee.

**International**

2015-2016 International Agency for Research on Cancer (IARC). IARC Monographs Working Group for Volume 115 – “Some Industrial Chemicals.”

**University**

2016-2018 Elected Representative, School of Public Health Faculty Council  
 2016-2018 Search Committee, Departmental Chair, Occupational and Environmental Health Sciences  
 2016-2018 Curriculum Committee, School of Public Health  
 2015-16 Promotion and Tenure Committee Member, School of Public Health  
 2013 Search Committee Member, School of Dentistry



2012	WVU Energy Council
2011	Member, Internal Advisory Committee, Research Training in Behavioral and Biomedical Sciences T32 Grant
2011-	Member, Search Committee, Family Medicine Chair
2010-	Member of the MD/PhD Admissions Committee
2010-	Member of the MD/PhD Advisory Committee
2010-2011	Clinical Council of Chairs
2010	Member of the Discovery and Innovation Input Group, WVU Strategic Planning Council
2009	Member of Search Committee for WVU Provost
2007-2009	Steering Committee Member, WVU National Children's Center Project
2006-2008	Steering Committee Member, Center for Immunopathology and Microbial Pathogenesis
2005-2008	Steering Committee Member, Center for Respiratory Biology and Lung Disease
2005-present	Steering Committee Member, Injury Control Research Center
2004	Chair, United Way Campaign, School of Medicine
2003-2009	Scientific Advisory Board, School of Medicine
2003-2005	West Virginia Prepares: Virtual Medical Campus Continuing Education Partnership Advisory Board
2003	Search Committee Chair, Center for Rural Emergency Medicine Director
2002-2010	Executive Council (formerly known as Council of Chairs)
2001-2007	Mary Babb Randolph Cancer Center (MBRCC) Prevention, Education, and Outreach Advisory Committees
2001-2003	Prevention Research Center (PRC) Executive Planning Committee
2000-2001	Clinical Research Development Grant Study Section
1999	Ad hoc interdisciplinary committees
1999	Internal Reviewer, Grants and Contracts, West Virginia University School of Medicine
1997-2009	Basic Science Chairs Committee
1995-1997	External Advisory Committee, Department of Microbiology and Immunology
1992-1997	West Virginia University Safety Committee
1992-1999	School of Medicine Clinical Council
1992-2002	School of Medicine Executive Committee (Executive Faculty)

## **EXTERNAL PEER REVIEW**

### **Peer Publications reviewed** (by journal)

2018	BMJ Open, Chemosphere, Environment International, Environmental Health, Environmental Research (2), PLOS Biology (Ad hoc reviewer for all)
2017	Environmental Research, Nutrition and Metabolism, Occupational and Environmental Medicine, PLOS Biology, PLOS ONE, Preventive Medicine Reports (Ad hoc reviewer for all)
2016	Environmental Research (3), Environmental Toxicology and Pharmacology (2), PLoS ONE
2015	Environmental Health (2), Environmental Health Perspectives, Environmental Research (2), Military Medicine, Nutrition and Metabolism, PLoS ONE (Ad hoc reviewer for all)
2014	Environmental Health Perspectives (2), Environmental Research (3), Environment International, Occupational Medicine (2), Toxicology Letters (2). (Ad hoc reviewer) American Journal of Industrial Medicine (contributing editor)
2013	BMJ (Open), BMC Endocrine disorders, Diabetologia, Environmental Health Perspectives, Environment International, Nutrition and Metabolism, Public Health Reports (ad hoc reviewer)
2011	Archives of Environmental and Occupational Health (ad hoc reviewer)
2010	Public Health Reports (ad hoc reviewer)
2006-present	Journal of Occupational and Environmental Medicine (ad hoc reviewer)
2006-present	International Journal of Occupational and Environmental Health (ad hoc reviewer)
2005-present	Environmental Health Perspectives (ad hoc reviewer)
1990-	American Journal of Industrial Medicine (Contributing Editor)

2003 National Occupational Injury Research Symposium (abstract reviewer)  
 2003 USEPA reviewer: Human Health Research Implementation Plan for the National Health and Environmental Effects Research Laboratory  
 1996-2002 International Journal of Occupational Health (ad hoc reviewer)  
 1995 Southern Medical Journal (ad hoc reviewer)  
 1994 Cancer Prevention International (Topical Editor: Occupational and Environmental Health)  
 1994 American Journal of Public Health (ad hoc reviewer)  
 1993 Agency for Toxic Substances Disease Registry, Center for Disease Control, Case Studies Reviewer. Ionizing Radiation ATSDR 34; Oct. 1993.  
 1992-93 Applied Radiology (Environmental Editor)  
 1991 Journal of Occupational Medicine (ad hoc reviewer)  
 1990 Toxicology, Occupational Medicine and Environmental Series (TOMES), MICROMEDEX (Assistant Editor)  
 1990 Congress of United States, Office of Technology Assessment, OTA Reports (Reviewer)  
 1989-92 Van Nostrand Reinhold (new proposals reviewer)  
 1987-99 Occupational Environmental Medicine Report (Contributing Editor)

**External Peer Review: Promotion and Tenure**

2015 Mount Sinai School of Medicine  
 2012 School of Medicine, University of Virginia; School of Public Health, University of Illinois at Chicago  
 2011 College of Public Health, East Tennessee State University  
 2010 Department of Preventive Medicine, State University of New York At Stony Brook  
 2008 University of Virginia, University of Illinois at Chicago, University of Texas Health Science Center at Houston  
 2007 University of Illinois at Chicago, Tufts University, Yale University  
 2005 Uniformed University of the Health Sciences  
 2004 Dartmouth University School of Medicine, Uniformed Services University of the Health Sciences  
 2002 University of Pittsburgh  
 2001 Johns Hopkins University  
 2000 University of Pennsylvania  
 1999 Yale University, Univ. of Miami (Fla), UMDNJ-Robert Wood Johnson, Univ. of Utah, Boston University, Uniformed Services University of Health Sciences  
 1998 Texas A&M University  
 1997 Jefferson Medical College, University of Maryland  
 1996 University of Miami (FL), Medical College of Wisconsin  
 1995 University of Texas, University of Iowa, University of Michigan, University of California, Los Angeles  
 1994 Tufts University, University of Mississippi

**Other External Advising**

2006 Asked by WV DHHR to review and assist with Childhood Lead Poisoning Prevention supplemental submission.  
 2005 Provided opinion to WV DHHR concerning the use of spit tobacco as a harm-reduction cessation therapy. Opinion cited (Ducatman, Meckstroth, Walker, and Swarm) by Governor Joe Manchin III in memorandum of November 1, 2005.  
 1999 Provided CDC-sponsored Health Officer Seminar in public health environmental issues, June 1999

**Grant Peer Review (Study Section)**



- 2018-9 PAR-15 Centers for Agricultural Health and Safety. Disease. Disability, and Injury Prevention and Control Special Emphasis Panel Meeting, Arlington, VA February 12-13, 2019
- 2016 PAR-15 353 Centers for Agricultural Health and Safety. Disease. Disability, and Injury Prevention and Control Special Emphasis Panel Meeting. Atlanta, GA, May 9-13, 2016
- 2004-2009 Wayne State University Institute for Population Studies, Health Assessment, Administration, Services and Economics (INPHAASE).
- 1995 National Cancer Institute RFA, CA-95-002. Occupational Exposure and Cancer Prevention Agency for Toxic Substances Disease Registry, Centers for Disease Control

### **Other National Peer Review or Service**

Consultation to US EPA Region 3 and WVDHHR concerning environmental contamination in Minden, WV, 2017

Vaccine Injury Compensation Program (VICP), Medical Expert Panel, appointed 2015 (current).

Board of Appeals Panel Member. American Board of Preventive Medicine (Current)

Health Consultation: Dimock Groundwater Site, Released May 24, 2016 by USDHHS/Agency for Toxic Substances and Disease Registry, Division of Community Health Investigations (acknowledged external reviewer).

National Occupational Injury Research Symposium, National Institutes of Occupational Safety and Health, Pittsburgh, PA, October 28-30, 2003. Abstract and paper reviewer.

US Environmental Protection Agency: Human Health Research Implementation Plan for the National Health and Environmental Effects Research Laboratory (NHEERL), 2003. Ten-year plan reviewer.

### **RESEARCH and PUBLICATIONS**

#### **Books**

Ducatman AM, Liberman DR (Eds). The Biotechnology Industry: "State of the Art Reviews - Occupational Medicine." Hanley and Belfus, Inc. Philadelphia 1991; 6:2, 326 pp.

#### **Monographs**

Hornberger GM, Cullen AC, Ducatman A, Jackson JK, Kappel WM, Krannich RS, Matthews V, Robinson AL, Sandler DP, Stout SL, Swackhammer DL, Zhang J. Strategic Research Agenda on the Potential Impacts of 21<sup>st</sup> Century Oil and Natural Gas Development in the Appalachian Region and Beyond. 2015, 240pp. Health Effects Institute, Boston MA. Available at [www.healtheffects.org](http://www.healtheffects.org)

Abdallah MA, Cattley RC, Ducatman A, Dunnick JK, et al., Some Industrial Chemicals/IARC Working Group on the Evaluation of Carcinogenic Risks to Humans Vol 115 (2016: Lyon, France). ISBN 978-92-832-0181-6 ISSN 1017-1606 Distributed by WHO Press, Geneva, Switzerland.

#### **Practice Guidelines**

Sokas R, Fagan K, Ducatman A. The Association of Occupational and Environmental Clinics (AOEC) Practice Guidelines for Lead-Exposed Adults, Revised 04/24/2007. Available on-line at [http://www.aeec.org/documents/positions/MMG\\_FINAL.pdf](http://www.aeec.org/documents/positions/MMG_FINAL.pdf) . Last accessed 4/9/18

### **Technical Reports**

Gerber BJ, Ducatman A, Fischer M, Althouse R. The Potential for an Uncontrolled Mass Evacuation of the DC Metro Area Following a Terrorist Attack: A Report of Survey Findings. Dec 6, 2006. Research Supported by West Virginia Department of Military Affairs and Public Safety. DOI: 10.13140/RG.2.2.28585.39529 . Affiliation: West Virginia University Available online at <http://www.hsp.wvu.edu/r/download/20487> Last Accessed 27 Dec 2016

### **Book Chapters**

Jin CJ, Wertz C, Ducatman AM. Occupational Toxicology: Applying Toxicology to Individuals. In Ballantyne B, Marrs TC, Syberston T (Eds.). *General and Applied Toxicology* (3<sup>rd</sup> Ed). Wiley-Blackwell. Chichester, UK. ISBN 978-0-470-7327-4. 3755 pages, chapter pp. 2375-2399.

Ducatman, AM. Multiple Chemical Sensitivity. In Rom WN (Ed). *Environmental and Occupational Medicine* (4th Ed). Lippincott-Raven. Philadelphia, 2006.

Martin C, Ducatman AM. Nonionizing radiation. In Rosenstock L, Cullen M, Brodtkin C, Redlich C (Eds). *Textbook of Clinical Occupational and Environmental Medicine*, 2<sup>nd</sup> Ed. Elsevier, Philadelphia, 2005. pp. 870-879.

Ducatman AM. Clinical environmental medicine. In McCunney R. (Ed). *A Practical Approach to Occupational and Environmental Medicine*. (3<sup>rd</sup> Ed). Lippincott Williams and Wilkins. Philadelphia, 2003. pp 737-745.

Ducatman, AM. Multiple Chemical Sensitivity. In Rom WN (Ed). *Environmental and Occupational Medicine* (3<sup>rd</sup> Ed). Lippincott-Raven. Philadelphia, 1998. pp 891-904.

Ducatman AM. Chemical exposures and causation. In Kaufman HH, Lewin JL (Eds). *The Physician's Perspective on Medical Law*. American Association of Neurologic Surgeons, Park Ridge, IL, 1997. pp 263-278.

Emmett MS, Emmett DC, Simoyi PM, Ducatman AM. The Changing Shape of Public Health Education. In Rowe and Joby (Eds). *Advances in Health Care Research*. Omni Press, Madison, WI, 1996.

Ducatman AM. Recombinant Biology. In Stave GM (Ed). *Physical and Biological Hazards of the Workplace*. Van Nostrand Reinhold, New York, 1994. pp. 479-482.

Ducatman AM. Vaccinia. In Stave GM (Ed). *Physical and Biological Hazards of the workplace*. Van Nostrand Reinhold, New York, 1994. pp. 312-315.

Ducatman AM. Hazardous environments and occupational physicians: Clinical cluster observations and etiologic causation. In Mehlman MA, Upton A (Eds). *The Identification and Control of Environmental and Occupational Diseases*. Princeton Scientific Publishing, Princeton, NJ, 1994. pp. 55-73.

Ducatman AM. Clinical Environmental Medicine. In McCunney RJ (Ed). *A Practical Approach to Occupational and Environmental Medicine* (2nd Ed). Little Brown, Boston, 1994, pp. 623-632.

Ducatman AM, Haes DL. Nonionizing radiation. In Cullen MR, Rosenstock L (Eds). *Clinical Occupational Medicine*. Saunders, Philadelphia, 1994, pp. 646-657.

Ducatman AM. Biotechnology, occupational health issues. In Corn M (Ed). *Handbook of Hazardous Materials*. Academic Press, San Diego, 1993, pp. 81-89.

Ducatman AM, Liberman DF. Biotechnology Companies. In Sullivan J, Krieger G (Eds). *Hazardous Materials Toxicology*. Williams Wilkins, Baltimore, 1991, pp. 556-562.

Ducatman AM, Coumbis J. Chemical hazards in the biotechnology industry. In Ducatman AM, Liberman DF (Eds). The Biotechnology Industry: "State of the Art Reviews - Occupational Medicine." Hanley and Belfus, Inc. Philadelphia 1991; 6:2, 193-208.

Liberman DF, Ducatman AM, Fink R. Biotechnology: Is there a role for medical surveillance? In Hyer WC (Ed). Bioprocessing Safety: Workers and Community Safety and Health Considerations. American Society for Testing and Materials, Philadelphia, 1990, pp. 101-110.

Ducatman AM. United States OSHA Laboratory Standard: "Regulation of toxic substances in laboratories." In Liberman DF, Gordon J (Eds). Biohazards Management Handbook. Marcel Dekker, New York, 1989 pp. 403-415.

### **Federal Reports**

Chair (first author), Report Committee. Centers for Disease Control and Prevention, NCEH/ATSDR Peer Review. "Report on Peer Review and Clearance Policies and Functions in the National Center for Environmental Health and the Agency for Toxic Substances and Disease Registry." (Report is now in the Federal Register.)

### **State Reports**

Ducatman A, Ziemkiewicz P, Quaranta J, Vandivort T, Mack B, Van Aken B. Coal Slurry Waste Underground Injection Assessment, Final Report: Phase II. West Virginia University Water Research Institute. July 30, 2010. 261 pp.

### **Papers Submitted**

Yucel Tufekcioglu E, Koksall S, Ducatman A, Erdogan S. Burnout, depression and psychosocial risk factors among call center workers in three different regions.

### **Papers Published**

Jain RB, Ducatman A. Dynamics of associations between perfluoroalkyl substances and uric acid across various stages of glomerular function. Environmental Science and Pollution Res. 2019 March 7 PMID 30847808 doi: [10.1007/s11356-019-04666-5](https://doi.org/10.1007/s11356-019-04666-5)

Bassler J, Ducatman A, Elliott M, Wen S, Wahlang B, Barnett J, Cave MC. Environmental perfluoroalkyl acid exposures are associated with liver disease characterized by apoptosis and altered serum adipocytokines. Environmental Pollution. 2019; 247:1055-63 PMID: 30823334 doi: [10.1016/j.envpol.2019.01.064](https://doi.org/10.1016/j.envpol.2019.01.064). Epub 2019 Jan 18

Jain RB, Ducatman A. Selective Associations of recent low concentrations of perfluoroalkyl substances with liver function biomarkers: NHANES 2011-2014 data on US adults aged  $\geq 20$  years. J Occup Environ Med 2018 .PMID 30589657 <https://doi.org/10.1097/JOM.0000000000001532>

Jain RB, Ducatman A. Perfluoroalkyl substances follow inverted U-shaped distributions across various stages of glomerular function: implications for future research. Environmental Research 2019; 169:476-82 PMID: 30530087 <https://doi.org/10.1016/j.envres.2018.11.033>

Jain RB, Ducatman A. Roles of gender and obesity in defining correlations between perfluoroalkyl substances and lipid/lipoproteins. Science of the Total Environment 2019; 653: 74-81 <https://doi.org/10.1016/j.scitotenv.2018.10.362>

Jain RB, Ducatman A. Associations between lipid/lipoprotein levels and perfluoroalkyl substances among US children aged 6-11 years. Environ Pollut. 2018; 243 (Pt A):1-8 DOI: [10.1016/j.envpol.2018.08.060](https://doi.org/10.1016/j.envpol.2018.08.060) PMID: 30170203

George C, Ducatman A, Conway BN. Increased risk of respiratory diseases in adults with type 1 and type 2 diabetes. *Diabetes Research and Clinical Practice* 2018 doi:

<https://doi.org/10.1016/j.diabres.2018.05.029>

Jain RB, Ducatman A. Associations between smoking and lipid/lipoprotein concentrations among US adults aged  $\geq 20$  years. *J Circulating Biomarkers* 2018. 7:1-10 DOI: 10.1177/1849454418779310

Heibati B, Godri Pollitt KJ, Charati JY, Ducatman A, et al. Biomonitoring-based exposure assessment of benzene, toluene, ethylbenzene, and xylene among workers at petroleum distribution facilities. *Exotoxicol Environ Saf* 2018; 149: 19-25. doi: 10.1016/j.ecoenv.2017.10.070

Ducatman AM, Tacker DH, Ducatman BS, Long D, et al. Quality improvement intervention for reduction of redundant testing. *Academic Pathology* 2017; 4:1-10 DOI: 10.1177/2374289517707506

Heibati B, Godri Pollitt KJ, Karimi A, Charati JY, Ducatman A, Shokrzadeh M, Mohammadyan M. BTEX exposure and quantitative risk assessment among petroleum product distributors. *Ecotoxicol Environmental Safety* 2017;144: 445-49. doi: 10.1016/j.ecoenv.2017.06.055

Bruton TA, Blum A. Proposal for coordinated health research in PFAS-contaminated communities in the United States (Commentary. Co-signatory and contributing author). *Environ Health* 2017: 16: 120 doi: 10.1186/s12940-017-0321-6

Ducatman BS, Hashmi M, Darrow M, Flanagan MB, Courtney P, Ducatman AM. Use of pathology data to improve high-value treatment of cervical neoplasia. *Academic Pathology* 2016;3: doi:10.1177/2374289516679849

Alfaraj WA, McMillan B, Ducatman AM, Wertz CL. Tetryl exposure: forgotten hazards of antique munitions. *Ann Occup Environ Med* 2016 April 8; 28:20. doi: 10.1186/s40557-016-0102-7 PMID 27066259

Ducatman AM, Zhang J, Fan H. Response to prostate cancer and PFOA (letter). *J Occup Environ Med* 2015 Jun;57(6): e61. doi: 10.1097/JOM 0000000000000470 PMID 26053372

Ducatman A, Zhang J, Fan H. Prostate-specific antigen and perfluoroalkyl acids in the C8 health study population. *J Occup Environ Med* 2015; 57 (1): 111-14 doi:10.1097/JOM.0000000000000319 PMID 25563548

Fan H, Ducatman A, Zhang J. Perfluorocarbons and Gilbert syndrome (phenotype) in the C8 health study population. *Environ Res* 2014: Published on line September 2014 DOI 10.1016/j.envres.2014.08.011 PMID 25262077

Van Aken B, Quaranta JD, Mack B, Yu H, Ducatman A, Ziemkiewicz P. Environmental Contaminants in coal slurry intended for underground injection in the state of West Virginia. *J Environ Eng.* 2015. E- Published Nov 2014 DOI 10:1061/(ASCE)EE.1943-7870.0000874

Quaranta JD, Mack B, Van Aken B, Ducatman A, Ziemkiewicz P. Practical application of dilution analysis for estimating groundwater effects due to coal slurry injection into underground mine voids. *Mine Water Environment* 2014; 33: 353-361. Published online April 8, 2014. DOI 10.1007/s10230-014-0274-8

Alshaarawy O, Zhu M, Ducatman AM, Conway B, Andrew ME. Urinary polycyclic aromatic hydrocarbon biomarkers and diabetes mellitus. *Occup Environ Med* 2014;71(6):437-41.

Innes KE, Wimsatt JH, Frisbee S, Ducatman AM. Inverse association of colorectal cancer prevalence to serum levels of perfluorooctane sulfonate (PFOS) and perfluorooctanoate (PFOA) in a large Appalachian population. *BMC Cancer* 2014;14:45.

Geiger SD, Xiao J, Ducatman A, Frisbee S, Innes K, Shankar A. The association between PFOA, PFOS and serum lipid levels in adolescents. *Chemosphere* 2013. Epub Nov 13, 2013 doi: 10.1016/j.chemosphere.2013.10.005.

Alshaarawy O, Zhu M, Ducatman A, et al: Polycyclic aromatic hydrocarbon biomarkers and serum markers of

inflammation. A positive association that is more evident in men. *Environ Res* 2013;126:98-104,

Javins B, Hobbs G, Ducatman A, Pilkerton C, Tacker D, Knox S. Circulating maternal perfluoroalkyl substances during pregnancy in the C8 health study. *Environmental Science & Technology*. 2013 Jan8 [Epub ahead of print] PMID; 23272997.

Bhardwaj R, Ducatman A, Finkel MS, Petsonk E, Hunt J, Beto RJ. Chronic pulmonary dysfunction following acute inhalation of butyl acrylate. *West Virginia Medical Journal* 2012; 108:28-32.

Abraham RT, Walls RT, Fischer M, et al: Tabletop scenarios for realism in bioterrorism and threat preparedness. *W V Med J* 2012; 108:12-17

Luo J, Chen YJ, Narsavage GL, Ducatman A. Predictors of survival in patients with non-small cell lung cancer. *Oncol Nurs Forum* 2012; 39(6):609-16.

Shankar A, Xiao J, Ducatman A. Perfluorooctanoic acid and cardiovascular disease in US adults. *Arch Intern Med* 2012; 172: 1397-1403.

Hendryx M, Ducatman A, Zullig K, Ahern M, Crout R. Adult tooth loss for residents of us coal mining and Appalachian counties. *Community Dent Oral Epidemiol* 2012: 40: 488-97.]

Gallo V, Leonardi G, Genser B, Lopez-Espinosa MJ, Frisbee SJ, Karlsson L, Ducatman AM, Fletcher T. Serum perfluorooctanoate (PFOA) and perfluorooctane sulfonate (PFOS) concentrations and liver function biomarkers in a population with elevated PFOA exposure. *Environ Health Perspect* 2012; 120:655-60.

Bhardwaj R, Dod H, Finkel MS, Dar I, Hobbs GR, Ducatman AM, Warden B, Gharib W, Beto RJ, Jain AC. Left atrial volume by echocardiography in patients with false positive myocardial perfusion scans. *International Heart Journal* 2012; 53:18-22.

Cain LR, Ducatman AM, Shankar A. The relationship between gamma-glutamyl transferase levels and chronic kidney disease among Appalachian adults. *West Virginia Medical Journal* 2012; 108(1):8-13.

Shankar A, Xiao J, Ducatman A. Perfluoroalkyl chemicals and elevated serum uric acid in US adults. *Clinical Epidemiology* 2011; 3:251-258.

Luo J, Hendryx M, Ducatman A. Association between six environmental chemicals and lung cancer incidence in the United States. *J Environ Public Health* 2011; 463701. Doi: 10.1155/2011/463701 Epub 2011 Jul 10.

Knox SS, Jackson T, Frisbee SJ, Javins B, Ducatman AM. Perfluorocarbon exposure, gender, and thyroid function in the C8 Health Project. *Journal of Toxicological Sciences* 2011; 36(4): 403-410.

Innes KE, Ducatman AM, Luster MI, Shankar A. Association of osteoarthritis to serum perfluorooctanoate and perfluorooctane sulfonate in a large Appalachian population. *Am J Epidemiol* 2011; 174(4):440-450.

Shankar A, Xiao J, Ducatman A. Perfluoroalkyl chemicals and chronic kidney disease in US adults. *Am J Epidemiol* 2011; 174(8):893-900.

Ahern, M.M., Hendryx M, Conley J, Fedorko E, Ducatman A, Zullig KJ. The association between mountaintop mining and birth defects among live births in central Appalachia, 1996–2003. *Environ Res* 2011; 111(6): 838-46.

Lopez-Espinosa, MJ, Fletcher T, Armstrong B, Genser B, Dhatariya K, Mondal D, Ducatman A, Leonardi G. Association of perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate (PFOS) with age of puberty among children living near a chemical plant. *Environ Sci Technol* 2011; 8160-6.

Shankar A, Jie X, Ducatman A. Perfluoroalkyl chemicals and chronic kidney disease in US adults. *American Journal of Epidemiology* 2011 10.1093/aje/kwr/171.

Knox SS, Jackson T, Javins B, Frisbee SJ, Shankar A, Ducatman AM. Implications of early menopause in

women exposed to perfluorocarbons. *Journal of Clinical Endocrinology and Metabolism* June 2011; 96(6): 1747-53.

Sivak-Callcott JA, Diaz SR, Ducatman AM, Rosen CL, Nimbarte AD, Sedgeman JA. A survey study of occupational pain and injury in ophthalmic plastic surgeons. *Ophthal Plast Reconstr Surg* 2011; 27(1): 28-32.

Jin C, Sun Y, Islam A, Ducatman A, Qian Y. Perfluoroalkyl acids including perfluorooctane sulfonate and perfluorohexane sulfonate in firefighters. *J Occup Environ Med* 2011; 53(3):324-28.

Rockett IR, Hobbs G, De Leo D, Stack S, Frost J, Ducatman AM, Kapusta ND, Walker RL. Suicide and unintentional poisoning mortality trends in the United States, 1987-2006: Two unrelated phenomena? *BMC Public Health* 2010; 10:705.

Blake KB, Shankar A, Madhavan SS, Ducatman A. Associations among cardiometabolic risk factor clustering, weight status and cardiovascular disease in an Appalachian population. *Journal of Clinical Hypertension* 2010; 12(12):964-972.

Frisbee SJ, Shankar A, Knox S, Steenland K, Savitz DA, Fletcher T, Ducatman AM. Perfluorooctanoic acid, perfluorooctanesulfonate, and serum lipids in children and adolescents. *Archives of Pediatric and Adolescent Medicine* 2010; 164(9):860-869.

Teppala S, Shankar A, Ducatman A. The association between acculturation and hypertension in a multiethnic sample of US adults. *Journal of the American Society of Hypertension* 2010; 4(5): 236-43.

Rockett IR, Wang S, Stack S, De Leo D, Frost JL, Ducatman AM, Walker RL, Kapusta ND. Race/ethnicity and potential suicide misclassification: window on a minority suicide paradox? *BMC Psychiatry* 2010; 10:35-42.

Steenland K, Tinker S, Shankar A, Ducatman A. Association of perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate (PFOS) with uric acid among adults with elevated community exposure to PFOA. *Environ Health Perspect* 2010; 118:229-33.

Qian Y, Ducatman A, Ward R, Leonard S, Bukowski V, Guo NL, Shi X, Vallyathan V, Castranova V. Perfluorooctane sulfonate (PFOS) induces reactive oxygen species (ROS) production in human microvascular endothelial cells: role in endothelial permeability. *Journal of Toxicology & Environmental Health, Part A*, 2010; 73:12, 819-836.

Teppala S, Shankar A, Li J, Wong T, Ducatman A. Association between serum gamma-glutamyl transferase and chronic kidney disease among US adults. *Kidney and Blood Pressure Research* 2010; 33:1-6.

Cain L, Shankar A, Ducatman AM, Steenland K. Association between serum uric acid and chronic kidney disease among Appalachian adults. *Nephrology, Dialysis & Transplantation* 2010; 25(11):3593-3599.

Steenland K, Tinker S, Frisbee S, Ducatman A, Vaccarino V. Association of perfluorooctanoic acid and perfluorooctane sulfonate with serum lipids among adults living near a chemical plant. *American Journal of Epidemiology* 2009; 170:1268-1278.

MacNeil J, Steenland K, Shankar A, Ducatman A. A cross-sectional analysis of type II diabetes in a community with exposure to perfluorooctanoic acid (PFOA). *Environ Res* 2009; 109:997-1003.

Frisbee S, Brooks AP, Maher A, Flensburg P, Arnold S, Fletcher T, Steenland K, Shankar A, Knox S, Pollard C, Halverson J, Vieira V, Jin C, Leyden K, Ducatman A. The C8 Health Project: design, methods, and participants. *Environ Health Perspect* 2009; 117(12): 1873-1882.

Steenland K, Jin C, MacNeil J, Lally C, Ducatman A, Vieira V, Fletcher T. Predictors of PFOA levels in a community surrounding a chemical plant. *Environ Health Perspect* 2009; 117:1083-88.

Rockett IR, Lian Y, Stack S, Ducatman AM, Wang S. Discrepant comorbidity between minority and white suicides: a national multiple-cause-of-death analysis. *BMC Psychiatry* 2009; 9:10.

Charumathi S, Shankar A, Li J, Pollard C, Ducatman A. Serum gamma-glutamyl transferase level and



diabetes mellitus among US adults. *Eur J Epidemiol* 2009; 24:369-73.

Sun C, Jin C, Martin C, Gerbo R, Wang Y, Atkins J, Ducatman AM. Cost and outcome analyses on the timing of the first independent medical evaluation in patients with work-related lumbosacral sprain. *J Occup Environ Med* 2007; 49:1264-8.

Haut MW, Kuwabara H, Ducatman AM, et al. Corpus callosum volume in railroad workers with chronic exposure to solvents. *J Occup Environ Med* 2006; 48(6): 615-24.

Harber P, Ducatman AM. Training pathways for occupational medicine. *J Occup Environ Med* 2006; 48: 366-75.

Ducatman BS, Ducatman AM. Longitudinal case-based evaluation of diagnostic competency among pathology residents: a statistical approach. *Arch Pathol Lab Med* 2006; 130: 188-93.

Ducatman AM, Vanderploeg JM, Johnson M, et al. Residency training in preventive medicine: challenges and opportunities. *Am J Prev Med* 2005; 28: 403-412.

Ducatman BS, Ducatman AM. How expert are the experts? Implications for proficiency testing in cervicovaginal cytology (editorial). *Arch Pathol Lab Med* 2005; 129: 604-605.

Jin CH, Haut M, Ducatman AM. Industrial solvents and psychological effects. *Clin Occup Environ Med* 2004; 4: 597-620.

Martin CT, Wertz CL, Ducatman AM. The interpretation of zinc protoporphyrin changes in lead intoxication: a case report and review of the literature. *Occupational Medicine* 2004; 54 (7): 587-591.

Erdogan MS, Islam SS, Chaudhari A, Ducatman AM. Occupational carbon monoxide poisoning among West Virginia workers' compensation claims: diagnosis, treatment duration, and utilization. *J Occup Environ Med* 2004, 46(6) 577-83.

Ehrlich PF, McLellan WT, Ducatman AM, Helmkamp JC, Islam SS. Understanding work-related injuries in children: a perspective in West Virginia using the state-managed workers' compensation system. *J Pediatric Surgery* 2004; 39: 768-772.

Abdul-Razzaq WN, Lee V, Islam S, Ducatman AM. Quantification of lead in telephone cord: use of x-ray photoelectron spectroscopy technique. *Appl Occup and Env Hygiene*. 2003. 18: 553-557.

Islam SS, Edla S, Mujuru P, Doyle EJ, Ducatman AM. Risk factors for physical assault: state-managed workers' compensation experience. *Am J Prev Med* 2003; 25:31-37.

Li H, Wang M-L, Seixas N, Ducatman AM, Petsonk EL. Respiratory protection: associated factors and effectiveness of respirator use among underground coal miners. *Am J Indus Med* 2002; 42: 55-62.

Ducatman AM. ATDSR Case Studies in Environmental Medicine. Disease clusters: an overview. USDHHS/ATDSR. Course SS3096. August 2002. Document also available online at [www.atsdr.cdc.gov/HEC/CSEM](http://www.atsdr.cdc.gov/HEC/CSEM).

Ducatman AM. Educational module "Lead, it's everywhere." With the support of the American Occupational and Environmental Clinics (AEOC) and National Institute for Occupational Safety and Health (NIOSH), Cooperative Agreement U60/CCU317613-03, for a seminar/presentation at AEOC in 2002. Also available on CD-ROM, and via e-mail at [AEOC@aoec.org](mailto:AEOC@aoec.org) and on-line at [www.aoec.org](http://www.aoec.org)

Islam SS, Biswas RS, Nambiar A, Syamlal G, Velilla AM, Doyle EJ, Ducatman AM. Incidence of work-related fracture injuries: experience of a state-managed workers' compensation system. *J Occup Environ Med* 2001; 43: 140-146.

Islam SS, Velilla AM, Doyle EJ, Ducatman AM. Gender differences in work-related injury/illness: analysis of workers' compensation claims. *Am J Indus Med* 2001; 38: 84-91.

Hogan T, Lamm D, Ducatman AM. Smoking and renal cell carcinoma. *WV Med J* 2001; 97: 32-5.

Hogan T, Lamm D, Riggs D, Ducatman AM. Smoking and bladder cancer. *WV Med J* 2001; 97: 29-31.

Ducatman AM, McLellan R. American College of Occupational and Environmental Health Position Statement. Epidemiologic basis for an occupational and environmental policy on environmental tobacco smoke. *J. Occup Environ Med* 2000; 42: 575-581.

Franklin P, Goldenberg WS, Ducatman AM, Franklin E. Too Hot to Handle: An Unusual Exposure of HDI in Specialty Painters. *Am J Indus Med* 2000; 37: 431-437.

Islam SS, Doyle EJ, Velilla AM, Martin CJ, Ducatman AM. Epidemiology of compensable work-related ocular injuries and illnesses: incidence and risk factors. *J Occup Environ Hlth* 2000; 42: 575-581.

Islam SS, Nambiar AM, Doyle EJ, Velilla AM, Biswas RS, Ducatman AM. Epidemiology of work-related burn injuries: experience of a state-managed workers' compensation system. *J Trauma* 2000; 49: 1045-51.

Haut MW, Leach S, Kuwabara H, Whyte A, Ducatman AM, Lombardo LJ, Gupta N. Verbal working memory and solvent exposure: a position emission tomography study. *Neuropsychology* 2000; 14: 551-8.

Meyer JD, Becker PE, Stockdale T, Ducatman AM. The West Virginia Occupational Safety and Health Initiative: Practicum Training for a New Marketplace. *Am J Prev Med* 1999. 16(4): 347-350.

McClellan R, Becker CE, Borak J, Coplein C, Ducatman AM, et al. American College of Occupational & Environmental Medicine Position Statement. Multiple chemical sensitivities; idiopathic environmental intolerances. ACOEM Position Statement. *J Occup Environ Med* 1999; 41: 940-942.

Westra CS, Ducatman AM, Niewiadomska-Bugaj M, Hobbs GR. An estimate of prostate cancer prevalence for a demographically similar workforce population. *WV Med J* 1999; 95:116-122

Cohen A, Ducatman AM. Employing self-directed computer and printed resources to reform a medical school, epidemiology and biostatistics curriculum. *Medical Education Outline (On-line)* July 1998

Magnetti SM, Wyant W, Greenwood J, Roder N, Linton J, Ducatman AM. Injuries to volunteer firefighters in West Virginia. *J Occup Environmental Med.* 1999 Feb; 41 No. 2: 104-110.

Simoyi P, Islam S, Haque A, Meyer J, Doyle EJ, Ducatman AM. Evaluation of occupational injuries among young workers in West Virginia. *Human Eval Risk Assess* 1998; 4: 1405-15.

Bucklew NS, D'Alessandri R, Ducatman AM. The mentoring of the department chair: a new partnership model between the health sciences and business administration. *Issues in the Cornerstone of Higher Education*, 1998; 48:71-55 Vol. 48, pp. 71-75.

Meyer JD, Islam SS, Ducatman AM, McCunney RJ. Prevalence of small lung opacities in populations unexposed to dusts: a literature-analysis. *Chest* 1997; 111: 404-410.

Shy C, Anderson H, Ducatman A, Fleissner ML, et al. Summary report of the panel. Panel of the workshop on nasopharyngeal radium irradiation. *Otolaryngol Head Neck Surg* 1996; 115: 442-6. PMID 8903445

Ducatman AM. Disease clusters: paradoxes of perception and public health (editorial). *Int J Occup Environ Hlth* 1995; 1:289-290.

Moore RS, Ducatman AM, Jozwiak JA. Home on the range: childhood lead exposure due to family occupation. *Arch Pediatric Adolescent Med* 1995; 149:1276-1277.

Boswell RT, DiBerardinis L, Ducatman AM. Descriptive epidemiology of indoor odor complaints at a large teaching institution. *Appl Occup Environ Hyg* 1994; 9:281-286.

Barbanel CS, Ducatman AM, Garston MJ, Fuller T. Laser hazards in research laboratories. *J Occup Med* 1993; 35:369-374.



Ducatman AM. Occupational physicians and environmental medicine. *J Occup Med*. 1993; 35:251-259.

Ducatman AM. On "B-reading," radiology, the ILO system, and dust-related diseases. *Applied Radiology* 1993; 22: 72-73.

Fleming LE, Ducatman AM, Shalat SL. Disease clusters in occupational medicine: a protocol for their investigation in the workplace. *Am J Indus Med* 1992; 22: 33-47.

Perry GF, Hawes Clever L, Ducatman AM, et al. Scope of occupational and environmental health programs and practice. *J Occup Med* 1992; 34:436-440.

Fleming LE, Ducatman AM, Shalat SL. Disease clusters: a central and ongoing role in occupational medicine. *J Occup Med* 1991; 33:818-825.

Ducatman AM. Variability in interpretation of radiographs for asbestotic abnormalities: problems and solutions. *Annals NY Acad Sci* 1991; 643:108-120.

Stinson MC, Green BL, Marquardt CJ, Ducatman AM. Autoclave inactivation of infectious radioactive laboratory waste contained within a charcoal filtration system. *Health Physics* 1991; 61:137-142.

Ducatman AM, Forman SA, Teichman R, Gleason R. Occupational physician staffing in large U.S. corporations. *J Occup Med* 1991; 32:613-618.

Ducatman AM. Cost-shifting in workers' compensation: methods, money, and meaning (editorial). *Am J Indus Med* 1991; 19:279-282.

Ducatman AM, Chase KH, Farid I, et al. What is environmental medicine? (Editorial). *J Occup Med* 1990; 32:1130-1132.

Ducatman AM, Withers B, Yang WN. Smoking and roentgenographic opacities in U.S. Navy asbestos workers. *Chest* 1990; 97:810-813.

Stinson MC, Galanek MS, Ducatman AM, et al. Model for inactivation and disposal of infectious human immunodeficiency virus and radioactive waste in a P3 facility. *Applied and Environmental Microbiology* 1990; 56: 264-268.

Withers B, Ducatman AM, Yang WN. Roentgenographic evidence for predominant left-sided location of unilateral pleural plaques. *Chest* 1989; 95:1262-1264.

Ducatman AM. Career options of occupational physicians. *J Occup Med* 1988; 30:776-779.

Ducatman AM, Yang WN, Forman SA. "B-readers" and asbestos medical surveillance. *J Occup Med* 1988; 30:644-647.

Committee Report (Lewy R, Anstadt GW, Curtis EC, Ducatman AM, et al.) AIDS in the workplace: guidelines. *J Occup Med* 1988; 30:578-579.

Ducatman AM, Ducatman BS, Barnes JA. Lithium battery health hazard: old-fashioned planning implications of new technology. *J Occup Med* 1988; 30:309-311.

Ducatman AM, Bigby M. Systemic contact dermatitis after inhalation of 2-aminothiophenol. *Contact Derm* 1988; 18:57-58.

Ducatman AM, Crawl JR, Conwill CE. Cancer clusters, causation, and common sense. *CHEMTECH (American Chemical Society)* 1988; 18:204-210.

Garland FC, Gorham ED, Garland CF, Ducatman AM. Testicular cancer in U.S. Navy personnel. *Am J Epidemiol* 1988; 127:411-414.

Ducatman AM. Inevitable growth of workers' compensation. *Best's Review Property/Casualty Insurance* 1987; 88:50-53.

Ducatman AM. Workers' compensation cost-shifting: a unique concern of providers and purchasers of prepaid health care. *J Occup Med* 1986; 28:1174-1176.

Ducatman AM, Conwill DE, Crawl J. Germ cell tumors of the testicle among military aircraft repairmen. *J Urol* 1986; 136:834-836.

Ducatman AM, Moyer TP. Environmental exposure to common industrial solvents. *Therapeutic Drug Monitoring, American Association for Clinical Chemistry, Washington, D.C., Vol 5, May 1984.*

Ducatman AM, Moyer TP. The role of the clinical laboratory in the evaluation of the polyhalogenated-polycyclic toxins: DDT, PBBs, dibenzodioxins and dibenzofurans, chlordane (Kepone) and hexachlorophene. *Therapeutic Drug Monitoring, American Association for Clinical Chemistry, Washington, D.C., Vol 4, Jan 1983.*

Ducatman AM, Moyer TP. Clinical laboratory role in the evaluation of the patient exposed to acetylcholinesterase-inhibiting pesticides. *Therapeutic Drug Monitoring, American Association for Clinical Chemistry, Washington, D.C., Vol 4, Jan. 1983.*

Ducatman AM, Amundsen MA, Moyer TP. Case report: Evaluation of the role of organophosphate pesticides. *Therapeutic Drug Monitoring, American Association for Clinical Chemistry, Washington, D.C., Vol 3, July 1982.*

Ducatman AM, Hirschhorn K, Selikoff IJ. Vinyl chloride exposure and human chromosome aberrations. *Mutation Research* 1975; 31:163-168.

### **Web Communications**

Ducatman A, Frisbee S, Stanley S, Shankar S, Knox S, Pollard C, Hobbs G, Firestone C, Mutambudzi M, Bunner E, Halverson J, Jin C, Leyden K, Tan J, Wang X, Wang Y. The C8 Health Project: WVU data-hosting website. Documents and summaries of results for the C8 Health Project. (Contained thousands of graphs and tables.) 2007 to 2013. Some parts of the information included from this effort are still housed at <http://www.hsc.wvu.edu/resoff/research/c8/project/data-collection/>

### **Letters and Other Documents**

- Ducatman A. Ebola article highlights EHR usability problems. TechTarget. Nov 12, 2014. Available at <http://searchhealthit.techtarget.com/opinion/Ebola-article-highlights-EHR-usability-problems-says-doc>
- Harber P, Ducatman AM. Training pathways for occupational medicine (response). *J Occup Environ Med* 2006; 48: 1115.
- Ducatman AM. Comparison of B readers' interpretations of chest radiographs for asbestos-related changes. *Academic Radiology* 2004; 11: 1398-99.
- Mitchell CS, Moline J, Avery AN, Blessman JE, et al. (Authors include Ducatman AM.) In response to the 2002, Vol 22, No. 4 article entitled: The rise and fall of occupational medicine in the US. *Am J Prev Med* 2002; 23:307-309.

- Frumkin H, Ducatman AM, Kirkland K. Solvent exposure in the railroad industry. *J Occup Environ Med* 1997; 39: 926-30.
- Ducatman AM. Preventive pulmonary medical education (ltr). *Chest*. 1992; 102:326.
- Ducatman AM, Farber SA. Radium exposure in U.S. military personnel (ltr). *NEJM*. 1992; 326:71.
- Bakshi R, Ducatman AM, Hochberg FH. Glioblastomas in New England ophthalmologists (ltr). *NEJM*. 1991; 324:1440-1441.
- Masse FX, Coutu-Reilly J, Galanek M, Ducatman AM. The need for additional warning in x-ray diffraction equipment: a shutter failure incident (ltr). *Health Physics*. 1990; 58; 219.
- Ducatman BS, Wang HH, Jonasson JG, Ducatman AM. Cervical screening (ltr). *Lancet* 1989; 11: 628-629.
- Ducatman AM. Roentgenographic underestimation of early asbestosis (ltr). *Chest* 1989; 95:1165.
- Ducatman AM. Dimethylformamide, metal dyes, and testicular cancer (ltr). *Lancet* 1989; 1:911.
- Ducatman AM. Prader-Willi syndrome and paternal hydrocarbon exposure (ltr). *Lancet* 1988; 1:641.
- Ducatman AM. Industrial toxins and fulminant hepatitis (ltr). *Mayo Clinic Proc* 1985; 60:640.

### **Guidelines**

Sokas R, Fagan K, Ducatman AM. Medical Management Guidelines for Lead-Exposed Adults. *American Occupational and Environmental Clinics*. [www.aoec.org/principles.htm](http://www.aoec.org/principles.htm).

### **Abstracts**

Misra R, Bhandari R, Sambamoorthi U, Khan R, Ducatman A. Association between liver enzymes and BMI Categories in the C8 Health Project. American Public Health Association Conference. Chronic Disease Epidemiology Poster Session Hepatotoxicity and Drug Induced Injury. San Diego, CA Nov 9, 2018

Cave MC, Bassler J, Elliott M, Wen S, Wahlang B, Barnett J, Ducatman A. Environmental perfluoroalkyl substances are associated with the unusual combination of apoptotic liver disease and decreased serum pro-inflammatory cytokines: implications for nonalcoholic liver disease. Number 0724 American Association of Liver Disease Conference San Francisco, CA Nov 9-13, 2018

Misra R, Khan R, Bhandari R, Sambamoorthi U, Ducatman A. Gender differences in liver function biomarkers in the C8 Health Study. West Virginia Rural Health Association Conference, Pipestem, WV Oct 17, 2018

Ducatman A, Zhang J, Luster M, Fletcher T. Perfluoroalkyl substance excretion: effects of organic anion-inhibiting and resin-binding drugs in a community setting. International Society of Environmental Epidemiology Conference, Exposures and Health Impacts of Perfluorinated Substances Session. Ottawa, Canada August 26-30, 2018

Ducatman BS, Hashmi M, Darrow M, Flanagan MB, Courtney P, Ducatman AM. Use of pathology data to improve high-value treatment of cervical neoplasia. Association of Pathology Chairs 51s Annual Meeting, Coronado, CA, July 16, 2018

Lee J, Ducatman A. Occupational lung disease clusters – does investigation of disease clusters continue to play a significant role in occupational health. American College of Occupational and Environmental Medicine Conference. New Orleans, LA April 29-May 2, 2018

Darrow MA, Ducatman BS, Hashmi M, Flanagan M, Long D, Ducatman AM. Look before you "LEEP." A retrospective quality assurance study. 103<sup>rd</sup> Annual Meeting of the United States and Canadian Academy of Pathology, San Diego, CA, March 7, 2014

Frisbee SJ, Frisbee JC, Ducatman AM. Abstract P380. Obesity and non-alcoholic fatty liver disease in children. *Circulation* 2012; 125: AP380. Available at:

[https://circ.ahajournals.org/cgi/content/meeting\\_abstract/125/10\\_MeetingAbstracts/AP380](https://circ.ahajournals.org/cgi/content/meeting_abstract/125/10_MeetingAbstracts/AP380)

Geiger S, Shankar A, Ducatman A. Association between Serum PFOA Levels and Hyperuricemia in Children. Presented at the 3rd North American Congress of Epidemiology, June 21-24, 2011, in Montreal, Canada.

Frisbee SJ, Frisbee JC, Shankar A, Knox, SS, Ducatman AM. Associations between obesity and obesity-related systemic inflammation and markers of immune function in children. Presented to the American Heart Association, March 23, 2011.

Frisbee SJ, Frisbee JC, Shankar A, Knox, SS, Ducatman AM. Contribution of Dyslipidemia vs. obesity to inflammation in children. Presented to the American Heart Association, March 23, 2011.

Frisbee SJ, Shankar A, Knox, SS, Ducatman AM. Associations between non-8-carbon-chain perfluoroalkyl acids and cholesterol in children. Presented to the American Heart Association, March 23, 2011.

Hendryx M, Crout R, Ducatman AM, Zullig K, Ahern M. Tooth loss among residents of Appalachian coal-mining counties. Presented to the American Public Health Association annual meeting, November 2010.

Rockett, IRH, Hobbs G, De Leo D, Stack S, Ducatman AM, Frost J. Relationship of suicide and unintentional poisoning mortality trends in the United States, 1987-2006. Presented to the American Public Health Association annual meeting, November 2010.

Rockett IRH, Wang S, Stack S, De Leo D, Frost J, Ducatman AM, Walker R. Race/ethnicity and potential suicide misclassification: window on a minority suicide paradox? Presented to the American Public Health Association annual meeting, November 2010.

Qian Y, Ducatman A, Leonard S, Ward R, Vallyathan V, Castranova V. PFOA- and PFOS-induced oxidative stress response in human microvascular endothelial cells. Society of Toxicology Annual Meeting, Salt Lake City, UT, March 7-11, 2010.

Cain L, Ducatman A, Shankar A. The relationship between uric acid and chronic kidney disease. *Am J Epidemiol* 2009; 169(suppl): 397-S.

Rockett IRH, Lian Y, Stack S, Ducatman AM, Wang S. Discrepant comorbidity between minority and white suicides: a national multiple-cause-of-death analysis. Population Association of America Annual Meeting, Detroit, MI, May 1, 2009.

Blake K, Shankar A, Madhavan S, Ducatman AM. Prevalence of obesity and other cardiac risk factors in an Appalachian region. WVU Health Sciences Center Research Day and Van Liere Convocation, April 28-29, 2009. Also presented to the annual meeting of the American Public Health Association, November 7-11, 2008.

Teppala S, Sabanayagam S, Shankar A, Ducatman A. Association between sleep duration and cardiovascular disease among US adults. WVU Health Sciences Center Research Day and Van Liere Convocation, April 28-29, 2009. Also presented to the annual meeting of the American Public Health Association, November 7-11, 2008.

Peluso E, Haut M, Morrow L, Ducatman A, Kuwabara H. Hippocampal volume and functional brain abnormalities associated with chronic organic solvent exposure. Poster presented at the 2008 American Academy of Clinical Neuropsychology convention, Boston, MA, June 2008.

Gerber BJ, Scotti JR, Althouse R, Ducatman AM, Fischer M. Behavioral response of large populations to disaster and terrorism: where will they go? International Society for Traumatic Stress Studies, Baltimore, MD. ISTSS Conference Tracking ID 180248. Poster Session 3, November 17, 2007.

Haut M, Hatfield G, Kuwabara H, Morrow L, Parsons M, Ducatman AM. Solvent-related neuroimaging changes in railroad workers. International New Psychological Society Meeting, February 25, 2005. St. Louis, MO.

Islam S, Hassan M, Doyle E, Becker J, Weikle P, Ducatman A. Quantification of suspected addiction treatment of narcotic analgesics using prescription sequence analysis. Experience of a state-based workers' compensation system (abstr). International Society for Pharmacoeconomic and Outcome Research, Hamburg, Germany. October 25, 2004. Appeared in Value in Health 2004;7:727-8.

Goldberg RL, Vanderploeg J, Wald P, Ducatman AM. American Board of Preventive Medicine Certification Procedure. American Occupational Health Conference, April 29, 1999, New Orleans.

Ducatman AM, Lane DS, Johnson MB, Etzel RA. Preventive Medicine Certification and Recertification. Prevention '99, March 19, 1999, Arlington, VA.

Haut MW, Whyte S, Callahan TS, Ducatman, AM, et al. Verbal working memory in solvent exposure: a PET activation study. Intl neuropsychological society. Honolulu, HI, Feb 6, 1998.

Lombardo LJ, Meyer JD, Haut MW, Islam SS, Haque A, Ducatman AM. The health effects of solvent exposure in railroad workers. J Occup Environ Med 1997; 39:363.

Simoyi P, Islam S, Haque A, Ducatman AM. Evaluation of Occupational injuries among teenage workers in West Virginia. National Occupational Injury Research Symposium (NIOSH), Morgantown, WV, October 15, 1997.

Islam S, Hobbs G, Murray W, Suppa S, Ducatman, AM. Use of Narcotic and Non-Narcotic Analgesic Medications in occupational injuries: analysis of reimbursed prescriptions in a state run Workers' Compensation Database. National Occupational Injury Research Symposium (NIOSH). Morgantown, WV, October 15, 1997.

Islam S, Hobbs G, Haque A, Greenwood J, Bowers C, Ducatman AM. Differences in occupational injuries by gender in West Virginia: Analysis of Workers' Compensation Claims in Database. National Occupational Injury Research Symposium (NIOSH), Morgantown, WV, October 15, 1997.

Haut MW, Ducatman AM, Morrow L, Eckert RK. Neuropsychological functioning in railroad workers exposed to organic solvents. J Intl Neuropsych Soc 1996; 2: 63.

Ducatman AM, Simoyi RM, Emmett MS. Needs of prevention researchers West Virginia. CDC Prevention Center Meeting. Atlanta, GA. February 16-18, 1995.

Simoyi PM, Ducatman AM, et al. Protection and regulatory awareness of Appalachian workers. CDC Prevention Center Meeting. Atlanta, GA. February 16-18, 1995.

Martin KP, Ducatman AM. Actual vs. reported chance of encountering nonchrysotile asbestos types in O & M activities. Health Effects Institute-Asbestos Research, March 8-9, 1995.

Stinson M, Green B, Ducatman AM. Autoclave inactivation of infectious radioactive laboratory waste contained within a charcoal filtration system. 1990 ASM Annual Meeting. Anaheim, CA, May 13-17.

Ducatman AM, Ducatman BS, Barnes JA. Lithium battery health hazard. Aviation, Space and Environ Med 1986; 57:1216.

Ducatman AM. Clusters associated with chemical exposures, their significance and causation. Amer Chem Soc 193rd meeting abstracts. CHAS 46.

Lieberman DF, Fink R, Ducatman AM. The evaluation of toxicity of chemicals and associated health risks for nontechnical workers in biotechnology facilities. International Symposium on Health and Environment in Developing Countries. Haikko, Finland, August 27-30, 1986.

Garland FC, Gorham BA, Garland CF, Ducatman AM. Testicular cancer in U.S. Navy personnel. Am J Epidemiol 1986; 124: 531.

### **Book Reviews**

- Ducatman A. Airborne Hazards Related to Deployment (Book Review). J Occup Environ Med 2016; 58(2): e60
- *Coal River*, by Michael Shnayerson, in the Journal of Occupational and Environmental Medicine 2008; 50:856-7.
- Environmental and Occupational Medicine, 2nd Ed in J Occup Med 1993; 35:1069-1070.
- Dermatotoxicology, 4th ed. in J Occup Medicine 1992; 34:1126-1127.

**Occupational Medicine Forum:** Published in the Journal of Occupational Medicine (major contributions listed).

### **Lerner AJ, Belleville B, Cassidy S, Hawes Clever L, Conage T, Ducatman AM, et al.**

Can jet injector devices transmit pathogens? 1999; 41: 553-4

### **Lerner PJ, Belleville B, Hawes Clever L, Ducatman, AM, et al.**

Can heavy lifting cause epididymitis? 1997; 39:609-610

### **Whorton D, Weisenberger BI, Milroy WC, Hawes Clever L, Ducatman AM, et al.**

Health effects of oxygenated fuels	1993; 35:980
X-ray technician with ulcerative colitis	1993; 35:650-652
Contact lenses in the chemical industry	1993; 35:650-652
Pros and cons of vaccinia immunization	1992; 34:757-758
Trichloroethane and connective tissue disorders	1992; 34:5-8
In-house medical officers	1991; 33:1206
Hepatitis B Immunization	1991; 33:845

### **Perry GF, Brissendon R, Chase KH, Hawes Clever L, Ducatman AM, et al.**

Benzene and Hodgkin's Lymphoma	1990; 32:775
"Environmental Illness"	1990; 32:211
Hepatitis B Vaccination	1990; 32:5
OSHA and the pharmaceutical and biomedical industries	1989; 31:955-956
Risks of Xylene Substitute	1989; 31:202
Headaches in a bookbinding/ Screen-making company	1989; 31:422-423
Reading asbestos exposure films	1989; 31:728-731

### **Anstadt GW, Baker EL, Bender JR, Chase KH, Hawes Clever L, Ducatman AM, et al.**

Contamination from photocopiers	1988; 30:762-766
QMS - Lasergrafix RSI 8024 printer	1987; 29:692
Cutting, sanding, and heat welding polyvinyl chloride	1987; 29:693
Guidelines for use of respirators during pregnancy	1987; 29:782-786
Bacterial growth in eyewash stations	1987; 29:854

### **Anstadt GW, Chase KJ, Hawes Clever L, Ducatman AM, et al.**

Chemical components of diesel fuel	1987; 29:13-14
Vanadium pentoxide exposure	1987; 29:14-17
Screening for hepatic damage	1987; 29:266-267



Research chemist with chronic  
lymphocytic leukemia  
The costs of defensive medicine

1987; 29:268-269  
1986; 28:1132-1136

### **Federal Testimony**

United States Senate, Subcommittee on Clean Air and Nuclear Regulation. Re: Nasopharyngeal Radiation of Military and Civilian Populations. Invited by Senator Joseph I. Lieberman, Sept. 27, 1994.

Court-Appointed Advisory Panel, United States District Court, Eastern and Southern Districts of New York. Re: Johns-Manville Corporation Personal Injury Settlement Trust and Populations of U.S. Asbestos Victims, 1991-1994.

Department of Labor 29CFR1910. Occupational Exposure to Hazardous Chemicals in Laboratories; Final Rule, January 31, 1990; 55 (21): 3314.

### **Areas of Research Interest**

1. Clinical Quality Improvement, with an emphasis on laboratory orders and interdisciplinary teamwork for improvement
2. Occupational/Environmental epidemiology and toxicology, including:
  - Perfluorocarbons
  - Neurotoxicity
  - Environmental health and endocrine disruption
  - Use of administrative data in health services research, including workers' compensation
  - Training and evaluation in preventive medicine and public health
  - Disease Clusters

### **Certificates**

Certificate of Completion NIH Office of Human Studies Research computer-based training course on the Protection of Human Subjects, September 1, 2000, Serial: 967812471. Updated continuously as CITI training.

Annual HIPAA and compliance training.

### **RESEARCH SUPPORT**

#### **Submitted in 2016:**

**Source:** US Environmental Protection Agency  
**Title:** Investigating if Unconventional Oil and Gas Development in the Appalachian Region Impacts Environmental Health  
**Role:** Co-Investigator  
**Outcome:** Funding outcome anticipated May 2017

**Source:** USDHHS-NIH-NIEHS  
**Title:** Cove Point Maryland Liquefied Natural Gas Facility Project  
**Role:** Co-investigator  
**Outcome:** Not funded

**Source:** CDC-ATSDR  
**Title:** Brownfield-to-Trail Redevelopment  
**Role:** Co-investigator  
**Outcome:** Approved, not funded

**Completed****National**

**Source:** NIH/University of Pittsburgh (primary), WVU subrecipient of NIH grant  
**Title:** National Children's Health Study  
**Period:** 9/28/08-9/29/09  
**Amount:** \$673,725  
**Role:** Co-investigator (10%)

**Source:** NIH/University of Pittsburgh (primary), WVU subrecipient of NIH grant  
**Title:** National Children's Health Study  
**Period:** 9/27/07-9/28/08  
**Amount:** \$455,467  
**Role:** Co-investigator (10%)

**Source:** NIOSH/Johns Hopkins University, WVU subrecipient of University of Maryland grant  
**Title:** Occupational Injuries of Developmentally Disabled Sheltered-Workshop Workers in West Virginia  
**Period:** 10/30/07-10/2/09  
**Amount:** \$1,000  
**Role:** Co-investigator

**Source:** Office of Domestic Preparedness  
**Title:** VMC Development Project for Online Training, Access, and Knowledge Resources for Weapons of Mass Destruction: IOC Phase  
**Amount:** \$1,360,959  
**Period:** 9/1/03-3/31/05  
**Role:** Co-Investigator (6 percent)

**Source:** USDHHS  
**Title:** West Virginia Prepares: CE Education Partnership  
**Amount:** \$2,242,659  
**Period:** 9/30/02-9/29/05  
**Role:** Co-Investigator (10 percent)

**Source:** CDC/NIOSH (contract 256809)  
**Title:** Review Database of Chemicals Used in Coal Preparation  
**Amount:** \$2400  
**Period:** 2001-2002  
**Role:** Principal Investigator

**Source:** CDC/NIOSH & University of Pittsburgh (RO1 OHO3646-01A2)  
**Title:** Solvent-Related Functional Brain Abnormalities  
**Amount:** \$227,822  
**Period:** 2001-2004  
**Role:** Co-Investigator (5%)

**Source:** Department of Health and Human Services (DHHS 233-01-0064)  
**Title:** Online Course and Knowledge Base for Improving Local-Level First and Emergency Responders' Coordination of Healthcare Response and Consequence Management for Weapons of Mass Destruction (Virtual Medical Campus)  
**Period:** 10/1/02-3/31/04  
**Amount:** \$258,372  
**Role:** Co-Investigator (10%)



**Source:** CDC/UNC  
**Title:** SE Public Health Training Center Project  
**Period:** 9/1/01-8/31/05  
**Amount:** \$47,000  
**Role:** Co-Investigator; WVU-PI Subrecipient agreement (5%)

**Source:** CDC (H75/CCH322130)  
**Title:** Center for Healthy Communities  
**Period:** 2002-2003  
**Amount:** \$1,997,974  
**Role:** Co-Investigator (5%)

**Source:** CDC/NIOSH (T01/CCT/310455-09)  
**Title:** New Directions in Occupational Health  
**Period:** 2001-2005  
**Amount:** \$292,000/yr (7/1/02-6/30/03)  
**Role:** Co-Investigator (10%)

**Source:** NIOSH  
**Title:** New Directions in Occupational Health  
**Period:** 1997-2001  
**Amount:** \$403,419/yr.  
**Role:** Principal Investigator

**Source:** Centers for Disease Control and Prevention  
**Title:** Work Organization and Depression  
**Period:** 1998-2000  
**Amount:** \$106,923  
**Role:** Co-Investigator and Subrecipient Agreement with University of Maryland

**Source:** Environmental Protection Agency  
**Title:** Occupational Asthma: in and out of the workplace (national conference)  
**Period:** 1998  
**Amount:** \$7,166  
**Role:** Principal Investigator

**Source:** National Institute for Occupational Safety and Health  
**Title:** Workshop on Solvent Exposure among Railroad Workers  
**Period:** 1996 (Nov 7-8)  
**Amount:** \$25,000  
**Role:** Co-Investigator (AOEC grant)

**Source:** National Institute for Occupational Safety and Health - R13/CCR312621-01  
**Title:** Educational Conference on Occupational Safety and Health for Small Business  
**Period:** 1995-1996  
**Amount:** \$12,000 (+ additional state matching funds)  
**Role:** Co-Principal Investigator

**Source:** National Institute for Occupational Safety and Health  
**Title:** New Directions in Occupational Health Training - T01/CCT310455-01  
**Period:** Fiscal Year 1994-1997  
**Amount:** \$488,460/year  
**Role:** Principal Investigator, Director

**Source:** Centers for Disease Control and Prevention  
**Title:** West Virginia University Prevention Center: Addressing the Risk Factors in Rural Appalachia

**Period:** 1994-1998  
**Amount:** \$100,000 of \$1,000,000 grant  
**Role:** Co-Investigator

**Source:** National Institute for Occupational Safety and Health  
**Title:** National Environmental Education and Training Center  
**Period:** 1994-1995  
**Amount:** \$13,500 of \$86,500  
**Role:** Co-Investigator

**Source:** Department of Energy, National Research Center for Coal & Energy  
**Title:** Winfield, WV, Risk Communication  
**Period:** 1994-1995  
**Amount:** \$10,000

**Source:** EPA Hazardous Substance Research Center  
**Title:** Integrating Safety and Waste Management Practices in Laboratory Organizations  
**Period:** January 1991 - January 1992  
**Amount:** \$42,664  
**Role:** Principal Investigator

**Source:** DOE/Oak Ridge Associated Universities  
**Title:** IND for DTPA  
**Period:** 1990-1992  
**Role:** Co Investigator

**Source:** EPA Hazardous Substance Research Center  
**Title:** Hazardous Substance Management Program; Laboratory Safety Training Program - R-815734-01  
**Period:** 3/89 - 3/90  
**Amount:** \$20,000  
**Role:** Principal Investigator

**State**

**Source:** West Virginia Department of Health and Human Resources  
**Title:** GEO-22: Coal Slurry ATSDR Assessment  
**Period:** 4/1/09-3/31/10  
**Amount:** \$221,519  
**Role:** Principal Investigator

**Source:** West Virginia Insurance Commission  
**Title:** WVU Data Analysis Project  
**Period:** 4/1/07-2/29/08  
**Amount:** \$242,627  
**Role:** Principal Investigator

**Source:** West Virginia Insurance Commission  
**Title:** WVU Data Analysis Project  
**Period:** 1/1/07-12/31/07  
**Amount:** \$242,627  
**Role:** Principal Investigator, 10% support

**Source:** West Virginia Higher Education Policy Commission  
**Title:** Health Study of Hardy County  
**Period:** 7/1/05-6/30/07  
**Amount:** \$250,000/yr  
**Role:** Principal Investigator, 10% support

**Source:** WV Workers' Compensation Division  
**Title:** Workers' Compensation Data Analysis  
**Period:** 1/1/06-12/31/06  
**Amount:** \$454,277  
**Role:** Principal Investigator, 10% support

**Source:** West Virginia Insurance Commission  
**Title:** Insurance Commission-WVU Data Analysis Project  
**Period:** 3/1/06-12/31/06  
**Amount:** \$165,683  
**Role:** Principal Investigator, 10% support

**Source:** WV Workers' Compensation Division  
**Title:** Medical Support Project  
**Period:** 7/1/05-12/31/05  
**Amount:** \$353,104  
**Role:** Clinician, 10% support

**Source:** WV Bureau of Employment Programs  
**Title:** Workers' Compensation Data Analysis Project  
**Amount:** \$203,000  
**Period:** 7/1/05-12/31/05  
**Role:** Principal Investigator (10 percent support)

**Source:** WV Workers' Compensation Division  
**Title:** Medical Support Project  
**Amount:** \$706,209  
**Period:** 7/1/04-6/30/05  
**Role:** Clinician (10 percent)

**Source:** WV Bureau of Employment Programs  
**Title:** Workers' Compensation Data Analysis Project  
**Amount:** \$234,855  
**Period:** 7/1/04-6/30/05  
**Role:** Principal Investigator (10 percent, 8% FY 2005)

**Source:** WV Higher Education Policy Commission/WV Economic Development Office  
**Title:** WVU Health Study of Hardy County  
**Amount:** \$250,000  
**Period:** 7/1/03-6/30/05  
**Role:** Principal Investigator (10%)

**Source:** WV Bureau of Employment Programs  
**Title:** Workers' Compensation Data Analysis Project  
**Amount:** \$230,666  
**Period:** 7/1/03-6/30/04  
**Role:** Principal Investigator (10 percent)

**Source:** WV Bureau of Employment Programs  
**Title:** WVU Transitional Medical Support Project  
**Amount:** \$500,019  
**Period:** 7/1/03-6/30/04  
**Role:** Co-Investigator (10 percent)

**Source:** WV Department of Health & Human Resources

**Title:** Childhood Lead Poisoning Prevention project  
**Period:** 7/1/02-6/30/03  
**Amount:** \$10,000/yr (contract)  
**Role:** Principal Investigator (5%)

**Source:** WV Workers' Compensation Division  
**Title:** WVU-Office of Medical Services Support  
**Period:** 1/1/99-6/30/02  
**Amount:** \$1,382,333/yr.  
**Role:** Principal Investigator

**Source:** WV Department of Health & Human Services  
**Title:** Childhood Lead Poisoning Prevention Project  
**Period:** 7/01- 6/02  
**Amount:** \$8,071  
**Role:** Principal Investigator

**Source:** WV Bureau for Employment Programs  
**Title:** Enhanced Approach to Health Care Cost Data Systems and Analysis  
**Period:** 7/1/02-6/30/03 - \$348,416  
1/01-12/01 - \$139,945  
1/99-12/01 - \$378,850  
**Role:** Co-Investigator through 2001; PI in 2002 (15%)

**Source:** WV Workers' Compensation Division  
**Title:** Medical Support and Medical Services Contract  
**Period:** 1/1/03-6/30/03  
**Amount:** \$813,355  
**Role:** Co-Investigator (15%)

**Source:** WV Bureau of Employment Programs  
**Title:** WVU-Office of Medical Services Support  
**Period:** 1/01-6/30/03 - \$1,382,333  
1/01-12/01 - \$1,291,726  
1/99-12/01 - \$3,473,939  
**Role:** Co-Investigator through 2001, Principal Investigator in 2002 (10%)

**Source:** WV Bureau of Employment Programs  
**Title:** Enhanced Approach to Health Care Cost Data Systems and Analysis  
**Period:** 1/01-12/01 - \$139,945  
1/99-12/01 - \$ 378,850  
**Role:** Co-Investigator (5%)

**Source:** WV Bureau of Employment Programs  
**Title:** Assisting Policy (Targeted Analysis Project)  
**Period:** 7/02-12/02 - \$220,614/yr  
7/01-6/02 - \$200,149  
**Role:** Co-Investigator (5%)

**Source:** WV Workers' Compensation Division, Bureau of Employment Programs, RIA/WC Research  
**Title:** Health Care Cost Data Systemization & Analysis Project  
**Period:** 1999-2002  
**Amount:** \$812,039  
**Role:** Principal Investigator

**Source:** WV Workers' Compensation Division

**Title:** Small Business Safety Outreach  
**Period:** 1999-2002  
**Amount:** \$214,968/yr.  
**Role:** Co-Investigator

**Source:** WV Workers' Compensation Division  
**Title:** Targeted Analysis of Outcomes and Effectiveness of Workers' Health Care Services and Interventions  
**Period:** 1999-2002  
**Amount:** \$163,977/yr  
**Role:** Co-Investigator

**Source:** West Virginia Bureau of Employment & Education  
**Title:** Evaluation of Managed Care Occupational Health Service  
**Period:** 1996-99  
**Amount:** \$88,201  
**Role:** Co-Investigator

**Source:** West Virginia Department of Health and Human Services, Bureau for Public Health, CDC grant  
**Title:** Lead Poisoning Prevention  
**Period:** 1998-2001  
**Amount:** \$10,000/yr  
**Role:** Consultant

**Source:** West Virginia Department of Labor, Workers' Compensation Division  
**Title:** Health Care Advisory Panel  
**Period:** 7/92-7/98  
**Amount:** \$10,000/yr  
**Role:** Occupational Medical Illness Protocol

**Source:** West Virginia Bureau of Employment  
**Title:** Trend and Cluster Analysis  
**Period:** 1996-98  
**Amount:** \$55,265  
**Role:** Co-Investigator

**Source:** West Virginia Bureau of Employment  
**Title:** Point of Sale Drug Utilization Review  
**Period:** 1996-98  
**Amount:** \$55,815  
**Role:** Co-Investigator

**Source:** West Virginia Bureau of Employment  
**Title:** Vertically Integrated Intervention Access  
**Period:** 1996-97  
**Amount:** \$284,492  
**Role:** Principal Investigator

### **Corporate and Foundation**

**Source:** Claude Worthington Benedum Foundation  
**Title:** Interprofessional Education: Translating Research into Improved Practice in Rural Hospitals  
**Period:** December 15, 2014 – Dec 15, 2015  
**Amount:** \$10,000  
**Role:** Subrecipient co-principle investigator

**Source:** Health Effects Institute (Professional Services Agreement with WVU)  
**Title:** Special scientific committee on unconventional oil and gas development  
**Period:** August 2014-August 2015  
**Amount:** \$10,500 and related expenses  
**Role:** Participant, document writer, concerning regional and national research needs

**Source:** Claude Worthington Benedum Foundation  
**Title:** Project Hope  
**Period:** 1/1/2014-12/31/2014  
**Amount:** \$150,000 for entire grant, \$50,000 for specific project  
**Role:** Author and project leader for the Quality Clinical Health Care Analytics aim (Suresh Madhavan, PI for entire grant).

**Source:** Claude Worthington Benedum Foundation  
**Title:** WVU School of Public Health Project (20110033 – 2W537)  
**Period:** 4/1/11-9/30/12  
**Amount:** \$185,000  
**Role:** Principal Investigator

**Source:** Brookmar, Inc.  
**Title:** C8 Health Project Supplement  
**Period:** 7/1/08-8/31/08  
**Amount:** \$8,000  
**Role:** Principal Investigator

**Source:** Brookmar, Inc.  
**Title:** Data Hosting for the C8 Health Project  
**Period:** 7/1/06-6/30/08  
**Amount:** \$315,044  
**Role:** Principal Investigator

**Source:** Brookmar, Inc.  
**Title:** Data Hosting for the C8 Health Project  
**Period:** 6/1/06-6/30/08  
**Amount:** \$54,463  
**Role:** Principal Investigator

**Source:** Brookmar, Inc.  
**Title:** Quality Assurance for the C8 Health Project  
**Period:** 7/1/06-6/30/08  
**Amount:** \$37,397  
**Role:** Principal Investigator

**Source:** BrickStreet Mutual Insurance Company  
**Title:** WVU Data Analysis Project  
**Period:** 1/1/08-12/31/08  
**Amount:** \$448,668  
**Role:** Principal Investigator

**Source:** BrickStreet Mutual Insurance Company  
**Title:** BrickStreet Mutual-WVU Data Analysis Project  
**Period:** 1/1/07-12/31/07  
**Amount:** \$417,385  
**Role:** Principal Investigator, 8% support

**Source:** Brookmar, Inc.  
**Title:** C8 Health Projects (several)  
**Period:** 7/25/06-8/31/08  
**Amount:** \$373,510  
**Role:** Principal Investigator (effort varies by subproposal)

**Source:** Brookmar, Inc.  
**Title:** Hourly Consulting for C8 Health Project  
**Period:** 7/1/05-present  
**Amount:** service contracted to UHA  
**Role:** Consultant

**Source:** Brookmar, Inc.  
**Title:** Data Hosting for C8 Health Project  
**Period:** 7/1/06-6/30/08  
**Amount:** \$365,510  
**Role:** Principal Investigator

**Source:** MIT Licensure Agreement with COSTAR  
**Title:** Mixed Waste Disposal OSP #74329  
**Period:** 1989-91  
**Role:** Laboratory Director

### **University**

**Source:** West Virginia University  
**Title:** Summer Research Project for M1 Student: On Line Interactive Resources for Epidemiology  
**Period:** Summer, 1997  
**Amount:** \$1,000  
**Role:** Principal Investigator

**Source:** Medical University of South Carolina  
**Title:** Environmental Consultant to Major DOE grantee  
**Period:** 1994-96  
**Amount:** \$10,000/year  
**Role:** Consultant

**Source:** Office of the Dean of Graduate Studies  
**Title:** Summer Research Project for M1 Student: State Policy for Controversial Compensable Diagnosis  
**Period:** Summer, 1996  
**Amount:** \$2,000  
**Role:** Principal Investigator

### **PROFESSIONAL AFFILIATIONS**

#### **Current Professional and Scientific Organizations and Societies**

- **Fellow**, American College of Occupational Medicine
- **Fellow**, American College of Physicians
- American Teachers of Preventive Medicine

### **Offices in Professional and Accreditation Organizations**

2012-2014	Member, West Virginia State Public Health Assessment Advisory Group
1999-2004	Chair, Residency Review Committee, Preventive Medicine. Accreditation Council on Graduate Medical Education
1999-2001	Steering Committee, SE Public Health Leadership Institute (NC, SC, TN, VA & WV)
1988-92	Council on Scientific Affairs, American College of Occupational Medicine
1988-93	Chair, Occupational & Clinical Toxicology Committee, American College of Occupational Medicine
1993-2002	Trustee, American Board of Preventive Medicine
1986-2003	Occupational Medicine Practice Committee, American College of Occupational Medicine

### **National/International Committees of Professional Organizations or Foundations**

- International Agency for Research on Cancer (IARC). IARC Monographs Working Group for Volume 115 – “Some Industrial Chemicals.” Lyon, France. March 2016
- Health Effects Institute. Unconventional Special Committee on unconventional oil and gas development. 2014-2015
- American College of Occupational and Environmental Medicine. Environmental Medicine Committee. 1992-2002
- American National Standards Institute (ANSI). Medical Surveillance Subcommittee Z136, Safe use of lasers. 1989-1992.
- American College of Occupational and Environmental Medicine, Practice Committee, 1985-94
- Office of Science and Technology Policy. Study on Risk Assessment, 1985-1986.

### **HONORS AND AWARDS**

- First author publication cited among “Compilation of Best Papers, 1979-1991.” J Occup Environ Med 2016; 58(2); 111-13
- Appointed, Best Doctors in America, November 2015
- Inducted as faculty to WVU chapter of Delta Omega, the national honor society in public health, May 2014
- Appointed to the Governor’s Advisory Council on Substance Abuse, August 2011.
- Appointed Guest Researcher, National Institute of Occupational Safety and Health (NIOSH), September 2010.
- NCEH/ATSDR (National Center for Environmental Health and Agency for Toxic Substances and Disease Registry, CDC) Director’s Award for Outstanding Service, October 2008.
- The Department of Community Medicine was selected as the “Health Care Heroes” for the state of West Virginia, August 2008.
- Invited attendee, NIOSH Digital Imaging Workshop, March 11-13, 2008, Rockville, MD.
- Appointed Chair, Board of Scientific Counselors, National Center for Environmental Health/Agency for Toxic Substances and Disease Registry, 2007.
- Selected as one of the Best Doctors in America, by Best Doctors, Inc., Aiken, SC (2007-2010).
- Nominated to the US Task Force on Community Prevention Services, CDC, 2006.
- Appointed by the US Secretary for Health and Human Services to the Board of Scientific Counselors, National Center for Environmental Health/Agency for Toxic Substances and Disease Registry, 2006.
- Appointed Clinical Professor, West Virginia School of Osteopathic Medicine, 2004.
- Department of Community Medicine: Dean’s Award for Excellence in Research, 2002.
- Certificate of Appreciation for Service to the West Virginia Public Health Association, 2000.
- On behalf of Department of Community Medicine, State Health Education Award for Outstanding Organizational Leadership to SHEC and Health Promotion in West Virginia, 1999.
- Certificate of Appreciation, Service to the Executive Council, West Virginia Public Health Association, 1999.
- Robert A. Kehoe Award of Merit, American College of Occupational and Environmental Medicine, 1998.
- Harriet Hardy Award for the physician who exemplifies the highest ideals of occupational and environmental medicine. New England College of Occupational and Environmental Medicine, 1997.



- Adolph H. Kammer Merit in Authorship Award, American College of Occupational and Environmental Medicine, 1994.
- Top Ten Percent Award, Teachers of Introduction to Clinical Medicine, West Virginia University, 1994.
- Robert J. Hilker Lectureship Award, American College of Occupational and Environmental Medicine, 1993.
- Navy Achievement Medal, 1984
- Navy Letters of Commendation (several)
- Finalist, Leo Friend Award for Best Professional Paper, 1988
- Fellow, American College of Occupational Medicine
- Fellow, American College of Physicians

### **Postgraduate Presentations and Teaching**

**Invited CDC/ATSDR presentation.** PFAS: Findings, Gaps, Opportunities. Atlanta, GA May 17, 2018

**Grand Rounds WVU Department of Medicine.** 25 Years of Toxic Exposures in WV. Morgantown WV, April 13, 2018

**Association of Pathology Chairs 2017 Annual Meeting.** (Podium Presentation): Use of laboratory data to improve high value care in the diagnosis of myocardial infarction. Washington, DC, July 26, 2017.

**Highly Fluorinated Compounds – Social and Scientific Discovery.** (Podium Presentation): State of the Science on PFAS. Boston, MA, June 14, 2015.

**American College of Nutrition** (Podium Presentation): Personal poisons: the role of nutrition. San Diego, CA. November 10, 2016

**Inter-professional Education Speaker Series:** Across professions and institutions, what does it take to improve care? August 26, 2016, at West Virginia University

**WV Data for Improving Clinical Orders.** Panel address to WV Choosing Wisely Quality Improvement meeting. Charleston, WV. Sponsored by CAMC Institute and West Virginians for Affordable Health Care, May 6, 2015

**Toxicologic Challenges: Population and Occupational Health Risks.** Keynote address to the 28<sup>th</sup> Annual meeting of the Allegheny-Erie Society of Toxicology Regional Chapter. May 16, 2014

**West Virginia's Public Health: What Can We Achieve?** Keynote address to the West Virginia Public Health Association Annual Conference, September 19, 2012.

**Coal Slurry Waste Underground Injection Study.** Presented to the Joint Committee on Water Resources of the WV Legislature, August 9 and 10, 2010 (two presentations).

**Air Pollution and Climate Change.** Presented to PUBH 605: Introduction to International Public Health, June 16, 2010.

**Environmental Issues in West Virginia.** Presented to the Occupational Medicine Grand Rounds, December 1, 2009.

**Secondhand Smoke, Primary Prevention.** Presented to the Department of Medicine Grand Rounds, October 20, 2009.

**Environmental Questions and Community Concerns: The Role of Public Health Research.** Presented to PUBH 706: Current Research Issues, August 27, 2009.

**Air Pollution and Climate Change.** Presented to PUBH 605: Introduction to International Public Health, June 10, 2009.

**Environmental Issues in West Virginia.** Presented to the Occupational Medicine Grand Rounds, May 12, 2009.

**From the Mountains to the Valleys: Recent Environmental Issues in West Virginia.** Presented to the Department of Medicine Grand Rounds, February 20, 2009.

**Low Back Pain.** Presented to the Occupational Medicine Grand Rounds, November 11, 2008.

**Environmental Health Issues in West Virginia.** Presented to the Annual Conference of the West Virginia Public Health Association, September 17, 2008.

**Lead and Health.** Presented to the Occupational Medicine Grand Rounds, August 26, 2008.

**Air Pollution and Climate Change.** Presented to PUBH 605: Introduction to International Public Health, June 11, 2008.

**Pandemic Influenza.** Presented to CCMD 712: Epidemiology and Biostatistics (for medical students), November 1, 2007.

**Air Quality.** (Television presentation, seen in Clarksburg/Morgantown – WBOY, Huntington/Charleston – WOWK, Wheeling/Steubenville – WTRF, Beckley/Bluefield/Lewisburg – WVNS), June 11, 2007.

**Asbestos in Buildings and Health Effects.** Public Health Grand Rounds. November 30, 2006. Simulcast, web-archived, and used for training at WVU. Used by permission at other universities.

**Influenza: Preparing to Prevent a Pandemic Disaster – Pandemic and Other Public Health Concerns.** The Tuberculosis Association of Ohio County (WV), November 14, 2006.

**Toxic Industrial Symposium** (ATSDR and WV Poison Center, Charleston, WV). Toxic Industrial Chemicals. September 11, 2006.

**State Health Education Council of West Virginia.** Trails to a Healthy West Virginia: Pandemic Flu and Mass Migration. May 3, 2006.

**Southeast Public Health Leadership Center.** Disease Clusters, Causation, and Common Sense. Teleconference, February 16, 2005.

**Wheeling-Charleston Diocese, Appalachian Institute.** Health: A Comprehensive Checkup for Rural West Virginia. Being Well in Rural West Virginia Conference. Bishop Hodges Pastoral Center, Huttonsville, WV. April 22, 2005.

**US National Conservation Training Center.** Emerging Contaminants and Water Supply Workshop. Environmental questions and Community Concerns: The Role of Public Health Research. September 19, 2005.

**Biology Department Invited Seminar.** Hardy County Research Findings and Plans. October 17, 2005.

**Parkersburg Academy of Medicine.** Pandemics. November 8, 2005.

**Public Health Grand Rounds.** Influenza: Preparing to Prevent a Pandemic Disaster. December 8, 2005.

**Hardy County (West Virginia) Health Care Professionals.** Cancer and Other Health Outcomes in Hardy County. Moorefield, WV. November 15, 2004. (Grant funded, 30 attendees).

**West Virginia Public Health Association.** Epidemiology of Disease Clusters. Huntington, WV. September 23, 2004.

**American Association of Legal Nurse Consultants Fifteenth National Educational Conference.** Disease clusters, causation, and common sense. Chicago, IL, April 1, 2004.

**Respiratory Risk Factors in a Rural State.** West Virginia Lung Association, Morgantown, WV. March 27, 2004.

**Media Science Forum: Making Prevention Research News.** Research America! And the West Virginia Prevention Research Center (panelist).

**Molds.** Pediatrics Grand Rounds. December 17, 2003.

**Gatekeepers' Response to a Bioterrorism Attack.** Eighth Annual Mountain Retreat, Snowshoe, WV. September 18, 2004.

**Healthy West Virginia Summit 2003.** Preventing chronic illness: closing the gap between research and prevention. August 4, 2003, Stonewall Resort, Lewis County, WV.

**West Virginia Bar Association.** Understanding disease clusters and causation in environmental medicine. Greenbrier Hotel, White Sulphur Springs, WV, July 12, 2003.

**WAJR, Morgantown, WV. ("Talk Radio").** Mold. April 3, 2003.

**National Institute of Occupational Safety and Health.** Best Practices in Workplace Surveillance Conference. Identification and tracking of workplace injury. Illness, exposure, and hazards. A system for rapid analysis of transactional insurance data to identify trends in costs of work-related injuries. Cincinnati, OH, November 2001.

**American Occupational Health Conference** on behalf of ACOEM Millennium Series: Occupational Disease. San Francisco, CA, April 2001.

**Massachusetts Medical Society.** Environmental Issues in Clinical Practice. Cluster Analysis in Environmental Medicine. Boston, MA. Earth Day, April 22, 2001.

**Governor's Occupational Safety and Health Conference (PA).** "What's new in workers' health?" Hershey, PA, October 29, 2001

**Fifth Annual Cost-Effectiveness Evaluation and Management of Low Back Pain Conference.** The epidemiology of low back injuries. Morgantown, WV, November 5, 1999.

**75<sup>th</sup> West Virginia Public Health Association Meeting.** Health Effects of Air Pollution, Canaan Valley, WV, September 23, 1999

Sentinel Events in the Clinic. **Cleveland Clinic Foundation**, Cleveland, OH, June 4, 1998.

Lead Poisoning, Issues and Treatment. **Northern Panhandle Childhood Lead Poisoning Prevention Project**, Wheeling, WV, May 14, 1998.

Occupational Asthma: in and out of the workplace. **NIOSH-West Virginia University Conf.** Session Co-Chair Overview and Clinical Session, Morgantown, WV, April 30, 1998.

Core Curriculum in Environmental Medicine. **American College of Occupational and Environmental Medicine**, Nashville, TN, October 30-31, 1998.

Coping in the Trenches. **New England College of Occupational and Environmental Medicine**, Boston, MA, December 5, 1997.

Inhalation and Toxicity Injuries. **West Virginia University School of Medicine**. Emergency Medicine Grand Rounds, October 2, 1997.

Multiple Chemical Sensitivity. **AASCIF Claims/Rehab. Seminar**, Charleston, WV, September 18, 1997.

Occupational and Environmental Cluster Management. **American College of Occupational and Environmental Medicine**. Orlando, FL, May 13, 1997.

Occupational Asthma. **Tri-State Medical Association**. Lakeview, WV, September 27, 1996.

Laser eye injuries in academic research settings. **NIOSH Division of Safety Research**. Morgantown, WV, August 15, 1996.

Pesticides: Health-related issues. **Assoc. Southern Feed, Fertilizer, and Pesticide Control Officials**. Lakeview Conference Center, Morgantown, WV, June 18, 1996.

Low-dose risks, reproductive hazards, and risk assessment. **Medical University of South Carolina, Department of Family Medicine**. Spoleto Festival. Charleston, SC, May 25, 1996.

Epidemiology and cluster assessment. **American College of Occupational and Environmental Medicine**. Core Curriculum in Environmental Medicine. Alexis Park Resort, Las Vegas, May 6-7, 1995 and San Antonio, TX, April 27-28, 1996.

"Twitchy airways in the 21st century." **Industrial Health Foundation Conference**. Occupational Health Issues of the Next Decade. Orlando, FL, March 28, 1996.

The wherefore of risk assessment and discussion. **Medical University of South Carolina Environmental Hazards Assessment Program**. Charleston, SC, October 26, 1995.

Risk in the practice of medicine and risk assessment as it extends to the community. **Medical University of South Carolina Environmental Hazards Assessment Program**. Charleston, SC, October 26, 1995.

Air Pollution (outdoor). **American College of Occupational and Environmental Medicine**. Environmental exposures and susceptibility: a clinical and policy focus. Las Vegas, May 4, 1995.

Three mini-epidemics: goodwill and regulation. **US Dept of Labor**, Occupational Safety and Health Administration, Washington, DC, April 24, 1995.

Public Health in the Clinic: Three West Virginia Mini-epidemics. Internal Medicine Grand Rounds. **West Virginia University**, Morgantown, WV, March 31, 1995.

Disease clusters & causation. **Michigan Occupational and Environmental Medicine Association**. Lansing, MI, June 3, 1994.

Keynote address: Health care reform, you, and me. Mixed chemical exposures. **Midwest Center for Occupational Health and Safety**. Minneapolis, MN, March 15-16, 1994.

Occupational physician in environmental health. **Southern Medical Association**. 87th Annual Scientific Assembly, New Orleans, October 19, 1993.

Introduction to environmental medicine (ATSDR-sponsored course). **American College of Occupational/Environmental Medicine**. State of the Art Conference. Dallas, TX, October 27, 1993.

Between "B"-ing and nothingness (The ILO system). **CDC-NIOSH**, invited speaker. Morgantown, WV, July 14, 1993.

Occupational Health and Environmental Medicine: comparisons, not contrasts. **CSOMA Robert J. Hilker, MD, Award Lecture**. Chicago, March 19, 1993.

Occupational Epidemiology. **Thirty-fourth Navy Occupational Health and Preventive Medicine Workshop**. Norfolk, VA, February 27, 1993.

Occupational health and the primary care physician. **Philadelphia County Medical Society**. October 19, 1992.

Environmental Medicine: What it is and isn't. **American Occupational Health Conference**. Washington, DC, May 6, 1992.

Workplace cancer clusters: causation and the limits of technical common sense. **Semiconductor Safety Association**, 14th Annual Meeting, Phoenix, AZ. April 6, 1992.

Disease clusters: environmental causation and common sense. **MIT-Lincoln Laboratory Distinguished Lecture Series**. Lexington, MA, March 18, 1992.

Grand Rounds. **Baystate Medical Center**, Springfield, MA, March 11, 1992.

Keynote Address: Occupational Environmental Medicine: Comparisons and Contrasts. **American College of Occupational Medicine State of the Art Conference**. St. Louis, MO, October 30, 1991.

Introduction. Conference on Laboratory Waste Management. **Massachusetts Institute of Technology**, Cambridge, MA, October 24, 1991.

Solvents in the workplace. Hazard Control in Semiconductor Manufacturing. **Semiconductor Industry Association**. Westborough, MA, October 17, 1991.

Biotechnology Industry Issues: Genetic Engineering and Worker Health. **American College of Occupational Medicine**. San Francisco, CA. May 2, 1991.

Epidemiology of Toxic Clusters. Neurology in the 1990's, **Harvard Medical School**. Boston, MA, March 23, 1991.

OSHA Laboratory Standard: Regulation of Toxic Substances in Laboratories and Waste Management in Laboratories. U.S. Dept of Commerce, **National Institute of Standards and Technology**. Gaithersburg, MD, Sept. 26, 1990.

Variability in interpretation of radiographs of x-rays for asbestos abnormalities: problems and solutions. **Collegium Ramazzini**. The Third Wave of Asbestos Disease. New York. June 7, 1990.

Workplace Medical Surveillance: Goals, Principles, and Breaking the Rules. **American Chemical Society**, Division of Chemical Health and Safety. Boston, MA, April 24, 1990.

Occupational Health Aspects of Biotechnology. **Society for Occupational and Environmental Health**. Washington, DC, April 24, 1990.

Approaching a Cancer Cluster. Thirty-Second Environmental Health Center Conference. **United States Navy**, Virginia Beach, VA. March 23, 1990.

Cancer Clusters. The Charles A. Dana Seminar Series in Environmental Epidemiology. New York, **Mt. Sinai Medical School**, February 16, 1990.

Conference on Laboratory Waste Management (conference organizer, supported by EPA #R-815734-01.) **Massachusetts Institute of Technology**, Cambridge, MA, January 31, 1990.

Protecting research laboratory workers. **American College of Occupational Medicine Conference**. Boston, MA, May 5, 1989.

Postgraduate seminar: Medical Surveillance Programs. **American College of Occupational Medicine Conference**. Boston, MA, May 1, 1989.

Biotechnology and Occupational Health. **American Public Health Association**. Annual Meeting, Boston, MA, November 14, 1988.

**Eighth International Pneumoconiosis Conference**. Pittsburgh, PA, August 23-26, 1988.

1. "B-Readers" and asbestos medical surveillance
2. Smoking and radiologic opacities in U.S. Navy asbestos workers
3. Asbestos medical surveillance population: predominant left-sided location of unilateral plaques

Asbestos medical surveillance: clinical and radiographic basis. **American Occupational Medical Association Conference**. New Orleans, LA, April 29, 1988.

Clusters, environmental causation, and common sense. **American Occupational Medical Association Conference**. New Orleans, LA, April 27, 1988.

Grand Rounds: Disease Clusters. **Mount Auburn Hospital**. Cambridge, MA, July 14, 1988.

Government regulation and occupational exposures of biotechnology researchers and production staff. Biotechnology, Regulation, and Human Health Symposium. **Massachusetts Institute of Technology**, August 7, 1987.

Risks from lithium batteries. The New Technologies Health and Safety Institute. **Worcester Polytechnic Institute**. Worcester, MA, May 28, 1987.

Occupational Health Issues in Biotechnology. **American Occupational Medical Association Conference**. Philadelphia, PA, April 1987.

An occupational physician looks at low back pain. Environmental Health Center Annual conference. **United States Navy**. Virginia Beach, VA, April 1984.

Potential health hazards of lithium manganese oxide and lithium carbon monofluoride batteries. **Power Sources Symposium**. Cherry Hill, NJ, June 1984.

Recognition of disease caused by chemical exposure: taking the history. Risk Management of Toxic Substances: Recognition, Prevention, Potential Liability. The **Hampton Institute** Center for Marine and Coastal Studies. Hampton, VA, July 1984.

Potential health hazards of lithium thionyl chloride batteries. **Lithium Battery Tri-Service Working Group**. San Diego, CA, February 1984.

Worker fitness and health responsibilities. **American Public Works Association**. Minneapolis, MN, May 1983.

Neurotoxicity of industrial solvents. Current Concepts for Cardiopulmonary and Occupational Medicine, **Midwest Center for Occupational Health**, St. Paul, MN, March 1983.

PCB's, PBB's, Dibenzodioxins, and resources for assistance. Medical and Legal Management of Workplace Health Concerns. **Midwest Center for Occupational Health**. Minneapolis, MN, November 1982.

## **OTHER ACTIVITIES**

### **Community Activities:**

- . Provided public comments to State of NJ Drinking Water Quality Institute available on line at [http://www.nj.gov/dep/watersupply/g\\_boards\\_dwqi.html](http://www.nj.gov/dep/watersupply/g_boards_dwqi.html)
- Southwest Pennsylvania Environmental Health Project ([www.environmentalhealthproject.org](http://www.environmentalhealthproject.org)). Scientific Advisory Committee Member, 2016-December, 2018)
- Public Comments Submitted: Health-Based Maximum Contaminant Level Support Document: Perfluorooctanoic acid (PFOA) (See Response to Public Comments available at: <http://www.nj.gov/dep/watersupply/pdf/pfoa-appendixd.pdf> )
- Pathology and Population Health Steering Committee for the Association of Pathology Chairs, 2016-17.
- United Way Volunteer Leader, WVU School of Medicine Faculty, 2004
- Troop 62 Committee, Boy Scouts of America, Morgantown, WV, 1996-97
- Emergency Planning Boards, Cities of Cambridge and Lexington, MA, 1989-1992
- Environmental Hazards of Fires (lecture series) City of Cambridge, MA, Fire Department, 1990, 1992
- Health Right Free Clinic, Morgantown, WV Environmental Consultant, 1992-1994
- Numerous lectures to community groups, religious organizations, senior citizen groups, rotary clubs, PTAs, boards of education, etc., concerning environmental health and safety.
- Community Health Advocacy and Transformation Team. Monongalia County Health Department, 1997-98.



EXHIBIT B TO DECLARATION OF ALAN  
DUCATMAN, M.D. IN SUPPORT OF  
PLAINTIFFS' MOTION FOR CLASS  
CERTIFICATION

NYDEC Private Well Sampling Results  
(18 pages)

EXHIBIT SUBJECT TO PENDING MOTION  
TO SEAL FILED ON APRIL 6, 2020



EXHIBIT C TO DECLARATION OF ALAN  
DUCATMAN, M.D. IN SUPPORT OF  
PLAINTIFFS' MOTION FOR CLASS  
CERTIFICATION

NYSDOH Blood Testing Results  
(72 pages)

EXHIBIT SUBJECT TO PENDING MOTION  
TO SEAL FILED ON APRIL 6, 2020

# **EXHIBIT D**

EXHIBIT D

REFERENCE LIST

1. Frisbee SJ, Brooks AP, Jr., Maher A, et al. The C8 health project: design, methods, and participants. *Environ Health Perspect.* 2009;117(12):1873-1882.
2. Emmett EA, Shofer FS, Zhang H, Freeman D, Desai C, Shaw LM. Community exposure to perfluorooctanoate: relationships between serum concentrations and exposure sources. *J Occup Environ Med.* 2006;48(8):759-770.
3. Winqvist A, Lally C, Shin HM, Steenland K. Design, methods, and population for a study of PFOA health effects among highly exposed mid-Ohio valley community residents and workers. *Environ Health Perspect.* 2013;121(8):893-899.
4. Raymond J, Brown MJ. Childhood blood lead levels in children aged <5 years -United States, 2009-2014. *MMWR Surveill Summ.* 2017;66(3):1-10.
5. Wones R, Pinney SM, Buckholz JM, Deck-Tebbe C, Freyberg R, Pesce A. Medical monitoring: a beneficial remedy for residents living near an environmental hazard site. *J Occup Environ Med.* 2009;51(12):1374-1383.
6. Signorini S, Gerthoux PM, Dassi C, et al. Environmental exposure to dioxin: the Seveso experience. *Andrologia.* 2000;32(4-5):263-270.
7. Noonan CW, Conway K, Landguth EL, et al. Multiple pathway asbestos exposure assessment for a Superfund community. *J Expo Sci Environ Epidemiol.* 2015;25(1):18-25.
8. Olsen GW, Burris JM, Ehresman DJ, et al. Half-life of serum elimination of perfluorooctanesulfonate, perfluorohexanesulfonate, and perfluorooctanoate in retired fluorochemical production workers. *Environ Health Perspect.* 2007;115(9):1298-1305.
9. Fabrega F, Kumar V, Schuhmacher M, Domingo JL, Nadal M. PBPK modeling for PFOS and PFOA: Validation with human experimental data. *Toxicol Lett.* 2014.
10. Perez F, Nadal M, Navarro-Ortega A, et al. Accumulation of perfluoroalkyl substances in human tissues. *Environ Int.* 2013;59:354-362.
11. Karrman A, Domingo JL, Llebaria X, et al. Biomonitoring perfluorinated compounds in Catalonia, Spain: concentrations and trends in human liver and milk samples. *Environ Sci Pollut Res Int.* 2010;17(3):750-758.
12. Steenland K, Jin C, MacNeil J, et al. Predictors of PFOA levels in a community surrounding a chemical plant. *Environ Health Perspect.* 2009;117(7):1083-1088.
13. Steenland K, Tinker S, Frisbee S, Ducatman A, Vaccarino V. Association of perfluorooctanoic acid and perfluorooctane sulfonate with serum lipids among adults living near a chemical plant. *Am J Epidemiol.* 2009;170(10):1268-1278.

14. Nelson JW, Hatch EE, Webster TF. Exposure to polyfluoroalkyl chemicals and cholesterol, body weight, and insulin resistance in the general U.S. population. *Environ Health Perspect.* 2010;118(2):197-202.
15. Frisbee SJ, Shankar A, Knox SS, et al. Perfluorooctanoic acid, perfluorooctanesulfonate and serum lipids in children and adolescents: results from the C8 Health Project. *Arch Pediatr Adolesc Med.* 2010;164(9):860-869.
16. Geiger SD, Xiao J, Ducatman A, Frisbee S, Innes K, Shankar A. The association between PFOA, PFOS and serum lipid levels in adolescents. *Chemosphere.* 2013.
17. Eriksen KT, Raaschou-Nielsen O, McLaughlin JK, et al. Association between plasma PFOA and PFOS levels and total cholesterol in a middle-aged Danish population. *PLoS One.* 2013;8(2):e56969.
18. Lopez-Espinosa MJ, Fitz-Simon N, Bloom MS, Calafat AM, Fletcher T. Comparison between free serum thyroxine levels, measured by analog and dialysis methods, in the presence of perfluorooctane sulfonate and perfluorooctanoate. *Reprod Toxicol.* 2012;33(4):552-555.
19. Fletcher T, Galloway TS, Melzer D, et al. Associations between PFOA, PFOS and changes in the expression of genes involved in cholesterol metabolism in humans. *Environ Int.* 2013;57-58:2-10.
20. Jain RB. Contribution of diet and other factors to the levels of selected polyfluorinated compounds: Data from NHANES 2003–2008. *International Journal of Hygiene and Environmental Health.* 2014;217(1):52-61.
21. Starling AP, Engel SM, Whitworth KW, et al. Perfluoroalkyl substances and lipid concentrations in plasma during pregnancy among women in the Norwegian Mother and Child Cohort Study. *Environ Int.* 2013;62C:104-112.
22. Fu Y, Wang T, Fu Q, Wang P, Lu Y. Associations between serum concentrations of perfluoroalkyl acids and serum lipid levels in a Chinese population. *Ecotoxicol Environ Saf.* 2014;106:246-252.
23. Winquist A, Steenland K. Modeled PFOA exposure and coronary artery disease, hypertension, and high cholesterol in community and worker cohorts. *Environ Health Perspect.* 2014;122(12):1299-1305.
24. Zeng XW, Qian Z, Emo B, et al. Association of polyfluoroalkyl chemical exposure with serum lipids in children. *Sci Total Environ.* 2015;512-513:364-370.
25. Skuladottir M, Ramel A, Rytter D, et al. Examining confounding by diet in the association between perfluoroalkyl acids and serum cholesterol in pregnancy. *Environ Res.* 2015;143(Pt A):33-38.
26. Maisonet M, Nayha S, Lawlor DA, Marcus M. Prenatal exposures to perfluoroalkyl acids and serum lipids at ages 7 and 15 in females. *Environ Int.* 2015;82:49-60.

27. Kishi R, Nakajima T, Goudarzi H, et al. The association of prenatal exposure to perfluorinated chemicals with maternal essential and long-chain polyunsaturated fatty acids during pregnancy and the birth weight of their offspring: The Hokkaido Study. *Environ Health Perspect.* 2015;123(10):1038-1045.
28. Sakr CJ, Kreckmann KH, Green JW, Gillies PJ, Reynolds JL, Leonard RC. Cross-sectional study of lipids and liver enzymes related to a serum biomarker of exposure (ammonium perfluorooctanoate or APFO) as part of a general health survey in a cohort of occupationally exposed workers. *J Occup Environ Med.* 2007;49(10):1086-1096.
29. Lin CY, Lin LY, Chiang CK, et al. Investigation of the associations between low-dose serum perfluorinated chemicals and liver enzymes in US adults. *Am J Gastroenterol.* 2010;105(6):1354-1363.
30. Gallo V, Leonardi G, Genser B, et al. Serum perfluorooctanoate (PFOA) and perfluorooctane sulfonate (PFOS) concentrations and liver function biomarkers in a population with elevated PFOA exposure. *Environ Health Perspect.* 2012;120(5):655-660.
31. Gleason JA, Post GB, Fagliano JA. Associations of perfluorinated chemical serum concentrations and biomarkers of liver function and uric acid in the US population (NHANES), 2007-2010. *Environ Res.* 2014;136c:8-14. 3
32. Yamaguchi M, Arisawa K, Uemura H, et al. Consumption of seafood, serum liver enzymes, and blood levels of PFOS and PFOA in the Japanese population. *J Occup Health.* 2013;55(3):184-194.
33. Grandjean P, Andersen EW, Budtz-Jorgensen E, et al. Serum vaccine antibody concentrations in children exposed to perfluorinated compounds. *JAMA.* 2012;307(4):391-397.
34. Looker C, Luster MI, Calafat AM, et al. Influenza vaccine response in adults exposed to perfluorooctanoate and perfluorooctanesulfonate. *Toxicol Sci.* 2014;138(1):76-88.
35. Grandjean P, Heilmann C, Weihe P, Nielsen F, Mogensen UB, Budtz-Jorgensen E. Serum vaccine antibody concentrations in adolescents exposed to perfluorinated compounds. *Environ Health Perspect.* 2017.125(7): 077018
36. Dalsager L, Christensen N, Husby S, et al. Association between prenatal exposure to perfluorinated compounds and symptoms of infections at age 1-4 years among 359 children in the Odense Child Cohort. *Environ Int.* 2016;96:58-64.
37. Goudarzi H, Miyashita C, Okada E, et al. Prenatal exposure to perfluoroalkyl acids and prevalence of infectious diseases up to 4years of age. *Environ Int.* 2017.
38. Timmermann CA, Budtz-Jorgensen E, Jensen TK, et al. Association between perfluoroalkyl substance exposure and asthma and allergic disease in children as modified by MMR vaccination. *J Immunotoxicol.* 2017;14(1):39-49.

39. Granum B, Haug LS, Namork E, et al. Pre-natal exposure to perfluoroalkyl substances may be associated with altered vaccine antibody levels and immune-related health outcomes in early childhood. *J Immunotoxicol.* 2013;10(4):373-379.
40. Steenland K, Tinker S, Shankar A, Ducatman A. Association of perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate (PFOS) with uric acid among adults with elevated community exposure to PFOA. *Environ Health Perspect.* 2010;118(2):229-233.
41. Geiger SD, Xiao J, Shankar A. Positive association between perfluoroalkyl chemicals and hyperuricemia in children. *Am J Epidemiol.* 2013;177(11):1255-1262.
42. Kataria A, Trachtman H, Malaga-Dieiguez L, Trasande L. Association between perfluoroalkyl acids and kidney function in a cross-sectional study of adolescents. *Environ Health.* 2015;14:89.
43. Qin XD, Qian Z, Vaughn MG, et al. Positive associations of serum perfluoroalkyl substances with uric acid and hyperuricemia in children from Taiwan. *Environ Pollut.* 2016;212:519-524.
44. Melzer D, Rice N, Depledge MH, Henley WE, Galloway TS. Association between serum perfluorooctanoic acid (PFOA) and thyroid disease in the U.S. National Health and Nutrition Examination Survey. *Environ Health Perspect.* 2010;118(5):686-692.
45. Knox SS, Jackson T, Frisbee SJ, Javins B, Ducatman AM. Perfluorocarbon exposure, gender and thyroid function in the C8 Health Project. *J Toxicol Sci.* 2011;36(4):403-410.
46. Piralì B, Negri S, Chytiris S, et al. Perfluorooctane sulfonate and perfluorooctanoic acid in surgical thyroid specimens of patients with thyroid diseases. *Thyroid.* 2009;19(12):1407-1412.
47. Lopez-Espinosa MJ, Mondal D, Armstrong B, Bloom MS, Fletcher T. Thyroid function and perfluoroalkyl acids in children living near a chemical plant. *Environ Health Perspect.* 2012;120(7):1036-1041.
48. Wen LL, Lin LY, Su TC, Chen PC, Lin CY. Association between serum perfluorinated chemicals and thyroid function in U.S. adults: the National Health and Nutrition Examination Survey 2007-2010. *J Clin Endocrinol Metab.* 2013;98(9):E1456-1464. 4
49. Jain RB. Association between thyroid profile and perfluoroalkyl acids: data from NHNAES 2007-2008. *Environ Res.* 2013;126:51-59.
50. Winqvist A, Steenland K. Perfluorooctanoic acid exposure and thyroid disease in community and worker cohorts. *Epidemiology.* 2014;25(2):255-264.
51. Webster GM, Rauch SA, Marie NS, Mattman A, Lanphear BP, Venners SA. Cross-Sectional Associations of Serum Perfluoroalkyl Acids and Thyroid Hormones in U.S. Adults: Variation According to TPOAb and Iodine Status (NHANES 2007-2008). *Environ Health Perspect.* 2016;124(7):935-942.

52. Coperchini F, Awwad O, Rotondi M, Santini F, Imbriani M, Chiovato L. Thyroid disruption by perfluorooctane sulfonate (PFOS) and perfluorooctanoate (PFOA). *J Endocrinol Invest.* 2017;40(2):105-121.
53. Kim S, Choi K, Ji K, et al. Trans-placental transfer of thirteen perfluorinated compounds and relations with fetal thyroid hormones. *Environ Sci Technol.* 2011;45(17):7465-7472.
54. Webster GM, Venners SA, Mattman A, Martin JW. Associations between Perfluoroalkyl acids (PFASs) and maternal thyroid hormones in early pregnancy: a population-based cohort study. *Environ Res.* 2014;133:338-347.
55. Yang L, Li J, Lai J, et al. Placental transfer of perfluoroalkyl substances and associations with thyroid Hormones: Beijing prenatal exposure study. *Sci Rep.* 2016;6:21699.
56. Kim DH, Kim UJ, Kim HY, Choi SD, Oh JE. Perfluoroalkyl substances in serum from South Korean infants with congenital hypothyroidism and healthy infants--Its relationship with thyroid hormones. *Environ Res.* 2016;147:399-404.
57. de Cock M, de Boer MR, Lamoree M, Legler J, van de Bor M. Prenatal exposure to endocrine disrupting chemicals in relation to thyroid hormone levels in infants - a Dutch prospective cohort study. *Environ Health.* 2014;13:106.
58. Shrestha S, Bloom MS, Yucel R, et al. Perfluoroalkyl substances and thyroid function in older adults. *Environ Int.* 2015;75:206-214.
59. Vieira VM, Hoffman K, Shin HM, Weinberg JM, Webster TF, Fletcher T. Perfluorooctanoic acid exposure and cancer outcomes in a contaminated community: a geographic analysis. *Environ Health Perspect.* 2013;121(3):318-323.
60. Steenland K, Woskie S. Cohort mortality study of workers exposed to perfluorooctanoic acid. *Am J Epidemiol.* 2012;176(10):909-917.
61. Barry V, Winquist A, Steenland K. Perfluorooctanoic acid (PFOA) exposures and incident cancers among adults living near a chemical plant. *Environ Health Perspect.* 2013;121(11-12):1313-1318.
62. Wang IJ, Hsieh WS, Chen CY, et al. The effect of prenatal perfluorinated chemicals exposures on pediatric atopy. *Environ Res.* 2011;111(6):785-791.
63. Dong GH, Tung KY, Tsai CH, et al. Serum polyfluoroalkyl concentrations, asthma outcomes, and immunological markers in a case-control study of Taiwanese children. *Environ Health Perspect.* 2013;121(4):507-513, 513e501-508.
64. Qin XD, Qian ZM, Dharmage SC, et al. Association of perfluoroalkyl substances exposure with impaired lung function in children. *Environ Res.* 2017;155:15-21.
65. Romano ME, Xu Y, Calafat AM, et al. Maternal serum perfluoroalkyl substances during pregnancy and duration of breastfeeding. *Environ Res.* 2016;149:239-246.

66. Sheng N, Li J, Liu H, Zhang A, Dai J. Interaction of perfluoroalkyl acids with human liver fatty acid-binding protein. *Arch Toxicol.* 2016;90(1):217-227.
67. Beggs KM, McGreal SR, McCarthy A, et al. The role of hepatocyte nuclear factor 4-alpha in perfluorooctanoic acid- and perfluorooctanesulfonic acid-induced hepatocellular dysfunction. *Toxicol Appl Pharmacol.* 2016;304:18-29.
68. Goudarzi H, Araki A, Itoh S, et al. The association of prenatal exposure to perfluorinated chemicals with glucocorticoid and androgenic hormones in cord blood samples: The Hokkaido Study. *Environ Health Perspect.* 2017;125(1):111-118.
69. Apelberg BJ, Witter FR, Herbstman JB, et al. Cord serum concentrations of perfluorooctane sulfonate (PFOS) and perfluorooctanoate (PFOA) in relation to weight and size at birth. *Environ Health Perspect.* 2007;115(11):1670-1676.
70. Fei C, McLaughlin JK, Tarone RE, Olsen J. Perfluorinated chemicals and fetal growth: a study within the Danish National Birth Cohort. *Environ Health Perspect.* 2007;115(11):1677-1682.
71. Washino N, Saijo Y, Sasaki S, et al. Correlations between prenatal exposure to perfluorinated chemicals and reduced fetal growth. *Environ Health Perspect.* 2009;117(4):660-667.
72. Stein CR, Savitz DA, Dougan M. Serum levels of perfluorooctanoic acid and perfluorooctane sulfonate and pregnancy outcome. *Am J Epidemiol.* 2009;170(7):837-846.
73. Andersen CS, Fei C, Gamborg M, Nohr EA, Sorensen TI, Olsen J. Prenatal exposures to perfluorinated chemicals and anthropometric measures in infancy. *Am J Epidemiol.* 2010;172(11):1230-1237.
74. Chen MH, Ha EH, Wen TW, et al. Perfluorinated compounds in umbilical cord blood and adverse birth outcomes. *PLoS One.* 2012;7(8):e42474.
75. Maisonet M, Terrell ML, McGeehin MA, et al. Maternal concentrations of polyfluoroalkyl compounds during pregnancy and fetal and postnatal growth in British girls. *Environ Health Perspect.* 2012;120(10):1432-1437.
76. Wu K, Xu X, Peng L, Liu J, Guo Y, Huo X. Association between maternal exposure to perfluorooctanoic acid (PFOA) from electronic waste recycling and neonatal health outcomes. *Environ Int.* 2012;48:1-8.
77. Lee YJ, Kim MK, Bae J, Yang JH. Concentrations of perfluoroalkyl compounds in maternal and umbilical cord sera and birth outcomes in Korea. *Chemosphere.* 2013;90(5):1603-1609.
78. Darrow LA, Stein CR, Steenland K. Serum perfluorooctanoic acid and perfluorooctane sulfonate concentrations in relation to birth outcomes in the Mid-Ohio Valley, 2005-2010. *Environ Health Perspect.* 2013;121(10):1207-1213.



79. Johnson PI, Sutton P, Atchley DS, et al. The Navigation Guide - evidence-based medicine meets environmental health: systematic review of human evidence for PFOA effects on fetal growth. *Environ Health Perspect.* 2014;122(10):1028-1039.
80. Alkhalawi E, Kasper-Sonnenberg M, Wilhelm M, Volkel W, Wittsiepe J. Perfluoroalkyl acids (PFAAs) and anthropometric measures in the first year of life: Results from the Duisburg Birth Cohort. *J Toxicol Environ Health A.* 2016;79(22-23):1041-1049.
81. Minatoya M, Itoh S, Miyashita C, et al. Association of prenatal exposure to perfluoroalkyl substances with cord blood adipokines and birth size: The Hokkaido Study on environment and children's health. *Environ Res.* 2017;156:175-182.
82. Ashley-Martin J, Dodds L, Arbuckle TE, et al. Maternal and neonatal levels of perfluoroalkyl substances in relation to gestational weight gain. *Int J Environ Res Public Health.* 2016;13(1): 146
83. Lenters V, Portengen L, Rignell-Hydbom A, et al. Prenatal phthalate, perfluoroalkyl acid, and organochlorine exposures and term birth weight in three birth cohorts: Multi-pollutant models based on elastic net regression. *Environ Health Perspect.* 2016;124(3):365-372.
84. Verner MA, Luccisano AE, Morken NH, et al. Associations of perfluoroalkyl substances(PFAS) with lower birth weight: An evaluation of potential confounding by glomerular filtration rate using a physiologically based pharmacokinetic model (PBPK). *Environ Health Perspect.* 2015;123(12):1317-1324.
85. Steenland K, Zhao L, Winquist A, Parks C. Ulcerative colitis and perfluorooctanoic acid(PFOA) in a highly exposed population of community residents and workers in the mid-Ohio valley. *Environ Health Perspect.* 2013;121(8):900-905.
86. Savitz DA, Stein CR, Elston B, et al. Relationship of perfluorooctanoic acid exposure to pregnancy outcome based on birth records in the mid-Ohio Valley. *Environ Health Perspect.* 2012;120(8):1201-1207.
87. Avanasri R, Shin HM, Vieira VM, Savitz DA, Bartell SM. Impact of exposure uncertainty on the association between perfluorooctanoate and preeclampsia in the C8 Health Project population. *Environ Health Perspect.* 2016;124(1):126-132.
88. Uhl SA, James-Todd T, Bell ML. Association of Osteoarthritis with Perfluorooctanoate and Perfluorooctane Sulfonate in NHANES 2003-2008. *Environ Health Perspect.* 2013;121(4):447-452, 452e441-443.
89. Galloway TS, Fletcher T, Thomas OJ, Lee BP, Pilling LC, Harries LW. PFOA and PFOS are associated with reduced expression of the parathyroid hormone 2 receptor (PTH2R) gene in women. *Chemosphere.* 2015;120:555-562.
90. Innes KE, Ducatman AM, Luster MI, Shankar A. Association of osteoarthritis with serum levels of the environmental contaminants perfluorooctanoate and perfluorooctane sulfonate in a large Appalachian population. *Am J Epidemiol.* 2011;174(4):440-450.

91. Raymer JH, Michael LC, Studabaker WB, et al. Concentrations of perfluorooctanesulfonate (PFOS) and perfluorooctanoate (PFOA) and their associations with human semen quality measurements. *Reprod Toxicol.* 2012;33(4):419-427.
92. Joensen UN, Bossi R, Leffers H, Jensen AA, Skakkebaek NE, Jorgensen N. Do perfluoroalkyl compounds impair human semen quality? *Environ Health Perspect.* 2009;117(6):923-927.
93. Toft G, Jonsson BA, Lindh CH, et al. Exposure to perfluorinated compounds and human semen quality in Arctic and European populations. *Hum Reprod.* 2012;27(8):2532-2540.
94. Vested A, Ramlau-Hansen CH, Olsen SF, et al. Associations of in utero exposure to perfluorinated alkyl acids with human semen quality and reproductive hormones in adult men. *Environ Health Perspect.* 2013;121(4):453-458, 458e451-455.
95. Louis GM, Chen Z, Schisterman EF, et al. Perfluorochemicals and human semen quality: the LIFE study. *Environ Health Perspect.* 2015;123(1):57-63.
96. Hu Q, Franklin JN, Bryan I, Morris E, Wood A, DeWitt JC. Does developmental exposure to perfluorooctanoic acid (PFOA) induce immunopathologies commonly observed in neurodevelopmental disorders? *Neurotoxicology.* 2012;33(6):1491-1498.
97. Strom M, Hansen S, Olsen SF, et al. Persistent organic pollutants measured in maternal serum and offspring neurodevelopmental outcomes--a prospective study with long-term follow-up. *Environ Int.* 2014;68:41-48.7
98. Goudarzi H, Nakajima S, Ikeno T, et al. Prenatal exposure to perfluorinated chemicals and neurodevelopment in early infancy: The Hokkaido Study. *Sci Total Environ.* 2016;541:1002-1010.
99. Hoffman K, Webster TF, Weisskopf MG, Weinberg J, Vieira VM. Exposure to polyfluoroalkyl chemicals and attention deficit/hyperactivity disorder in U.S. children 12-15 years of age. *Environ Health Perspect.* 2010;118(12):1762-1767.
100. Lien GW, Huang CC, Shiu JS, et al. Perfluoroalkyl substances in cord blood and attention deficit/hyperactivity disorder symptoms in seven-year-old children. *Chemosphere.* 2016;156:118-127.
101. Ducatman AM, Withers BF, Yang WN. Smoking and roentgenographic opacities in US Navy asbestos workers. *Chest.* 1990;97(4):810-813.
102. Ducatman AM, Yang WN, Forman SA. 'B-readers' and asbestos medical surveillance. *J Occup Med.* 1988;30(8):644-647.
103. Ducatman AM, Zhang J, Fan H. Prostate-specific antigen and perfluoroalkyl acids in the C8 health study population. *J Occup Environ Med.* 2015;57(1):111-114.

- 104.** Post GB, Cohn PD, Cooper KR. Perfluorooctanoic acid (PFOA), and emerging drinking water contaminant: a critical review of recent literature. *Environ Res* 2012 Jul; 116:93-117 doi: 10.1016/j.envres.2012.03.007.
- 105.** Wilhelm M, Wittsiepe J, Volkel W, Fromme H, et al. Perfluoroalkyl acids in children and their mothers: Association with drinking water and time trends of inner exposures – Results of the Duisburg birth cohort and Bochum cohort studies. *Int J Hyg Environ Health* 2015 Oct; 218(7); 645-55 doi: 10.1016/j.ijheh.2015.07.001
- 106.** Domingo JL, Ericson-Jogsten I, Perello G, Nadal M, et al. Human exposure to perfluorinated compounds in Catalonia, Spain: contribution of drinking water and fish and shellfish. *J Agric Food Chem* 2012 May 2;60(17)4408-15 doi: 10.1021/jf300355c.
- 107.** US EPA Technical Fact Sheet – Perfluorooctane Sulfonate (PFOS) and Perfluorooctanoic Acid (PFOA) November, 2017.
- 108.** Grandjean P, Clapp R. Perfluorinated alkyl substances: Emerging insights Into health risks. *New Solut.* 2015;25(2):147-163.
- 109.** Bartell SM. Online serum PFOA calculator for adults. *Environ Health Perspect.* 2017;125(10):104502.
- 110.** Holzer J, Midasch O, Rauchfuss K, et al. Biomonitoring of perfluorinated compounds in children and adults exposed to perfluorooctanoate-contaminated drinking water. *Environ Health Perspect.* 2008;116(5):651-657.
- 111.** Hernandez M, Lopez C, Soldevila B, et al., Impact of TSH during the first trimester of pregnancy and foetal complications: Usefulness of 2.5mIU/L cut-off value. *Clin Endocrinol (Oxford).* 2018; 88: 728-734.
- 112.** Papadopoulou E, Sabaredzovic A, Namork E, et al., Exposure of Norwegian toddlers to perfluoroalkyl substances (PFAS): The association with breastfeeding and maternal PFAS concentrations. *Environment International.* 2016; 94: 687-94
- 113.** Khalil N, Ebert JR, Honda M, et al. Perfluoroalkyl substances, bone density, and cardio-metabolic risk factors in obese 8-12 year old children: A pilot study. *Environ Res.* 2017;160:314-321.
- 114.** Liu HS, Wen LL, Chu PL, Lin CY. Association among total serum isomers of perfluorinated chemicals, glucose homeostasis, lipid profiles, serum protein and metabolic syndrome in adults: NHANES, 2013-2014. *Environ Pollut.* 2018;232:73-79.
- 115.** Kato K, Wong LY, Chen A, et al. Changes in serum concentrations of maternal poly- and perfluoroalkyl substances over the course of pregnancy and predictors of exposure in a multiethnic cohort of Cincinnati, Ohio pregnant women during 2003-2006. *Environ Sci Technol.* 2014;48(16):9600-9608.

- 116.** Mondal D, Weldon RH, Armstrong BG, et al. Breastfeeding: a potential excretion route for mothers and implications for infant exposure to perfluoroalkyl acids. *Environ Health Perspect.* 2014;122(2):187-192.
- 117.** Kang H, Choi K, Lee HS, et al. Elevated levels of short carbon-chain PFCAs in breast milk among Korean women: Current status and potential challenges. *Environ Res.* 2016;148:351-359.
- 118.** Newton S, McMahan R, Stoeckel JA, Chislock M, Lindstrom A, Strynar M. Novel polyfluorinated compounds identified using high resolution mass spectrometry downstream of manufacturing facilities near Decatur, Alabama. *Environ Sci Technol.* 2017;51(3):1544-1552.
- 119.** Post GB, Gleason JA, Cooper KR. Key scientific issues in developing drinking water guidelines for perfluoroalkyl acids: Contaminants of emerging concern. *PLoS Biol.* 2017;15(12):e2002855.
- 120.** Zhang Y, Beeson S, Zhu L, Martin JW. Biomonitoring of perfluoroalkyl acids in human urine and estimates of biological half-life. *Environ Sci Technol.* 2013;47(18):10619-10627.
- 121.** Li Y, Fletcher T, Mucs D, et al. Half-lives of PFOS, PFHxS and PFOA after end of exposure to contaminated drinking water. *Occup Environ Med.* 2018;75(1):46-51.
- 122.** Kieskamp KK, Worley RR, McLanahan ED, Verner MA. Incorporation of fetal and child PFOA dosimetry in the derivation of health-based toxicity values. *Environ Int.* 2017. 111:260-267
- 123.** Ballesteros V, Costa O, Iñiguez C, Fletcher T, Ballester F, Lopez-Espinosa M-J. Exposure to perfluoroalkyl substances and thyroid function in pregnant women and children: A systematic review of epidemiologic studies. *Environ Int* 2017 Feb; 99:15-28.
- 124.** Andersson EM, Scott K, Xu YY, Li Y, Olsson DS, Fletcher T, Jakobsson K. High exposure to perfluorinated compounds in drinking water and thyroid disease. A cohort study from Ronneby, Sweden. *Environ Res* 2019;176:108540.
- 125.** Fitz-Simon N, Fletcher T, Luster MI, Steenland K, Calafat AM, Kato K, Armstrong B. Reductions in serum lipids with a 4-year decline in serum perfluorooctanoic acid and perfluorooctanesulfonic acid. *Epidemiology.* 2013 Jul;24(4):569-76.
- 126.** Rappazzo KM, Coffman E, Hines EP. Exposure to perfluorinated alkyl substances and health outcomes in children: A systematic review of the epidemiologic literature. *Int J Environ Res Public Health* 2017;201; 14(7).
- 127.** Xu Y, Li Y, Scott K, Lindh C, Jakobsson K, Tony Fletcher T, Ohlsson B, Andersson E. Inflammatory bowel disease and biomarkers of gut inflammation and permeability in a

community with high exposure to perfluoroalkyl substances through drinking water. 2020; 181: 108923.

**128.** Raleigh KK, Alexander BH, Olsen GW, Ramachandran G, Morey SZ, Church TR, Logan PW, Scott LL, Allen EM. Mortality and cancer incidence in ammonium perfluorooctanoate production workers. *Occup Environ Med.* 2014;71(7):500-6.

**129.** Huang R, Chen Q, Zhang L, Luo K, Chen L, Zhao S, Feng L, Zhang J. Prenatal exposure to perfluoroalkyl and polyfluoroalkyl substances and the risk of hypertensive disorders of pregnancy. *Environ Health.* 2019;18(1):5.

**130.** Wikström S, Lindh CH, Shu H, Bornehag CG. Early pregnancy serum levels of perfluoroalkyl substances and risk of preeclampsia in Swedish women. *Sci Rep.* 2019 Jun 24;9(1):9179.

**131.** Liew, Z, Goudarzi H, Oulhote Y. Developmental Exposures to Perfluoroalkyl Substances (PFASs): An Update of Associated Health Outcomes. *Curr Environ Health Rep* 2018;5(1): 1-19.

**132.** Impinen A., Longnecker MP, Nygaard UC, London SJ, Ferguson KK, LHaug LS, Granum B. Maternal levels of perfluoroalkyl substances (PFASs) during pregnancy and childhood allergy and asthma related outcomes and infections in the Norwegian Mother and Child (MoBa) cohort. *Environ Int* 2019; 124: 462-472.

**133.** Impinen A, Nygaard UC, Lodrup Carlsen KC, Mowinckel P, Carlsen KH, Haug LS, Granum B. Prenatal exposure to perfluoroalkyl substances (PFASs) associated with respiratory tract infections but not allergy- and asthma-related health outcomes in childhood. *Environ Res* 2018;160: 518-523.

**134.** Steenland K, Zhao L, Winquist A. A cohort incidence study of workers exposed to perfluorooctanoic acid (PFOA). *Occup Environ Med.* 2015;72(5):373-80.

**135.** Shin HM, Vieira VM, Ryan PB, Steenland K, Bartell SM. Retrospective exposure estimation and predicted versus observed serum perfluorooctanoic acid concentrations for participants in the C8 Health Project. *Environ Health Perspect.* 2011 Dec; 119(12):1760-5.

# **EXHIBIT E**



credit accident and health insurance directly related to extensions of credit, pursuant to § 225.25(b)(8)(i) of the Board's Regulation Y.

Board of Governors of the Federal Reserve System, July 24, 1995.

Jennifer J. Johnson,

*Deputy Secretary of the Board.*

[FR Doc. 95-18569 Filed 7-27-95; 8:45 am]

BILLING CODE 6210-01-F

### South Banking Company; Formation of, Acquisition by, or Merger of Bank Holding Companies

The company listed in this notice has applied for the Board's approval under section 3 of the Bank Holding Company Act (12 U.S.C. 1842) and § 225.14 of the Board's Regulation Y (12 CFR 225.14) to become a bank holding company or to acquire a bank or bank holding company. The factors that are considered in acting on the applications are set forth in section 3(c) of the Act (12 U.S.C. 1842(c)).

The application is available for immediate inspection at the Federal Reserve Bank indicated. Once the application has been accepted for processing, it will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing to the Reserve Bank indicated for that application or to the offices of the Board of Governors. Any comment on an application that requests a hearing must include a statement of why a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute and summarizing the evidence that would be presented at a hearing.

Comments regarding this application must be received not later than August 11, 1995.

A. Federal Reserve Bank of Atlanta (Zane R. Kelley, Vice President) 104 Marietta Street, N.W., Atlanta, Georgia 30303:

1. *South Banking Company*, Alma, Georgia; to acquire 100 percent of the voting shares of Pineland State Bank, Metter, Georgia.

Board of Governors of the Federal Reserve System, July 24, 1995.

Jennifer J. Johnson,

*Deputy Secretary of the Board.*

[FR Doc. 95-18568 Filed 7-27-95; 8:45 am]

BILLING CODE 6210-01-F

### FEDERAL TRADE COMMISSION

#### Regulations under the Comprehensive Smokeless Tobacco Health Education Act of 1986; Information Collection Requirement

**AGENCY:** Federal Trade Commission.

**ACTION:** Notice of application to OMB under the Paperwork Reduction Act (44 U.S.C. 3501 *et seq.*) for clearance of information collection requirements contained in the Regulations under the Comprehensive Smokeless Tobacco Health Education Act of 1986.

**SUMMARY:** This publication provides notice that the Federal Trade Commission is seeking renewed approval for three years from OMB for the information collection requirements contained in the Regulations under the Comprehensive Smokeless Tobacco Health Education Act of 1986. The present OMB approval for the information collection requirements is scheduled to expire on August 31, 1995.

The Smokeless Tobacco Act requires, among other things, that manufacturers, packagers, and importers of smokeless tobacco products include health warnings on packages and in advertisements. The Act also requires each manufacturer, packager, and importer of a smokeless tobacco product to submit a plan to the Commission that specifies the methods used to rotate, display, and distribute the warning statements required to appear in advertising and labeling. Section 3(d) directs the Commission to approve plans that provide for rotation, display, and distribution of the warning statements in accordance with the regulations. All the affected companies have previously filed plans, but the plan submission requirement continues to apply to a company that amends its plans, or to a new company that enters the market.

#### Estimate of Information Collection Burden

In 1986, staff estimates that as many as ten domestic and four foreign smokeless tobacco companies would submit plans specifying the method used to rotate, display, and distribute health warnings in their labeling and advertising. This prediction was accurate. Fourteen plans were received.

When the regulations were first proposed, representatives of the Smokeless Tobacco Council, Inc., indicated that six companies that it represented would require a total of 700 to 800 hours (or about 133 hours apiece, on average) to prepare the required plans. We also assumed that the other

companies, whose plans were prepared by other representatives, would require more time, on average, and used 150 hours per plan to account for the remainder of the expected submissions. Based on these assumptions staff estimated that no more than 2,000 hours would be spent to prepare and submit compliance plans. (Six companies total=800 hours, plus eight companies at 150 hours=1,200 hours.) The Commission provided a burden estimate to OMB of 2,000 hours for the reporting requirements.

In 1992, the Commission proposed amendments to the rotation of health warnings on point-of-sale and non-point-of-sale promotional materials. Pursuant to the proposed amendment, affected firms will have to submit new plans for Commission approval. The amendment of previously submitted plans to incorporate plans for promotional materials should require less time than was devoted to the original submissions. As in 1992, there is no substantial basis for calculating the proportion of the original burden estimate that will be attributable to the amendment process and accordingly, the Commission proposes to retain the existing burden estimate for purposes of seeking this extension.

**DATES:** Comments on this application must be submitted on or before August 28, 1995.

**ADDRESSES:** Send comments both to the Office of Information and Regulatory Affairs, Office of Management and Budget, New Executive Office Building, Room 3228, Washington, D.C. 20503, ATN: Desk Officer for the Federal Trade Commission, and the Office of the Secretary, Room 159, Federal Trade Commission, Washington, D.C. 20580. Copies of the application may be obtained from the Public Reference Section, Room 130, Federal Trade Commission, Washington, D.C. 20580.

#### FOR FURTHER INFORMATION CONTACT:

Phillip S. Priesman, Attorney, Federal Trade Commission, Washington, D.C. 20580 (202) 326-2484.

Stephen Calkins,

*General Counsel.*

[FR Doc. 95-18595 Filed 7-27-95; 8:45 am]

BILLING CODE 6750-01-M

**DEPARTMENT OF HEALTH AND HUMAN SERVICES****Agency for Toxic Substances and Disease Registry**

[ATSDR-96]

**ATSDR's Final Criteria for Determining the Appropriateness of a Medical Monitoring Program Under CERCLA**

**AGENCY:** Agency for Toxic Substances and Disease Registry (ATSDR), Public Health Service (PHS), Department of Health and Human Services (HHS).

**ACTION:** Notice.

**SUMMARY:** This notice announces the criteria for determining the appropriateness of a medical monitoring program under the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA). Draft criteria were published for public comment on September 9, 1994 (59 FR 46648). The public comment period ended October 24, 1994. Comments were received from 15 individuals representing States, industry, activist groups, and environmental medicine clinics. This document reflects those comments received on the draft criteria.

**ADDRESSES:** Division of Health Studies, Agency for Toxic Substances and Disease Registry, 1600 Clifton Road, NE., Mailstop E-31, Atlanta, Georgia 30333, telephone (404) 639-6200.

**FOR FURTHER INFORMATION CONTACT:** Dr. Wendy E. Kaye, Chief, Epidemiology and Surveillance Branch, Division of Health Studies, ATSDR, telephone (404) 639-6203.

**SUPPLEMENTARY INFORMATION:** Section 104(i)(9) of the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA), as amended [42 U.S.C. 9604(i)(9)], provides for the Administrator of the Agency for Toxic Substances and Disease Registry (ATSDR) to initiate a health surveillance program for populations at significantly increased risk of adverse health effects as a result of exposure to hazardous substances released from a facility. A program included under health surveillance is referred to as "Medical Monitoring or Screening" by ATSDR and is defined in the legislation as "the periodic medical testing to screen people at significant increased risk for disease." ATSDR has established criteria to determine when medical monitoring is an appropriate health activity and the requirements for establishing a medical monitoring program at a site. The legislation also

states that a mechanism to refer people for treatment should be included in the program. Statutory language only allows ATSDR to provide medical care or treatment in cases of public health emergencies as declared by the President.

**Background**

ATSDR is responsible for the public health-related activities of CERCLA. ATSDR's primary initial response at a hazardous waste site is the public health assessment, which is required for every site on the National Priorities List (NPL). A public health assessment can also be conducted in response to a petition from the public. Other important components of ATSDR's initial response at sites include health consultations and public health advisories. During the process of developing the public health assessments and health advisories, ATSDR invites the participation of communities through a variety of avenues such as public meetings, public availability sessions, and Community Assistance Panels (CAPs). The documents produced by ATSDR during the process are placed in a public repository to allow the public access to the documents. The public health assessments, health consultations, and public health advisories undergo review by ATSDR to determine if follow-up health-related activities are needed for populations at risk in the affected community.

The types of follow-up health activities recommended for a site will depend on the amount of information on the possible exposures and their suspected pathways. In any case in which an association has not been established between an exposure and a specific adverse health outcome, several research and health education activities may be considered. Those activities could include health outcome studies, an exposure assessment at the site, epidemiologic studies, or professional education.

ATSDR's Division of Health Assessment and Consultation has established a program for the investigation of exposures in communities which enables a more timely response to questions on whether individuals in a community are being exposed. The program incorporates a variety of industrial hygiene techniques for measuring chemicals in the environment, as well as selected biological markers of exposure.

The Division of Health Education provides a wide variety of services to educate health care professionals and communities on the effects of exposures

to hazardous substances. Activities in a community around a hazardous waste site may include conducting grand rounds for health care providers on the effects of a specific chemical, providing fact sheets on chemicals, conducting workshops on clues to environmental disease, and producing case studies in environmental medicine.

The Division of Health Studies is responsible for conducting epidemiologic research, including several types of studies (cluster investigations, disease and symptom prevalence studies, analytic epidemiologic studies), surveillance programs, and exposure registries. Cluster investigations and disease and symptom prevalence studies investigate the occurrence of disease in populations. Analytic epidemiology studies are conducted to evaluate the causal nature of associations between exposure to hazardous substances and disease outcomes. The surveillance program focuses on exposures to substances at hazardous waste sites and includes systems that follow populations exposed to hazardous wastes because of where they live or their occupation. It also includes surveillance of emergency events in which hazardous substances are released into the environment. The National Exposure Registry maintains a listing of people exposed to hazardous substances. The Registry is composed of chemical specific subregistries. The chemicals are selected from the ATSDR/EPA priority list of hazardous substances.

Medical monitoring is considered one of several follow-up health activity options under the site-specific work conducted by ATSDR. A medical monitoring program for the community around a site will be considered with other health follow-up activities when the information from ATSDR's initial response at the site is reviewed. In cases in which there is no known association between the exposure and specific adverse health effects (which could include health outcomes, illnesses, or markers of effect), medical monitoring is not an appropriate public health activity. In cases in which there is limited information on a specific health effect's relationship to an exposure, then options such as epidemiologic surveillance, a disease and symptom prevalence study, or an epidemiologic study are more appropriate. When adequate information exists that links exposure to a chemical with a specific adverse health effect, further consideration will be given to the appropriateness of medical monitoring in that population.



Medical monitoring should be directed toward a target community identified as being at "significant increased risk for disease" on the basis of its exposure. Significant increased risk will vary for particular sites depending upon such factors as the underlying risk of the selected outcome, the risk attributable to the exposure, and the presence of sensitive subpopulations. These factors will be considered when evaluating the appropriateness of medical monitoring in a community. The CERCLA legislation also provides for a mechanism for referral for treatment of those who are screened positive for the selected health outcomes; therefore, a mechanism to refer people for diagnosis, interventions, or treatment should be in place prior to the initiation of a medical monitoring program.

The primary purpose of a medical monitoring program is not considered to be a research activity that further investigates the cause-effect relationship between exposure and outcome. The purpose of a medical monitoring program is case-finding in order to refer individuals for further evaluation and, as appropriate, treatment. Within this framework, medical monitoring includes both testing for early biological effect and an assessment of exposure using biological specimens (for example, blood or urine), when appropriate. This is provided as a service to individuals in communities where there is believed to be an increased risk of disease from exposure to hazardous substances released into the environment.

#### Criteria for Considering Medical Monitoring

The criteria outlined below will be used to determine the appropriateness of conducting medical monitoring in a community and will be applied in a phased approach. Phase I, conducted by ATSDR, consists of an evaluation of the exposure and outcome criteria. Phase II consists of an evaluation of the system criteria. Phase II will be conducted with the input of a panel consisting of community, State and local health officials, and ATSDR. At the end of Phase II, a detailed medical monitoring plan will be written at sites where a monitoring program is established. All of the criteria must be met at a site in order for a medical monitoring program to be established at that site. In addition, resources must be available to initiate and sustain the program.

#### Phase I

##### *Exposure Criteria*

A. There should be evidence of contaminant levels in environmental media that would suggest the high likelihood of environmental exposure to a hazardous substance and subsequent adverse health outcomes.

The National Research Council (NRC) defines exposure as "an event that occurs when there is contact at a boundary between a human and the environment at a specific contaminant concentration for a specified period of time; the units to express exposure are concentration multiplied by time" (NRC, 1991). The specific contaminant concentration and period of time will vary for different chemicals and different media. The exposure must be to a hazardous substance as defined under CERCLA, and the result of a release from a CERCLA-covered facility. A release from a CERCLA-covered facility includes those events that establish an open pathway of exposure (i.e., an unfenced area with high soil contamination could be considered a "release") or allows contaminants to go off-site via air, surface water, ground water, or other pathway. The primary criteria for medical monitoring should be documented evidence of exposure of a population to a hazardous substance in the environment. An exposure will be considered to be at a sufficient level if there is documentation of an increased opportunity for exposure to a level that meets or exceeds some health-based comparison value (such as Minimum Risk Levels (MRLs) or Reference Doses (RfDs)) or that meets or exceeds a level reported in the peer-reviewed literature to result in some adverse health effect. Documentation is considered sufficient if it is from an exposure assessment, environmental exposure modeling, or sampling from a general area (for example, water samples from an aquifer or a town water supply). Documentation of individual levels of exposure is not required. In cases in which exposures are unknown or undocumented, environmental monitoring is a more appropriate initial activity.

B. There should be a well-defined, identifiable target population of concern in which exposure to a hazardous substance at a sufficient level has occurred.

Initially, the target population of concern will be defined geographically on the basis of exposure. In addition, all populations considered will be assessed for the presence of any sub-population at increased risk of the adverse health effects associated with the exposures. An example of a subpopulation at

increased risk would be preschool children in an area with known lead exposures. The size of the target population of concern is not a factor in the decision for monitoring. In areas where biological markers of exposure have not been collected, environmental sampling can be used to estimate exposure levels. The target population of concern is the population in which there is documented exposure at a sufficient level to place the individuals in that population at significant increased risk for developing some specific adverse health effect.

##### *Outcome Criteria*

A. There should be documented human health research that demonstrates a scientific basis for a reasonable association between an exposure to a hazardous substance and a specific adverse health effect (such as an illness or change in a biological marker of effect).

Previous studies on human populations must demonstrate a reasonable association between a particular exposure and an adverse health effect. In order to make that inference, consideration should be given to the strength, specificity, and consistency of the association among the identified studies. The period of exposure (including the timing and duration of the exposure) and its relationship to the latency period for the disease or illness should also be examined if information is available. Consideration should be given to whether the association has demonstrated a dose-response relationship and whether the association is consistent with the existing body of knowledge. This information could include a variety of occupational, epidemiological, or other studies involving human populations.

B. The monitoring should be directed at detecting adverse health effects that are consistent with the existing body of knowledge and amenable to prevention or intervention measures.

The monitoring should be established for specific adverse health effects. The specific adverse health effect being monitored should be a result of the possible exposure consistent with the existing body of knowledge. An adverse health effect is consistent with the existing body of knowledge if it has been described in the literature as caused by that agent or by similar agents, taking into account structure-activity relations.

In addition, the adverse health effects (disease process, illness, or biomarkers of effect) should be such that early detection and treatment or intervention

interrupts the progress to symptomatic disease, improves the prognosis of the disease, improves the quality of life of the individual, or is amenable to primary prevention. If the adverse health effects that are of concern in an individual or in a community are not easily detectable and not medically treatable, then medical monitoring would not be beneficial and would not be an appropriate public health activity. An easily detectable effect is one that can be found on clinical examination, or through the use of simple, diagnostic tests in an outpatient setting. Also, the test procedures must be acceptable to the patient and the community. The diagnostic tests must be nonexperimental, relatively noninvasive (such as the drawing of a tube of blood for laboratory tests), and simple to administer.

#### Monitoring for Evidence of Continuing Exposure

At sites with exposure in the community, the monitoring program might include biological markers of continuing exposure. For example, the Bunker Hill Superfund site has had lead screening of children for many years. Those sites would be ones in which the exposure is known to have a variety of adverse health effects, but for which no tests are available to detect those effects at a time when intervention could affect the course of the disease process. In those instances, the primary intervention is to remove the individual from the exposure. This allows the medical monitoring system to recommend referral for intervention prior to the onset of detectable adverse health effects. A monitoring system that includes biomarkers of continuing exposure is similar to medical surveillance of hazardous waste workers where changes indicative of increasing or continued exposures occur sufficiently early that the exposure can be curtailed and the risk for disease reduced (Gochfeld 1990).

#### Phase II

##### *General Information*

Phase II of the program is carried out by ATSDR with assistance from the community. When ATSDR has determined that exposure from a site has met the exposure and outcome criteria, a site panel will be formed based on recommendations from the community and the State and/or local health departments to review the system criteria and to assist in the development of a site-specific medical monitoring plan. The site panel will include representatives from ATSDR, the

community, State or local health departments, local medical societies, and subject experts as necessary. The site panel will function in much the same manner as the Community Assistance Panels (CAPs) that are established at some sites during the public health assessment process. The site panel will follow the established procedures for those CAPs. The site panel will be responsible for assessing the available community health resources and determining the feasibility and extent of the screening program for the community. If the panel determines that a screening program is feasible in the community and ATSDR concurs with that decision, ATSDR will develop a site-specific monitoring plan. That plan will be presented to the site panel for review and concurrence. After the plan has been developed and has undergone peer review, it will be presented to the community at large for their input prior to establishing the program.

##### *System Criteria*

A. The general requirements for a medical screening program should be satisfied.

The monitoring aspect of a health surveillance program consists of the periodic medical testing to screen individuals who are at increased risk of disease. Monitoring serves to identify those individuals with an unrecognized adverse health effect. This is consistent with the definition of screening as "the presumptive identification of unrecognized disease or defect by the application of tests, examinations, or other procedures which can be applied rapidly. Screening tests sort out apparently well persons who probably have a disease from those who probably do not. A screening test is not intended to be diagnostic. Persons with positive or suspicious findings must be referred to their physicians for diagnosis and necessary treatment." (Commission on Chronic Illness, 1957) In general, the ability to predict the presence or absence of disease from test results depends on the sensitivity and specificity of the test and the prevalence of the disease in the population being tested. The higher the prevalence, the more likely a positive test indicates disease (Mausner & Kramer, 1985). In order for a screening program to be of public health benefit, the population being screened should be at a significantly high risk for the undiagnosed disease (i.e., the disease should have a sufficiently high prevalence in the population).

Given that definition, there are certain requirements for screening programs

that should be considered when evaluating a possible medical monitoring program for a site (adopted from Mausner & Kramer, 1985). Those requirements are:

- ★ The natural history of the disease process should be understood sufficiently for screening.

- ★ The early detection through screening should be known to have an impact on the natural history of that disease process. For example, the detection of breast cancer while it is localized has been shown to increase the ten-year survival rate. For that reason, several groups have made recommendations for the early detection of breast cancer in asymptomatic women. Those recommendations include breast self-examination, breast physical examination, and mammography (Mettlin & Dodd, 1991; Kelsey & Gammon, 1991).

- ★ There should be an accepted screening test that meets the requirements for validity, reliability, estimates of yield, sensitivity, specificity, and acceptable cost. The purpose of ATSDR-sponsored medical monitoring is not to develop new screening tests. The medical monitoring program will use tests that have been recommended and used for screening in other settings.

The U.S. Preventive Services Task Force has established criteria for determining the effectiveness of preventive strategies including screening tests. The criteria for effectiveness of a screening test include the efficacy of the screening test and the effectiveness of early detection. The Task Force used efficacy to mean accuracy and reliability. The accuracy is measured using four indices: sensitivity, specificity, positive predictive value, and negative predictive value (see table below for definitions). A test with poor sensitivity will result in a large proportion of persons with disease being told they are free of disease (false-negatives). A test with poor specificity will result in healthy persons being told they have the disease (false-positives). There may be serious consequences in the use of screening tests with poor sensitivity and/or specificity. Persons with false negative results may have delays in diagnosis and treatment. False positive results can result in follow-up testing that is uncomfortable, expensive and potentially harmful. The evaluation and selection of a screening test must include a determination of the likelihood of producing false positive results (the positive predictive value (PPV)). The PPV changes in accordance with the prevalence of the condition in the screened population. PPV is unlike

sensitivity and specificity in that it is not a constant characteristic of a screening test. If the condition is sufficiently rare in the screened population, even tests with excellent sensitivity and specificity can have low PPV, having more false positive results than true positive results.

Another important aspect in determining the efficacy of a screening test is the reliability of the test. The reliability (reproducibility) is the ability of the test to give the same result when it is repeated. An accurate test with poor reliability can produce results that vary widely from the correct value, even

though the average of the results approximates the true value. Poor reliability may be due to either interobserver variation or intraobserver variation (U.S. Preventive Services Task Force, 1989).

#### DEFINITION OF TERMS

Term	Definition	Formula*
Sensitivity .....	Proportion of persons with the condition who test positive.	$\frac{a}{a + c}$
Specificity .....	Proportion of persons without the condition who test negative.	$\frac{d}{b + d}$
Positive Predictive Value .....	Proportion of persons with positive test who have condition.	$\frac{a}{a + b}$
Negative Predictive Value .....	Proportion of persons with negative test who do not have the condition.	$\frac{d}{c + d}$
*Explanation of Symbols	Condition absent	Condition present
Positive Test .....	a	b
Negative Test .....	c	d

Legend: a=true +; b=false +; c=false -; d=true -.

★ The screening program should be one that is feasible and acceptable to individuals and the community. Therefore, plans and possible screening tests for a medical monitoring program will be presented to the community for input prior to the initiation of any recommended program.

B. An accepted treatment, intervention, or both, for the condition (outcome or marker of exposure) must exist and a referral system should be in place prior to the initiation of a medical monitoring program.

There should be established criteria for determining who should receive referral for intervention or treatment. These criteria will be based on the selected effect being screened for and the screening test being used. Results will be evaluated by ATSDR longitudinally and cross-sectionally to identify changes in the system or screening tools that require follow-up (Gochfeld 1990). A referral mechanism should exist so that those who are eligible for the intervention can be referred to a qualified health care provider for further diagnosis, treatment, or intervention. The referral must be for treatment or intervention that is standard practice and not experimental in nature. The medical monitoring (screening) program is not responsible for the cost of the referral, the intervention, or the treatment of individuals participating in the program.

C. The logistics of the system must be resolved before the program can be initiated.

After medical monitoring has been determined to be appropriate for a site, the specifics of the monitoring system will be detailed in a site-specific medical monitoring plan. The site panel consisting of the community members, appropriate health officials, and subject experts as necessary will work with ATSDR to develop and review the site-specific medical monitoring plan. The specifics of the medical monitoring system recommended can vary for each site. The monitoring plan is the protocol for the specific program to be proposed in a community. The plan will outline the target community, the types of outcomes to be screened for, the participants in the referral system, and the program reports. The plan will include a review of the latency period for the outcomes being monitored and the duration of the exposure to define the period of time that the program will operate in a specific site population. The target population; the completeness with which the exposed population can be identified, contacted, and followed; the screening tests; and the selected health outcomes will all influence the specifics of the system. Existing medical facilities and personnel will be used when possible.

The monitoring plan will be submitted for peer review prior to its implementation at a site. The plan for a site might require additional review by an expert panel (ethicists, NRC) to

evaluate the screening tests recommended. ATSDR's Division of Health Studies will work closely with the Division of Health Education to provide professional health education when needed to enhance the medical monitoring program.

Medical monitoring is one of ATSDR's service activities and is not considered to be a research tool. The monitoring activity at each site will be routinely evaluated for the effectiveness of the screening tests in place and the types of effects being detected. Due to confidentiality issues in dealing with small groups of people, the reporting from the system will consist of annual reports noting the number of individuals screened, the number of referrals made, and the number of conditions diagnosed in the referral system. ATSDR will develop a list that includes information on the types of exposures seen in the communities and the types of screening tests that were included in the monitoring. ATSDR can provide this information as available to the site panels to assist them in deciding on the types of screening tools based on what has been used in other areas.

The referral system will consist of the review of the screening results and the referral to appropriate health care providers or referral physicians. The specific mechanisms for determining who needs referral and for selecting the health care providers in the referral pool must be in place prior to the initiation of the medical monitoring. Once the participant has been referred to the



referral providers, those providers will be responsible for any subsequent diagnosis, treatment, or intervention.

#### Summary of Medical Monitoring

Medical monitoring will be considered along with the other health follow-up activities to be recommended for populations around specific sites. The Division of Health Studies will make a determination on whether a site meets the exposure and outcome criteria for medical monitoring. If a site meets the previously discussed criteria and is selected for further consideration of a medical monitoring program, ATSDR will work with the community and other appropriate entities in designing the specific monitoring and referral system for that site's target population. ATSDR will notify, and where appropriate, work with the state health department to establish the program. The Division of Health Studies will monitor the program and be responsible for the oversight on the annual reports.

#### References

- Commission on Chronic Illness. *Chronic Illness in the United States*, Vol. 1. Commonwealth Fund, Harvard University Press, Cambridge, 1957, page 45.
- Gochfeld M. Medical surveillance of hazardous waste workers. In *Principles and Problems in Occupational Medicine State of the Art Reviews: Hazardous Waste Workers*. Gochfeld M and EA Favata, editors. Philadelphia: Hanley & Belfus, Inc., 1990; 5(1):1-8.
- Kelsey JL and MD Gammon. The epidemiology of breast cancer. *CA—A Cancer Journal for Clinicians* 1991; 41(3):146-165.
- Mausner JS and S Kramer. *Epidemiology—an introductory text*. Philadelphia: W.B. Saunders, 1985, pages 220-230.
- Mettlin C and GD Dodd. The American Cancer Society guidelines for the cancer-related checkup: An update. *CA—A Cancer Journal for Clinicians* 1991; 41(5):279-282.
- NRC (National Research Council). *Human Exposure Assessment for Airborne Pollutants: Advances and Opportunities*. Washington, D.C.: National Academy Press, 1991, pages 17-37.
- U.S. Preventive Services Task Force. *Guide to Clinical Preventive Services: An Assessment of the Effectiveness of 169 Interventions*. Baltimore: Williams & Wilkins, 1989, pages xxix-xxxviii.
- Dated: July 24, 1995.

Claire V. Broome,

*Deputy Administrator, Agency for Toxic Substances and Disease Registry.*

[FR Doc. 95-18578 Filed 7-27-95; 8:45 am]

BILLING CODE 4163-70-P

## Centers for Disease Control and Prevention

### [Announcement 562]

### Analytic Studies to Elaborate the Impact of Race, Ethnicity, and Socioeconomic Status Upon the Health of Minority Populations

#### Introduction

The Centers for Disease Control and Prevention (CDC) announces the availability of fiscal year (FY) 1995 funds for cooperative agreements to conduct analytic studies to elaborate the impact of race, ethnicity, and socioeconomic status (SES) upon the health of minority populations in the United States. Research sponsored by this announcement will focus on the performance of special studies and analyses of existing data to:

1. Identify the critical features of SES which determine health, delineate the mechanisms and processes whereby social stratification produces disease, and specify the psychological and interpersonal processes that can intensify or mitigate the effects of social structure on health behaviors, access to care, and health outcomes;
2. Explore the need for more accurate descriptions of racial and ethnic status to monitor the differential impact of health policy changes and system reform on minority subpopulations; and,
3. Increase understanding of the impact of ethnicity on health by identifying the ways in which SES, cultural factors, and racial/ethnic variables and discrimination impact on health behaviors, access to health care, and health outcomes.

The "Disadvantaged Minority Health Improvement Act of 1990" (Pub.L. 101-527) which established the Minority Health Statistics Grants Program and subsequent reauthorizing legislation contained in the "Preventive Health Amendments of 1993" (Pub.L. 103-183), recognized the need for improved and refined data to monitor and focus on the differences in health status between and among minority populations.

The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," a PHS-led national activity to reduce morbidity and mortality and improve the quality of life. This announcement is related to the priority area of Surveillance and Data Systems. (For ordering a copy of "Healthy People 2000," see the section "Where to Obtain Additional Information.")

#### Authority

This program is authorized under section 306(m) of the Public Health Service Act [42 U.S.C. 242k(m)] as amended.

#### Smoke-Free Workplace

The PHS strongly encourages all grant recipients to provide a smoke-free workplace and promote the non-use of all tobacco products, and Public Law 103-227, the Pro-Children Act of 1994, prohibits smoking in certain facilities that receive Federal funds in which education, library, day care, health care, and early childhood development services are provided to children.

#### Eligible Applicants

Applications may be submitted by nonprofit organizations and institutions, and governments and their agencies. Thus, universities, colleges, research institutions, hospitals, other public and private nonprofit organizations, State and local governments or their bona fide agents, federally recognized Indian tribal governments, Indian tribes or Indian tribal organizations, are eligible to apply.

#### Availability of Funds

Approximately \$500,000 will be available in FY 1995 to fund approximately 3 to 7 awards ranging from \$50,000 to \$200,000. It is expected that the average award will be \$150,000. It is expected that the awards will begin on or about September 30, 1995, and will be made for a 12-month budget period within a project period of up to 3 years. Funding estimates may vary and are subject to change. Applications requesting funds greater than an upper limit of \$250,000 total costs for any 12-month budget period will be returned to the applicant without review. Continuation awards within the project period will be made on the basis of satisfactory progress and the availability of funds.

#### Purpose

The purpose of this program announcement is to support special studies and analyses that will elucidate the impact of race/ethnicity and SES upon the health of minority populations in the United States.

Research priorities for race/ethnicity and SES have been divided into several categories. Genetics is an important variable; however, it diverts attention from the more influential social and environmental differences which have erroneously been attributed as race differences. Implicit in these priorities are a number of methodological and analytical issues, such as finding and

# **EXHIBIT F**

APPENDIX A

**HEALTH-BASED MAXIMUM CONTAMINANT LEVEL  
SUPPORT DOCUMENT:  
PERFLUOROCTANOIC ACID (PFOA)**

**New Jersey Drinking Water Quality  
Institute Health Effects Subcommittee  
February 15, 2017**

***Subcommittee Members:***

**Jessie A. Gleason, M.S.P.H., Chair**

**Keith R. Cooper, Ph.D.**

**Judith B. Klotz, M.S., Dr.P.H.**

**Gloria B. Post, Ph.D., DABT**

**George Van Orden, Ph.D.**

*Page intentionally left blank*

### **Acknowledgements**

The Health Effects Subcommittee would like to recognize former Subcommittee members - Daniel Caldwell, Perry Cohn, Leslie McGeorge, and David Pringle - for their contributions to the Subcommittee's earlier evaluation of PFOA in 2009-10.

The Subcommittee also thanks Alan Stern of the NJDEP Division of Science, Research and Environmental Health (DSREH) for assistance with Benchmark Dose modeling, Sandra Goodrow of DSREH for assistance with analysis of New Jersey PFOA drinking water occurrence data, and Gwen Haile and Theresa Tucker of DSREH for technical and editorial assistance.

Finally, this work would not have been possible without the ongoing support of the librarians of the NJDEP Environmental Research Library - Dorothy Alibrando, Mary Kearns-Kaplan (former), and Tonia Wu.



*Page intentionally left blank*

**TABLE OF CONTENTS**

ABSTRACT..... 1

EXECUTIVE SUMMARY ..... 2

INTRODUCTION ..... 18

BACKGROUND INFORMATION ..... 20

GUIDANCE AND STANDARDS DEVELOPED BY NEW JERSEY, OTHER STATES,  
AND USEPA..... 23

ENVIRONMENTAL FATE, TRANSPORT, AND OCCURRENCE..... 27

HUMAN BIOMONITORING..... 34

SOURCES OF HUMAN EXPOSURE..... 39

TOXICOKINETICS ..... 42

HEALTH EFFECTS - HUMAN STUDIES..... 60

HEALTH EFFECTS - ANIMAL TOXICOLOGY ..... 104

MODE OF ACTION..... 180

DEVELOPMENT OF RECOMMENDED HEALTH-BASED MCL ..... 204

DISCUSSION OF UNCERTAINTIES ..... 219

CITATIONS ..... 221

**Appendices**

APPENDIX 1. Literature Search Criteria and Documentation - PFOA.....3

APPENDIX 2: Comparison of USEPA Office of Water Health Advisory and DWQI  
recommended Health-based MCL for PFOA.....5

APPENDIX 3: Risk Assessment Considerations for Butenhoff et al. (2002) Subchronic  
Cynomolgus Monkey Study..... 18

APPENDIX 4. Individual tables for epidemiology studies.....21

APPENDIX 5: Individual Tables for Toxicology Studies.....78

APPENDIX 6: Outputs of Benchmark Dose Modeling for Mammary Gland Development  
Endpoints..... 112

APPENDIX 7: Benchmark dose analysis of relative liver weight in response to PFOA  
(linear/branched) using BMR of 10% increase relative to controls.....162

APPENDIX 8: Benchmark dose analysis of testicular tumor data in response to  
PFOA using 5%BMR of tumor incidence .....176

**TABLE OF TABLES**

Table 1. PFOA concentrations in raw or finished water from PWS included in NJDEP database.....	33
Table 2. New Jersey versus national UCMR3 PFC occurrence data as of January 2016 .....	34
Table 3. Serum PFOA concentration from NHANES (ng/ml) .....	36
Table 4: Serum/plasma elimination half-lives of PFOA.....	46
Table 5. Increase in serum PFOA concentrations predicted from various concentrations of PFOA in drinking water.....	59
Table 6A. Summary of findings from epidemiologic studies of PFOA and serum lipids .....	93
Table 6B. Summary of findings from epidemiologic studies of PFOA and liver enzymes/bilirubin .....	97
Table 6C. Summary of findings from epidemiologic studies of PFOA and thyroid hormones and diseases .....	99
Table 6D. Summary of findings from epidemiologic studies of PFOA and uric acid .....	102
Table 6E. Summary of findings from epidemiologic studies of PFOA and antibody concentrations (following vaccination).....	103
Table 7. Relative Liver Weight (compared to controls) in 90 Day Rhesus Monkey Study (Goldenthal, 1978).....	106
Table 8. Liver enzymes (relative to control) in serum of mice exposed to PFOA in drinking water for 21 days (Son et al., 2008).....	116
Table 9. Developmental events in human and rodent mammary tissue (Fenton, 2006) .....	129
Table 10. Summary of Increased Relative Liver Weight Data from Rodents Studies Using Doses < 1 mg/kg/day, and 90 Day Non-Human Primate Study.....	153
Table 11. Summary of toxicological studies of effects of oral exposure to PFOA on the immune system.....	155
Table 12: Summary of studies of effects of gestational/lactational exposure to PFOA in mice (most sensitive effect(s) in each study are shown in <i>red italics</i> )* .....	160
Table 13. Identification of most sensitive endpoints in mouse developmental studies of PFOA* .....	170
Table 14A. Summary of publications/studies evaluating effects of PFOA on mammary gland (MG) development in mice – Includes studies with exposure during pregnancy, gestation, and/or lactation (6 publications/10 studies). .....	174
Table 14B. Summary of publications/studies evaluating effects of PFOA on mammary gland (MG) development in mice – Studies with peripubertal exposure (3 publications).....	178
Table 15. Mammary gland development parameters selected for dose-response modeling from PND 21 female offspring after exposure on GD 10-17 .....	207
Table 16. Benchmark Dose modeling of serum PFOA data (PND1) for mammary gland developmental effects (PND 21) in CD-1 mouse pups .....	208
Table 17: Serum PFOA and relative liver weight in Male CD-1 mice dosed with branched/linear PFOA for 14 days .....	212
Table 18. Benchmark Dose analysis for a 10% increase in relative liver weight from linear/branched PFOA in male mice (Loveless et al., 2006) <sup>a</sup> .....	213
Table 19. BMD modeling (0.05 BMR; 5% response) of rat testicular tumor data (Butenhoff et al., 2012) <sup>a</sup> .....	218

**TABLE OF FIGURES**

Figure E-1. Increases in serum PFOA concentrations predicted from mean and upper percentile consumption of drinking water with various concentrations of PFOA, as compared to U.S median and 95 <sup>th</sup> percentile serum PFOA levels (NHANES, 2011-12)....	6
Figure E-2. From Verner et al. (2016a). Modeling simulation of the ratio of PFOA in blood plasma in breast fed infants/children to plasma concentration in mother.....	7
Figure 1. Increases in serum PFOA concentrations predicted from consumption of drinking water with various concentrations of PFOA.....	26
Figure 2. Major transport pathways of PFCs to the Arctic (and other remote locations), by Annika Jahnke (Butt et al., 2010).....	28
Figure 3. APFO (PFOA) transport near discharge source (Davis et al., 2007).....	29
Figure 4. Structure of diPAPs 8:2.....	30
Figure 5. PFOA concentration in cord blood and blood collected in infants around six and nineteen months after birth.....	53
Figure 6. Serum PFOA concentrations over time in 12 infants from Mogensen et al. (2015).....	54
Figure 7. Monte Carlo simulations (n = 10 000) of child/mother ratios of plasma PFOA levels (ng/ml; right side of figure) and doses (ng/kg/day; left side of figure) for a breastfeeding period of 30 months.....	55
Figure 8. Increases in serum PFOA concentrations predicted from mean and upper percentile consumption of drinking water with various concentrations of PFOA, as compared to U.S median and 95 <sup>th</sup> percentile serum PFOA levels (NHANES, 2011-12).....	60
Figure 9. Adjusted-predicted total cholesterol change with increasing group median deciles. (A). Adults, Steenland et al., 2009 (B). Adolescents,.....	91
Figure 10. Timeline of critical periods of mammary gland development and potential effects of endocrine disrupting compounds on mammary gland development (Fenton, 2006). .....	129
Figure 11. White et al. (2011b) study design and experimental timeline. ....	136
Figure 13. Relative liver weight and relative PCO activity (compared to controls) versus serum PFOA concentrations in male mice dosed with linear/branched, linear, or branched PFOA for 14 days (Loveless et al., 2006).....	184
Figure 14. Relative liver weight and relative PCO activity (compared to controls) versus serum PFOA concentrations in male rats dosed with linear/branched, linear, or branched PFOA for 14 days (Loveless et al., 2006).....	185
Figure 15. Relative liver weight and relative PCO activity (compared to controls) versus serum PFOA concentrations in male rats and mice dosed with PFOA for 4, 7, or 13 weeks (Perkins et al., 2004). .....	186
Figure 16. Changes in PFOA levels in breast-fed infants from birth to later timepoints (Fromme et al., 2010; Mogensen et al., 2015).....	216
Figure 17. Monte Carlo simulations of child/mother ratios of plasma PFOA levels (ng/ml) a breastfeeding period of 30 months. Black line - 50 <sup>th</sup> percentile; blue line - 5 <sup>th</sup> percentile; red line - 95 <sup>th</sup> percentile; dotted lines - minimum and maximum values..	216

## **ABBREVIATIONS**

ALP — alkaline phosphatase  
ALT /SGPT — alanine aminotransferase  
APFO — ammonium perfluorooctanoate, the ammonium salt of PFOA  
AST /SGOT — aspartate aminotransferase  
BMD — Benchmark Dose  
BMDL — lower 95% confidence limit on the Benchmark Dose  
BMR — Benchmark Response  
CAR — constitutive androstane receptor  
C8 — a synonym for PFOA  
DWQI — New Jersey Drinking Water Quality Institute  
FTOH — fluorotelomer alcohol  
GD — gestational day  
GFR — glomerular filtration rate  
GGT — gamma-glutamyl transferase  
GM — geometric mean  
H & E — hematoxylin and eosin  
HDL — high-density lipid cholesterol  
IARC — International Agency for Cancer Research  
IRIS — USEPA Integrated Risk Information System  
LDL — low-density lipid cholesterol  
LOAEL — Lowest Observed Adverse Effect Level  
MCL — Maximum Contaminant Level  
NHANES — National Health and Nutrition Examination Survey  
NJDEP — New Jersey Department of Environmental Protection  
NJDOH — New Jersey Department of Health  
NOAEL — No Observed Adverse Effect Level  
NTP — National Toxicology Program  
OR — odds ratio  
PAPs — polyfluoroalkyl phosphoric acid diesters  
PCO — palmitoyl CoA oxidase  
PFC — perfluorinated compound  
PFOA — perfluorooctanoic acid  
PFOS — perfluorooctane sulfonate  
PFNA — perfluorononanoic acid  
PND — postnatal day  
POD — Point of Departure  
PPAR — peroxisome proliferator activated receptor  
PTFE — polytetrafluoroethylene  
PWS — public water supplies  
PXR — pregnane X receptor  
RfD — Reference Dose  
RL — Reporting Level  
RSC — Relative Source Contribution  
SAB — Science Advisory Board  
SDWA — Safe Drinking Water Act

SMR — standardized mortality ratio

TSH — thyroid stimulating hormone

TT3 — total triiodothyronine

TT4 - total thyroxine

UCMR3 — Unregulated Contaminant Monitoring Rule 3

UF — uncertainty factor

VLDL — very low-density lipid cholesterol

USEPA — United States Environmental Protection Agency

WY — Wyeth 14,643 (4-Chloro-6-[2,3-xylidino]-2-pyrimidinylthio)acetic acid), a model  
PPAR-alpha activating compound

## **ABSTRACT**

A Health-based Maximum Contaminant Level (Health-based MCL) for perfluorooctanoic acid (PFOA, C8) was developed using a risk assessment approach intended to protect for chronic (lifetime) drinking water exposure. A public health-protective approach in developing a Health-based MCL based on animal toxicology data is supported by associations of PFOA with a number of health effects in the general population and communities with drinking water exposure, as well as PFOA's biological persistence and bioaccumulation from drinking water in humans. PFOA was described as "likely to be carcinogenic to humans" by the USEPA Science Advisory Board, "possibly carcinogenic to humans" by the International Agency for Research on Cancer (IARC), and as having "suggestive evidence of carcinogenic potential" by the USEPA Office of Water. Both non-carcinogenic and carcinogenic effects were evaluated for Health-based MCL development. Delayed mammary gland development and increased liver weight were the most sensitive non-carcinogenic endpoints with data needed for dose-response modeling. For each of these endpoints, benchmark dose modeling of serum PFOA levels from mouse studies was performed and appropriate uncertainty factors were applied to develop a Target Human Serum Level (analogous to a Reference Dose but on a serum level basis). A clearance factor ( $1.4 \times 10^{-4}$  L/kg/day) which relates serum PFOA concentrations to human PFOA doses was applied to the Target Human Serum Levels to develop Reference Doses. For delayed mammary gland development, the Target Human Serum Level is 0.8 ng/ml, which is below the median serum PFOA level in the U.S. general population. The Reference Dose for this endpoint is 0.11 ng/kg/day. Because the use of delayed mammary gland development as the basis for quantitative risk assessment is a currently developing topic, a Health-based MCL using this endpoint as its primary basis was not recommended. However, it was concluded that an uncertainty factor for sensitive endpoints is needed to protect for this and other effects that occur at similarly low doses. A Health-Based MCL protective for increased relative liver weight was derived based on a study in which male mice were exposed to PFOA for 14 days. For increased relative liver weight, the Target Human Serum Level is 14.5 ng/ml and the Reference Dose is 2 ng/kg/day. This Target Human Serum Level and Reference Dose incorporate uncertainty factors to protect sensitive human subpopulations, to account for toxicodynamic differences between human and experimental animals, and to protect for more sensitive endpoints that occur from developmental exposures (delayed mammary gland development, persistent hepatic toxicity, and others). Default values for drinking water exposure assumptions (2 L/day water consumption; 70 kg body weight) and Relative Source Contribution factor (20%) were used to develop a Health-based MCL of 14 ng/L was based on the Reference Dose for increased relative liver weight. A cancer slope factor of  $0.021 \text{ (mg/kg/day)}^{-1}$  was developed based on increased incidence of testicular tumors in a chronic rat study. This slope factor was used to develop a Health-based MCL protective for cancer effects at the  $1 \times 10^{-6}$  (one in one million) lifetime cancer risk level of 14 ng/L, identical to the Health-based MCL based on non-cancer endpoints. The recommended Health-based MCL is therefore 14 ng/L (0.014  $\mu\text{g/L}$ ).

## **EXECUTIVE SUMMARY**

Perfluorooctanoic acid (PFOA, C8) is a member of the group of substances called perfluorinated compounds (PFCs), chemicals that contain a totally fluorinated carbon chain which varies in length and a functional group such as carboxylic or sulfonic acid. PFCs are part of a larger group of chemicals called poly- and perfluoroalkyl substances (PFAS).

The New Jersey Drinking Water Quality Institute (DWQI) voted to pursue development of a Maximum Contaminant Level (MCL) recommendation for PFOA on January 27, 2009 based on its potential health effects and its occurrence in New Jersey public water supplies (PWS). The Health Effects Subcommittee began its evaluation of PFOA during 2009-2010, but a Health-based MCL recommendation was not finalized at that time. A review of PFOA as an emerging drinking water contaminant was subsequently published by several current and former Subcommittee members in 2012 (Post et al., 2012). On March 21, 2014, New Jersey DEP Commissioner Bob Martin requested that the DWQI recommend an MCL for PFOA and two other perfluorinated compounds, perfluorononanoic acid (PFNA, C9) and perfluorooctane sulfonic acid (PFOS). The Subcommittee's evaluation and recommended Health-based MCL for PFOA are presented in this document.

As is the case for Health-based MCLs recommended by the DWQI in general, the recommended Health-based MCL for PFOA is based on the goals specified in the 1984 Amendments to the New Jersey Safe Drinking Water Act (SDWA) at N.J.S.A. 58:12A-20. This statute specifies a one in one million ( $10^{-6}$ ) risk of cancer from lifetime exposure to carcinogens, and that no "adverse physiological effects" are expected to result from lifetime ingestion for non-carcinogenic effects. Human health risk assessment approaches used by the DWQI to develop Health-based MCLs generally follow USEPA risk assessment guidance.

### **Manufacturing and Use**

Because carbon-fluorine bonds are among the strongest found in organic chemistry, PFOA and other PFCs are extremely stable and resistant to chemical reactions. PFOA has been produced for use in commercial products and industrial processes for over 60 years. Its unique surfactant properties and resistance to chemical and thermal degradation make it useful in many applications including water-, soil-, and stain-resistant coatings, fire-fighting foams, and industrial uses. Large amounts of PFOA were used industrially as a processing aid (emulsifier) in the production of fluoropolymers and fluoroelastomers for use as non-stick coatings.

Because of concerns about its ubiquitous presence in environmental media (including wildlife) and human blood serum worldwide, its persistent and bioaccumulative nature, and its potential health effects, the eight major U.S. producers of PFOA entered into a voluntary agreement with USEPA in 2006 to reduce emissions and product content of PFOA and its precursors by 95% by 2010 and to work towards eliminating them by 2015. However, other manufacturers and users of PFOA that are not participants in the voluntary agreement with USEPA continue to emit large



amounts of PFOA to the environment, particularly overseas. Although the production and use of PFOA and its precursors has been phased out by major U.S. manufacturers, environmental contamination and resulting human exposure to PFOA are anticipated to continue for the foreseeable future due to its persistence, formation from precursor compounds, and continued production by other manufacturers.

### **Environmental Fate and Transport**

Because of the extreme stability of their carbon–fluorine bonds, PFOA and other PFCs are extremely resistant to degradation in the environment and thus persist indefinitely. PFOA and other PFCs are found in many environmental media and in wildlife worldwide including in remote polar regions. PFOA is much less bioaccumulative in fish than PFOS or perfluorinated carboxylates with more than eight carbons, and PFOA concentrations in wildlife are generally lower than for these other PFCs. PFOA and other PFCs can be taken up into plants from contaminated soil or irrigation water. In general, PFOA and other longer chain PFCs are preferentially taken up into the root and shoot parts of the plant.

PFOA and some other PFCs are distinctive from other persistent and bioaccumulative organic compounds because of their importance as drinking water contaminants. PFOA does not bind well to soil, migrates readily from soil to ground water, and is highly water-soluble. These properties of PFOA differ from those of other well-known persistent and bioaccumulative organic pollutants such as polychlorinated dioxins and polychlorinated biphenyls (PCBs) that have a high affinity for soil and sediments but low water solubility.

PFOA that is released into the environment can contaminate surface water and groundwater used as drinking water sources. Environmental sources include industrial discharge to soil, air, and water; release of aqueous firefighting foams; disposal in landfills; wastewater treatment plant discharge; street and storm water runoff; and land application of biosolids, industrial solid waste, and wastewater. PFOA also enters the environment through the breakdown of precursor compounds such as the fluorotelomer alcohol 8:2 FTOH and larger molecules that can release 8:2 FTOH. These precursor compounds are used industrially and in consumer products. They are converted to PFOA by microbes in soil, sludge, and wastewater and through atmospheric chemical reactions.

As is the case for other ground water contaminants, PFOA can reach drinking water wells via migration of a ground water plume. Unlike many other environmental contaminants, PFOA emitted to air from industrial facilities can also contaminate distant groundwater wells through air transport, followed by deposition from air onto soil, and migration through the soil to groundwater.

### **Occurrence in Drinking Water**

PFOA and other PFCs are not effectively removed from drinking water by standard treatment processes but can be removed from drinking water by granular activated carbon (GAC) or reverse osmosis. Therefore, unless specific treatment for removal of PFCs is in place, concentrations of PFOA detected in raw drinking water can be considered to be representative of concentrations in finished drinking water.

The occurrence of PFOA and other PFCs in public water supplies (PWS) has been evaluated more extensively in New Jersey than in most or all other states. More than 1,000 samples from 80 NJ PWS were analyzed with relatively low Reporting Levels (RLs; generally  $\leq 5$  ng/L) in 2006-2016. PFOA was the most frequently detected PFC and was found in samples from approximately 60% of the 80 NJ PWS tested. In the 2013-2015 USEPA Unregulated Contaminant Monitoring Rule 3 (UCMR3) survey of all large (>10,000 users) and a subset of smaller PWS in the U.S., PFOA was detected more than five times more frequently in New Jersey PWS (10.5%) than nationally (1.9%). The RL in UCMR3 was 20 ng/L, much higher than the RLs for most other NJ PWS monitoring. PFOA has also been detected in NJ private wells near sources of industrial discharge.

### **Human Biomonitoring**

PFOA and other PFCs are found ubiquitously in the blood serum of the general population in the U.S. and worldwide. The most recent (2011-2012) National Health and Nutrition Examination Survey (NHANES), a representative sample survey of the U.S. general population conducted by the U.S. Centers for Disease Control and Prevention (CDC), determined the geometric mean and 95<sup>th</sup> percentile serum PFOA concentrations as 2.08 and 5.68 ng/ml, respectively. Serum PFOA levels in the U.S. general population have declined since the first NHANES monitoring in 1999-2000 when the geometric mean and 95<sup>th</sup> percentile values were 5.21 and 11.9 ng/ml. In communities exposed through contaminated drinking water, serum PFOA levels are elevated compared to the general population. Exposures to industrially-exposed workers or others with occupational exposure are much higher than in the general population. Serum PFOA concentrations of greater than 100,000 ng/ml (100 ppm) have been reported in industrially exposed workers, although levels in most workers were lower.

### **Sources of Exposure**

Sources of exposure to PFOA and/or its precursors include drinking water, food and food packaging, treated fabrics, protective sprays and waxes, cosmetics and personal care products, house dust, and inhalation of indoor and outdoor air. Most studies predict that food and food packaging are the predominant exposure sources, and several studies suggest that PFOA and its precursors in indoor air and/or house dust can be a major exposure source. It should be noted that migration of PFOA from polytetrafluoroethylene (PTFE)-coated non-stick cookware into food is not considered to be a significant source of exposure. The contribution of ingested drinking water to total exposure from all sources (e.g. diet, consumer products, etc.) is dependent

on the concentration of PFOA in the drinking water, and relatively low concentrations in water substantially increase human body burden. Inhalation from showering, bathing, laundry, and dishwashing, and dermal absorption during showering, bathing, or swimming, are not expected to be significant sources of exposure from contaminated drinking water.

Exposures to PFOA may be higher in young children than in older individuals because of age-specific behaviors such as greater drinking water and food consumption on a body weight basis, hand-to-mouth behavior resulting in greater ingestion of house dust, and more time spent on floors where treated carpets are found.

### **Toxicokinetics**

PFOA is well absorbed orally, and it was also absorbed dermally and by inhalation in toxicological studies. It is water soluble and distributes primarily to the liver and serum, and, to a lesser degree, to the kidney. Unlike most other bioaccumulative organic compounds, it does not distribute to fat. In the serum, PFOA is almost totally bound to albumin and other proteins. Since it is chemically non-reactive, it is not metabolized. The rate of excretion is largely dependent on the extent of secretion and reabsorption by organic anion transporters in the kidney. The excretion rate varies widely among species, and in some cases between males and females of the same species.

PFOA's half-life in humans is several years and is similar in males and females. Because of its long half-life, it remains in the human body for many years after exposures cease. PFOA is persistent in both male and female mice and in male rats, with half-lives of days to weeks. However, PFOA is rapidly excreted in female rats (half-life of 2-4 hours); thus, this species is not an ideal model for studying potential human developmental effects. Because of the large variation in half-lives, the internal dose resulting from a given administered dose varies widely among species and, in some cases, genders of the same species. For this reason, interspecies (e.g. animal-to-human) comparisons are made on the basis of internal dose, as indicated by serum level, rather than administered dose.

### **Relationship between drinking water exposure and human serum levels**

Data from communities with contaminated drinking water indicate that ongoing human exposure to PFOA in drinking water increases serum levels, on average, by at least 100 times the drinking water concentration. A human clearance factor for PFOA of  $1.4 \times 10^{-4}$  L/kg/day was developed by USEPA researchers (Lorber and Egeghy, 2011) to relate serum PFOA concentration to administered dose. Assuming an average U.S. daily water consumption rate, the clearance factor predicts a serum:drinking water ratio of 114:1, consistent with the ratios that have been observed in exposed communities.

Continued exposure to even low drinking water concentrations results in substantially increased serum PFOA levels. Based on the clearance factor, each 10 ng/L in drinking water is predicted

to increase serum PFOA by 1.1 ng/ml with an average water consumption rate, and 2.0 ng/ml with an upper percentile water consumption rate. These increases in serum PFOA from drinking water can be compared to the most recent NHANES geometric mean, 2.08 ng/ml, and 95<sup>th</sup> percentile, 5.68 ng/ml, serum PFOA concentrations. Increases in serum PFOA levels predicted from average and upper percentile drinking water consumption at various drinking water PFOA concentrations are shown in Figure E-1.




Figure E-1. Increases in serum PFOA concentrations predicted from mean and upper percentile consumption of drinking water with various concentrations of PFOA, as compared to U.S median and 95<sup>th</sup> percentile serum PFOA levels (NHANES, 2011-12).

### Exposures to infants

In humans, PFOA has been measured in amniotic fluid, maternal serum, umbilical cord blood, and breast milk. Serum PFOA concentrations in infants at birth are similar to those in maternal serum. Both breast-fed infants whose mothers ingest contaminated drinking water and infants fed with formula prepared with contaminated drinking water receive much greater exposures to PFOA than older individuals who consume drinking water with the same PFOA concentration. PFOA exposure in breast-fed infants is greatest during the first few months of life because both PFOA concentrations in breast milk and the rate of fluid consumption are highest then. As a result, serum PFOA concentrations in breast-fed infants increase several fold from levels at birth within the first few months of life (Figure E-2). Exposures to infants who consume formula prepared with contaminated water are also highest during this time period. While serum PFOA levels peak during the first year of life, they remain elevated for several years. These elevated

exposures during infancy and early childhood are of particular concern because early life effects are sensitive endpoints for the toxicity of PFOA.




Figure E-2. From Verner et al. (2016a). Modeling simulation of the ratio of PFOA in blood plasma in breast fed infants/children to plasma concentration in mother. Black line - 50th percentile. Blue line - 5th percentile. Red line - 95th percentile. Dotted lines - minimum and maximum values.

### **Health Effects**

Because the scientific database related to health effects of PFOA is very large, the Subcommittee focused its evaluation on specific endpoints from human and animal studies. Relevant studies were identified through literature searches of the PubMed database, from earlier evaluations of PFOA by the Health Effects Subcommittee, and through backwards searching.

### **Epidemiology**

The choice of endpoints selected for comprehensive review from epidemiology studies was largely based on knowledge gained from previous evaluations by the Subcommittee. Health endpoints evaluated comprehensively were serum cholesterol/lipids, liver enzymes/bilirubin and liver disease, uric acid, thyroid function and thyroid disease, and antibody concentrations following vaccination. In total, 54 epidemiological studies were evaluated in depth, including studies from the general population, communities with drinking water exposures including most notably the C8 Health Study - a large study of about 70,000 Ohio and West Virginia residents exposed to a wide range of PFOA concentrations (>50 ng/L to over 3000 ng/L) in drinking water, and occupationally exposed workers. Recent comprehensive reviews by other authoritative scientific groups were evaluated for two additional critical endpoints, fetal growth following developmental exposure and cancer.

Of the endpoints that were evaluated comprehensively, the evidence for associations with PFOA was strongest for increases in serum levels of cholesterol, the liver enzyme ALT, and uric acid.

PFOA was associated with clinically defined hypercholesterolemia in a community exposed through drinking water. The epidemiological evidence supports multiple criteria for a causal relationship between PFOA and both serum cholesterol and ALT. Notably, the steepest dose-response for associations with these endpoints was within the range of serum PFOA concentrations found in the general population and communities with drinking water exposures, with a much flatter curve at higher serum concentrations.

For some other endpoints that were comprehensively reviewed, limited evidence of an association with PFOA was found. Although there is consistent evidence of decreased antibody concentrations following vaccination, most of the vaccine types were evaluated in only one or two studies. Other endpoints with limited evidence of an association include LDL, the liver enzymes GGT and AST, bilirubin, liver disease, and thyroid disease. There was limited or no evidence of association of PFOA with TSH and thyroid hormones, and no evidence for association with HDL or the liver enzyme ALP.

A systematic review using the Navigation Guide methodology concluded that there is “sufficient” human evidence, the strongest descriptor for strength of evidence, that developmental exposure to PFOA reduces fetal growth (e.g. birth weight) in humans (Johnson et al., 2015). The Health Effects Subcommittee found that the basis for this conclusion is reasonable and supportable. Maternal glomerular filtration rate (GFR) was evaluated as a potential confounding factor for this effect, and it was concluded that decreased GFR does not account for the major portion of the decrease in fetal growth associated with PFOA.

PFOA was associated with increased incidence of testicular and kidney cancer in communities with drinking water exposure. These studies accounted for smoking history and other relevant factors. The USEPA SAB (2006) described PFOA as “likely to be carcinogenic to humans.” based on the criteria provided in USEPA (2005b) cancer risk assessment guidance. More recently, IARC (2015) concluded that PFOA is possibly carcinogenic to humans, and the USEPA Office of Water (2016a) described it as having suggestive evidence of carcinogenic potential.

Although the magnitude of change for some of the parameters associated with PFOA was relatively small, they are of public health concern because population-level changes of this magnitude will result in a shift in the overall distribution of values such that the number of individuals with clinically abnormal values is increased. Additionally, small changes in a clinical biomarker may be an indicator of other effects that were not evaluated. For example, relatively small decreases in birth weight may be an indication of changes in other more subtle developmental parameters which were not assessed.

In summary, associations of PFOA with numerous health endpoints have been found in human populations with evidence supporting criteria for causality for some endpoints. These health endpoints include non-carcinogenic effects in the general population, and both non-carcinogenic

effects and cancer in communities with drinking water exposure. The epidemiologic data for PFOA are notable because of the consistency between results among human epidemiologic studies in different populations, the concordance with toxicological findings from experimental animals, the use of serum concentrations as a measure of internal exposure, the potential clinical importance of the endpoints for which associations are observed, and the observation of associations within the exposure range of the general population. These features of the epidemiologic data distinguish PFOA from most other organic drinking water contaminants and justify concerns about exposures to PFOA through drinking water. Although there is evidence to support causality for some epidemiological endpoints, the human data have limitations and therefore are not used as the quantitative basis for the Health-based MCL. Instead, the potential Health-based MCLs developed below are based on sensitive and well established animal toxicology endpoints that are considered relevant to humans based on mode of action data.

### Toxicology

The toxicological database for PFOA includes evaluation of numerous effects in non-human primates and rodents. The Health Effects Subcommittee's review focused on endpoints that were identified as sensitive and potentially appropriate for use in risk assessment. The effects selected for detailed review were hepatic toxicity, developmental effects, immune system toxicity, and carcinogenicity. As discussed above, effects relevant to these endpoints have been associated with PFOA in human epidemiological studies. Additionally, information is presented on general toxicity in non-human primates, as well as thyroid, neurobehavioral, and male reproductive effects.

The non-human primate studies have limitations that preclude their consideration as the basis for risk assessment. These include very small numbers of animals, severe toxicity at the lowest dose, loss of animals during the study due to toxicity and/or mortality, and lack of dose-response for key endpoints (e.g. increased liver weight).

Increased liver weight is a sensitive toxicological endpoint for PFOA which has been observed in many studies in both non-human primates and rodents. Increased liver weight can co-occur with and/or progress to more severe hepatic effects including hepatocellular necrosis, fatty liver, increased serum liver enzymes, and hyperplastic nodules. Recent studies show that developmental exposure to low doses of PFOA in mice causes cellular changes indicative of liver toxicity that persist until adulthood.

Reproductive or developmental effects of PFOA have not been studied in non-human primates. The mouse is an appropriate species for evaluating effects on reproduction and development since the female mouse excretes PFOA slowly, as do humans. In contrast, rats and rabbits are not ideal models for studying these effects because they excrete PFOA very quickly, with a half-life of a few hours. Effects from developmental exposures in mice include full litter resorptions,



decreased postnatal survival and growth, delayed development, accelerated sexual maturation in males, persistent liver toxicity (noted above), and delayed mammary gland development. PFOA also causes reproductive toxicity in male mice.

Delayed mammary gland development and persistent liver toxicity after perinatal (prenatal and/or neonatal) exposure are sensitive endpoints which occur in mice at lower doses of PFOA than other developmental effects. Delayed mammary gland development has been reported in nine separate studies presented in five publications, while only one study which has several general problematic issues did not find this effect. Gestational and/or lactational exposures to PFOA caused delayed mammary gland development in pregnant dams and/or female offspring in two strains of mice. Histological changes in the mammary gland of exposed offspring occurred in a dose-related fashion, persisted until adulthood, and were considered permanent. However, available toxicological information is not sufficient to make conclusions about the effects of PFOA on lactational function. Maternal PFOA exposure was associated with shorter breastfeeding in the three human studies that evaluated this effect, and there is no information indicating that the histological changes observed in mice are not relevant to humans.

Additional studies evaluated effects of peripubertal (around the time of puberty) exposure on mammary gland development in mice. These studies cannot be directly compared to studies of perinatal exposure because effects on mammary gland development differ depending on the lifestage when exposure occurs. Additionally, interpretation of the peripubertal studies is problematic because each PFOA dose level was used in only one study in each of the strains of mice evaluated, such that dose-response interpretations can only be made by combining data from different studies.

PFOA suppressed the immune system in studies of rhesus monkeys and mice. Decreased bone marrow cellularity and lymphoid atrophy occurred in monkeys, while effects in mice included decreased spleen and thymus weights, decreased thymocyte and splenocyte counts, decreased immunoglobulin response, and changes in total numbers and/or specific populations of lymphocytes. Immune system effects were not observed in two rat studies which included doses higher than those which generally caused these effects in mice.

Review of the toxicological data indicates that increased liver weight is an endpoint that is as sensitive or more sensitive than immune system toxicity or reproductive/developmental effects, with the exception of delayed mammary gland development.

PFOA caused tumors of the liver, pancreatic acinar cells, and testicular Leydig cells in male rats. Since PFOA is rapidly excreted by female rats, chronic studies in another species in which PFOA is persistent in both sexes, such as the mouse, would provide important information



specific to females. A recent study suggests that prenatal exposure to PFOA in mice caused an increased incidence of liver tumors. However, this study was not designed as a carcinogenicity bioassay and does not provide definitive information on this issue. Additional research on carcinogenicity later in life after developmental exposures to PFOA is needed.

### **Mode of Action**

The mode(s) of action of PFOA have not been fully characterized. Based on the information reviewed by the Health Effects Subcommittee, the toxicological effects of PFOA are generally considered relevant to humans for the purposes of risk assessment.

PFOA is not chemically reactive. Thus, it is not metabolized to reactive intermediates and does not covalently bind to nucleic acids and proteins. Consistent with these properties, available data indicate that it is not genotoxic.

### **Activation of nuclear receptors and role of PPAR-alpha**

Effects of PFOA occur through multiple modes of action including activation of receptors that control the expression of genes involved in many biological pathways. Much attention has been focused on the potential human relevance of effects that occur through activation of the nuclear receptor, peroxisome proliferator-activated receptor-alpha (PPAR-alpha). This question arises because many PPAR-alpha activating compounds cause rodent liver tumors; the human relevance of these tumors is subject to debate due to lower levels and/or differences in intrinsic activity of PPAR-alpha in human liver. However, the uncertainty about human relevance does not necessarily apply to PPAR-alpha mediated effects other than liver tumors. Both human and mouse PPAR-alpha are activated by PFOA *in vitro*, and the results do not clearly indicate that human PPAR-alpha is less sensitive than rodent PPAR-alpha in these *in vitro* systems.

### **Hepatic effects**

Studies of non-human primates, standard strains of rats and mice, PPAR-alpha null mice, and humanized PPAR-alpha mice support the conclusion that hepatic effects of PFOA are relevant to humans for the purposes of risk assessment. As noted above, PFOA is associated with increased liver enzymes in human epidemiological studies.

In a subchronic study of cynomolgus monkeys, a species in which human relevance of hepatic effects is not in question, PFOA caused increased liver weight and peroxisomal proliferating activity similar in magnitude to that seen in rats, demonstrating that hepatic PPAR-alpha activity in response to PFOA is not limited to rodents. In this study, several animals exhibited notably increased liver weight, highly elevated serum liver enzymes, and/or severe hepatic toxicity.

Observations in standard strains of laboratory rodents indicate that PFOA causes PPAR-alpha independent hepatic effects in rodents with normal PPAR-alpha function. In these strains,

increased relative liver weight caused by PFOA did not directly correspond with hepatic peroxisome proliferating activity. Additionally, PFOA caused fatty liver in these standard strains, although PPAR-alpha activation decreases hepatic lipids. Finally, developmental exposure to PFOA caused abnormal mitochondria in livers of a standard mouse strain, with no evidence of peroxisome proliferation.

PFOA caused decreased serum lipids, typically associated with PPAR-alpha activation, in rodents, while increased serum lipids are associated with PFOA exposure in humans. Recent studies suggest that these differences may be related to the low fat diet generally used in laboratory rodent studies versus the higher fat content of a typical Westernized human diet, rather than solely to interspecies differences.

Studies comparing wild type (with normal PPAR-alpha) and PPAR-alpha null (lacking PPAR-alpha) mice provide further evidence that hepatic effects occur through both PPAR-alpha dependent and independent pathways. PFOA caused similar increases in liver weight in wild type and PPAR-alpha null strains. Increased liver enzymes and histopathological changes, particularly damage to the bile duct, also occurred in PFOA-treated PPAR-alpha null mice. Additionally, developmental exposures to PPAR-alpha null mice caused persistent histopathological changes in the liver.

Studies of strains of mice which express human PPAR-alpha in the liver (humanized PPAR-alpha mice) indicate that PFOA causes hepatic effects through activation of human PPAR-alpha. In humanized PPAR-alpha mice, PFOA caused increased liver weight similar to that in wild type mice, activation of hepatic genes associated with PPAR-alpha, and histopathological changes in the liver. Fetal liver weight was increased similarly in wild type and humanized PPAR-alpha mice after *in utero* exposure, and expression of genes associated with PPAR-alpha in fetal liver was increased to a greater degree in humanized PPAR-alpha mice than in wild type mice.

#### Immune system effects

PFOA suppresses the immune system in both non-human primates and mice. As noted above, decreased response to vaccinations has been associated with PFOA in human epidemiological studies. Data from mouse studies indicate that these effects on the immune system occur through both PPAR-alpha dependent and independent modes of action. Both PPAR-alpha dependent and independent effects on the immune system are considered relevant to humans for the purposes of risk assessment.

#### Developmental and reproductive effects

As noted above, decreased fetal growth is associated with PFOA in human epidemiological studies. Developmental effects of PFOA in rodents appear to occur primarily through PPAR-alpha dependent mechanisms, while some reproductive effects such as full litter resorptions

appear to be PPAR-alpha independent. PPAR-alpha and other PPARs are present in human fetal tissues and are expected to have important roles in reproduction and development. Therefore, PPAR-alpha mediated effects of PFOA on development are considered relevant to humans for the purposes of risk assessment. Toxicity to the placenta may play a role in PFOA's developmental effects such as fetal growth retardation; more research is needed on this question.

Delayed mammary gland development after developmental exposure is a sensitive endpoint for PFOA toxicity in mice. The rodent is considered a good model for human mammary gland development, and there is no mode of action evidence suggesting that the effects of PFOA on this endpoint are not relevant to humans.

PFOA also causes male reproductive toxicity in mice, and there is no mode of action information to suggest that these effects are not relevant to humans.

#### Carcinogenicity

As noted above, PFOA has been associated with increased incidence of kidney and testicular cancer in communities exposed through drinking water after adjustment for smoking and other relevant factors. The USEPA Science Advisory Board (2006) concluded that the liver tumors caused by PFOA in rats are potentially relevant to humans, based on similarities in hepatic effects of PFOA in monkeys and rodents and the limited evidence available at the time on hepatic effects of PFOA in PPAR-alpha null mice. Subsequent studies in PPAR-alpha null mice have provided substantial additional relevant data. Importantly, hepatic cell proliferation, a causal event for tumor formation, is increased similarly by PFOA in wild type and PPAR-alpha null mice. Although a carcinogenicity bioassay of PFOA has not been conducted in PPAR-alpha null mice, a recent study suggests that developmental exposures to PFOA may cause hepatic tumors in adulthood in this strain. Finally, studies in rainbow trout, a species used as a model for human liver cancer because it lacks PPAR-alpha, suggest that PFOA causes liver tumors through an estrogenic mode of action.

The mode of action for the testicular and pancreatic tumors caused by PFOA in rats has not been established. Therefore, they are considered relevant to humans for the purposes of risk assessment.

#### Additional modes of action

A number of other modes of action for PFOA have been suggested including effects on intercellular gap junction communication, effects on mitochondria, changes in expression of microRNAs (miRNAs), and effects related to transporter proteins such as organic anion transporters (OATs) and multidrug resistance-associated proteins (MRPs).

### **Development of Recommended Health-based MCL**

Health-based MCLs developed by the DWQI are intended to be protective for chronic (lifetime) exposure through drinking water. The 1984 Amendments to the New Jersey Safe Drinking Water Act (N.J.S.A. 58:12A-20) stipulate that Health-based MCLs be based on a one in one million lifetime cancer risk level for carcinogens and no adverse effects from lifetime ingestion for non-carcinogens. PFOA was described as “likely to be carcinogenic to humans” by the USEPA Science Advisory Board and “possibly carcinogenic to humans” by the International Agency for Research on Cancer (IARC), and as having “suggestive evidence of carcinogenic potential” by the USEPA Office of Water. As such, the Health Effects Subcommittee evaluated both non-carcinogenic and carcinogenic effects using approaches consistent with USEPA risk assessments guidance and previous risk assessments developed by NJDEP and the DWQI.

Both the human epidemiology data and the animal toxicology data were considered as part of the overall weight of evidence for the potential human health effects of PFOA. As discussed above, PFOA is associated with non-carcinogenic effects in the general population, and with both non-carcinogenic effects and cancer in communities with drinking water exposure. Although the data for some endpoints support multiple criteria for causality, the human epidemiology data have limitations and are therefore not used as the quantitative basis for the Health-based MCL. As such, the recommended Health-based MCL is based on sensitive and well established animal toxicology endpoints that are considered relevant to humans. Notwithstanding, the human data suggest that continued human exposure to even relatively low concentrations of PFOA in drinking water results in elevated body burdens that increase the risk of health effects, indicating a need for caution about exposures from drinking water. Therefore, the human epidemiological data support the use of a public health-protective approach in developing a Health-based MCL recommendation based on animal toxicology data.

### **Health-based MCL based on non-carcinogenic effects**

Delayed mammary gland development and increased relative liver weight were identified as the most sensitive non-carcinogenic endpoints with data appropriate for dose-response modeling, and it was concluded that these endpoints are relevant to humans for the purposes of risk assessment. Benchmark dose (BMD) modeling of serum PFOA data from toxicological studies was performed to determine the BMDLs (lower 95% confidence limit on the doses corresponding to a minimal response) for the serum concentrations that are used as the points of departure (PODs) for these endpoints. Only studies that provide serum PFOA data were considered for dose-response modeling for these effects, since measured serum levels are associated with less uncertainty than serum level estimates from pharmacokinetic modeling or interspecies extrapolations based on half-life differences.

### Effects on mammary gland development

Delayed mammary gland development is the most sensitive systemic endpoint with data appropriate for dose-response modeling, and a Reference Dose (RfD) was developed for this endpoint. To the knowledge of the Health Effects Subcommittee, this endpoint has not previously been used as the primary basis for health-based drinking water concentrations or other human health criteria. Because the use of delayed mammary gland development as the basis for quantitative risk assessment is a currently developing topic, a Health-based MCL with this RfD as its primary basis was not recommended. However, it was concluded that an additional uncertainty factor (UF) should be incorporated into the RfD based on increased liver weight (the endpoint used as the basis for the recommended Health-based MCL - see below) to protect for mammary gland effects, persistent liver toxicity, and other effects from developmental exposures at doses far below those that cause increased relative liver weight.

A study of exposure to pregnant mice on days 10-17 of gestation (Macon et al., 2011) is the only developmental exposure study of mammary gland development that provides serum PFOA data appropriate for dose-response modeling. Of the multiple time points assessed in this study, delays in mammary gland development were most evident on postnatal day (PND 21). Of the several endpoints related to mammary gland development that were evaluated, decreases in mammary gland developmental score and number of terminal end buds were selected for dose-response modeling because they showed a statistically significant dose-related decrease at PND 21. BMD modeling was based on serum levels at PND 1, since they were higher at this time than at later time points. The serum concentration BMDLs for a 10% change in decreased developmental score and decreased number of terminal end buds were 24.9 and 22.9 ng/ml, respectively.

A total UF of 30, including UFs of 10 for intra-human variability and 3 for animal-to-human toxicodynamic differences, was applied to the serum level BMDL for decreased number of terminal end buds, 22.9 ng/ml, to derive a Target Human Serum Level of 0.8 ng/ml. The typical UF of 3 for toxicokinetic variability between species is not included because the risk assessment is based on comparison of internal dose (serum levels) rather than administered dose. The Target Human Serum Level is analogous to a RfD in terms of internal, rather than administered, dose. This Target Human Serum Level for delayed mammary gland development of 0.8 ng/ml is below the median serum PFOA level in the U.S. general population (2.1 ng/ml). The clearance factor mentioned above,  $1.4 \times 10^{-4}$  L/kg/day, was applied to the Target Human Serum Level, 0.8 ng/ml, to calculate an RfD of 0.11 ng/kg/day.

### Hepatic effects

Increased relative liver weight is a well-established effect of PFOA which is more sensitive than most other toxicological effects such as immune system toxicity and most

reproductive/developmental effects (Table 12 of Animal Toxicology section). The recommended Health-based MCL for non-carcinogenic effects is based on this endpoint.

A study of male mice exposed to branched/linear PFOA for 14 days (Loveless et al., 2006) that showed a dose-related increase in relative liver weight was selected for dose-response modeling. This isomeric mixture is relevant to environmental contamination and human exposure, and it was used in almost all toxicological studies of PFOA. Because review of studies of increased relative liver weight indicated that the magnitude of this effect does not increase with exposure durations longer than 14 days, this study was considered to be of sufficient duration for use as the basis for a Health-based MCL. BMD modeling of the serum PFOA data from the study determined a serum level BMDL for a 10% increase in relative liver weight of 4350 ng/ml.

A total UF of 300 was applied to the serum level BMDL of 4350 ng/ml to derive a Target Human Serum Level of 14.5 ng/ml. This UF includes UFs of 10 for intra-human variability, 3 for animal-to-human toxicodynamic differences, and 10 to protect more sensitive toxicological effects. These more sensitive effects, including delayed mammary gland development and hepatic toxicity after developmental exposures, occurred at doses 100-fold lower than the Lowest Observed Adverse Effect Level (LOAEL) for increased liver weight. Although the study duration was only 14 days and the Health-based MCL is intended to protect for chronic exposure, a UF for less-than-chronic duration of exposure was not applied because increased liver weight does not appear to increase in magnitude when exposures continue beyond two weeks. The clearance factor mentioned above,  $1.4 \times 10^{-4}$  L/kg/day, was applied to the Target Human Serum Level, 14.5 ng/ml, to calculate an RfD of 2 ng/kg/day.

#### Relative Source Contribution factor

A Relative Source Contribution (RSC) factor that accounts for non-drinking water sources including food, soil, air, water, and consumer products is used by USEPA, NJDEP, and the DWQI in the development of health-based drinking water concentrations based on non-carcinogenic effects. The default value for the RSC is 20%, meaning that 20% of total exposure is assumed to come from drinking water and 80% from non-drinking water sources. If supported by available data, a higher chemical-specific value (up to 80%) can be used (i.e. the percent exposure from non-drinking water sources is lower than the default assumption of 80%). The Health Effects Subcommittee concluded that there are insufficient data to develop a chemical-specific RSC for PFOA. USEPA UCMR3 monitoring shows that PFOA occurs (at concentrations greater than 20 ng/L) more frequently in PWS located throughout New Jersey (10.5%) than nationwide (1.9%).

There are no New Jersey-specific biomonitoring data for PFOA, and the more frequent occurrence in NJ PWS suggests that New Jersey residents may also have higher exposures from non-drinking sources, such as contaminated soils, house dust, or other environmental media,

than the U.S. general population. Additionally, the default RSC of 20%, while not explicitly intended for this purpose, also partially accounts for the greater exposures to infants who are breast-fed or consume formula prepared with contaminated drinking water, as compared to older individuals. These higher exposures during infancy must be considered because short term exposures to infants are relevant to the effects of concern (delayed mammary gland development and increased relative liver weight). Therefore, the default RSC of 20% was used to develop the Health-based MCL.

#### Health-based MCL based on non-carcinogenic effects

The Health-based MCL protective for increased liver weight, based on the RfD of 2 ng/kg/day, standard drinking water exposure assumptions (2 L/day water consumption; 70 kg body weight), and a 20% RSC is 14 ng/L (0.014 µg/L).

#### Health-based MCL based on carcinogenic effects

Testicular tumor data from the chronic dietary exposure rat study (Butenhoff et al., 2012) are the only tumor data appropriate for dose-response modeling and were used to develop a cancer potency factor. The BMDL for 5% tumor incidence is 2.36 mg/kg/day, and the corresponding cancer potency factor is 0.021 (mg/kg/day)<sup>-1</sup>. The dose in rats corresponding to a  $1 \times 10^{-6}$  risk level,  $4.8 \times 10^{-5}$  mg/kg/day, was converted to the human equivalent dose of  $4 \times 10^{-7}$  mg/kg/day (0.4 ng/kg/day) using a pharmacokinetic adjustment based on the ratio of half-lives in the two species. Using default drinking water assumptions (2 L/day water consumption; 70 kg body weight), the Health-based MCL at the  $1 \times 10^{-6}$  lifetime cancer risk level is 14 ng/L. This value is identical to the Health-based MCL based on non-cancer endpoints developed above.

#### Potential for additive toxicity with other PFCs

The Health Effects Subcommittee notes that available information indicates that the target organs and modes of action are generally similar for PFOA and some other PFCs, such as PFNA. Therefore, the toxicity of PFOA and other PFCs may be additive. Although PFOA and other PFCs, including PFNA, are known to co-occur in some NJ public water supplies, the potential for additive toxicity of PFOA and other PFCs was not considered in development of the Health-based MCL.

**The recommended Health-based MCL is 14 ng/L (0.014 µg/L).**



## **INTRODUCTION**

### **Development of Health-based MCLs by New Jersey Drinking Water Quality Institute**

The New Jersey Drinking Water Quality Institute (DWQI) was established by the 1984 amendments to the New Jersey Safe Drinking Water Act (SDWA) at N.J.S.A. 58:12A- 20. It is charged with developing standards (Maximum Contaminant Levels; MCLs) for hazardous contaminants in drinking water and for recommending those standards to the New Jersey Department of Environmental Protection (NJDEP). The Health Effects Subcommittee (formerly “Lists and Levels Subcommittee”) of the DWQI is responsible for developing health-based drinking water levels (Health-based MCLs) as part of the development of MCL recommendations (for example: DWQI, 1987; 1994; 2009a).

Health-based MCLs are based on the goals specified in the 1984 Amendments to the NJ SDWA. For carcinogens, it is generally assumed that any level of exposure results in some level of cancer risk, and a one in one million ( $10^{-6}$ ) risk level from lifetime exposure is specified in the statute. Health-based MCLs for carcinogens are thus set at levels that are not expected to result in cancer in more than one in one million persons ingesting the contaminant for a lifetime. For non-carcinogenic effects, it is generally assumed that exposure below a threshold level will not result in adverse effects. As specified in the statute, Health-based MCLs are set at levels which are not expected to result in “any adverse physiological effects from ingestion” for a lifetime. The risk assessment approach used to develop Health-based MCLs is generally consistent with USEPA risk assessment guidance.

Other factors such as analytical quantitation limits and availability of treatment removal technology are also considered in the final MCL recommendation. For carcinogens, the 1984 Amendments to the NJ SDWA require that MCLs are set as close to the one in one million lifetime risk goal as possible “within the limits of medical, scientific and technological feasibility.” For non-carcinogens, MCLs are set as close to the goal of no adverse effects as possible “within the limits of practicability and feasibility.”

To support the development of an MCL recommendation by the DWQI, the Health Effects Subcommittee has developed a draft Health-based Maximum Contaminant Level for PFOA. As specified in the 1984 Amendments to the NJ SDWA, this Health-based MCL is intended to be protective for chronic (lifetime) drinking water exposure.

### **Timeline of Health Effects Subcommittee’s evaluation of PFOA**

On January 27, 2009, the DWQI voted unanimously to add PFOA to its work plan for development of an MCL recommendation (DWQI, 2009b). On September 10, 2010, the Health Effects Subcommittee reported to the DWQI Testing and Treatment Subcommittees that it had made progress in its evaluation PFOA. Although no decision on a Health-based MCL recommendation had been made, the Subcommittee provided a memo stating that it was



considering potential values for a PFOA Health-based MCLs within the range of 10 ng/L to 40 ng/L, or as low as reasonably achievable (DWQI, 2010).

In 2012, several current and former members of the Health Effects Subcommittee published a comprehensive review of PFOA as an emerging drinking water contaminant in a peer-reviewed journal (Post et al., 2012). This publication was based in part on the literature review and evaluation conducted by the Health Effects Subcommittee in 2009-2010.

On March 21, 2014, New Jersey DEP Commissioner Bob Martin requested that the DWQI recommend MCLs for three perfluorinated compounds: perfluorononanoic acid (PFNA, C9), PFOA, and perfluorooctane sulfonic acid (PFOS). The Health Effects Subcommittee commenced its evaluation of PFOA after completing its work on PFNA, for which the DWQI recommended an MCL on July 1, 2015 (DWQI, 2015a).

### **Document development process**

The Subcommittee began its current evaluation of PFOA by formulating an approach for the review of relevant information and document development. Because the scientific database related to health effects of PFOA is very large, the Subcommittee chose to focus on specific endpoints from human and animal studies for hazard identification and/or dose-response. Criteria for selection of the human and animal endpoints that were reviewed in depth are discussed in the Epidemiology and Toxicology sections.

The Health Effects Subcommittee conducted a literature search of the PubMed database through April 2015 using relevant search terms which are provided in Appendix 1. The U.S. National Library of Medicine's Toxline database was searched using similar keywords as the PubMed search strings. The Toxline search yielded a significant number of non-peer reviewed documents including articles, policy papers, and grant proposals, and ultimately Toxline did not identify additional peer-reviewed literature for inclusion in the Subcommittee's review. Studies evaluated by the Subcommittee also included relevant citations from the earlier Subcommittee evaluations of PFOA mentioned above, as well as backward searching. PubMed is searched on a monthly basis by the NJDEP Environmental Research Library, and an ongoing title review of these searches was conducted to identify any additional studies for inclusion.

The original PubMed search identified 2,016 references. All of these references were screened by title, abstract, and/or full text. Title and abstract review was used to sort studies into inclusion categories for consideration for detailed evaluation related to hazard identification and/or dose-response evaluation using EndNote (Appendix 1). Studies were excluded if they were "Unrelated" (did not assess PFOA, proposals, or reviews), or "Non-health" (studies of a analytical methods, environmental occurrence, sources of human or wildlife exposure, and other topics not directly related to health effects). Some studies categorized as "Non-health" are cited

in relevant sections of the document, when appropriate. Remaining studies were identified as either “*in vitro*”, “Experimental Animal”, or “Human”. Further categorization of included studies is described in more detail in the Epidemiology and Toxicology sections. The number of records retrieved and number of studies sorted into inclusion/exclusion categories are also provided in Appendix 1. Following identification of studies to be reviewed in depth, data were extracted from included studies into individual study tables and/or summary tables, as described in the Epidemiology and Toxicology sections. Individual study tables for the Epidemiology section are provided in Appendix 4 and for the Toxicology section in Appendix 5.

Some sections of the document that provide background information but do not directly impact development of the Health-based MCL (e.g. Environmental Sources, Fate, and Occurrence) are based on updates of the Subcommittee’s previous evaluations of PFOA.

In 2014, the DWQI posted a request for public input regarding data or technical information about the toxicology, epidemiology, toxicokinetics, or other health effects topics related to PFOA that should be considered in developing an MCL. The DWQI received one submission on PFOA, and relevant comments from this submission were considered by the Health Effects Subcommittee.


A draft of the Health-based MCL Support Document was completed on June 27, 2016. Public comments on the draft document were accepted from September 22 to November 21, 2016. Minor revisions were made to the draft document based on consideration of the comments, to add relevant recent information, and to update a few citations. The conclusions presented herein in the final document do not differ from those presented in the draft document.

## **BACKGROUND INFORMATION**

PFOA is a member of a class of anthropogenic chemicals called perfluorinated chemicals (PFCs) with structures consisting of a totally fluorinated carbon chain of varying length and a charged functional group, such as carboxylate or sulfonate (Lindstrom et al., 2011a). PFCs are members of a larger class of compounds, poly- and perfluoroalkyl substances (PFAS) which also includes fluorinated compounds with structures that differ from PFCs (Buck et al., 2011). The eight-carbon PFCs, PFOA and PFOS, were the most intensively investigated compounds in earlier studies, while current research focuses on a wider range of PFAS.

**Physical and Chemical Properties (PubChem, 2016)**

Chemical Name:	Perfluorooctanoic acid
Synonyms:	PFOA, C8
CAS #:	335-67-1
Chemical Formula:	C <sub>8</sub> HF <sub>15</sub> O <sub>2</sub>
Chemical Structure:	CF <sub>3</sub> (CF <sub>2</sub> ) <sub>6</sub> COOH



Molecular Weight:	414.07
Physical State:	Solid
Melting Point:	54.3 °C
Boiling Point:	189 – 192.4 °C
Vapor Pressure:	0.017 mm Hg at 20 °C
Density:	1.8 g/cm <sup>3</sup> at 20 °C
Water Solubility:	9.5 g/L at 25 °C
Log octanol/water partition coefficient:	Not applicable (see below).
Taste Threshold (water):	No data
Odor Threshold (water):	No data
Odor Threshold (air):	No data

PFOA is a fully fluorinated carboxylic acid. Because carbon-fluorine bonds are among the strongest found in organic chemistry due to fluorine's electronegativity, PFOA and other PFCs are extremely stable and resistant to chemical reactions. PFOA is resistant to biodegradation, direct photolysis, atmospheric photooxidation, and hydrolysis, and is not known to degrade in the environment (Vaalgamaa et al., 2011).

PFOA contains a long perfluorocarbon tail that is both hydrophobic and oleophobic (repels both water and oil) and a charged end (the carboxylate group) that is hydrophilic. Because it forms a separate layer when mixed with hydrocarbons and water, measurement of the octanol:water partition coefficient is not practical (Prevedouros et al., 2006).

PFOA has been manufactured as salts such as ammonium perfluorooctanoate (APFO) or sodium perfluorooctanoate (NaPFOA) which dissociate in water. The PK<sub>a</sub> of PFOA is 2.8. At the pH range found in drinking water (6.5-8.5) and within the body, PFOA is present almost totally in the non-volatile anionic form, the perfluorooctanoate anion (Goss, 2008; Rayne and Forest, 2010).

### **Production and Use**

PFOA and other PFCs have been produced for use in commercial products and in industrial processes for over 60 years. Because of their unique surfactant properties and their resistance to chemical and thermal degradation, they have been used in many applications including water-, soil-, and stain-resistant coating for fabrics used in clothing, upholstery, and carpets, oil-resistant coatings for food contact paper, aviation hydraulic fluids, fire-fighting foams, paints, adhesives, waxes, and polishes, and other products. They are used industrially as surfactants, emulsifiers, wetting agents, additives, and coatings. PFOA is used as a processing aid (emulsifier) in the production of fluoropolymers such as polytetrafluoroethylene (PTFE) and fluoroelastomers used as non-stick coatings on cookware, membranes for waterproof/breathable clothing, electrical wire casing, fire and chemical resistant tubing, and plumbing thread seal tape (Lau et al., 2007; Buck et al., 2011; Lindstrom et al., 2011a; Post et al., 2012).

PFOA has been produced by two different manufacturing methods, electrochemical fluorination (ECF) and telomerization. The ECF process was primarily used from 1947 to 2002. In this process, 1-heptanecarbonyl fluoride is dissolved in anhydrous hydrogen fluoride, and an electrical current is passed through the solution causing all hydrogen atoms on the carbon backbone to be replaced with fluorine atoms. This process produces a mixture of isomeric forms including branched, linear, and cyclic isomers of various chain lengths (Prevedouros et al., 2006; Buck et al, 2011; Lindstrom et al., 2011a).

The second process, telomerization, has been primarily used since 2002. This process involves reacting pentafluoroiodoethane with tetrafluoroethane in the molar ratio that gives the desired chain length. The product of this reaction is then oxidized to form the carboxylic acid. This process produces straight chain (linear) PFOA (Prevedouros et al., 2006; Buck et al, 2011; Lindstrom et al., 2011a).

Historically, PFOA and PFOS were the two PFCs produced in the greatest amounts. PFOS was principally manufactured by the 3M Company, which completed its phase-out of production of this chemical in 2002. In 2006, the eight major U.S. producers of PFOA voluntarily agreed to reduce emissions and product content of PFOA and related substances, including precursors of PFOA, on a global basis by 95% by 2010 and to work towards elimination of these substances by 2015 (USEPA, 2016b). According to USEPA, reports submitted by the participating companies in 2013 and 2014 indicated that they were on track to achieve the goal of phasing out these chemicals by the end of 2015. However, other manufacturers and users of PFOA that are not participants in the voluntary agreement with USEPA continue to emit large amounts of PFOA to the environment, particularly in nations overseas including China, India, Russia, and Poland (USEPA, 2009; Lindstrom et al., 2011; OECD, 2015).

In 2009, the USEPA Office of Pollution Prevention and Toxics (OPPT) developed action plans for several groups of chemicals of concern including PFCs (USEPA, 2009a). According to the USEPA Action Plan, concerns about PFOA and other PFCs include their worldwide presence in the environment, wildlife, and humans; their persistence in the environment and bioaccumulative potential in humans and wildlife; and the significant adverse effects observed in wildlife and laboratory animals. USEPA stated that “given the long half-life of these chemicals in humans (years), it can reasonably be anticipated that continued exposure could increase body burdens to levels that would result in adverse outcomes.”

USEPA (2009a) stated that PFOA and other long-chain PFCs are of concern for children’s health, based on studies in laboratory animals that have demonstrated developmental toxicity, including neonatal mortality. They stated that: “Children’s exposures are greater than adults due to increased intakes of food, water, and air per pound of body weight, as well as child-specific exposure pathways such as breast milk consumption, mouthing and ingestion of non-food items, and increased contact with the floor. Biomonitoring studies have found PFCs in cord blood and breast milk, and have reported that children have higher levels of some PFCs compared to adults. Thus, given the pervasive exposure to PFCs, the persistence of PFCs in the environment, and studies finding deleterious health effects, USEPA will examine the potential risks to fetuses and children.”

USEPA (2009a) stated that it intended to propose actions to address the potential risks from long-chain PFCs in 2012 under the Toxic Substances Control Act (TSCA). USEPA stated that potential actions could include banning or restricting their manufacture (including import), processing, and use, depending on the findings of more detailed analysis of information on these compounds.

In 2013, the European Chemical Agency (ECHA) Member State Committee unanimously agreed that PFOA should be classified as a Substance of Very High Concern (SVHC) because it has potential to cause reproductive toxicity and is persistent, bioaccumulative, and toxic (ECHA, 2013). ECHA (2015) is currently considering restrictions on the manufacture, marketing and use of PFOA, its salts and PFOA-related substances, as well as of articles and mixtures containing these substances.

## **GUIDANCE AND STANDARDS DEVELOPED BY NEW JERSEY, OTHER STATES, AND USEPA**

### **New Jersey Health-based Drinking Water Guidance**

New Jersey DEP developed chronic (lifetime) drinking water guidance for PFOA in drinking water of 40 ng/L in 2007 (NJDEP, 2007). The basis for the NJDEP guidance was subsequently published in a peer-reviewed journal (Post et al., 2009a).

The New Jersey guidance is based on the NOAELs (No Observed Adverse Effects Levels) and LOAELs from toxicology studies identified in the draft USEPA (2005a) PFOA risk assessment and considered the conclusions of the USEPA Science Advisory Board (2006) review of this draft risk assessment. The draft USEPA (2005a) risk assessment compared PFOA exposures prevalent within the U.S. general population with NOAELs and LOAELs for various life stages identified in toxicology studies. As such, the USEPA (2005a) draft risk assessment did not develop a Reference Dose or a cancer slope factor for PFOA, and it did not address the relationship between drinking water concentration and human body burden, as measured by serum level.

Because the half-life of PFOA is much longer in humans (several years) than in the animal species used in the toxicological studies (several hours to 30 days), a given external dose (mg/kg/day) results in a much greater internal dose (as indicated by serum level) in humans than in animals. Therefore, comparisons between effect levels in animal studies and human exposures were made on the basis of serum levels rather than external dose. This approach was recommended by USEPA (2005a) and the USEPA Science Advisory Board (2006).

Target Human Serum Levels (analogous to RfDs, but on a serum level basis) were derived by applying UFs to the measured or modeled serum levels at the NOAELs or LOAELs identified by USEPA (2005a). The default RSC of 20% was applied to the Target Human Serum Levels to account for contributions to serum PFOA from non-drinking water exposures. The default RSC value is used when the relative contributions of drinking water versus non-drinking water sources are not fully characterized, as is the case for PFOA.

USEPA (2005a) classified PFOA as having “suggestive evidence of carcinogenic potential”, whereas the USEPA Science Advisory Board (2006) disagreed and recommended a classification of “likely to be carcinogenic to humans”. For the cancer end point, the serum level resulting in a one in one million ( $10^{-6}$ ) risk level was estimated by linear extrapolation from the modeled serum level in animals at a dose resulting in an approximate 10% tumor incidence.

The mean ratio of approximately 100:1 between serum PFOA levels and drinking PFOA water concentrations in exposed communities was used to determine the drinking water concentrations that are expected to result in a given increase in serum PFOA level (Post et al., 2009a). Data supporting a ratio of 100:1 or greater is discussed in the Toxicokinetics section below. Because this approach is based on the observed relationship between serum and drinking water concentrations, assumptions for body weight, volume of water ingested daily, or half-life of PFOA in humans or experimental animals were not explicitly used in the calculation of the health-based drinking water concentrations.

The range of health-based drinking water concentrations for the seven endpoints assessed was 0.04-0.26 µg/L, and several of the concentrations fell within a similar range (0.04, 0.05, 0.06, 0.07, and 0.08 µg/L). The most sensitive endpoints, resulting in a drinking water concentration of 40 ng/L, were decreased body weight and hematological effects in the adult female rat in a chronic dietary study (Sibinski, 1987). This value was determined to be protective for carcinogenic effects, as the drinking water concentration at the 10<sup>-6</sup> cancer risk level was estimated as 60 ng/L.

It should be noted that a large body of health effects information, including toxicology studies reporting sensitive developmental effects in mice and epidemiology studies reporting associations of PFOA with numerous health effects, has become available subsequent to the USEPA (2005a) risk assessment that served as the basis for the New Jersey guidance. These data were therefore not considered in the development of the NJDEP (2007) guidance, and they are considered in the development of the recommended Health-based MCL presented in this document.

#### **USEPA Drinking Water Health Advisory**

In May 2016, the USEPA Office of Water finalized a drinking water Health Advisory for PFOA of 70 ng/L (USEPA, 2016a). This Health Advisory is intended to apply to both lifetime exposure and short term exposure. It replaces the earlier the USEPA Office of Water (2009b) Provisional Health Advisory for PFOA of 400 ng/L, developed in 2009, which was stated to be intended to protect for “short-term exposure” (defined by the USEPA Integrated Risk Information System (IRIS) as up to 30 days; USEPA, 2011a).

USEPA (2016c) also finalized a Health Advisory for PFOS of 70 ng/L, and USEPA (2016d) states that the total concentration of PFOA and PFOS in drinking water should not exceed 70 ng/L.

A detailed discussion of the basis for the USEPA (2016a) Health Advisory for PFOA and a comparison with the recommended DWQI Health-based MCL are provided in Appendix 2. In summary, the USEPA Health Advisory is based on a Reference Dose (RfD) of 20 ng/kg/day. The RfD is based on delayed ossification and accelerated puberty in male offspring in a mouse developmental toxicology study (Lau et al., 2006). The default Relative Source Contribution factor of 20% was used to account for non-drinking water exposures. The USEPA Health Advisory uses a drinking water consumption rate of 0.054 L/kg/day, based on the 90<sup>th</sup> percentile for lactating women, which is higher than the default consumption rate of based on adult exposure factors.

Figure 1 shows the predicted increases in serum PFOA levels from ongoing exposure in drinking water at the USEPA Health Advisory (70 ng/L), the NJDEP (2007) guidance (40 ng/L), and the



Health-based MCL (14 ng/L) recommended in this document. Predictions based on both average (0.016 L/kg/day) and upper percentile (0.029 L/kg/day) drinking water ingestion rates are shown. A clearance factor developed by USEPA scientists (Lorber and Egeghy, 2011) to relate human PFOA exposures to human serum PFOA levels was used to predict the increases in serum PFOA from exposures to these level in drinking water. With average water consumption, ongoing exposure to 70 ng/L (the USEPA Health Advisory) is predicted to increase serum PFOA by 8.0 ng/ml, a 4.8-fold increase from the U.S. general population (NHANES) median of 2.1 ng/ml (CDC, 2015). With upper percentile water consumption, the increase in serum PFOA level from 70 ng/L is predicted as 14 ng/ml, a 7.7-fold increase from the general population (NHANES) median.




Figure 1. Increases in serum PFOA concentrations predicted from consumption of drinking water with various concentrations of PFOA (14 ng/L – Recommended Health-based MCL; 40 ng/L – NJDEP guidance (2007); 70 ng/L – USEPA Lifetime Health Advisory).

### **Guidance and standards of other states**

Several other states (e.g. Minnesota, Maine, and North Carolina) developed standards or guidance for PFOA in drinking water or groundwater prior to 2016. Because many states have stated that their earlier PFOA values will be updated or are under review in light of the finalization of the USEPA (2016a) Health Advisory, the basis for these earlier values is not presented here. New Hampshire recently adopted 70 ng/L for the total of PFOA and PFOS as a groundwater standard that is also applicable to public water systems (NH, 2017; NH DES, 2017).



In 2016, Vermont developed a drinking water health advisory (VT DOH, 2016) that was used for a basis for a Ground Water Enforcement Standard (VT DEC, 2016a) which is also applied as a drinking water standard (VT DEC, 2016b) for PFOA, PFOS, and the total of the two compounds of 20 ng/L. These Vermont values are based on the Reference Dose (RfD) of  $2 \times 10^{-5}$  mg/kg/day from the draft USEPA (2014) PFOA Health Advisory (which is the same as the RfD in the final USEPA [2016a] PFOA Health Advisory), drinking water exposure assumptions for a child less than 1 year of age (instead of default adult exposure assumptions), and the default Relative Source Contribution (RSC) factor of 20%.

## **ENVIRONMENTAL FATE, TRANSPORT, AND OCCURRENCE**

### **Environmental Fate and Transport**

Because of the extreme stability of their carbon–fluorine bonds, PFOA and other PFCs are extremely resistant to degradation in the environment and thus persist indefinitely (Buck et al., 2011; Lindstrom et al., 2011a). As discussed above, the production and use of PFOA and its precursors has been phased out by major U.S. manufacturers. However, environmental contamination and resulting human exposure to PFOA are anticipated to continue for the foreseeable future due to its environmental persistence, formation from precursor compounds, and continued production by other manufacturers.

PFOA and other PFCs are found in many environmental media (e.g. drinking water, surface water, groundwater, air, sludge, soils, sediments, outdoor and indoor dust, and ice caps) in locations around the world including remote polar regions (Lau et al., 2007). PFCs are also found in wildlife (fish, birds, mammals) including in remote polar regions. However, the bioconcentration factor for PFOA is lower than for PFOS or longer chain perfluorocarboxylates such as PFNA (Martin et al., 2003; Conder et al., 2008), and concentrations of PFOA in wildlife in remote locations are generally lower than for these other compounds (Butt et al., 2010).

Two major pathways have been proposed for long-range transport of PFOA and other PFCs to remote locations worldwide, including the Arctic (Figure 2; Lau et al., 2007, 2013; Butt et al., 2010). The relative contributions of each of these pathways are not known. The first pathway involves the atmospheric transport of volatile precursors such as 8:2 fluorotelomer alcohol (8:2 FTOH), followed by oxidation of the precursors to PFOA and other PFCs which are then deposited onto the land or the water. The second pathway involves long-range aqueous transport of emitted perfluorinated carboxylates such as PFOA in their anionic forms to remote locations by currents on the ocean's surface.




Figure 2. Major transport pathways of PFCs to the Arctic (and other remote locations), by Annika Jahnke (Butt et al., 2010)

### Fate and Transport Relevant to Drinking Water Contamination

PFOA and some other PFCs are distinct from other persistent and bioaccumulative organic compounds because of their importance as drinking water contaminants. PFOA exists predominantly as an anion under environmental conditions, does not bind well to soil, migrates readily from soil to groundwater, and is highly water-soluble (Davis et al., 2007). These properties of PFOA differ from those of other persistent and bioaccumulative organic pollutants such as polychlorinated dioxins and furans, PCBs, and pesticides like chlordane and DDT. These other compounds are generally not significant as drinking water contaminants because they have high octanol/water partition coefficients. Thus, they have a high affinity for soil and sediments but low water solubility (Post et al., 2011).

PFOA that is released to the environment can contaminate surface water and groundwater used as sources of drinking water. Sources of PFOA in the environment include discharge to air and water from industrial facilities where it is made or used (Davis et al., 2007); release of aqueous firefighting foams, particularly at military sites, airports, and fire fighter training facilities (Moody et al., 2003; Backe et al., 2013); disposal in landfills (Eggen et al., 2010); discharge from wastewater treatment plants treating domestic and/or industrial waste (Sinclair and Kannan, 2006); street runoff (Murakami et al., 2009); storm water runoff (Kim and Kannan, 2007); land application of biosolids (sludge) from wastewater treatment plants treating industrial waste (Clarke and Smith, 2011; Lindstrom et al., 2011b; Sepulvado et al., 2011); land application of wastewater from industrial sources (Konwick et al., 2008); and use of contaminated industrial waste as a soil amendment (Skutlarek et al., 2006; Hölzer et al., 2008).

Environmental transport pathways that can result in surface water and groundwater contamination by PFOA after release from an industrial source are shown in Figure 3 (Davis et al., 2007) and were reviewed by Lau et al. (2007) and Butt et al. (2010).

As is the case for other groundwater contaminants, PFOA can reach drinking water wells via the well-established pathway of migration of a groundwater plume that has been contaminated either directly from surface spills or by contaminated surface water mixing with groundwater drawn in by pumping wells. Unlike many other environmental contaminants, PFOA can also reach groundwater from air emissions from nearby industrial facilities, followed by deposition from air onto soil, and migration through the soil to groundwater (Davis et al., 2007).

In West Virginia and Ohio, drinking water wells as far as 20 miles away were contaminated with PFOA by releases from an industrial facility where it was used as a processing aid in fluoropolymer production. Groundwater contamination occurred via soil deposition of PFOA that had been emitted into the air followed by migration to groundwater, and, to some extent, recharge of the groundwater aquifer with contaminated surface water from the Ohio River (Steenland et al., 2009a; Shin et al., 2011). PFOA was detected in public water supply wells in this vicinity at levels up to > 4000 ng/L (DuPont and URS Diamond Corporate Remediation Group, 2008) and in private wells at up to >13,000 ng/L (Hoffman et al., 2011). In New Jersey, PFOA was detected at up to 190 ng/L in shallow unconfined wells of a public water supply located near an industrial source (Post et al., 2009a), and at > 40 ng/L, with a maximum above 400 ng/L, in 59 of 104 private wells within a radius of slightly more than 2 miles of this facility (DuPont, 2009); contamination of the distant wells was likely due to air deposition (Post et al., 2012).




Figure 3. APFO (PFOA) transport near discharge source (Davis et al., 2007)

#### Formation from precursor compounds

An additional source of PFOA in the environment is the breakdown of precursor compounds such as the fluorotelomer alcohol, 8:2 FTOH [ $\text{F}_3(\text{CF}_2)_7\text{CH}_2\text{CH}_2\text{OH}$ ], used industrially and in consumer products (Butt et al., 2010; Buck et al., 2010; Butt et al., 2014).



Larger molecules such as polyfluoroalkyl phosphoric acid diesters (diPAPs) (e.g. diPAPs 8:2; Figure 4) are found in greaseproof food contact papers, wastewater treatment plant sludge, and paper fibers from paper mills (D'eon et al., 2009). These larger molecules release 8:2 FTOH that can degrade to PFOA.




Figure 4. Structure of diPAPs 8:2

PFOA is formed from these precursor compounds through biodegradation in soil, sludge, and wastewater (Sinclair and Kannan, 2006; Lee et al., 2010) as well as through chemical reactions in the atmosphere (Figure 2). PFOA and other PFCs have been found at higher concentrations in effluent than influent at wastewater treatment plants. This increase is believed to result from the biodegradation of telomer alcohols and other precursors from domestic and industrial sources within the wastewater treatment plant (Sinclair and Kannan, 2006; Lee and Mabury, 2011). Fluoroacrylate polymers, used in commercial products, may also degrade in soil to release FTOH which can degrade to PFCs such as PFOA (Russell et al., 2008; Washington et al., 2009). Since PFOA, once formed, does not degrade appreciably, environmental PFOA levels are increased by conversion of even a small fraction of the precursors to the terminal breakdown product, PFOA.

### **Occurrence in drinking water**

PFOA and other PFCs occur in raw and finished drinking water from both groundwater and surface water sources in New Jersey, other parts of the United States, and nations around the world (reviewed by Mak et al., 2009; Post et al., 2012; Post et al., 2013). PFOA and other PFCs are found in drinking water impacted by discharges from industrial facilities, release of aqueous firefighting foam, and other known sources of contamination, as well as where the source is unknown (Post et al., 2012).

PFOA has been detected at high frequency in some river basins that are important sources of drinking water. For example, it was detected (>1 ng/L) in 82.3% of samples from 80 locations throughout the Cape Fear River (North Carolina) drainage basin, population 1.7 million, at a median of 12.6 ng/L and a maximum of 287 ng/L (Nakayama et al., 2007). In the Upper Mississippi River drainage basin in the Midwestern U.S., population 30 million, it was detected (>1 ng/L) in 73% of 88 locations with a median of 2.07 ng/L and a maximum of 125 ng/L. Elevated levels at certain sites were attributed to point sources in this study (Nakayama et al., 2010). In the Tennessee River in Alabama, PFOA levels were 395±128 ng/L in samples from the 35 river miles downstream of the site of discharge from a fluorochemical manufacturing

facility, with the highest levels (521-598 ng/L) in the 6 river miles furthest downstream (Hansen et al., 2002). In Germany, PFOA and other PFCs in organic material applied to agricultural land contaminated the Moehne and Ruhr Rivers, important sources of drinking water. PFOA was detected at up to 33,900 ng/L in a creek near the site of contamination upstream of these rivers, and at up to 519 ng/L in drinking water from the Moehne River (Skutlarek et al., 2006).

PFOA and other PFCs are not effectively removed from drinking water by standard treatment processes such as coagulation/flocculation, sand filtration, sedimentation, medium-pressure ozonation, chloramination, and chlorination. However, PFOA can be removed from drinking water by granular activated carbon (GAC) or reverse osmosis (Rumsby et al., 2009, Bartell et al., 2010a, Tagaki et al., 2011; Eschauzier et al., 2012; Appleman et al., 2014; DWQI, 2015b). Therefore, unless specific treatment for removal of PFCs is in place, concentrations of PFOA and other PFCs detected in raw drinking water can be considered to be representative of concentrations in finished drinking water (Post et al., 2013).

#### Occurrence in New Jersey drinking water

Considerable information is available on the occurrence of PFOA and other PFCs in New Jersey public water systems (PWS). This includes data from 53 PWS from two NJDEP occurrence studies of PFCs, substantial additional data submitted to NJDEP by PWS and other parties, and data from the nationwide USEPA Unregulated Contaminant Monitoring Rule 3 (UCMR3) survey. For the two NJDEP occurrence studies and most of the additional data submitted to NJDEP, analysis of samples was performed by certified laboratories with Reporting Levels (RLs) that were generally 4-5 ng/L or lower. To the knowledge of the Health Effects Subcommittee, statewide drinking water studies of PFOA with sensitive RLs such as these have not been conducted in states other than New Jersey. In contrast, the RL for PFOA in USEPA UCMR3 is much higher (20 ng/L) than the RLs in the other NJ PWS monitoring data.

#### NJDEP studies of occurrence in New Jersey public water systems

Following detection of PFOA in a New Jersey PWS at up to 190 ng/L in a groundwater source and up to 64 ng/L in tap water, two statewide studies of the occurrence of PFOA and other PFCs in drinking water were conducted by NJDEP. The 2006 study tested 23 PWS for PFOA and PFOS, and the 2009-10 study tested 33 additional PWS for PFOA, PFOS, and eight other PFCs (NJDEP, 2007b; NJDEP, 2014; Post et al., 2009a; Post et al., 2013).

The 2006 NJDEP study included 29 samples of raw and/or finished water from 23 NJ PWS including 14 with groundwater sources, 8 with surface water sources, and one using both groundwater and surface water. In the 4 PWS where both raw and finished water were analyzed, PFOA concentrations were similar in both samples. Of the PWS in this study, PFOA was detected in 15 of 23 systems (65%) at or above the RL (4 ng/L), and in 3 of 23 systems below the RL. PFOA was detected above the RL (9 of 13) at up to 33 ng/L, or below the RL (1 of 13), in

10 of 13 groundwater samples (77%) from unconfined or semiconfined aquifers, but was not detected in the two groundwater samples from confined aquifers. Additionally, PFOA was detected above the RL (7 of 9; 78%) at up to 39 ng/L, or below the RL (2 of 9; 22%), in samples from all 9 PWS using surface water sources. In this study, PFOS was detected (>4 ng/L) in 30% of the PWS, less frequently than PFOA (NJDEP, 2007; Post et al., 2009a).

The 2009-2010 NJDEP study tested raw water from 30 PWS for PFOA, PFOS, and 8 other PFCs. The sites for this study were chosen for geographic diversity, representing 19 of NJ's 21 counties. The study included 18 PWS with groundwater sources (17 unconfined, one confined) and 12 PWS with surface water sources. One or more PFC was detected (>5 ng/L) at 21 sites (70%), with the number of individual compounds detected varying from one (in 8 samples) to a maximum of 8 in one sample. PFOA was the most commonly detected PFC (17 of 30 samples; 57%), including 6 of 18 of groundwater samples (33%) and 11 of 12 of surface water samples (92%). When PFOA was detected, other PFCs were often but not always found in the same sample. PFOA was found at the highest maximum concentration of any of the PFCs analyzed in the study, 100 ng/L. This highest detection was in a PWS intake from a river, and the likely source was subsequently identified as discharge from an upstream facility that made and used products containing PFOA and other PFCs (Post et al., 2013; NJDEP, 2014).

#### *NJDEP database of PFCs in New Jersey Public Water Systems*

The NJDEP Division of Science, Research, and Environmental Health maintains an internal database of PFC results from NJ PWS including the two NJDEP occurrence studies, additional raw and finished water data submitted to NJDEP by PWS and other parties, and detections from UCMR3 data. As of January 2016, the database included 1035 samples (423 raw water, 549 finished water, and 63 distribution system) from 282 sampling locations in 80 PWS (including 72 PWS with data from NJDEP studies and/or submitted to NJDEP, and 8 additional PWS with PFC detections in UCMR3). Of these samples, 374 were analyzed for only PFOA and PFOS, and 661 were analyzed for a broader suite of PFCs.

PFOA was the most frequently detected PFC in NJ PWS. It was detected at some level in 65% of 72 PWS included in the NJDEP database (excluding UCMR3 data; Table 1). The highest detection in finished water was 100 ng/L, and concentrations exceeding 40 ng/L were reported in at least one finished water sample from 12 of 72 PWS (17%). It was also detected at >20 ng/L in UCMR3 monitoring in finished water from six additional PWS that are not otherwise included in the database, including two PWS that had levels above 40 ng/L.



Table 1. PFOA concentrations in raw or finished water from PWS included in NJDEP database*		
PFOA Concentration (ng/L)	Number of PWS	% of PWS
ND**	25	35%
RL - <10**	15	21%
10 - <20**	10	14%
20 - <40	10	14%
>40	12	17%

\*Data shown are highest concentration found in raw or finished water from the PWS. Levels in finished water from some water supplies included may be lower because several raw water sources are blended in the treatment plant.

\*\*Reporting levels (RLs) vary among samples and range from 2.5 - 20 ng/L. Therefore, the percentage of PWS with RL-<10, and 10 - <20, may actually be higher than shown.

#### *Comparison of NJ occurrence to nationwide UCMR3 data and studies from other nations*

Data on PFOA in PWS in New Jersey and nationwide is available through the USEPA UCMR3. Under UCMR3, nationwide monitoring of finished water for 30 unregulated contaminants, including PFOA and 5 other PFCs, was conducted in 2013–2015 by all U.S. large PWS (serving more than 10,000 people) and 800 representative smaller PWS (serving less than 10,000 people) (USEPA, 2012b). UCMR3 data therefore provide useful information on occurrence of PFCs in NJ in comparison to the rest of the United States. However, comparison of the UCMR3 PFC data with other New Jersey PFC occurrence data is complicated by the fact that the UCMR3 RLs for PFOA (20 ng/L) and other PFCs are much higher than the RLs for other PFC data in the NJDEP database (generally  $\leq 5$  ng/L).

UCMR3 monitoring in New Jersey includes all 165 large community PWS, 13 of about 435 small community PWS, and 8 of about 700 non-transient non-community water systems. A comparison of national versus New Jersey PFC data from UCMR3 reported through January 2016 is shown in Table 2 (data obtained from USEPA, 2016f). PFOA was detected ( $\geq 20$  ng/L) in PWS at locations throughout the state, and was detected more than five times more frequently in New Jersey PWS (10.53%) than nationally (1.93%). PFNA was also detected much more frequently in NJ (2.34%) than nationally (0.22%). However, PFNA was detected only in the vicinity of a likely industrial source located in Gloucester County (DWQI, 2015c) but not in other parts of New Jersey. The occurrence of the other PFCs included in UCMR3 (PFHpA, PFOS, PFHxS, PFBS) was similar or slightly higher in New Jersey compared to nationally.

Table 2. New Jersey versus national UCMR3 PFC occurrence data as of January 2016							
Compound*	Reporting Level (RL) (ng/L)	New Jersey			United States (other than NJ)		
		Number of PWS	Number above RL	Percent above RL	Number of PWS	Number above RL	Percent above RL
PFOA	20	171	18	10.53 %	4617	89	1.93 %
PFNA	20	171	4	2.34 %	4617	10	0.22 %
PFHpA	10	171	5	2.92 %	4617	77	1.67 %
PFOS	40	171	5	2.92 %	4617	88	1.91 %
PFHxS	30	171	2	1.17 %	4617	52	1.13 %
PFBS	90	171	0	0 %	4617	6	0.13 %

\*PFHpA – perfluoroheptanoic acid (C7); PFBS – perfluorobutane sulfonate; PFHxS – perfluorohexane sulfonate.

The occurrence of PFCs in NJ PWS in the 2009-10 NJDEP study was also compared to similar occurrence studies in other nations by Post et al. (2013). PFOA was detected more frequently and at a higher maximum concentration in the 2009-10 New Jersey PWS study than in comparable drinking water studies in France, Spain, and China which had RLs similar to the RL in the NJ study.

#### Occurrence in NJ private wells

A statewide study of PFOA or other PFCs in New Jersey private wells has not been conducted. PFOA was detected at >40 ng/L, with a maximum above 400 ng/L, in 59 of 104 private wells within a radius of slightly more than 2 miles of a New Jersey industrial source (DuPont, 2009); contamination of the distant wells was likely due to air deposition. More recently, PFOA has been detected in private wells near another facility which used and discharged a mixture of PFCs that consisted primarily of PFNA and also contained PFOA (DWQI, 2015c).

### **HUMAN BIOMONITORING**

Human biomonitoring studies show that exposure to PFOA and/or its precursors is ubiquitous in the U.S. and throughout the world. PFOA has a human half-life of several years and remains in the body for a long period of time after exposure occurs. Data on blood serum concentrations from the general population, communities with contaminated drinking water, and workers with occupational exposure are summarized below. Consumption of contaminated drinking water results in increased blood serum concentrations, while the highest blood serum concentrations have been found in occupationally exposed workers. PFOA is detected in human breast milk, amniotic fluid, and umbilical cord blood, demonstrating that exposure occurs during prenatal and postnatal development, and it has also been detected in human seminal fluid.



## **Blood Serum**

### General population

PFOA and other PFCs are present in the serum of the general population in the United States and in countries worldwide. This topic was recently comprehensively reviewed by Kato et al. (2015).

Data from archived serum samples from the United States and Norway indicate that human exposure to PFOA has been ongoing for decades, and that exposure increased greatly in the 1980s in these two locations. Analysis of serum samples collected up to 56 years ago found that the median level in serum from pregnant California women sampled in 1960-63 (n=40) was 0.27 ng/ml, approximately 10-fold lower than the median in serum from California women sampled in 1981-86 (n=30) and 2009 (n=35), which were 2.71 and 2.08 ng/ml, respectively (Wang et al., 2011a). In pooled serum samples from Norwegian men (age 40-50) collected over a 29 year period (1977-2006), PFOA levels gradually increased from 0.58 ng/ml in 1976 to 4.9 ng/ml in 2001, an 8-fold increase, followed by a yearly decline to 2.7 ng/ml in 2006. A similar temporal pattern was seen in serum samples collected from Norwegian children and male and female adults of other age groups between 1976 and 2007 (Haug et al., 2009).

The largest studies of the U.S. general population are from the National Health and Nutrition Examination Survey (NHANES) conducted by the U.S. Centers for Disease Control and Prevention (CDC) (Kato et al., 2011; CDC, 2015) and American Red Cross blood donors (Olsen et al., 2012). PFOA is one of four PFCs (PFOA, PFOS, PFNA, and perfluorohexane sulfonate [PFHxS]) that have been detected in the serum of greater than 99% of a representative sample of the U.S. population, age 12 or older, in NHANES (Kato et al., 2011). PFOA and these other PFCs are biologically persistent, with human half-lives of several years, as discussed in the Toxicokinetics section below.

Data from six cycles of NHANES monitoring between 1999-2000 and 2011-12 show that serum PFOA levels have decreased in the U.S. general population during this time period (Table 3). In the first NHANES (1999-2000), the geometric mean serum concentration was 5.21 ng/ml and the 95<sup>th</sup> percentile was 11.9 ng/ml, while the most recent NHANES (2011-12) found a geometric mean and 95<sup>th</sup> percentile of 2.08 and 5.68 ng/ml, respectively. In the NHANES surveys, PFOA concentrations were lower in those 12-19 years of age than in older individuals, and were somewhat higher in males than females. In data from the three ethnic groups that were analyzed over time, levels were consistently lowest in Mexican Americans, intermediate in non-Hispanic blacks, and highest in non-Hispanic whites (CDC, 2015).

Year	Geometric Mean	Percentile				n
		50th	75th	90th	95th	
2011-12	2.08	2.08	3.03	4.35	5.68	1904
2009-10	3.07	3.20	4.60	6.00	7.50	2233
2007-08	4.12	4.30	5.90	7.90	9.60	2100
2005-06	3.92	4.20	6.20	9.00	11.3	2120
2003-04	3.95	4.10	5.80	7.80	9.80	2094
1999-2000	5.21	5.20	6.90	9.40	11.9	1562

CDC, 2015

A similar pattern of decreasing serum PFOA concentrations over time was seen in three studies of American Red Cross blood donors in 2000-2001, 2006, and 2010 (Olsen et al., 2012). Each study included samples from 600-645 subjects from six locations throughout the U.S., with an approximately equal number in each of five 10-year age categories (20-29 through 60-69 years of age) from each location. Geometric means and 95<sup>th</sup> percentile concentrations, respectively, were 4.7 and 12.0 ng/ml in 200-01, 3.44 and 7.9 ng/ml in 2006, and 2.44 and 6.6 ng/ml in 2010. As in the NHANES studies, serum concentrations were generally higher in males than females.

Serum PFOA levels are generally comparable to those found in the U.S in developed countries throughout the world, including Europe, Asia, and Australia (Post et al., 2012; Kato et al., 2015). In contrast to industrialized nations where serum PFOA is almost universally detected, PFOA was detected at > 0.5 ng/ml in only 12 of 55 serum samples from Afghan children and adults, with a maximum of 1.5 ng/ml; relatively low serum levels have also been reported in other developing countries where exposure to PFOA and other PFCs may be lower than in industrialized nations (Hemat et al., 2010).

PFOA concentrations in pooled serum samples from children (age 3-11) in 2001-2002 NHANES ranged from about 6-8 ng/ml, significantly higher than in pooled serum samples from adults in this study (Kato et al., 2009). Median and maximum serum PFOA levels in 300 Texas children, age <1 to 12 years, were 2.85 ng/ml and 13.50 ng/ml; adults were not included in this study. In the Texas study, the median level did not differ between genders, and was lower in those less than 3 years of age than in the older age groups (Schechter et al., 2011). Exposures to infants and young children are discussed in detail in the section on developmental exposures below.

#### Communities with drinking water exposures

Continued exposure to even relatively low concentrations of PFOA in drinking water concentrations results in substantial increases in serum levels. The quantitative relationship between drinking water exposure and human serum PFOA levels is discussed below.

A recent study (Hurley et al., 2016) found substantially increased serum PFOA levels in individuals served by PWSs reporting detection of PFOA in UCMR3 monitoring. PFOA detections were relatively low, ranging from 20 ng/L (the UCMR3 RL) to 53 ng/L, with a mean of 28 ng/L. The study group consisted of middle aged and older California women (n=1,333; 70% between 60 and 79 years of age). Of this group, 4.5% resided in a zipcode where a PWS reporting detection of PFOA in UCMR3 monitoring is located. The distribution of serum concentrations differed significantly ( $p < 0.0001$ ) in those served by a PWS where PFOA was detected (“exposed”) as compared to those served by a PWS without a detection (“unexposed”). The median serum PFOA concentrations in the “exposed” group was 38% higher (3.46 ng/ml) than in the “unexposed” group (2.51 ng/ml). The authors note that the contribution of drinking water to serum PFOA is likely actually greater than observed in the study since some of those classified as “exposed” may have received their drinking water from another point of entry (e.g. treatment plant) within the PWS that detect PFOA. Additionally, the serum PFOA levels of some participants classified as “not exposed” may have been increased by PFOA in drinking water at concentrations below the UCMR3 RL of 20 ng/L.

Public water supply wells and private wells in several Ohio and West Virginia communities were contaminated by PFOA emissions from an industrial facility. In Little Hocking, Ohio, the concentration in drinking water was 3550 ng/L in 2002-2005, and the median serum PFOA concentration in 282 individuals tested in 2004-2006, with occupationally exposed individuals excluded, was 371  $\mu\text{g/L}$  (Emmett et al., 2006a). The C8 Health Study (described in more detail below) is a much larger study of Little Hocking and several other communities in this vicinity with drinking water PFOA concentrations ranging from  $>50$  ng/L to over 3000 ng/L (Post et al., 2009a). In approximately 69,000 C8 Health Study participants, including some with occupational exposures, the median serum PFOA concentration in 2005-2006 was 28.2 ng/ml, as compared to the median of 4 ng/ml in the 2003-2004 NHANES study (Steenland et al., 2009a). The upper 25% of C8 Health Study participants had serum PFOA levels greater than 71 ng/ml, only slightly below the highest concentration found in 2003-2004 NHANES, 77.1 ng/ml. As in the NHANES and Red Cross blood donor studies of the general population discussed above, the median serum concentrations in males (33.7 ng/ml) were higher than females (23.7 ng/ml) in this large study of an exposed population.

Emmett et al. (2006a) observed higher serum levels in children ages 2-5 than in older children and adults in their study of Little Hocking, Ohio residents with exposure to PFOA in drinking water. Adults over 60 years of age also had higher levels than other age groups. In the larger C8 Health Study population, serum concentrations were also higher in children and older adults, with the lowest levels in those age 20-29 (Steenland et al., 2009a). More recently, Shin et al. (2011) estimated a median one-year old child:maternal serum ratio of 1.27:1 from data on 40 child-mother pairs in the C8 Health Study. In a much larger study of almost 5000 mother-child

pairs from the C8 Health Study, serum levels in children up to age 12 were higher than in their mothers in this population; in the youngest age category ( $\leq 5$  years), mean levels were 44% higher than maternal levels (Mondal et al., 2012).

Serum PFOA levels were also higher than in the general population in several other communities with exposure from drinking water. These include communities in Germany whose surface water source of drinking water was contaminated by runoff from industrial waste used as a soil amendment (Hölzer et al., 2008); in Alabama where a river used as a public water supply source was contaminated by industrial discharge, and PFOA from contaminated biosolids applied to agricultural land reached drinking water wells (ATSDR, 2013); in Minnesota communities where private wells and public water supply wells were contaminated by disposal of industrial waste (Landsteiner et al., 2014); in Pease, NH where public water supply wells were contaminated by military use of aqueous firefighting foam (NHDHHS, 2015); and in Hoosick Falls, NY, where drinking water was contaminated by releases from an industrial facility (NYS DOH, 2016)

#### Occupationally exposed workers

Serum PFOA levels in workers at facilities where PFOA is made or used in fluoropolymer production are much higher than in the general population. Biomonitoring data from workers at such facilities were reviewed by Olsen (2015). Mean or median serum concentrations of several 1000 ng/ml (several ppm) were reported for some job categories at some facilities, with maximum serum concentrations of over 100,000 ng/ml (100 ppm), although levels in most workers were lower. In the C8 Health Study participants, the median serum level among those currently working at the Washington Works plant where PFOA was used in fluoropolymer production (n=1,171) was 148 ng/ml, as compared to 24 ng/ml in those who did not work there at or prior to the time of sampling (Steenland et al., 2009a).

Serum concentrations of PFOA and other PFCs are also elevated in professional ski waxing technicians due to exposures to fluorinated ski waxes that contain both the compounds themselves and their precursors (reviewed by Olsen, 2015).

#### Other human biological matrices

##### Seminal plasma

PFOA and other PFCs were found in human seminal plasma in a study of Sri Lankans. The mean and median concentrations were 6.38 and 4.02 ng/ml, respectively, and PFOA concentrations were significantly correlated with serum PFOA concentrations (Guruge et al., 2005).

##### Amniotic fluid

PFOA was detected in amniotic fluid in a study in the United States (Stein et al., 2012). The median blood serum:amniotic fluid concentration ratio was about 13:1.

### Umbilical cord blood serum

PFOA and other PFCs were detected in numerous studies of umbilical cord blood from the general population worldwide in studies reviewed by Post et al. (2012). Locations of these studies included Baltimore, Maryland (Abelberg et al., 2007), Ontario, Canada (Monroy et al., 2008), Denmark (Fei et al., 2007), Germany (Midasch et al., 2007), Norway (Gützkow et al., 2011), the Faroe Islands (Needham et al., 2011), Australia (Toms et al., 2009), South Africa (Hannsen et al., 2010), Korea (Kim et al., 2011), and Taiwan (Lien et al., 2011). Mean serum (or plasma) levels in these studies ranged from 1.1 ng/ml in Korea (Kim et al., 2011) to 4.4 ng/ml in Taiwan (Lien et al., 2011). No geographic pattern was apparent from this dataset, as the levels reported from Africa, Australia, Europe, and North America fell in between the levels in the two Asian studies. More recent additional data are reviewed by Kato et al. (2015).

### Breast milk

PFOA was detected in human breast milk in studies from locations worldwide (reviewed by Liu et al., 2010; White et al., 2011a; Post et al., 2012) including Massachusetts (Tao et al., 2008a), Japan (Tao et al., 2008b), China (So et al., 2006; Liu et al., 2010), Korea (Kim et al., 2011), Belgium (Roosens et al., 2010), Spain (Llorca et al., 2010), Norway (Haug et al., 2011; Thomsen et al., 2010), and Sweden (Sunstrom et al., 2011). Concentrations in breast milk were generally similar in studies from different parts of the world. In studies using sensitive analytical methods enabling detection of lower concentrations, median PFOA levels were 36 ng/L (Massachusetts; Tao et al., 2008a), 67 ng/ml (Japan; Tao et al., 2008b), and 46 ng/L (China; Liu et al., 2010), while PFOA was not detected or was infrequently found in breast milk in some other studies with higher detection limits (Fromme et al., 2010; von Ehrenstein et al., 2009). In the studies cited above, PFOA was frequently found in breast milk at concentrations higher than 40 ng/L, with some detections exceeding 100 ng/L (for example, in Belgium; Roosens et al., 2010).

Notably, breast milk concentrations were much higher in both rural and urban samples from Shanghai province (urban mean, 616 ng/L; rural mean, 814 ng/L) than in 12 other Chinese provinces (mean, 46 ng/L). Maternal exposures were likely higher in Shanghai than in the other areas sampled because PFOA levels are higher in Shanghai drinking water and surface water, likely because many fluorochemical manufacturing plants are located there (Liu et al., 2010).

## **SOURCES OF HUMAN EXPOSURE**

The human body burden of PFOA results from exposure to both PFOA itself and to precursor compounds that can be metabolized to PFOA, such as FTOH and diPAPs (D'eon and Mabury, 2011a; Lee and Mabury, 2011). Sources of exposure to PFOA and/or its precursors include drinking water, food, migration from food packaging into food, treated fabrics (carpets, upholstery, and clothing), protective sprays, ski waxes, cosmetics and personal care products, house dust, and inhalation of indoor and outdoor air (Trudel et al., 2008; Guo et al., 2009;

Gewurtz et al., 2009; Freberg et al., 2010; Nilsson et al., 2010; Fraser et al., 2012; Knobloch et al., 2012; Fujii et al., 2013; Fraser et al., 2013; Kotthoff et al., 2015). Migration into food from non-stick (PTFE-coated) cookware is not considered to be a significant exposure source (Trudel et al., 2008).

The relative contributions from direct exposure to PFOA and exposure to its precursors, used in products including food contact paper and stain resistant carpet and textile coatings, is uncertain and varies among individuals (D'Leon and Mabury, 2011b; Gebbink et al., 2015a). Other classes of precursor molecules, some of which are known or suspected to be metabolically converted to PFOA in humans, have also been detected in human serum (Lee and Mabury, 2011). Some of these precursor compounds are known to be present in consumer products at much higher levels than PFOA itself (Lee and Mabury, 2011).

Efforts have been made to model the relative contributions of consumer products, indoor and outdoor air, house dust, diet, and/or other sources to exposures of PFOA and other PFCs in the general population. Some of these studies estimated the contributions of precursors (Fromme et al., 2008; Vestergren and Cousins, 2009; Gebbink et al., 2015b) while others did not (Washburn et al., 2005; Tittlemeier et al., 2007; Trudel et al., 2008; Cornelius et al., 2012); a high level of uncertainty is associated with the precursor estimates.

Most of these studies predict that diet is the predominant exposure source. Typical adult total exposures of about 2-3 ng/kg/day in Europe or North American were estimated in several studies (Fromme et al., 2009; Trudel et al., 2008; Vestergren and Cousins, 2009), while some more recent studies give higher dietary estimates (6.1 ng/kg/day in Flanders, Belgium; Cornelis et al., 2012) or lower dietary estimates (0.6 ng/kg/day in Norway, Haug et al., 2010a; 0.2 ng/kg/day in The Netherlands, Noorlander et al., 2011; 0.16 ng/kg/day (location not specified), Gebbink et al., 2015b). Such dietary exposure estimates, in general, are highly uncertain because there are relatively few data on PFOA levels in food, analytical methods for food lack sufficient sensitivity, detection limits vary greatly among food types, and PFOA levels differ greatly in samples of the same foods obtained from different sources and/or locations.

PFOA has been detected in at least some samples of several types of foods including milk, butter, meats, fish, vegetables (including potatoes), bread, and microwave popcorn, but was not detected in most food samples tested (reviewed by D'Hollander et al., 2010; Domingo et al., 2012).

Commercially available infant formula products do not appear to be a major source of exposure to PFOA or other PFCs in the U.S. Tao et al. (2008a) evaluated PFCs in 21 samples of five brands of infant formula representing >99% of the U.S. market. Products tested included milk-, organic- and soy-based formula, packed in cans, glass, or plastic, in liquid, powdered, and concentrated



liquid forms. PFOA was not detected (<0.048 ng/L) in any sample. Other PFCs (for which detection levels varied) were also not detected or were infrequently found (PFOS – one detection at 11.3 ng/L; perfluorohexane sulfonate (PFHxS)-two detections at up to 3.59 ng/L). In this study, PFCs were also analyzed in 12 samples of 11 brands of dairy milk purchased in Albany, NY in 2008, and there was only one detection of PFHxS at 3.83 ng/L. However, it should be noted that exposure to infants occurs when powdered or concentrated formula is prepared with drinking water contaminated with PFOA.

Llorca et al. (2010) analyzed two brands of dry infant cereal and three brands of powdered milk-based infant formula purchased in Spain. PFOA concentrations in the cereals were 166 and 438 ng/kg, and in the formulas, 374, 488, and 723 ng/kg. The concentrations in these products when prepared for consumption were not given.

PFOA and other PFCs can be taken up into plants grown on contaminated soil (e.g. from application of PFOA-contaminated biosolids) or irrigated with contaminated water, including into the parts of some vegetables and grains that are consumed by humans and by grazing livestock (Stahl et al., 2009; Lechner and Knapp, 2011; Yoo et al., 2011). The potential for human exposure to PFOA through this route generally depends on the part of the plant that is consumed. In general, shorter chain PFCs are preferentially taken up into the fruit of the plant, while longer chain PFCs such as PFOA are preferentially taken up into the root and shoot parts of the plant (Blaine et al., 2013a, b, 2014; Felizeter et al., 2012, 2014). In the C8 Health Study population, consumption of locally grown or home grown vegetables was associated with higher serum PFOA levels (Emmett et al., 2006a; Steenland et al., 2009a; Hoffman et al., 2011).

PFOA is much less bioaccumulative in fish than other PFCs that have a longer fluorinated carbon chain, including PFOS (Conder et al., 2008). Thus, consumption of fish from waterways contaminated with PFOA does not result in the high exposures typical of other persistent organic contaminants, including PFOS, which are bioaccumulative in fish (Hölzer et al., 2011). However, PFOA has been detected in edible fish and other seafood, and consumption of aquatic organisms may represent a significant portion of total dietary exposure in some populations (Haug et al., 2010 b; Zhang et al., 2011).

Several studies suggest that PFOA and its precursors in indoor air and/or house dust may be a major exposure source for some individuals (Haug et al., 2011; Shoeib et al., 2011; Schlummer et al., 2013; Gebbink et al., 2015a). Fraser et al. (2013) reported that the concentration of the PFOA precursor 8:2 FTOH in indoor air in offices is a predictor of serum PFOA concentration. Levels of this compound were greatly elevated in offices with new carpets compared to other offices.



Greater exposures to PFOA may occur in young children than in older individuals because of age-specific behaviors such as greater drinking water and food consumption on a body weight basis, hand-to-mouth behavior resulting in greater ingestion of house dust, and more time spent on floors where treated carpets are found (Section 5.1; Trudel et al., 2008; Shoeib et al., 2011).

Occupational exposure to PFOA is believed to occur primarily through inhalation (Vestergren and Cousins, 2009).

### **Exposures from drinking water**

It is well established that serum PFOA concentrations are greatly elevated in communities with highly contaminated drinking water resulting from environmental discharges (discussed in Biomonitoring, above). As discussed in Biomonitoring (above) and Toxicokinetics (below), continued exposure to even relatively lower drinking water concentrations which are more widespread (Section 3 above) can also substantially increase total human exposure, as indicated by serum PFOA levels.

The total exposure studies discussed above provide varying conclusions about the relative importance of drinking water to total exposure; these conclusions are highly dependent on the concentration of PFOA in drinking water assumed in the analyses. For example, Fromme et al. (2008) and Cornelis et al. (2012) concluded that drinking water contributed <1% to total exposure, assuming drinking water levels of 1 ng/L and 2 ng/L, respectively, while Noorlander et al. (2011) estimated that 55% of exposure comes from drinking water, assuming 9 ng/L. Vestergren and Cousins (2009) and Thompson et al. (2011) demonstrated that the contribution of drinking water to total exposure depends on the concentration of PFOA, and Thompson et al. (2011) predicted that a drinking water level of 9.66 ng/L contributed 24% to total exposure.

PFOA exists in drinking water in its non-volatile anionic form, and the formation of inhalable water droplets during showering or bathing is minimal. Therefore, inhalation exposure is not expected to be significant from non-ingestion uses of drinking water such as showering, bathing, laundry, and dishwashing (Trudel et al., 2008; USEPA, 2016e). In contrast, these are important exposure routes for volatile drinking water contaminants. Similarly, dermal absorption of PFOA during showering, bathing, or swimming is not expected to be significant compared to exposure through ingestion, based on analysis by NJDOH (2014) using skin permeability data from Franko et al. (2012).

## **TOXICOKINETICS**

### **Absorption, Distribution, Metabolism, and Excretion**

#### **Summary**

PFOA is well absorbed orally, and can also be absorbed dermally and by inhalation. The ammonium (APFO) or sodium (NaPFO) salts dissociate to PFOA (the anionic form) in the body.

PFOA is water soluble and distributes primarily to the liver and serum, and, to a lesser degree, to the kidney. Unlike most other bioaccumulative organic compounds, it does not distribute to fat. In the serum, PFOA is almost totally bound to albumin and other proteins. Since it is chemically non-reactive, it is not metabolized. The rate of excretion of PFOA varies widely among species, and in some cases between males and females of the same species. The excretion rate is largely dependent on the extent of secretion and reabsorption by organic anion transporters in the kidney. In humans, the half-life is several years, and half-lives in male and female mice and male rats are days to weeks, so that PFOA reaches steady-state in these species/genders after continued dosing. However, PFOA is rapidly excreted in female rats (half-life of 2-4 hours) and does not reach steady-state after continued once-daily dosing. For this reason, the rat is not an ideal model for studying developmental effects of PFOA. Because of the large variations in half-lives, the internal dose resulting from a given administered dose varies widely among species and, in some cases, genders of the same species. For this reason, interspecies (e.g. animal-to-human) comparisons are made on the basis of internal dose, as indicated by serum level, rather than administered dose.

### Absorption

PFOA is well absorbed by the oral route (Lau et al., 2007). More than 95% of a single dose of 0.1 to 25 mg/kg APFO (the ammonium salt of PFOA) was absorbed in male and female rats (Kemper, 2003). It was also well absorbed in mice, rats, hamsters, and rabbits in studies by Hundley et al. (2006). About 98.7% of an oral dose given to pregnant rats on gestation day (GD) 8 or 9 was excreted in the urine within 24 hours (Gibson and Johnson, 1983). Additionally, a recent study in mice (Fujii et al., 2015) estimated the oral absorption of PFOA as 98.7% in males and 99.8% in females. The extent of oral absorption was determined by comparing fecal excretion after intravenous dosing (representing biliary excretion of PFOA into the gastrointestinal tract) and oral dosing (representing both unabsorbed PFOA and biliary excretion). PFOA is well absorbed by humans exposed orally, as demonstrated by elevated serum concentrations in residents of communities with contaminated drinking water (discussed above).

PFOA penetrated rat and human skin in an *in vitro* system (Fasano et al., 2005), and dermal exposure caused liver toxicity in rats (Kennedy, 1985) and immune effects in mice (Fairley et al., 2007). The dermal permeability coefficient of PFOA (14,000 ng/L [14 µg/L] in water, pH 5.01) was estimated as  $8.8 \times 10^{-5}$  cm/hr (Fasano et al., 2005). As above, dermal absorption is not expected to be a significant source of exposure from contaminated drinking water (NJDOH, 2014).

Inhalation exposure to APFO in rats caused hepatic effects (Kennedy et al., 1986). Elevated serum levels of PFOA in workers in facilities making or using PFOA are likely to result primarily from inhalation exposure (Olsen, 2015). As above, PFOA does not volatilize from

water, and inhalation is not expected to be a significant source of exposure from contaminated drinking water (Trudel et al., 2008; USEPA, 2016e).

### Distribution

After oral administration, the highest concentrations of PFOA are found in the liver and serum, followed by the kidney, with lower concentrations in other organs (Vanden Heuvel et al., 1991; Kemper, 2003; Hundley et al., 2006; Fujii et al., 2015). After *in utero* exposure to mice, PFOA persisted in bone until adulthood (Koskela et al., 2016). In the serum, PFOA is almost totally bound to albumin and other proteins (SRI, 2003; Han, 2003). Unlike many other persistent bioaccumulative compounds, PFOA does not distribute to fat, and the concentrations of PFOA in the fat after dosing are very low (Vanden Heuvel et al., 1991; Hundley et al., 2006; Fujii et al., 2015).

The fraction of the dose found in the liver is dose-dependent and varies between male and female animals. For example, in male rats two hours after a single intravenous dose, 52% of a low dose (0.041 mg/kg) and 27% of a higher dose (16.56 mg/kg) were found in liver (Kudo et al., 2007). Serum concentrations were similar in male and female CD-1 mice after a single oral gavage dose of 1 or 10 mg/kg PFOA (Lou et al., 2009). However, the concentration in the liver was higher in males than in females.

In another study in which rats were given a single dose of 25 mg/kg, the absolute concentrations in the livers of males were higher than in females, as expected based on the slower excretion by male rats (see below), and the percentage of PFOA in the cytosolic fraction of the liver was higher in females (49%) than in males (26%) (Han et al., 2005).

The subcellular distribution within the liver of male rats was also found to be dose-dependent (Kudo et al., 2007). Over 40% of a low dose (0.041 mg/kg) distributed to the 8000xg pellet (nuclei, mitochondria, and cellular debris), followed by lysosomes and peroxisomes, microsomes, with the least amount found in cytosol (less than 5%), while over 43% of a higher dose (16.56 mg/kg) distributed to cytosol, followed by the 8000xg pellet, lysosomes and peroxisomes, and microsomes. In another part of this study using a range of doses, there was a dose-dependent increase in the percentage found in cytosol.

### Metabolism

PFOA is chemically unreactive due to its carbon-fluorine bonds, one of the strongest found in organic chemistry (Vaalgamaa et al., 2011). Therefore, it is not metabolized by biological systems.

### Excretion

PFOA is excreted in the urine and the feces, and the proportion in the urine versus the feces varies among species (Hundley et al., 2006; Cui et al., 2010). It is believed that PFOA undergoes enterohepatic circulation (Kudo and Kawashima, 2003) since oral administration of cholestyramine (an anion exchange resin which is not absorbed from the gastrointestinal tract) increased the fecal elimination of PFOA in male rats by 10-fold (Johnson et al., 1984).

Data from several studies indicate that blood loss (e.g. through menstruation, blood donation, or venesection) is an additional excretion route for PFCs (Harada and Koizumi, 2009; MDH, 2013; Taylor et al., 2014; Lorber et al., 2015)

The half-life of PFOA varies among species, and it also differs between males and females in some species, most notably rats and hamsters (Table 4; Hundley et al., 2006, Lau et al., 2007). PFOA is excreted much more quickly in female rats ( $t_{1/2} = 2-4$  hours) than in male rats ( $t_{1/2} = 4-6$  days), while the excretion rate in hamsters is much more rapid in males than in females. The half-life in both sexes of mice is similar (17 days in females and 19 days in males), while excretion is rapid in both sexes of rabbits with half-lives of 5.5 hours in males and 7 hours in females.

The differences in excretion rates between species and between male and female rats are thought to be due to variations in renal clearance rates. These rates are controlled by specific organic anion transporters that are responsible for the active transport (secretion or reabsorption) of many organic anions, including endogenous substances and xenobiotics, across membranes in several organs including the kidney (Weaver et al., 2010; Han et al., 2012). The specific transporters believed to be responsible for renal reabsorption of PFOA have been identified in male rats as Oatp1a1 and in humans as OAT4 and URAT1 (Han et al., 2012).

<i>Species</i>	<i>Females</i>	<i>Males</i>	<i>References</i>
Rat	2–4 hours	4–6 days	Johnson et al. (1979); Kemper and Jepson (2003)
Mouse	17 days	19 days	Lau et al. (2005)
Rabbit	7 hours	5.5 hours	Hundley et al. (2006)
Dog	8–13 days	20–30 days	Hanhijarvi et al. (1988)
Cynomolgus Monkey	30 days	21 days	Butenhoff et al. (2004a)
Human (males and females combined)	3.8 years (retired workers)		Olsen et al. (2007)
	2.3 years (adults after cessation of exposure from contaminated drinking water)		Bartell et al. (2010a)
	3.3 years (average of adults and children after cessation of exposure from contaminated drinking water)		Brede et al. (2010)
	Adults and children after cessation of exposure to contaminated drinking water.  Highly exposed group: 2.9 years (initial 4 years post-exposure); 10.1 years (>4 years post-exposure).  Less exposed group: 8.5 years (initial 9 years post-exposure); no apparent decline (>9 years post-exposure).		Seals et al. (2011)

Adapted from Lau, 2012

Renal excretion of PFOA appears to be under hormonal control (Ylinen et al., 1989; Kudo et al., 2002). Kudo et al. (2002) found that the clearance of PFOA in female rats (15 ml/min/kg) is greater than the glomerular filtration rate (10 ml/min/kg), suggesting that PFOA is actively excreted through renal tubular secretion, while the renal clearance was much lower in male rats, 0.6 ml/min/kg (Kudo et al., 2002). Castration of male rats increased the clearance to a rate similar to that in females, and this increase was reversed by administration of testosterone to the castrated rats (Ylinen et al., 1989; Kudo et al., 2002). Administration of estradiol to male rats increased the renal excretion of PFOA, and administration of testosterone to female rats reduced the clearance to a rate similar to that of male controls (Ylinen et al., 1989; Kudo et al., 2002). Probenecid, an inhibitor of renal tubular secretion of organic anions, greatly reduced the clearance of PFOA in female and castrated male rats, but had little effect on the excretion rate in control male rats (Hanhijarvi et al., 1982; Kudo et al., 2002).

The gender-dependent differences in excretion rate in rats appear to develop between 3 and 5 weeks of age (Hinderliter et al., 2006). At 4 weeks of age, serum concentrations 24 hours after a single oral dose of 10 mg/kg PFOA were similar (within 3-fold) in male and female rats, while at 5 weeks and older, serum levels were at least 30-fold higher in males than in females receiving the same dose. This greater difference in older rats resulted from age-dependent changes in both males and female. At 5 weeks of age or older, serum levels in males at this dose were about 5-fold higher than serum levels at 4 weeks, while serum levels in females 5 weeks or older are 2-3 fold lower than at 4 weeks of age.

### **Human half-life**

The half-life of PFOA in humans is several years and does not appear to differ significantly between males and females. Inter-individual differences in half-life may be due to differences in renal transport by OATs. A mean half-life of 3.8 years was estimated from data from 26 retired workers with occupational exposure, with no difference found between men and women (Olsen et al., 2007). Bartell et al (2010a) estimated a half-life of 2.3 years in a more heterogeneous study population consisting of 200 adults exposed to PFOA in drinking water. This estimate was based on average decreases in serum level of 26% and 24% for a one-year period after treatment to remove PFOA was initiated in two water districts contaminated by PFOA emissions from a West Virginia manufacturing facility. There was no evidence of age- or gender-dependence in elimination rates in this study. During the second year of follow-up of the same individuals, serum PFOA levels decreased more slowly (9% and 15% in the two water districts), suggesting either ongoing exposures from sources other than residential drinking water or that kinetics do not follow first-order elimination (Bartell et al., 2010b).

Seals et al. (2011) studied the rate of decline of serum PFOA levels in former residents of Little Hocking (n = 602) and Lubeck (n = 971), the two water districts with the highest drinking water PFOA levels of the six districts included in the C8 Health Study. Median serum levels in current and former residents of Little Hocking (current residents, 241.0 ng/ml; former residents regardless of years elapsed, 60.6 ng/ml) were much higher than in Lubeck (current residents, 69.4 ng/ml; former residents regardless of years elapsed, 31.0 ng/ml), due to the much higher drinking water PFOA concentrations in Little Hocking than Lubeck. The number of years elapsed since the former residents moved and thus stopped consuming contaminated water ranged from less than one year to almost 25 years. The data on the relationship between years elapsed since moving and serum PFOA levels suggest that PFOA elimination is biphasic and dependent on serum concentration. In former residents of Little Hocking, the half-life was 2.9 years for the first 4 elapsed years, and about 8.5 years after the first 4 elapsed years. In former residents of Lubeck, the half-life was about 8.5 years for the first 9 elapsed years, with no apparent decline in serum levels after 9 elapsed years.

PFOA levels in serum of exposed individuals were also studied in Arnsberg, Germany, where the Moehne River which is used a drinking water source was contaminated by runoff from PFOA-contaminated industrial waste applied to agricultural land (Brede et al., 2010). In a two-year study of 138 individuals before and after drinking water treatment removal was initiated, the geometric mean PFOA plasma levels declined by 39% in children and mothers, and by 26% in men; the geometric mean half-life was estimated as 3.26 years.

### **Isomer-specific kinetics**

PFOA exists as a mixture of linear and branched isomers, and the isomer profile varies depending on the manufacturing process used. PFOA made by the telomerization process is primarily linear, while PFOA produced by electrochemical fluorination consists of a mixture of linear and branched isomers. Differences in the rates of elimination of the isomers have been investigated (Loveless et al., 2006; DeSilva et al., 2009). Loveless et al. (2006) reported that, after equivalent doses, serum levels of branched PFOA were lower than for linear PFOA in rats and mice. Similarly, after subchronic administration to rats, most branched isomers were eliminated more quickly than linear PFOA, with the exception of two minor unidentified branched isomers which had half-lives about twice that of linear PFOA (DeSilva et al., 2009). In humans, branched isomers were also more rapidly eliminated than linear isomers (Zhang et al., 2013; Gao et al., 2015). PFOA isomer profiles differed in maternal and cord serum within human infant-mother pairs, indicating that most branched isomers cross the placenta more efficiently than the linear forms (Beesoon et al., 2011). It has recently been reported that linear PFOA has a higher binding affinity than branched PFOA for human serum albumin and serum proteins in general, providing a potential explanation for the more rapid excretion of branched isomers of PFOA (Beesoon and Martin, 2015).

### **Toxicokinetics Relevant to Developmental Exposures**

#### **Summary**

It is important to consider toxicokinetics relevant to developmental exposures of PFOA in detail. Developmental effects are the most sensitive known endpoints for PFOA toxicity in experimental animals, and prenatal exposure is associated with decreased fetal growth in humans (see Toxicology and Epidemiology sections, below).

The toxicokinetics of PFOA during gestation and lactation have been studied in rats and mice but have not been evaluated in non-human primates. In rodents, PFOA is present in fetuses of dosed dams, as well as in the placenta and amniotic fluid. PFOA is also present in the breast milk of gestationally exposed dams.

Because it is excreted very quickly in female rats but very slowly in humans, the rat is not an ideal model for study of developmental effects of PFOA. In contrast, the mouse is a preferable



model for evaluation of developmental effects because PFOA is excreted slowly in female mice. For this reason, many recent developmental studies have been conducted in mice.

In humans, PFOA has been measured in amniotic fluid, maternal serum, umbilical cord blood, and breast milk. PFOA concentrations are similar in maternal serum and umbilical cord blood serum, which is reflective of serum levels in the newborn. PFOA exposure in breast-fed infants is greatest during the first few months of life because both PFOA concentrations in breast milk and the rate of fluid consumption are highest during this time period. As a result, serum PFOA concentrations in breast-fed infants increase several fold from levels at birth within the first few months of life. Exposures to infants who consume formula prepared with contaminated water are also highest during this time period. These greatly elevated exposures during the first months of life are of special concern because the neonatal period is a sensitive time period for the toxicological effects of PFOA.

#### Rats

As discussed above, PFOA is excreted very rapidly by female rats (half-life of 2-4 hours). Because of its rapid excretion, PFOA is not continuously present in female rats dosed once daily, and the fetuses are thus not exposed continuously to PFOA from such a dosing regimen. Because PFOA is highly persistent in humans, the rat is not an ideal model for evaluation of developmental effects of PFOA.

In female rats given a single oral dose of PFOA, the maximum plasma concentration occurred about 1.25 hours after dosing (Kemper and Jepson, 2003). About 98.7% of an oral dose given to pregnant rats on gestation day (GD) 8 or 9 was excreted in the urine within 24 hours (Gibson and Johnson, 1983).

Kinetics of PFOA were studied in pregnant rats (strain not stated) dosed once daily by gavage with 3, 10, or 30 mg/kg/day on GD 4 to postnatal day (PND) 21, and their pups (Hinderliter et al., 2005). Because the gender difference in kinetics in rats develops at about 5 weeks of age (Hinderliter et al., 2006), plasma levels were similar in male and female pups until PND 21, the time period evaluated in this study. Plasma was taken from the dams 2 hours after dosing to allow maximum detection of PFOA, since virtually all PFOA is excreted within 24 hours after dosing of female rats. Mean PFOA concentrations in maternal plasma approximately 2 hours after doses of 3, 10, or 30 mg/kg were 11,000, 27,000, and 67,000 ng/ml, respectively. On GD 21, levels in fetal plasma were about half of those in the dams. Concentrations in milk were fairly constant on PND 3 through PND 21, and were about 10-fold lower than maternal serum levels. Pup plasma levels were about 4-fold lower than maternal plasma levels on PND 3, and about 10-fold lower at later time points. PFOA was also detected in the placenta and amniotic fluid. Interpretation of these data is complicated by the fact that maternal plasma levels varied

widely during the course of the day between the daily doses, and milk and fetal/pup levels are compared to maternal plasma levels in samples taken near their daily peaks.

### Mice

In contrast to female rats, PFOA is slowly excreted in female mice with a half-life of several weeks (discussed above). Therefore, the fetus is continuously exposed when pregnant mice are dosed once daily. Because PFOA is persistent in humans, the mouse is a preferable model for evaluation of PFOA's developmental effects than the rat, and many recent developmental studies have been conducted in mice.

Fenton et al. (2009) studied the disposition of PFOA in pregnant CD-1 mice and their pups after a single oral gavage dose of 0.1, 1, or 5 mg/kg on GD 17. On GD 18 prior to delivery, the PFOA concentration in the amniotic fluid was about half of the concentration in maternal serum. PFOA concentrations in the whole pup on GD 18 were similar to those in maternal serum. On PND 1 (the earliest time at which serum was measured in pups), pup serum PFOA concentrations were about 1.5 times the concentrations in maternal serum. The exposure of pups at this stage was thought by the authors to result primarily from *in utero* exposure rather than through lactation.

PFOA concentrations in maternal serum and in aspirated milk followed a U-shaped curve over time between PND 1 (serum) or PND 2 (milk) and PND 18, with decreases between the earliest time point (PND 1 or 2) and mid-lactation (PND 8, pups, and PND 11, milk), and increases from mid-lactation to PND 18. This increase between PND 8 and 18 was thought to result from decreased dilution of maternal serum and milk at PND 18. PFOA concentrations in pup serum and in whole pups decreased over time from postnatal day 1 to 18 on a ng/ml or ng/g basis, while the total PFOA pup body burden increased from GD 18 to PND 8, and decreased between PND 8 and 18, presumably because the intake of milk has decreased during this period. Milk concentrations were lower than maternal serum concentrations at all doses and time points, ranging from 11% to 56% of the serum concentration, with the higher percentages at early and late lactation time points.

Serum PFOA concentrations in lactating CD-1 mouse dams and their pups were also measured in a cross-fostering study of mammary gland developmental effects (White et al., 2009) in which dams were treated by gavage with 5 mg/kg/day from GD 8-17. After birth, litters of similar ages and exposures were mixed and fostered, resulting in four treatment groups: untreated dam with unexposed pup, treated dam with unexposed pup, untreated dam with pup exposed during gestation, and treated dam with pups exposed during gestation. Consistent with the single dose study (Fenton et al., 2009), serum PFOA levels on PND 1 in pups exposed *in utero* were about 50% higher than in treated dams. On PND 1, PFOA in the pups is primarily attributable to *in utero* exposure, rather than lactational exposure during the first postnatal day, since serum PFOA concentrations in pups not exposed *in utero* but nursing on treated dams were only about 3% of

the concentrations in pups exposed *in utero*. Serum levels in treated dams and pups decreased between PND 1 and PND 10, with a greater decrease in pups exposed *in utero* that nursed from untreated dams than in pups exposed *in utero* that nursed from treated dams. Serum levels from pups not exposed *in utero* that nursed from treated dams rose over time, and by PND 10 serum levels in these pups were similar to levels in the treated dams they nursed from. Interestingly, serum levels in untreated dams that nursed pups exposed *in utero* increased between PND 1 and PND 10, presumably due to maternal behavior (grooming, and ingestion of urine and feces) resulting in ingestion of PFOA from the pups.

In a more recent study of effects on mammary gland development from lower doses of PFOA (Macon et al., 2011), pregnant CD-1 mice were dosed by gavage on GD 10 to 17 with 0, 0.01, 0.1, or 1 mg/kg/day. At PND 1, serum levels in the pups were 24, 285, 2304, and 16,306 ng/ml in the untreated, 0.01, 0.1, and 1 mg/kg groups, respectively. The pup serum levels decreased over time to 3, 17, 132, and 2683 ng/ml at PND 21. Maternal serum levels were not measured by Macon et al. (2011). However, in other studies in which serum data are available for dams and pups within the same study (e.g. Fenton et al., 2009), serum levels on PND 1 were higher in pups than dams.

White et al. (2011) provide data on serum PFOA concentrations in CD-1 dams and female pups exposed to 5000 ng/L (5 µg/L) PFOA in drinking water over multiple generations. Results of this study are discussed in the section on Developmental Effects. Exposure began in P0 dams on GD 7 and continued throughout the F1 and F2 generations (except during F1 breeding and early gestation, to avoid exposing control males). Serum concentrations were 74.8 ng/ml in the P0 dams and 86.09 ng/ml in the F1 dams at weaning on PND 22, as compared to 4 and 2 ng/ml, respectively, in the corresponding control groups of dams. At this time point, the P0 dams had been exposed for about 32 days and the F1 dams had been exposed throughout their lifetimes beginning *in utero*, except during breeding and early gestation. As discussed below, serum concentrations in humans with ongoing exposure PFOA in drinking water are, on average, more than 100-fold higher than the concentration in drinking water. Thus, the serum PFOA concentrations in the mice exposed to 5000 ng/ml (5 µg/L) in drinking water are much lower than the average serum concentrations of more than 500 ng/ml expected in humans chronically exposed to this drinking water concentration.

Serum PFOA concentrations were similar in F1 and F2 pups, and concentrations in the pups were lower than in the dams at weaning. The serum concentrations in the F1 and F2 pups at PND 22 were 21.3 and 26.6 ng/ml, respectively; at PND 42, they were 48.9 and 57.4 ng/ml; and at PND 63, they were 66.2 and 68.4 ng/ml.

## Humans

### *Relationship between maternal and fetal/neonatal exposures*

PFOA has been detected in umbilical cord blood serum in studies of the general population worldwide. In seven studies reviewed by Post et al. (2012) in which both maternal and cord blood were analyzed, the mean cord blood serum:maternal serum (or plasma) ratio ranged from 0.68:1 to 1.26:1, with a mean ratio of less than 1:1 in all but one study. However, cord:maternal serum (or plasma) ratios for some individual neonate-maternal pairs within these studies were greater than 1:1. Since umbilical cord serum (or plasma) is reflective of neonatal serum (or plasma), these data indicate that serum (or plasma) levels are generally similar in the neonate and the mother. A more recent review by Kato et al. (2015) that evaluated 12 studies in total also concluded that the maternal:cord serum ratios for PFOA is approximately 1:1.

### *Exposure to infants through breast milk and infant formula*

PFOA is detected in human breast milk worldwide (reviewed by Liu et al., 2010; White et al., 2011a; Post et al., 2012). Factors which may potentially affect the concentration of PFOA in breast milk include whether the mother has previously nursed other infants and how soon after birth the sample is taken (Tao et al., 2008a; Haug et al., 2011; Thomsen et al., 2010). Thomsen et al. (2010) found that average breast milk concentrations were highest initially and decreased by about 7.7% per month, or about 94% during the first year of breast feeding, presumably due to decreased maternal body burden resulting from excretion into breast milk.

Breast milk PFOA concentrations were reported to be about 1% of mean general population serum levels by Tao et al. (2008a), and to be 2.5% and 9% of median maternal serum levels by Kim et al. (2011) and Liu et al. (2011), respectively. These data suggest a breast milk:maternal serum ratio of about 1:100 to 1:11. Based on a breast milk:maternal serum ratio of greater than or equal to 1:100 (Tao et al., 2008a; Kim et al., 2011; Liu et al., 2011) and a serum:drinking water ratio of greater than or equal to 100:1 (discussed below), the initial PFOA concentration in breast milk is expected to be greater than or equal to the concentration in the maternal drinking water source (Post et al., 2012).

Exposures to infants to PFOA from breast milk or formula are higher than in older individuals exposed to the same concentration of PFOA in drinking water. Mean breast milk consumption is 150 ml/kg/day during the first post-partum month when PFOA levels in breast milk are highest (Thomsen et al., 2010), and it is 83 ml/kg/day from 6-12 months of age (USEPA, 2008a). Similarly, the mean drinking water intakes in infants who consume drinking water (e.g. in formula prepared with water) are 137 ml/kg/day from birth to 1 month of age, and 53 ml/kg/day at 6-12 months of age (USEPA, 2011b). These fluid intakes are much higher than the mean drinking water consumption rates in lactating women, 26 ml/kg/day (USEPA, 2011b), and the general population (11 years of age or older), 13 ml/kg/day (USEPA, 2008a). Although breast milk or

formula consumption on a body weight basis decreases as the infant gets older, it remains much higher than adult water consumption throughout infancy.

As noted above, serum PFOA levels are similar in newborns and in their mothers. Several studies, summarized below, have consistently demonstrated that serum PFOA concentrations in breast-fed infants increase by several fold during the first few months of life, presumably because both breast milk PFOA concentrations and intake of breast milk on a body weight basis are highest during this time period. Infants fed with formula prepared with contaminated drinking water also receive the greatest exposures during the first few months of life because the rate of fluid intake is highest then.

Serum PFOA levels were measured in umbilical cord blood at delivery and at 6 month and 19 months of age in infants from the German general population (Fromme et al., 2010). Average body burdens, as indicated by serum levels, were increased, typically by several-fold, from birth to 6 months by exposure through breast milk. Levels declined between 6 months and 19 months, a time point at which breast feeding had stopped or was decreased, but remained higher at 19 months than at birth (Figure 5).




Figure 5. PFOA concentration in cord blood and blood collected in infants around six and nineteen months after birth (Fromme et al., 2010)

Duration of breastfeeding was also associated with higher serum PFOA concentrations in infants (n=49) from a community with PFOA-contaminated drinking water (the C8 Health Study). The increases were estimated as 6% per month of breastfeeding and 96% for one year of breastfeeding (Mondal et al., 2014). The authors noted that these values may underestimate the actual increases from exposure through breastfeeding, because they are based on comparisons to non-breastfed infants from the same communities who may also have had increased serum PFOA concentrations from exposures via formula prepared with contaminated drinking water.

Similarly, a study of Faroese infants (n= 80) with serum PFOA data at birth and 11, 18, and 60 months estimated an increase in serum PFOA concentrations of about 28% per month during the period of exclusive breast feeding (median of 4.5 months in the study group) and about 4% per month during the period of partial breast feeding (median of 4 additional months) (Mogensen et al., 2015). Serum PFOA concentration did not increase in non-breastfed (e.g. formula-fed) infants; presumably, the drinking water in this location was not contaminated with PFOA. Data for 12 infants from the study are shown in Figure 6.




Figure 6. Serum PFOA concentrations over time in 12 infants from Mogensen et al. (2015).

Finally, Verner et al. (2016a,b) developed a pharmacokinetic model that predicts PFOA doses and plasma levels in breastfed infants and children, and their mothers. Monte Carlo simulations were used to predict the distribution of child:mother ratios for doses and plasma levels starting at birth (Figure 7). Doses (ng/kg/day) to infants were much higher than in their mothers during the first year of life. The infant:mother dose ratio peaked right after birth, with a median ratio of about 75:1 and a maximum of 231:1, and declined thereafter (Figure 7, right side). The infant:mother plasma level ratio peaked during the first year of life, with predicted ratios of 4.5-fold (median), 7.8-fold (95<sup>th</sup> percentile), and 15.3-fold (maximum) higher plasma PFOA concentrations in infants than in their mothers during the period of greatest infant exposure (Figure 7, left side).






Figure 7. Monte Carlo simulations ( $n = 10\,000$ ) of child/mother ratios of plasma PFOA levels (ng/ml; right side of figure) and doses (ng/kg/day; left side of figure) for a breastfeeding period of 30 months. The black line represents the 50th percentile, the blue line represents the 5th percentile, the red line represents the 95th percentile, and the dotted lines represent minimum and maximum values (Verner et al., 2016a,b).

While peak serum PFOA concentrations occur during the first year of life, levels remain elevated for at least several additional years. Serum PFOA levels in children up to age 5 (or older) were higher than in adults in communities exposed through contaminated drinking water (Emmett et al., 2006a; Steenland et al., 2009a; Mondal et al., 2012, discussed above). In the study of Faroese children (Mogensen et al., 2015), serum PFOA levels declined after their peak in infancy but remained elevated above initial levels at birth until at least age 5 years, the last time point assessed. Similarly, the model developed by Verner et al. (2016a) predicts that plasma PFOA concentrations will remain several fold higher than at birth until at least age 3 years, the last time point modeled.

In summary, both breast-fed and formula-fed infants receive much greater exposures to PFOA from contaminated drinking water (directly or indirectly) than older individuals. Serum PFOA levels peak during the first year of life and remain elevated for several years. These elevated exposures during early life are of special concern because effects from neonatal exposure are sensitive endpoints for the toxicity of PFOA.

### **Relationship between administered dose and internal dose**

#### **Repeated Dose Animal Studies**

Information on kinetics in repeated dose animal studies was reviewed by Post et al. (2012). At higher doses, the kinetics of PFOA in rodents and primates (Griffith and Long, 1980; Ylinen et al., 1990; Mylchreest, 2003; Butenhoff et al., 2004a; Perkins et al., 2004; Loveless et al., 2006; Lau et al., 2006; Das et al., 2010) are not consistent with one-compartment or simple first-order models (Anderson et al., 2006; Clewell, 2009). Serum levels did not increase proportionally with increasing dose, except at lower doses in some studies. Additionally, steady-state was reached more rapidly at high doses than predicted by classical kinetics (4 to 5 half-lives).



However, at lower doses closer to those relevant to human environmental exposures, kinetics are consistent with first order processes, and serum levels are proportional to administered dose (Clewell, 2009; Lou et al., 2009; Loveless et al., 2006; Das et al., 2010). Available data indicate that serum levels in mice from doses below the administered range can be estimated by linear extrapolation from data on doses of 1 mg/kg/day or lower. The kinetics are consistent with the saturation of OATs responsible for renal reabsorption at high doses, resulting in a higher excretion rate at high doses than at low doses (Anderson et al., 2006; Clewell, 2009).

### Human studies

#### *Relationship between drinking water and serum concentrations in exposed communities*

In communities with drinking water contaminated by PFOA, mean and median serum PFOA levels higher than in the general population. Variations in serum PFOA concentrations among individuals using the same source of drinking water arise from inter-individual differences in daily water consumption rates (L/kg/day) and/or toxicokinetic factors.

The relationship between drinking water concentration and serum concentration has been extensively evaluated for PFOA. It is well established that ongoing human exposure to PFOA in drinking water increases serum levels, on average, by at least 100 times the drinking water concentration. This conclusion is based on data from several studies of populations whose public water supplies or private wells were contaminated with a wide range of PFOA concentrations (60 ng/L to 13,300 ng/L).

In 282 residents of Little Hocking, Ohio at least six years of age exposed for two years or more, with occupationally exposed individuals excluded, the median ratio between the PFOA concentration in serum (371 ng/ml) and drinking water (3,550 ng/L) was 105:1 (25th-75th percentile range, 62:1-162:1), with a higher median ratio in young children (Emmett et al., 2006a).

This approximate 100:1 central tendency value for the serum:drinking water ratio was confirmed in communities with lower drinking water PFOA concentrations (Post et al., 2009a) based on data from approximately 70,000 residents of Little Hocking and five other Ohio and West Virginia water districts, when background serum levels found in the general population from non-water sources of exposure were taken into account. Drinking water levels in four of these districts were in the range of about 60 ng/L to 400 ng/L, while levels in a fifth district and Little Hocking were higher (Anderson-Mahoney et al., 2008).

Additionally, Hoffman et al. (2011) studied the relationship between drinking water concentrations and serum levels in the same region of Ohio and West Virginia in a study of 108 individuals using 62 private wells, with 1 to 4 participants using each well. Since the PFOA concentrations differed in each private well, this study included a greater range of drinking water

concentrations than studies of the six affected public water districts in this vicinity. The median and mean PFOA levels in the wells were 200 ng/L and 800 ng/L, respectively, and the maximum concentration was 13,300 ng/L. An adjusted robust regression model of the serum and drinking water data provided an estimated serum:drinking water ratio of 141:1 (95% CI: 135:1 – 148:1), while a one-compartment pharmacokinetic model based on assumed water intake of 1.41 L/day and half-life of 2.3 years provided an estimated ratio of 114:1.

An approximate ratio of 100:1 or greater between serum and drinking water concentrations is also consistent with observations in 98 Minnesota residents tested 34 months after exposure to contaminated drinking water ended (MDH, 2009), when the expected post-exposure decline in serum levels is considered.

A lower serum:drinking water PFOA ratio of approximately 50:1 was observed in a German community whose drinking water source was contaminated with PFOA and other PFCs (Hölzer et al., 2008). Possible reasons for this difference are the use of bottled water by some participants who were aware of the contamination for up to 6 months before their blood was sampled, uncertainty about the duration and time course of the water contamination, or differences in drinking water consumption patterns between German and U.S. residents.

*Pharmacokinetic modeling of the relationship between dose and serum concentration*

Biologically based pharmacokinetic modeling predicts a linear relationship in humans between external dose and internal dose, as measured by serum PFOA level, at doses relevant to environmental exposures such as from contaminated drinking water (Clewell, 2009). Increased serum levels that are linearly proportional to exposure levels have been observed in communities using contaminated drinking water (discussed above). However, non-linear kinetics such as observed in animals at higher doses, may occur at higher (occupational) human exposures (Clewell, 2009).

Lorber and Egeghy (2011) developed a simple single-compartment pharmacokinetic model that predicts the relationship in humans between PFOA dose (ng/kg/day) and serum concentration (ng/ml) based on volume of distribution and elimination rate, as follows:

$$\text{Serum concentration (ng/ml)} = \frac{\text{Dose (ng/kg/day)}}{\text{Volume of distribution (ml/kg) x Elimination rate (day}^{-1}\text{)}}$$

This model uses a volume of distribution of 170 ml/kg (0.17 L/kg), based on a model calibrated with data from an Australian population exposed to PFOA through drinking water (Thompson et al., 2010), and an elimination rate of 0.0008 day<sup>-1</sup>, based on the human half-life of 2.3 years observed in the C8 Health Study population (Bartell et al., 2010a). The product of these two values provides a clearance factor that relates serum concentration (ng/ml) to dose (ng/kg/day) of

0.14 ml/kg/day (or 0.00014 L/kg/day). It is noted that the half-life of 2.3 years (Bartell et al., 2010a) is the shortest value reported in the literature (Table 4) and is based on data from a community whose exposure to PFOA in drinking water had ended. Use of the other values reported in the literature (shown in Table 4) would result in a clearance factor that predicts a higher serum level from a given dose of PFOA.

The USEPA Office of Water (2016a) used the same values for volume of distribution and human half-life (elimination rate) selected by Lorber and Egeghy (2011) to derive the same clearance factor, 0.00014 L/kg/day. This value is very close to the clearance factor of 0.127 ml/kg/day (0.000127 L/kg/day) from the earlier unpublished model developed by Clewell (2006) that is discussed in Post et al. (2012).

USEPA (2016f) presents the following equation, which is equivalent to the equation presented by Lorber and Egeghy (2011) above:

$$\text{Serum Concentration } (\mu\text{g/L}) \times \text{Clearance } (1.4 \times 10^{-4} \text{ L/kg/day}) = \text{Human Dose } (\mu\text{g/kg/day})$$

The relationship between the concentration of PFOA in drinking water and serum predicted by the clearance factor of 0.00014 L/kg/day (Lorber and Egeghy, 2011; USEPA, 2016a) was compared with the empirically observed average ratio of > 100:1 in communities with drinking water exposure to PFOA (discussed above) as follows:

The daily dose from a given concentration of PFOA in drinking water is:

$$\text{Human Dose } (\mu\text{g/kg/day}) = \text{Drinking Water Concentration } (\mu\text{g/L}) \times 0.016 \text{ L/kg/day}$$

Where: 0.016 L/kg/day is the mean daily water ingestion rate in the U.S. (USEPA, 2011b).

Therefore:

$$\text{Drinking Water Conc. } (\mu\text{g/L}) \times 0.016 \text{ L/kg/day} = \text{Serum Conc. } (\mu\text{g/L}) \times \text{Clearance } (1.4 \times 10^{-4} \text{ L/kg/day})$$

And:

$$\frac{\text{Serum Concentration } (\mu\text{g/L})}{\text{Drinking Water Concentration } (\mu\text{g/L})} = \frac{0.016 \text{ L/kg/day}}{1.4 \times 10^{-4} \text{ L/kg/day}} = 114:1$$

The serum:drinking water ratio of 114:1 based on the clearance factor and average daily water consumption is consistent with the observed ratios in communities exposed to contaminated drinking water. This calculation verifies that the clearance factor accurately predicts the relationship between human dose and human serum level. The clearance factor can therefore be

used in the development of a Reference Dose (RfD) for PFOA from the Target Human Serum Level (RfD in terms of serum level).

*Increases in serum levels associated with PFOA in drinking water*

The increase in serum PFOA level, on average, expected from ongoing consumption of a given concentration of PFOA in drinking water can be predicted using the clearance factor, 0.00014 L/kg/day, and an assumed drinking water ingestion rate (L/kg/day). As above, the half-life of 2.3 years used in the clearance factor is shorter than other human half-life values reported in the literature (Table 4). Use of a longer half-life value would result in a higher predicted serum PFOA level from a given daily dose or drinking water concentration.

The mean daily water ingestion rate in the U.S. is 0.016 L/kg/day (from above), and the daily water ingestion rate based on the upper percentile factors (2 L/day water consumption; 70 kg body weight) used to derive Health-based MCLs is 0.029 L/kg/day. For each 10 ng/L in drinking water, on average, ongoing exposure at the mean ingestion and upper percentile ingestion rates are predicted to increase serum PFOA by 1.2 ng/ml and 2.0 ng/ml, respectively. Increases in serum levels from various concentrations of PFOA in drinking water, and the percent increases from the most recent median serum level, 2.1 ng/ml, from NHANES (2011-12; CDC, 2015) are shown in Table 5 and Figure 8.

Drinking Water Conc. (ng/L)	Mean Water Ingestion Rate (0.016 L/kg/day)			Upper Percentile Water Ingestion Rate (0.029 L/kg/day)		
	Increase in serum (ng/ml)	Total serum* (ng/ml)	% increase from drinking water*	Increase in serum (ng/ml)	Total serum* (ng/ml)	% increase from drinking water*
1	0.1	2.2	5%	0.2	2.3	10%
10	1.1	3.2	52%	2.0	4.1	95%
20	2.3	4.4	110%	4.0	6.1	190%
40	4.6	6.7	219%	8.0	10.1	381%
100	11.4	13.5	543%	20.0	22.1	952%
400	45.6	47.7	2171%	80.0	82.1	3810%

\*Total serum concentrations and % increases from drinking water are based on assumption of 2.1 ng/ml in serum (U.S. median value from NHANES, 2011-12; CDC, 2015) from non-drinking water exposures.




Figure 8. Increases in serum PFOA concentrations predicted from mean and upper percentile consumption of drinking water with various concentrations of PFOA, as compared to U.S median and 95th percentile serum PFOA levels (NHANES, 2011-12).

It is evident from Table 5 and Figure 8 that relatively low concentrations of PFOA in drinking water are associated with substantial increases in serum PFOA concentrations; this has recently been observed in a study of serum PFOA levels in individuals served by PWS with PFOA detections in UCMR3 (median UCMR3 detection – 28 ng/L; Hurley et al., 2016). For example, ongoing exposure to 20 ng/L at the upper percentile ingestion rate is predicted to result in a serum concentration of 6.1 ng/ml, which is above the 95<sup>th</sup> percentile in the U.S population of 5.7 ng/ml (NHANES, 2011-12; CDC, 2015). With an average (mean) water ingestion rate, exposure to 40 ng/L is expected to result in an elevation in serum level to 6.7 ng/ml, also above the 95<sup>th</sup> percentile from NHANES. Additionally, it should be kept in mind that (as discussed above), the increases in serum levels in infants are expected to be several fold higher than those shown in Table 5 and Figure 8.

## **HEALTH EFFECTS - HUMAN STUDIES**

### **Overview**

The epidemiological database for PFOA is much larger than for most other drinking water contaminants, including those previously evaluated by the DWQI. Considering the large body of epidemiologic studies assessing associations with PFOA, the Health Effects Subcommittee chose

to narrow and focus the human health effects section of this report. Studies of selected health endpoints were comprehensively reviewed, while information on other endpoints is summarized in the text. Conclusions of reviews of selected additional key health endpoints performed by other groups were also evaluated by the Subcommittee and are cited. This method allowed the Subcommittee to focus its resources while maintaining a high level of scientific review.

The basis for selection of endpoints for comprehensive review was largely supported by a previous detailed evaluation of the scientific literature on PFOA by the Health Effects Subcommittee in 2009-2010, and a subsequent comprehensive review of PFOA as an emerging drinking water contaminant (Post et al., 2012). These efforts represent a large amount of work that had already been completed in reviewing information relevant to the development of a Health-based MCL recommendation for PFOA and served as a starting point for the evaluation presented in this document.

Health endpoints evaluated comprehensively include: serum cholesterol/lipids, liver enzymes/bilirubin and liver disease, uric acid, thyroid function and thyroid disease, and antibody concentrations following vaccination. Some of the factors considered in selection of these endpoints were the extent and consistency of the data, whether the effect has been observed at exposures relevant to potential drinking water exposures, and evidence for reverse causality. Comprehensive evaluation involved the review of peer-reviewed studies identified through an *a priori* literature search and screening criteria. An individual study table summarizing the study design, location, study population characteristics, outcome and exposure assessment, study population exposure, statistical methods, results, major limitations which addresses risk of bias, and funding source for each reviewed study can be found in Appendix 4, and tables summarizing all studies of each endpoint are found below. Two other critical endpoints, fetal growth following developmental exposure and cancer, were recently comprehensively reviewed by other authoritative scientific groups. Review reports by these groups are evaluated and summarized in this document.

In total, 54 epidemiological studies assessing associations with serum cholesterol/lipids, liver enzymes/bilirubin, uric acid, thyroid function and thyroid disease, and/or antibody concentrations following vaccination were evaluated in depth. The studies were conducted on populations in the U.S., Canada, and several European and Asian countries. The studies evaluated the general population, communities with drinking water contaminated with PFOA, and occupationally-exposed workers, thereby assessing health effects over a wide range of PFOA exposures and serum concentrations.

In human environmental health effect studies in general, confounding by co-exposure to contaminants other than the one being evaluated may be particularly important since it may bias results. In some instances, PFOA has been shown to be strongly correlated with other co-

occurring PFCs which may not have been controlled for, and the same may be true for other environmental contaminants. This confounding bias could impact studies in any type of population, but may play a more important role in occupational populations which may be more likely than the general population to be exposed to co-occurring contaminants at meaningful levels. In general, co-exposure to other chemicals could also be more likely in communities where there are high levels of environmental contamination. However, this is not likely the case in the C8 Health Project, a large community study of populations with drinking water exposure to PFOA (discussed in more detailed below), since PFOA is the only contaminant that was reported to be present at elevated levels in drinking water or other environmental media.

As is the case for epidemiologic studies of environmental contaminants in general, the nature of these observational epidemiology studies, in contrast to experimental studies, limits our ability to definitively conclude that PFOA causes health effects. However, the findings from observational epidemiology studies are useful in assessing consistency, strength of association, exposure-response, temporality, specificity, and biologic plausibility - criteria which are useful in assessing causation.

#### **Studies of Exposure Levels Found in the General Population**

For the endpoints that were comprehensively reviewed, the majority of studies evaluated the general population and/or study populations with general population-level exposures to PFOA. Twenty nine (29) studies with general population, low-level exposures were identified. The serum PFOA concentrations (based on a measure of central tendency, which was presented as median, mean, or geometric mean) in these studies range from 0.9 to 7.1 ng/ml. A strength of the general population studies is their use of serum PFOA levels as the basis for exposure assessment. Because of the long human half-life of PFOA, serum levels do not rapidly fluctuate with short term variations in exposure, and serum levels taken at a single time therefore reflect long-term exposures. Serum levels thus provide an accurate measure of internal exposure for each study participant, an advantage over studies based on external exposure metrics such as drinking water concentrations. Among these studies, the large majority are cross-sectional (23 studies, plus one which includes a cross-sectional component).

A general limitation of cross-sectional studies is that they evaluate information on both exposure and outcome at the same point in time, limiting their ability to establish temporality.

#### **Studies in Exposed Communities**

For the endpoints selected for comprehensive evaluation, 15 studies evaluated highly-exposed individuals residing in communities with known PFOA drinking water contamination or in close proximity to a factory utilizing or producing PFOA. A large majority of these studies (14) occurred among communities in the Mid-Ohio Valley near the DuPont Washington Works plant in Parkersburg, WV. This industrial facility used large amounts of PFOA in the manufacturing of



a fluoropolymer, polytetrafluoroethylene (PTFE), and discharged PFOA to the environment resulting in widespread drinking water contamination. Many of the studies in this population are the result of the settlement of a class-action lawsuit by residents exposed to PFOA-contaminated drinking water which mandated that DuPont fund a health study called the C8 Health Project. Additional epidemiologic studies of associations with PFOA and health endpoints in this population have also been published by other researchers.

The C8 Health Project is a community health study of approximately 70,000 Ohio and West Virginia residents of all ages (infants to very elderly) with at least one year of exposure to drinking water contaminated with PFOA at >50 ng/L to over 3000 ng/L (Frisbee et al, 2009; C8 Science Panel, 2014). The C8 Health Project was conducted by the C8 Science Panel, which consisted of three epidemiologists chosen jointly by the parties involved in the legal settlement. This study is notable because of its large size, the wide range of exposure levels, and the large number of parameters evaluated. Data collected included serum levels of PFOA and other PFCs, clinical laboratory values, and health histories. The median serum PFOA concentration in this population was 28 ng/ml (ppb), and serum concentrations in the lowest two deciles were within the U.S. general population range at the time (<10 ng/ml).

The C8 Science Panel was charged with determining if “probable links” exist between diseases and PFOA exposure in the C8 study population, based on the results of their studies and other information from the scientific literature. Probable links were defined as “... given the scientific evidence available, it is more likely than not that a connection exists between C8 exposure and a particular human disease among class members...”. Probable links were established with PFOA exposure and six health endpoints (clinically defined high cholesterol, kidney and testicular cancer, ulcerative colitis, thyroid disease, and pregnancy-induced hypertension). For a number of other endpoints, no probable link with PFOA exposure was reported. Associations were also found with additional health endpoints for which no probable link evaluation was conducted because they were not considered to be clinically defined diseases. These endpoints include increased serum levels of liver enzymes, uric acid, C-reactive protein, and others. C8 Science Panel reports and citations for peer-reviewed publications presenting the results of these studies are found at the C8 Science Panel website (C8 Science Panel, undated, b).

### **Occupational Studies**

There are 14 peer-reviewed occupational studies of the endpoints chosen for detailed evaluation, three of which also studied exposed community populations (Wang et al., 2012, Winquist and Steenland, 2014a, and Winquist and Steenland, 2014b). Eight of the 14 occupational studies are cross-sectional. Locations include industrial facilities in the U.S., Italy, Belgium, and China. Occupational studies are often considered useful for evaluating effects of environmental contaminants because exposure levels are generally higher than in general population or in communities exposed through site-specific environmental contamination. Mean or median serum

PFOA levels in occupational studies reviewed in this report were generally over 1,000 ng/ml (ppb), several orders of magnitude higher than the median concentrations in the general population or in communities with drinking water exposure.

Associations of PFOA with some clinical parameters, including cholesterol, liver enzymes, and uric acid, exhibit a steep dose-response curve in the lower exposure range found in the general population, with a much flatter slope (approaching a plateau) at higher exposure such as those found occupationally (discussed in more detail below). For dose-response curves of this type, the associations found in populations with lower exposures may not be observed in workers because even the least exposed workers used as the comparison/reference group in occupational studies may have exposure levels that are high enough to fall on the much flatter upper portion of the dose-response curve.

Occupational studies may also have a selection bias from a “healthy worker effect” whereby workers usually have lower overall mortality and morbidity than individuals of the same age as a whole, since severely ill and disabled persons are typically not included in the workforce, especially in industrial settings (Shah, 2009). Longer duration of employment may also increase the effects of this bias, since sick people will be more likely to leave or change to safer work. Therefore, data based on duration of employment may not accurately reflect higher prevalence or larger magnitude of effects that are associated with longer exposures to the contaminant being evaluated.

Another issue with occupational studies of PFOA is the small number of exposed female employees which limits the ability of the occupational epidemiology to adequately address specific effects among women.

An additional issue is the possibility of effect modification due to exposure to other chemicals. Exposure to other PFCs, including PFOS at the 3M Decatur plant, may have played a role in the observed associations. Differences in exposures to other chemicals among manufacturing facilities may result in differences in degree of association with various effects.

### **Comprehensively Reviewed Endpoints**

#### **Serum lipids**

Associations of serum lipids and PFOA were evaluated in 24 studies, each of which included one or more of the following endpoints: total cholesterol, high density lipid cholesterol (HDL), non-HDL, ratio of total cholesterol to HDL, low-density lipid cholesterol (LDL), very low-density lipid cholesterol (VLDL), ratio of HDL to LDL, and triglycerides. There is also one additional study which only evaluated expression of genes related to cholesterol transport in humans (Fletcher et al., 2013). Study details are provided in the tables for individual studies (Appendix 4) and the summary table for serum lipids (Table 6A).

In total, 20 studies evaluated serum total cholesterol and two evaluated self-reported clinically defined high cholesterol (Steenland et al., 2015 and Winquist and Steenland, 2014). Among the 20 serum total cholesterol studies, 15 were cross-sectional (Emmett et al., 2006b; Eriksen et al., 2013; Fisher et al., 2013; Frisbee et al., 2010; Fu et al., 2014; Geiger et al., 2014; Gilliland et al., 1996; Nelson et al., 2010; Olsen et al., 2000; Olsen and Zobel 2007; Sakr et al., 2007a; Starling et al., 2014; Steenland et al., 2009; Wang et al., 2012; and Zeng et al., 2015) and two studies included cross-sectional and other analyses (Costa et al., 2009; and Olsen et al., 2003). The cross-sectional studies include seven studies of the general population or individuals with low-level exposures (Eriksen et al., 2013; Fisher et al., 2013; Fu et al., 2014; Geiger et al., 2014; Nelson et al., 2010; Starling et al., 2014; and Zeng et al., 2015); four studies of residents of highly exposed communities (Emmett et al., 2006b; Frisbee et al., 2010; Steenland et al., 2009; Wang et al., 2012); and five studies of occupationally exposed individuals (Gilliland et al., 1996; Olsen et al., 2000; Olsen and Zobel 2007; Sakr et al., 2007a; and Wang et al., 2012). Five remaining studies evaluating serum total cholesterol and PFOA include an occupational case-control study (Costa et al., 2009), and four cohort studies including one study of residents of a highly-exposed community (Fitz-Simon et al., 2013) and three studies of occupationally exposed individuals (Olsen et al., 2003; Olsen et al., 2012; and Sakr et al., 2007b).

Six of seven cross-sectional studies of the general population or populations with low-level exposures found evidence of statistically significant positive associations with serum cholesterol and PFOA. These studies of general population level exposures include a study nested in a larger cohort in Denmark of adults, aged 50 to 65 years, with mean serum PFOA concentration of 7.1 ng/ml (Eriksen et al., 2012); a general population study in Canada with a PFOA geometric mean of 2.5 ng/ml (Fisher et al., 2013); a small study of individuals randomly selected from attendees at a health check-up clinic with a median serum PFOA concentration of 1.4 ng/ml (Fu et al., 2014); a study of children in the U.S. general population with a serum PFOA mean concentration of 4.3 ng/ml (Geiger et al., 2014); a study of the general U.S. population aged 12 years older with a median PFOA concentration of 3.8 ng/ml (Nelson et al., 2010); and a study of subjects recruited from the control group of another study in Taiwan with median PFOA exposures of 1.1 ng/ml in boys and 0.9 ng/ml in girls (Zeng et al., 2015). A study of pregnant women recruited from a larger cohort in Norway, with a median serum PFOA concentration of 2.3 ng/ml, did not find a statistically significant positive association with PFOA and serum cholesterol; however, results showed a positive and increasing association of cholesterol with increasing quartiles of PFOA (Starling et al., 2014).

Two large cross-sectional studies evaluated individuals residing in communities located in the mid-Ohio Valley with drinking water contaminated with PFOA. One study included 12,476 children aged 1 to 17.9 years with a mean serum PFOA concentration of 69.2 ng/ml (Frisbee et al., 2010) and the other included 46,294 individuals aged 18 years or older with a median serum

PFOA concentration of 27 ng/ml (Steenland et al., 2009). Both studies found a positive, statistically significant association of serum PFOA and cholesterol. A third smaller (n=371) cross-sectional study from the water district in the mid-Ohio Valley with the highest PFOA levels in its drinking water, with a much higher median serum PFOA concentration, 354 ng/ml, did not find a statistically significant association (Emmett et al., 2006)b. A fourth study from China, which in addition to a study of 132 residents located near a plant utilizing PFOA with a median PFOA concentration of 284 ng/ml also included a worker study, did not find an association with serum cholesterol in either group (Wang et al., 2012).

Of the five occupational cross-sectional studies, only one U. S. occupational study (n=840) with a median serum PFOA concentration of 189 ng/ml found a positive statistically significant association with serum cholesterol (Sakr et al., 2007a). The remaining four occupational cross-sectional studies which did not find evidence of an association include two U.S. male only worker studies, one with a mean serum PFOA concentration of 3,300 ng/ml and a sample size of 115 (Gilliland et al., 1996), and one with a mean serum PFOA concentration of 1,190 ng/ml with a sample size of 265 (Olsen et al., 2000). The third study took place in both the U.S. and Belgium with a median PFOA concentration of 2210 ng/ml and a sample size of 506 (Olsen and Zobel 2007) and the fourth cross-sectional study included 55 workers in China with a median PFOA concentration of 1,636 ng/ml (Wang et al., 2012).

Five of the 20 studies had study designs other than cross-sectional. A longitudinal analysis of workers from Belgium and U.S. with a range of PFOA means of 1,220 to 1,900 ng/ml (Olsen et al., 2003), and another longitudinal worker cohort analysis from the U.S. with a range of PFOA exposure from 1,010 to 1,160 ng/ml (Sakr et al., 2007b), both found evidence of an association with PFOA and serum cholesterol. A third occupational cohort study utilizing matched-pair analysis of 98 to 179 workers (highly exposed of 881 ng/ml PFOA mean v. lower exposed of 28.9 ng/ml PFOA mean) did not find a statistically significant association (Olsen et al., 2012). None of these studies found evidence of a statistically significant inverse association with serum cholesterol and PFOA. An Italian male occupational case-control study with PFOA median concentration 4,400 among formerly exposed workers and a median of 5,700 ng/ml among currently exposed workers, with cross-sectional analysis, found evidence of a positive association (Costa et al., 2009). Among the cohort studies, a longitudinal study of individuals in highly-exposed mid-Ohio Valley communities, with geometric mean PFOA concentrations of 74.8 ng/ml at baseline and 30.8 ng/ml at follow-up, found evidence of a positive association (Fitz-Simon et al., 2013).

Although 15 of the 20 studies evaluating associations of PFOA and serum cholesterol were cross-sectional, thereby limiting the interpretation of temporality since exposures and outcomes are measured at the same point in time, four studies included longitudinal analyses (Fitz-Simon et al., 2013; Sakr et al., 2007b; Costa et al., 2009; Olsen et al., 2003). Each of these studies had

multiple measurement data, and all four found a significant correlation over time between cholesterol and PFOA levels (Fitz-Simon et al., 2013; Steenland et al., 2010b). In summary, the epidemiologic data provide evidence of consistency, strength and dose-response, including some evidence of temporality, of PFOA and serum cholesterol.

Several of the studies mentioned above showed statistically significant trends for increased serum cholesterol with increasing serum PFOA. A decile analysis of PFOA with total cholesterol among a large study of residents of a highly exposed community showed an increasing effect of PFOA on cholesterol and additionally the odds of clinically defined hypercholesterolemia ( $\geq 240$  mg/dL) increased 40-50% from the lowest to the highest quartile of PFOA (Steenland et al., 2009). A statistically significant trend of increasing serum cholesterol with increasing PFOA was also reported in at least five other studies (Frisbee et al., 2010, Fu et al., 2014, Geiger et al., 2014; and Zeng et al., 2015).

In summary, general population level exposure studies (seven), found consistent evidence of a positive association between PFOA and serum cholesterol. Additionally, three very large studies (two cross-sectional and a cohort study) of highly exposed community populations found evidence of a positive association between PFOA and serum cholesterol. Two longitudinal occupational studies also found a positive association, along with one case-control occupational study. In contrast, results from two much smaller cross-sectional studies of highly exposed community populations (with higher median population exposures than the three larger studies) and a matched-pairs occupational study did not find an association. Although findings from the occupational cross-sectional studies in general (four out of five) found no evidence of an association, they may be biased toward the null by a healthy worker effect. This is suggested by a similar pattern of inconsistency among these study's findings as compared to the findings from the corresponding database were also noted for other serum lipid endpoints (HDL and LDL – discussed below).

In general, studies of the general population, as well as large, mid-exposure range community studies and occupational studies with longitudinal designs, found consistent evidence of an association, while a few smaller, higher exposure range community and occupational studies found no evidence. None of the 20 studies evaluated found evidence of an inverse association.

A review by Steenland et al. (2010a) summarized and evaluated the epidemiologic literature on PFOA and cholesterol available at that time. The authors noted that the lower the range of PFOA that was studied, the greater the change in cholesterol per unit change in PFOA. They suggest that, as discussed in Occupational Studies (above), an exposure-response relationship that is steep at low PFOA concentrations and then flattens out (i.e. approaches a plateau) at higher serum PFOA concentrations is a possible explanation for the observed differences in effect magnitudes. Therefore, studies of populations with high serum PFOA concentrations may not detect an association of PFOA with serum cholesterol if there is a steep dose-response curve for

the association in the lower exposure ranges. For dose-response curves of this type, associations may not be evident in populations with higher exposures since even the least exposed individuals in the comparison group may have exposures that fall on the much flatter (approaching a plateau) portion of the exposure/response curve.

Associations of PFOA and high density lipid cholesterol (HDL), non-HDL, ratio of total cholesterol to HDL, low-density lipid cholesterol (LDL), very low-density lipid cholesterol (VLDL), ratio of HDL to LDL, and/or triglycerides were evaluated in 20 studies. All but two of these 20 studies also evaluated serum cholesterol.

HDL and PFOA were evaluated in 19 studies. It should be noted that an increase in HDL is considered to be beneficial, as compared to increases in total cholesterol, LDL, and non-HDL, which are considered to be undesirable. None of these studies found an association with increased HDL, while four of the 19 studies found evidence of statistically significant decreased association with HDL (Gilliland et al., 1996; Olsen et al., 2000; Olsen and Zobel 2007; and Wang et al., 2012). Interestingly, these four studies are all occupational cross-sectional studies which also did not find evidence of an association with PFOA and increased serum cholesterol (described above), whereas the only other additional occupational cross-sectional study found no evidence of an association with HDL but did find a statistically significant positive association between PFOA and cholesterol (Sakr et al., 2007a). These differences in findings suggest that these occupational cross-sectional studies may be biased from a healthy worker effect. There was no evidence of statistically significant associations with HDL in any of the other 15 studies (Costa et al., 2009; Fisher et al., 2013; Fitz-Simon et al., 2013; Frisbee et al., 2010; Fu et al., 2014; Geiger et al., 2014; Lin et al., 2011; Nelson et al., 2010; Olsen et al., 2003; Olsen et al., 2012; Sakr et al., 2007a; Sakr et al., 2007b; Starling et al., 2014; Steenland et al., 2009; Wang et al., 2012 [resident study]; and Zeng et al., 2015).

Non-HDL was evaluated in four studies: two general population cross-sectional studies (Fisher et al., 2013; and Nelson et al., 2010), a U.S. occupational longitudinal study (Olsen et al., 2012), and a large cross-sectional study of residents in highly exposed communities (Steenland et al., 2009). Three of the studies found statistically significant positive associations with non-HDL and PFOA (Fisher et al., 2013; Nelson et al., 2010; and Olsen et al., 2012), while the occupational longitudinal study had a negative association with non-HDL which was not statistically significant (Olsen et al., 2012).

The ratio of total cholesterol to HDL was evaluated in three studies with inconsistent findings. A general population study in Canada did not find evidence of a statistically significant association (Fisher et al., 2013), U.S. occupational longitudinal study found a statistically significant negative association (Olsen et al., 2012), and a large study of residents from a highly exposed community found a statistically significant positive association (Steenland et al., 2009).



Associations of LDL and PFOA were evaluated in 16 studies. Fourteen of the studies are cross-sectional, which includes seven low level exposure populations (Fisher et al., 2013; Fu et al., 2014; Geiger et al., 2014; Lin et al., 2013; Nelson et al., 2010; Starling et al., 2014; and Zeng et al., 2015), three studies of residents from a highly exposed community (Frisbee et al., 2010; Steenland et al., 2009; Wang et al., 2012), and five studies of occupationally exposed individuals (Gilliland et al., 1996; Olsen et al., 2000; Olsen and Zobel 2007; Sakr et al.; 2007a ; and Wang et al., 2012). The other two studies of LDL and PFOA include an occupational longitudinal study (Sakr et al., 2007b) and a cohort study of residents from the highly exposed community, mid-Ohio Valley (Fitz-Simon et al., 2013).

Among the cross-sectional studies of populations with low level exposure, three found evidence of statistically significant positive associations with LDL (Fu et al., 2014; Geiger et al., 2014; and Zeng et al., 2015) and four found no statistically significant evidence of an association (Fisher et al., 2013; Lin et al., 2013; Nelson et al., 2013; and Starling et al., 2014). Of the three cross-sectional studies of residents from a highly exposed community; the two large studies in the mid-Ohio Valley, one which included children and the other of adults, found evidence of statistically significant positive association (Frisbee et al., 2010, and Steenland et al., 2009); while the third smaller study of 132 residents in China found no evidence of an association (Wang et al., 2012). Four of the five occupational cross-sectional studies found no association (Gilliland et al., 1996; Olsen et al., 2000; Olsen and Zobel, 2007; and Wang et al., 2012) while only one of the studies found evidence of a statistically significant association with both LDL and VLDL (Sakr et al., 2007a). Additionally, an occupational longitudinal study found a positive, non-statistically significant association with LDL (Sakr et al., 2007b) while a cohort study of residents from a highly exposed community found a statistically significant positive association (Fitz-Simon et al., 2013). Finally, the ratio of HDL to LDL was evaluated in a cross-sectional study which assessed both occupational and highly exposed residential populations and found a negative association with the worker population and no evidence of a statistically significant association with the residential population (Wang et al., 2012).

In summary, positive associations with PFOA and LDL were inconsistent among low level exposure populations, and largely unassociated in occupational studies, but there is consistent evidence of an association with PFOA and LDL among larger studies of the highly exposed mid-Ohio Valley communities: two cross-sectional studies one among children and another among adults, and a longitudinal study.

Sixteen studies evaluated triglycerides with inconsistent findings. Four of the studies found evidence of positive statistically significant association (Frisbee et al., 2010; Olsen et al., 2003; Olsen and Zobel, 2007; and Zeng et al., 2015), one found evidence of a negative statistically significant association (Lin et al., 2013), and 11 studies found no evidence of a statistically



significant association (Costa et al., 2009; Fisher et al., 2013; Fitz-Simon et al., 2013; Fu et al., 2014; Geiger et al., 2014; Lin et al., 2011; Olsen et al., 2000; Sakr et al., 2007a; Sakr et al., 2007b; Starling et al., 2014; and Wang et al., 2012).

Selection bias may be an issue in Fu et al. (2014) since the study included only individuals attending a health clinic check-up such that individuals concerned with existing health issues may be more likely to be included. Selection bias may also be an issue in Lin et al. (2013), which included individuals with an abnormal urinalysis from a population-based screening program in which the final study population was made up of 246 (37%) individuals with elevated blood pressure. Information bias is unlikely to have an impact in the general population studies which relied on serum concentrations and clinical biomarkers. In contrast, some occupational studies relied on medical record abstraction of clinical parameters. Other limitations of occupational studies include small sample size that may limit power to detect associations, possibility of healthy worker effect, inclusion of few or no women, and the possibility that exposure in the least exposed groups may be well above the population exposure range in occupationally exposed individuals.

The biological plausibility of the association of PFOA and serum cholesterol was investigated in a study of associations of serum PFOA and changes in expression of genes involved in cholesterol metabolism. In this cross-sectional study, expression of 13 genes involved in cholesterol metabolism (cholesterol biogenesis, peroxisome proliferation, cholesterol transport, downstream transcriptional activation of PPAR-alpha, and mobilization of cholesterol) was evaluated in whole blood from 290 subjects from a highly exposed community (geometric mean serum PFOA, 32.2 ng/ml). Statistically significant associations between genes involved in cholesterol transport and mobilization and PFOA were found, and the affected genes differed in men and women. The authors state that these change in gene expression “appear consistent with PFOA promoting a hypercholesterolemic environment” (Fletcher et al., 2013).

Effects of PFOA on serum lipids in laboratory animals are considered in evaluating the biological plausibility of the associations of PFOA and cholesterol found in humans. Serum cholesterol was not affected by PFOA in a 6-month study of cynomolgus monkeys (Butenhoff et al., 2002), while triglycerides were significantly increased compared to controls at several time points in the monkeys in the mid- and high dose groups (10 and 20/30 mg/kg/day). As discussed above, the dose-response curve for increased cholesterol in humans appears steepest at serum PFOA levels below about 40 ng/ml, with a much flatter dose-response at higher serum levels. In the monkey study, the mean serum PFOA level in the control group was 134 ng/ml. If the dose-response curve is similar in monkeys such that effects on serum cholesterol are steepest at lower serum PFOA levels, effects may not be observable because the control exposure levels could be high enough to fall on the much flatter portion of the dose-response curve.

Although PFOA is consistently associated with increased serum cholesterol in humans, serum cholesterol and triglycerides are generally decreased by PFOA in rodents. This effect in rodents is attributed to PPAR-alpha activation (Lau, 2013). As discussed in detail in the Mode of Action section below, PPAR-alpha activators typically reduce serum lipids in both rodents and humans, and this is the basis for the use of fibrates as hypolipidemic drugs in humans. It is well established that the effects of PFOA in rodents differ from those of other PPAR-alpha activators, and that PFOA affects rodents through both PPAR-alpha independent and PPAR-alpha dependent pathways. It is possible that the dissimilar effects of PFOA on serum lipids in humans and rodents could arise from a different balance of PPAR-alpha dependent and independent processes with opposite effects on this endpoint.

Two recent studies, discussed in detail in the Mode of Action section, suggest the important possibility that the contrasting effects on serum cholesterol observed in humans and animals may result from differences in dietary fat content, rather than intrinsic interspecies biochemical or physiological differences (Tan et al., 2013; Rebholz et al., 2016). In these studies, mice were fed a diet with a high fat content, similar to that of a typical U.S. diet, instead of standard lower fat laboratory chow. Serum cholesterol was either increased or unaffected in mice fed the high fat diets. In contrast, serum cholesterol was decreased, as is typically seen in mice fed the regular diet in Tan et al. (2013), while Rebholz et al. (2016) did not include a regular diet group. These results suggest that effects of PFOA on cholesterol may be similar in rodents and humans consuming the same dietary fat content, and they provide evidence for biological plausibility for PFOA's effects on serum cholesterol in humans.

In summary, the epidemiologic database for serum cholesterol and PFOA, which included twenty studies, provides evidence of consistency, strength and dose-response, including some evidence of temporality. Associations with clinically defined hypercholesterolemia were reported in some studies. These findings provide evidence supporting a causal relationship between PFOA and serum cholesterol. Overall, the epidemiologic evidence suggests no evidence of an association with HDL and PFOA. There were a limited number of epidemiologic studies evaluating an association with non-HDL or the ratio of total cholesterol to HDL and PFOA. The epidemiologic database for PFOA and LDL appears inconsistent. Although there is some evidence of an association with LDL, it remains limited due to the interpretation of other studies which found no evidence of an association. There is limited epidemiologic evidence evaluating associations of VLDL, the ratio of HDL to LDL, and triglycerides with PFOA.

#### Liver enzymes/bilirubin

A total of 16 studies evaluated associations between PFOA and clinical biomarkers used in the diagnosis and/or evaluation of treatment of liver function or metabolic disease. These biomarkers include the following liver enzymes: alanine aminotransferase (ALT /SGPT), gamma-glutamyl transferase (GGT), aspartate aminotransferase (AST /SGOT), and alkaline phosphatase (ALP), as well as total bilirubin or unspecified bilirubin (TB) and direct bilirubin (DB). Additionally,

two studies assessed PFOA and liver disease (LD). Study details are provided in the tables for individual studies (Appendix 4) and the summary table for liver enzymes/bilirubin (Table 6B).

Two larger cross-sectional general population studies utilizing different survey cycles of the U.S. National Health and Nutrition Examination Survey (NHANES) both found evidence of statistically significant positive associations with PFOA and the liver enzyme ALT (Gleason et al., 2015 and Lin et al., 2010). Two other cross-sectional studies of a population with low-level exposure cross-sectional studies have also evaluated this association. A study that was based on a population recruited from a larger cohort in Taiwan (n=608) found a positive statistically significant correlation (Yamaguchi et al., 2013), while a small study (n=141) of pregnant women in China did not find a significant correlation between PFOA and ALT (Jiang et al., 2014). Of the three cross-sectional studies of mid-Ohio Valley residents, the smaller study (n=371) with a higher median and narrower range of PFOA exposure found no evidence of an association (Emmett et al., 2006b), while the two larger studies (n=47,092) with a wider range of exposures found a consistent positive statistically significant association with ALT and PFOA (Gallo et al., 2012; and Gallo et al., 2016). Nine additional occupational studies investigated associations of ALT and PFOA with inconsistent findings. Among these studies only one cross-sectional study found evidence of a positive association (Olsen et al., 2007), one found evidence of a negative association (Gilliland et al., 1996) and four cross-sectional studies found no consistent evidence of an association (Olsen et al., 2000; Olsen et al., 2003; Sakr et al., 2007a; and Wang et al., 2012). An occupational case-control study, with cross-sectional components, found some evidence of a positive association (Costa et al., 2009); one longitudinal occupational study found evidence of a negative association (Olsen et al., 2012), and a second longitudinal occupational study found no evidence of an association (Sakr et al., 2007b).

Although results of occupational studies were inconsistent, both cross-sectional general population studies found evidence of an increasing trend (Gleason et al., 2015 and Lin et al., 2010). The much larger studies of a highly-exposed community also found increasing levels of ALT with increasing serum concentrations of PFOA (Darrow et al., 2016; Gallo et al., 2012). Further, the associations noted by Gallo et al. (2012) were consistent both between water districts and among individuals within the same district, which also increased the strength of evidence. Additionally, the modeled serum PFOA exposure assessment used by Darrow et al. (2016) complements evidence from previous studies because these estimates are not affected by reverse causation.

Thirteen studies evaluated associations of PFOA and GGT: six studies found evidence of a positive statistically significant association (Costa et al., 2009; Gallo et al., 2012; Gleason et al., 2015; Lin et al., 2010; Olsen and Zobel, 2007; and Sakr et al., 2007a) and the remaining seven studies found no statistically significant evidence of an association (Darrow et al., 2016; Emmett et al., 2006b; Gilliland et al., 1996; Olsen et al., 2000; Olsen et al., 2003; Sakr et al., 2007b; and

Yamaguchi et al., 2013). Twelve studies also evaluated the association of PFOA and AST; three found evidence of a positive statistically significant negative association (Gleason et al., 2015; Sakr et al., 2007b; Yamaguchi et al., 2013); two studies found some evidence of a negative association (Gilliland et al., 1996 and Wang et al., 2012) and seven other studies found no evidence (Emmett et al., 2006; Jiang et al., 2014; Olsen et al., 2000; Olsen et al., 2003; Olsen and Zobel 2007; Olsen et al., 2012; and Sakr et al., 2007a).

Eight studies evaluated the association of PFOA and the liver enzyme ALP. Only one found some limited evidence of a positive statistically significant association (Costa et al., 2009), while the other seven studies found no evidence of an association (Emmett et al., 2006b; Gleason et al., 2015; Olsen et al., 2000; Olsen et al., 2003; Olsen and Zobel, 2007; Olsen et al., 2012; and Sakr et al., 2007b).

Thirteen studies evaluated the association of PFOA and either total or direct bilirubin. A component of total bilirubin is direct bilirubin, a product of hemoglobin metabolism for which increased serum concentrations reflect increases in liver and bile duct disease. Therefore, total bilirubin serves only as an inferential measure of liver function. Among studies of total bilirubin, three studies found evidence of a statistically significant association (Costa et al., 2009; Olsen and Zobel, 2007; and Sakr et al., 2007b); one study found a positive statistically significant association (Gleason et al., 2015); and seven found no association with total bilirubin (Emmett et al., 2006b; Jiang et al., 2014; Lin et al., 2010; Olsen et al., 2000; Olsen et al., 2003; Olsen et al., 2012; and Sakr et al., 2007a). Two additional studies found no association with direct bilirubin (Gallo et al., 2012; and Darrow et al., 2016), and Olsen et al. (2000) also found no association with total or direct bilirubin.

Three studies investigated association with PFOA and clinical liver disease. Melzer et al., 2011 found no statistically significant association of PFOA and current liver disease in a cross-sectional study of the U.S. general population (NHANES). Also Darrow et al. (2016) found no evidence of an association with modeled serum PFOA and medically-validated liver disease when categorized as either any liver disease or restricted to enlarged liver, fatty liver, or cirrhosis among the highly exposed C8 Health Study community. A retrospective cohort of a U.S. occupational population also found no association with self-reported liver disease and estimated serum PFOA concentration (Steenland and Zhao et al., 2015).

As previously described, cross-sectional studies limit interpretation of temporality. Information bias is unlikely to have an impact in the general population studies which relied on serum concentrations and clinical biomarkers. Small sample sizes in some studies may have limited their power to detect associations (Emmett et al., 2006b; Jiang et al., 2014; Wang et al., 2012; and Yamaguchi et al., 2013). In addition to small sample size, some occupational studies relied on abstraction of clinical parameters from medical records. Other limitations of occupational

studies include the possibility of healthy worker effect, inclusion of few or no women, and the possibility that exposure in the least exposed groups may be well above the population exposure range in occupationally exposed individuals.

Toxicological and mode of action data support the biological plausibility of hepatic effects of PFOA in humans. As discussed in detail in the Toxicology and Mode of Action sections below, it is well established that hepatic toxicity is a sensitive effect of PFOA in experimental animals. Based on studies in non-human primates, standard strains of rodents, and rodents lacking a functional PPAR-alpha receptor, hepatic effects of PFOA are considered relevant to humans.

In summary, the evaluation of epidemiologic studies provides evidence of some inconsistencies among the group of studies evaluated. However, there was consistency among the larger non-occupational studies, as well as evidence of specificity, exposure-response, strength, and biologic plausibility for PFOA and ALT. These findings provide evidence supporting a causal relationship between PFOA and ALT. The epidemiologic evidence of an association with PFOA and GGT, AST, and bilirubin is inconsistent, while there was no evidence of an association with PFOA and ALP. There is also limited epidemiologic evidence of a causative relationship with PFOA and liver disease, and the available studies did not find an association.

#### Thyroid hormones, TSH, and thyroid disease

Twenty studies were identified as evaluating thyroid hormones, TSH, hypo- and hyperthyroidism, thyroid disease in general, and/or other thyroid conditions. Study details are provided in the tables for individual studies (Appendix 4) and the summary table for thyroid effects (Table 6C).

Thyroid stimulating hormone (TSH) was the most commonly evaluated thyroid endpoint, and there was limited evidence of a positive statistically significant relationship with PFOA. Three general population studies which include a cross-sectional U.S. population study (Jain, 2013), a South Korean prospective birth cohort (Kim et al., 2011), and a prospective cohort study in Canada (Webster et al., 2014) found some evidence of a positive statistically significant association of elevated TSH and PFOA. The remaining 12 studies found limited or no evidence of a positive association. These 12 studies are all cross-sectional study design, which include six general population studies (Bloom et al., 2010; Ji et al., 2012; Lin et al., 2013; Shrestha et al., 2015; Wang et al., 2014; and Wen et al., 2013), three studies of residents in a highly exposed community (Emmett et al., 2006b; Knox et al., 2011; Lopez-Espinosa et al., 2012), and three occupational studies (Olsen et al., 1998; Olsen et al., 2003; Olsen and Zobel 2007). Three of the 12 studies also included components of other study designs in addition to the cross-sectional design: birth cohort (Lopez-Espinosa et al., 2012), longitudinal (Olsen et al., 1998), and prospective birth cohort (Wang et al., 2014)

Additionally, total thyroxine (TT4) has been extensively evaluated with little evidence of a positive statistically significant association. Only two studies found some evidence of statistically significant positive association (de Cock et al., 2014, and Knox et al., 2011), while 11 others found no evidence of a statistically significant association (Jain 2013; Ji et al., 2012; Kim et al., 2011; Lin et al., 2013; Lopez-Espinosa et al., 2012; Olsen et al., 2003; Olsen and Zobel 2007; Shrestha et al., 2015; Wang et al., 2014; Webster et al., 2014; and Wen et al., 2013). A case-control study of hypothyroxemic pregnancy matched with non-hypothyroxemic pregnant women in Canada evaluated the association of PFOA and maternal hypothyroxemia, a common condition in pregnant women characterized by low maternal free thyroid hormone (fT4) and normal TSH levels, and found no evidence of a statistically significant association (Chan et al., 2011).

Eight studies evaluated PFOA and associations with total triiodothyronine (TT3). Four of these studies found some evidence of a statistically significant positive association, including two larger (n=1,540 and 1,180) cross-sectional studies of the U.S. general population (Jain 2013 and Wen et al., 2013, respectively) as well as both of the occupational studies (Olsen et al., 2003; Olsen and Zobel 2007). Three studies did not find any statistically significant evidence of an association (Kim et al., 2011; Shrestha et al., 2015; and Wang et al., 2014), while a large (n=50,113) cross-sectional study of the mid-Ohio Valley which found some evidence of an inverse association (Knox et al., 2011). Two of these studies also evaluated free triiodothyronine (FT3) and neither found evidence of a statistically significant association (Jain, 2013; and Wen et al., 2013). These same two studies also evaluated associations of PFOA and thyroglobulin and found no evidence of a statistically significant association (Jain, 2013 and Wen et al., 2013).

Three studies evaluated the association of PFOA and hypo- and hyperthyroidism, with mixed results. Hypothyroidism is a condition in which the thyroid gland is under-active and is characterized by elevated TSH serum levels combined with low serum FT4. Hyperthyroidism is a condition involving an over-active thyroid gland and is characterized by very low TSH hormone and raised FT4. Lopez-Espinosa et al. (2012) found a borderline statistically significant positive association with measured PFOA concentrations and self-reported subclinical hypothyroidism, but found non-statistically significant results for modeled PFOA, including modeled *in utero* exposure to PFOA, and subclinical measures of hypothyroidism. Odds ratio for PFOA and hyperthyroidism were mixed and not statistically significant. A study by Wen et al. (2013) of the U.S. adult general population found a statistically significant positive association of hypothyroidism among women but not men, and a statistically significant negative association of hyperthyroidism among men and not women. Winqvist and Steenland (2014b) found increasing hazards with increasing PFOA exposure for hypothyroidism, although the trend was not statistically significant, while retrospective and prospective analyses were statistically significantly positively associated among men. A statistically significant trend of hyperthyroidism and increasing PFOA exposure was found overall and for women.



Five studies evaluated thyroid disease in general, which may also include hypo- and hyperthyroidism. Three studies found some evidence of a statistically significant positive association with PFOA and thyroid disease. A large study of highly exposed children in the mid-Ohio Valley found a positive statistically significant association among measured PFOA concentrations, median of 29 ng/ml, and parent-reported thyroid disease, but this association was not statistically significant with modeled PFOA (Lopez-Espinosa et al., 2012). A cross-sectional study of the U.S. general population found increasing odds ratio of self-reported thyroid disease, both ever and current, with increasing quartiles of PFOA among women but not men (Melzer et al., 2011). A large retrospective cohort study with prospective analyses found evidence of a positive association with thyroid disease and increasing quintiles of PFOA which was strongest among women for retrospective analyses, but prospective analyses found no clear associations with PFOA and thyroid disease (Winqvist and Steenland, 2014b). The remaining two studies, a small study in a highly exposed community with median serum PFOA concentration of 354 ng/ml and a relatively narrow range of exposures (Emmett et al., 2006b), and a retrospective occupational cohort with a median PFOA exposure of 113 ng/ml (Steenland et al., 2015), found no evidence of a statistically significant association with thyroid disease and PFOA.

As discussed above, the C8 Science Panel concluded there was a probable link with PFOA and thyroid disease. The C8 Science Panel summarized the epidemiologic evidence of an association with PFOA and thyroid function or disease and, although the evidence was deemed inconsistent, concluded that "...the presence of some independent pieces of evidence indicative of an association was not easily dismissed, despite a lack of coherence among them." The C8 Science Panel determined the strongest evidence for an association was increased occurrence of medically validated thyroid disease (hyperthyroidism in women, hypothyroidism in men) with increasing measured PFOA exposure (2005-2006) in the prospective analyses (2005-2010). Therefore, despite inconsistencies in the evidence, the Panel concluded that there was evidence of a probable link between C8 and thyroid disease (C8 Science Panel, 2012).

Selection bias may be an issue in Lin et al. (2013b) which included individuals with an abnormal urinalysis from a population-based screening program. Information bias is unlikely to have had an impact in these studies, as they relied mostly on serum concentrations of exposure and outcomes. Although serum thyroid function measures are collected at a single time point in many studies, these thyroid function measures are maintained over time in the body. Also, reliance on recall for studies assessing thyroid disease, hypo-, and hyperthyroidism may bias results (Lopez-Espinosa et al., 2012). Small sample sizes in some studies may have limited their power to detect associations (Bloom et al., 2010; Kim et al., 2011b; Mundt et al., 2007; and Webster et al., 2014).



Although thyroid endpoints were not evaluated in most toxicology studies of PFOA, data from a limited number of studies, reviewed in the Toxicology section below, support the biological plausibility of effects of PFOA on human thyroid function. Although no effects on thyroid hormones were seen in a very small 29-day study of cynomolgus monkeys, changes in TSH, T3, and T4 occurred at multiple time points in a 6-month study in this species. Thyroid hormones were significantly decreased in rats in a short duration exposure study using a high dose of PFOA. Thyroid endpoints have not been evaluated in longer duration, lower dose, or rodent studies.

Overall, studies evaluating thyroid hormones, TSH, and thyroid disease provide inconsistent evidence of any associations with PFOA. The C8 Science Panel concluded that, despite the inconsistencies of findings among studies, compelling evidence for associations with thyroid disease could not be dismissed, and a probable link with PFOA and thyroid disease was determined.

#### Uric acid

Uric acid is a product of purine metabolism with both oxidant and antioxidant properties, and elevated levels are a marker of kidney disease. Additionally, some studies have shown that elevated uric acid is associated with cardiovascular disease and may trigger hypertension (Klein et al., 1973; Fang et al., 2000; and Freedman et al., 1995). Seven studies evaluated the association of uric acid and serum PFOA concentrations; three of these also assessed clinically defined hyperuricemia. Study details are provided in the tables for individual studies (Appendix 4) and the summary table for uric acid (Table 6D).

These studies include six cross-sectional studies and one occupational study which was a case-control study with cross-sectional components. All of these studies found strong, positively statistically significant associations of uric acid and PFOA (Costa et al. 2009; Geiger et al., 2013; Gleason et al., 2015; Sakr et al., 2007a; Shankar et al., 2011; and Steenland et al., 2010) with the exception of Lin et al., 2013 which did not find a statistically significant association. Additionally, all three studies which evaluated clinically defined hyperuricemia found strong evidence of a positive statistically significant association (Geiger et al., 2013; Shankar et al., 2011; and Steenland et al., 2010b).

Although the six studies with evidence of statistically significant association are mainly cross-sectional, they represent the general population, residents from a highly exposed community, and an occupationally exposed population. These studies therefore evaluated a wide range of serum PFOA concentrations - about 4 ng/ml in the general population studies (Geiger et al., 2013; Gleason et al., 2015; Shankar et al., 2011), a median of about 28 ng/ml in a highly exposed community population (Steenland et al., 2010b), and a median serum PFOA concentration range from 428 ng/ml (Sakr et al., 2007a) to 4,400 -5,700 ng/ml (Costa et al., 2009) among

occupationally exposure populations. Also, importantly, these studies evaluated a wide range of age groups as well, including children less than 19 years of age (Geiger et al., 2013), adolescents and adults greater than 11 years of age (Gleason et al., 2015), and adult populations 20 years or older (Costa et al., 2009, Shankar et al., 2011; and Steenland et al., 2010b).

The general population studies which evaluated associations of uric acid with increasing serum concentrations of PFOA found strong exposure-response relationships (Geiger et al., 2013; Gleason et al., 2015; and Shankar et al., 2011). Additionally, Steenland et al. (2010b) found a significant trend and some evidence of increased changes in uric acid with high level of serum PFOA concentrations among residents from a highly exposed community. Lin et al. (2013) did not find evidence of a statistically significant trend in mean uric acid across categories of PFOA exposure but there does appear to be a small, non-significant increase in uric acid level as serum PFOA concentrations increase.

Information bias is unlikely to have an impact in the general population studies which relied on serum concentrations and clinical biomarkers. Selection bias may have impacted findings in Lin et al. (2013), which included individuals with an abnormal urinalysis from a population-based screening program in which the final study population was made up of 246 (37%) individuals with elevated blood pressure.

Reverse causality is a potential explanation for increased uric acid with increasing PFOA. It has been proposed that PFOA could be higher in individuals with reduced excretion due to reduced kidney function, and that this would also result in increased uric acid (Kataria et al., 2015). Also, Kataria et al., (2015) reviewed toxicology evidence and suggests that PFOA and other PFCs can adversely impact renal function. Unfortunately, a hypothesis of reverse causality cannot be assessed because the six studies which evaluated uric acid and PFOA are limited by their cross-sectional design in which exposures and outcomes are measured at the same point in time.

Epidemiologic evidence provides evidence of consistency among findings, strength of findings with clinically defined outcomes, and exposure-response with PFOA and uric acid. These findings provide evidence supporting a causal relationship between PFOA and uric acid. However, there are limitations in use of the epidemiologic evidence to draw conclusions regarding temporality and there remain some questions of biologic plausibility due to possible reverse causality explanation.

### Antibody concentrations following vaccination

Five studies evaluated associations of serum PFOA concentrations and antibody concentrations following six types of vaccines. Study details are provided in the tables for individual studies (Appendix 4) and the summary table for this effect (Table 6E). Only one type of vaccine (tetanus) was evaluated in three of the five studies, each of four vaccine types were evaluated in two studies each, and one (mumps) was evaluated in only one study. These five studies include a prospective cohort following 656 singleton births recruited from birth and followed to seven years of age (n=587) in the Faroe Islands (Grandjean et al., 2012). In this group of children with a median serum PFOA concentration at 5 years of age of 4.1 ng/ml, researchers found strong statistically significant evidence of a decrease in antibody concentrations following a tetanus or diphtheria vaccination at age 5 and 7 years. Another prospective birth cohort study in Norway collected blood samples at delivery from 99 pregnant women with a subsequent follow-up sample of 56 children at 3 years of age (Granum et al. 2013). The median PFOA maternal serum concentration was 1.1 ng/ml. Investigators found strong evidence of decreased rubella-induced antibodies with increasing PFOA maternal serum concentrations, but associations with PFOA and responses to tetanus, measles, and influenza vaccines were not statistically significant. A prospective cohort of 12 adults recruited from hospital staff in Denmark with median serum PFOA concentration of 1.7 ng/ml found no statistically significant associations with antibody response to tetanus or diphtheria vaccines (Kielsen et al., 2015). A larger prospective cohort of 411 adults from the mid-Ohio valley with a high median serum PFOA concentration of 31.5 ng/ml found evidence of decreasing antibody concentrations following Influenza A H3N2 vaccination; however no statistically significant associations were found with responses to vaccines for Influenza Type B or Influenza Type A H1N1 (Looker et al., 2014). The largest of the studies includes a sample size of 1,191 adolescents aged 12 to 19 years of age from the U.S. general population with a geometric mean serum PFOA concentration of 4.1 ng/ml. This cross-sectional study found some evidence of a statistically significant decrease of rubella- and mumps vaccine induced antibody concentration, but a decreased antibody response to measles vaccine was not statistically significant (Stein et al., 2016).

Associations between decreased antibody concentration and increasing PFOA concentration may be related to a threshold such that limited evidence of associations was found among the two studies with median serum PFOA concentrations below 2 ng/ml (Granum et al, 2013 and Kielsen et al., 2015). Both of these studies also had small sample sizes which may have restricted the power of the study to detect a statistically significant decrease.

Specificity of the observed association may also be difficult to interpret since responses to many different vaccines were evaluated, with each type of vaccine included only in a few (and often in only one or two) studies. Unlike many of the other outcomes evaluated in studies of the human health effects of PFOA, four of the studies that assessed associations with antibody concentrations following vaccination had a prospective study design, allowing temporality

assessment. Since the exposures and outcomes were followed over time, it can be concluded that exposures preceded the outcome.

Data from other human studies and toxicology studies provide support for biological plausibility of decreased immune system response to vaccines in humans. As discussed in the Toxicology and Mode of Action sections, PFOA suppressed the immune system in studies of both non-human primates and rodents. Fletcher et al. (2009) reported several statistically significant associations between several markers of immune function (decreased IgA; decreased IgE in females only; increased anti-nuclear antibody; decreased C-reactive protein) and serum PFOA levels in communities with drinking water exposure to PFOA in a C8 Science Panel status report (Fletcher et al., 2009). As yet, only the information on C-reactive protein has been published (Genser et al., 2015). Genser et al. (2015) found consistent and significant associations of serum PFOA with this effect, both within each of the six water districts included in the study and on an aggregated basis. They concluded that these within- and between-district associations strengthen the evidence of causality for this effect.

Review of epidemiologic studies provides evidence of consistent findings among studies of decreased antibody concentrations following vaccination and PFOA. There is epidemiologic evidence of temporality. However, there are a limited number of comparisons across the same vaccination types, making consistency/specificity difficult to evaluate.

Additionally, the National Toxicology Program (NTP) recently completed a draft systematic review of immunotoxicity of PFOA, based on consideration of human and animal studies, along with mechanistic data (NTP, 2016). The draft NTP assessment concluded that PFOA is presumed to be an immune hazard to humans based on (1) a high level of evidence from animal studies and a moderate level of evidence from human studies that PFOA suppresses antibody response, and (2) a high level of evidence from animal studies and a low level of evidence from human studies that PFOA increases hypersensitivity-related outcomes. NTP also considered additional, although weaker, evidence primarily from epidemiological studies that PFOA reduced infectious disease resistance and increased autoimmune disease. NTP states that the evidence for effects on multiple aspects of the immune system supports the overall conclusion that PFOA alters immune function in humans.

### **Endpoints Evaluated by Other Researchers:**

#### **Fetal growth**

A collaborative team of scientists developed a methodology for the systematic review of environmental health data titled the “Navigation Guide.” The Navigation Guide is intended as a “systematic and rigorous approach to research synthesis” that will “reduce bias and maximize transparency in the evaluation of environmental health information” (Woodruff and Sutton, 2014). The Navigation Guide methodology utilizes a three-step process in which a study

question is specified, evidence is selected, and the quality and strength of the evidence is evaluated. Developmental exposure to PFOA and fetal growth was selected by the research group as a proof-of-concept of the methodology. This effort included evaluation of human epidemiologic data (Johnson et al., 2014), animal toxicology data (Kouostas et al., 2014), and a synthesis of both types of data to develop overall conclusions (Lam et al., 2014).

The application of the Navigation Guide methodology to human studies required that each identified study was evaluated for risk of bias, and that the quality and strength of the evidence across all studies was rated. The authors reviewed 19 datasets available from 18 studies which met the inclusion criteria. Additionally, a meta-analysis of 10 studies with combinable study attributes was performed. Investigators concluded there was a low risk of bias across the studies. The meta-analyses of birth weight resulted in an overall continuous regression estimate per ng/ml serum PFOA of -18.9 g (95% CI -29.8, -7.9), an estimate of -0.06 cm (95% CI -0.1, -0.02) in birth length, a -0.01 (95% CI 0.03, 0.01) reduction in ponderal index (birth weight/length<sup>3</sup> x 100), and a -0.03 cm (95% CI -0.08, 0.01) reduction in head circumference. The quality of the human evidence was rated as “moderate”. By evaluating the quality of studies, direction of effect estimate, confidence of effect, and other possible compelling attributes, it was concluded that there is “sufficient” human evidence, the strongest descriptor for strength of evidence, that developmental exposure to PFOA reduces fetal growth in humans (Johnson et al., 2014).

The conclusions of another recent meta-analysis of human data (Verner et al., 2015) were generally consistent with Johnson et al. (2014). Verner et al. (2015) estimated a decrease in birth weight per ng/ml PFOA in maternal or cord blood serum of -14.7 g (95% CI -21.7, -7.8). They note that their analysis was less formal than the one conducted by Johnson et al. (2014) and that it did not include two studies included in the analysis of Johnson et al. (2014).

The animal evidence was also reviewed by the Navigation Guide research group, and it was concluded that there is “sufficient” evidence that exposure to PFOA adversely affects fetal growth in animals (Kouostas et al., 2014). The human and non-human evidence was integrated to develop an overall conclusion on whether developmental exposure to PFOA affects fetal growth in humans. The human and non-human mammalian evidence were both rated as being of “moderate” quality and “sufficient” strength. The authors concluded that there is “sufficient” evidence that developmental exposure to PFOA adversely affects human health based on decreased fetal growth in both human and non-humans (Lam et al., 2014).

Although previous research in the C8 Health Study population did not find an association with clinically defined birth weight and PFOA (Stein et al., 2009, C8 Science Panel, 2011), a subsequent study in this population found associations with low birth weight evaluated as a continuous variable (Savitz et al., 2012). Thus, findings from the C8 Health Study do not contradict conclusions reached by the Navigation Guide.

Evidence supporting biological plausibility for decreased fetal growth from PFOA is provided by studies (discussed in the Toxicology section) showing that PFOA adversely affects prenatal and postnatal growth and development. As discussed in the Mode of Action section, cellular receptors that play a role in the developmental toxicity of PFOA are found in human tissues, and developmental effects observed in laboratory animals are believed to be relevant to humans.

#### Potential impact of glomerular filtration rate on association of PFOA and fetal growth

Glomerular filtration rate (GFR) is the flow rate of fluids being filtered through the kidneys. GFR increases during the first half of pregnancy and declines slightly during the second half (Gibson 1973). Decreased GFR has been associated with lower infant birth weight in some studies (reviewed by Lam et al., 2014; Morken et al., 2014). Because decreased GFR might also result in higher serum PFOA levels due to slower excretion, it has been hypothesized that lower GFR could be a confounding factor for the association of PFOA and decreased fetal growth.

Lam et al. (2014) considered the evidence for reverse causality related to decreased GFR for the association of PFOA with decreased fetal growth. They concluded that the available data did not justify revision of their conclusion of sufficient human evidence for association of PFOA and decreased fetal growth. Vesterinen et al. (2015) subsequently adapted and applied the Navigation Guide methodology, described above, to assess the evidence of an association between fetal growth and GFR. The authors identified 35 relevant studies (31 human observational, two non-human observational, and two non-human experimental), all of which were rated as either “low” quality or “very low” quality. All three of these evidence streams were classified as “inadequate,” indicating that the association between GFR and fetal growth was “not classifiable.” Based on their review, Vesterinen et al. (2015) concluded that the current evidence is insufficient to support the plausibility of a reverse causality hypothesis for the associations between environmental chemicals during pregnancy and fetal growth. In an additional recent study not included in the review of Vesterinen et al. (2015), Morken et al. (2014) analyzed data from 953 pregnant Norwegian women (470 with pre-eclampsia and 483 without pre-eclampsia) and estimated GFR in the second trimester based on plasma creatinine. The association of estimated GFR and infant birth weight was not significant at  $p < 0.05$  when women with pre-eclampsia, which is associated with decreased kidney function, were excluded from the analysis. When these women with pre-eclampsia were included, the association was significant.

Verner et al. (2015) used data from three studies that provide data on maternal GFR and birth weight on an individual basis to modify a physiologically based pharmacokinetic (PBPK) model for PFOA during pregnancy (previously developed by Loccisano et al., 2013) to include the relationship between GFR and birth weight. A Monte Carlo simulation using the modified model was used to estimate the population distribution of PFOA levels in maternal and cord blood plasma during pregnancy and at delivery. Based on an assumed PFOA half-life of 3.8 years, the



model simulation predicted a decrease in birth weight per ng/ml PFOA of -7.9 g (CI -9.4, -6.4) based on maternal plasma at term and -7.1 g (95% CI -8.5, -5.8) based on cord plasma at delivery. When a shorter half-life of 2.3 years (which is likely more appropriate, discussed in Toxicokinetics section) was assumed, greater effects on birth weight per ng/ml PFOA were predicted: -9.6 g (95% CI -11.0, -8.2) based on maternal plasma at delivery and -8.1 g (95% CI -9.4, -6.8) based on cord plasma at delivery. The data from the simulation were compared to the results of a meta-analysis of the effect of maternal or cord plasma PFOA on birth weight (-14.7 g per ng/ml, 95% CI -21.7, -7.8) to estimate the effect of GFR on this association. Results of this study suggests that GFR may confound a portion (less than 50%) of the association between PFOA and decreased birth weight, and that it would be desirable to control for GFR in studies of PFOA and birth weight to account for potential confounding by GFR.

Based on review of the relevant information, the Health Effects Subcommittee concludes that confounding by GFR does not account for the major portion of the decrease in fetal growth that is associated with PFOA.

### Cancer

The USEPA Science Advisory Board (USEPA, 2006) described PFOA as “likely to be carcinogenic to humans” according to the criteria provided in the USEPA Guidelines for Carcinogen Risk Assessment (2005b). This determination was made prior to the publication of the epidemiology studies summarized below and was based on the toxicology and mode of action data available at that time.

The International Agency for Research on Cancer (IARC) is the specialized cancer agency of the World Health Organization (WHO). One of IARC’s major activities is the evaluation of the evidence of human carcinogenicity of specific exposures, including environmental contaminants, by international expert working groups which it convenes. IARC considers human, animal, and mechanistic data in making its determinations of evidence for cancer risk to humans. It has classified PFOA as “possibly carcinogenic to humans” (Group 2B) based on “limited evidence that PFOA causes testicular and renal cancer, and limited evidence in experimental animals” (IARC, 2016). The human data considered by IARC (2016) in making this determination included increases in kidney cancer among workers in the DuPont Washington Work plant in Parkersburg, WV (Steenland and Woskie, 2012) and in kidney and testicular cancer among highly exposed members of the C8 Health Project study population (Barry et al., 2013 and Vieira et al., 2013). IARC (2016) also notes that a second occupational study (Raleigh et al., 2014) from another location did not find evidence for increased incidence of kidney cancer. The epidemiological studies cited by IARC (2016) as the basis for its conclusion are presented in more detail below.



More recently, the USEPA Office of Water (2016a) concluded that PFOA has suggestive evidence of carcinogenic potential for PFOA based on the human studies mentioned above that found an association of serum PFOA with kidney and testicular tumors in communities with drinking water exposure and increased incidence of tumors in one more organs in two chronic rat bioassays.

It is also noted that an evaluation by Health Council of the Netherlands published in 2013 concludes that the available data are insufficient to evaluate PFOA's carcinogenic properties. However, the document states that this group primarily relies on IARC evaluations, when available. The more recent IARC (2016) review, which concluded that PFOA is possibly carcinogenic to humans, was not available when the Health Council of the Netherlands (2013) conducted its evaluation. Additionally, the criteria used by the Health Council of the Netherlands to determine carcinogenicity classifications are different from those used by USEPA, NJDEP, and the DWQI.

Steenland and Woskie (2012) studied the mortality of 5,791 workers at the DuPont chemical plant in Parkersburg, West Virginia from 1952-2008. Exposure to PFOA in workers was estimated using a job exposure matrix developed from serum data available for a smaller set of workers. Standardized Mortality Ratios (SMRs) were calculated using other DuPont workers in the region and the U.S. population as referent groups. PFOA exposure was categorized into quartiles. The SMR for kidney disease increased with increasing quartiles of exposure (Quartile 1: SMR=1.07, 95% CI 0.02, 3.62 (based on 1 death); Quartile 2: SMR=1.37, 95% CI 0.28, 3.99 (based on 3 deaths); Quartile 3: SMR=0.00, 95% CI 0.00, 1.42 (based on 0 deaths); Quartile 4: SMR=2.66, 95% CI 1.15, 5.24 (based on 8 deaths). Mesothelioma and chronic renal disease (malignant and non-malignant) also both had exposure-response relationships with PFOA. When investigators lagged models by 10-years and 20-years, kidney cancer and chronic renal disease remained most elevated in the highest quartile of exposure compared to the lower quartiles. An important potential confounder in this occupational cohort could be tetrafluoroethylene (TFE) which was also used in the manufacture fluoropolymers at the Parkersburg, WV facility and has been identified as a rodent kidney carcinogen (NTP, 1997). However, the authors believe that appreciable exposures would have been unlikely, since TFE exposure would have been well controlled due to its explosive and volatile nature.

Raleigh et al. (2014) studied the mortality and cancer incidence among 9,027 employees of two 3M facilities in Minnesota. The exposed population came from an ammonium perfluorooctanoate (AFPO), the ammonium salt of PFOA, production company and the non-exposed referent population from a non-AFPO facility. Among the AFPO exposed employees, 4,668 were from a previous study of this population (Gilliland et al., 1993; Lundin et al., 2009) and an additional 675 employees were recruited. Cancer outcomes of interest included cancers

of the liver, pancreas, testes, kidney, prostate and breast. There were too few incidence testicular cancer cases to include in analyses. Incidence cancers were identified through the Minnesota and Wisconsin cancer registries and a vital status assessment was used to determine vital status and case of death. Occupational exposure to AFPO was characterized from work history records, industrial hygiene monitoring data, information from current and former workers and industrial hygiene professionals, and average annual APFO production levels. Exposure among AFPO workers was classified into quartiles, and employees of the non-AFPO production facility served as the referent population. There were no statistically significant SMRs by exposure quartile for any of the outcomes, with the state of Minnesota serving as the comparison group. The workers had modestly elevated risk of death from prostate cancer (Q4: HR=1.32, 95% CI 0.61 to 2.84), pancreatic cancer (Q4: HR=1.2, 95% CI 0.50, 3.00), bladder cancer (Q3-4: HR=1.96, 95% CI 0.63 to 6.15), and chronic renal disease (Q4: HR=1.37, 95% CI 0.38 to 4.95), but the effects were not statistically significant. There was no evidence of elevated risk for kidney cancer. There was little evidence that APFO increased the risk of prostate cancer (Q4: HR=1.11, 95% CI 0.82 to 1.49), pancreatic cancer (Q3-Q4: HR=1.36, 95% CI 0.59 to 3.11) and bladder cancer (Q4: HR=1.66, 95% CI 0.86 to 3.18) but these also were not statistically significant. There was no evidence of increased risk for kidney cancer. Investigators noted that unlike the PFOA-exposed occupational cohort in Parkersburg, WV this population was not exposed to the potential confounder TFE, which could account for absence of an association with kidney cancer.

Vieira et al. (2013) performed an ecological study in 13 counties which encompass six PFOA-contaminated water districts in Ohio and West Virginia located near the DuPont chemical plant in Parkersburg, West Virginia. Cases of 18 types of cancer were obtained from the Ohio and West Virginia cancer registries, in which the final data set included 7,869 Ohio cases and 17,328 West Virginia cases. To calculate adjusted odds ratios (OR) with logistic regression, controls were selected from the state cancer registries as all other cases of cancers (excluding cases of kidney, pancreatic, testicular, and liver cancers, the types which have been associated with PFOA in animal or human studies). Exposure estimates were based on estimated 1995 median serum PFOA concentrations in the six water districts. The analysis was adjusted for age, sex, diagnosis year, smoking status, and insurance provider. The first of two analyses, using water district of residence as the exposure of interest and including both Ohio and West Virginia cases, found the odds of testicular cancer was statistically significantly increased (OR=5.1, 95% CI 1.6-15.6) and the odds of kidney, non-Hodgkin lymphoma, and prostate cancer were also increased, in the highest exposed water district of Little Hocking, although not statistically significant. Kidney cancer was also elevated in the third highest exposed water district of Tupper's Plain (OR=2.0, 95% CI 1.3-3.1). Lung cancer was statistically significantly associated with PFOA in the total exposed group and in two of the water districts. For the second analysis, serum PFOA levels were estimated at a finer geographic scale and restricted to Ohio-only cases. Kidney cancer was elevated in both the very highly exposed category (serum concentration of 110-665

ng/ml; OR=2.0, 95% CI 1.0, 3.9) and the highly exposed category (serum concentration of 30.8-109 ng/ml; OR=2.0, 95% CI 1.3, 3.2) groups.

Barry et al. (2013) evaluated cancer incidence among individuals exposed to PFOA through contaminated drinking water in the mid-Ohio Valley, as well as subjects who worked at the local chemical plant where PFOA was used (n=32,254). Associations between self-reported cancers and cumulative (based on retrospective yearly estimates for each individual) serum PFOA concentrations were evaluated using a proportional hazards model. The model was adjusted for time-varying smoking, time-varying alcohol consumption, sex, education, and 5-year birth year period. Analyses were restricted to the 21 types of reported primary cancers validated through medical records and state cancer registries (n=2,507, 70% validated). Among the cancer types, only testicular cancer was statistically significantly associated with cumulative serum PFOA concentration (OR=1.34, 95% CI 1.00, 1.79), and the effect was stronger when restricted to community members only (OR=1.73 95% CI 1.24,2.40). Thyroid cancer was statistically significantly associated with cumulative serum PFOA concentrations among occupational workers (OR=1.93, 95% CI 1.00, 3.71) but not among the community study population. Results for cumulative serum PFOA concentrations by quartiles show that estimated risk ratios for kidney cancer (p-value=0.10) and testicular cancer (p-value=0.05) generally increased across quartiles. This pattern was less consistent for thyroid cancer (p-value=0.20), except when restricted to the occupational study population (p-value=0.04). Since this is largely a survivor cohort, differences in cancer survival rates could cause cancer types with shorter than 5-year survival to be likely to be captured by the study. Additionally, if individuals with cancers caused by high exposure were more likely to die before being captured in the cohort, results could be biased towards the null (less likely to find an association). Therefore, results about these cancer types should be interpreted with caution.

A comprehensive review of PFOA as an emerging drinking water contaminant (Post et al., 2012) found evidence that occupational studies showed some consistency of increased cancer mortality and/or incidence for bladder, kidney, and prostate cancer. Post et al. (2012) also reviewed studies showing that white blood cell neoplasms (Leonard, 2003; Leonard et al., 2008), thyroid cancer (Leonard et al., 2008), and carcinoid tumors (Morel-Symons et al., 2007) were also increased at one industrial facility.

A recent review of PFOA's carcinogenic potential focusing on human epidemiological studies (Chang et al., 2014) concludes that the "existing epidemiological evidence does not support the hypothesis of a causal association between PFOA exposure and cancer in humans. However, further research on this topic is warranted." Specifically, Chang et al. (2014) suggest that quantitative exposure assessment at industrial facilities in Asia that continue to produce or use PFOA (now phased out in the U.S.) could be used as the basis for future cohort studies with sufficient follow up time. Additionally, continued follow-up of existing cohorts with use of

cancer incidence data from cancer registries could provide further information about human cancer risk of PFOA.

Information on human breast cancer and PFOA is of interest because toxicological findings provide some evidence suggesting biological plausibility, although the available toxicological data do not support firm conclusions on this topic. Developmental exposures to PFOA cause delayed mammary gland development in mice. Several researchers have stated that, in general, such disruptions of mammary gland development may result in adverse effects later in life resulting in increased cancer risk, although no information specific to PFOA is available on this question (Fenton 2006; Rudel and Fenton, 2009; IOM, 2011; Rudel et al., 2011; Fenton et al., 2012). Developmental exposures to PFOA in mice also caused increased numbers of darkly stained foci (described in detail in the Toxicology section) that persisted into adulthood and are considered permanent (White et al., 2009). Gore et al. (2015) notes that abnormalities of this type can be associated with increased breast cancer risk. However, chronic carcinogenicity studies have not been conducted in mice.

Epidemiological studies of associations of PFOA with breast cancer did not evaluate early life exposures. Studies of workers with occupational exposures to PFOA include very few women and are thus not informative about disease incidence in females. The incidence of breast cancer was not increased in a study of many types of cancer in the C8 Health Study population in Ohio and West Virginia communities with drinking water exposure to PFOA that included about 17,000 women (Barry et al., 2013). A small study (31 cases and 98 controls) in the Inuit population in Greenland found significantly increased risk of breast cancer associated with PFOA, perfluorooctane sulfonic acid (PFOS), total perfluorinated carboxylates, and total perfluorinated sulfonates (Bonefeld-Jorgensen et al., 2011). A subsequent study of this small group of cases and controls found a greatly elevated odds ratio for breast cancer in women with both high PFC levels and specific polymorphisms of xenobiotic metabolizing enzymes that affect levels of hormones such as estrogens, suggesting that inter-individual variations in these polymorphisms may affect sensitivity to the effects of PFCs on breast cancer risk (Ghisari et al., 2014). Because this was the only such study and it is of small size, these data are considered preliminary and suggest the need for further research on this topic.

In regard to biological plausibility for human carcinogenicity, PFOA caused hepatic, testicular Leydig cell, and pancreatic acinar cell tumors in two chronic studies in male rats (discussed in Toxicology section). Potential human relevance of these tumors is discussed in the Mode of Action section. Although liver tumors in rodents caused by compounds that activate PPAR-alpha are generally not considered relevant to humans, activation of this receptor may not be the sole mode of action for liver tumors caused by PFOA. Additionally, a PPAR-alpha mode of action may be involved in hepatic effects in the fetus, infants, and children. Therefore, the potential for

human relevance of the tumors observed in rodents cannot be dismissed. The mode of action for the testicular and pancreatic tumors has not been established.

### **Additional endpoints**

In addition to the epidemiologic endpoints reviewed above, there remain a large number of peer-reviewed studies that have evaluated other endpoints. Associations with PFOA have been found in some of these studies and not in others. Although these endpoints are not evaluated in this document, other organizations and publications may provide a more comprehensive review

Additional endpoints evaluated in studies but not reviewed in this report include biomarkers of kidney function or damage such as blood urea nitrogen, serum creatinine, renal glomerular filtration rate (eGFR) and chronic kidney disease; heart disease and hypertension; cerebrovascular disease including stroke, diabetes, immune function (with the exception of immune response following vaccination which was reviewed above) including asthma and other allergies, autoimmune disease including osteoarthritis, lupus, juvenile diabetes, rheumatoid arthritis, multiple sclerosis, and Crohn's disease; osteoporosis and bone mineral density; neurological and neurodegenerative disorders including self-reported memory impairment and Parkinson's disease; cognitive and behavioral developmental milestones; performance testing, and attention deficit hyperactivity disorder (ADHD) in children; reproductive and developmental outcomes (with the exception of lower birth weight and birth size of neonates), including decreased sperm count, longer time to pregnancy, birth defects, miscarriage and stillbirth, and overweight and obesity measured by BMI and waist circumference in offspring. It is noted that the C8 Science Panel concluded that there are "probable links" with PFOA exposure in the C8 Health Study population for two adverse health conditions, pregnancy-induced hypertension and ulcerative colitis, that were not reviewed above.

Health effects that occur later in life from prenatal and early life exposures to environmental contaminants are a current focus of research in toxicology and epidemiology (Barouki et al., 2012; Heindel and Vandenberg, 2015). Exposures of developing tissues to toxic substances during sensitive time periods can result in increased risk or severity of later disease or dysfunction (Heindel and Vandenberg, 2015). Recent studies have found that developmental exposures to PFOA cause toxicological effects that persist into adulthood and/or become evident later in life, including hepatic toxicity, delayed mammary gland development, and bone morphology and mineral density (Macon et al., 2011; White et al., 2009; Filgo et al., 2015; Quist et al., 2015; Koskela et al., 2016). However, the effects of developmental exposures to PFOA on these endpoints have not been evaluated in humans.

### **Summary of conclusions for epidemiologic information**

Of the endpoints that were evaluated comprehensively by the Health Effects Subcommittee, the evidence for association with PFOA is strongest for serum cholesterol which demonstrates

consistency, strength, dose-response and some evidence of temporality. PFOA was associated with clinically defined hypercholesterolemia in a community exposed through drinking water. There was also consistency among the larger non-occupational studies, as well as evidence of specificity, exposure-response and strength for associations between PFOA and both serum cholesterol and the liver enzyme ALT. These findings provide evidence supporting a causal relationship between PFOA and both cholesterol and ALT. There is evidence of consistency, strength, and exposure-response with PFOA and uric acid as well, but interpretation for temporality is limited.

In general, the human data for PFOA are notable because of the consistency between results among human epidemiologic studies in different populations for some endpoints, the concordance with toxicological findings from experimental animals, the use of serum concentrations as a measure of internal exposure, the potential clinical importance of the endpoints for which associations are observed, and the observations of associations within the exposure range of the general population.

As mentioned above, the epidemiologic databases for cholesterol, the liver enzyme ALT, and other endpoints are sufficient to support one or more of the criteria for causality. The sufficiency of the database to support these criteria is particularly evident when compared to the human epidemiologic databases for numerous other environmental contaminants for which quantitative risk assessment is based on animal toxicological studies in the absence of substantial support from human epidemiologic data (for example, 1,2,3-trichloropropane and methyl tertiary butyl ether [MTBE]).

For some endpoints, studies of populations from varied locations including the U.S., Canada, and several European and Asian countries, with study populations including children, young adults, adults, the elderly, and pregnant women, demonstrate a congruence of consistent findings. Although the human epidemiologic database is largely driven by cross-sectional studies, consistency is supported from studies with stronger study designs such as cohort and/or case-control, especially in studies of the general populations and populations exposed to drinking water contaminated with PFOA.

A particular strength of epidemiologic studies of PFOA and other PFCs is the availability of serum concentrations, a direct and accurate measure of internal dose in individuals. In contrast, human studies of most other environmental contaminants usually rely on estimates of external exposure. Exposure assessment tends to be susceptible to misclassification that may lead to biased findings. However, information bias is unlikely to have an impact in most general population studies of PFOA because of their reliance on serum concentrations and clinical biomarkers



Application of the Navigation Guide systematic review methodology to epidemiologic data resulted in the conclusion that there is sufficient evidence that developmental exposure to PFOA adversely affects fetal growth. The methodology developed and utilized to assess the relationship of PFOA and fetal growth was substantive and robust such that conclusions reached through application of the Navigation Guide are reasonable and supportable.

Reviews by several authoritative groups concluded that there is evidence of carcinogenic potential in humans for PFOA. The USEPA SAB (2006) described PFOA as “likely to be carcinogenic to humans” based on the criteria provided in USEPA (2005b) cancer risk assessment guidance. More recently, IARC (2015) concluded that, based on its evaluation criteria, PFOA is possibly carcinogenic to humans. Finally, the USEPA Office of Water (2016a) concluded that there is suggestive evidence of human carcinogenicity for PFOA.

For some other endpoints, limited evidence of an association with PFOA was found. There is consistent evidence of decreased antibody concentrations following vaccination, with evidence of temporality. However, most of the vaccine types were evaluated in only one or two studies, limiting the ability to determine specificity. The epidemiologic database for PFOA and LDL appears inconsistent, although there is some evidence of an association. Epidemiologic evidence for other serum lipid endpoints is limited. The epidemiologic evidence of a casual association with PFOA and GGT, AST, and bilirubin lacks consistency, and there is a limited evidence of associations with PFOA and liver disease. Evidence of thyroid disease remains limited.

There was no evidence of an association with PFOA and the liver enzyme ALP. Overall the epidemiologic evidence suggests no evidence of an association with HDL and PFOA. Overall studies evaluating thyroid hormones and TSH provide limited or no evidence of any associations with PFOA.

Although the magnitude of change for the parameters associated with PFOA is generally relatively small, they are of public health concern because population-level changes of this magnitude in parameters such as serum cholesterol or liver enzymes will result in a shift in the overall distribution of values such that the numbers of individuals with clinically abnormal values is increased. Additionally, small changes in a clinical biomarker may be an indicator of other effects which were not assessed. For example, birth weight represents a gross measure of development, and relatively small decreases in birth weight may be an indication of changes in other subtler developmental parameters which were not assessed.

The steepest dose-response for associations of some health endpoints with PFOA has been observed within the lower range of serum PFOA concentrations. Epidemiologic studies of smaller numbers of highly exposed participants may not be inclusive of these low level exposure ranges and thus may not detect associations. Therefore, an important limitation of studies of



participants with extremely high serum PFOA concentrations may be that there are an insufficient number of study participants with low(er) level exposures who can serve as a comparison.

To illustrate this point, Figures 9A and 9B show changes in total serum cholesterol across deciles of serum PFOA concentrations in adults (Steenland et al., 2009) and children (Frisbee et al., 2010) from the mid-Ohio Valley. In both children and adults, associations increased steeply at low ranges of serum PFOA concentrations, with a much flatter dose-response at higher levels. In the absence of data from the lower range of serum PFOA concentrations, modeling techniques might not be able to detect statistically significant changes of this effect with increasing serum PFOA concentrations.




Figure 9. Adjusted-predicted total cholesterol change with increasing group median deciles. (A). Adults, Steenland et al., 2009 (B). Adolescents, Frisbee et al., 2009

For instance, in Emmett et al. (2006b), almost all participants had highly elevated serum PFOA levels (25<sup>th</sup> percentile value was 184 ng/ml), and comparisons were made only within the study population. Most or all of the lowest exposed individuals in this study may have had serum levels that fall on the flatter portion of the dose-response curve for serum cholesterol, limiting the ability to detect an association. Additionally, Olsen and Zobel (2007) provide data on serum cholesterol and other lipids in workers with PFOA exposure which indicate that the median serum PFOA level in the lowest exposed group, 60 ng/ml, lies on the flatter portion of the dose-response curve in Figure 9A and 9B above.

In summary, the consistency between results in different populations, the concordance with toxicological findings from experimental animals, the potential clinical importance of the endpoints for which associations are observed, and the observation of associations within the exposure range of the general population justify concerns about exposures to PFOA through drinking water. Although there is evidence to support causality for some epidemiological

endpoints, the epidemiological data have limitations and therefore are not used as the quantitative basis for the Health-based MCL. Instead, the human data are considered as part of the weight of evidence for the health effects of PFOA and are used to support a public health-protective approach in development of a recommended Health-based MCL based on animal toxicology data.

Table 6A. Summary of findings from epidemiologic studies of PFOA and serum lipids											
Citation	Study Population	Study Details	TC	HDL	Non-HDL	TC/HDL	LDL	VLDL	HDL/LDL	TG	Genes
1. Costa et al., 2009	Italy., Occupational: Cases – Male workers engaged in the PFOA production department; Controls – Male workers never exposed to PFOA	* <i>Study Design:</i> Exposure case-control & Cross-sectional * <i>Study Size:</i> n=160 * <i>Study Population Age:</i> 20-63 years * <i>Exposure Range (Median):</i> 4400 – 5700 ng/ml	↑	—						—	
2. Emmett et al., 2006b	U.S., Highly exposed community	* <i>Study Design:</i> Cross-sectional * <i>Study Size:</i> n=371 * <i>Study Population Age:</i> 2.5-89 years * <i>Exposure Range (Median):</i> 354 ng/ml	—								
3. Eriksen et al., 2013	Denmark, nested in a larger cohort, General population	* <i>Study Design:</i> Cross-sectional * <i>Study Size:</i> n=753 * <i>Study Population Age:</i> 50-65 years * <i>Exposure Range (Mean):</i> 7.1 ng/ml	↑								
4. Fisher et al., 2013	Canada, General population	* <i>Study Design:</i> Cross-sectional * <i>Study Size:</i> n=5,604 * <i>Study Population Age:</i> 6-79 years * <i>Exposure Range (Geo Mean):</i> 2.46 ng/ml	↑-	—	↑-	—	—			—	
5. Fitz-Simon et al., 2013	U.S., Highly exposed community	* <i>Study Design:</i> Cohort * <i>Study Size:</i> n=560 * <i>Study Population Age:</i> 20-60 years * <i>Exposure Range (Geo Mean):</i> 30.8 – 74.8 ng/ml	↑-	—			↑			—	
6. Fletcher et al., 2013	U.S., Highly exposed community	* <i>Study Design:</i> Cross-sectional * <i>Study Size:</i> n=290 * <i>Study Population Age:</i> 20-60 years * <i>Exposure Range (Median):</i> 30.1 ng/ml									<sup>1</sup> ↑-
7. Frisbee et al., 2010	U.S., Highly exposed community	* <i>Study Design:</i> Cross-sectional * <i>Study Size:</i> n=12,476 * <i>Study Population Age:</i> 1-17.9 years * <i>Exposure Range (Mean):</i> 69.2 ng/ml	↑	—			↑			↑-	
8. Fu et al., 2014	China, random selection of attendees to health check-up clinic (General population)	* <i>Study Design:</i> Cross-sectional * <i>Study Size:</i> n=133 * <i>Study Population Age:</i> 0-88 years * <i>Exposure Range (Median):</i> 1.43 ng/ml	↑	—			↑			—	
Citation	Study Population	Study Details	TC	HDL	Non-HDL	TC/HDL	LDL	VLDL	HDL/LDL	TG	Genes

9. Geiger et al., 2014	U.S., General population	* <i>Study Design:</i> Cross-sectional * <i>Study Size:</i> n=815 * <i>Study Population Age:</i> ≤ 18 years * <i>Exposure Range (Mean):</i> 4.3 ng/ml	↑-	—			↑			—	
10. Gilliland et al., 1996	U.S., Occupational - men	* <i>Study Design:</i> Cross-sectional * <i>Study Size:</i> n=115 * <i>Study Population Age:</i> Mean 39.2 years * <i>Exposure Range (Mean):</i> 3300 ng/ml	—	↓-			—				
11. Lin et al., 2011	Taiwan, Recruited from hypertension cohort (General population)	* <i>Study Design:</i> Cross-sectional * <i>Study Size:</i> n=287 * <i>Study Population Age:</i> 12-30 years * <i>Exposure Range (Median):</i> 2.39 ng/ml		—						—	
12. Lin et al., 2013	Taiwan, Individuals with abnormal urinalysis results from population-based screening program in Taiwan	* <i>Study Design:</i> Cross-sectional * <i>Study Size:</i> 664 (246 w/ elevated blood pressure and 398 w/ normal blood pressure) * <i>Study Population Age:</i> 12-30 years * <i>Exposure (Median):</i> 3.49 ng/ml					—			↓	
13. Nelson et al., 2010	U.S., General population	* <i>Study Design:</i> Cross-sectional * <i>Study Size:</i> n=416 to n=860 * <i>Study Population Age:</i> 12-80 years * <i>Exposure Range (median):</i> 3.8 ng/ml	↑-	—	↑		—				
14. Olsen et al., 2000	U.S., Occupational – male workers	* <i>Study Design:</i> Cross-sectional * <i>Study Size:</i> n=265 * <i>Study Population Age:</i> Adults * <i>Exposure Range (Median):</i> 1190 ng/ml	—	↓-			—			—	
15. Olsen et al., 2003	Belgium & U.S., Occupational	* <i>Study Design:</i> Cross-sectional & Longitudinal * <i>Study Size:</i> n=421 & 174 * <i>Study Population Age:</i> Adults * <i>Exposure Range (Mean):</i> 1220-1990 ng/ml	↑	—						↑	
16. Olsen and Zobel 2007	Belgium & U.S., Occupational - male	* <i>Study Design:</i> Cross-sectional * <i>Study Size:</i> n=506 * <i>Study Population Age (Mean):</i> 37-41 * <i>Exposure Range (Median):</i> 2210 ng/ml	—	↓-			—			↑-	
<b>Citation</b>	<b>Study Population</b>	<b>Study Details</b>	<b>TC</b>	<b>HDL</b>	<b>Non-HDL</b>	<b>TC/HDL</b>	<b>LDL</b>	<b>VLDL</b>	<b>HDL/LDL</b>	<b>TG</b>	<b>Genes</b>

17. Olsen et al., 2012	U.S., Occupational, direct employed and contract workers	* <i>Study Design</i> : Longitudinal * <i>Study Size</i> : n=179 * <i>Study Population Age</i> : Adults * <i>Exposure Range (Mean)</i> : Baseline/mean change - direct employed (881/-218.3 ng/ml), contract (28.9/32.1 ng/ml)	—	—	—	↓					
18. Sakr et al., 2007a	U.S., Occupational	* <i>Study Design</i> : Cross-sectional * <i>Study Size</i> : n=840 * <i>Study Population Age</i> : Adults * <i>Exposure Range (Median)</i> : 189 ng/ml	↑	—			↑	↑		—	
19. Sakr et al., 2007b	U.S., Occupational	* <i>Study Design</i> : Longitudinal * <i>Study Size</i> : n=454 * <i>Study Population Age</i> : Adults * <i>Exposure Range (Median)</i> : 1040/1160 ng/ml	↑	—			—			—	
20. Starling et al., 2014	Norway, Pregnant women recruited from larger cohort	* <i>Study Design</i> : Cross-sectional * <i>Study Size</i> : n=891 * <i>Study Population Age</i> : not stated - Adults * <i>Exposure Range (Median)</i> : 2.25 ng/ml	—	—			—			—	
21. Steenland et al., 2009	U.S., Highly exposed community	* <i>Study Design</i> : Cross-sectional * <i>Study Size</i> : n=46,294 * <i>Study Population Age</i> : ≥ 18 years * <i>Exposure Range (Median)</i> : 27 ng/ml	↑	—	↑	↑	↑				
22. Steenland et al., 2015	U.S., Occupational	* <i>Study Design</i> : Retrospective cohort * <i>Study Size</i> : n=3,713 * <i>Study Population Age</i> : Adult (mean year of birth 1951) * <i>Exposure Range (Median)</i> : 113 ng/ml	<sup>2</sup> —								
23. Wang et al., 2012	China, Occupational (male) and Highly exposed community	* <i>Study Design</i> : Cross-sectional * <i>Study Size</i> : Workers: n=55 / Residents: n=132 * <i>Study Population Age</i> : Adult * <i>Exposure Range (Median)</i> : 1636 / 284 ng/ml	—/ —	↓/ —			—/ —		↓/ —	—/ —	
24. Winquist and Steenland, 2014a	U.S., Occupational (male) and Highly exposed community	* <i>Study Design</i> : Retrospective cohort (prospective analyses) * <i>Study Size</i> : Workers: n=3,713/ Residents: n=28,541 * <i>Study Population Age</i> : Adult * <i>Exposure Range (Median)</i> : 112/ 24 ng/ml	<sup>2</sup> ↑								
<b>Citation</b>	<b>Study Population</b>	<b>Study Details</b>	<b>TC</b>	<b>HDL</b>	<b>Non-HDL</b>	<b>TC/HDL</b>	<b>LDL</b>	<b>VLDL</b>	<b>HDL/LDL</b>	<b>TG</b>	<b>Genes</b>
25. Zeng et al., 2015	Taiwan, recruited from control group of another study	* <i>Study Design</i> : Cross-sectional * <i>Study Size</i> : n=255 * <i>Study Population Age</i> : 12-15 years * <i>Exposure Range (Median)</i> : Boys=1.1, Girls=0.9 ng/ml	↑	—			↑			↑	

↑ = statistically significant increased association, ↓ = statistically significant decreased association, ↑- = inconsistent positively associated finding (findings from different models resulted in both statistically and non-statistically significant associations), ↓- = inconsistent negatively associated finding, — = not statistically significant, [statistical significant determined at  $\alpha=0.05$ ]

TC= total cholesterol, HDL= high density lipoprotein cholesterol, LDL=low density lipoprotein cholesterol, TG=triglycerides

1. Changes in the expression of genes 2. Self-reported high cholesterol

Table 6B. Summary of findings from epidemiologic studies of PFOA and liver enzymes/bilirubin									
Citation	Study Population	Study Details	ALT	GGT	AST	ALP	TB	DB	LD
1. Costa et al., 2009	Italy, Occupational (male)	*Study Design: Exposure case-control & Cross-sectional *Study Size: n=160 *Study Population Age: 20-63 years *Exposure Range (Median): 4400 – 5700 ng/ml	↑-	↑-		↑-	↓-		
2. Darrow et al., 2016	U.S., Highly exposed community	*Study Design: Cross-sectional *Study Size: up to n=32,254 including 3,713 workers *Study Population Age: >20 years of age *Exposure Range (Median): 16.5 ng/ml	↑	—				↓	— <sub>1</sub>
3. Emmett et al., 2006b	U.S., Highly exposed community	*Study Design: Cross-sectional *Study Size: n=371 *Study Population Age: 2.5-89 years *Exposure Range (Median): 354 ng/ml	—	—	—	—	—	—	
4. Gallo et al., 2012	U.S., Highly exposed community	*Study Design: Cross-sectional *Study Size: n=47,092 *Study Population Age: ≥ 18 years *Exposure Range (Median): 23.1 ng/ml	↑	↑-				—	
5. Gilliland et al., 1996	U.S., Occupational (male)	*Study Design: Cross-sectional *Study Size: n=115 *Study Population Age: Mean 39.2 years *Exposure Range (Mean): 3300 ng/ml	↓-	—	↓-				
6. Gleason et al., 2015	U.S., General population	*Study Design: Cross-sectional *Study Size: n=4,333 *Study Population Age: ≥ 12 years *Exposure Range (Median): 3.7 ng/ml	↑	↑	↑-	—	↑		
7. Jiang et al., 2014	China, pregnancy women	*Study Design: Cross-sectional *Study Size: 141 *Study Population Age: Not stated - adults *Exposure Range (Median): 4.2 ng/ml	—		—		—		
8. Lin et al., 2010	U.S., General population	*Study Design: Cross-sectional *Study Size: n=2,216 *Study Population Age: ≥ 18 years *Exposure Range (Mean): 4.5 ng/ml	↑	↑			—		
9. Melzer et al., 2011	U.S., General population	*Study Design: Cross-sectional *Study Size: n=3,974 *Study Population Age: ≥ 20 years *Exposure Range (Geo Mean): Men=4.9, Women=3.8 ng/ml							—
Citation	Study Population	Study Details	ALT	GGT	AST	ALP	TB	DB	LD



10. Olsen et al., 2000	U.S., Occupational – (male)	* <i>Study Design</i> : Cross-sectional * <i>Study Size</i> : n=265 * <i>Study Population Age</i> : Adults * <i>Exposure Range (Median)</i> : 1190 ng/ml	—	—	—	—	—	—	
11. Olsen et al., 2003	Belgium & U.S., Occupational	* <i>Study Design</i> : Cross-sectional & Longitudinal * <i>Study Size</i> : n=421 & 174 * <i>Study Population Age</i> : Adults * <i>Exposure Range (Mean)</i> : 1220-1990 ng/ml	—	—	—	—	—	—	
12. Olsen and Zobel 2007	Belgium & U.S., Occupational (male)	* <i>Study Design</i> : Cross-sectional * <i>Study Size</i> : n=506 * <i>Study Population Age (Mean)</i> : 37-41 * <i>Exposure Range (Median)</i> : 2210 ng/ml	↑-	↑-	—	—	↓-		
13. Olsen et al., 2012	U.S., Occupational	* <i>Study Design</i> : Longitudinal * <i>Study Size</i> : n=98-179 * <i>Study Population Age</i> : Adults * <i>Exposure Range (Mean)</i> : Baseline/mean change -direct employed (881/-218.3ng/ml), contract (28.9/32.1ng/ml)	↓-		—	—	—		
14. Sakr et al., 2007a	U.S., Occupational	* <i>Study Design</i> : Cross-sectional * <i>Study Size</i> : n=840 * <i>Study Population Age</i> : Adults * <i>Exposure Range (Median)</i> : 189 ng/ml	—	↑	—		—		
15. Sakr et al., 2007b	U.S., Occupational	* <i>Study Design</i> : Longitudinal * <i>Study Size</i> : n=454 * <i>Study Population Age</i> : Adults * <i>Exposure Range (Median)</i> : 1040/1160 ng/ml	—	—	↑	—	↓		
16. Steenland et al., 2015	U.S., Occupational	* <i>Study Design</i> : Retrospective cohort * <i>Study Size</i> : n=3,713 * <i>Study Population Age</i> : Adult (mean year of birth 1951) * <i>Exposure Range (Median)</i> : 113 ng/ml							—
17. Wang, et al., 2012	China, Occupational (male) and Highly exposed community	* <i>Study Design</i> : Cross-sectional * <i>Study Size</i> : Workers: n=55 / Residents: n=132 * <i>Study Population Age</i> : Adults * <i>Exposure Range (Median)</i> : 1636 / 284 ng/ml	—/ —		—/ ↓				
18. Yamaguchi et al., 2013	Taiwan, recruited from larger cohort	* <i>Study Design</i> : Cross-sectional * <i>Study Size</i> : n=608 * <i>Study Population Age</i> : 16-76 years * <i>Exposure Range (Median)</i> : 2.1 ng/ml	↑	—	↑				

↑ = statistically significant increased association, ↓ = statistically significant decreased association, ↑- = inconsistent positively associated finding (findings from different models resulted in both statistically and non-statistically significant associations), ↓- = inconsistent negatively associated finding, — = not statistically significant, [statistical significant determined at  $\alpha=0.05$ ], —- findings from some analyses are negative, positive, and non-significant

ALT (SGPT)=alanine aminotransferase, GGT=gamma-glutamyl transferase, AST (SGOT)=aspartate aminotransferase, ALP=alkaline phosphatase, TB=total bilirubin or unspecified bilirubin, DB=direct bilirubin, LD=liver disease

<sup>1</sup>Includes findings from both any liver disease and second category of liver disease which includes enlarged liver, fatty liver, and cirrhosis

Citation	Study Population	Study Details	TSH	TT4	FT4	TT3	FT3	TG	TD	Hypo	Hyper	OC
1. Bloom et al., 2010	U.S., Subgroup of sportfish anglers	*Study Design: Cross-sectional *Study Size: n=31-38 *Study Population Age: 31-45 years *Exposure Range (Geo Mean): 1.3 ng/ml	—		—							
2. Chan et al., 2011	CAN, Cases – hypothyroxemic pregnant women; Controls – nonhypothyroxemic pregnant women	*Study Design: Matched case-control *Study Size: n=271 *Study Population Age: Adults *Exposure Range (Median): Cases -3.9, Controls – 3.6 ng/ml										— <sup>a</sup>
3. de Cock et al., 2014	The Netherlands, Mother-child pairs	*Study Design: Cross-sectional *Study Size: n=83 pairs *Study Population Age: Newborns *Exposure Range (Median): 0.9 ng/ml		<sup>1</sup> ↑-								
4. Emmett et al., 2006b	U.S., Highly exposed community	*Study Design: Cross-sectional *Study Size: n=371 *Study Population Age: 2.5-89 years *Exposure Range (Median): 354 ng/ml	—						—			
5. Jain 2013	U.S., General population	*Study Design: Cross-sectional *Study Size: n=1,540 *Study Population Age: > 12 years *Exposure Range (Median): 4.1 ng/ml	↑	—	—	↑	—	—				
6. Ji et al., 2012	South Korea, Recruited from cohort study	*Study Design: Cross-sectional *Study Size: n=633 *Study Population Age: > 12 years *Exposure Range (Median): 2.7 ng/ml	—	—								
7. Kim et al., 2011	South Korea, Mother-Infant pairs	*Study Design: Prospective birth cohort *Study Size: Mothers – n=44, Pairs - n=26 *Study Population Age: > 25 years *Exposure Range (Median): Maternal prepartum blood– 1.5, Cord Blood- 1.2 ng/ml	<sup>3</sup> ↑-	—		—						
8. Knox et al., 2011	U.S., Highly exposed community	*Study Design: Cross-sectional *Study Size: n=50,113 *Study Population Age: >20 years *Exposure Range (Mean): 86.6 ng/ml	—	↑-		↓-						
Citation	Study Population	Study Details	TSH	TT4	FT4	TT3	FT3	TG	TD	Hypo	Hyper	OC
9. Lin et al., 2013	Individuals with abnormal urinalysis results from	*Study Design: Cross-sectional	—	—								

	population-based screening program in Taiwan	*Study Size: 664 (246 w/ elevated blood pressure and 398 w/ normal blood pressure) *Study Population Age: 12-30 years *Exposure (GM): 2.7 ng/ml										
10. Lopez-Espinosa et al., 2012	U.S., Highly exposed community	*Study Design: Cross-sectional and birth cohort *Study Size: n=10,725 *Study Population Age: 1-17 years *Exposure Range (Median): 29 ng/ml	—	—					↑-	↑-	—	
11. Melzer et al., 2011	U.S., General population	*Study Design: Cross-sectional *Study Size: n=3,974 *Study Population Age: ≥ 20 years *Exposure Range (Geo Mean): Men=4.9 and Women=3.8 ng/ml							↑-			
12 Olsen et al., 1998	U.S., Male, Occupational	*Study Design: Cross-sectional *Study Size: 111 (1993) and 80 (1995) *Study Population Age: Not presented *Exposure Range (Range) 0 to 80,000 (1993) and 0 to 115,000 (1995) ng/ml	—									
13. Olsen et al., 2003	Belgium & U.S., Occupational	*Study Design: Cross-sectional & Longitudinal *Study Size: n=421 & 174 *Study Population Age: Adults *Exposure Range (Mean): 1220-1990 ng/ml	—	—	—	↑						
14. Olsen and Zobel 2007	Belgium & U.S., Occupational - male	*Study Design: Cross-sectional *Study Size: n=506 *Study Population Age (Mean): 37-41 *Exposure Range (Median): 2210 ng/ml	—	—	↓-	↑-						
15. Shrestha, et al., 2015	U.S., Community-based	*Study Design: Cross-sectional *Study Size: n=87 *Study Population Age: 55-74 years *Exposure Range (Median): 9.3 ng/ml	—	—	—	—						
<b>Citation</b>	<b>Study Population</b>	<b>Study Details</b>	<b>TSH</b>	<b>TT4</b>	<b>FT4</b>	<b>TT3</b>	<b>FT3</b>	<b>TG</b>	<b>TD</b>	<b>Hypo</b>	<b>Hyper</b>	<b>OC</b>
16.	U.S., Occupational	*Study Design: Retrospective cohort *Study Size: n=3,713							—			

Steenland et al., 2015		* <i>Study Population Age</i> : Adult (mean year of birth 1951) * <i>Exposure Range (Median)</i> : 113 ng/ml									
17. Wang et al., 2014	Taiwan, pregnant women recruited from cohort	* <i>Study Design</i> : Cross-sectional and prospective birth cohort * <i>Study Size</i> : n=285 women and n=116 neonates * <i>Study Population Age</i> : Adult and newborns * <i>Exposure Range (Median)</i> : maternal=2.4 ng/ml	—	—	—	—					
18. Webster et al., 2014	Canada, Euthyroid pregnant women recruited from study	* <i>Study Design</i> : Prospective cohort study * <i>Study Size</i> : n=152 * <i>Study Population Age</i> : >18 years * <i>Exposure Range (Median)</i> : 1.7 ng/ml	<sup>4</sup> ↑-	—	—						
19. Wen et al., 2013	U.S., General population	* <i>Study Design</i> : Cross-sectional * <i>Study Size</i> : n=1,180 * <i>Study Population Age</i> : > 20 years * <i>Exposure Range (Geo Mean)</i> : 4.2ng/ml	—	—	—	<sup>1</sup> ↑-	—	—		<sup>1</sup> ↑-	<sup>2</sup> ↓-
20. Winquist and Steenland, 2014b	U.S., Highly exposed community and Occupational	* <i>Study Design</i> : Retrospective cohort, prospective analyses * <i>Study Size</i> : Resident, n=28,541; Worker, n=3,713 * <i>Study Population Age</i> : > 20 years * <i>Exposure Range (Median)</i> : 26.1 ng/ml							<sup>1</sup> ↑-	<sup>2</sup> ↑-	↑-
<p>↑ = statistically significant increased association, ↓ = statistically significant decreased association, ↑- = inconsistent positively associated finding (findings from different models resulted in both statistically and non-statistically significant associations), ↓- = inconsistent negatively associated finding, — = not statistically significant, [statistical significant determined at α=0.05]</p> <p>TSH=thyroid stimulating hormone, TT4=total thyroxine, FT4=free thyroxine, TT3=total triiodothyronine, FT3= free triiodothyronine, TG=thyroglobulin, TD=thyroid disease, Hypo=hypothyroidism, Hyper=hyperthyroidism, OC=other thyroid conditions (a. Maternal hypothyroxemia)</p> <p>1. In girls/women only. 2. Men only 3. Outcome is fetal thyroid concentrations. 4.Sensitivity analysis indicates association in High TPOAb (marker of autoimmune hypothyroidism) only</p>											

Citation	Study Population	Study Details	Uric Acid	Hyper
1. Costa et al., 2009	Italy, Occupational: Cases – Male workers engaged in the PFOA production department; Controls – Male workers never exposed to PFOA	* <i>Study Design</i> : Exposure case-control & Cross-sectional * <i>Study Size</i> : n=160 * <i>Study Population Age</i> : 20-63 years * <i>Exposure Range (Median)</i> : 4400 – 5700 ng/ml	↑	
2. Geiger et al., 2013	U.S., General population	* <i>Study Design</i> : Cross-sectional * <i>Study Size</i> : n=1,772 * <i>Study Population Age</i> : ≤ 18 years * <i>Exposure Range (Median)</i> : 4.3 ng/ml	↑	↑
3. Gleason et al., 2015	U.S., General population	* <i>Study Design</i> : Cross-sectional * <i>Study Size</i> : n=4,333 * <i>Study Population Age</i> : ≥ 12 years * <i>Exposure Range (Median)</i> : 3.7 ng/ml	↑	
4. Lin et al., 2013	Taiwan, Individuals with abnormal urinalysis results from population-based screening program in Taiwan	* <i>Study Design</i> : Cross-sectional * <i>Study Size</i> : 664 (246 w/ elevated blood pressure and 398 w/ normal blood pressure) * <i>Study Population Age</i> : 12-30 years * <i>Exposure (Median)</i> : 3.5 ng/ml	—	
5. Sakr et al., 2007a	U.S., Occupational	* <i>Study Design</i> : Cross-sectional * <i>Study Size</i> : n=840 * <i>Study Population Age</i> : Adults * <i>Exposure Range (Median)</i> : 189 ng/ml	↑	
6. Shankar et al., 2011	U.S., General population	* <i>Study Design</i> : Cross-sectional * <i>Study Size</i> : n=3,883 * <i>Study Population Age</i> : > 20 years * <i>Exposure (Median)</i> : Women, 3.5; Men 4.6 ng/ml	↑	↑
7. Steenland et al., 2010b	U.S., Highly exposed community	* <i>Study Design</i> : Cross-sectional * <i>Study Size</i> : n=54,591 * <i>Study Population Age</i> : > 20 years * <i>Exposure (Median)</i> : 27.9 ng/ml	↑	↑
<p>↑ = statistically significant increased association, ↓ = statistically significant decreased association, ↑- = inconsistent positively associated finding (findings from different models resulted in both statistically and non-statistically significant associations), ↓- = inconsistent negatively associated finding, — = not statistically significant, [statistical significant determined at <math>\alpha=0.05</math>]</p> <p>Hyper= hyperuricemia</p>				

Table 6E. Summary of findings from epidemiologic studies of PFOA and antibody concentrations (following vaccination)								
Citation	Study Population	Study Details	Tetanus	Diphtheria	Rubella	Measles	Mumps	Influenza
1. Grandjean et al., 2012	Faroe Islands, singleton births following through age 7 years	* <i>Study Design</i> : Prospective birth cohort * <i>Study Size</i> : n=656 → 587 * <i>Study Population Age</i> : Birth to 7 years * <i>Exposure Range (Median)</i> : Children (age 5) 4.1 ng/ml	↓	↓				
2. Granum et al., 2013	Norway, Sub-cohort recruited from cohort	* <i>Study Design</i> : Prospective birth cohort * <i>Study Size</i> : n=99 → 56 * <i>Study Population Age</i> : Birth to 3 years * <i>Exposure Range (Median)</i> : 1.1 ng/ml	—		↓	—		<sup>1</sup> —
3. Kielsen et al., 2015	Denmark, recruited from hospital staff	* <i>Study Design</i> : Prospective cohort * <i>Study Size</i> : n=12 * <i>Study Population Age</i> : 23-66 years * <i>Exposure Range (Median)</i> : 1.7 ng/ml	—	—				
4. Looker et al., 2014	U.S., Highly exposed community	* <i>Study Design</i> : Prospective cohort * <i>Study Size</i> : n=411 * <i>Study Population Age</i> : Adult * <i>Exposure Range (Median)</i> : 31.5 ng/ml						<sup>2</sup> ↓-
5. Stein et al., 2016	U.S., General population	* <i>Study Design</i> : Cross-sectional * <i>Study Size</i> : n=1,191 * <i>Study Population Age</i> : 12-19 years * <i>Exposure Range (Geo Mean)</i> : 4.1 ng/ml			↓-	—	↓-	
<p>↑ = statistically significant increased association, ↓ = statistically significant decreased association, ↑- = inconsistent positively associated finding (findings from different models resulted in both statistically and non-statistically significant associations), ↓- = inconsistent negatively associated finding, — = not statistically significant, [statistical significant determined at <math>\alpha=0.05</math>]</p> <p>Tetanus=tetanus antibody concentrations; diphtheria=diphtheria antibody concentrations; Rubella = rubella antibody concentrations; Measles = measles antibody concentrations; Influenza= Influenza antibody titer</p> <p>1. Haemophilus influenza type B (HiB) antibody concentrations 2. Influenza A H3N2 virus and an increased risk of not attaining the antibody threshold considered to offer long-term protection, other virus studied included Influenza Type B and Influenza Type A H1N1.</p>								

## **HEALTH EFFECTS - ANIMAL TOXICOLOGY**

### **Overview**

The toxicological database for PFOA includes studies of numerous effects in non-human primates and rodents. As discussed in the Introduction, a literature search was performed to identify publications relevant to health effects of PFOA including toxicological studies. The Health Effects Subcommittee's review focused on toxicological endpoints identified as sensitive and potentially relevant for use in risk assessment. The effects selected for detailed review were hepatic toxicity, developmental effects, immune system toxicity, and carcinogenicity. As discussed in the Epidemiology section, effects relevant to these endpoints have been associated with PFOA in humans. Studies related to these endpoints were summarized in summary tables and/or individual study tables, as described in the sections on each endpoint below.

Additionally, information is presented on general toxicity in non-human primates, as well as thyroid, neurobehavioral, and male reproductive effects.

### **General issues**

In reviewing the toxicology data, it should be kept in mind that female rats excrete PFOA much more quickly than males. Therefore, assuming that both genders are equally sensitive based on internal dose, effects are expected from lower administered doses of PFOA in male rats than female rats.

Another general issue for some of the animal toxicology studies is that, using sensitive analytical methods, measurable levels of PFOA were detected in the serum of animals in the untreated control groups. This exposure was likely due to a combination of two factors. First, there is likely some level of unavoidable background exposure to PFOA in laboratory animals, just as in the general human population, due to the ubiquitous presence of PFOA at low levels in the environment. Second, in some studies, the controls may have experienced some level of inadvertent exposure to the PFOA used to dose the treated animals. Serum levels of PFOA in control groups from the some of the studies discussed below were: Butenhoff et al. (2004a) cynomolgus monkey – 134 ng/ml; Loveless et al. (2006) rat and mouse – 100-400 ng/ml; DeWitt et al. (2008) mouse – 25-600 ng/ml; Abbott et al. (2007) mouse developmental: adults – 28-131 ng/ml, pups – 17-29 ng/ml; Macon et al. (2011) low dose mouse developmental: pups – 4-23 ng/ml.

Such low level exposure in laboratory control groups from sources such as diet and bedding also occurs for many other chemicals that are ubiquitous environmental contaminants. However, this issue is of particular relevance to PFOA because, unlike most other environmental contaminants, the dose-response curves for several of the associations seen in human epidemiology studies appear to be steepest at serum levels below about 40 ng/ml (discussed in Human Studies, above). Quantitation levels for serum PFOA in animal toxicology studies (e.g. 5 ng/ml, Reiner et al., 2009) are higher than in studies of human populations (e.g. 0.1 ng/ml in NHANES; CDC, 2015),



and serum levels in the control groups in some animal studies are within or above the range in which associations are found in the general population. Thus, the shape of the dose-response curve within the lower range of serum levels (at which associations were observed in some epidemiology studies) cannot be determined in these animal studies.

Finally, it should be noted that ammonium perfluorooctanoate (APFO, the ammonium salt of PFOA) was administered in some studies. Because APFO dissociates to PFOA in the body, results of studies of APFO are applicable to the evaluation of PFOA's toxicity.

### **Acute Toxicity**

Oral LD<sub>50</sub> values of 680 mg/kg (95% CI 399-1157 mg/kg) and 430 mg/kg (95% CI 295-626 mg/kg) were reported for male and female albino rats, respectively, after a single gavage doses of APFO and observation for 14 days (Griffith and Long 1980). In this study, five rats per sex per dose group were administered 100, 215, 464, 1000, or 2150 mg/kg. One or more deaths occurred in all groups except the 215 mg/kg group, and all animals in the 2150 mg/kg group died on day 1. Ptosis, piloerection, hypoactivity, decreased limb tone, ataxia, and corneal opacity were reported. These signs were intermittent, and there was no apparent dose-response relationship for them. Changes in the lungs (congestion, pitting, red foci) and the stomach (distension, hyperemic and thickened mucosa) were commonly seen in animals that died during the study, and many survivors had mottled kidneys and stomach changes similar to those in the animals that died. Other oral acute toxicity studies, as well as dermal and inhalation studies, are summarized by Kennedy et al. (2004).

### **Subchronic Studies in Non-Human Primates**

#### **90-day rhesus monkey study (Goldenthal, 1978)**

Goldenthal (1978) dosed rhesus monkeys (2/sex/group) with 0, 3, 10, 30 or 100 mg/kg/day APFO by gavage for 90 days (13 weeks). All 3 and 10 mg/kg/day animals survived the study. Soft stools, diarrhea, and frothy emesis were seen in the 3 mg/kg/day group, and one monkey in the 10 mg/kg/day group was anorexic during week 4, had a pale and swollen face in week 7, and had black stools for several days in week 12. In the 3 and 10 mg/kg-day groups, body weight gains were similar to controls, and no treatment related hematology or clinical chemistry changes were reported. Serum PFOA data are not provided in this study.

Mortality occurred in the two higher dose groups. In the 30 mg/kg/day group, 3 of 4 monkeys died during the study, one male during week 7 and the two females during weeks 12 and 13. All 30 mg/kg/day animals showed decreased activity, beginning in week 4. One monkey in this group had emesis and ataxia, swollen face, eyes, and vulva, as well as pallor of the face and gums. Beginning in week 6, two monkeys in this group had black stools, and one monkey had slight to moderate dehydration and ptosis of the eyelids.

All monkeys in the 100 mg/kg/day group died by week 5, with the first death occurring during week 2. These animals showed signs and symptoms that first appeared during week 1 including

anorexia, frothy emesis, pale face and gums, swollen face and eyes, decreased activity, prostration and trembling. Weight loss occurred in the two higher dose groups after week 1.

No treatment related gross pathological lesions were reported. Histopathological examination revealed effects on the adrenal gland, bone marrow, spleen, and lymph nodes in the two higher dose groups. Notably, all animals that died during the study had marked diffuse lipid depletion in the adrenal glands. All animals (including the one 30 mg/kg/day survivor) in the two higher dose groups had slight to moderate hypocellularity of the bone marrow and moderate atrophy of lymphoid follicles in the spleen, and one 30 mg/kg/day female and all 100 mg/kg/day animals had moderate atrophy of the lymphoid follicles in the lymph nodes.

Statistically significant changes in absolute or relative organ weights at either 3 or 10 mg/kg/day in either males or females (but not both) were reported for heart, brain, and pituitary. The biological significance of these changes was stated to be unknown.

Relative liver weight data are of interest because this endpoint was affected by PFOA in cynomolgus monkeys and rodents (see below). Since each dose group consisted of only two animals, a large change would be needed to reach statistical significance for this effect. Although there were no statistically significant effects on this endpoint, the data presented in Table 7 suggests that PFOA caused increased relative liver weight at 30 and 100 mg/kg/day.

Dose (mg/kg/day)	Relative Liver Weight	
	Males (2 per group)	Females (2 per group)
0	1	1
3	1.1	1
10	1.1	1
30	1.4 (1.5)	(1.9)
100	(1.6)	(1.4)

(Numbers in parentheses include dead animals)

The LOAEL for this study was 3 mg/kg/day based on the toxicity described above in this group, and no NOAEL was identified.

Because serum PFOA levels were not measured in this study, it is not possible to compare the internal dose at which effects occurred in the rhesus monkeys with the results from cynomolgus monkeys and rodents (detailed below).

4 week cynomolgus monkey study (Thomford, 2001a)

In a range finding study, the toxicity of APFO was studied in male cynomolgus monkeys (young adult to adult) dosed daily by capsule for 4 weeks (Thomford, 2001a). Dose levels were 0 (n=2), 2 mg/kg/day (n=3), and 20 mg/kg/day (n=3). Parameters evaluated in blood (prior to treatment and on Day 30) included serum PFOA (although data were not reported in Thomford et al., 2001a), hematology, clinical chemistry (also evaluated on Day 2, about 24 hours after first dose), and hormones (estradiol, estrone, estriol, thyroid stimulating hormone, total and free triiodothyronine, and total and free thyroxine). Of the parameters measured in blood, estrone was notably lower in both treated groups

All animals survived until the end of the study, no clinical signs of toxicity were observed in the treated groups, and body weight was not affected by treatment. Low or no food consumption occurred in one animal dosed with 20 mg/kg-day. Microscopic evaluation of the adrenals, liver, pancreas, spleen, and testes found minimal mineralization in the adrenals of one animal given 2 mg/kg/day and immature testes in one animal in each of the two dosed groups (2 of 6 dosed animals). The authors stated that these findings were not related to PFOA treatment. There was no evidence of peroxisome proliferation (assessed by palmitoyl CoA oxidase activity; PCO) in the liver, or increased cell proliferation (assessed by the proliferating cell nuclear antigen; PCNA) in the liver, testes, and pancreas of treated monkeys. The authors concluded that NOAEL was 20 mg/kg, and no LOAEL was established.

6 month (26 week) cynomolgus monkey study (Thomford, 2001b; Butenhoff et al., 2002)

The toxicity of APFO was studied in male cynomolgus monkeys dosed daily by capsule for 6 months (Thomford, 2001b; Butenhoff et al., 2002). This study is described in detail because it has been used as the partial or entire basis for several earlier final and draft PFOA risk assessments (USEPA, 2005a; MDH, 2008; Post et al., 2009a; Tardiff et al., 2009; NC SAB, 2010; ATSDR, 2015), and because it is considered in evaluating the human relevance of hepatic effects of PFOA (See Mode of Action section, below). Concerns related to use of this study as the basis for risk assessment and the reasons why the data do not support Benchmark Dose modeling based upon it (Butenhoff et al., 2004a) are discussed in detail in Appendix 3 of this document. A table summarizing this study, with a focus on hepatic effects, is included in Appendix 5. Data for increased liver weight from this study are included in Table 10.

In this study as originally designed, male monkeys, age 3 to 9 years, were to be administered doses of 0, 3, 10, or 30 mg/kg/day by capsule, 7 days per week for 26 weeks. Six animals were dosed per group, except for the 3 mg/kg/day group which had four animals. However, as detailed below, the high dose (30 mg/kg/day) was reduced to 20 mg/kg/day due to overt toxicity. Additionally, only three of the four low dose (3 mg/kg/day) and two of the six high dose (30 mg/kg/day) monkeys tolerated the administered dose well enough to complete the study, while all six animals in the mid-dose group (10 mg/kg/day) completed the study. Two animals from the control and 10 mg/kg/day groups were observed for delayed effects for 13 weeks following the 6 months of dosing.

One low dose (3 mg/kg/day) monkey was sacrificed on day 137 (week 19) after loss of about 10% of its weight in one week accompanied by low food consumption, few feces, hind-limb paralysis, ataxia, and lack of response to pain. No specific organ pathology or clinical chemistry changes explaining the morbidity were found, and the study authors stated that it was unclear whether or not these effects resulted from exposure to PFOA. It is notable that the liver-to-body weight ratio in this animal, 2.44, was much higher than for other animals in this group and was comparable to the ratios in the high dose group. Also, the liver-to-brain weight ratio in this animal, 1.66, was the highest of any animal in the study. However, the serum and liver PFOA levels in this animal were not higher than for other animals in the same treatment group. These findings suggest that this animal may have been particularly susceptible to the hepatic effects of PFOA.

Dosing of the high dose (30 mg/kg/day) group was stopped on day 12 due to toxicity in the first week, including low food consumption, weight loss, and few or no feces. The dosing of this group was restarted at 20 mg/kg/day on day 22, after a 10-day break to allow for recovery from the toxicity in first week.

One high dose monkey was sacrificed on day 29 due to decreased body weight, lack of eating, hypoactivity, and coldness to touch. The liver of this animal had lesions including mid-zonal and centrilobular hepatocellular degeneration and necrosis, diffuse hepatocellular vacuolation, and centrilobular hepatocyte basophilia indicative of liver regeneration. Other effects observed in this monkey included necrosis, erosions, and ulcerations of the esophagus and stomach, and involution of the thymus. This animal had increased serum enzymes indicative of substantial liver and muscle injury, and a marked decrease in serum cholesterol to about 10% of control levels. The study authors state that the liver lesions were likely related to treatment.

Dosing of three high dose (30/20 mg/kg/day) monkeys was stopped on days 43, 66, and 81 due to low or no food consumption, dramatic weight loss (18-23% of body weight), and few or no feces. These three monkeys were monitored without dosing for the rest of the study, and their body weights increased to above pre-dosing levels by the end of the study.

In the study, serum PFOA levels were analyzed every 2 weeks, including in animals for which dosing was stopped. Steady state was reported to have been reached after 4-6 weeks. The complete set of serum data was reported in a separate publication (Butenhoff et al., 2004a). Means and standard deviations for serum levels in the control, 3, 10, and 30/20 mg/kg/day groups, excluding animals for which dosing was stopped, were reported as 134±113 ng/ml, 80,000±40,000 ng/ml, 99,000±49,000 ng/ml, and 155,000±103,000 ng/ml. It is evident from the data that there was a wide variation in serum levels within the same treatment group, and that serum levels did not increase proportionally with dose. The ratios between mean serum levels at steady-state in the 3, 10, and 30/20 mg/kg/day groups were approximately 1:1:2 (i.e. serum

levels were similar in the 3 and 10 mg/kg/day groups), and the mean serum levels at 3 mg/kg/day and 10 mg/kg/day did not differ significantly at the  $p < 0.05$  level (Butenhoff et al., 2002).

Hepatic PFOA concentrations at sacrifice did not differ between the 3 and 10 mg/kg/day groups ( $15,000 \pm 3600$  ng/g and  $14,000 \pm 7600$  ng/g, respectively) and were very disparate in the two high dose (20/30 mg/kg/day) animals that completed the study (16,000 and 83,000 ng/g). It is notable that the highest liver concentration by far (154,000 ng/g) was found in the high dose animal sacrificed due to treatment-related morbidity at week 5.

Average body weight gains during the dosing period in the 0, 3, and 10 mg/kg/day groups were 19, 20, and 20%, while the weight changes in the two 30 mg/kg/day animals that completed the study were -8% and 18%.

Serum cholesterol was not affected by PFOA treatment in this study, while triglycerides were significantly increased compared to controls at several time points in the mid- and high dose group. These observations are notable, since decreases in serum cholesterol have been observed in rodent studies with PFOA, consistent with the effects of other PPAR-alpha activators, and since human PFOA exposure has been associated with increases in cholesterol (see Epidemiology section, above). As discussed above, the dose-response curves for increased cholesterol in humans appears steepest at serum PFOA levels below about 40 ng/ml, with a much flatter dose-response between about 40 and 350 ng/ml PFOA in serum (Nelson et al., 2010; Steenland et al., 2009b). Since the mean serum PFOA level in the control monkeys was 134 ng/ml, the shape of the dose response curve for cholesterol at serum levels relevant to effects observed in humans is not known.

In the high dose group, including the three monkeys in which treatment was stopped, total neutrophils, total serum protein, and albumin were decreased. In the two monkeys in this group that were dosed until the end of the study, the changes were not significant but were consistent over time. In one of the monkeys whose dosing was stopped, serum liver enzyme levels and elevated serum bile acids were greatly increased three days prior to the stopping of the dosing. Additionally, the high dose monkey that was sacrificed in moribund condition on Day 29 had markedly elevated liver enzymes and markedly low cholesterol.

Changes in thyroid hormone levels occurred in treated groups; these are described in detail in the section on thyroid effects below. Although estradiol levels in the high dose group appeared to decrease with treatment, the authors did not attribute these findings to treatment.

Absolute liver weight and liver-to-body weight ratios were increased in all treated groups (Butenhoff et al., 2002). The increase in absolute liver weight was statistically significant ( $p < 0.01$ ) in all groups, but was only significant for relative liver weight in the high dose group. However, this analysis does not include the animals that were sacrificed in moribund condition during the study. The absolute and relative liver weight of the sacrificed low dose monkey was

far higher than the others in its group, and inclusion of data for this animal increases the mean value for these parameters (Table 10). Liver-to-brain weight ratio is considered to be a reliable measure of effects on liver weight, because brain weight tends to remain stable when body weight changes. This ratio was increased in all treated groups compared to controls, but did not increase with administered dose or serum level (Butenhoff et al., 2004c). In the control, 3, 10, and 30/20 mg/kg/day groups, the liver-to-brain weight ratios were 0.934, 1.34, 1.30, and 1.22, respectively.

No gross or microscopic pathological changes were seen in the organs examined from animals that completed the study. However, as mentioned above, multiple pathological changes were found in the high dose monkey sacrificed in moribund condition on Day 29. These included edema and inflammation of the esophagus and stomach (attributed to dosing injury); liver lesions including mid-zonal and centrilobular hepatocellular degeneration and necrosis, diffuse hepatocellular vacuolation, and hepatocyte basophilia in centrilobular areas indicative of liver regeneration; involution of the thymus (noted as a common stress response); and degeneration and necrosis of the heart (noted as likely an agonal change).

Two monkeys from the control group and two from the 10 mg/kg/day group were observed for 13 weeks following the 6-month treatment period. Weight gain during the recovery period was lower in the 10 mg/kg/day animals than in the controls. During the recovery period, the control group monkeys gained 10 and 11% of their body weight, while one treated monkey gained 5% and the other lost 3%.

Studies of hepatic biochemical markers in this study are discussed in the Mode of Action section, below.

The LOAEL in this study is 3 mg/kg/day based on mortality possibly related to treatment (25%) and increased liver weight, and the NOAEL is unknown. Mean serum levels at this dose were reported by Butenhoff et al. (2004a) as  $80,600 \pm 40,000$  ng/ml. It is important to note that 6 months represents less than 2% of the lifespan of about 30 years in this species of monkey. It is not known whether additional or more severe effects would have occurred with continued dosing of the monkeys that tolerated dosing for the full 6 months of the study. Additionally, this study did not include female monkeys and, because exposure was initiated at age 3 to 9 years, effects specific to exposures during development or at younger ages would not be evident.

Comparison of the results of this study with chronic rat studies discussed below suggests that cynomolgus monkeys are more sensitive to the overt toxicological effects of PFOA than are rodents. As discussed above, four of the six high dose monkeys exhibited severe toxicity that necessitated removal from the study. The serum PFOA level in the high dose monkey that was sacrificed on Day 29 with severe multi-organ toxicity was 822,000 ng/ml. The serum levels of the other three high dose monkeys removed from the study on days 43, 66, and 81 due to overt toxicity (low or no food consumption, dramatic weight loss of 18-23%, and few or no feces)



were 102,000 ng/ml, 467,000 ng/ml, and 235,000 ng/ml, respectively, at the times when dosing was stopped. These severe toxic effects occurred after dosing for about 0.3-0.7% of the monkeys' lifespans. In contrast, survival was unaffected or increased compared to controls, and no overt toxicity was observed, in male rats with lifetime (2 year) exposure to PFOA doses that were estimated to result in serum PFOA levels of almost 600,000 ng/ml (Sibinski 1987; Biegel et al., 2001; USEPA, 2005a). Thus, severe toxicity resulted from relatively short exposures to PFOA in primates at serum levels below those that were well tolerated chronically by rats.

### **Hepatic Effects in Rodents and Non-Human Primates**

PFOA causes liver toxicity in experimental animals, including rodents and non-human primates (reviewed by Kennedy et al., 2004; Lau, 2012). As discussed in the Epidemiology section, increased liver enzymes are associated with exposure to PFOA in humans.

Increased liver weight is a sensitive toxicological endpoint for PFOA that has been observed in many toxicological studies. Although studies of PFOA that report increased liver weight do not always include evaluation of other hepatic endpoints, numerous studies of PFOA have demonstrated that increased liver weight co-occurs with and/or progresses to more severe hepatic effects including increased serum liver enzymes, hepatocellular necrosis, fatty liver, and/or hyperplastic nodules. Additionally, recent studies show that cellular damage indicative of liver toxicity persists until adulthood following developmental exposure to PFOA.

This section first reviews data indicative of liver damage from toxicological studies of PFOA. This is followed by a presentation of data on increased relative liver weight from PFOA. Numerous toxicological studies of PFOA have evaluated liver weight, and a separate discussion of each of these is beyond the scope of this document. Because studies of increased liver weight that include relatively low doses of PFOA are most relevant to quantitative risk assessment, they are reviewed in detail and are summarized in Table 10.

Chronic exposure to PFOA also caused hepatic adenomas in rats (See Chronic Studies, below). The mode of action for hepatic effects, particularly as related to human relevance, is discussed in detail in the Mode of Action section.

### **Histopathological changes in the liver**

Hepatocellular hypertrophy is a consistently reported histopathological finding for PFOA that accompanies increased absolute and relative liver weight. A number of studies in both non-human primates and rodents also report other histopathological changes that are indicative of liver injury and/or lipid accumulation in the liver. These effects occurred at doses similar to those causing increased liver weight. Notably, prenatal exposure to a very low dose (0.01 mg/kg/day) of PFOA caused liver toxicity that persisted until adulthood at doses below those which caused increased liver weight (Quist et al., 2015).



International harmonization of diagnostic criteria and terminology for histopathologic lesions has recently been developed to provide consistency and to reflect current knowledge of the biochemical and cellular processes involved in changes in the liver and other organs (Mann et al., 2012). The terminology and current definitions that are recommended by the international harmonization group to describe hepatic damage were applied where appropriate to describe the histopathological findings discussed below.

Information from some studies that reported histopathological effects indicative of liver damage is summarized below. It should be noted that this summary does not represent a complete compilation of all studies such effects. The significance of these effects as related to the mode of action of PFOA is discussed in the Mode of Action section.

As discussed above, the high dose (30/20 mg/kg/day) male cynomolgus monkey sacrificed in moribund condition on Day 29 of the 90-day study had liver lesions including mid-zonal and centrilobular hepatocellular degeneration and necrosis, diffuse hepatocellular vacuolation, and centrilobular hepatocyte basophilia indicative of liver regeneration (Butenhoff et al., 2002).

In a 28-day study of male and female Chr-CD albino rats with dietary exposure to 30-1000 ppm APFO, degeneration and/or necrosis of hepatocytes and focal bile duct proliferation occurred in all treated groups (Kennedy et al., 2004). The dose from 30 ppm in the diet was estimated as 1.5 mg/kg/day. Similar changes were seen in livers of rats dosed with 3 to 1000 ppm in the diet for 90 days, and were stated to be more frequent in males, and most pronounced at the highest dose (Griffith and Long, 1980).

Individual cell and focal necrosis, increased hepatocellular mitotic figures, fatty changes, and bile duct hyperplasia were observed in male CD-1 mice dosed by gavage with linear APFO for 29 days (Loveless et al., 2008). The LOAEL for individual cell and focal necrosis was reported by the authors as 1 mg/kg/day, and the NOAEL as 0.3 mg/kg/day. Focal necrosis occurred in one of ten mice at 0.3 mg/kg/day but was stated by the authors to not be related to PFOA treatment. Increased mitotic figures, fatty changes, and bile duct hyperplasia occurred at  $\geq 10$  mg/kg/day.

Multiple histopathological changes were observed in the livers of three strains (wild type, PPAR-alpha null, and humanized PPAR-alpha) of male Sv/129 mice dosed with 1 or 5 mg/kg/day PFOA for 6 weeks (Nakagawa et al., 2011). PFOA caused a dose-dependent increase in macrovesicular steatosis in the PPAR-alpha null mice, while this effect was not seen in the wild type mice. Additionally, microvesicular steatosis occurred at both doses in the PPAR-alpha null and humanized PPAR-alpha mice. Lobular inflammation was observed only in the PPAR-alpha null mice treated with PFOA. Single cell necrosis occurred in all three strains of PFOA treated mice and appeared to be most severe in the wild type mice. Hydropic degeneration of hepatocytes was seen in the PPAR-alpha null and humanized PPAR-alpha strains treated with PFOA, but not the wild type strain.

Adverse histological changes including deranged liver architecture, severe edema, vacuolar degeneration, focal necrosis, and obvious inflammatory infiltration were observed in livers of male Kunming (KM) mice dosed by gavage with 2.5 to 10 mg/kg/day PFOA for 14 days (Yang et al., 2014). These changes were more severe with increasing dose and were not seen in the control mice.

Bile duct injury, which was much more severe in PPAR-alpha null mice than in wild type mice (male 129S4 strain), occurred after 4 weeks of gavage dosing with 4.4, 10.8, or 21.6 mg/kg/day APFO (Minata et al., 2010). Microvesicular steatosis was also more prominent in treated PPAR-alpha null than similarly treated wild type mice, and focal necrosis occurred at the highest dose in the null mice.

Focal and multi-focal hepatic necrosis was observed at sacrifice on PND 109-120 in F1 male offspring in the 3, 10, and 30 mg/kg/day dose groups (but not at 1 mg/kg/day) in a two-generation rat reproductive developmental study that is discussed in detail below (Butenhoff et al., 2004b).

Histopathological changes occurred in the livers of male Sprague-Dawley rats sacrificed one day after the end of dietary exposure to 300 ppm APFO for 1, 7, or 28 days (Elcombe et al., 2010). This study was conducted twice, and the daily doses were estimated as 19 mg/kg/day and 23 mg/kg/day in the two studies. In both studies, PFOA caused periportal glycogen depletion after 1, 7, and 28 days of exposure to PFOA, hepatocellular hypertrophy after 7 and 28 days, and hepatocellular hyperplasia in all treated rats after 28 days.

In a chronic rat study discussed in detail below (Sibinski, 1987; Butenhoff et al., 2012), focal hepatocellular necrosis occurred in 6/15 high dose (14.2 mg/kg/day) males but not in any of the 15 controls at the one-year sacrifice. (The low dose group was not evaluated at one year). At the two-year sacrifice, the incidence of focal hepatocellular necrosis was similar in control and treated groups, but the incidence of hepatic hyperplastic nodules was increased in the high dose males compared to the control and low dose groups. Butenhoff et al. (2012) concluded that the increased incidence of focal necrosis and vacuolation at one year, but not at later time points, may have been due to the higher background incidence of these changes in older rats.

Additionally, PFOA caused hepatocellular adenomas in chronically exposed male rats in one of the two chronic rat studies that have been conducted (Biegel et al. 2001). Although these tumors were not increased in the other chronic rat study (Sibinski et al., 1987), the EPA Science Advisory Board (2006) concluded that the increased in hepatic hyperplastic nodules in Sibinski et al. (1987) may have been part of the continuum of proliferative lesions in the hepatic carcinogenic process. More recently, Butenhoff et al. (2012) suggested that the observations at one year and two years in Sibinski et al. (1987) suggest a progression of lesions “from hepatocellular hypertrophy to fatty degeneration to necrosis followed by regenerative

hyperplasia.” Butenhoff et al. (2012) also note that the diagnostic criteria for these nodules, which indicate a regenerative process, have changed since the study was evaluated in 1986.

PFOA caused hepatic triglyceride accumulation (fatty liver) in male Wistar rats after 7 days of dietary exposure (Kawashima et al., 1995). Hepatic triglyceride levels were significantly increased at the lowest dose (25 ppm) and were 3.5 times control levels in the 100 ppm dose group.

Several studies have evaluated hepatic effects of PFOA in mice that were fed diets containing specific types of lipids or higher general fat content. Kudo and Kawashima (1997) studied the effect of PFOA (2.5 - 10 mg/kg/day by intraperitoneal injection for 7 days) on hepatic triglyceride accumulation in male mice that had been fed diets containing soy bean oil, perilla oil, or fish oil for 4 weeks. Fish oil, but not the other two types of oil, was known to generally decrease hepatic triglycerides. PFOA caused a dose-dependent increase in hepatic triglycerides in mice exposed to perilla oil and soybean oil, but had no effect in mice exposed to fish oil.

Additionally, necrotic cell death, lipid droplet accumulation, and inflammatory cell infiltration were found in male C57BL/6N mice dosed with 5 mg/kg/day PFOA in a liquid diet for 3 weeks (Tan et al., 2013). These effects of PFOA were more severe in mice receiving a high fat diet than a regular diet. PFOA caused increased hepatic triglyceride levels in mice receiving regular diets or high fat diets, and relative white adipose tissue weight was decreased by PFOA treatment.

Finally, PFOA (5, 10, or 20 mg/kg/day by gavage for 14 days) caused lipid accumulation in the livers of male Balb/C mice fed either a regular diet or a high fat diet (Wang et al., 2013). Consistent with Tan et al. (2013), PFOA caused decreased relative weight of adipose tissue in mice receiving either diet. The authors concluded that lipids were both being released from the adipose tissue and accumulating in the liver. Evaluation of hepatic ultrastructural changes showed that PFOA caused a dose-dependent increase in the accumulation of lipid droplets in the nucleus of hepatic cells; the dose-response for this effect was similar in the regular and high fat diet groups. In the regular diet mice dosed with 10 and 20 mg/kg/day, dilation of the endoplasmic reticular was observed. More severe changes were seen in high fat diet mice at these doses including mitochondrial swelling, irregular nuclei, and condensed chromatin suggesting apoptosis.

Two recent studies found persistent hepatic damage in female mouse offspring after maternal gestational exposure to low doses of PFOA. Quist et al. (2015) evaluated hepatic effects in female CD-1 mouse offspring from dams dosed with 0.01 to 1 mg/kg/day PFOA on GD 1-17. Livers from offspring were evaluated on PND 21 (weaning) and PND 91. On PND 21, relative liver weight was significantly increased at 0.3 and 1 mg/kg/day, with no effect at 0.01 or 0.1 mg/kg/day, and PFOA treatment did not cause hepatocellular hypertrophy at any dose at this time point. In contrast, hepatocellular hypertrophy was significantly increased ( $p < 0.01$ ) at PND 91 in all dosed groups (0.01 mg/kg/day; NOAEL not identified), although the increased relative

liver weight observed at higher doses on PND 21 had been resolved. Additionally, dose-related hepatic periportal inflammation occurred in treated offspring on PND 21 and 91, and was more severe on PND 21 than on PND 91. On PND 21, the severity score for this effect was significantly ( $p < 0.05$ ) increased at all doses ( $\geq 0.01$  mg/kg/day) in a dose-related fashion, with no NOAEL identified. In this study, periportal inflammation was a more sensitive indicator of toxicity from prenatal exposure to PFOA than increased liver weight in female CD-1 mice.

Quist et al. (2015) also evaluated ultrastructural hepatic changes in control and highest dose (1 mg/kg/day) mice using transmission electron microscopy. Mitochondrial proliferation and abnormal mitochondrial morphology occurred in PFOA-treated mice at both PND 21 and PND 91 and was more severe at the later time point. Peroxisomes were present only in a single liver section from one treated animal and were closely associated with areas of mitochondrial proliferation in this section.

In summary, hepatocellular hypertrophy was observed by Quist et al. (2015) at low doses ( $\geq 0.01$ ) on PND 91, a time point when PFOA had almost completely been eliminated from the body and the transient increased relative liver weight observed at the higher PFOA doses on PND 21 had resolved. Although hepatocellular hypertrophy from PFOA in adult rodents has typically been associated with proliferation of peroxisomes or smooth endoplasmic reticulum, these changes were not seen in adult (PND 91) female mice after prenatal exposure to PFOA (1 mg/kg/day). Instead, hepatocellular hypertrophy was associated with mitochondrial proliferation and abnormal mitochondria. The significance of these observations is further discussed in the Mode of Action section.

Filgo et al. (2015) evaluated histopathological effects in the liver at age 18 months in female offspring of dams dosed during gestation. The study evaluated three strains of mice: CD-1, 129/Sv wild type, and 129/Sv PPAR-alpha null. CD-1 dams were dosed with PFOA at 0, 0.01, 0.1, 0.3, 1, and 5 mg/kg/day, and 129/Sv wild type and PPAR-alpha null dams were dosed with 0, 0.1, 0.3, 1, and 3 mg/kg/day. Findings related to non-neoplastic hepatic changes in CD-1 mice included significant dose-related trends for increased incidence of centrilobular hepatocyte hypertrophy, Ito cell hypertrophy, and oval cell hyperplasia, and for increased severity of chronic active inflammation. In the 129/Sv strains, non-neoplastic hepatic changes caused by PFOA were primarily observed in the PPAR-alpha null mice. These included increased incidence of bile duct hyperplasia, hyaline droplet accumulation in the bile duct, hematopoietic cell proliferation, and centrilobular hepatocyte hypertrophy. In the wild type 129/Sv mice, only severity of centrilobular hepatocyte hypertrophy was increased by PFOA treatment.

The incidence of liver tumors was also evaluated by Filgo et al. (2015) because of the unexpected finding of hepatic tumors in some animals that died before the scheduled end of the study. However, the authors emphasize that the study was not designed or intended to be a carcinogenicity bioassay. In CD-1 mice, single or multiple hepatocellular adenomas were found in one or more animals in each of the treated groups (n=21 to 37 per group) except for at the

lowest dose (0.01 mg/kg/day), but were not found in controls (n=29). In total, adenomas occurred in 4.9% (7 of 144) treated CD-1 mice, compared to a historic control incidence of 0.4% in untreated female CD- mice. Hepatocellular carcinomas occurred in two treated CD-1 mice (0.3 and 5 mg/kg/day) but not in controls. In 129/Sv wild type mice, hepatocellular adenomas did not occur in control or treated groups (n=6 to 10 per group). In PPAR-alpha null mice of this strain, in contrast, there were no adenomas in the controls (n=6), one adenoma in the 0.1, 0.3, and 1 mg/kg/day groups (n=9 or 10), and two adenomas at 3 mg/kg/day (n=9). These tumors occurred in 13.2% of all treated PPAR-alpha null mice. The significance of these findings is further discussed in the Mode of Action section below.

#### Serum liver enzymes and bile acids

Most toxicology studies of PFOA's effects on liver weight and histopathology did not assess serum levels of hepatic enzymes or bile acids. However, several studies in rodents have reported that these parameters were increased by PFOA, and these data are summarized below. As above, this summary does not represent a complete compilation of all data on these endpoints. These endpoints are of interest because they are indicative of hepatic damage, and because increased serum liver enzymes are associated with PFOA in human studies of the general population, communities with drinking water exposure, and workers (see Epidemiology section, above).

In the 90 day cynomolgus monkey study, ALT and AST were greatly elevated (about 10 to 50 times control levels) in two of the high dose animals that experienced toxicity from PFOA prior to the end of the scheduled dosing period (Butenhoff et al., 2002).

The liver enzymes alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were increased in all dose groups ( $\geq 0.49$  mg/kg/day) in a study of mice dosed with PFOA in drinking water for 21 days (Table 8). These increases were statistically significant ( $p < 0.05$ ) at  $\geq 2.64$  mg/kg/day for AST and  $\geq 17.62$  mg/kg/day for ALT (Son et al., 2008).

Table 8. Liver enzymes (relative to control) in serum of mice exposed to PFOA in drinking water for 21 days (Son et al., 2008)		
Dose (mg/kg/day)	ALT	AST
0	1	1
0.49	1.5	2.0
2.64	2.9*	1.5
17.62	4.2*	3.3*
47.21	5.2*	4.0*

\* $p \leq 0.05$ .

Numerical data for liver enzymes (mean  $\pm$  SD) are presented in Son et al. (2008).

PFOA caused dose-related increases in serum levels of four liver enzymes (ALT, AST, alkaline phosphatase, and lactic dehydrogenase [LDH]), as well as total bile acids, in male mice (Yang et al., 2014). The LOAEL for increased ALT was 2.5 mg/kg/day (the lowest dose in the study), while the LOAEL for increases in the other liver enzymes and total bile acids was 5 mg/kg/day. All parameters were increased to several-fold above control levels at 5 and/or 10 mg/kg/day.

Dose-related increases in ALT, AST, total bilirubin, and total bile acids occurred in both wild type and PPAR-alpha null mice treated with PFOA (Minata et al., 2010). For all of these parameters, the maximum increase at the highest dose was much greater in the PPAR-alpha null mice than in the wild type mice.

Nakagawa et al. (2011) also reported small but statistically significant increases in ALT in all three strains of mice (wild type, PPAR-alpha knockout, humanized PPAR-alpha) studied. The greatest increase was 2.3-fold in wild type mice given 5 mg/kg/day PFOA, with smaller increases in the PPAR-alpha null and humanized PPAR-alpha strains.

Liver enzymes (AST, ALT, GGT, and LDH) were significantly elevated on GD 18 in pregnant ICR mice dosed with 10 mg/kg/day PFOA on GD 1-17. AST and ALT were elevated at 5 mg/kg/day, but this effect was not significant, while no changes were observed at 1 mg/kg/day. (Yahia et al., 2010).

In a chronic rat study discussed below, ALT, AST, and alkaline phosphatase were increased in males in both low (1.3 mg/kg/day) and high dose (14.2 mg/kg/day) groups between 2 and 18 months of dosing, and in the high dose group after 24 months of dosing (Sibinski, 1987; Butenhoff et al., 2012). Butenhoff et al. (2012) conclude that these increases may result from the hepatic hypertrophy and/or “borderline chronic liver toxicity” caused by PFOA.

#### Detailed review of selected data for increased relative liver weight

Numerous studies have consistently reported that PFOA causes increased absolute and relative liver weight in laboratory animals. Increased relative liver weight is a sensitive endpoint for PFOA that co-occurs and/or can progress to more severe manifestations of hepatic toxicity. Data on increased relative liver weight from rodent studies that used relatively low doses (1 mg/kg/day or less), as well as the 90 day cynomolgus monkey study (Butenhoff et al., 2002), are summarized in Table 10. This group of studies includes five studies that provide data on serum PFOA levels at the end of the dosing period (Butenhoff et al., 2002; Lau et al., 2006; Loveless et al., 2006; Perkins et al., 2004; Macon et al., 2011) and six additional studies that do not include such serum data. Studies providing serum PFOA data at the end of the dosing period are most appropriate for dose-response evaluation in risk assessment, because serum levels are highest at this time point and thus represent the maximum internal doses that could have caused the observed effect. Detailed individual study tables are found in Appendix 5 for the five studies that provide relevant serum PFOA levels.



Rodent data on increased relative liver weight

Three studies (Perkins et al., 2004; Loveless et al., 2006; Loveless et al., 2008) evaluated effects in male rats exposed to APFO. Perkins et al. (2004) and Loveless et al. (2006) provide serum PFOA data useful for dose-response modeling, while Loveless et al. (2008) does not include serum PFOA levels. Individual study tables for the two rat studies that include serum data (Perkins et al., 2004 and Loveless et al., 2006) are found in Appendix 5.

APFO formulations containing differing isomeric compositions (linear/branched, linear, or branched) were used in the three male rat studies (Perkins et al., 2004; Loveless et al., 2006; Loveless et al., 2008). Both linear/branched and linear PFOA were produced industrially, while information on effects of the branched form, which was not produced industrially, contributes to the understanding of the toxicology and mode of action of PFOA. Perkins et al. (2004) evaluated effects of linear/branched PFOA for 4, 7, and 13 weeks, while Loveless et al. (2006) studied the effects of 2 weeks of exposure to the linear isomer, branched isomers, or a mixture of linear/branched isomers. Both of these studies evaluated absolute and relative liver weight, hepatic palmitoyl CoA oxidase activity (PCO; a marker of peroxisome proliferation), and serum PFOA levels at sacrifice. The third male rat study, Loveless et al. (2008) evaluated the linear isomer of PFOA and reported relative liver weight data after exposure for 29 days, but did not report serum PFOA levels or PCO activity. (Both Loveless et al., 2006, and Loveless et al., 2008, also evaluated male mice, discussed below.)

In Perkins et al. (2004), serum PFOA levels in rats reached steady state by 4 weeks. The dose-response curves for increased liver weight relative to body weight were almost identical at all three time points (4, 7, and 13 weeks), indicating that relative liver weight did not continue to increase over time with exposures longer than 4 weeks.

In the study evaluating the three PFOA formulations with differing isomer content (Loveless et al., 2006), serum PFOA levels from branched PFOA were lower than from the same doses of linear/branched or linear PFOA. This difference is likely to result from the more rapid excretion of the branched isomers (Benskin et al., 2009; DeSilva et al., 2009). The serum level LOAELs for male rats after 2 weeks of exposure to linear/branched PFOA reported by Loveless et al. (2006) are consistent with those from the longer exposure periods in Perkins et al. (2004). The serum level dose response curves for increased relative liver weight from linear/branched PFOA in these two male rat studies with differing exposure durations are also consistent at the lower serum PFOA levels (less than 75,000 ng/ml) and are generally similar at the higher serum PFOA levels. Additionally, the dose-response curves for male rats based on administered doses of linear PFOA in the 2-week study (Loveless et al., 2006) and the 29-day study (Loveless et al., 2008) are generally consistent; serum PFOA data are not provided in the 29-day study.

Effects in male mice from exposure for 2 weeks to the three isomeric formulations of PFOA were also studied by Loveless et al. (2006). The same parameters that were evaluated in rats were studied in the mice, including absolute and relative liver weight, hepatic PCO activity, and



serum PFOA levels at sacrifice. The dose-response curves for male mice based on administered doses of linear PFOA in the the 2-week study (Loveless et al., 2006) and the 29-day study (Loveless et al., 2008) were generally similar. However, as above, serum PFOA data are not provided in the 29-day study.

The LOAEL for increased in liver weight in male mice was 0.3 mg/kg/day (the lowest dose in the study) for the linear form and the branched form. The serum levels at this dose were 13,000 ng/ml for the linear form and 14,000 ng/ml for the branched form. These are the lowest serum level LOAELs that were identified for increased relative liver weight. The relative liver weight at this dose was 1.17 for the linear form and 1.19 for the branched form, compared to the controls. For linear/branched PFOA, the serum level at 0.3 mg/kg/day was 10,000 ng/ml, and relative liver weight was 1.19 compared to the controls (similar to the increase at 0.3 mg/kg/day for the other isomeric forms). However, this change was not reported to be statistically significant, and the authors reported 0.3 mg/kg/day as the NOAEL and 1 mg/kg/day as the LOAEL for the linear/branched mixture.

PFOA increased hepatic peroxisome proliferation (as indicated by PCO activity) in rats in Perkins et al. (2004) and in rats and mice in Loveless et al. (2006). Evaluation of these PCO data reveals that, in the standard strains of rodents used in these experiments, increased liver weight did not correlate well with this biochemical marker of hepatic peroxisome proliferation, particularly in mice. Additionally (as mentioned above), PFOA caused increased hepatic peroxisome proliferation (as indicated by PCO activity) in primates as well as rodents. These PCO data are informative in evaluating the role of PPAR-alpha activation in the increased liver weight caused by PFOA and are discussed in detail in the Mode of Action section below.

In another study that includes serum PFOA data from the end of the dosing period, pregnant mice were dosed on GD 1-17 with 1, 3, 5, 10, 20, or 40 mg/kg/day PFOA (Lau et al, 2006; Table 10; Appendix 5A). At sacrifice on GD 18, the serum level LOAEL for increased liver weight was 22,000 ng/ml (from an administered dose of 1 mg/kg/day) and a NOAEL was not identified (Lau et al., 2006). (Numerical data are not shown in publication and were provided by the investigator.)

A second study of pregnant mice evaluated liver weight and serum PFOA levels on PND 21 in wild type and PPAR-alpha null mice dosed throughout gestation (Abbott et al., 2007). The NOAELs and LOAELs for increased liver weight based on serum PFOA from this study are not comparable to those from the other studies because serum PFOA was evaluated 3 weeks after dosing ended.

Two additional studies in male (Son et al., 2008) or female (DeWitt et al., 2008) adult mice exposed to PFOA in drinking water for 15 or 21 days that did not report serum PFOA data are also included in Table 10. As shown in the table, LOAELs based on administered dose from

these studies are generally consistent with the other mouse studies discussed above. NOAELs were not identified in these studies.

Three studies included in Table 10 evaluated increased liver weight in mouse pups after developmental exposures to PFOA. One of these studies (Macon et al., 2011) evaluated liver weight in offspring on PND 1, 4, 7, 14, and 21 after maternal exposure on GD 10-17 (late gestation). This study provides serum PFOA data from PND 1, one day after gestational exposure ended. As shown in the detailed table for this study in Appendix 5B and in Table 12, delayed mammary gland development (LOAEL – 0.01 mg/kg/day) was a much more sensitive endpoint than increased liver weight (LOAEL – 1 mg/kg/day) in this study. In an additional component of this study with full gestational exposure (GD 1-17) to PFOA, serum PFOA levels were not measured. The LOAEL for increased liver weight on PND 7 was lower with the longer exposure period (GD 1-17) than for the late gestational (GD 10-17) exposure discussed above, consistent with the greater total dose from longer exposure.

Another study (Tucker et al., 2015) assessed relative liver weight on PND 21 and later time points in CD-1 and C57/Bl mouse pups after maternal exposure to 0.01 – 1 mg/kg/day PFOA on GD 1-17. As in Macon et al. (2011), delayed mammary gland development was a more sensitive endpoint than increased liver weight in this study.

Finally, Abbott et al. (2007) evaluated relative liver weight in wild type and PPAR-alpha null offspring, as well as maternal relative liver weight (above), on PND 21. In this study, the LOAEL for increased relative liver weight in wild type pups (0.1 mg/kg/day) was 10-fold lower than the maternal LOAEL (1 mg/kg/day), while the LOAEL for this effect in PPAR-alpha null mice was the same in pups and dams (3 mg/kg/day).

#### *Cynomolgus monkey data on increased relative liver weight*

Liver weight (absolute and relative to body weight) was increased in all treated groups in the 90-day study of cynomolgus monkeys (Appendix 5; Butenhoff et al., 2002). The increase in absolute liver weight was statistically significant ( $p < 0.01$ ) in all groups, but relative liver weight was significantly increased only in the high dose group. However, this analysis did not include the animals sacrificed during the study due to overt toxicity. The absolute and relative liver weight in the sacrificed low dose monkey was far higher than the others in its group, and inclusion of data for this animal increases the mean value for these parameters in the low dose group. Liver-to-brain weight ratio is considered to be a reliable measure of effects on liver weight, because brain weight tends to remain stable when body weight changes. This ratio was increased in all treated groups compared to controls, with statistical significance at the two lower dose levels, but there was no dose-response based on either administered dose or serum level. As discussed above, serum PFOA levels did not differ significantly between the low and mid dose groups (Butenhoff et al., 2004c).

The data from Butenhoff et al. (2002) are not informative as to the dose-response curve or the NOAEL for PFOA's effects on increased liver weight in this species of monkey, because this effect did not increase with either administered or internal dose. Additionally, mortality of one of four animals at the lowest dose was possibly treatment-related, and four of the six high dose monkeys did not complete the study because of overt toxicity or mortality.

Comparison of the relative liver weight and serum PFOA level data from the 90 day cynomolgus monkey study and the rat studies (Perkins et al., 2004; Loveless et al., 2006) reveals similar increases in liver weight at comparable serum levels in both species. Additionally, comparable increases in PCO activity occurred at similar serum PFOA levels in monkeys and rats (discussed further in Mode of Action section). These data suggest that cynomolgus monkeys and rats have similar sensitivity to the hepatic effects of PFOA.

### **Immune system effects in rodents and non-human primates**

PFOA causes suppression of the immune response in experimental animals. As discussed in the Epidemiology section, decreased response to vaccinations has been associated with PFOA in humans. Toxicological studies that evaluated effects of oral exposure to PFOA on the immune system in rodents are summarized in Table 13. Sixteen publications of such studies were identified. Of these, 14 publications report only studies of mice, one publication reports only studies in rats, and one publication includes studies in both species. Both of the rat studies, and 11 of the 15 mouse studies, were conducted in males, while two of the mouse studies evaluated adult females, and two of the mouse studies evaluated effects of developmental exposures on offspring. Additionally, effects on the immune system were reported in the 90-day oral study of rhesus monkeys (Goldenthal, 1978). Studies of effects on the immune system from dermal exposure to PFOA are not reviewed in this document. Toxicological effects on the immune system are of particular interest because PFOA and other PFCs have been associated with decreased vaccine response in humans (see Epidemiology section).

#### Non-human primates

In the 90-day rhesus monkey study (Goldenthal, 1978), histopathological changes related to the immune system occurred in all animals in the two higher dose groups (30 and 100 mg/kg/day). All animals in these two dose groups had slight to moderate hypocellularity of the bone marrow and moderate atrophy of lymphoid follicles in the spleen, and one 30 mg/kg/day female and all 100 mg/kg/day animals had moderate atrophy of the lymphoid follicles in the lymph nodes. These changes were not seen in the lower dose groups (3 and 10 mg/kg/day). Because serum PFOA levels are not provided in this study, it cannot be used for dose-response in risk assessment.

#### Rodents

PFOA consistently suppressed the immune system in studies of mice (Table 13). Effects in mice include decreased absolute and relative spleen and thymus weights, decreased thymocyte and splenocyte counts, decreased immunoglobulin response, and changes in total numbers and/or

specific populations of lymphocytes in the spleen, thymus, peripheral blood, and bone marrow. The available data indicates that rats are less sensitive than mice to immunotoxic effects of PFOA, since immune system effects were not observed in the two studies that have been conducted in rats. These rat studies included doses higher than those which generally caused immune effects in mice.

Relative liver weight was evaluated along with immune parameters in nine of the 13 studies of adult mice. In all of these nine studies, the LOAEL for increased relative liver weight was the same or lower than the LOAEL for immune system effects. As shown in Table 13, the lowest dose at which immune effects were clearly demonstrated in mice is 0.49 mg/kg/day in a 21-day drinking water study, with no NOAEL reported (Son et al., 2009). Increased liver weight also occurred at this dose in this study, as reported in the accompanying paper (Son et al., 2008). Therefore, the data available at this time suggest that increased relative liver weight is an endpoint that is as sensitive as or more sensitive than immune system effects in rats and mice. For this reason, immune system effects from toxicology studies were not used as the basis for the dose-response in this risk assessment, and individual study tables are not provided for these studies.

## **Reproductive and Developmental Effects**

### Overview

As discussed in the Pharmacokinetics section (above), PFOA exposures in the developing human fetus are similar to those experienced by the mother, and neonatal exposure from breast-feeding or consuming formula prepared with contaminated drinking water is much higher than in the mother or other older individuals using the same drinking water source. As discussed in the Epidemiology section, prenatal exposure to PFOA is associated with decreased birth weight in human epidemiology studies (Johnson et al., 2014).

Reproductive or developmental effects of PFOA have not been studied in non-human primates. Prior to 2006, the reproductive and developmental effects of PFOA had been studied only in rats and rabbits. These species are not the most appropriate models for evaluation of the potential for human reproductive and developmental effects of PFOA because the half-life of PFOA in female rats and female (as well as male) rabbits is only a few hours (see Table 4 in Toxicokinetics section). Because of this rapid elimination, serum levels from a given dose of PFOA in females of these species are much lower than in other species with long half-lives, such as mice and humans, and PFOA does not reach steady state in females of these species with daily dosing by gavage.

Beginning in 2006, the reproductive and developmental toxicity of PFOA has been studied in mice. The mouse is a more appropriate species for evaluating the potential human effects of PFOA on reproduction and development, since the female mouse excretes PFOA slowly and steady state is achieved with continued dosing. As discussed in detail below, effects observed in mice include full litter resorptions, decreased postnatal survival and growth, delayed development, and accelerated sexual maturation in males. More recent studies have found that

delayed mammary gland development is caused by developmental exposure to doses as low as 0.01 mg/kg/day.

In this section, the mouse studies of developmental and reproductive effects from gestational dosing with PFOA are presented in Table 12 and discussed in the text. This is followed by a detailed discussion of effects of developmental exposures to PFOA on mammary gland development, the most sensitive developmental endpoint with serum data appropriate for dose-response modeling. Summaries of additional studies of effects of pre-pubertal exposure to PFOA on reproductive organs in female mice, and of reproductive effect in male mice, are then presented. Finally, the studies of developmental and reproductive effects in rats and rabbits that were conducted prior to the mouse studies are summarized.

### Mouse developmental studies

#### Summary of study designs

Table 12 summarizes data on reproductive and developmental effects from gestational and/or lactational exposure to PFOA in mice. Sixteen publications reporting such studies are included in the table. Several of these publications include multiple studies with different exposure protocols, in one case, different aspects of the same study are described in two publications (Wolf et al., 2007; White et al., 2009). In total, 18 separate studies, three of which used multiple strains of mice, are reported. Most but not all of the studies assessed both maternal/reproductive endpoints and developmental endpoints in the offspring. The table includes the six publications that evaluated developmental effects of PFOA on mammary gland development in the dam and/or the female offspring, as well as other endpoints. Effects on mammary gland development are further discussed in detail in a separate section below.

Several additional studies of effects of gestational dosing with PFOA are not included in the Table 12 because they did not evaluate standard reproductive or developmental endpoints and/or because they used non-standard exposure protocols. These papers are discussed elsewhere in this document. These include two studies of histopathological changes in the livers of mice in adulthood after low dose developmental exposures (Filgo et al., 2015; Quist et al., 2015), a study of intestinal tumorigenesis in wild type and genetically susceptible strains of mice (Ngo et al., 2014), and three studies of neurobehavioral effects at age 5-8 weeks in offspring of dams dosed during gestation (Johansson et al., 2008; Onishchenko et al., 2011; Sobolewski et al., 2014).

Most (11 of 16) of the studies in Table 12 used CD-1 mice, three used C57Bl/6 mice, one study (Tucker et al., 2015) used both strains, and one study used ICR mice (Yahia et al., 2010). Two studies included strains of mice with differing PPAR-alpha status (wild type, null, and/or humanized) and are discussed in more detail in the Mode of Action section.

In most of the studies (13), dosing was by oral gavage, while one study used drinking water exposure (Hu et al., 2010), one study used drinking water exposure with or without additional

gavage exposure in some, but not all, dose groups (White et al., 2011b), and one study used dietary exposure (van Esterik et al., 2016).

In most of the studies (10), the dams were dosed with PFOA throughout gestation, and postnatal development of the offspring was assessed. However, other protocols were used in some studies. In two studies (Hu et al., 2012; van Esterik et al., 2016), maternal dosing began before mating and continued until weaning. In other studies, the dosing period was shorter than the full period of gestation. Fenton et al. (2009) was primarily a pharmacokinetic study of a single dose of PFOA administered on GD 17 and is included because offspring body weight was assessed. In several other studies, PFOA was administered for only a portion of gestation (Hu et al., 2010, GD 6-17; Macon et al., 2011 “late gestation study”, GD 10-17; Suh et al., 2011, GD 11-16; White et al., 2007 “restricted exposure study”, GD 1-17, 8-17, and 12-17; Wolf et al., 2007, “restricted exposure study”, GD 7-17, 10-17, 13-17, and 15-17). Two studies, one with exposure on GD 8-17 (White et al., 2009) and one with exposure on GD 1-17 (Wolf et al., 2007; White et al., 2009) used a cross-fostering protocol in which offspring were exposed during gestation and/or lactation. In these studies, treated dams were dosed during gestation. The dams that were not dosed but fostered pups from dosed dams were exposed to PFOA via grooming of the pups and ingestion of excreted pup urine and feces. One study (White et al.; 2011b) was a multi-generation study in which effects on three generations were evaluated (P0, F1, and F2). Effects on P0 dams and F1 offspring are shown in Table 12; complete information on the study is presented in the section on mammary gland development (below).

Most of the studies (15) assessed both maternal/reproductive endpoints and endpoints of postnatal developmental in the offspring, although the specific endpoints that were evaluated differed among studies. Only two of the studies evaluated malformations at birth. These were Lau et al. (2006), which also evaluated postnatal development, and Yahia et al. (2010). Two studies (Macon et al., 2011, and Tucker et al., 2015) assessed effects in the offspring, but not maternal or reproductive effects. Several studies focused on specific effects in addition to standard developmental endpoints or mammary gland development. Hines et al. (2009) evaluated effects in female offspring of developmental exposures on body weight and hormones (insulin and leptin) in adulthood. Hu et al. (2010) and Hu et al. (2012) assessed effects of developmental exposures on immune endpoints at age 7 to 9 weeks and are also included in the summary table of immune effects (Table 13). Finally, Suh et al. (2011) focused on placental toxicity and other reproductive endpoints, and did not evaluate the offspring.

Two additional studies assessed the effects of pre-pubertal exposure to PFOA on the reproductive system in female mouse pups (Dixon et al., 2012; Yao et al., 2014). These are not included in the table and are discussed in the text later in this section.

#### Maternal and reproductive effects

PFOA caused reproductive effects in mice including increases in full litter resorptions (Abbott et al., 2007), increased litter loss, prenatal loss per live litter, or fetal resorptions/dead fetus (Abbott



et al., 2007; Lau et al., 2006; Suh et al., 2011; White et al., 2007; White et al., 2011b), and decreased number of live fetuses per litter or decreased litter size (Lau et al., 2006; Suh et al., 2010; van Esterik et al., 2016; Wolf et al., 2007; White et al., 2011b). In all of these studies, one or more of these reproductive effects occurred at doses below those which caused decreased maternal weight gain, an indicator of general maternal toxicity.

PFOA caused toxicity to the placenta, including decreased placental weight, decreased fetal/placental weight ratio, and decreased expression of genes for prolactin family hormones (hormones that support fetal growth and nutrition), after treatment on GD 11-16 at the lowest dose tested, 2 mg/kg/day (Suh et al., 2011). Higher doses caused placental necrosis and reduced numbers of placental trophoblast cells. These results suggest that placental toxicity may contribute to the increased number of dead fetuses/decreased number of live fetuses and decreased fetal growth observed in this and other developmental studies of PFOA.

Effects on maternal relative liver weight and maternal mammary gland development are discussed below.

#### *Effects in Offspring: Fetal through Weaning*

##### *Fetal teratology*

Two studies evaluated fetal teratology. In CD-1 mice, gestational exposure to PFOA caused reduced ossification of phalanges, limb and tail defects, and microcardia at doses below those which affected maternal weight gain (Lau et al., 2006). Reduced ossification of proximal phalanges of both the forelimb and the hindlimb was significantly increased at the lowest dose used (1 mg/kg/day) but was not significantly increased in some higher dosed groups. This effect represents a delay in timing of development rather than a permanent structural change, since the phalanges developed normally in mice treated with PFOA that were not sacrificed prior to delivery in this study (personal communication with C. Lau). Ossification at other sites (caudal vertebrae, metacarpals, and metatarsals) was delayed only at a much higher dose (20 mg/kg/day) which also caused maternal and reproductive toxicity.

In ICR mice, gestational exposure to PFOA caused increased incidence of cleft sternum, delayed ossification of phalanges, and delayed incisor eruption. The LOAEL and NOAEL for increased incidence of cleft sternum, delayed ossification of phalanges, delayed incisor eruption were 10 mg/kg/day and 5 mg/kg/day, respectively (Yahia et al., 2010). In this study, maternal weight gain, fetal weight, and pup survival until PND 4, were significantly decreased at dose(s) below the LOAEL for increased cleft sternum, delayed ossification, and delayed incisor eruption. No pups survived until PND 4 at 10 mg/kg/day, the LOAEL for delayed ossification.

##### *Birth weight, and growth and postnatal development until weaning*

PFOA caused decreased body weight at birth, postnatal mortality, reduced postnatal growth until weaning, and delayed development (as indicated by day of eye opening) in mice. As shown in Table 12, one or more of these effects was reported by Abbott et al. (2007), Hines et al. (2009),



Hu et al. (2010), Hu et al. (2012), Lau et al. (2006), Tucker et al. (2015), van Esterik et al. (2016), White et al. (2007), White et al. (2009), Wolf et al. (2007), White et al. (2011b), and Yahia et al. (2010). Exposure during only the latter part of gestation (GD 15-17) was sufficient to cause decreased body weight at birth, increased postnatal mortality, and decreased postnatal growth (Wolf et al., 2007). Furthermore, decreased postnatal growth resulted from either gestational or lactational exposure, as shown by the results of the cross-fostering study by White et al. (2009).

Effects on relative liver weight and mammary gland development during the period from birth until weaning are discussed below.

#### Effects in Offspring: Post-Weaning

In studies which continued to assess offspring during the post-weaning period, effects at these later time points were observed in some studies (summarized below) but not in others (e.g. no effect on body weight in Abbott et al., 2007, or on immune parameters in Hu et al., 2012).

In the restricted exposure component of Wolf et al. (2007), developmental exposure to 5 mg/kg/day PFOA beginning on GD 10 caused decreased body weight in male offspring until age 10-11 weeks. In the cross fostering study component of the same publication, body weight remained decreased until PND 36 in male offspring after *in utero* and lactational exposure to 5 mg/kg/day PFOA, and until PND 85 in females exposed to the same dose *in utero* even without postnatal exposure from breastmilk.

Markers of sexual maturation (vaginal opening and first estrus) were delayed in female CD-1 mouse offspring with gestational exposure to PFOA. However, sexual maturation (preputial separation) in male offspring was accelerated by PFOA exposure, despite the fact that PFOA caused decreased body weight at 6.5 weeks of age (Lau et al., 2006). Notably, acceleration puberty in males did not follow a typical dose-response curve. The greatest acceleration occurred at the lowest dose (1 mg/kg/day) with a smaller effect at each increasing dose. At the highest dose (20 mg/kg/day), puberty was delayed rather than accelerated.

Body weight and hormone (insulin and leptin) levels were increased in early adulthood (20-29 weeks) in CD-1 mice with gestational exposure to low doses (0.01 to 0.1 mg/kg/day for obesity; 0.01 to 0.3 mg/kg/day for hormones) but not at higher doses. In this study, body weight at birth or early in life was not affected by the low doses that caused increased body weight later in life (Hines et al., 2009). In contrast, Ngo et al. (2014) found no effect on body weight at age 12-20 weeks in male or female wild type or Min/+ (a strain susceptible to intestinal tumorigenesis) C57Bl/6 mice offspring of dams dosed with 0.01, 0.1, and 3 mg/kg/day PFOA during gestation. These studies are of interest because several epidemiology studies evaluated associations of prenatal and/or early life PFOA exposure with parameters associated with increased body weight in childhood or adulthood. Three studies found associations of maternal serum PFOA levels during pregnancy with increased risk of overweight/obesity and changes in metabolic hormones

in young women (Halldorsson et al., 2012), more rapid weight gain in girls (Maisonet et al., 2012), or greater adiposity and more rapid increase in BMI in childhood (Braun et al., 2016), while two studies did not find such an association with prenatal or early childhood exposure to PFOA (Andersen et al., 2013; Barry et al., 2014).

Splenic T cells were decreased at age 6 weeks in C57Bl/6 mice exposed gestationally to 2 mg/kg/day PFOA, with no effect at 0.2 mg/kg/day (Hu et al., 2012). The NOAEL and LOAEL for this effect were the same as for decreased body weight gain on PND 1-21, suggesting that the immune system effect from developmental exposure was not a more sensitive endpoint than other developmental effects in this study.

Effects on relative liver weight and mammary gland development during the post-weaning period are discussed below.

#### Relative liver weight

Increased relative liver weight is a sensitive toxicological endpoint for PFOA. This effect was evaluated in dams and/or offspring in 12 of the 18 mouse developmental studies summarized in Table 12. Maternal relative liver weight was assessed at delivery in three studies, between delivery and weaning in two studies, and at weaning in five studies. In offspring, relative liver weight was evaluated at birth in two studies, between birth and weaning in three studies, at weaning in five studies, and post-weaning in five studies.

The NOAELs and LOAELs for increased relative liver weight in dams and/or offspring and for other reproductive and developmental effects are presented in Table 12. (*Note:* Fenton et al., 2009, is not included in this table because no effects were seen at the single dose used.) In all studies except one (Hu et al., 2010), the LOAEL and/or NOAEL for increased relative liver weight in the dam and/or the offspring is the same or lower than the LOAEL and/or NOAEL for reproductive developmental effects (other than delayed mammary gland development). In Hu et al. (2010), offspring liver weight was evaluated on PND 48 and PND 63; these are post-weaning time points at which PFOA was almost totally eliminated from the body. These data indicate that increased relative liver weight (maternal and/or offspring) is an endpoint for PFOA toxicity in mice that is as sensitive or more sensitive than most of the other reproductive and developmental effects that were evaluated, with the exception of delayed mammary gland development which is discussed below.

#### **Mammary gland development**

##### Background information on mammary gland development as a toxicological endpoint

Because the developmental patterns of the mammary gland are similar in humans and rodents, rodents provide a good model for studying the effects of environmental contaminant on human mammary gland development (Rudel and Fenton, 2009; Fenton et al. 2012; Rudel et al., 2011; Fenton and Birnbaum, 2015; Osborne et al., 2015). The development of the mammary gland in

these species involves a complex series of events that is regulated by a balance of hormones, growth factors and stromal factors (Osborne et al., 2015; Gore et al., 2015). Agents that affect any of these steps can interfere with the normal process of mammary gland development, and this process is particularly sensitive to effects of endocrine disrupting chemicals, including environmental contaminants such as bisphenol A, atrazine, and dioxin (Gore et al., 2015; Fenton and Birnbaum, 2015; Fenton et al., 2012; IOM 2011; Rudel et al., 2011). As reviewed in detail below, adverse effects on mammary gland development are sensitive toxicological endpoints for PFOA, and a NOAEL for these effects has not been identified.

The mammary gland is most sensitive to the effects of toxic substances during critical periods when development occurs including fetal, neonatal, puberty, and pregnancy (Gore et al., 2015; Osborne et al., 2015), while the mammary glands of non-pregnant adult females may not be affected by the same exposures. Adverse effects on the mammary gland from early life exposures can include accelerated or delayed development (Macon and Fenton, 2013; Osborne et al., 2015), and effects of the same chemical on mammary gland development may vary depending on the life stage when exposure occurs (Osborne et al., 2015). These disruptions of mammary gland development may result in adverse effects later in life including impaired lactation and increased cancer risk (Fenton 2006; IOM, 2011; Rudel et al., 2011; Fenton et al., 2012).

The mammary gland is distinct from other tissues in that it undergoes a significant portion of its development postnatally; in addition to the fetal/neonatal period, puberty and pregnancy are critical periods of mammary gland development (Osborne et al., 2015). The mammary gland grows and differentiates slowly during embryonic and juvenile life and does not mature until after puberty. Mammary gland development in rodents has been reviewed by Sakakura (1987) and Daniel and Silberstein (1987) and in humans by Russo and Russo (1987) and Howard and Gusterson (2000).

The mammary gland is an organ that is unique to the class *Mammalia*, and its embryonic, postnatal, and adult development is highly conserved between species. Mammary gland development in humans and rodents takes place at a similar biological pace, although the absolute timeframes differ (Table 12 and Figure 10, both from Fenton, 2006). The description of mammary gland development below is taken from concise summaries provided by Osborne et al. (2015) and Fenton et al. (2012).

In rodents and humans, mammary gland development begins with the formation of the mammary, or milk line, during embryonic development. This structure separates into individual placodes (areas of thickening of the ectodermal layer), each of which develops into a ductal tree that embeds in a fat pad to form the mammary bud. Although there are slight timing differences in mammary gland development among species, ductal branching begins during the prenatal period in both rodents and humans. Subsequent to the fetal/neonatal period, there is little epithelial growth until puberty. During puberty, exponential growth of the female mammary

gland occurs for several weeks in rodents and several years in humans. During puberty, the fat pad rapidly fills with epithelial cells to become the adult form of the gland. The epithelium develops bundles of ducts, which then form club-like structures, called terminal end buds (TEB) in humans. Each TEB cleaves into alveolar buds and sprouts into ductules, forming a structure called the terminal ductal lobular unit. In rodents, TEBs are the sites of future ductal branching and disappear as the gland differentiates, and they are the structures considered to be most functionally equivalent to the terminal ductal lobular unit in humans. TEBs are particularly susceptible to the effects of carcinogens, and it has been suggested that “factors that lengthen the period when TEBs are present lengthen the period during which the mammary gland is susceptible to carcinogens (Osborne et al., 2015).” After puberty, the mammary gland remains in a resting state until pregnancy occurs. During pregnancy, the gland undergoes another period of rapid differentiation, involving branching and the development of lobulo-alveoli to prepare for lactation.

Developmental Event	Human	Rodent
Milk Streak Evident	EW4-6	GD10-11 (mice)
Mammary Epithelial Bud Forms	EW10-13	GD12-14 (mice), GD14-16 (rat)
Female Nipple and Areola Form	EW12-16	GD18 (mice), GD20 (rat)
Branching and Canalization of Epithelium	EW20-32	GD16 to birth (mice, GD18 to birth (rat)
Secretion is Possible	EW32-40 (ability lost Postnatally)	At birth, with hormonal stimuli
Isometric Development of Ducts	Birth to Puberty	Birth to Puberty
TEBs Present (Peripubertal)	8 to 13 yr old girls	23-60 d old (rat)
Formation of Lobular Units	EW32-40, or within 1-2 yr of first menstrual cycle	Puberty and into Adulthood

EW – embryonic week; GD – gestation day




Figure 10. Timeline of critical periods of mammary gland development and potential effects of endocrine disrupting compounds on mammary gland development (Fenton, 2006).

Effects on mammary gland development in rodents are commonly assessed by evaluation of “whole mounts”. In this approach, the entire fourth and/or fifth abdominal mammary gland fat pad is mounted flat on a slide, fixed, stained, defatted, and permanently affixed to the slide.

Whole mounts are assessed microscopically for parameters such as numbers of mammary terminal ductal structures (i.e., TEBs, terminal ducts, alveolar buds, and lobules), extension of the epithelial cells through the fat pad, and branching patterns and density at different times during development branching (Rudel et al., 2011). Whole mounts were evaluated in the nine studies of the effects of PFOA on mammary gland development in mice described below, and tissue sections stained with hematoxylin and eosin (H&E) were also examined in some of these studies. Effects on mammary gland development are reported as overall age-adjusted developmental scores based on a number of parameters and/or as quantitative values for specific parameters.

#### Effects of PFOA on mammary gland development in mice

Delayed mammary gland development in mice is a sensitive toxicological endpoint that is considered relevant to humans because developmental patterns are similar in both species. Nine publications have reported the effects of PFOA on mammary gland development in mice, and some of these publications include multiple studies. These studies are summarized in Table 16, and details of each study are provided in an individual study table for each publication in Appendix 5. Information related to the mode of action of PFOA's effects on mammary gland development is reviewed in the Mode of Action section, below.

#### Studies of effects of maternal and fetal/neonatal exposure to PFOA

Six publications evaluated effects of PFOA exposure during gestation and/or lactation on mammary gland development. Studies presented in these publications are summarized in Table 16A, and details for each study are provided in Appendix 5. Some of these publications include multiple studies, and, in total, ten separate studies were reported. Nine of these studies reported delayed mammary gland development, and one reported no effect on mammary gland development. Five of these publications report studies in CD-1 mice (White et al., 2007, three studies; White et al., 2009, two studies; Macon et al., 2011, two studies; White et al., 2011b; Tucker et al., 2015), and one of these also includes C57Bl/6 mice (Tucker et al., 2015). The sixth publication evaluated wild type, PPAR-alpha null, and PPAR-alpha humanized mice of the Sv/129 genetic background (Albrecht et al., 2013). Nine of the ten studies evaluated female offspring, and four of the studies (White et al., 2007; White et al., 2009; White et al., 2011b) evaluated pregnant and/or lactating dams.

#### Effects on structure of the mammary gland development

PFOA exposure during critical developmental periods (fetal, neonatal, pregnancy, and lactation) caused delayed mammary gland development in both lactating dams (White et al., 2007; White et al., 2009; White et al., 2011b) and pups (White et al., 2007; White et al., 2009; Macon et al., 2011; White et al., 2011b; Tucker et al., 2015), while even a high dose (5 mg/kg/day) did not affect mammary gland development in non-pregnant adult female mice (White et al., 2007).

As shown in the comparison of LOAELs and NOAELs for mammary gland development and other endpoints in Table 12, mammary gland development was a more sensitive endpoint for PFOA than other effects found in dams and pups in mouse developmental studies including

reproductive endpoints (number of fetuses per litter, prenatal loss, prenatal survival), pubertal markers (day of vaginal opening or day of first estrus; Tucker et al., 2015), estrogen or progesterone levels (Tucker et al., 2015), body weight, or liver weight (Macon et al., 2011; Tucker et al., 2015).

#### Lactating dams

Delayed mammary gland development occurred in lactating dams after dosing with PFOA during gestation (White et al., 2007; 2009; 2011b) or from exposure via treated pups (White et al., 2009). At the end of pregnancy just prior to initiation of nursing (GD 18; White et al., 2007) and on PND 1 after one day of nursing (White et al., 2009), mammary glands of treated dams were not saturated with milk filled alveoli, as is normally seen, but rather exhibited stunted, immature development. On PND 10, normally the peak of lactation, mammary glands from treated mice were delayed in development and resembled those normally seen earlier in lactation (White et al., 2007; 2009). On PND 20-22, mammary glands from treated dams had milk-filled alveoli and resembled normal mammary glands at the peak of lactation on PND 10, instead of the normal involution that occurs at weaning, indicating delayed development of up to 10 days (White et al., 2007; 2011b).

#### Female offspring

Delayed mammary gland development occurred in female pups in both CD-1 and C57Bl/6 strains (Tucker et al., 2015). In CD-1 mice, the mammary gland developmental score was significantly decreased compared to controls at all doses including the lowest dose (0.01 mg/kg/day). In C57Bl/6 mice, the developmental score was decreased compared to controls at all doses at both timepoints assessed (PND 21 and PND 61). However, this difference was not statistically significant at the two lowest doses (0.01 and 0.1 mg/kg/day), but was significant at 0.3 and 1 mg/kg/day. Serum PFOA levels in C57Bl/6 pups were lower than in CD-1 pups at the same administered dose. Lack of statistical significance in C57Bl/6 offspring at the two lowest doses may be due to the lower serum PFOA levels and/or small number of animals in the two lower dose groups for this strain (n=2-5 per dose group) as compared to CD-1 mice (n=8-22 per dose group), rather than differences in intrinsic sensitivity to effects of PFOA on mammary gland development in the two strains mice (Tucker et al., 2015). It should be noted that the LOAELs in female offspring for other well-established developmental effects of PFOA (decreased body weight and increased relative liver weight, both on PND 21) were also higher in C57Bl/6 mice than in CD-1 mice in this study, possibly due to the factors mentioned above.

PFOA is found in breast milk after maternal exposure in both rodents and humans, resulting in lactational exposure to offspring (reviewed in Post et al., 2012; also Mogensen et al., 2015). Cross-fostering studies in which pups with no prenatal exposure were exposed via breast milk from exposed dams, and pups with prenatal exposure were fostered by untreated dams, show that delayed mammary gland development results from exposure during gestation, lactation, or both. Significant delays in mammary gland development occurred as early as PND 1 in non-gestationally exposed pups nursing from treated dams for only 12-24 hours, and as early as PND



3 in non-gestationally exposed dams nursing treated pups. The exposure in these dams was only through maternal behavior such as ingestion of treated pups' waste and grooming of treated pups (White et al., 2009).

In White et al. (2009), effects on the mammary gland persisted in exposed offspring until 18 months of age, long after PFOA had been eliminated from the body; these effects are considered to be permanent. Although the study was not designed to quantitatively evaluate mammary gland development in older animals, epithelial density appeared to be reduced in the mammary glands of exposed animals at 18 months. An increase in the number of unusual darkly staining foci per gland of approximately 5-fold was also seen at 18 months in the mammary glands of exposed mice. According to the authors, these foci appeared to result from hyperplasia of ductal epithelium, infiltration of inflammatory cells into ductal regions, increased stromal density surrounding the ducts, and/or inappropriate differentiation of the ductal epithelium. Gore et al. (2015) notes that abnormalities of this type can be associated with increased breast cancer risk.

Mammary gland development, as assessed on PND 21 by overall developmental score, number of terminal end buds, and other measures of mammary gland development, was delayed in a dose-related fashion in CD-1 mouse pups after late gestational exposure (GD 10-17) to doses lower than those used in earlier studies (Macon et al., 2011). The LOAEL was 0.01 mg/kg/day, with no NOAEL identified. These effects occurred at serum PFOA levels of 285 ng/ml or below, lower than the mean serum level (371 ng/ml) in a community exposed to highly contaminated drinking water (Emmett et al., 2006a).

In a multi-generation study of CD-1 mice exposed to 5000 ng/L (5 µg/L) PFOA in drinking water, mammary gland development was delayed in both F1 dams (PND 22) and F1 female pups (PND 22, 42, and 63) at serum levels relevant to human environmental exposures (White et al., 2011b). Pups were significantly affected at serum levels as low as 21.3 ng/ml on PND 22 (compared 0.6 ng/ml in controls at this time point). This serum level is below the mean serum level of 28 ng/ml in the six Ohio and West Virginia communities with contaminated drinking water that comprise the C8 Health Study population, and is within about 10-fold of the mean and 4-fold of the 95<sup>th</sup> percentile serum levels in the U.S. general population (CDC, 2015). This serum level would be expected in humans with ongoing exposure to drinking water concentrations of approximately 200 ng/L (0.2 µg/L), based on the serum:drinking water ratios discussed above.

In contrast to the delays in mammary gland development observed in CD-1 and C57Bl/6 mice in the five studies discussed above, no significant effects on mammary gland development were found in wild type, PPAR-alpha null, or humanized PPAR-alpha Sv/129 mouse pups exposed gestationally to 3 mg/kg/day PFOA (Albrecht et al., 2013). This is the only study of mammary gland development in these strains. Albrecht et al. (2013) report that postnatal lethality occurred in the wild type mice, but not in the PPAR-alpha null or humanized PPAR-alpha mice. They conclude that the study confirms the PPAR-alpha dependent postnatal lethality of PFOA



previously reported by Abbott et al. (2007). However, several problematic issues with this study limit the consideration of its results:

- Although postnatal lethality in wild type mice treated with 3 mg/kg/day (the only dose used in the study) on PND 20 was reported as statistically significant ( $p < 0.05$ ), this conclusion appears to be based on an inappropriate statistical comparison. In evaluating postnatal lethality, the number of pups per litter on PND 20 in the control and PFOA-treated groups of wild type mice were compared. However, this comparison does not appear to be valid because the control and PFOA treated litters initially had different numbers of pups on PND 0. The appropriate evaluation of this parameter is a comparison of the number of pups within the same litter on PND 0 and PND 20 (i.e. percent mortality within the litter between PND 0 and PND 20). In wild type pups, 96% of controls and 70% of PFOA-treated survived from PND 0 to PND 20. From the analysis presented, it is unclear whether postnatal lethality is actually significantly increased by PFOA in wild type pups. For this reason, the basis for the conclusion that wild type, but not humanized PPAR-alpha, mice are sensitive to developmental effects of PFOA is uncertain.
- An important concern is that Albrecht et al. (2013) state that elevated PFOA levels (up to > 1000 ng/ml) were found in liver and serum from some control fetuses, pups, and dams. However, no further information such as which groups of animals these samples came from, how many samples had elevated PFOA concentrations, or statistical data for serum levels in the control samples is provided. Importantly, data from control animals with elevated PFOA exposures do not appear to have been excluded in the comparisons of endpoints of toxicity in control and treated groups. Inclusion of these data from the control animals could have affected the results of these comparisons, especially since serum levels in some of the treated groups were only a few fold higher than those in some of the controls.
- Developmental effects observed in the same strain of mice (SV/129) in another study (Abbott et al., 2007) at lower doses (0.6 and 1 mg/kg/day) were not observed at the higher dose (3 mg/kg/day) used by Albrecht et al. (2013). Abbott et al. (2007) observed significantly increased postnatal lethality in wild type pups exposed gestationally to 0.6 and 1 mg/kg/day PFOA. Additionally, eye opening was significantly delayed in the 0.6 and 1 mg/kg/day wild type pups in Abbott et al. (2007), but not at 3 mg/kg/day in Albrecht et al. (2013).
- Although both studies used SV/129 mice, Albrecht et al. (2013) obtained them from NIH and Abbott et al. (2007) obtained them from Jackson Laboratories. Albrecht et al. (2013) suggest that pharmacokinetic differences in the wild type mice from the two different sources may explain the differences in effects of PFOA in these mice in the two studies. However, a close review of the data from the two studies (Table 3 of Abbott et al., 2007; Figure 10 of Albrecht et al., 2013) indicates that the serum levels in wild type pups in Albrecht et al. (2013) at which no developmental effects occurred were higher than the

serum levels in wild type pups at which delayed eye opening and postnatal mortality were reported by Abbott et al. (2007). Furthermore, the serum PFOA data for wild type dams on PND 20 appear to be inconsistent within the publication. Maternal serum levels in wild type dams on PND 20 are stated to range from 2066 – 6812 ng/ml, and no statistical parameters (e.g. median, mean, S.D.) are provided. However, the estimated serum level from the bar graph of maternal serum levels is 6700 $\pm$ 3600 in the wild type dams (higher than what would be expected from the range provided in the text).

In summary, no effect of PFOA on mammary gland development was reported in pups from the three strains on PND 20; this is the only study that evaluated PFOA's effect on this endpoint in these strains. It is possible that these strains are less sensitive to this effect than are the other strains in which effects were reported. However, the general issues with this study create uncertainty about its conclusions related to mammary gland development. As discussed above, the inclusion of data from controls with elevated PFOA exposures may have affected the ability to observe effects in treated groups. Pertinent data on serum levels is not presented or appears to be presented inconsistently. The differences in developmental effects in wild type pups in Albrecht et al. (2013) versus Abbott et al. (2007) cannot be explained on the basis of pharmacokinetic differences in the two studies, since effects occurred at pup serum levels in Abbott et al. (2007) that are lower than the pup serum levels in Albrecht et al. (2013).

#### Effects on milk quality and quantity

In dams exposed to PFOA during pregnancy, the morphological delays observed in mammary glands during lactation suggest that milk production and/or composition may be impacted. Potentially relevant to this issue, maternal PFOA exposure was associated with shorter duration of breast feeding in all three human studies that evaluated this effect (Fei et al., 2010; Romano et al., 2016; Timmermann et al., 2016). However, the available toxicological information is not sufficient to make conclusions about the effects of developmental exposure to PFOA on lactational function, as only one study (White et al., 2007) evaluated effects on the composition of milk, and only one study (White et al., 2011b) evaluated the amount of milk produced. Evaluation of effects on growth of offspring is complicated by the fact that PFOA itself can cause decreased postnatal growth in mouse pups from only *in utero* exposure in a cross-fostering study (Wolf et al., 2007). Therefore, effects on postnatal growth could result from the intrinsic toxicity of PFOA and/or from decreased lactational function.

In the only toxicological study of effects on milk composition, expression of genes for four milk proteins (beta-casein, EGF, alpha-Lac, and LactoF) in mammary gland tissue were altered in dams exposed to 5 mg/kg/day PFOA during gestation. For example, peaks in LactoF expression normally seen early and late in lactation were delayed, consistent with the observed structural delays in mammary gland development at these time points (White et al., 2007).

The only toxicological data on effects of prenatal and early life exposure to PFOA on milk production in adulthood comes from the two-generation study in CD-1 mice (White et al.,

2011b). The design of this study is shown in Figure 11. As part of this study, a lactational challenge experiment was conducted in F1 dams and their F2 litters on PND 10, the time point at which lactation is at its peak. Except for the dose group receiving 5000 ng/L (5 µg/L) PFOA in drinking water throughout the experiment, the F1 dams that were evaluated for lactational function were exposed prenatally and in neonatal life until weaning through breast milk, but not after weaning or while pregnant and lactating. Milk production was evaluated by weighing a litter of 10 F2 pups before and after a nursing period of 30 minutes. There were no statistically significant effects on milk production, as measured by weight gain in the litter, or on time to initiate nursing behavior. However, high variability, the small number of animals assessed, and the lack of sensitivity of this assay may have limited the ability to detect effects on lactational function. Additionally, postnatal survival and body weight were not affected in the F2 pups, indicating that the ability of the F1 dams to provide nutritional support was not decreased. The authors note that it is not known whether deficits in lactational function were present, but were compensated for by increased frequency or longer duration of nursing events, since these parameters were not assessed.

Possibly relevant to this issue, the three available human studies all suggest that maternal exposure to PFOA may be related to shorter duration of breastfeeding. A study of 1400 Danish women from the general population found that serum PFOA concentration during early pregnancy was associated with shorter duration of breastfeeding among multiparous, but not nulliparous, women (Fei et al., 2010). Because women who breastfed previously were more likely to do so again, and because longer duration of lactation would result in decreased serum PFOA due to excretion via breast milk, reverse causality could not be ruled out. A second study evaluated 336 U.S. women from a community with median serum PFOA levels about twice those in the U.S. general population, possibly due to past exposure to contaminated drinking water (Romano et al., 2016). Finally, Timmermann et al. (2016) found an association of serum PFOA (median - 2.40 ng/ml) and duration of breastfeeding in Faroese women (n=1092).

In contrast to Fei et al. (2010), both Romano et al. (2016) and Timmermann et al. (2016) controlled for prior breast feeding history. Notably, serum PFOA levels during pregnancy were associated with shorter duration of breast feeding even after adjustment for previous breast feeding in these two studies.




Figure 11. White et al. (2011b) study design and experimental timeline. Bar color denotes dose – green, 0 mg PFOA/kg body weight/day; yellow, 1 mg PFOA/kg body weight/day; red, 5 mg PFOA/kg body weight /day; blue, 5 ppb PFOA in drinking water – and bar thickness denotes timing of treatment – thick bars denote on-going direct treatment, thin bars denote only group identity subsequent to treatment.

### Studies of effects of peripubertal exposure to PFOA

Three studies reported effects of peripubertal (during periods between 3 and 7 weeks of age) exposure to PFOA on mammary gland development in female mice. Studies presented in these publications are summarized in Table 16B, and details for each study are provided in Appendix 5. Two studies used C57Bl/6 and Balb/C mice (Yang et al., 2009a; Zhao et al, 2012). One of these studies (Zhao et al., 2012) and an additional study (Zhao et al., 2010) evaluated C57Bl/6 PPAR-alpha null mice. Data on serum PFOA levels from all three of these studies are presented in Zhao et al. (2012). Interpretation of the combined results of these three studies is problematic because each PFOA dose level was used in each strain in only one of the three studies, and any dose-response interpretations must be made based on combining data from different studies. Because conditions (e.g. animals, housing conditions, time) may vary during different studies, dose-response curves based on combining data from different studies are difficult to interpret and conclusions based on such dose-response curves are highly uncertain.

Yang et al. (2009a) reported stimulation of mammary gland development in C57Bl/6 mice at 1 and 5 mg/kg/day PFOA, but complete inhibition at 10 mg/kg/day. In contrast, mammary gland development was inhibited at these three doses in a dose-related manner in Balb/c mice in this same study (Yang et al., 2009a).

A subsequent study (Zhao et al. 2012) attempted to further elucidate the dose response for mammary gland effects in these two strains by using a single dose in between those used in the first study in each strain (2.5 mg/kg/day in Balb/c; 7.5 mg/kg/day in C57Bl/6). Mammary gland development was inhibited at these doses in both strains. However, the doses used in the Yang et al. (2009) were not repeated in Zhao et al. (2012), and, importantly, the stimulatory effects

reported at 1 and 5 mg/kg/day in C57Bl/6 mice by Yang et al. (2009a) were not replicated in Zhao et al. (2012).

It is important to note that the stimulation of mammary gland development in C57Bl/6 mice exposed to 5 mg/kg/day by Yang et al. (2009a) was not replicated in a second study. Additionally, this observation does not contradict the findings of delayed mammary development in this strain after gestational exposure (Tucker et al., 2015), since effects on mammary gland development may differ depending on life stage of exposure.

In C57Bl/6 PPAR-alpha null mice, mammary gland development was not affected by 7.5 mg/kg/day PFOA (Zhao et al., 2012), and was reported to be stimulated at 5 mg/kg/day, although quantitative data are not shown by Zhao et al. (2010). As was the case for the studies of C57Bl/6 wild type mice and Balb/C mice discussed above, each dose was used in PPAR-alpha null mice in only one of the studies (Zhao et al., 2010; Zhao et al., 2012). The effects on mammary gland development in the PPAR-alpha null mice therefore were similar to those in wild type mice of the same strain at 5 mg/kg/day and differed at 7.5 mg/kg/day. As above, interpretation of these data is problematic because only one dose was used in each study.

#### **Effects of pre-pubertal PFOA exposure on reproductive organs in female mice**

Two studies evaluated effects of pre-pubertal exposure to PFOA on reproductive organs in female mice. Groups of female CD-1 mouse pups (8 per group) to 0.01, 0.1, or 1 mg/kg/day were exposed to PFOA by gavage for three days starting on PND 18 (Dixon et al., 2012) and sacrificed one day after the last dose. Uterine weight (absolute and relative) was significantly increased (about 1.5-fold) only at 0.01 mg/kg/day, the lowest dose, while body weight was not affected by any dose of PFOA. As expected in this model, administration of 17-beta-estradiol greatly increased uterine weight by about 10-fold, and PFOA had no effect on uterine weight in the estradiol treated animals. In mice treated with PFOA alone, histopathological changes in the uteri in some, but not all, sections included minimal to mild endometrial and myometrial edema, and hyperplasia of the mucosal and endometrial glandular epithelia and smooth muscle layers. There was also focal minimal stromal edema of the cervix and focal areas of mucification of the vagina in some, but not all, sections from PFOA treated mice. The severity scores for these changes were statistically significant ( $p < 0.05$ ) only in the low dose (0.01 mg/kg/day) and may have contributed to the increased uterine weight in this dose group, indicating a non-monotonic dose response curve for this effect. In reproductive organs from mice treated with estradiol, histological changes that are known to result from estradiol were observed and these changes were more severe than those seen in PFOA treated mice. The authors note that PFOA did not appear to have anti-estrogenic effects in this study, since it did not decrease the uterine weight gain induced by estradiol, and that more research is needed regarding the mechanism for the observed histopathologic effects of PFOA.

In a second study of similar design, groups of 15 female CD-1 mouse pups were dosed with 0.005, 0.01, 0.02, 0.05, 0.1, or 1 mg/kg/day PFOA for 3 days beginning on GD-18 (Yao et al.,

2014). Another group of 15 female mouse pups was dosed with 17-beta-estradiol (0.5 mg/kg/day) for the same 3-day time period. Mice were sacrificed one day after the last dose. In this study, PFOA did not affect relative uterine weight at any dose, while estradiol caused the expected increase in relative uterine weight. Body weight was not affected by PFOA or estradiol treatment. In histological examination of the uterus, cervix, and vagina from 5 mice from each treatment group, there were no differences in types or severity of observations between controls and PFOA treated groups, while estradiol treatment produced the expected histopathological changes. In uterine tissue from the other 10 mice per treatment group, expression of estrogen receptor target genes in the uterus was not changed in PFOA-treated mice. Additionally, the human estrogen receptor was not activated by PFOA *in vitro* studies. Based on these results, the authors concluded that PFOA does not activate the mouse or human estrogen receptor.

### **Reproductive effects in male mice**

Adverse reproductive effects were observed in four studies of male mice.

Li et al. (2011) studied the effects of 6 weeks of oral exposure to 0, 1, and 5 mg/kg/day APFO in wild type, PPAR-null, and humanized PPAR-alpha 129/sv mice. Serum testosterone was significantly decreased and the percentage of abnormal sperm was significantly increased in a dose-dependent manner in wild type and humanized PPAR-alpha mice, but not in PPAR-alpha null mice. Histopathological examination of the testis found increased vacuolated cells in the seminiferous tubules of wild type and humanized PPAR-alpha at both doses, while no obvious effects occurred in the PPAR-alpha null mice.

Male Balb/C mice (10 per group) were dosed with PFOA by gavage for 28 days with 0, 0.31, 1.25, 5, and 20 mg/kg/day (Zhang et al., 2014). Sperm parameters were evaluated in five mice from the control and 5 mg/kg/day groups, histopathological studies were performed on testes from three mice from each dose group, and testes from the remaining animals were used in mode of action studies not described here. Relative testes weight was not affected by PFOA treatment, and absolute testes weight was decreased only at the highest dose (20 mg/kg/day). Sperm numbers, sperm motility, and sperm progression were significantly decreased, and percent teratosperm was markedly and significantly increased, by treatment with 5 mg/kg/day PFOA. Histopathological examination found no differences in testes in the two lower dose groups (0.31 and 1.25 mg/kg/day) as compared to controls, while the seminiferous tubules in the testes of the two higher dose groups (5 and 20 mg/kg/day) were severely damaged.

In a second study from this research group, fertility of male Balb/C mice (6-8 weeks old) was significantly reduced after 28 days of gavage dosing with 5 mg/kg/day PFOA (Lu et al., 2015). The number of mated females and the number of pregnant females per male mouse were significantly decreased by treatment of the males with PFOA. Further studies found that the blood-testis barrier was disrupted after 28 days of exposure to 1.25 or 5 mg/kg/day.



Finally, Liu et al. (2015), reported testicular toxicity in Kunming mice dosed with 2.5, 5, or 10 mg/kg/day PFOA for 14 days. Testicular damage including atrophy of seminiferous tubules, disrupted arrangement of spermatogenic cells, depletion of spermatogonial cells, detachment of germ cells from seminiferous epithelium, and decreased sperm production occurred in all treated groups, with severity increasing with dose. Epididymal sperm count was decreased in a dose-related fashion, with no NOAEL identified. Other parameters evaluated in this study are discussed in the Mode of Action section.

These adverse reproductive effects in male mice are in contrast to the results of the two generation study in rats (Butenhoff et al., 2004b, see below). In this study, mating, fertility, and sperm parameters in F0 and F1 male rats were unaffected by PFOA at up to 30 mg/kg/day. Additionally, Cui et al. (2009) did not observe distinct histopathological changes in the testes of male Sprague-Dawley rats treated with 5 or 20 mg/kg/day of PFOA for 28 days and found that testes weight relative to body weight was significantly increased at both doses. As discussed below, PFOA increased the incidence of testicular Leydig cell tumors in two chronic studies of male rats (Biegel et al., 2001; Butenhoff et al., 2012). In the chronic study of male rats dosed with 13.6 mg/kg/day PFOA in the diet for 24 months (Biegel et al., 2001), absolute testes weight was significantly increased by PFOA at 24 months but not at 21 months or earlier time points.

### **Reproductive and developmental studies in rats and rabbits**

As discussed above, the rat and the rabbit are not the most appropriate animal models for human reproductive and developmental effects of PFOA because of their rapid excretion of this chemical in female rats and both male and female rabbits. Studies of reproductive and developmental effects in these species are summarized below.

#### Rabbit developmental study

Gortner (1982, cited in USEPA, 2005a) studied developmental effects in New Zealand white rabbits (18/dose group) given 0, 1.5, 5, or 50 mg/kg/day PFOA on gestation days 6-18. Maternal body weight was decreased in treated groups on GD 6-9 but returned to control levels on GD 12-29. Parameters such as number of resorptions and implantations, and fetal viability, sex ratio, and weight, were not affected by treatment. A dose related increase in incidence of the skeletal variation, extra ribs or 13<sup>th</sup> rib, was observed, with incidence of 16, 20, 30, and 38% in the 0, 1.5, 5, and 50 mg/kg/groups. This increase was statistically significant in the highest dose group.

#### Rat studies

##### Rat developmental study

Gortner (1981, cited in USEPA, 2005a) gave Sprague-Dawley rats (22/dose group) 0, 0.05, 1.5, 5, and 150 mg/kg/day APFO on gestation days 6-15. The maternal NOAEL was 5 mg/kg/day and the LOAEL was 150 mg/kg/day, based on decreased body weight, ataxia, and mortality seen only in the high dose group. Parameters including number of resorptions and implantations, or fetal viability, sex ratio of offspring, and pup weight, were not affected by treatment. A significantly increased incidence of missing sternbrae occurred in the high dose group. Since



this effect was also seen in the control and lower dose groups at lower frequency, the study authors did not believe that it was treatment related.

Two-generation rat reproductive study

A two-generation reproductive study in Sprague-Dawley rats using gavage doses of 0, 1, 3, 10, and 30 mg/kg/day APFO was conducted by York (2002) and was also reported by Butenhoff et al. (2004b). Various parameters related to reproduction and development, as well as general toxicology endpoints, were evaluated in each generation (F0, F1, F2). Because of the design of the study, some observed effects may have been due to developmental/reproductive toxicity and others due to adult toxicity (USEPA, 2005a).

The parental (F0) generation (30 per sex per group) were dosed for at least 70 days prior to cohabitation beginning at age 6 weeks and until after mating in males and through pregnancy and lactation until weaning of pups for females. Males of the F0 generation were sacrificed after mating, and females were sacrificed at weaning of offspring on PND 22.

Mean serum levels on the day of sacrifice in the F0 males in the control, 10, and 30 mg/kg/day groups were 34 ng/ml, 51,500 ng/ml and 45,300 ng/ml, with no increase in serum levels with increasing dose. In females, serum levels were much lower, < 5 ng/ml, 370 ng/ml, and 1020 ng/ml in the control, 10 and 30 mg/kg/day groups. Serum levels were not measured in the 1 and 3 mg/kg/day groups.

In the F0 males, there were no effects on mating, fertility, or sperm parameters. There were dose-related statistically significant decreases in body weight and body weight gain at 3, 10, and 30 mg/kg/day of 6, 11, and 25%, respectively, although relative food consumption was increased in these groups. Liver weights (absolute, relative to body weight, and relative to brain weight) were increased significantly in all dose groups (1 mg/kg/day and above). Kidney weights were also increased relative to brain and liver weights in all dose groups. Livers and kidneys were not examined histologically. Reproductive and endocrine organs were examined histologically, and hypertrophy and/or vacuolation of the zona glomerulosa of the adrenal glands were seen in 20% of the 10 mg/kg/day group and 70% of the 30 mg/kg/day group.

In F0 females, there were no effects on estrous cyclicity, mating, fertility, pup sex ratio, pup viability, pup birth weight, or other related parameters. Relative kidney weights were reduced at 30 mg/kg/day, and relative liver weight was reduced at 3 and 10 mg/kg/day. This decrease in relative liver weight is in contrast to findings in many other studies in which increased liver weight increases occurred. Histological examination was not performed on the kidneys or livers. Lau et al. (2006) concluded that the profile of maternal effects in the rat study differed from those seen in similar studies in mice because of the more rapid excretion in the adult female rat compared to the adult female mouse.

Dosing of F1 offspring with the same dose levels that their parents had received began at weaning (PND 22). Most of the F1 animals were sacrificed after sexual maturation (about 5 weeks in females and 7 weeks in males). From the F1 generation, 30 pairs per dose group were selected to be bred to produce the F2 generation. These F1 males were sacrificed at about 133 days of age, after 113 days of treatment, and F1 females were sacrificed at weaning of the pups, at 13 to 15 weeks of age.

The weight of the F1 pups (males and females combined) was reduced compared to controls through lactation on a per litter basis in the 30 mg/kg/day group. During the post-weaning period, signs of toxicity in the F1 males included increased incidence of annular constriction of the tail at all doses (significant at 1, 10, and 30 mg/kg/day), significant increases in the number of emaciated pups at 10 and 30 mg/kg/day, and significantly increased urine-stained fur, decreased motor activity, and abdominal distention at 30 mg/kg/day. Deaths were significantly increased in the 30 mg/kg/day males during the post-weaning period. Sexual maturation, as indicated by day of preputial separation, was significantly delayed in the high dose group (52.2 days) compared to controls (48.5 days).

No effects were observed on mating, fertility, or sperm parameters in the F1 males. There was a significant dose-related reduction in body weight gain at all doses (1 mg/kg/day and above) during the post-weaning period, although relative food consumption was significantly increased. At sacrifice (day 113 of dosing), body weights were reduced by 6, 6, 11, and 22% in the 1, 3, 10, and 30 mg/kg/day groups compared to controls. Absolute and relative liver weights were increased at all doses, and hepatocellular hypertrophy and necrosis were seen in livers of some animals in the 3, 10, and 30 mg/kg/day groups. Kidney weight relative to body and brain weight was increased in all treated groups, but histopathological examination was not performed. Hypertrophy and vacuolation of the adrenal cortex was seen in 70% of high dose animals, but not in other groups.

In F1 females, there was a significant increase (6/60) in mortality in the high dose group 2-8 days post-weaning. Sexual maturation, as indicated by day of vaginal opening, was significantly delayed in the 30 mg/kg/day group, from 34.9 days in controls to 36.6 days in treated females. Significant reductions in body weight were seen at several time points during post-weaning, gestation, and lactation, although relative food intake was not decreased and body weight was not decreased at terminal sacrifice. No effects were seen in F1 females on mating or fertility parameters, or number of implantations, number of stillborn pups, or length of gestation.

The F2 pups were followed until weaning at PND 22. In the F2 generation, no treatment-related effects were seen on pup viability until weaning, percentage of male pups, litter size, average pup body weight on days 1, 5, 8, 15, or 22, or anogenital distance. Because these pups were sacrificed at weaning, post-weaning effects were not assessed.

Several LOAELs and NOAELs were identified in this study for males and females at different life stages, and the serum PFOA levels at these NOAELs and LOAELs were modeled (USEPA, 2005a). The LOAEL for adult males in this study was 1 mg/kg/day (modeled serum concentration – 42,000 ng/ml) with no NOAEL identified, based on increased liver weight in the F0 and F1 generations and decreased body weight in the F1 generation. For pregnant females, the LOAEL was 10 mg/kg/day, based on decreased body weight in F1 pups during post-weaning, and the NOAEL was 3 mg/kg/day (modeled serum concentration – 3500 ng/ml). For the male rat pups during post-weaning, the LOAEL was 10 mg/kg/day and the NOAEL was 3 mg/kg/day (modeled serum concentration - 8400 ng/ml at week 4), based on decreased body weight in the F1 generation. For the female rat pups during post-weaning, the LOAEL was 30 mg/kg/day and the NOAEL was 10 mg/kg/day (modeled serum concentration -13,000 ng/ml) at week 7, based on decreased body weight in the F1 generation.

### **Thyroid effects**

Effects of PFOA on the thyroid in animal toxicology studies are of interest because there have been many human epidemiological studies of PFOA and thyroid hormones and/or thyroid disease. However, only a few toxicology studies have evaluated effects of PFOA on thyroid function.

In the 4-week study of male cynomolgus monkeys (Thomford et al., 2001a), there were no effects on thyroid hormones (thyroid stimulating hormone, TSH; total and free triiodothyronine, T3; total and free thyroxin, T4) after 29 days of exposure to 0, 2, or 20 mg/kg/day APFO. It should be noted that the number of animals per dose group in this study was very small (controls, n=2; treated, n=3).

Changes in thyroid hormones were observed in PFOA-treated male cynomolgus monkeys in the 6-month study (Butenhoff et al., 2002). This study is described in detail above. At the beginning of the study, there were 6 monkeys in the control and high dose group, and 4 in the other two groups. Some animals in the treated groups did not complete the study because of mortality or overt toxicity (3 mg/kg/day, n=3; 30/20 mg/kg/day, n=2 at end of study.) Thyroid hormones (total and free triiodothyronine, T3; total and free thyroxin, T4) and TSH (thyroid stimulating hormone) were measured before dosing, and after 5, 10, 14, and 27 weeks of dosing with 0, 3, 10, 30/20 mg/kg/day APFO. Interpretation of the data is complicated by the fact that comparisons for these parameters are made both to the pretreatment values for the same animals and to the control animals at the concurrent time point. Statistically significant changes were reported for all hormones at one or more time points in one or more dosed groups.

TSH was significantly increased at week 35 compared to pretreatment values at 3 and 10 mg/kg/day. Total T4 was significantly decreased compared to concurrent controls in all dosed groups (3, 10, and 30/20 mg/kg/day) at week 35, at all time points during treatment (weeks 5 to 35) at 10 mg/kg/day, and at week 10 and week 35 at 30/20 mg/kg/day. Free T4 was significantly lower than in concurrent controls at 10 mg/kg/day at weeks 5, 10, and 27, and at 30/20

mg/kg/day at weeks 5 and 27. Total T3 was significantly increased compared to pretreatment values at two time points (weeks 10 and 14) at 3 mg/kg/day, and was decreased compared to concurrent controls in all dosed groups at 30/20 mg/kg/day; this change was not significant at 10 weeks. Finally, free T3 was significantly decreased compared to concurrent controls in the 30/20 mg/kg/day group at weeks 5, 10, and 35.

The authors reported that all thyroid hormone values were within normal range, and that no relevant histological observations were observed. They also state that there were no relevant changes in TSH or T4, despite the changes in levels of these hormones noted above. It is stated, in the 3 high dose monkeys that were removed from the study due to toxicity, the decreased T3 observed during treatment trended upward after treatment ceased. The authors state that the observed changes in thyroid hormone levels were likely due to stress or normal variation rather than a direct effect of APFO (PFOA).

Thyroid hormones (total T4, free T4, and total T3) were measured in male Sprague-Dawley rats one day after dosing for 1, 3, or 5 days with a high dose (20 mg/kg/day) of PFOA (Martin et al., 2007). Levels of free and total T4 in PFOA treated animals were significantly reduced to several fold below control levels at all three time points. Total T3 was also significantly decreased at all three time points, although the magnitude of the decreases was smaller than for T4. The effects were similar or greater than those caused by PFOS at 10 mg/kg/day in the same study. Unfortunately, thyroid hormones have not been evaluated in longer term, lower dose rodent studies of PFOA.

### **Neurobehavioral and Central Nervous System Effects**

Several studies have found neurobehavioral effects, particularly increased activity, in rodents exposed to low doses of PFOA during development. Although human studies on these effects are not reviewed in this document, toxicological studies of neurobehavioral effects are of interest because some human studies have reported associations of PFOA and other PFCs with behavioral effects, particularly attention deficit hyperactivity disorder, in children (Hoffman et al., 2010; Ode et al., 2014).

Johansson et al. (2008) found significant behavioral effects in adult male NMRI mice given a single gavage dose of 0.58 or 8.7 mg/kg PFOA at 10 days of age. Behavioral tests were conducted at 2 and 4 months of age. These behavioral tests included spontaneous behavior (locomotion, rearing, total activity) over three consecutive 20-minute time periods (an indicator of habituation over time), nicotine-induced motor activity (locomotion, rearing, total activity), and behavior in an elevated plus-maze (a measure of anxiety). These single doses of PFOA did not affect weight gain or cause any overt signs of toxicity. At 2 and 4 months, some or all measures of spontaneous behavior were affected in both the low and high dose groups, with greater effects in the high dose group (8.7 mg/kg) and at the later time point (4 months). Habituation was greatly decreased at both 2 and 4 months in the high dose group compared to

controls. This effect increased with age of the treated mice. Lack of effect in the elevated plus-maze test indicated that these effects were not likely to be caused by anxiety.

Responses over three 20 minute periods following an injection of 80 µg/kg nicotine, a measure of the susceptibility of the cholinergic system, was also significantly altered in high and low dose mice at 4 months. Control mice showed an increase in activity from the nicotine, followed by a decrease to baseline behavior. Low dose mice also showed increased activity after receiving nicotine, but less so than controls, and this increased activity was followed by greater activity than in controls during the last 20-minute time period. In contrast, high dose mice showed decreased activity during the first 20 minutes after receiving nicotine but were hyperactive during the later time period. The authors concluded that neonatal PFOA exposure caused deranged spontaneous behavior such as lack of habituation and hyperactivity that worsened with age in adult mice, and that PFOA exposure also affected the cholinergic system.

Significant effects were seen at both doses in this study. Therefore, the LOAEL was 0.58 mg/kg, and no NOAEL was identified. Serum levels were not measured in this study and have not been measured in neonatal mice administered a single dose of PFOA. A single oral dose of 1 or 10 mg/kg to adult CD-1 mice resulted in maximum serum concentrations of about 10,000 and 100,000 ng/ml (Lou et al., 2009). From these data, the serum concentrations from 0.58 and 8.7 mg/kg can be estimated as 5800 and 87,000 ng/ml, assuming that kinetics in these neonatal mice are similar to in adult mice.

The authors stated that the effects caused by PFOA in this study are similar to those seen with PCBs and PBDEs, known developmental neurotoxicants, and that PFOA should be classified as a developmental neurotoxicant along with these other persistent chemicals. It is noted that studies from this laboratory using the same dosing protocol (a single dose given to 10 day old mice) and the same behavioral tests are the basis for the chronic USEPA IRIS Reference Doses developed in 2008 for two PBDEs, 2,2',4,4'-tetrabromodiphenyl ether (BDE-47) and 2,2',4,4',5-pentabromodiphenyl ether (BDE-99) (USEPA 2008b,c). Because the effects persisted into adulthood and were permanent, these effects were regarded by USEPA IRIS as chronic, not acute, even though only a single dose was given.

A second study in this laboratory (Johansson et al., 2009) examined the effects of a single gavage dose of 8.7 mg/kg PFOA to 10 day old mice on proteins important for neuronal growth and synaptogenesis in the developing brain. The mice were sacrificed 24 hours after dosing. Rapid brain development, the "brain growth spurt," occurs in mice during this time period. Levels of two proteins known to be involved with neuronal survival, growth, synaptogenesis, and other aspects of neuronal development were significantly increased in the hippocampus but not the cerebral cortex of treated mice, and two other proteins were increased in both areas of the brain. PBDEs, which are known to affect behavior after developmental exposures, had previously been found by these researchers to cause similar effects. The authors conclude that these changes may relate to some of the observations in their earlier behavioral study.

Onishchenko et al. (2010) found sex-related behavioral changes in offspring of C57Bl/6 mice exposed to 0.3 mg/kg/day PFOA throughout gestation. Liver weights were significantly increased in treated pups that were sacrificed at birth. PFOA exposure did not affect locomotor behavior in 5-8 week old mice tested individually, but significant sex-related effects were seen on circadian activity when these mice were housed in social groups. Initially, PFOA treated males were more active than controls, while treated females were less active than controls. After habituation, activity in both light and dark phases was increased during the remainder of the first 24 hours in exposed males, while no effects were seen in exposed females. During the second 24-hour period when the mice were more adapted to the test environment, the number of inactive periods during the light phase was decreased in both male and female PFOA-treated mice, and also in the dark phase in PFOA-treated males. No effects of PFOA were seen in other tests, including the elevated plus-maze test for anxiety-like behavior, the forced swimming test for depression-like behavior, or muscle strength in the hanging wire test. Serum PFOA levels in this study were not measured, but they are not expected to be below the serum levels at the LOAELs and NOAELs in some other studies which evaluated other effects. The NOAEL for these effects is not known.

Finally, Sobolewski et al. (2014) studied behavioral effects of developmental exposures to PFOA in C57Bl/6 mice. Three other unrelated environmental contaminants and a mixture of all four chemicals were also evaluated; only results for PFOA alone are reported here. PFOA (0.1 mg/kg/day) was administered to dams in puffed wheat cereal on GD7 through weaning. Behavioral effects were evaluated in male and female offspring (one or two per sex per litter) beginning at age 60 days.

PFOA treatment caused behavioral effects, which differed between males and females. Locomotor behavior was increased in males treated with PFOA, while no effect was seen in females. Horizontal movement and ambulatory movements were increased and resting time was decreased during one or more of three test sessions, while vertical activity was unaffected in males. Behaviors related to novel object exploration and recognition were altered in both PFOA-treated males and females to a highly significant degree, although the specific parameters affected differed between sexes. Fixed interval reinforcement schedule-controlled behavior was not affected by PFOA treatment in males or females.

### **Chronic toxicity and carcinogenicity**

As discussed in the Epidemiology section, PFOA has been associated with increased incidence of kidney and testicular cancer in humans exposed through drinking water, after adjustment for smoking and other relevant factors. The chronic toxicity and carcinogenicity of PFOA has been evaluated in two dietary studies in rats. One study (Sibinski et al., 1987; Butenhoff et al., 2012) included male and female rats, while Biegel et al. (2001) studied only males. As such, chronic toxicity and carcinogenicity have been studied only in the rat, a species in which PFOA is rapidly excreted by females. Chronic studies in another species in which PFOA is persistent in both



sexes, such as the mouse, would provide important information specific to females. Furthermore, the chronic studies did not assess effects including carcinogenicity which might result from exposures during the critical developmental stages now known to be sensitive periods for PFOA toxicity.

Two year chronic/carcinogenicity study in male and female rats

Sprague-Dawley rats (30 per sex per group) were dosed with APFO through diets containing 0, 30, or 300 ppm APFO for two years (Sibinski, 1987; Butenhoff et al., 2012). Additional animals (15 per sex) were included in the control and high dose groups for evaluation at sacrifice after one year. From food consumption data, mean APFO doses were determined to be 1.3 and 14.2 mg/kg/day in males, and 1.6 and 16.1 mg/kg/day in females, for the 30 and 300 ppm groups, respectively.

Body weight gains were decreased in both sexes in the high dose group, with maximum differences between the high dose group and controls of 21% in males at 6 weeks and 11% in females at 92 weeks. Smaller decreases were seen in low dose males, and decreases were not consistently seen in low dose females. Decreases in weight gain were treatment-related, since food consumption on a body weight basis was increased in treated males, by about 13% in the high dose group. Mortality was not increased by APFO treatment, and 2-year survival rates were 70%, 72% and 88% in males and 50%, 48% and 58% in females in the 0, 30 ppm, and 300 ppm groups, respectively.

The incidence of ataxia was increased in female rats treated with PFOA and occurred most frequently in moribund animals. Ataxia occurred in 3%, 18% and 23% of rats in the control, low- and high-dose groups (including animals sacrificed at one year), respectively.

Clinical chemistry changes occurred in high and low dose males, but not in females. The liver enzymes alanine aminotransferase, aspartate aminotransferase, and alkaline phosphatase were increased in both low dose and high dose males between 2 and 18 months, but only in the high dose group at 24 months. Albumin was significantly increased in the male low dose group at 3 and 6 months, and until 24 months in the high dose group. Butenhoff et al. (2012) concluded that the elevations in liver enzymes in both high and low dose males may represent “borderline chronic liver toxicity”.

Hematological parameters including red blood cell counts, hemoglobin concentrations and hematocrit were significantly decreased in high and low dose males and females at different time points. In high dose males, these erythrocyte-related hematological parameters were decreased from 3 to 18 months. Additionally, leukocytes were increased in both dose groups of males during the first year. Statistically significant changes included increases in lymphocytes and neutrophils at 3 and 12 months in both dose groups, and in lymphocytes and 6 and 18 months in the low dose group.



In females, hematological parameters were significantly changed with equal frequency in the high and low dose groups. At 3 months, red blood cells were decreased in the low dose group and hematocrit was decreased in the high dose group. At 6 months, erythrocytes, hemoglobin, and hematocrit were decreased only in the low dose group, while at 12 months, these three parameters were decreased only in the high dose group.

At the one-year interim sacrifice, statistically significant changes in organ weights in high dose males included increased liver weight and decreased pituitary weight (absolute and relative to body or brain weight), increased kidney weight (only relative to body weight), decreased adrenal and heart weight (absolute and relative to brain weight). No organ weight changes were observed in high dose females sacrificed at one year.

At the one-year interim sacrifice, histopathological changes in the livers of high dose males included diffuse hepatocellular hypertrophy in 12/15 (compared to 0/15 controls); portal mononuclear cell infiltration in 13/15 (compared to 7/15 controls); and focal hepatocellular necrosis in 6/15 (compared to 0/15 controls). In high dose females, hepatocellular vacuolation occurred in 11/15 (compared to 5/15 controls). Testicular tubular atrophy and marked aspermatogenesis was found in 2/15 high dose males but in none of the controls.

At the two-year sacrifice, slight non-significant increases in liver weight occurred in all treated groups of males and females. Relative kidney weight was slightly increased in male and female high dose rats, and this change was significant in females.

Several non-neoplastic liver lesions were also increased in treated animals at two years. Hepatocellular hypertrophy did not occur in controls but was found in 12% and 80% of the males, and 2% and 16% of the females, in the low and high dose groups, respectively. Hepatic cystoid degeneration occurred in 8%, 14% and 56% of the control, low, and high-dose males. However, hepatocellular necrosis or hepatocellular vacuolation was not increased in treated animals compared to controls, although an increase of focal hepatocellular necrosis in high dose males and hepatocellular vacuolation in high dose females was observed at the one-year sacrifice.

Hepatocellular carcinomas were found in the control (6%), low dose (10%), and high dose (2%) males, and occurred in females only in the high dose group (2%). The incidence of hepatic hyperplastic nodules was 6% in high-dose males, and they were not found in the other groups of males. In females, these nodules were found in 2% of the control and high dose animals, but not in the low dose group. Butenhoff et al. (2012) state that diagnostic criteria for these nodules, which represent a regenerative process, have changed since the histopathological evaluation for this study was performed. The USEPA SAB (2006) concluded that these nodules may have been part of the continuum of proliferative lesions in the liver carcinogenic process. Butenhoff et al. (2012) further conclude that the increased incidence of focal necrosis and vacuolation in treated animals, which was observed at the one year sacrifice but not at the two year sacrifice (because of the higher background incidence of these changes in older rats), suggests a progression of lesions

“from hepatocellular hypertrophy to fatty degeneration to necrosis followed by regenerative hyperplasia.”

The incidence of neoplastic lesions of the testes differed significantly between control and treated rats. Leydig cell adenomas of the testes were found in 0, 4, and 14% of the control, low, and high dose males, respectively, with a significantly increased incidence in the high dose group. Additionally, vascular mineralization of the testes occurred in 0, 6, and 18% of control, low, and high dose males, respectively, and reached statistical significance in the high-dose group.

The incidence of mammary gland fibroadenomas was 22%, 42%, and 48% in the control, low dose, and high dose females, and the increase in the high dose group was significant. Mammary gland adenocarcinomas were present in 15, 31, and 11% of the control, low, and high dose females, respectively. A subsequent Pathology Working Group reevaluation of the mammary gland slides concluded that the incidence of mammary gland proliferative lesions was not increased by PFOA in this study (Hardisty et al., 2010).

A statistically significant, dose-related increase in the incidence of ovarian tubular hyperplasia was found in female rats at the two-year sacrifice, with incidence of 0%, 14%, and 32% in the control, low, and high dose groups. The authors of the study report stated that the biological significance of this effect was unknown, as there was no evidence of progression to tumors. Slides of the ovaries were later re-evaluated (Mann and Frame, 2004) using more recent pathology criteria. In the reevaluations, no statistically significant increases in hyperplasia (total number), adenomas, or hyperplasia/adenoma combined were seen in treated groups compared to controls. Although the size of stromal lesions was increased in the high dose group, the incidence of ovarian adenomas was higher in the controls than in the treated groups.

USEPA (2005a) concluded that “based on these toxic effects, the high dose selected in this study appears to have reached the Maximum Tolerated Dose. Based on a decrease in body weight gain, increase in liver and kidney weights and toxicity in the hematological and hepatic systems, the LOAEL for male rats is 300 ppm and the NOAEL is 30 ppm. The LOAEL for female rats is 300 ppm based on a decrease in body weight gain and hematologic effects and the NOAEL is 30 ppm.”

However, as noted above, a significant increase in the incidence of ataxia, as well as hematological effects equivalent to those in the high dose group, occurred in low dose females in this study. Also, in males in this study, there were significant changes in several clinical chemistry parameters at multiple time points in the low dose group. Thus, statistically significant effects occurred at multiple time points in the low dose males and female in this study. It should be noted that the study authors concluded that the elevation of the three liver enzymes, alkaline phosphatase, alanine aminotransferase, and aspartate aminotransferase, in both dosed groups of males, in conjunction with liver weight changes and histopathology observations, suggested that PFOA affected hepatocytes in both the low dose and the high dose groups of male rats.

The serum level in the low dose (1.6 mg/kg/day) females, considered to be the NOAEL by USEPA (2005a), was estimated at 1800 ng/ml, based on average AUC (USEPA, 2005a; Post et al., 2009a). The serum levels in the low dose (1.3 mg/kg/day) males were much higher, and can be estimated at 55,000 ng/ml from the kinetic data presented by USEPA (2005a).

#### Chronic mechanistic study in male rats

The second chronic study (Biegel et al., 2001) was designed to investigate the mode of action for testicular tumors observed in male rats in the first chronic study (Sibinski et al., 1987; Butenhoff et al., 2012). Male Sprague-Dawley rats were given 300 ppm PFOA in the diet (mean dose of 13.6 mg/kg/day) for up to two years. Serum levels at this dose were estimated as 572,000 ng/ml (USEPA, 2005a). Two controls groups were used, an *ad libitum* fed (AL) group and a pair-fed (PF) group in which the food intake was controlled to match the food intake of the PFOA exposed group. Another group of rats was treated with Wyeth 14,643 (WY), a model peroxisome proliferator. There were 156 rats in each of the control and dosed groups.

At interim time points of 1, 3, 6, 9, 12, 15, 18, and 21 months, the liver and testes from six rats per treatment group were weighed and evaluated for cell proliferation. At each time point, peroxisome proliferation (PCO) was evaluated in 6 additional rats per group, and serum hormone levels (estradiol, testosterone, LH, FSH, and prolactin) were measured in 10 rats from each group.

Liver-to-body weight ratios were increased in PFOA treated animals at all time points compared to controls. This increase was greatest at the earliest time point (1 month) and decreased over time. At 24 months, there was only a slight difference in liver-to-body weight ratio between the treated and control animals. Similarly, the increase in peroxisomal beta-oxidation (PCO), a measure of peroxisome proliferation, in the liver was greatest at 1 month, and the magnitude of the increase over controls decreased with time. WY also increased liver weight and peroxisomal beta-oxidation (PCO). Liver cell proliferation was increased by WY but not by PFOA.

In contrast to the liver, relative organ weight, PCO activity, and cell proliferation in testes were not affected in PFOA or WY treated rats except for increased relative testicular weight at 18 and 24 months in PFOA treated animals and at 24 months in WY treated animals. In the pancreas, PFOA increased acinar cell proliferation at 12, 16, 18, and 21 months, while WY did not have this effect.

Estradiol levels were significantly increased by PFOA at the 1, 3, 6, 9, and 12-month time points. WY also increased serum estradiol. Testosterone, prolactin, LH, and FSH were not changed compared to pair-fed controls.

In this study, there was a significant increase of three types of tumors (Leydig cell adenomas, hepatic adenomas, and pancreatic acinar cell adenomas) in the PFOA treated group at the 24-month sacrifice. The incidence of these tumors in the *ad libitum* control (AL), pair fed control

(PF), and treated groups was: Leydig cell adenomas (AL – 0/80; PF – 2/78, treated – 8/76), hepatic adenomas (AL – 2/80, PF – 1/79, treated – 10/76), and pancreatic acinar cell adenomas (AL – 0/80, PF- 1/79, treated – 7/76). These same three types of tumors also occurred at a higher rate in the WY treated animals. As discussed above, the incidence of testicular Leydig cell adenomas was also increased by PFOA in a dose-related fashion in the first chronic study (Sibinski et al., 1987; Butenhoff et al., 2012).

#### Information relevant to carcinogenicity from developmental exposure

Carcinogenicity studies using prenatal or perinatal exposure protocols have not been reported for PFOA. Very limited information is available that is relevant to carcinogenicity after developmental exposure to PFOA.

As discussed in the section on hepatic effects above, Filgo et al. (2015) evaluated hepatic histopathological effects, including tumor incidence, at age 18 months in female offspring of dams dosed on GD 1-17. The study evaluated three strains of mice - CD-1, 129/Sv wild type, and 129/Sv PPAR-alpha knockout. CD-1 dams were dosed with 0, 0.01, 0.1, 0.3, 1, and 5 mg/kg/day, and 129/Sv wild type and PPAR-alpha null dams dosed with 0, 0.1, 0.3, 1, and 3 mg/kg/day.

The authors emphasize that the study was not designed or intended to be a carcinogenicity bioassay. Rather, the incidence of liver tumors was evaluated by Filgo et al. (2015) because of the unexpected finding of liver tumors in some treated animals that died before the scheduled end of the study. In CD-1 mice in this study, single or multiple hepatocellular adenomas were found in one or more animals in each of the treated groups (n=21 to 37 per group) except for at the lowest dose (0.01 mg/kg/day), but not in controls (n=29). In total, adenomas occurred in 4.9% (7 of 144) treated animals, compared to a historic control incidence of 0.4% in untreated female CD-1 mice. Hepatocellular carcinomas occurred in two treated mice (0.3 and 5 mg/kg/day) but not in controls.

In 129/Sv mice, hepatocellular adenomas did not occur in control or treated groups (n=6 to 10 per group). In PPAR-alpha null mice of this strain, in contrast, there were no adenomas in the controls (n=6), one adenoma in the 0.1, 0.3, and 1 mg/kg/day groups (n=9 or 10), and two adenomas at 3 mg/kg/day (n=9). These tumors occurred in 13.2% of all treated PPAR-alpha null mice.

Possibly because of the small numbers of animals per dose-group, tumor incidences were not significantly increased in PFOA-treated groups compared to control in this study, with the exception of the CD-1 mice dosed with 0.3 mg/kg/day in which adenomas were found in 4 of 26 animals. The results of this study are suggestive of the potential for developmental exposures to PFOA to cause tumors in mice later in life, and also suggest that these tumors may occur through a PPAR-alpha independent pathway. An additional study with larger numbers of animals and designed to detect increased tumor incidence is needed to further evaluate these questions.

Ngo et al. (2014) evaluated the incidence of intestinal tumors and other endpoints in wild type and Min/+ C57Bl/6 mice offspring of dams dosed with 0.01, 0.1, and 3 mg/kg/day PFOA during gestation. The Min/+ strain has a mutation of a tumor suppressor related to intestinal adenomatous polyps and is a sensitive model for chemical-induced intestinal tumorigenesis. PFOA did not cause increased intestinal tumorigenesis at sacrifice at age 11 weeks in either wild type or Min/+ mice.

### Discussion

Leydig cell testicular tumors were the only tumor type that were increased by PFOA in the chronic study of Butenhoff et al. (2012), and the incidence of these tumors was also increased by PFOA in Biegel et al. (2001). In Biegel et al. (2010), the incidence of hepatic and pancreatic tumors was also increased to a similar degree as testicular tumors in male rats treated with PFOA.

Although hepatic tumors were not significantly increased in treated animals in Butenhoff et al. (2012), both the USEPA SAB (2006) and Butenhoff et al. (2012) point out that the incidence of hepatic hyperplastic nodules was increased in the high dose males in comparison to the control and low dose groups in this study. Butenhoff et al. (2012) state that diagnostic criteria for these nodules, which represent a regenerative process, have changed since the histopathological evaluation for this study was performed. The EPA SAB (2006) concluded that these nodules may have been part of the continuum of proliferative lesions in the liver carcinogenic process, and Butenhoff et al. (2012) further conclude that the increased incidence of focal necrosis and vacuolation found at the one year sacrifice but not at the two year sacrifice (because of the higher background incidence of these changes in older rats) suggests a progression of lesions “from hepatocellular hypertrophy to fatty degeneration to necrosis followed by regenerative hyperplasia.”

In regard to pancreatic tumors, Frame and McConnell (2003) reevaluated the slides of the pancreas from both studies and found that different diagnostic criteria and nomenclature were used by the pathologists in Sibinski et al. (1987) and Biegel et al. (2001). Frame and McConnell (2003) concluded that the incidence of pancreatic focal acinar lesions, which can progress to adenomas, was increased by 300 ppm PFOA in the diet in both studies and that these lesions were larger, more frequent, and had a greater tendency to progress to adenomas in Biegel et al. (2001).

PFOA has been shown to promote liver carcinogenesis in rats initiated with diethylnitrosamine as well as with a more complex initiating protocol (Abdellatif et al., 1991; Nilsson et al., 1991). PFOA also promoted hepatocarcinogenicity in rainbow trout, a model species for human liver cancer (discussed in Mode of Action section, below).

An increased incidence of liver tumors from prenatal exposure to PFOA in CD-1 and PPAR-alpha null mice is suggested by the results of Filgo et al. (2015). However, this study is not definitive, and additional research on carcinogenicity later in life after developmental exposures to PFOA is needed.

Information related to the mode of action for carcinogenicity is discussed in the Mode of Action section below.

### **Summary of Conclusions of Toxicology Studies**

The Subcommittee's review of the toxicology data identified increased relative liver weight and delayed mammary gland development from developmental (perinatal) exposure as the most sensitive systemic toxicological endpoints with data appropriate for dose-response modeling. Delayed mammary gland development in mice is the most sensitive systemic endpoint with data appropriate for dose-response modeling. Increased liver weight is a more sensitive endpoint than most other systemic effects, and it co-occurs with and/or progresses to more severe hepatic effects including increased serum liver enzymes, hepatocellular necrosis, fatty liver, and/or hyperplastic nodules. PFOA also causes other types of toxicity including reproductive effects in both males and females, delayed growth and development, immune system toxicity, and neurobehavioral effects. PFOA caused tumors in two chronic rat studies, and one of these studies provides data for testicular tumors that is appropriate for dose-response modeling. All of these toxicological effects are considered relevant to humans for the purposes of risk assessment, as discussed in the Mode of Action section.

Table 10. Summary of Increased Relative Liver Weight Data from Rodents Studies Using Doses  $\leq 1$  mg/kg/day, and 90 Day Non-Human Primate Study**TABLE 10A: STUDIES PROVIDING SERUM PFOA DATA AT END OF DOSING PERIOD\***

<i>Citation</i>	<i>Species</i>	<i>Life-stage</i>	<i>Doses (mg/kg/day)</i>	<i>Duration</i>	<i>NOAEL (mg/kg/day)</i>	<i>Serum NOAEL (ng/ml)</i>	<i>LOAEL (mg/kg/day)</i>	<i>Serum LOAEL (ng/ml)</i>	<i>Comments</i>
Lau et al. (2006)	Female mouse	Pregnant GD 18	0, 1, 3, 5, 10, 20, 40	GD 1-18	----	----	1	22,000	<ul style="list-style-type: none"> <li>Data for absolute liver weight are presented in bar graph in publication. Numerical data were obtained from the investigator.</li> <li>Data on relative liver weight are based on comparisons with body weight after gravid uterus was removed. These data are not shown in the publication and were obtained from the investigator.</li> </ul>
Loveless et al. (2006)	Male rat	Adult	0, 0.3, 1, 3, 10, 30	2 weeks	Linear/Branched 0.3	19,000	1	51,000	<ul style="list-style-type: none"> <li>Three formulations of PFOA of differing isomer compositions were tested.</li> <li>This study also provides data on peroxisomal beta-oxidation. In mice, increased relative liver weight does not correlate with increased peroxisomal beta oxidation among formulations with differing isomer compositions, indicating PPAR-alpha independent effects on liver weight.</li> </ul>
					Linear 0.3	20,000	1	65,000	
					Branched 0.3	16,000	1	48,000	
	Male mouse	Adult	0, 0.3, 1, 3, 10, 30	2 weeks	Linear/Branched 0.3	10,000	1	27,000	
					Linear ---	---	0.3	13,000	
					Branched ---	---	0.3	14,000	
Macon et al. (2011)	Female mouse	Female pup PND 1	0, 0.01, 0.1, 1	GD 10-17	0.1	2300	1	16,000	<ul style="list-style-type: none"> <li>LOAEL for increased relative liver weight is 100 fold higher than LOAEL for delayed mammary gland development.</li> <li>PFOA serum levels were measured on PND 1.</li> <li>With longer GD 1-17 exposure, LOAEL for increased relative liver weight was 0.3 mg/kg/day in male and female pups on PND 7. PFOA serum levels were not measured in this component of the study.</li> </ul>
Perkins et al. (2004)	Male rat	Adult	0, 1, 10, 30, 100 ppm in diet	4, 7, 13 weeks	0.07 (1 ppm) at 4 weeks	6500	0.71 (10 ppm) at 4 weeks	55,000	Steady-state serum levels were reached by 4 weeks. Dose-related increases in relative liver weight were similar at 4, 7, and 13 wks (see individual study table in Appendix 5).
Thomford et al. (2001); Butenhoff et al. (2002)	Male cynomolgus monkey	Adult	0, 3, 10, 20/30	26 weeks	----	---	3	72,000	<ul style="list-style-type: none"> <li>PFOA serum levels did not significantly differ at 3 and 10 mg/kg/day.</li> <li>NOAEL was not identified.</li> </ul>

\*LOAELs are based on statistical significance at  $p < 0.05$ . Effects that were not statistically significant occurred at doses below the NOAELs in some studies.



**TABLE 10B: STUDIES NOT PROVIDING SERUM PFOA DATA AT END OF DOSING PERIOD\***

<i>Citation</i>	<i>Species</i>	<i>Life-stage</i>	<i>Doses (mg/kg/day)</i>	<i>Duration</i>	<i>NOAEL (mg/kg/day)</i>		<i>Serum NOAE L (µg/L)</i>	<i>LOAEL (mg/kg/day)</i>	<i>Serum NOAEL (µg/L)</i>	<i>Comments</i>
Abbott et al. (2007)	Mouse (PND 21)	WT** dam	0, 0.1, 0.3, 0.6, 1.0	GD 1-17	0.3		NA	1	NA	<ul style="list-style-type: none"> <li>• Serum data are not presented in this table because they are from PND 21 and do not reflect maximum exposure at end of dosing period.</li> <li>• Liver weight was assessed in offspring on PND 21 and later time points. No data are available from earlier time points closer to the end of dosing.</li> </ul>
		WT pup			--			0.1		
		PPAR-α null dam			1			3		
		PPAR-α null pup			1			3		
DeWitt et al. (2008)	Female mouse	Adult	0, 0.94, 1.88, 3.75, 7.5	15 days	----		NA	0.94	NA	Serum PFOA data are not available for the two lowest doses in this study.
Loveless et al. (2008)	Male mouse	Adult	0, 0.3, 1, 10, 30	29 days	0.3		NA	1	NA	<ul style="list-style-type: none"> <li>• Linear PFOA was used in this study.</li> <li>• Relative liver weight increased in a dose-related manner at all doses below the LOAELs, but changes were not statistically significant.</li> </ul>
	Male rat	Adult			1			10	NA	
Quist et al. (2015)	Female mouse (PND 21)	Pup	0, 0.01, 0.1, 0.3, 1  (On control or high fat diet from PND 35-77)	GD 1-17	0.1  (Note: No NOAEL was identified for other hepatic effects including chronic active inflammation on PND 21 and hepatocellular hypertrophy on PND 91)		NA	0.3  (Note: LOAEL was 0.01 mg/kg/day for chronic active inflammation on PND 21 and hepatocellular hypertrophy on PND 91)	NA	<ul style="list-style-type: none"> <li>• Relative liver weight was increased on PND 21, but not on PND 91.</li> <li>• Frequency and severity of hepatocellular hypertrophy increased on PND 91 in all dosed groups, in the absence of increased liver weight. Statistical analysis was not presented.</li> <li>• Increased severity of chronic active hepatic periportal inflammation on PND 21 was significantly increased in all dosed groups. This effect occurred at doses below those that caused increased liver weight on PND 21.</li> <li>• Increased severity of periportal inflammation also occurred on PND 91, but was less severe than on PND 21.</li> <li>• Hepatic mitochondrial abnormalities occurred at 1 mg/kg/day on PND 21 and PND 91; they were more severe on PND 91. This effect was not evaluated at other doses.</li> <li>• Hepatic peroxisome proliferation was not observed at 1 mg/kg/day on PND 91; other doses were not evaluated.</li> </ul>
Son et al. (2008)	Male mouse	Adult	0.049, 2.64, 17.63, 47.21	4 weeks	-----		NA	0.49	NA	<ul style="list-style-type: none"> <li>• PFOA serum data are not available from this study.</li> <li>• Significantly increased levels of one or both liver enzymes, ALT and AST, occurred at all doses (data shown in Table 8).</li> </ul>
Tucker et al. (2015)	Female mouse	Pup PND 21	0, 0.01, 0.1, 0.3, 1	GD 1-17	CD-1	0.3	NA	1	NA	<ul style="list-style-type: none"> <li>• Serum data are not presented here because they are from PND 21 and do not reflect maximum exposure at end of dosing period.</li> <li>• Liver weight was assessed in offspring on PND 21 and later time points. No data are available from earlier time points closer to the end of dosing. Increased liver weight was not observed at time points later than PND 21. At these time points, PFOA body burdens would be lower than on PND 21.</li> <li>• Delayed mammary gland development occurred at lower doses than liver effects in both strains.</li> </ul>
		C57/BI			1	NA	-----	NA		
		WT pup			--			0.1		
		PPAR-α null dam			1			3		
		PPAR-α null pup	0, 0.1, 0.3, 1.0, 3.0		1			3		

\*LOAELs are based on statistical significance at p<0.05. Effects that were not statistically significant occurred at doses below the NOAELs in some studies. \*\*WT – Wild Type

<i>Citation</i>	<i>Species &amp; Strain</i>	<i>Lifestage for Dosing</i>	<i>Dose(s) (mg/kg/day)</i>	<i>Dosing Duration</i>	<i>Endpoint(s)*</i>	<i>NOAEL** (mg/kg/day)</i>	<i>LOAEL** (mg/kg/day)</i>	<i>PFOA Serum Concentration (ng/ml)</i>	<i>Comments</i>
<b>Botelho et al. (2015)</b>	Male C57BL/6 (H-2) <sup>b</sup> mice	Adult	0, 20, 50, 100, and 200 ppm in diet  (20 ppm estimated as 3 mg/kg/day from Qazi et al., 2013)	10 days	↓ complement activation (various parameters) at end of dosing period.	100 ppm  (estimated as 15 mg/kg/day based on data for lower dose in Quazi et al., 2013)	200 ppm  (estimated as 30 mg/kg/day based on data for lower dose in Quazi et al., 2013)	Estimated serum level at 200 ppm (LOAEL): 152,000 ng/ml (Qazi et al., 2009b)	Effects associated with PPAR-alpha occurred at doses below the LOAEL for ↓ complement activation; authors concluded that ↓ complement activation is PPAR-alpha independent.  LOAEL for ↑ liver weight was lower than for immune effect.
<b>DeWitt et al. (2008)</b>	Female C57/BL6N mice	Adult	0, 3.75, 7.5, 15, and 30 mg/kg/day in drinking water.	15 days	↓ IgM, ↑ IgG after immunization with sheep red blood cells	1.88 mg/kg/day	3.75 mg/kg/day	74,913 ng/ml at 3.75 mg/kg/day (LOAEL), one day post-dosing	NOAEL and LOAEL for ↓ relative spleen and thymus weight were higher than for other effects.  NOAEL and LOAEL for ↓ relative thymus weight were higher than for other effects.  LOAEL for ↑ liver weight was lower than for immune effect.
			0, 0.94, 1.88, 3.75, and 7.5 mg/kg/day in drinking water.		↓ IgM, ↑ IgG after immunization with sheep red blood cells  ↓ relative spleen weight	-----	3.75 mg/kg/day		
<b>DeWitt et al. (2009a)</b>	Female C57/BL6N mice	Adult	0, 3.75, 7.5, and 15 mg/kg/day in drinking water	10 days	↓ IgM	7.5 mg/kg/day (sham operated)  3.75 mg/kg/day (adrenalectomized)	15 mg/kg/day (sham operated)  3.75 mg/kg/day (adrenalectomized)	Not assessed	Authors conclude that effects on immune system are not due to increased serum corticosterone.
<b>Hu et al. (2010)</b>	Female C57/BL6N mice	Pregnant	0, 0.5, and 1 mg/kg/day  Gavage	GD 6-17	IgM (PND 49), IgG (PND 63) after immunization with sheep red blood cells.  Absolute and relative spleen and thymus weight (PND 49 and 63) in offspring	1 mg/kg/day	-----	Not assessed at end of dosing	

<i>Citation</i>	<i>Species &amp; Strain</i>	<i>Lifestage for Dosing</i>	<i>Dose(s) (mg/kg/day)</i>	<i>Dosing Duration</i>	<i>Endpoint(s)*</i>	<i>NOAEL** (mg/kg/day)</i>	<i>LOAEL** (mg/kg/day)</i>	<i>PFOA Serum Concentration (ng/ml)</i>	<i>Comments</i>
<b>Hu et al. (2012)</b>	Female C57/BL6N mice	Pregnant and lactating	0, 0.02, 0.2, and 2 mg/kg/day Gavage	Pre-pregnancy (10.1-15.7 days) through weaning	↓ percentage of splenic T regulatory cells in offspring (age - at least 6 weeks old)	0.2 mg/kg/day/---- (see Comments)	2 mg/kg/day/0.02 mg/kg/day (see Comments)	Not assessed	<i>Ex vivo</i> IL-10 production by splenic CD4+ T cells was ↓ at ≥ 0.02 mg/kg/day in male offspring; it was ↑ at 0.02 mg/kg/day but not other doses in females.  No effect on two serum autoantibodies. For 3rd serum autoantibodies (anti-ssDNA), ↓ at 0.02 and 2, but not 0.2 mg/kg/day, in females only. Significance of changes at 0.02 mg/kg/day are not clear.
<b>Iwai and Yamashita (2006)</b>	Male Crj:CD (SD)IGS rats	Adult	0, 0.5, 5, and 50 mg/kg/day Gavage	14 days	Percent lymphocytes in peripheral blood  Percent or number of lymphocytes subsets in peripheral blood  Absolute or relative spleen weight	50 mg/kg/day	-----	Not assessed	Relative liver weight ↑ at NOAEL for immune effects (50 mg/kg/day).
<b>Loveless et al. (2008)</b>	Male Crj:CD (SD)IGS rats	Adult	0, 0.3, 1, 10, 30 mg/kg/day	28 days Gavage	Several immune parameters	30 mg/kg/day	-----	Not assessed	Other immune effects in mice occurred at doses above LOAEL for decreased relative spleen weight.  LOAEL in mice was also 1 mg/kg/day for ↑ relative weight and necrosis in liver.  Although authors concluded immune effects are secondary to ↑ corticosterone, corticosterone was not ↑ at LOAEL for ↓ relative spleen weight.
	Male Crj:CD (SD)IGS mice				↓ relative spleen weight	0.3 mg/kg/day	1 mg/kg/day		

<i>Citation</i>	<i>Species &amp; Strain</i>	<i>Lifestage for Dosing</i>	<i>Dose(s) (mg/kg/day)</i>	<i>Dosing Duration</i>	<i>Endpoint(s)*</i>	<i>NOAEL** (mg/kg/day)</i>	<i>LOAEL** (mg/kg/day)</i>	<i>PFOA Serum Concentration (ng/ml)</i>	<i>Comments</i>
<b>Qazi et al. (2009a)</b>	Male C57BL/6 (H-2) <sup>b</sup> mice	Adult	10 or 200 ppm in diet	10 days	Numerous parameters related to immune function	10 ppm (data not shown)  Estimated as 1.5 mg/kg/day from Qazi et al. (2013).	200 ppm  Estimated as <30 mg/kg/day from Qazi et al. (2013)	Estimated serum level at 200 ppm (LOAEL) was 152,000 ng/ml (Qazi et al., 2009b)	
<b>Qazi et al. (2009b)</b>	Male C57BL/6 (H-2) <sup>b</sup> mice	Adult	200 ppm in diet	10 days	↓ relative spleen and thymus weight.  ↓ spleen and thymus cellularity.  ↓ splenocyte and thymocyte cell populations.  Histopathological changes in thymus.	-----	200 ppm  Estimated as <30 mg/kg/day from Qazi et al. (2013)	152,000 µg/L	Relative liver weight also ↑ at LOAEL.
<b>Qazi et al. (2010)</b>	Male C57BL/6 (H-2) <sup>b</sup> mice	Adult	20 ppm in diet	10 days	Several parameters of hepatic immune status	-----	20 ppm  Estimated as 3 mg/kg/day from Qazi et al. (2013).	87,600 ng/ml	↑ liver weight and histopathological changes in the liver also occurred at this dose.
<b>Qazi et al. (2012)</b>	Male C57BL/6 (H-2) <sup>b</sup> mice	Adult	10, 20, or 200 ppm in diet	10 days	↓ numbers of beta-lymphoid cells and beta-lymphoid cell subpopulations in bone marrow.	10 ppm  Estimated as 1.5 mg/kg/day from Qazi et al. (2013).	20 ppm  Estimated as 3 mg/kg/day from Qazi et al. (2013).	Estimated serum level at 20 ppm (LOAEL) was 87,600 ng/ml (Qazi et al., 2010)	Effects at 200 ppm may be secondary to decreased food consumption. Food consumption not decreased at LOAEL of 20 ppm.  ↑ relative liver weight at NOAEL for immune effects of 10 ppm.

<i>Citation</i>	<i>Species &amp; Strain</i>	<i>Lifestage for Dosing</i>	<i>Dose(s) (mg/kg/day)</i>	<i>Dosing Duration</i>	<i>Endpoint(s)*</i>	<i>NOAEL** (mg/kg/day)</i>	<i>LOAEL** (mg/kg/day)</i>	<i>PFOA Serum Concentration (ng/ml)</i>	<i>Comments</i>
<b>Qazi et al. (2013)</b>	Male C57BL/6 (H-2) <sup>b</sup> mice	Adult	0.5 or 20 ppm in diet  0.07 or 3 mg/kg/day	10 days (high dose)  28 days (low dose)	↑ Concavalin A-induced liver damage.  Changes in cytokine levels (both with and without response to Con A).	0.07 mg/kg/day (0.5 ppm) for 28 days	3 mg/kg/day (20 ppm) for 10 days	Estimated serum level at 20 ppm (LOAEL) was 87,600 ng/ml (Qazi et al., 2010)	
<b>Son et al. (2009)</b>	Male ICR mice	Adult	0.49, 2.64, 17.63, 47.21 mg/kg/day	21 days	↓ numbers of splenic T cell subpopulations (CD4-CD8+, CD4+CD8+).	---	0.49 mg/kg/day		These T cell subpopulations were not evaluated in other studies of PFOA.  ↑ liver weight at LOAEL for immune effects in this study, as reported in accompanying paper (Son et al., 2008)
<b>Yang et al. (2000)</b>	Male C57BL/6 mice	Adult	200 ppm in diet	Up to 10 days	↓ absolute and relative thymus and spleen weight beginning at 5 days.  ↓ thymocyte and splenocyte numbers, selective ↓ in immature thymocyte subpopulations, ↓ T and B cells in spleen, ↓ numbers of splenic T cell subpopulations (CD4+, CD4+CD8+), inhibition of thymocyte proliferation at 7 days (other time points not evaluated).	-----	200 ppm in diet  Estimated as <30 mg/kg/day from Qazi et al. (2013)	Estimated serum level at 200 ppm (LOAEL) was 152,000 ng/ml (Qazi et al., 2009b)	Relative liver weight also ↑ at LOAEL.

<i>Citation</i>	<i>Species &amp; Strain</i>	<i>Lifestage for Dosing</i>	<i>Dose(s) (mg/kg/day)</i>	<i>Dosing Duration</i>	<i>Endpoint(s)*</i>	<i>NOAEL** (mg/kg/day)</i>	<i>LOAEL** (mg/kg/day)</i>	<i>PFOA Serum Concentration (ng/ml)</i>	<i>Comments</i>
<b>Yang et al. (2002a)</b>	Male C57BL/6 mice	Adult	200 ppm in diet	10 or 16 days	↓ IgM and IgG response to horse red blood cell (HRBC) immunization.	-----	200 ppm in diet  Estimated as <30 mg/kg/day from Qazi et al. (2013)	Estimated serum level at 200 ppm (LOAEL) was 152,000 ng/ml (Qazi et al., 2009b)	
<b>Yang et al. (2002b)</b>	Male C57BL/6 mice (wild type)	Adult	200 ppm in diet	7 days	<i>C57BL/6 wild type:</i> ↓ spleen and thymus weight. ↓ # of splenocytes and thymocytes. ↓ CD4+CD8+ thymocytes. ↓ T and B cells in spleen. ↓ % of proliferating thymocytes. ↓ proliferation of splenocytes ex vivo in response to proliferative stimulation.		200 ppm in diet  Estimated as <30 mg/kg/day from Qazi et al. (2013)		Comparison of wild type versus PPAR-alpha null mice was between two different strains. Strain differences unrelated to PPAR-alpha status may have affected the results.  Similar increase in relative liver weight occurred in both wild type C57BL/6 and Sv/129 PPAR-alpha null mice. Peroxisome proliferation only increased in wild type mice.  Effects of PFOA on thymus occurred in PPAR-alpha null mice, to a lesser degree than in wild type mice. WY also caused these effects in PPAR-alpha null mice.  Effects of PFOA on spleen seen in wild type mice did not occur in PPAR-alpha null mice.
	Male Sv/129 PPAR-alpha null mice				<i>Sv/129 PPAR-alpha null:</i> ↓ thymus weight and number of thymocytes (attenuated). ↓ CD4+CD8+ thymocytes (attenuated). ↓ % of proliferating thymocytes (attenuated).				

\* IgG and IgM evaluations were based response to injection with sheep or horse red blood cells (RBC). In some studies, additional endpoints that are not shown in the table were evaluated; data for the most sensitive immune-related endpoint(s) are shown.

\*\* NOAELs are defined as the highest dose that did not produce a statistically significant ( $p < 0.05$ ) effect, and LOAELs are defined as the lowest doses with statistically significant ( $p < 0.05$ ) effects.

Table 12: Summary of studies of effects of gestational/lactational exposure to PFOA in mice (most sensitive effect(s) in each study are shown in *red italics*)\*

Citation and Study Design				Maternal/ Reproductive Effects			Effects in Offspring: Fetal through Weaning			Effects in Offspring: Post-weaning			Comments
<i>Citation</i>	<i>Strain</i>	<i>Administered dose(s) and routes (mg/kg/day)</i>	<i>Duration</i>	<i>Effect</i>	<i>NOAEL</i>	<i>LOAEL</i>	<i>Effect</i>	<i>NOAEL</i>	<i>LOAEL</i>	<i>Effect</i>	<i>NOAEL</i>	<i>LOAEL</i>	
Abbott et al. (2007)	129S1/SvlmJ wild type	0, 0.1, 0.3, 0.6, 1, 5, 10, or 20  Gavage	GD 1-17	<ul style="list-style-type: none"> <li>• Maternal weight gain</li> <li>• % FLR</li> <li>• Implants/litter</li> <li>• % litter loss (includes FLR)</li> <li>• Pups/litter (live + dead; excludes FLR)</li> <li>• <b>↑ relative liver weight on PND 22.</b></li> </ul>	10 1 20 0.3 1 0.6	-- 5 -- 0.6 -- 1	<ul style="list-style-type: none"> <li>• Body weight at birth</li> <li>• Eye opening delay</li> <li>• Postnatal mortality</li> <li>• Neonatal growth</li> <li>• <b>↑ relative liver weight on PND 22.</b></li> </ul>	1 0.6 0.3 0.6 --	-- 1 0.6 1 <b>0.1</b>	<ul style="list-style-type: none"> <li>• Body weight at week 28 (M) &amp; week 52 (F)</li> </ul>	1 --	--	<ul style="list-style-type: none"> <li>• No wild type live pups at <math>\geq 5</math> mg/kg/day.</li> <li>• FLR is PPAR-alpha independent.</li> <li>• <b>↑ pup liver weight is most sensitive endpoint in both strains.</b></li> </ul>
	129S1/SvlmJ PPAR- $\alpha$ null	0, 0.1, 0.3, 1, 3, 5, 10, or 20  Gavage	GD 1-17	<ul style="list-style-type: none"> <li>• Maternal weight gain</li> <li>• % FLR</li> <li>• Implants/litter</li> <li>• % litter loss (includes FLR)</li> <li>• Pups/litter (live + dead; excludes FLR)</li> <li>• <b>↑ relative liver weight on PND 22.</b></li> </ul>	20 3 20 3 1 1	-- 5 -- 5 -- <b>3</b>	<ul style="list-style-type: none"> <li>• Body weight at birth</li> <li>• Eye opening</li> <li>• Postnatal mortality</li> <li>• Neonatal growth</li> <li>• <b>↑ relative liver weight on PND 22.</b></li> </ul>	20 3 3 3 1	-- -- -- -- <b>3</b>	<ul style="list-style-type: none"> <li>• Body weight at week 28 (M) &amp; week 52 (F)</li> </ul>	3 --	--	



Citation and Study Design				Maternal/Reproductive Effects			Effects in Offspring: Fetal through Weaning (including fetal body weight and malformations)			Effects in Offspring: Post-weaning			Comments
Citation	Strain	Administered dose(s) and routes (mg/kg/day)	Duration	Effect	NOAEL	LOAEL	Effect	NOAEL	LOAEL	Effect	NOAEL	LOAEL	
Albrecht et al. (2013)	Sv/129 wild- type	0 or 3  Gavage	GD 1-17	• Maternal weight gain	3	--	• Body weight and crown-to-rump length on GD 18	3	--	NA	NA	NA	• Issues related to this study are discussed in text and individual study table in Appendix 5. • No significant effect for any developmental endpoint in any strain. Not consistent with effects reported in Abbott et al. (2007). • ↑ maternal and pup liver weight is the most sensitive endpoint in all strains.
	• Day of parturition			3	--	• Postnatal mortality	3	--					
	• Implants/litter			3	--	• Postnatal growth	3	--					
• % litter loss	3	--	• Eye opening	3	--								
• Live fetuses/litter	3	--	• ↑ <b>relative liver weight on GD 18</b>	--	<b>3</b>								
• Male/female ratio	3	--	• ↑ <b>relative liver weight on PND 20</b>	--	<b>3</b>								
	Sv/129 PPAR- alpha null			• Maternal weight gain	3	--	• Body weight & crown-to-rump length on GD 18	3	--	NA	NA	NA	
				• Day of parturition	3	--	• Postnatal mortality	3	--				
				• Implants/litter	3	--	• Postnatal growth	3	--				
				• % litter loss	3	--	• Eye opening delay	3	--				
				• Live fetuses/litter	3	--	• ↑ <b>relative liver weight on GD 18</b>	3	--				
				• Male/female ratio	3	--	• ↑ <b>relative liver weight on PND 20</b>	3	--				
				• ↑ <b>relative liver weight on GD 18</b>	--	<b>3</b>	• <b>MG on PND 20</b>	3	--				
				• ↑ <b>relative liver weight on PND 20</b>	3	--							
	Sv/129 Human- ized PPAR- alpha			• Maternal weight gain	3	--	• Body weight & crown-to-rump length on GD 18	3	--	NA	NA	NA	
				• Day of parturition	3	--	• Postnatal mortality	3	--				
				• Implants/litter	3	--	• Postnatal growth	3	--				
				• % litter loss	3	--	• Eye opening	3	--				
				• Live fetuses/litter	3	--	• ↑ <b>relative liver weight on GD 18</b>	--	<b>3</b>				
				• Male/female ratio	--	<b>3</b>	• ↑ <b>relative liver weight on PND 20</b>	3	--				
				• ↑ <b>relative liver weight on GD 18</b>	--	<b>3</b>	• <b>MG on PND 20</b>	3	--				
				• ↑ <b>relative liver weight on PND 20</b>	3	--							

MG – delayed mammary gland development.

Citation and Study Design				Maternal/Reproductive Effects			Effects in Offspring: Fetal through Weaning (including fetal body weight and malformations)			Effects in Offspring: Post-weaning			Comments
Citation	Strain	Administered dose(s) and routes (mg/kg/day)	Duration	Effect	NOAEL	LOAEL	Effect	NOAEL	LOAEL	Effect	NOAEL	LOAEL	
Fenton et al. (2009)	CD-1	0, 0.1, 1, or 5 Gavage	GD 17 Single dose	<ul style="list-style-type: none"> <li>• Body weight on GD 17 and 18, and PND 1-18</li> <li>• <b>↑ relative liver weight on GD 18, PND 1,4, 8, 18</b></li> </ul>	5 5	-- --	Offspring body weight on GD 18 and PND 1-18	5	--	NA	NA	NA	<ul style="list-style-type: none"> <li>• This was primarily a pharmacokinetic study and used a single dose.</li> </ul>
Hines et al. (2009)	CD-1	0, 0.01, 0.1, 0.3, 1, 3 or 5	GD 1-17	<ul style="list-style-type: none"> <li>• Live pups/litter</li> </ul>	NA 5	NA --	<ul style="list-style-type: none"> <li>• ↓ Body weight at PND 1</li> <li>• ↓ Body weight at PND 22</li> </ul>	1 0.3	5 1	<ul style="list-style-type: none"> <li>• ↑ Body weight at 20-29 wks***</li> <li>• ↓ Body weight at 20-29 wks</li> <li>• ↑ insulin &amp; leptin at 21-33 wks*** (Only females evaluated)</li> </ul>	--- 1 ---	<b>0.01</b> <b>0.01</b>	<ul style="list-style-type: none"> <li>• Effects at 20-29 weeks on body weight (0.01-0.3 mg/kg/day) and hormones (0.01-0.1 mg/kg/day) occurred at low doses but not higher doses.</li> <li>• Mortality occurred in all groups including controls after 36 weeks.</li> <li>• Effects at 18 months are not in this table.</li> </ul>
Hu et al. (2010)	C57BL/6N	0, 0.5, 1 Drinking water	GD 6-17	<ul style="list-style-type: none"> <li>• Maternal body weight</li> <li>• M/F ratio</li> </ul>	1 1	-- --	<ul style="list-style-type: none"> <li>• ↓ Body weight at PND 2</li> <li>• ↓ Body weight at PND 7 &amp; 14</li> <li>• <b>↑ relative liver weight on GD 18</b></li> </ul>	-- 0.5 1	<b>0.5</b> 1 --	<ul style="list-style-type: none"> <li>• IgM on PND 48</li> <li>• IgG on PND 63</li> <li>• Spleen, adrenal, thymus weight, PND 48 &amp; 63</li> <li>• <b>↑ relative liver weight on PND 48 &amp; 63</b></li> </ul>	1 1 1 1	-- -- -- --	See also summary table of studies of immune effects (Table 11).
Hu et al. (2012)	C57BL/6N	0.02, 0.2 or 2 Gavage	Pre-mating – PND 21; (mean 12.9 days pre-pregnancy)	<ul style="list-style-type: none"> <li>• Maternal body weight (through weaning)</li> <li>• Pups/litter</li> <li>• M/F ratio</li> </ul>	2 2 2	-- -- --	<ul style="list-style-type: none"> <li>• ↓ Body weight at PND 1 - 21</li> </ul>	0.2	<b>2</b>	<ul style="list-style-type: none"> <li>• Body weight at 6 weeks.</li> <li>• ↓ T cells in spleen at ~ 6 wks (Only females evaluated).</li> </ul>	2 0.2	-- <b>2</b>	<ul style="list-style-type: none"> <li>• <i>Ex vivo</i> and inconsistent <i>in vivo</i> immune effects observed at 0.02 mg/kg/day; see summary table for immune effects (Table 11).</li> </ul>

Citation and Study Design				Maternal/ Reproductive Effects			Effects in Offspring through Weaning (including fetal body weight)			Effects in Offspring: Post-weaning			Comments
Citation	Strain	Administered dose(s) and routes (mg/kg/day)	Duration	Effect	NOAEL	LOAEL	Effect	NOAEL	LOAEL	Effect	NOAEL	LOAEL	
Lau et al. (2006)	CD-1	0, 1, 3, 5, 10, 20, or 40  Gavage	GD 1-17 (sacrificed GD 18)  GD 1-18 (allowed to deliver)	<ul style="list-style-type: none"> <li>• ↓ Maternal weight gain</li> <li>• FLR</li> <li>• # of implants</li> <li>• Live fetuses/litter</li> <li>• Prenatal loss/live litter</li> <li>• ↑ <b>relative liver weight on GD 18</b></li> </ul>	10 3 -- 10 10 --	20 5 40 20 20 <b>1</b>	<ul style="list-style-type: none"> <li>• ↓ fetal body weight</li> <li>• ↑ reduced ossification (several sites)</li> <li>• ↑ Limb &amp; tail defects</li> <li>• ↑ Micro-cardia</li> <li>• ↑ Postnatal mortality</li> <li>• ↓ Postnatal growth</li> <li>• Delayed eye opening</li> </ul>	10 -- 3 10 3 1 3	20 <b>1<sup>a</sup></b> 5 <sup>a</sup> 10 5 3 5	<ul style="list-style-type: none"> <li>• ↓ body weight in males at 6.5 weeks (p&lt;0.05 for treatment effect)</li> <li>• Delay in vaginal opening.</li> <li>• Delay in first estrus.</li> <li>• Accelerated preputial separation.</li> </ul>	Not started 20 3 --	Not started 10 5 <b>1<sup>a</sup></b>	<ul style="list-style-type: none"> <li>• Reduced ossification and increased limb defects did not increase as dose increased. These effects were not significant at one or more doses above the LOAEL.</li> <li>• Accelerated preputial separation was not observed at 20 mg/kg/day.</li> <li>• Body weight in treated animals tended to be higher than in controls as animals aged (until age 60 wks).</li> <li>• <b>Maternal serum levels on GD 18 shown graphically.</b></li> <li>• This study is also summarized in liver weight tables (Table 10).</li> </ul>
Macon et al. (2011)	CD-1	0, 0.3, 1, or 3  Gavage	GD 1-17	NA	NA	NA	<ul style="list-style-type: none"> <li>• Body weight PND 7-21</li> <li>• ↑ <b>relative liver weight on PND 7</b></li> <li>• <b>MG at PND 14 &amp; 21<sup>a</sup></b></li> </ul>	3 -- --	-- <b>0.3<sup>a</sup></b> <b>0.3</b>	<ul style="list-style-type: none"> <li>• Body weight on PND 42-84</li> <li>• <b>MG at PND 42 &amp; 84<sup>a</sup></b></li> </ul>	3 --	-- <b>0.3</b>	<ul style="list-style-type: none"> <li>• LOAELs for ↑ pup liver weight were higher at later pre-weaning and post-weaning time points.</li> <li>• LOAEL for MG was higher at PND 7.</li> <li>• MG was not significant at 3 mg/kg/day on PND 63 and 84, possibly due to small n (n=2)</li> </ul>
		0, 0.01, 0.1, or 1  Gavage	GD 10-17	NA	NA	NA	<ul style="list-style-type: none"> <li>• Body weight at birth (females)</li> <li>• Body weight on PND 1-21</li> <li>• ↑ <b>relative liver weight on PND 4, 7, 14<sup>a</sup></b></li> <li>• <b>MG at PND 21</b></li> </ul>	1 1 <b>0.1</b> --	-- -- <b>1</b> <b>0.01</b>	NA	NA	NA	<ul style="list-style-type: none"> <li>• <b>Pup serum levels measured on PND 1 (end of dosing).</b></li> <li>• Increased relative liver weight not significant on PND 1 and 21.</li> <li>• Delayed mammary gland development more sensitive endpoint than increased relative liver weight in offspring.</li> </ul>

<sup>a</sup> See comments.

Citation and Study Design				Maternal/Reproductive Effects			Effects in Offspring through Weaning (including fetal body weight and malformations)			Effects in Offspring: Post-weaning			Comments
<i>Citation</i>	<i>Strain</i>	<i>Administered dose(s) and routes (mg/kg/day)</i>	<i>Duration</i>	<i>Effect</i>	<i>NOAEL</i>	<i>LOAEL</i>	<i>Effect</i>	<i>NOAEL</i>	<i>LOAEL</i>	<i>Effect</i>	<i>NOAEL</i>	<i>LOAEL</i>	
Suh et al. (2011)	CD-1	0, 2, 10 or 25 Gavage	GD 11-16	↓ Maternal body weight on GD 13-16  <i>Endpoints assessed on GD 16.</i> <ul style="list-style-type: none"> <li>• ↓ placenta weight</li> <li>• Necrotic changes in placenta<sup>a</sup></li> <li>• ↓ levels of gene expression for three placental lactogens (PRL family) and two pituitary-specific positive transcription factor 1 isoforms.</li> <li>• ↓ # of placental trophoblast cells</li> <li>• ↓ fetal weight</li> <li>• ↓ fetal/ placental weight ratio</li> <li>• # of implantations</li> <li>• ↑ # of resorptions/dead fetus</li> <li>• ↓ # of live fetus</li> </ul>	10 <sup>a</sup>	25 <sup>a</sup>	NA	NA	NA	NA	NA	NA	<ul style="list-style-type: none"> <li>• Doses at which maternal body weight ↓ are not stated, although significance for trend is shown on various GDs. NOAEL &amp; LOAEL in this table is based on graph of data.</li> <li>• Effects on placenta and production of placental factors may contribute to decreased fetal growth.</li> <li>• Fetal/placental ratio indicates efficiency of placenta.</li> <li>• Levels of placental lactogens significantly correlate with fetal weight on individual basis.</li> <li>• Statistical evaluation for necrotic changes in placenta is not provided; doses where this effect occurred are discussed in text.</li> <li>• NOAELs for potentially important placental effects not identified.</li> </ul>

<sup>a</sup> See comments.

Citation and Study Design				Maternal/ Reproductive Effects			Effects in Offspring through Weaning (including fetal body weight and malformations)			Effects in Offspring: Post-weaning			Comments
Citation	Strain	Administered dose(s) and routes (mg/kg/day)	Duration	Effect	NOAEL	LOAEL	Effect	NOAEL	LOAEL	Effect	NOAEL	LOAEL	
Tucker et al. (2015)	CD-1	0, 0.01, 0.1, 0.3, 1 Gavage	GD 1-17	NA	NA	NA	<ul style="list-style-type: none"> <li>• ↓ body weight on PND 21</li> <li>• ↓ body weight minus liver weight on PND 21</li> <li>• Estrogen &amp; progesterone, PND 21</li> <li>• ↑ <b>relative liver weight, PND 21</b></li> <li>• <b>MG at PND 21</b></li> </ul>	1	--	<ul style="list-style-type: none"> <li>• Body weight &amp; body weight minus liver weight on PND 35 &amp; 56</li> <li>• Day of vaginal opening</li> <li>• Day of first estrus</li> <li>• Estrogen &amp; progesterone on PND 35 &amp; 56</li> <li>• ↑ <b>relative liver weight, PND 35 &amp; 56</b></li> <li>• <b>MG at PND 35 &amp; 56</b></li> </ul>	1	--	PFOA serum data provided from PND 21 and later time points.  Higher serum levels at same PFOA dose in CD-1 mice than C57Bl/6 mice may contribute to the greater sensitivity of CD-1.
	C57Bl/6						<ul style="list-style-type: none"> <li>• ↓ body weight on PND 21</li> <li>• ↓ body weight minus liver weight on PND 21</li> <li>• Estrogen &amp; progesterone on PND 21</li> <li>• ↑ <b>relative liver weight, PND 21</b></li> <li>• <b>MG at PND 21</b></li> </ul>	1	--	<ul style="list-style-type: none"> <li>• Body weight &amp; body weight minus liver weight on PND 61</li> <li>• Day of vaginal opening</li> <li>• Day of first estrus</li> <li>• Estrogen &amp; progesterone, PND 61</li> <li>• ↑ <b>relative liver weight on PND 61</b></li> <li>• <b>MG at PND 61</b></li> </ul>	1	--	

<sup>a</sup> See comments.

Citation and Study Design				Maternal/ Reproductive Effects			Effects in Offspring through Weaning (including fetal body weight and malformations)			Effects in Offspring: Post-weaning			Comments
<i>Citation</i>	<i>Strain</i>	<i>Administered dose(s) and routes (mg/kg/day)</i>	<i>Duration</i>	<i>Effect</i>	<i>NOAEL</i>	<i>LOAEL</i>	<i>Effect</i>	<i>NOAEL</i>	<i>LOAEL</i>	<i>Effect</i> <sup>a</sup>	<i>NOAEL</i>	<i>LOAEL</i>	
van Esterik et al. (2016)	C57Bl/6J	0, 003, 0,01, 0.1, 0.3, 1, or 3 mg/kg/day  Dietary	2 weeks before mating through weaning	<ul style="list-style-type: none"> <li>• Maternal weight gain</li> <li>• ↓ litter size</li> <li>• Male/female ratio</li> </ul>	3 <sup>a</sup>  0.3 <sup>a</sup> 3 <sup>a</sup>	--  1 <sup>a</sup> --	<ul style="list-style-type: none"> <li>• ↓ Body weight on PND 4</li> <li>• Neonatal survival</li> </ul>	--  3 <sup>a</sup>	0.003 <sup>a</sup>  --				<ul style="list-style-type: none"> <li>• Exposure regimen differed from other studies. Exposure began before mating and continued through lactation.</li> <li>• Data presented as BMD and BMDL for each endpoint. NOAELs and LOAELs in table are based on interpretation of graphs and/or discussion in text; statistical significance is not presented. Personal communication with authors indicates that study was not intended to identify LOAELs and NOAELs. Data for some endpoints (e.g. relative liver weight) not presented in usable form.</li> <li>• The LOAEL for decreased neonatal body weight appears to be much lower than in other studies. As above, personal communication with authors indicates that study was not intended to identify LOAELs and NOAELs.</li> <li>• Text states that body weight decrements persisted through lactation and until wk. 21. Doses at which this occurred not stated.</li> <li>• Later in life studies relate to mode of action and effects with high fat versus control diet.</li> </ul>

<sup>a</sup> See comments.

Citation and Study Design				Maternal/ Reproductive Effects			Effects in Offspring through Weaning (including fetal body weight and malformations)			Effects in Offspring: Post-weaning			Comments
Citation	Strain	Administered dose(s) and routes (mg/kg/day)	Duration	Effect	NOAEL	LOAEL	Effect	NOAEL	LOAEL	Effect	NOAEL	LOAEL	
White et al. (2007)	CD-1	0 or 5 Gavage	GD 1-17, GD 8-17, GD 12-17  <i>Restricted exposure study****</i>	<ul style="list-style-type: none"> <li>• ↓ Maternal weight gain, GD 18</li> <li>• # of implants</li> <li>• Live fetuses/litter</li> <li>• % prenatal loss/live litter</li> </ul>	GD 1-17 GD 1-17 GD 1-17 GD 8-17	-- -- -- GD 1-17	<ul style="list-style-type: none"> <li>• ↓ Body weight on PND 1, 5, 10, 20</li> <li>• <b>MG on PND 21</b></li> </ul>	-- --	<b>GD 12-17</b> <b>GD 12-17</b>	NA	NA	NA	
White et al. (2009)	CD-1	0 or 5 Gavage	GD 8-17  <i>Cross-foster study*****</i>	<ul style="list-style-type: none"> <li>• ↑ Maternal weight gain (GD 8-17)</li> <li>• Litter size</li> <li>• ↑ <b>relative liver weight, PND 1, 3, 5, 10</b></li> </ul>	-- 5 0 dam, 5U pups	5 -- 5 dam, control pups	<ul style="list-style-type: none"> <li>• ↓ Body weight on PND 1, 3</li> <li>• ↓ Body weight on PND 10, 20</li> <li>• ↑ <b>relative liver weight, PND 1, 3</b></li> <li>• ↑ <b>relative liver weight, PND 5, 10</b></li> <li>• <b>MG, PND 1, 3, 5, 10</b></li> </ul>	5L, 5U -- 5L -- --	5U+L <b>5L, 5U</b> 5U <b>5L, 5U</b> <b>5L, 5U</b>	NA	NA	NA	
White et al. (2009); Wolf et al. (2007)	CD-1	0, 3, or 5 Gavage	GD 1-17  <i>Cross-foster study*****</i>	<ul style="list-style-type: none"> <li>• ↑ Maternal wt. gain, GD 17</li> <li>• FLR</li> <li>• # of implants</li> <li>• Live fetuses/litter</li> <li>• Prenatal loss/live litter</li> <li>• ↑ <b>relative liver wt., PND 22</b></li> <li>• <b>MG at PND 22</b></li> </ul>	-- 3 5 5 5 5 -- 3L	3 5 -- -- -- -- 3 3U	<ul style="list-style-type: none"> <li>• ↓ Body weight at birth</li> <li>• ↓ Body weight on PND 22 (males)</li> <li>• ↓ Body weight on PND 22 (females)</li> <li>• Delayed eye opening</li> <li>• ↓ survival to PND 22</li> <li>• ↑ <b>relative liver weight, PND 22</b></li> <li>• <b>MG at PND 22</b></li> </ul>	3 3U, 5L 3U, 3L 3U, 5L 3U+L, 5U, 5L -- 3L	5 3U+L, 5U 3U+L, 5U, 5L 3U+L, 5U 5U+L <b>3L, 3U</b> 3U	<ul style="list-style-type: none"> <li>• ↓ Body weight until PND 36 (M)</li> <li>• ↓ Body weight until PND 85 (F)</li> <li>• <b>MG at PND 42, 63</b></li> </ul>	3U+L, 5U, 5L 3U+L, 5L --	5U+L 5U <b>3L, 3U</b>	Body weight of male 3U group was increased from PND 85 (week 12) to week 35.

U = exposure *in utero* only; L = exposure through lactation only; U + L = exposure both *in utero* and through lactation.



Citation and Study Design				Maternal/ Reproductive Effects			Effects in Offspring: Fetal through Weaning (including fetal body weight and malformations)			Effects in Offspring: Post-weaning			Comments
Citation	Strain	Administered dose(s) and routes (mg/kg/day)	Duration	Effect	NOAEL	LOAEL	Effect	NOAEL	LOAEL	Effect	NOAEL	LOAEL	
Wolf et al. (2007)  (See White et al., 2009 for additional study from this publication)	CD-1	0  5; GD 15-17, 13-17, 10-17, or 7-17.  20; GD 15-17 (Post-natal endpoints were not assessed at this dose due to decreased post-natal survival.)  Gavage	GD 15-17, GD 13-17, GD 10-17, GD 7-17  Restricted exposure study****	<ul style="list-style-type: none"> <li>• ↑ Maternal weight gain</li> <li>• # of implants</li> <li>• Pups/litter</li> <li>• % prenatal loss</li> </ul>	5, GD 10-17  5, GD 7-17  5, GD 7-17  5, GD 7-17	5, GD 13-17  --  --  --	<ul style="list-style-type: none"> <li>• ↓ Body weight at birth (males)</li> <li>• ↓ Body weight at birth (females)</li> <li>• ↓ survival until PND 22</li> <li>• Delayed eye opening</li> <li>• ↓ Body weight at PND 22</li> </ul>	5, GD 13-17  20, GD 15-17; 5, GD 7-17  5, GD 7-17  5, GD 13-17  --	20, GD 15-17; 5, GD 10-17  --  20, GD 15-17  5, GD 10-17  <b>5, GD 15-17</b>	<ul style="list-style-type: none"> <li>• ↓ Body weight until age 10-11 weeks (males)</li> </ul>	5, GD 13-17	5, GD 10-17	Body weight of 5 mg/kg/day females exposed on GD 13-17 was increased above controls after PND 161 (week 23).
White, et al. (2011b)	CD-1	0, 1 or 5 (gavage)  0 or 1 (gavage) plus 5 ppb (5000 ng/L) in drinking water  .	GD 1-17 (P0) for gavage exposures.  GD 1 (P0) – PND 63 (F2) for drinking water exposures  Multi-generation study. (See comments.)	<ul style="list-style-type: none"> <li>• ↓ Maternal weight gain</li> <li>• Implants/litter</li> <li>• Live fetus/litter</li> <li>• Prenatal loss</li> </ul>	5  5  1  1	--  --  5  5	<ul style="list-style-type: none"> <li>• ↓ Body weight at PND 22</li> <li>• ↓ Survival until PND 22</li> <li>• ↑ <b>relative liver weight, PND 22</b></li> <li>• <b>MG at PND 22</b></li> </ul>	5  --  --  --	--  5  1 (not significant at 1 + 5 ppb in drinking water)  <b>5 ppb in drinking water; 1 mg/kg/day</b>	<ul style="list-style-type: none"> <li>• ↓ Body weight at PND 42</li> <li>• ↓ Body weight at PND 63</li> <li>• ↑ <b>relative liver weight, PND 42</b></li> <li>• <b>MG at PND 42, 63</b></li> </ul>	1  5  1  --	5  --  5  <b>5 ppb in drinking water; 1 mg/kg/Day</b>	Only effects for P0 dams and F1 offspring presented here.  See Table 14 and individual study table in Appendix 5 for additional information on this study.

Citation and Study Design				Maternal/ Reproductive Effects			Effects in Offspring: Fetal through Weaning (including fetal body weight and malformations)			Effects in Offspring: Post-weaning			Comments
Citation	Strain	Administered dose(s) and routes (mg/kg/day)	Duration	Effect	NOAEL	LOAEL	Effect	NOAEL	LOAEL	Effect	NOAEL	LOAEL	
Yahia et al. (2010)	ICR	0, 1, 5, 10  Gavage	GD 0-17 (assessed on GD 18)  GD 0-18 (postnatal assessment)	<ul style="list-style-type: none"> <li>• ↓ Maternal weight gain</li> <li>• ↑ Relative kidney weight</li> <li>• ↓ absolute brain weight</li> <li>• ↑ serum liver enzymes.</li> <li>• ↓ serum lipids</li> <li>• ↑ <b>relative liver weight, PND 22.</b></li> </ul>	1 -- 5 5 5 --	5 1 10 10 10 <b>I</b>	<ul style="list-style-type: none"> <li>• ↓ fetal GD 18 body weight &amp; birth weight</li> <li>• ↓ survival until PND 4</li> <li>• ↑ cleft sternum, delayed ossification of phalanges, delayed incisor eruption</li> </ul>	1 1 1 5	5 5 5 10	NA	NA	NA	NOAEL for delayed ossification is higher than LOAEL (1 mg/kg/day) for this effect in Lau et al. (2006). All pups died by PND 4 at LOAEL for delayed ossification (10 mg/kg/day).

## \* General notes:

NOAEL is defined as the highest dose that did not produce a statistically significant effect ( $p \leq 0.05$ ) compared to control. LOAEL is defined as the lowest dose with statistically significant effects observed ( $p \leq 0.05$ ) compared to control. For some studies, there were dose-related trends that included non-statistically significant changes at lower doses.

- In some studies, not all dose groups were evaluated for some endpoints. For some studies, not all endpoints evaluated are listed.
- Several studies that focused on other specific endpoints also evaluated reproductive and/or developmental endpoints but did not present data for these endpoints in usable form, or did not provide statistical significance. These studies are mentioned in the text but are not included in this table.
- Serum data are useful for dose-response modeling only when measured at end of dosing period. Serum data in many studies were from later time points; these data provide useful pharmacokinetic information but are not appropriate for dose-response modeling.

\*\* See Table 14 and individual study tables in Appendix 5 for more details on studies in which mammary gland development was evaluated.

\*\*\* Effect occurred at low, but not high, doses.

\*\*\*\* In **restricted exposure studies**, gestational exposure was to the same dose for varying periods of time. In determining LOAELs and NOAELs, shorter time periods of dosing were considered to have been lower exposures than longer time periods of dosing.

\*\*\*\*\* In **cross foster studies**, pups were exposed *in utero* (U), through lactation (L), or both (U+L). In determining LOAELs and NOAELs, all groups to exposed lower doses (L, U, or U+L) were considered to have had lower exposure than those with higher doses. Within the same dosage level (mg/kg/day), L and U groups were considered to have had lower exposure than U+L groups.

FLR – full litter resorptions. MG – Delayed mammary gland development. NA – not assessed.

Table 13. Identification of most sensitive endpoints in mouse developmental studies of PFOA\*

Citation and Study Design				Most Sensitive Reproductive/Developmental Endpoint(s) (other than increased relative liver weight or delayed mammary gland development)	Delayed Mammary Gland Development	Increased Relative Liver Weight	
Citation	Strain	Administered dose(s) and routes (mg/kg/day)	Duration				
Abbott et al. (2007)	129S1/SvImJ wildtype	0, 0.1, 0.3, 0.6, 1, 5, 10, or 20 Gavage	GD 1-17	% litter loss (includes full litter resorption); postnatal mortality NOAEL – 0.3 LOAEL – 0.6	NA	Pup, PND 22  <b>NOAEL-ND</b> <b>LOAEL-0.1</b>	
	129S1/SvImJ PPAR-alpha null	0, 0.1, 0.3, 1, 3, 5, 10, or 20 Gavage	GD 1-17	% full litter resorptions; % litter loss (includes full litter resorption) NOAEL – 3 LOAEL – 5	NA	Maternal and pup, PND 22  <b>NOAEL - 1</b> <b>LOAEL - 3</b>	
Albrecht et al. (2013)	Sv/129 wild-type	0 or 3 Gavage	GD 1-17	All effects:  NOAEL – 3 LOAEL - ND	NOAEL – 3 LOAEL - ND	Maternal and offspring, GD 18 and PND 20  <b>NOAEL – ND</b> <b>LOAEL - 3</b>	
	Sv/129 PPAR-alpha null			All effects  NOAEL – 3 LOAEL - ND		NOAEL – 3 LOAEL - ND	Maternal, GD18, offspring GD 18 and PND 20  <b>NOAEL – ND</b> <b>LOAEL - 3</b>
	Sv/129 humanized PPAR-alpha			Male/female offspring ratio  <b>NOAEL – ND</b> <b>LOAEL - 3</b>		NOAEL – 3 LOAEL - ND	Maternal and offspring, GD 18  <b>NOAEL – ND</b> <b>LOAEL - 3</b>
Hines et al. (2009)	CD-1	0, 0.01, 0.1, 0.3, 1, 3 or 5 Gavage	GD 1-17	Increased body weight, insulin & leptin in female offspring at weeks 20-29  <b>NOAEL – ND</b> <b>LOAEL – 0.01</b> <i>(No effects at some higher doses)</i>	NA	NA	
Hu et al. (2010)	C57BL/6N	0, 0.5, 1 Drinking water	GD 6-17	Decreased offspring body weight at PND 2  <b>NOAEL – ND</b> <b>LOAEL – 0.5</b>	NA	Offspring, PND 48 and 63 NOAEL – 1 LOAEL – ND <i>(not evaluated at earlier times)</i>	
Hu et al. (2012)	C57BL/6N	0.02, 0.2 or 2 Gavage	Pre-mating – PND 21	↓ Body weight at PND 1 – 21; ↓ T cells in spleen at ~ 6 wks  <b>NOAEL – 0.2</b> <b>LOAEL – 2</b>	NA	NA	

Citation and Study Design				Most Sensitive Reproductive/Developmental Endpoint(s) (other than increased relative liver weight or delayed mammary gland development)	Delayed Mammary Gland Development	Increased Relative Liver Weight
Citation	Strain	Administered dose(s) and routes (mg/kg/day)	Duration			
Lau et al. (2006)	CD-1	0, 1, 3, 5, 10, 20, or 40  Gavage	GD 1-17 or GD 1-18	Reduced ossification (not significant at some doses >LOAEL); accelerated preputial separation (did not occur at 20 mg/kg/day)  <b>NOAEL – ND</b> <b>LOAEL – 1</b>	NA	Maternal, GD 18  <b>NOAEL – ND</b> <b>LOAEL – 1</b>
Macon et al. (2011)	CD-1	0, 0.3, 1, or 3  Gavage	GD 1-17	Offspring body weight, PND 7-84  NOAEL – 3 LOAEL – ND	Offspring, PND 21	Offspring, PND 7  <b>NOAEL – ND</b> <b>LOAEL – 0.3</b>
		0, 0.01, 0.1, or 1  Gavage	GD 10-17	Body weight, birth – PND 21  NOAEL – 1 LOAEL – ND		Offspring, PND 4,7, 14  NOAEL – 0.1 LOAEL – 1
Suh et al. (2011)	CD-1	0, 2, 10 or 25  Gavage	GD 11-16	Decreased placenta weight; decreased gene expression for placental factors; decreased fetal/ placental weight ratio; increased number of resorptions/dead fetuses  NOAEL – ND LOAEL – 2	NA	NA
Tucker et al. (2015)	CD-1	0, 0.01, 0.1, 0.3, 1  Gavage	GD 1-17	Decreased body weight minus liver weight, PND 21  NOAEL – 0.3 LOAEL – 1	Offspring, PND 35 and 56  <b>NOAEL – ND</b> <b>LOAEL – 0.01</b>	Offspring, PND 21  NOAEL – 0.3 LOAEL – 1
	C57Bl/6			All effects evaluated:  NOAEL – 1 LOAEL – ND	Offspring, PND 61  <b>NOAEL – 0.1</b> <b>LOAEL – 0.3</b>	Offspring, PND 21 and 61  NOAEL – 1 LOAEL – ND
van Esterik et al. (2016)	C57Bl/6 J	0, 0.03, 0.01, 0.1, 0.3, 1, or 3 mg/kg/day  Dietary	2 weeks before mating through weaning	Decreased body weight on PND 4  <b>NOAEL – ND</b> <b>LOAEL – 0.003</b>	NA	NA
White et al. (2007)	CD-1	0 or 5  Gavage	GD 1-17, GD 8-17, or GD 12-17  <i>Restricted exposure study**</i>	% prenatal loss per live litter  NOAEL – 5 mg/kg, GD 8-17 LOAEL – 5 mg/kg, GD 1 – 17	Offspring, PND 10, 20  <b>NOAEL – ND</b> <b>LOAEL - 5 mg/kg, GD 12-17</b>	NA

Citation and Study Design				Most Sensitive Reproductive/Developmental Endpoint(s) (other than increased relative liver weight or delayed mammary gland development)	Delayed Mammary Gland Development	Increased Relative Liver Weight
Citation	Strain	Administered dose(s) and routes (mg/kg/day)	Duration			
White et al. (2009)	CD-1	0 or 5  Gavage	GD 8-17  <i>Cross-foster Study***</i>	Decreased body weight on PND 10, 20  <i>NOAEL – ND</i> <i>LOAEL – 5L, 5U</i>	Offspring, PND 1-10  <i>NOAEL – ND</i> <i>LOAEL – 5L, 5U</i>	Offspring, PND 5-10  <i>NOAEL – ND</i> <i>LOAEL – 5L, 5U</i>
White et al. (2009); Wolf et al. (2007)	CD-1	0, 3, or 5  Gavage	GD 1-17  <i>Cross-foster Study***</i>	Decreased body weight on PND 22  NOAEL – 3U, 3L LOAEL – 3 U+L, 5L, 5U	Offspring, PND 42, 63  <i>NOAEL – ND</i> <i>LOAEL – 3L, 3U</i>	Offspring, PND 22  <i>NOAEL – ND</i> <i>LOAEL – 3L, 3U</i>
White, et al. (2011b)  <i>Multi-generation study – only P0 dam and F1 offspring data shown here</i>	CD-1	0, 1 or 5 (Gavage)  0 or 1 (gavage) with 5 ppb in drinking water	GD 1-17 (P0) for gavage exposures.  GD 1 (P0) – PND 63 (F2) for drinking water exposures	Increased prenatal loss; decreased live fetus/litter; decreased body weight on PND 42  NOAEL – 1 LOAEL - 5	NA	Offspring, PND 22  <i>NOAEL-ND</i> <i>LOAEL-1</i>  (Not significant at 1 mg/kg/day plus 5 ppb in drinking water)
Wolf et al. (2007)  <i>(See White et al., 2009 for other study from this publication)</i>	CD-1	0  5; GD 15-17, 13-17, 10-17, or 7-17.  20; GD 15-17  Gavage	GD 15-17, GD 13-17, GD 10-17, or GD 7-17  <i>Restricted exposure study**</i>	Increased maternal weight gain  NOAEL – 5 mg/kg, GD 13-17 LOAEL – 5 mg/kg, GD 15-17	Offspring, PND 10,20  <i>NOAEL – ND</i> <i>LOAEL – GD 15-17</i>	NA
Yahia et al. (2010)	ICR	0, 1, 5, 10  Gavage	GD 0-17 or GD 0-18	Increased maternal relative kidney weight, GD 18  <i>NOAEL – ND</i> <i>LOAEL - 1</i>	NA	Increased maternal relative liver weight, GD 18  <i>NOAEL – ND</i> <i>LOAEL - 1</i>

\* General notes:

- NOAEL is defined as the highest dose that did not produce a statistically significant effect ( $p \leq 0.05$ ) compared to control. LOAEL is defined as the lowest dose with statistically significant effects observed ( $p \leq 0.05$ ) compared to control. For some studies, there were dose-related trends that included non-statistically significant changes at lower doses.
- In some studies, not all dose groups were evaluated for some endpoints. For some studies, not all endpoints evaluated are listed.

- Several studies that focused on other specific endpoints also evaluated reproductive and/or developmental endpoints but did not present data for these endpoints in usable form, or did not provide statistical significance. These studies are mentioned in the text but are not included in this table.

\*\* In **restricted exposure studies**, gestational exposure is to the same dose for varying periods of time. In determining LOAELs and NOAELs, shorter time periods of dosing were considered to have been lower exposures than longer time periods of dosing.

\*\*\* In **cross foster studies**, pups were exposed *in utero* (U), through lactation (L), or both (U+L). In determining LOAELs and NOAELs, both all groups to exposed lower doses (L, U, U+L) were considered to have had lower exposure than those with higher doses. Within the same dosage level (mg/kg/day), L and U groups were considered to have had lower exposure than U+L groups.

FLR – full litter resorptions

NA – not assessed

ND – not determined

Table 14A. Summary of publications/studies evaluating effects of PFOA on mammary gland (MG) development in mice – Includes studies with exposure during pregnancy, gestation, and/or lactation (6 publications/10 studies). (Note: Other effects evaluated in these studies are discussed in other tables in main document and/or individual study tables in Appendix 5)

<b>Citation</b>	<b>Strain</b>	<b>Lifestage(s) for Dosing</b>	<b>Dose(s) (mg/kg/day)</b>	<b>Dosing Duration</b>	<b>Lifestage for MG Assessment</b>	<b>Timepoint for MG Assessment</b>	<b>Endpoint(s) Assessed</b>	<b>Effect</b>	<b>NOAEL* (mg/kg/day)</b>	<b>LOAEL* (mg/kg/day)</b>	<b>Comments/Other Mammary Gland Effects</b>
<b>Albrecht et al. (2013)</b>	Sv/129 Wild Type (KO), PPAR-alpha null (KO), and humanized PPAR-alpha (H)	Gestation	0, 3	GD 1-17	Female pups	PND 20	MG whole mounts. # terminal end buds/gland; ductal length	No effect	3	----	-This is the only study of MG gland development in this strain. -Other developmental effects seen at similar serum PFOA levels in this strain by Abbott et al. (2007) were not observed in this study. - Some control animals had elevated PFOA levels in serum and liver. - These issues create uncertainty about the conclusion that PFOA did not affect MG development in this study.
<b>Macon et al. (2011)</b>	CD-1	Gestation	0, 0.3, 1, 3	GD 1-17 "Late Gestation"	Female pups	PND 7, 14, 21, 28, 42, 63, 84	MG whole mounts, scored 1-4.	Delayed development	-----	0.3	- Delays occurred in absence of effects on body weight. - Delays persisted until end of study on PND 84 (12 weeks of age)
<b>Macon et al. (2011)</b>	CD-1	Gestation	0, 0.01, 0.1, 1	GD 10-17 "Full Gestation"	Female pups	PND 14, 21	MG whole mounts. PND 14- longitudinal growth, change in long. Growth PND 22 – Score 1-4, longitudinal and later growth, lateral growth, change in long. and lateral growth, # terminal endbuds and terminal ends.	Delayed development	----	0.01 (Developmental Score, p<0.05)	- Serum levels in offspring on PND 1 are provided and can be used for dose-response modeling. Serum levels are highest on PND 1 (end of dosing period) and decline thereafter. - The serum level at the LOAEL (0.01 mg/kg/day) in PND offspring was 285 ng/ml. - Liver weight and body weight in the pups were not affected at 0.01 mg/kg/day and higher doses, indicating that MG development is a more sensitive endpoint than decreased body weight or increased liver weight



Table 14A. Summary of publications/studies evaluating effects of PFOA on mammary gland (MG) development in mice – Includes studies with exposure during pregnancy, gestation, and/or lactation (6 publications/10 studies). (Note: Other effects evaluated in these studies are discussed in other tables in main document and/or individual study tables in Appendix 5)

<b>Citation</b>	<b>Strain</b>	<b>Lifestage(s) for Dosing</b>	<b>Dose(s) (mg/kg/day)</b>	<b>Dosing Duration</b>	<b>Lifestage for MG Assessment</b>	<b>Timepoint for MG Assessment</b>	<b>Endpoint(s) Assessed</b>	<b>Effect</b>	<b>NOAEL* (mg/kg/day)</b>	<b>LOAEL* (mg/kg/day)</b>	<b>Comments/Other Mammary Gland Effects</b>
<b>Tucker et al. (2015)</b>	CD-1 C57Bl/6	Gestation	0, 0.01, 0.1, 0.3, 1	GD 1-17	Female pups	CD-1: PND 21, 35, 56 C57Bl/6: PND 21, 61	MG whole mounts. Scored 1-4.	Delayed development	--- (CD-1) 0.1 (C57Bl/6)	0.01 (CD-1) 0.3 (C57Bl/6)	- Delayed MG development occurred in the absence of effects on body wt, liver wt, day of vaginal opening, day of first estrus, or serum estradiol and progesterone in both strains. - Serum PFOA levels were first measured on PND 21 (3 weeks after dosing ended) and therefore cannot be used for dose-response modeling. - Higher serum levels from same dose in CD-1 mice than C57Bl/6 mice may contribute to the greater sensitivity of CD-1 to effects on MG development.
<b>White et al. (2007)</b>	CD-1	Gestation	0, 5	GD 1-17	Dams	GD 18	MG whole mounts, scored 1-4	Delayed development	-----	5, GD 1-17	
<b>White et al. (2007)</b>	CD-1	Gestation	0, 5	GD 1-17, 8-17, or 12-17 "Restricted Exposure"	Dams	PND 10 and 20	MG whole mounts, scored 1-4; H&E slides also evaluated.	Delayed development	5 GD 8-17 exposure (PND 10)	5 GD 12-17 exposure (PND 10). All treated groups on PND 20.	- No effect in non-pregnant adult females dosed for 17 days. - Expression of milk proteins changed on PND 10 and 20, consistent with delays on PND 20.
					Female Pups		MG whole mounts, scored 1-4	Delayed development	-----	5, GD 8-17 exposure	

Table 14A. Summary of publications/studies evaluating effects of PFOA on mammary gland (MG) development in mice – Includes studies with exposure during pregnancy, gestation, and/or lactation (6 publications/10 studies). (Note: Other effects evaluated in these studies are discussed in other tables in main document and/or individual study tables in Appendix 5)

<i>Citation</i>	<i>Strain</i>	<i>Lifestage(s) for Dosing</i>	<i>Dose(s) (mg/kg/day)</i>	<i>Dosing Duration</i>	<i>Lifestage for MG Assessment</i>	<i>Timepoint for MG Assessment</i>	<i>Endpoint(s) Assessed</i>	<i>Effect</i>	<i>NOAEL* (mg/kg/day)</i>	<i>LOAEL* (mg/kg/day)</i>	<i>Comments/Other Mammary Gland Effects</i>
<b>White et al. (2009)</b>	CD-1	Gestation	0, 5	GD 8-17 (Cross-fostering: exposure during gestation, lactation, or both)	Dams	PND 1,3,5, 10	MG whole mounts, numerical data not shown.	Delayed development	-----	5	In both treated dams nursing treated or untreated pups beginning on PND 1, and untreated dams nursing treated pups beginning on PND 3.
					Female pups		MG whole mounts, scored 1-4	Delayed development	-----	5	All treated groups beginning on PND 1, including lactation only exposure (serum level ~2000 ng/ml).
<b>White et al. (2009)</b>	CD-1	Gestation	0, 3, 5	GD 1-17 (Cross-fostering: exposure during gestation and/or lactation)	Female pups	PND 22, 42, 63, and 18 months	MG whole mounts, scored 1-4	Delayed development	-----	3	At 18 months, changes in MG persisted in treated groups (whole mounts and H&E slides) including increased number of darkly staining foci per gland and reduced epithelial density. These effects could not be scored using the criteria that were used at earlier time points.
<b>White et al. (2009)</b>	CD-1	Gestation	0, 5	GD 15-17, 13-17, 10-17, 7-17 "Restricted Exposure"	Female pups	PND 29, 32 and 18 months	MG whole mounts, scored 1-4	Delayed development	-----	5, GD 15-17 exposure.	At 18 months, changes in MG persisted in treated groups (whole mounts and H&E slides) including increased numbers of darkly staining foci per gland in all treated groups. These effects could not be scored

Table 14A. Summary of publications/studies evaluating effects of PFOA on mammary gland (MG) development in mice – Includes studies with exposure during pregnancy, gestation, and/or lactation (6 publications/10 studies). (Note: Other effects evaluated in these studies are discussed in other tables in main document and/or individual study tables in Appendix 5)

<b>Citation</b>	<b>Strain</b>	<b>Lifestage(s) for Dosing</b>	<b>Dose(s) (mg/kg/day)</b>	<b>Dosing Duration</b>	<b>Lifestage for MG Assessment</b>	<b>Timepoint for MG Assessment</b>	<b>Endpoint(s) Assessed</b>	<b>Effect</b>	<b>NOAEL* (mg/kg/day)</b>	<b>LOAEL* (mg/kg/day)</b>	<b>Comments/Other Mammary Gland Effects</b>
											using the criteria used at earlier time points
<b>White et al. (2011b)</b>	CD-1	Gestation and/or postnatal (multi-generation study)	GD 1-17 (0, 1, 5 mg/kg/day) and/or 5 ppb in drinking water (through PND 22 in P0 and F1 dams; through PND 63 in F1 and F2 pups)	P0 Dams	PND 22	MG whole mounts, scored 1-4. H&E slides for some groups.	Delayed development	----	(P0 dams)	1 mg/kg/day (exposure P0 GD 1-17) or 5 ppb in drinking water (exposure P0 GD 7- F1 PND 22)	In lactational challenge test in F1 dams and F2 litters on PND 10, milk volume was decreased and time to initiate was increased in all treated groups. However, these changes were not statistically significant. High variability limited power to detect statistically significant differences.
				F1 Dams	PND 10, 22			----	(F1 dams on PND 10).	On PND 10: 1 mg/kg/day (exposure P0 GD 1-17) or 5 ppb in drinking water (exposure P0 GD 7- F2 PND 22)	
				F1 Female pups	PND 22,42, 63			-----	(F1 pups)	1 mg/kg/day (exposure P0 GD 1-17) or 5 ppb in drinking water (exposure P0 GD 7- F1 PND 63). Serum PFOA level in 5 ppb group was 21.3 ng/ml	
				F2 Female pups	PND 10, 22, 42, 63			No significant effects at most doses and time points. Significant delays at 3 of 16 data points.		(F2 pups)	

Table 14B. Summary of publications/studies evaluating effects of PFOA on mammary gland (MG) development in mice – Studies with peripubertal exposure (3 publications)

<b>Citation</b>	<b>Strain</b>	<b>Lifestage(s) for Dosing</b>	<b>Dose(s) (mg/kg/day)</b>	<b>Dosing Duration</b>	<b>Lifestage for MG Assessment</b>	<b>Timepoint for MG Assessment</b>	<b>Endpoint(s) Assessed</b>	<b>Effect</b>	<b>NOAEL* (mg/kg/day)</b>	<b>LOAEL* (mg/kg/day)</b>	<b>Comments/Other Mammary Gland Effects</b>
<b>Yang et al. (2009a)</b>	Balb/C C57Bl/6	Peripubertal	0,1,5,10	4 weeks, starting at 3 wks of age.	Peripubertal females	7 weeks of age	MG whole mounts. Ductal length, # terminal end buds, # terminal ducts	Balb/C - Delayed development  C57Bl/6 - Stimulated development & totally inhibited development	Balb/C - 1  C57Bl/6 - 1	Balb/C - 5  C57Bl/6 - Stimulation at 5  Total inhibition at 10	MG cell proliferation measured by BrDu incorporation: - In Balb/C, proliferation of MG cells was inhibited at 1 and 5 mg/kg/day. - In C57Bl/6, proliferation of MG cells was stimulated at 1 and 5 mg/kg/day, and totally stopped at 10 mg/kg/day  Serum PFOA data provided in Zhao et al. (2012)
<b>Zhao et al. (2010)</b>	C57Bl/6 Wild Type Ovariectomized (OVX)	Peripubertal. OVX at 3 weeks (before PFOA treatment)	0, 5	4 weeks starting at 4 weeks of age	Peripubertal OVX females	8 weeks of age	MG whole mounts scored based on longitudinal growth, # of terminal end buds, stimulated/enlarged terminal ducts.	Total inhibition of development in both control and PFOA-treated OVX mice	NA	NA	Groups of non-OVX mice were not included in these studies.
	C57Bl/6 PPAR-alpha null (KO)	Peripubertal. OVX at 7 weeks (after PFOA treatment)		4 weeks starting at 3 weeks of age	Peripubertal OVX Females, treated with saline, or progesterone and/or estradiol after OVX	9 weeks of age	Numerical data not shown.	In mice treated with hormones, stimulation of development by PFOA compared to controls (no PFOA).	NA	NA	
			Peripubertal		4 weeks, starting at 3 wks of age.	Peripubertal females	7 weeks of age		Stimulated development	----	5

Table 14B. Summary of publications/studies evaluating effects of PFOA on mammary gland (MG) development in mice – Studies with peripubertal exposure (3 publications))

<b>Citation</b>	<b>Strain</b>	<b>Lifestage(s) for Dosing</b>	<b>Dose(s) (mg/kg/day)</b>	<b>Dosing Duration</b>	<b>Lifestage for MG Assessment</b>	<b>Timepoint for MG Assessment</b>	<b>Endpoint(s) Assessed</b>	<b>Effect</b>	<b>NOAEL* (mg/kg/day)</b>	<b>LOAEL* (mg/kg/day)</b>	<b>Comments/Other Mammary Gland Effects</b>
<b>Zhao et al. (2012)</b>	Balb/C  C57Bl/6 (WT)  C57Bl/6 PPAR-alpha null (KO)	Peripubertal	Balb/C: 0, 2.5  C57Bl/6 WT and KO: 0, 7.5	4 weeks, starting at 3 wks of age.	Peripubertal females	7 weeks of age	MG whole mounts. Ductal length, # terminal end buds, # terminal ducts	Balb/C – Delayed development  C57Bl/6 WT – Delayed development  KO – no effect	<i>Balb/C</i> & <i>C57Bl/6</i> <i>WT</i> – -----  <i>C57Bl/6</i> <i>KO</i> - 7.5	<i>Balb/C</i> – 2.5  <i>C57Bl/6 WT</i> – 7.5  <i>C57Bl/6 KO</i> – -----	- PFOA doses in all 3 strains of mice in this study are different than those used in earlier studies of these strains (Yang et al., 2009a; Zhao et al., 2010). Doses from the earlier study in each strain were not repeated in this study. Data from different studies may not be directly comparable. - Lack of inhibition of MG development in KO mice may be due to lower serum PFOA levels rather than PPAR status. - Serum PFOA levels for this study and the 2 earlier studies are presented in this study.

## **MODE OF ACTION**

### **Overview**

The mode(s) of action of PFOA are not fully characterized. PFOA structurally resembles a free fatty acid, and it thus may act similarly to a free fatty acid in activating nuclear receptors, binding to transporters and carrier proteins, and interacting with membranes (Butenhoff, 2009). However, it is non-reactive and therefore is not a substrate for biochemical reactions involving fatty acids. It also has been shown to have estrogenic activity and to act through other mechanisms. The mode of action for some of the effects of PFOA is unknown. A summary of information on PFOA's mode of action, with emphasis on potential human relevance, is presented below.

### **Genotoxicity**

Since PFOA is not chemically reactive, it is not metabolized to reactive intermediates and does not covalently bind to nucleic acids and proteins. Therefore, it is considered unlikely to be genotoxic. Information on the genotoxicity of PFOA was reviewed by Butenhoff et al., (2014). PFOA was not mutagenic or genotoxic in most of a series of *in vitro* assays in bacterial and mammalian cells, with or without metabolic activation. It did not cause chromosomal aberrations in Chinese hamster ovary cells at non-cytotoxic concentrations, although some positive results were reported at cytotoxic concentrations. It did not cause chromosomal aberrations in human lymphocytes in whole blood with or without metabolic activation, and it did not transform cells in culture. Although PFOA caused DNA strand breaks and increased the incidence of micronuclei in cultured human hepatoma cells in a dose-related manner (Yao and Zhong, 2005), high doses of PFOA did not induce micronuclei in mice *in vivo*. In male rats, PFOA increased the levels of 8-hydroxydeoxyguanosine in liver DNA, but not in kidney DNA (Takagi et al., 1991). These effects were accompanied by a significant increase in reactive oxygen species, which the investigators suggested caused the DNA damage. In contrast, PFOA increased the formation of reactive oxygen species but was not genotoxic in *in vitro* studies by other investigators.

### **PPAR-alpha and Other Nuclear Receptors**

PFOA activates the nuclear receptor, peroxisome proliferator-activated receptor-alpha (PPAR- alpha) as well as other nuclear receptors including PPAR-gamma, CAR (constitutive activated receptor), PXR (pregnane X receptor) and estrogen receptor-alpha (reviewed by Peters and Gonzalez, 2011). When activated, nuclear receptors bind to DNA and alter the expression of genes that control many biological processes involved in development, homeostasis, and metabolism. PPAR-alpha and other nuclear receptors are found at varying levels in many tissues in rodents, humans, and other species. PPARs affect many biological processes beyond stimulation of peroxisome proliferation in rodents, the effect for which they were originally named. Levels of PPARs may vary during different stages of development, and their role in development is discussed further below.

Much attention has been focused on the role of PPAR-alpha activation in the toxicity of PFOA and on the potential human relevance of effects that occur through activation of this receptor. The major role of PPAR-alpha is regulation of energy homeostasis. Levels of PPAR-alpha are highest in tissues with high rates of catabolism of fatty acids and peroxisomal activity, including liver, brown adipose tissue, heart, kidney, and intestine. Hepatic effects of PPAR-alpha include increased fatty acid oxidation, increased degradation of

cholesterol, increased gluconeogenesis, synthesis of ketone bodies, and control of lipoprotein assembly. By increasing oxidation of fatty acids, activation of PPAR-alpha decreases serum triglycerides and serum cholesterol and prevents the accumulation of fat in the liver (Michalik et al., 2006). Consistent with PPAR-alpha's inhibition of hepatic lipid accumulation, PPAR-alpha null mice developed fatty livers, which were more severe with a high fat diet, while fatty liver did not occur in wild type mice on either a regular or high fat diet (Abdelmegeed et al., 2011). In addition to its effects on metabolism, activation of PPAR-alpha also decreases inflammatory response. PPAR-alpha activators such as fibrate drugs are used in humans to decrease serum lipids. The anti-inflammatory effects of these drugs may contribute to their actions in preventing atherosclerosis and reducing the incidence of cardiovascular events (Michalik et al., 2006).

*In vitro* activation of human and rodent PPAR-alpha by PFOA has been evaluated in several studies of cultured cells transfected with plasmids containing PPAR-alpha from these species. As noted by Vanden Heuvel et al. (2006), these *in vitro* assays measure only the first step in the series of complex steps involved in regulation of gene expression by PPAR-alpha. Therefore, interspecies comparisons based solely on these *in vitro* data may not necessarily be valid.

Relative sensitivities of human and rodent PPAR-alpha to PFOA differed among these studies, and the results do not clearly indicate that human PPAR-alpha is less sensitive than rodent PPAR-alpha in *in vitro* systems. Maloney and Waxman (1999) reported that somewhat higher concentrations of PFOA were needed to cause maximal activation of human PPAR-alpha as compared to mouse PPAR-alpha. In contrast, Vanden Heuvel et al. (2006) found that mouse and human PPAR-alpha were similarly responsive to PFOA, while rat PPAR-alpha was less responsive than mouse or human PPAR-alpha. Two studies from the same laboratory reported differing results on the responsiveness of mouse and human PPAR-alpha to PFOA. In the first study (Wolf et al., 2008), human PPAR-alpha was somewhat less responsive to PFOA than mouse PPAR-alpha. In the second study (Wolf et al., 2012), the dose-response curves for activation by PFOA were identical for mouse and human PPAR-alpha.

Many PPAR-alpha activators (e.g. phthalates, trichloroethylene, and perchloroethylene) cause liver tumors in rodents. The human relevance of these tumors is subject to debate because of the lower levels and/or differences in intrinsic activity of hepatic PPAR-alpha in humans as compared to rodents (NRC, 2006; Corton, 2010). However, the uncertainty about human relevance does not necessarily apply to PPAR-alpha mediated effects other than liver tumors, as illustrated by the use of fibrate drugs to decrease cholesterol and lipids in humans by activation of PPAR-alpha.

Furthermore, as discussed in detail below, effects of PFOA clearly occur through both PPAR-alpha independent and PPAR-alpha dependent processes. Therefore, conclusions from studies with pure PPAR-alpha activators such as Wyeth 14,643 (WY) cannot necessarily be extrapolated to PFOA.

### **Hepatic Toxicity**

As discussed in the Epidemiology section, PFOA is associated with increased serum liver enzymes in human. The studies in non-human primates, standard strains of rats and mice, PPAR-alpha null mice, and humanized PPAR-alpha mice that are summarized below support the conclusion that hepatic effects of PFOA in experimental animals are relevant to humans for the purposes of risk assessment.

### **Data from non-human primates**



In the 13-week study in male cynomolgus monkeys (Butenhoff et al., 2002), PFOA increased relative liver weight in a dose-related fashion. Several monkeys that did not complete the study due to overt toxicity exhibited notable increases in liver weight, highly elevated serum liver enzymes, and/or severe hepatic toxicity.

Subcellular biochemical markers were evaluated in the livers of the monkeys that completed the study; animals that had been removed due to toxicity were not included. Hepatic DNA content was decreased by PFOA (statistically significant at highest dose); a marker of peroxisome proliferation (palmitoyl CoA oxidation; PCO) was increased in a dose-related manner (2.6-fold and statistically significant at highest dose; Figure 12); and the mitochondrial enzyme, succinate dehydrogenase, was increased although not in a dose related manner (statistically significant at highest dose). Hepatic alkaline phosphatase (a lysosomal marker) and glucose-6-dehydrogenase (a marker for endoplasmic reticulum) were not affected by PFOA treatment.

Although no histopathological changes were reported in the livers of the treated monkeys that completed the study, the authors state that the dose-related decrease in hepatic DNA content is indicative of hepatocellular hypertrophy. The dose-related increase in peroxisome proliferating activity (PCO) was similar in magnitude to the increases reported in PFOA treated rats (below), demonstrating that substantial hepatic PPAR-alpha activity occurs in response to PFOA in non-human primates. The authors also state that the increased succinate dehydrogenase activity suggests mitochondrial proliferation, although this possibility was not evaluated by microscopic studies.

As discussed below, data from rats (Perkins et al., 2004) indicate that the increase in PCO activity in response to PFOA becomes smaller in magnitude with longer exposure duration, while the increase in relative liver weight remains stable over time. Since PCO data are available only from a single time point (13 weeks) in the monkeys, it is unknown whether they represent the maximum PCO activity in response to PFOA. The USEPA SAB (2006) stated: “Because the available data for PFOA in rats and monkeys indicate similar responses in the livers of rodents and primates (increased liver weight and induction of hepatic peroxisomal enzyme activity), about three quarters of the Panel members shared the view that human relevance for liver effects induced by PFOA by a PPAR $\alpha$  agonism mode of action cannot be discounted.”




Figure 12. Relative liver weight and relative PCO activity (compared to controls) versus serum PFOA concentrations in male cynomolgus monkeys dosed with PFOA for 6 months (Butenhoff et al., 2002).

Data from a 90-day study of rhesus monkeys (Goldenthal, 1978) also suggest that PFOA caused increased liver weight, although this effect was not statistically significant likely due to the small number of animals.

Data from standard strains of laboratory rodents

In a standard strain of laboratory rats, PFOA activated PPAR-alpha, as indicated by increased PCO activity, and also activated other nuclear receptors, CAR and PXR, as indicated by induction of specific cytochrome P450 proteins associated with these receptors (Elcombe et al., 2010). Similarly, PFOA treatment increased gene expression for cytochrome P450 proteins associated with each of these three receptors in wild type mice (Cheng and Klaasen, 2008).

Loveless et al. (2006) evaluated the effects of three isomeric forms of PFOA (linear isomers, branched isomers, and mixed linear/branched isomers) on relative liver weight and hepatic PCO activity in standard strains of male rats and mice. As can be seen in Figure 13, increased relative liver weight did not correlate with hepatic peroxisome proliferation, as indicated by PCO activity. In mice, liver weight increased with administered dose and serum PFOA level, but PCO activity was lower at the highest administered doses and serum levels than at lower doses and serum levels. Additionally, in rats (Figure 14), branched isomers of PFOA were more potent in increasing relative liver weight than linear isomers, but were less potent in increasing PCO activity. These results illustrate the involvement of PPAR-alpha independent processes in the increased relative liver weight caused by PFOA even in standard strains of rodents with normal PPAR-alpha function.





Figure 13. Relative liver weight and relative PCO activity (compared to controls) versus serum PFOA concentrations in male mice dosed with linear/branched, linear, or branched PFOA for 14 days (Loveless et al., 2006).  
 \*  $p < 0.05$ .






Figure 14. Relative liver weight and relative PCO activity (compared to controls) versus serum PFOA concentrations in male rats dosed with linear/branched, linear, or branched PFOA for 14 days (Loveless et al., 2006).

\*  $p < 0.05$ .

Data from a standard strain of male rats exposed for 4, 7, or 13 weeks (Figure 15) also indicate that PCO activity does not necessarily correlate with the increased liver weight caused by PFOA (Perkins et al., 2004). Although relative PCO activity was much greater at 7 weeks than 4 weeks, and was lower at 13 weeks than at the two earlier time points, the dose-response curve for increased relative liver weight was similar at all three time points.




Figure 15. Relative liver weight and relative PCO activity (compared to controls) versus serum PFOA concentrations in male rats and mice dosed with PFOA for 4, 7, or 13 weeks (Perkins et al., 2004).

A recent study of histopathological change in livers of female CD-1 mouse offspring with developmental exposure to PFOA does not support the involvement of peroxisome proliferation in the observed hepatic toxicity (Quist et al, 2015; described in the Animal Toxicology section). Transmission electron microscope studies of the livers found no evidence that PFOA caused peroxisome proliferation, but rather indicated that it caused mitochondrial proliferation and abnormal mitochondrial morphology.

Activation of PPAR-alpha inhibits accumulation of fat in the liver. In contrast, PFOA increased the accumulation of hepatic triglycerides, cholesterol, and phospholipids in a standard strain of laboratory rats, and the authors noted that these effect are not consistent with the actions of other peroxisome proliferators such as clofibric acid and di(2-ethylhexyl) phthalate (Kawashima et al., 1995). Additionally, PFOA caused a dose-dependent increase in hepatic triglycerides in mice exposed to perilla oil and soybean oil, although there was no effect in mice exposed to fish oil (Kudo and Kawashima, 1997). In more recent studies of standard strains of mice given either afregular or high fat diet, PFOA caused increased triglyceride levels in the liver and decreased relative adipose tissue weight in animals on both diets (Tan et al., 2013; Wang et al., 2013).

#### Data from wild type mice, PPAR-alpha null mice, and humanized PPAR-alpha mice

Studies comparing wild type and PPAR-alpha null mice clearly demonstrate that PFOA causes PPAR-alpha independent and PPAR-alpha dependent hepatic effects. Yang et al. (2002) reported that liver weight was

increased in both wild type and PPAR-alpha null mice treated with PFOA (0.02% in the diet) for 7 days, while peroxisomal acyl CoA oxidase (a marker of peroxisome proliferation) was increased only in wild type mice. In contrast, the model PPAR-alpha activator, WY, increased liver weight and peroxisome proliferating activity in wild type mice but had no effect in PPAR-alpha null mice. Based on this study, which was the only study of PFOA in wild type and PPAR-alpha null mice available at the time, the USEPA Science Advisory Board (2006) concluded that PPAR-alpha independent modes of action may be important in hepatic effects of PFOA in rodents. Numerous studies that have been published subsequent to the USEPA SAB (2006) review confirm this conclusion and provide additional relevant information.

Consistent with Yang et al. (2002), Wolf et al. (2008) also reported that PFOA (0, 1, 3, or 10 mg/kg/day for 7 days) increased liver weight similarly in both PPAR-alpha null mice and wild type mice, while WY increased liver weight only in wild type mice. Cell proliferation and hepatocyte hypertrophy were also increased by PFOA in a dose-related fashion in both wild type and PPAR-alpha null mice. However, the livers of wild type and PPAR-alpha null mice treated with PFOA differed histologically. Increased numbers of peroxisomes were seen in the livers of treated wild type mice, while the livers of PPAR-alpha null mice had no peroxisomes but had numerous vacuoles.

Gene profiling studies in wild type and PPAR-alpha null mice treated with PFOA and WY found that PFOA, but not WY, also activates CAR (constitutive activated/androstane receptor), a receptor that is activated by phenobarbital and other compounds, and possibly PXR (pregnane X receptor). Both compounds caused a similar profile of gene changes in wild type mice, including up-regulation of genes involved with PPAR-alpha activation. However, while there were few gene changes in WY treated PPAR-alpha null mice, gene expression was altered in PFOA-treated PPAR-alpha null mice, including some of the same genes affected by PFOA in the wild type mice (Rosen et al., 2008a). Further study (Rosen et al., 2008b) showed that 85% of the genes altered by PFOA were PPAR-alpha dependent. The PPAR-alpha independent genes included genes involved with lipid homeostasis and xenobiotic metabolism, and many were consistent with activation of CAR.

Additional studies suggest that PPAR-alpha may be protective against some types of hepatic toxicity caused by PFOA. Minata et al. (2010) showed that hepatic or biliary damage occurred in both wild type and PPAR-alpha null mice treated with PFOA, but the profile of toxicity differed greatly between the strains. They investigated the effects of PFOA in wild type and PPAR-alpha null mice given 4.4, 10.8, or 21.6 mg/kg/day for four weeks. Concentrations of PFOA in serum and liver were similar in wild type and PPAR-alpha null mice, but were much lower in bile of PPAR-alpha null mice than wild type mice, indicating a much lower capacity for transport of PFOA to bile in the null strain. Relative liver weights were similarly increased in both wild type and PPAR-alpha null mice at all doses of PFOA, to about three times the control value. Hepatocyte and bile duct injury was assessed by light and electron microscopy, by levels of serum enzymes, bile acids, and bilirubin, and by biochemical markers. Hepatocyte hypertrophy and elevated liver enzymes occurred in both wild type and PPAR-alpha null mice, but bile duct injury was much more severe in PPAR-alpha null mice. PFOA increased the levels of two inflammatory cytokines associated with liver injury in PPAR-alpha null, but not wild type, mice. The authors concluded that PPAR-alpha protects against cholestasis and bile duct injury caused by PFOA in mice. They suggested that rodents may, in fact, be less sensitive to PFOA than humans at some doses.

Finally, the hepatic effects of developmental PFOA exposure in 18-month old offspring of gestationally exposed dams were studied in CD-1, wild type, and PPAR-alpha null mice (Filgo et al., 2015). At this time point long after PFOA has been eliminated from the body, the incidence and/or severity of hepatocellular hypertrophy was increased by prenatal and early life exposure to PFOA in all three strains of mice, and this effect was more pronounced in PPAR-alpha null than wild type mice. Additionally, consistent with Minata et al. (2010), PFOA caused a dose-dependent increase in incidence and severity of bile duct toxicity in PPAR-alpha null, but not wild type, mice. Additional findings from this study related to carcinogenicity of PFOA are discussed below.

Three additional studies evaluated hepatic effects of PFOA in wild type, PPAR-alpha null, and humanized PPAR-alpha (having hepatic expression of human PPAR-alpha) mice of a Sv/129 genetic background (Nakamura et al., 2010; Nagakawa et al., 2011; Albrecht et al., 2013). PFOA caused hepatic toxicity in all three of these mouse strains, including in fetal liver. It should be noted that differences in response in humanized mice are not necessarily indicative of a different response of human PPAR-alpha to PFOA, for reasons that may include species differences in binding of PFOA to recognition sites on mouse DNA (cognate DNA). PFOA concentrations in liver and serum were measured in only one of these three studies (Albrecht et al., 2013).

Hepatic effects were studied in male wild type, PPAR-alpha null, and humanized PPAR-alpha mice treated with 0, 0.1, or 0.3 mg/kg/day PFOA for two weeks (Nakamura et al., 2009). Relative liver weight was not affected at 0.1 mg/kg/day in any strain and was increased at 0.3 mg/kg/day only in wild type mice. Expression (mRNA and protein levels) of five genes that are targets of PPAR-alpha was measured in the three strains. Expression of four of these genes was significantly increased only in the wild type mice, while expression of the fifth gene was significantly increased only in the humanized PPAR-alpha mice. None of the PPAR-alpha target genes were affected by PFOA in the PPAR-alpha null mice. Histopathological examination showed mild hepatocellular hypertrophy in both wild type and humanized PPAR-alpha mice. Cytoplasmic vacuoles indicating lipid accumulation were observed in PPAR-alpha null mice, consistent with those described in this strain by Wolf et al. (2008).

Interpretation of these results is complicated by the fact that PFOA levels in serum and liver were not measured in this study and may vary between strains. Relative liver weight was increased at 0.3 mg/kg/day in wild type mice, but was not increased at this dose in the other two strains. However, there was no effect in wild type mice at 0.1 mg/kg/day, indicating that 0.3 mg/kg/day is relatively close to the NOAEL in this strain. In the absence of serum and liver PFOA data, it is not known whether the increased liver weight observed at 0.3 mg/kg/day in wild type, but not PPAR-alpha null or humanized PPAR-alpha, strains is due to an intrinsic difference in sensitivity or to toxicokinetic differences.

Hepatic effects were also evaluated in male wild type, PPAR-alpha null and humanized PPAR-alpha mice treated with 0, 1, or 5 mg/kg/day for six weeks (Nagakawa et al., 2011). The results of this study do not support the conclusion that rodent PPAR-alpha is required for the hepatic toxicity of PFOA. Hepatocyte hypertrophy occurred in both strains with PPAR-alpha activity (wild type and humanized), and activity of the liver enzyme ALT was increased in all three strains including PPAR-alpha null. Single cell hepatocyte necrosis occurred in all three strains, but hydropic degeneration of hepatocytes occurred only in PPAR-alpha null and humanized mice. Macrovesicular steatosis and inflammatory cells were found only in the PPAR-alpha null mice, while microvesicular steatosis occurred in the PPAR-alpha null and humanized strains but not the wild type strain.



Liver triglyceride and cholesterol levels were increased several fold in the PPAR-alpha null mice, but not in the other strains, while plasma triglycerides were decreased only in the wild type mice. The authors concluded that PPAR-alpha may be important in protecting from hepatic damage caused by PFOA at the doses used in the study. They also concluded that, since hepatic PPAR-alpha may be weaker in its function and present in lower amounts in humans than in mice, humans may be susceptible to hepatic damage from similar doses of PFOA.

Finally, hepatic effects of PFOA were evaluated in pregnant wild type, PPAR-alpha null and humanized PPAR-alpha mice and their offspring after exposure to 3 mg/kg/day on GD 1-17 (Albrecht et al., 2013). Serum and liver PFOA levels were measured in dams and fetuses on GD 18, and in dams and offspring on PND 20. There were large differences in serum and/or liver PFOA concentrations among strains, and these differences were not consistent at the different life stages and time points. Therefore, differences in responses to PFOA among the strains may be due to toxicokinetic differences in addition to, or instead of, intrinsic strain differences in sensitivity to PFOA's effects.

In dams on GD 18, relative liver weight was significantly increased to a similar degree in all three strains. Expression of two target genes for PPAR-alpha was increased by PFOA in both wild type and humanized PPAR-alpha dams, but not PPAR-alpha null dams, although the increase in expression of one of the genes was not significant in the humanized mice. Expression of target genes for CAR and PXR was increased by PFOA in all three strains, with the biggest increase in the humanized PPAR-alpha dams. Minimal to mild hepatocellular hypertrophy was observed by histopathological examination in all three strains, although the morphological features differed among the strains.

On PND 20, relative liver weight remained increased in the wild type dams treated with PFOA, but not in PPAR-alpha null or humanized PPAR-alpha strains. Expression of a gene associated with PPAR-alpha was also increased by PFOA only in wild type dams. Expression of a gene associated with CAR was not affected in any strain, while expression of a gene associated with PXR remained significantly increased in all three strains. Histopathological changes were observed in livers from PFOA-treated dams of all three strains, but were decreased in incidence and severity compared to on GD 18 in wild type and humanized PPAR-alpha dams.

In fetuses on GD 18, relative liver weight was significantly increased in wild type and humanized PPAR-alpha, but not PPAR-alpha null, mice. Expression of two genes associated with PPAR-alpha was significantly increased in wild type and humanized fetal livers, but not in PPAR-null. The increased expression compared to controls was greater for both genes in the humanized PPAR-alpha fetuses than in the wild type fetuses, and the increase for one of them was about 5-fold greater in humanized than wild type (humanized PPAR-alpha significantly different from wild type). Fetal expression of a gene associated with CAR was not affected by PFOA in any of the three strains, and expression of a gene associated with PXR was increased only in the humanized PPAR-alpha fetal liver. Histopathological changes consistent with peroxisome proliferation were seen in some wild type mice, while no definitive changes were seen in the other strains.

In offspring on GD 20, relative liver weight and expression of genes associated with PPAR-alpha were increased only in wild type mice. Expression of a gene associated with CAR was increased in all three strains, with the largest increase in the PPAR-null offspring, while expression of a gene associated with PXR was increased in wild type and humanized, with the larger increase in wild type. At this time point,

histopathological changes in PFOA-treated wild type offspring were similar to those on GD 19, while changes were not clearly evident in livers from the other two strains.

These results indicate that hepatic effects of PFOA in adult, fetal, and neonatal mice are mediated by human PPAR-alpha and through PPAR-alpha independent pathways, as well as by mouse PPAR-alpha. As noted above, interpretation of these results is complicated by the fact that PFOA levels in serum and liver differed among the strains in dams, fetuses, and offspring. For example, serum and liver PFOA levels were lower in humanized dams and offspring than in wild type dams and offspring on PND 20. Therefore, it is unknown whether the greater hepatic effects in wild type than humanized PPAR-alpha mice at this time point are due to an intrinsic difference in sensitivity or to toxicokinetic factors.

### **Serum cholesterol and lipids**

As discussed above, activation of PPAR-alpha causes decreased serum cholesterol and triglycerides in both humans and experimental animals, and this is the basis for the use of fibrates as cholesterol-reducing agents in humans. Consistent with other PPAR-alpha activators, PFOA decreased serum lipids levels in rodents in a number of studies (e.g. Loveless et al., 2006, and other studies summarized in Rebholz et al., 2016). In contrast, as discussed in the Epidemiology section, serum PFOA has been consistently associated with increased serum cholesterol, suggesting a human versus rodent difference in the effect of PFOA on this endpoint.

Two recent studies suggest the possibility that dietary factors, specifically differences in dietary fat content, may contribute to the observed differences in effects of PFOA on serum lipids in rodents versus humans. Male Balb/C mice on a regular diet or a high fat diet were dosed with 0, 5, 10, or 20 mg/kg/day PFOA for 14 days (Tan et al., 2013). Consistent with earlier mouse studies, both serum cholesterol and serum triglycerides decreased in a dose-related fashion in mice on the regular diet. In contrast, serum cholesterol and triglycerides were unaffected by PFOA in mice on the high fat diet. Additionally, hepatic toxicity from PFOA was more severe in mice on the high fat diet (discussed in Animal Toxicity section).

In another study, male and female C57BL/6 and BALB/c mice were fed a high fat diet containing 32% of calories from fat (similar to the mean of 33% calories from fat in the U.S. diet; CDC, 2016) and 0.25% cholesterol for 6 weeks (Rebholz et al., 2016). In both sexes of C57BL/6 mice and male Balb/c mice, plasma cholesterol was significantly increased by PFOA treatment (3.5 ppm in the diet, resulting in a dose of about 0.5 mg/kg/day), while PFOA had no effect on plasma cholesterol in female Balb/C mice. These results contrast with the decreased serum cholesterol and triglycerides caused by PFOA reported in other studies in which rodents were fed a standard laboratory diet (e.g. containing 13% of calories from fat and 0.02 % cholesterol; LabDiet, 2016). Interestingly, Minata et al. (2010) also observed that cholesterol was increased at the highest PFOA dose, and triglycerides were increased at all doses, in PPAR-alpha null mice.

### **Immune System Toxicity**

Effects of PFOA on the immune system in humans and experimental animals are discussed in the Epidemiology and Toxicology sections above. Additionally, immunotoxicity of PFOA and other PFCs, including mode of action studies, was reviewed by DeWitt et al. (2012). PFOA suppressed the immune system in studies of both non-human primates and mice. Effects include decreased absolute and relative spleen and thymus weights, decreased thymocyte and splenocyte counts, decreased immunoglobulin response, and changes in total numbers and/or specific populations of lymphocytes in the spleen, thymus, peripheral blood, and bone marrow. Based

on the available data, rats are less sensitive than mice to immunotoxic effects of PFOA. Immune system effects were not observed in the two studies of rats; these studies included doses higher than those which generally caused immune effects in mice. In humans, exposures to PFOA within the general population range have been associated with decreased antibody levels in response to vaccination. Fletcher et al. (2009) also reported several statistically significant associations between several markers of immune function (decreased IgA, decreased IgE in females only, increased anti-nuclear antibody, decreased C-reactive protein) and serum PFOA levels in communities with drinking water exposure to PFOA in an unpublished C8 Science Panel report.

#### PPAR-alpha dependence of immune effects in rodents and humans

Two studies in wild type and PPAR-alpha null mice indicate that PFOA's effects on the immune system in mice occur through both PPAR-alpha dependent and PPAR-alpha independent mechanisms. Yang et al. (2002b) studied PFOA's effects on immune response in wild type and PPAR-alpha null mice given 0.02% PFOA in the diet (resulting in a dose of 30 mg/kg/day) for 7 days. Although food intake was similar in the treated wild type and PPAR-alpha null mice, body weight was significantly reduced by PFOA in the wild type mice, but not the null mice, suggesting that weight loss is related to activation of PPAR-alpha, possibly through PFOA's effects on metabolism, rather than to non-specific toxicity. Consistent with studies discussed in the section on hepatic effects (above), liver weights were increased by PFOA similarly in wild type and null mice, but peroxisome proliferation (as measured by PCO oxidation) occurred only in wild type mice, indicating that increased liver weight was not PPAR-alpha dependent. PFOA caused some immune system effects in wild type but not PPAR-alpha null mice, including decreased spleen weight and splenocyte numbers, and reduced splenocyte proliferation in response to mitogens. However, PFOA also caused other effects (reduced thymus weight and thymocyte numbers, and alterations in the distribution of thymocyte subpopulations) in the null mice, although to a lesser degree than in the wild type mice. These findings led the authors to conclude that PFOA's effects on the immune system are due to mechanisms both dependent and independent of PPAR-alpha.

DeWitt et al. (2009a) studied C57 and Sv/129 wild type and PPAR-alpha null mice exposed to 30 mg/kg/day PFOA in drinking water for 15 days to determine the involvement of PPAR-alpha in the immunotoxic effects of PFOA. Sensitivity to PFOA toxicity appeared to differ in the C57 and the Sv/129 mice, regardless of their PPAR-alpha status, as PFOA treatment decreased body weight, spleen weight, thymus weight, or antibody titer in the C57 wild type mice but did not have these effects in the Sv/129 wild type mice. IgM titer was decreased in both C57 and Sv/129 PPAR-alpha null mice, although this effect did not occur in the wild type Sv/129 mice, suggesting that this effect is not PPAR-alpha dependent. Relative liver weight was similarly increased in all four types of mice given 30 mg/kg/day PFOA in drinking water for 15 days, indicating that this response was not dependent on strain or PPAR-alpha status.

A more recent study suggests that the T-cell dependent antibody response (TDAR) in mice is independent of PPAR-alpha. DeWitt et al. (2016) evaluated the IgM response to immunization with a T-cell dependent antigen (sheep red blood cells: SRBC) in wild type and PPAR-alpha C57Bl/6 null mice exposed to 0, 7.5, or 30 mg/kg/day PFOA for 15 days. PFOA at 7.5 mg/kg/day did not affect TDAR, and production of sheep red blood cell-specific antigens was inhibited equally in wild type and PPAR-alpha null mice at 30 mg/kg/day.

In the C8 Health Study population, serum PFOA was significantly associated with a strong downward trend with C-reactive protein, a liver protein that is a marker for inflammation (Fletcher et al., 2009). Genser et al. (2015) found consistent and significant associations of serum PFOA with decreased C-reactive protein, both

within each of the six water districts included in the study and on an aggregated basis. They concluded that these within- and between-district associations strengthen the evidence of causality for this effect. Fibrate drugs act through activation of PPAR-alpha to decrease C-reactive protein in humans (Kleemann et al., 2003; Wagner et al., 2011). These drugs also cause decreases in other markers of inflammatory response *in vivo* in humans and animals, and *in vitro* through PPAR-alpha activation (Kleemann et al., 2003; Budd et al., 2007; Wagner et al., 2011). As it is well established that PFOA also activates PPAR-alpha, the decrease in C-reactive protein in populations exposed to PFOA through drinking water may have similarly occurred through PPAR-alpha activation.

Additionally, statins are a group of drugs that inhibit HMG-CoA reductase, a hepatic enzyme involved with cholesterol synthesis. Statins also activate PPARs including PPAR-alpha (Balakumar and Mahadevan, 2012). Two recent studies have reported that these drugs decrease the effectiveness of influenza vaccines in humans (Black et al., 2016; Omer et al., 2016). As above, it is well established that PFOA is an activator of PPAR-alpha, and HMG-CoA reductase activity was reduced by 50% in rats treated with 0.02% PFOA in the diet (22.7 mg/kg/day) for 7 days (Haughom and Spydevold, 1992). Taken together, these observations suggest that the decreased immune response associated with PFOA in humans may also be related to these effects.

Finally, an *in vitro* study in the human promyelocytic cell line THP-1 showed that PPAR-alpha plays a role in the immunotoxicity of PFOA in human cells (Corsini et al., 2011). Incubation of these cells with 100,000 ng/ml PFOA inhibited the lipopolysaccharide-stimulated release of two pro-inflammatory cytokines (TNF-alpha and IL-8) and matrix metalloproteinase-9, a molecule which plays a role in mobilization of inflammatory cells. This inhibition was reversed when PPAR-alpha was silenced by the addition of small interference RNA specific for PPAR-alpha.

#### Role of corticosterone production secondary to stress in immune effects in mice

Loveless et al. (2008) studied immune system and other effects in male CD rats and CD-1 mice given linear APFO by gavage at 0, 0.3, 1, 10, and 30 mg/kg/day for 29 days. This study evaluated the role of corticosterone in the immunotoxicity of PFOA. Hepatic effects from this study were described above.

Immunotoxicity caused by PFOA in the mice included decreased relative spleen weight at 1 mg/kg/day and above, and decreased numbers of spleen and thymus cells, decreased thymus weight, thymic depletion/atrophy, granulocytic bone marrow hyperplasia, and decreased anti-SRBC IgM titer at 10 and 30 mg/kg/day. The authors stated that the LOAEL for immunotoxic effects was 10 mg/kg/day, based on decreased IgM titers. However, the significant decrease in relative spleen weight at 1 mg/kg/day suggests that the LOAEL may actually have been 1 mg/kg/day.

Corticosterone levels were above the normal value of 400 ng/ml in 7 of 10 mice given 10 mg/kg/day PFOA and in 6 of 10 mice given 30 mg/kg/day PFOA, and decreased IgM correlated with increased corticosterone for individual mice ( $p < 0.002$ ). Based on this observation, the authors suggested that the IgM decreases from PFOA were secondary to stress-related increases in corticosterone.

In this study, rats were less sensitive to immunotoxic effects of PFOA than mice, and there were no effects of PFOA on spleen or thymus weight or on antibody production in the rats. Corticosterone levels were increased

above the level considered normal (300 ng/ml) in 2 of 10 rats in the 10 mg/kg/day group and 4 of 10 rats in the 30 mg/kg/day group.

DeWitt et al. (2009b) further investigated the hypothesis that immune effects of PFOA are secondary to corticosterone production in response to stress by studying adrenalectomized and sham-operated mice. Female C57BL/6N female mice (adrenalectomized or sham-operated) were dosed with 0, 7.5, or 15 mg/kg/day PFOA in drinking water for 10 days. Corticosterone levels were much higher in untreated sham-operated than adrenalectomized mice, and PFOA increased the levels of this hormone in sham-operated, but not adrenalectomized, animals. However, the immunotoxic effects of PFOA were not reduced by adrenalectomy, as SRBC-specific IgM levels were significantly reduced by 7.5 mg/kg/day PFOA in the adrenalectomized, but not sham-operated, mice, and in both groups of mice by 15 mg/kg/day PFOA. These authors concluded that the suppression of IgM synthesis by PFOA was not secondary to stress-related corticosterone production.

### **Developmental toxicity**

As discussed in the Epidemiology section, a systematic review of relevant epidemiological evidence concluded that there is “sufficient” human evidence (the highest strength of evidence in the evaluation scheme) that developmental exposure to PFOA reduces fetal growth in humans (Johnson et al., 2014). The developmental effects of PFOA in mice have PPAR-alpha dependent and independent components (Dewitt et al., 2009; Abbott et al., 2007) and may involve toxicity to the placenta. Based on the information presented below, developmental effects of PFOA in laboratory animals are considered relevant to humans for the purposes of risk assessment.

The USEPA Science Advisory Board (2006) concluded that PPAR-alpha mediated effects of PFOA in human fetuses, neonates, and children are of potential concern because there was minimal information about human levels of PPAR-alpha during these life stages. Subsequent to the USEPA SAB (2006) review, additional relevant information on the role of PPARs in human development became available. It is now known that PPAR-alpha, -beta, and -gamma are expressed in many fetal and adult tissues in rodents and humans. Abbott et al. (2010, 2012) found that PPARs are present in nine human fetal tissues examined (liver, heart, lung, kidney, intestine, stomach, adrenal, spleen, and thymus) from embryonic days 54 to 125. They found that the levels may increase or decrease with age of the fetus, or between the fetus and the adult. In some fetal tissues, PPARs were expressed at levels equivalent to or higher than in adults. Although the role of PPAR-alpha and other PPARs in human and animal development is not well characterized, based on their physiological actions, they are expected to have important roles in reproduction and development (Abbott et al., 2010). For these reasons, it can be assumed that PPAR-alpha mediated effects on development are relevant to humans.

In 129S1/Sv1mJ wild type and PPAR-alpha null mice dosed with PFOA on GD 1-17, full litter resorptions and increased pup liver weight caused by PFOA were independent of PPAR-alpha, while PFOA caused postnatal mortality, delayed eye opening, and decreased weight gain in wild type, but not PPAR-alpha null mice (Abbott et al., 2007). More recently, Albrecht et al. (2013) studied effects of gestational exposure of PFOA in wild-type, PPAR-alpha null, and humanized PPAR-alpha (expressing human PPAR-alpha) mice. They stated that PFOA decreased postnatal survival in wild type mice, but not PPAR-alpha null or humanized PPAR-alpha mice, suggesting that the humanized PPAR-alpha strain is less sensitive to this effect. However, a detailed review of this study, presented in the Animal Toxicology section, suggests that a firm conclusion on this point cannot be made from the data presented.



In the lungs and the liver of fetal (GD 18) CD-1 mice exposed during gestation, PFOA primarily affected the expression of genes related to intermediary metabolism and inflammation, including genes both associated and not associated with PPAR-alpha activation (Rosen et al., 2007). The authors suggested that PFOA tends to shift metabolism in the direction of a fasted animal, consistent with the metabolic changes and obesity in adult mice exposed to PFOA during gestation (Hines et al., 2009).

Developmental exposure to PFOA was found to alter the expression pattern of PPAR-alpha, -beta, and -gamma in many tissues in fetal and neonatal CD-1 mice (Abbott et al., 2012). The expression of genes regulated by PPARs and other nuclear receptors (CAR and PXR), including genes involved with homeostatic control of lipid and glucose metabolism, was also altered as early as GD14. The authors suggested that these effects on metabolism could contribute to the neonatal mortality and decreased rate of growth caused by gestational exposure to PFOA.

Wolf et al. (2010) discussed the potential human relevance of developmental effects of PFNA that are mediated by PPAR-alpha in mice, and these comments are applicable to PFOA as well. They state: "Relevance of the PPAR-alpha mechanism to humans has been criticized primarily based on the lower number of these receptors in the liver of human versus mouse. However, PPAR-alpha is implicated here in the developmental effects of PFNA as well, and the etiology of PPAR-alpha in other tissues of the embryo, fetus and neonate of the human and the mouse that are involved in gross development has not been fully determined. Therefore, the possibility of relevance of PPAR-alpha to a human response to PFNA cannot be dismissed."

Although many of the developmental effects of PFOA appear to be PPAR-alpha dependent, PFOA's developmental effects are not shared by other potent PPAR-alpha activators. Palkar et al. (2010) evaluated the developmental effects of two well-studied PPAR-alpha activating compounds, WY and clofibrate, in wild type and PPAR-alpha null mice. Pregnant mice were given doses of WY and clofibrate known to cause the same increase in maternal liver weight that is produced by doses of PFOA that also cause developmental toxicity. As expected, both WY and clofibrate caused increased maternal relative liver weight on GD 18 in wild type, but not PPAR-alpha null, mice. However, WY did not increase fetal liver weight on GD 18, although PFOA caused this effect on GD 18 and/or at early postnatal time points (GD 1, GD 4) in other studies (Albrecht et al., 2013; Macon et al., 2011; White et al., 2009). Although WY did not increase fetal liver weight, both WY and clofibrate increased expression of two genes associated with PPAR-alpha in fetal and maternal liver of wild type mice on GD 18. Furthermore, unlike PFOA, which is considered a low affinity PPAR-alpha agonist, the two higher affinity PPAR-alpha activators, WY and clofibrate, had no effect on reproductive and developmental parameters such as litter loss, number of live pups, fetal growth, day of eye opening, or post-natal mortality in either wild type or PPAR-alpha null mice. Although the reasons for these differences between PFOA and the two higher affinity PPAR-alpha activators is not known, these results suggest that PFOA may cause increased fetal liver weight, and reproductive and developmental effects, through a mechanism unrelated to PPAR-alpha activation.

Toxicity to the placenta may play a role in developmental effects of PFOA such as fetal growth retardation (Suh et al., 2011). In pregnant CD-1 mice treated with PFOA (2, 10, or 25 mg/kg/day) on GD 11-16, fetal and placental weights were decreased in a dose-dependent manner. PFOA also increased resorptions and dead fetuses, and decreased the number of live fetuses, resulting in significant increases in post-implantation loss.

Placental efficiency (ratio of fetal weight to placental weight) showed a dose-dependent decrease. Necrotic changes occurred in the placenta at the two higher doses, and decreases in several types of placental trophoblast cells occurred at all doses. These placental trophoblast cells produce prolactin family hormones that are vital to placental and fetal growth, adaptation to physiological stressors, and maintenance of pregnancy. Placental mRNA for these hormones was significantly decreased in all dose groups. Additionally, mRNA for the pituitary-specific transcription factor (Pit-1) that activates the prolactin family genes was also decreased. The authors concluded that reduced placental efficiency due to effects on placental trophoblast cells and placental hormones may play a role in PFOA's reproductive and developmental effects.

### **Male reproductive effects**

As discussed above, PFOA caused toxicity to the male reproductive system in several mouse studies. Additionally, PFCs have also been associated with adverse effects on sperm parameters and/or effects on male reproductive hormones in humans, although these associations are not necessarily specific to PFOA (Joensen et al., 2009; Toft et al., 2012). Additionally, prenatal exposure to PFOA was associated with decreased sperm count and concentration and increased LH and FSH in young men (Vested et al., 2013).

Li et al. (2011) suggest that PPAR-alpha plays a role in male reproductive effects of PFOA and that these effects occur through activation of either mouse or humanized PPAR-alpha. Decreased serum testosterone and an increased percentage of abnormal sperm were statistically significant effects in wild type and humanized PPAR-alpha mice, but statistically significant changes in these parameters did not occur in PPAR-alpha null mice. Additionally, abnormal seminiferous tubules with vacuoles or lack of germ cells were observed in the wild type and humanized PPAR-alpha mice, while no obvious structural changes occurred in the PPAR-alpha null mice.

Other studies suggest that PFOA may decrease levels of enzymes involved with testosterone synthesis (Zhang et al., 2014), disrupt the blood-testis barrier (Lu et al., 2015), and/or affect cellular pathways in the testes leading to increased oxidative stress (Liu et al., 2015). In regard to the latter effect, it was noted by Liu et al. (2015) that the testes are very sensitive to oxidative damage produced by reactive oxygen species, and that oxidative stress is known to be an important cause of male infertility in humans.

### **Effects on mammary gland development**

Because the developmental patterns of the mammary gland are similar in humans and rodents, rodents are considered to be a good model for studying the effects of environmental contaminants on human mammary gland development (Rudel and Fenton, 2009; Fenton et al. 2012; Rudel et al., 2011; Fenton and Birnbaum, 2015; Osborne et al., 2015).

PPAR-alpha null mice are viable, healthy, and fertile (Lee et al., 1995), suggesting that PPAR-alpha is not required for mammary gland development (Yang et al., 2006). However, activation of PPAR-alpha was shown to disrupt maternal mammary gland development in mice in two different mouse models (Yang et al., 2006). First, mammary gland development during pregnancy was impaired in transgenic mice with constitutively activated PPAR-alpha. Additionally, mammary gland development was suppressed in wild type mice administered the PPAR-alpha activator WY during pregnancy, and this effect was decreased when dosing with



WY was started later in pregnancy. In contrast, no significant effects on mammary gland development were observed in PPAR-alpha null mice similarly treated with WY during pregnancy.

The role of PPAR-alpha in PFOA's effects on mammary gland development in mice is not known. As discussed in detail above, prenatal and/or neonatal exposures to very low doses of PFOA cause persistent delays in mammary gland development in mice. However, the effects of gestational and/or lactational exposure to PFOA on mammary gland development have not been studied in wild type versus PPAR-alpha null mice. Limited data from two studies of effects of peripubertal exposure to PFOA on mammary gland in wild type and PPAR-alpha null mice (Zhang et al., 2010; Zhang et al., 2012) are insufficient to support a conclusion on this question.

In Zhao et al. (2010), PPAR-alpha null mice were treated with a single dose level of 5 mg/kg/day PFOA, 5 days per week for 4 weeks, starting at age 3 weeks. It was reported that PFOA caused stimulation of mammary gland development in the PPAR-alpha null mice, and, based on this single data point, the authors concluded that PFOA causes PPAR-alpha independent stimulation of mammary gland development. However, numerical data for this effect were not provided, and a similarly treated group of wild type mice was not included for comparison to the PPAR-alpha null mice in the study. A subsequent study (Zhao et al., 2012) reported no effect on mammary gland development in PPAR-alpha null mice from 7.5 mg/kg/day PFOA given 5 days per week for 4 weeks starting at age 3 weeks, while mammary gland development was inhibited in similarly treated wild type mice. However, the differences seen in the two strains may not have resulted from PPAR-alpha dependence of the effect, but rather from toxicokinetic differences, since the serum levels in the PPAR-alpha null mice (38,000 ng/ml) were much lower than in the wild type mice (93,000 ng/L). Additionally, the serum levels in PPAR-alpha null mice dosed with 5 mg/kg/day where stimulation was reported (28,000 ng/ml; Zhao et al., 2010) were close to the serum levels (38,000 ng/ml) in the same strain given 7.5 mg/kg/day at which no effects were reported. In summary, the stimulation of mammary gland development in PPAR-alpha null mice has not been clearly demonstrated. It was reported only in one study using a single dose level without a comparison group of wild type mice, and was not replicated in a second study of PPAR-alpha null mice with similar serum PFOA levels.

### **Estrogenic effects**

Estrogenic activity and/or increased estrogen levels may be involved in the mode of action of PFOA. As discussed in the Toxicology section, serum estradiol was increased in male Sprague-Dawley rats exposed to 13.6 mg/kg/day APFO in the diet for 1 month to 12 months in a two-year dietary study (Biegel et al., 2001). PFOA was also shown to bind to and/or activate human estrogen receptor-alpha in several *in vitro* studies (Benninghoff et al., 2011; Kjeldsen and Bonfeld-Jorgensen, 2013; Buhrke et al., 2015).

Exposure to PFOA increased levels of the sensitive estrogen-dependent biomarker protein, vitellogenin, and the expression of estrogen receptor-beta in the livers of mature male and female rare minnows (Wei et al., 2007). Male fish exposed to PFOA developed oocytes in the testes, and the ovaries of exposed females underwent degeneration. PFOA (as well as PFNA and perfluorodecanoic acid [PFDA, C10]), induced vitellogenin in young rainbow trout, and these PFCs also activated rainbow trout estrogen receptor *in vitro* (Benninghoff et al., 2011).

Studies in rainbow trout, a species used as a model for human liver carcinogenesis because it is insensitive to peroxisome proliferation, suggest that PFOA promotes liver tumor development through an estrogenic

mechanism (Tilton et al., 2008; Benninghoff et al., 2012). PFOA and two other peroxisome proliferating compounds (clofibrate and dehydroepiandrosterone, DHEA) were tested for tumor promoting activity in rainbow trout which had been initiated with aflatoxin. PFOA and DHEA (Tilton et al., 2008), as well as PFNA and PFDA (Benninghoff et al., 2012), increased the incidence and number of liver tumors and also induced a genomic signature similar to that induced by 17-beta-estradiol, while clofibrate did not promote liver tumors and did not regulate genes in common with 17-beta-estradiol (Tilton et al., 2008).

### **Carcinogenicity**

As discussed in the Epidemiology section, PFOA has been associated with testicular and kidney tumors in communities with drinking water exposure after adjustment for smoking and other relevant factors. As discussed in the Toxicology section, PFOA caused hepatic, testicular Leydig cell, and pancreatic acinar cell tumors in chronically exposed male rats (Biegel et al., 2001; Butenhoff et al., 2012). These tumor types are also caused by several other PPAR-alpha activating compounds in male rats (Klaunig et al., 2003).

### **Hepatic tumors**

Many PPAR-alpha activators cause liver tumors in rodents through a mode of action involving PPAR-alpha activation. These chemicals are not directly genotoxic, and thus cause tumors through a non-genotoxic mechanism. Activation of PPAR-alpha causes a number of effects in the liver, but all of these effects are not necessarily causal for carcinogenesis. As summarized by USEPA (2009c), peroxisome proliferation and increases in biochemical markers for peroxisome proliferation such as PCO are considered indicative of PPAR-alpha activation, but they are not considered causal events for carcinogenicity since their correlation with carcinogenic potency is poor. As discussed by the USEPA SAB (2006), the key causal events for PPAR-alpha induced liver carcinogenesis are believed to be PPAR-alpha activation, followed by increased cell proliferation and decreased apoptosis mediated by gene expression changes, leading to clonal expansion of preneoplastic foci and tumor formation (Klaunig et al., 2003; NRC, 2006). However, aside from the initial event (PPAR-alpha activation), the other causal events are not specific to a PPAR-alpha mode of action but rather are also common to other modes of action for hepatic carcinogenesis (USEPA, 2006; Klaunig et al., 2012).

Much attention has been focused on the potential human relevance of rodent liver tumors induced by PPAR-alpha activators. There is wide variation among species in the ability of PPAR-alpha activators to cause hepatic peroxisome proliferation and liver tumors, with rats and mice the most sensitive, hamsters intermediate in sensitivity, and humans, monkeys, and guinea pigs least sensitive to these effects. These species differences may be due to lower levels of PPAR-alpha expression in humans than in rodents (NRC, 2006) or to differences in PPAR-alpha structure and function among species (Corton, 2010). Studies of humans exposed to peroxisome proliferating fibrate drugs have not shown increased risk of liver cancer (NRC, 2006), although these studies have limitations that are discussed by Guyton et al. (2009).

The majority of the USEPA SAB (2006) panel believed that the human relevance of the PPAR-alpha mode of action for liver tumors caused by PFOA could not be dismissed. This conclusion was based on data indicating similar responses to PFOA in the livers of rodents and primates (increased liver weight and induction of hepatic peroxisomal enzyme activity, discussed above). Although increased cell proliferation was not found in the monkeys (Butenhoff et al., 2002), the USEPA SAB (2006) noted that this endpoint was only measured after 6 months of exposure in the monkeys but not at an earlier time point during the first 1-2 weeks of exposure when it would have been more likely to occur, and apoptosis was not evaluated at any time point. The lack of data on

cell proliferation at an appropriate time point and apoptosis at any time point in the monkeys treated with PFOA precluded analysis of dose-response concordance between these key events and tumor induction for PFOA as compared to other PPAR-alpha agonists. Subsequent to the USEPA SAB (2006) evaluation, hepatic effects of PFOA were observed in three studies of mice with humanized PPAR-alpha, although chronic studies to evaluate tumor incidence in humanized PPAR-alpha mice have not been conducted (Nakamura et al., 2009; Nagakawa et al., 2011; Albrecht et al., 2013; discussed above).

The USEPA SAB (2006) also noted that the role of hepatic PPAR-alpha in human fetuses, neonates, and children is not known, and that a PPAR-alpha mode of action for hepatic effects could not be ruled out in these age groups. As discussed above, it was subsequently demonstrated that PPARs are present in many human fetal tissues, including liver, and that levels of PPARs increase and decrease with age of the fetus, and between the fetus and the adult (Abbott et al., 2010, 2012). Additionally, PFOA caused increased liver weight and expression of genes associated with PPAR-alpha in fetal livers from mice with humanized PPAR-alpha (Albrecht et al., 2013).

The USEPA SAB (2006) further concluded that PPAR-alpha activation may not be the sole mode of action for liver tumors caused by PFOA. This conclusion was based on the single study of PFOA in wild type and PPAR-alpha null mice that was available at the time (Yang et al., 2002b). In this study, PFOA increased liver weight in both wild type and PPAR-alpha null mice, while a model PPAR-alpha activator (WY) increased liver weight in wild type mice but had no effect in PPAR-alpha null mice. Numerous studies published subsequent to the USEPA SAB (2006) review confirm this conclusion and provide additional relevant information. These include several studies demonstrating PPAR-alpha independent hepatic effects of PFOA in standard strains of rodents and PPAR-alpha null mice, as well as the PPAR-alpha independent hepatic tumors, possibly related to estrogenic effects, in rainbow trout exposed to PFOA. The USEPA SAB (2006) also noted that some of the causal events in the PPAR-alpha mode of action for liver tumors had not been demonstrated for PFOA, including increased cell proliferation in the liver at early time points after dosing and/or decreased apoptosis in liver cells.

Newer information relevant to this issue shows that the hepatic effects of PFOA and WY differ, and that increased hepatic cell proliferation caused by PFOA is not totally dependent on PPAR-alpha activation. PFOA caused liver tumors in a two-year study of male rats (Biegel et al., 2001), but it did not increase hepatic cell proliferation at any of eight time points between one and 21 months after dosing began. In contrast, the PPAR-activating compound WY, which also caused liver tumors in this study, significantly increased hepatic cell proliferation at most of these time points.

Elcombe et al. (2010) suggested that the earliest time point evaluated by Biegel et al. (2001), one month after dosing began, may have been too late to observe hepatic cell proliferation in response to PFOA since cell proliferation occurs early in the sequence of events leading to liver tumors. They studied effects of PFOA and WY on hepatic endpoints including nuclear receptor activation, cell proliferation, and apoptosis in male rats at earlier time points (one day after the end of dosing for 1, 7, or 28 days). While PFOA acted as an activator of PPAR-alpha, CAR, and PXR, WY was a specific activator of PPAR-alpha only. WY increased hepatic cell proliferation and decreased apoptosis, and these effects were accompanied by increased hepatic DNA content. PFOA also increased hepatocellular proliferation, but, unlike WY, it did not cause decreased apoptosis or increased liver DNA content.

Results from wild type and PPAR-alpha null mice demonstrate that PFOA causes hepatic cell proliferation, one of the key causal events for PPAR-alpha dependent liver carcinogenesis, through PPAR-alpha independent pathway(s). PFOA caused a similar or greater dose-dependent increase in hepatic cell proliferation in mice lacking PPAR-alpha as compared to wild type mice, and relative liver weight was also increased to a similar degree in both strains (Wolf et al., 2008). In contrast to PFOA, WY increased cell proliferation and relative liver weight only in the wild type mice in this study.

A carcinogenicity bioassay of PFOA has not been conducted in a standard strain of mice, or in wild type and PPAR-alpha null mice. However, the incidence of liver tumors at age 18 months was evaluated in female CD-1, 129/Sv wild type, and 129/Sv PPAR-alpha knockout offspring after developmental exposures to PFOA (Filgo et al., 2015). The authors emphasize that the study was not designed or intended to be a carcinogenicity bioassay, but that tumor incidence was assessed because of the unexpected finding of liver tumors in some animals that died before the scheduled end of the study.

In CD-1 mice, single or multiple hepatocellular adenomas occurred in one or more animals in each of the treated groups (n=21 to 37 per group; 0, 0.01, 0.1, 0.3, 1, and 5 mg/kg/day) except for at the lowest dose (0.01 mg/kg/day), but were not found in controls (n=29). In total, adenomas occurred in 4.9% (7 of 144) treated animals, compared to a historic control incidence of 0.4% in untreated female CD- mice. Additionally, hepatocellular carcinomas occurred in two treated mice (0.3 and 5 mg/kg/day) but not in controls.

In 129/Sv wild type mice, hepatocellular adenomas did not occur in control or treated groups (n=6 to 10 per group; 0, 0.1, 0.3, 1, and 3 mg/kg/day). In contrast, in PPAR-alpha null mice of this strain, there were no adenomas in the controls (n=6), one adenoma in each of the 0.1, 0.3, and 1 mg/kg/day PFOA-treated groups (n=9 or 10), and two adenomas in the 3 mg/kg/day group (n=9). These tumors occurred in 13.2% of all PFOA-treated PPAR-alpha null mice. The results of this study suggest the possibility that developmental exposure to low doses PFOA may cause hepatic tumors later in life through a PPAR-alpha independent mode of action, although more research is needed before any firm conclusions can be made.

#### Testicular Leydig cell and pancreatic acinar cell tumors

Modes of action that have been suggested for the non-hepatic tumors caused by PFOA are reviewed in USEPA (2005a) and Klaunig et al. (2012). Several other PPAR-alpha agonists have been found to induce the same three tumor types (hepatic adenomas, pancreatic acinar cell tumors, and testicular Leydig cell tumors) as PFOA in Sprague-Dawley rats. However, the modes of action for the latter two types of tumors have not been fully characterized, and it has not been shown that they occur through a PPAR-alpha mediated mode of action.

The mode of action for testicular Leydig cell tumor induction by PFOA is unknown. Proposed modes of action include 1) increased serum estradiol through PPAR-alpha mediated induction of hepatic aromatase activity, leading to estradiol-dependent increased production of growth factors inducing the tumors, and 2) inhibition of testosterone biosynthesis leading to an increase in luteinizing hormone (LH), which promotes Leydig cell tumor development (Klaunig et al., 2012). However, for each of these proposed modes of action, data from the chronic mechanistic rat study (Biegel et al., 2001) do not support one of the key events and the mode of action (Klaunig et al., 2012).

The key events in the first proposed mode of action above are:

Activation of PPAR-alpha in the liver → increased hepatic aromatase → increased serum and testicular interstitial fluid estradiol levels → increased transforming growth factor-alpha → increased testicular Leydig cell proliferation → testicular Leydig cell tumors (Klaunig et al., 2012).

As discussed by Klaunig et al. (2012), testicular Leydig cell proliferation was not increased by PFOA at numerous time points during the chronic rat study of Biegel et al. (2001).

The key events in the second proposed mode of action above are:

Decreased testosterone levels → increased LH levels → testicular Leydig cell tumors.

As discussed by Klaunig et al. (2012), LH was not increased by PFOA at numerous time points during the chronic rat study (Biegel et al., 2001).

The mode of action for pancreatic acinar cell tumor induction by PFOA is also unknown. One possible hypothesis that has been suggested is that these tumors occur as a result of an increase in cholecystokinin secondary to hepatic effects of PFOA, but this has not been demonstrated experimentally (Klaunig et al., 2012).

The USEPA SAB (2006) concluded that insufficient data were available to determine the mode of action for the testicular Leydig cell tumors and the pancreatic acinar cell tumors found in PFOA treated male rats (Biegel et al., 2001). More recently, Klaunig et al. (2012) concluded that, based on information presented above, the available data do not definitively establish a mode of action for these tumors. In the absence of a defined mode of action for these tumor types, the USEPA SAB (2006) concluded that “they must be presumed to be relevant to humans, as suggested by EPA’s Cancer Guidelines,” and this conclusion remains valid at this time.

### **Other possible modes of action**

A number of other modes of action for PFOA have been suggested. Although a complete review of this topic is beyond the scope of this document, information on several potential modes of action is summarized below.

PFOA and other perfluorinated carboxylates of carbon chain lengths C7-C10 inhibited intercellular gap junction communication *in vitro* in cultured rat liver cells, while non-fluorinated fatty acids and PFCs of chain length C2-C5 or C16 and C18 did not (Upham et al., 1998). In further *in vivo* studies, male F-344 rats fed diets containing 0.02% PFOA (resulting in a dose of 37.9 mg/kg/day) for 7 days had significantly increased liver weight and significantly decreased hepatic gap junction intercellular communication, as measured by the distribution of a fluorescent dye that travels through gap junction channels (Upham et al., 2009).

Perfluoropentanoic acid (C5) did not cause either of these effects. The authors suggested that disruption of gap junction intercellular communication can lead to tumorigenesis and can be important in tumor promotion. However, Lau et al. (2007) stated that inhibition of gap junction intercellular communication is a widespread phenomenon, and that these effects of PFOA and other PFCs have not been shown to be species or tissue specific.

The mode of action for PFOA may also involve effects on mitochondria. As discussed above, developmental exposure to PFOA in female mice caused hepatic mitochondrial proliferation and abnormal mitochondrial morphology later in life (Quist et al., 2015). Furthermore, hepatic activity of the mitochondrial enzyme, succinate dehydrogenase, was increased in cynomolgus monkeys treated with PFOA (Butenhoff et al., 2002).



Hepatic mitochondrial DNA copy number was also significantly increased in male rats 3 days after a single dose of 100 mg/kg PFOA and after 28 days of exposure to 30 mg/kg/day (Berthiaume and Wallace, 2002; Walters et al., 2009).

Starkov and Wallace (2002) investigated effects of PFOA and other PFCs in isolated mitochondria. The involvement of mitochondria in the mode of action of PFCs was suggested by earlier reports of proliferation of hepatic mitochondrial membranes after PFC exposure and uncoupling of mitochondrial respiration in isolated mitochondria exposed to high concentrations of PFCs (reviewed in Starkov and Wallace, 2002). They found that PFOA and PFOS caused slight effects only at high concentrations (e.g. 100  $\mu$ M for PFOA) which may have resulted from changes in membrane fluidity due to the surfactant properties of PFCs. In contrast, other PFCs were potent uncouplers of oxidative phosphorylation, such as perfluorooctane sulfonamide which had an  $IC_{50}$  of 1  $\mu$ M for this effect.

MicroRNAs (miRNAs) are small non-coding RNAs which affect gene expression by binding to complementary mRNA to block translation or trigger degradation. Changes in miRNA may play a role in various diseases by affecting the expression of relevant genes (Wang et al., 2012; Yan et al., 2014). Recent studies suggest that PFOA may alter miRNA levels in both humans and rodents. Elevated levels of specific miRNAs in serum were associated with serum PFOA concentrations in a study of Chinese residents and workers with PFOA exposures from a fluoropolymer manufacturing facility (Wang et al., 2012). In this study, 63 of the 754 miRNAs that were evaluated were detected in all serum samples. Levels of 9 miRNAs were significantly higher in workers compared to less highly exposed residents. In a further analysis, levels of two of these (miR-26b and miR-199a-3p) were significantly increased in an exposure-related fashion within the worker group. A subsequent study found that levels of circulating miRNAs were increased in male BALB/cJ mice dosed with PFOA for 28 days, and that more miRNAs were affected as PFOA dose increased. Interestingly, the two miRNAs that were associated with PFOA in workers in a dose-related fashion were also increased by PFOA exposure in mice (Yan et al., 2014).

In addition, the mode of action of PFOA may involve effects related to organic anion transporters (OATs), organic anion transporting polypeptides (OATPs), and other multispecific transporter proteins such as multidrug resistance-associated proteins (MRPs/Mrps). These highly conserved transporters are present in the membranes of many tissues throughout the body in humans, other mammalian species, and lower vertebrates. They are responsible for the transport of numerous endogenous and xenobiotic compounds both into and out of cells. Substrates for transporter proteins include fatty acids, hormones, bile acids, drugs, environmental contaminants, and other exogenous and endogenous substances that are critical in homeostatic pathways (Roth et al., 2011).

It is well established that renal tubular secretion and reabsorption of PFOA occur through transport by various OATs and OATPs, and that the slow rate of excretion of PFOA in male (in contrast to female) rats and both genders of humans is due to reabsorption of PFOA by specific renal OATs and/or OATPs (Han et al., 2012). Recent studies have shown that effects of PFOA in organs other than the kidney may involve these transporter proteins as well. PFOA can act as an inhibitor of specific OATs and OATPs (Yang et al., 2009b; 2010), and it induced MRP in cultured human cells (Rusiecka and Skladanowski, 2008) and Mrp in mouse liver (Maher et al., 2008), potentially affecting transport of endogenous substances, drugs, and other transporter substrates. The role of OAT4 in placental transfer of PFOA in humans was recently studied (Kummu et al., 2015). OAT4 is found primarily in human kidney and placenta and has been identified as one of the specific transporters

responsible for renal reabsorption of PFOA in humans (Han et al., 2012). The level of placental OAT4 was inversely correlated with the rate of transfer of PFOA from the maternal circulation to fetal circulation in studies of perfused human placenta, suggesting that higher levels of placental OAT4 may protect the fetus from PFOA after maternal exposure (Kummu et al., 2015).

### **Summary of conclusions about human relevance of toxicological effects of PFOA**

Based on the information presented above, the toxicological effects of PFOA are generally considered relevant to humans for the purposes of risk assessment.

#### Hepatic effects

Increased serum levels of liver enzymes are associated with exposure to PFOA in humans. Data from non-human primates, standard strains of rats and mice, PPAR-alpha null mice, and humanized PPAR-alpha mice support the conclusion that hepatic effects of PFOA in experimental animals are relevant to humans for the purposes of risk assessment.

PFOA caused increased relative liver weight in non-human primates, species for which the human relevance of hepatic effects is not in question. In a subchronic study in cynomolgus monkeys, several animals that did not complete the study due to overt toxicity exhibited notably increased liver weight, highly elevated serum liver enzymes and/or severe hepatic toxicity. In this study, hepatic peroxisome proliferating activity was increased in a dose-related fashion. As was noted by the USEPA SAB (2006), the effects of PFOA on both liver weight and peroxisome proliferation were similar in cynomolgus monkeys and rats. In contrast to rodents, the human relevance of hepatic effects mediated by PPAR-alpha in non-human primates is not subject to debate. Potential PPAR-alpha independent pathways for hepatic effects of PFOA have not been thoroughly investigated in non-human primates, although increased activity of a mitochondrial enzyme (succinate dehydrogenase) was reported in the subchronic cynomolgus monkey study.

Data from standard strains of mice and rats clearly show that PPAR-alpha independent mechanisms contribute to the hepatic effects of PFOA. Studies which evaluated both liver weight and hepatic peroxisome proliferating activity provide data relevant to this question. At the doses and time points evaluated in these studies, the dose-response curves for increased liver weight and hepatic peroxisome proliferating activity did not directly correspond. These data indicate that hepatic effects of PFOA involve PPAR-alpha independent mechanisms even in standard strains of rodents with normal PPAR-alpha status. Furthermore, PFOA caused fatty liver in standard strains of mice and rats, although PPAR-alpha activation causes decreased hepatic lipid accumulation. Additionally, recent studies suggest that the differences in the effects of PFOA on serum lipids in rodents (decreased cholesterol and triglycerides) versus humans (increased cholesterol and triglycerides) may be related to the low fat diet generally used in laboratory rodent studies versus the higher fat content of a typical Westernized human diet, rather than solely to interspecies differences. Finally, developmental exposure to PFOA caused abnormal mitochondria in livers of a standard strain of laboratory mice, with no evidence of peroxisome proliferation.

Data from studies comparing mice with normal PPAR-alpha status (wild type) and mice lacking PPAR-alpha (PPAR-alpha null) provide further evidence that hepatic effects occur through both PPAR-alpha dependent and PPAR-alpha independent pathways. PFOA causes similar increases in liver weight in wild type and PPAR-alpha null mice. PFOA also causes histopathological changes and increased liver enzymes in PPAR-alpha null



mice; the histopathological changes differ from those seen in wild type mice, particularly as related to damage to the bile duct. Additionally, developmental exposures to PPAR-alpha null mice caused persistent histopathological changes in the liver.

Data from mice expressing human PPAR-alpha in the liver indicate that activation of human PPAR-alpha by PFOA causes hepatic effects. PFOA caused similar increases in liver weight in humanized PPAR-alpha mice and wild type mice. Other hepatic effects of PFOA in humanized PPAR-alpha mice include activation of genes associated with PPAR-alpha, and histopathological changes including hepatocellular hypertrophy and single cell necrosis.

PPAR-alpha is known to be active in human fetal tissues, including liver. Fetal liver weight was increased similarly in wild type and PPAR-alpha humanized mice after *in utero* exposure. Additionally, PFOA increased the expression of genes associated with PPAR-alpha in fetal liver to a greater degree in PPAR-alpha humanized mice than in wild type mice.

#### Immune system effects

Data from epidemiological studies suggest that the immune system is a sensitive target for PFOA in humans. PFOA suppresses the immune system in both non-human primates and mice. Data from mouse studies indicate that these effects on the immune system occur through both PPAR-alpha dependent and PPAR-alpha independent modes of action. Both PPAR-alpha dependent and independent effects on the immune system are considered relevant to humans for the purposes of risk assessment. Potentially relevant to this conclusion, lipid-lowering drugs that activate PPAR-alpha have recently been associated with decreased effectiveness of the influenza vaccine in humans, consistent with inhibition of human immune response by agents that activate PPAR-alpha such as PFOA.

#### Developmental and reproductive effects

PFOA is associated with decreased fetal growth in humans. PPAR-alpha and other PPARs are present in human fetal tissues and are expected to have important roles in reproduction and development. Therefore, PPAR-alpha mediated effects of PFOA on development are considered relevant to humans for the purposes of risk assessment. Developmental effects of PFOA in rodents appear to occur primarily through PPAR-alpha dependent mechanisms, while some reproductive effects such as full litter resorptions appear to be PPAR-alpha independent. However, high affinity “pure” PPAR-alpha activators (WY and clofibrate) do not cause the developmental effects in mice that were caused by PFOA.

Delayed mammary gland development after developmental exposure is a sensitive endpoint for PFOA toxicity in mice. The rodent is considered a good model for human mammary gland development, and there is no mode of action evidence suggesting that the effects of PFOA on this endpoint are not relevant to humans.

PFOA also causes reproductive toxicity in male mice, and there is no mode of action information to suggest that these effects are not relevant to humans.

#### Carcinogenicity

PFOA is associated with testicular and kidney cancer in communities with drinking water exposure after adjustment for smoking and other relevant factors. PFOA caused tumors of the liver, testicular Leydig cells,

and pancreatic acinar cells in male rats. USEPA (2006) SAB did not dismiss the potential human relevance of the liver tumors in rats, based on similarities in hepatic effects of PFOA in monkeys and rodents and the limited evidence available at the time for hepatic effects of PFOA in PPAR-alpha null mice. Subsequent studies have provided substantial additional information showing hepatic effects of PFOA in PPAR-alpha null mice. Importantly, hepatic cell proliferation, a causal event for tumor formation, is increased similarly by PFOA in wild type and PPAR-alpha null mice. Although a carcinogenicity bioassay for PFOA has not been conducted in PPAR-alpha null mice, a recent study suggests that developmental exposures to PFOA may cause hepatic tumors in adulthood in this strain. Finally, studies in rainbow trout, a species used as a model for human liver cancer because it lacks PPAR-alpha, suggest that PFOA causes liver tumors through an estrogenic mode of action.

Because the modes of action for the testicular and pancreatic tumors caused by PFOA have not been established, these tumors are considered relevant to humans for the purposes of risk assessment.

### **DEVELOPMENT OF RECOMMENDED HEALTH-BASED MCL**

Health-based MCLs developed by the DWQI are intended to be protective for chronic (lifetime) exposure through drinking water. The 1984 Amendments to the New Jersey Safe Drinking Water Act (N.J.S.A. 58:12A-20) stipulate that Health-based MCLs are to be based on a one in one million lifetime cancer risk level for carcinogens and no adverse effects from lifetime ingestion for non-carcinogens.

### **Consideration of human epidemiological data**

Both the human epidemiology data and the animal toxicology data were considered as part of the overall weight of evidence for the potential human health effects of PFOA. As reviewed in the Epidemiology section, associations of PFOA with numerous health endpoints have been found in human populations, with evidence supporting multiple criteria for causality for some effects. These health endpoints include non-carcinogenic effects in the general population, and both non-carcinogenic effects and cancer in communities with drinking water exposure. The epidemiologic data for PFOA are notable because of the consistency between results among human epidemiologic studies in different populations, the concordance with toxicological findings in experimental animals, the use of serum concentrations as a measure of internal exposure, the potential clinical importance of the endpoints for which associations are observed, and the observation of associations within the exposure range of the general population and communities with contaminated drinking water. These features of the epidemiologic data distinguish PFOA from most other organic drinking water contaminants and justify concerns about exposures to PFOA through drinking water.

Although the data for some endpoints support multiple criteria for causality, the human epidemiology data have limitations and are therefore not used as the quantitative basis for the Health-based MCL. Instead, the potential Health-based MCLs developed below are based on sensitive and well established animal toxicology endpoints that are considered relevant to humans based on mode of action data. Notwithstanding, continued exposure to even relatively low levels of PFOA in drinking water are known to cause substantial increases in PFOA in blood serum, to levels several fold higher than those found in the general population. The considerable evidence for increased risks of health effects from the low-level PFOA exposures prevalent in the general population (e.g. <10 ng/ml, NHANES 2007-2010; CDC 2015) and in communities with contaminated drinking water suggests a need for caution about drinking water exposures that will result in such elevations in serum PFOA level. Relevant to this point, it is noted that the German Human Biomonitoring Commission recently developed a

Human Biomonitoring Level I (the serum level below which adverse health effects are not expected) for PFOA of 2 ng/ml, close to the current median PFOA serum level in the U.S. general population. This HBM I is based on the serum PFOA levels associated with increased time to pregnancy, decreased fetal growth, increased serum cholesterol, and decreased immune response in humans, and with delayed mammary gland development in mice (Apel et al., 2016). The human epidemiological data thus support the use of a public health-protective approach in developing a Health-based MCL recommendation based on animal toxicology data.

### **Weight of Evidence for Carcinogenicity**

PFOA caused tumors in male rats in two chronic studies (Sibinski et al., 1987, Butenhoff et al., 2012; and Biegel et al., 2001). It caused a statistically significant increase in testicular Leydig cell tumors in both studies, as well as a statistically significant increase in liver tumors and pancreatic tumors in Biegel et al. (2001). Human exposure to PFOA has also been associated with increased risk of cancer, including increased risk of kidney and testicular cancer in communities with contaminated drinking water after adjustment for smoking and other relevant factors (Barry et al, 2013; Vieira et al., 2013).

Based on the chronic animal data and mode of action studies available at the time, PFOA was described as “likely to be carcinogenic to humans” by the USEPA Science Advisory Board (USEPA, 2006). PFOA was classified as “possibly carcinogenic to humans” by IARC based on review of data from human epidemiology, animal toxicology, and mechanism of action studies (Benbrahim-Tallaa et al., 2014). More recently, PFOA was described by the USEPA Office of Water (2016a) as having “suggestive evidence of carcinogenic potential”, a descriptor similar to the classification of “possibly carcinogenic to humans” used by IARC (2015).

The USEPA Guidelines for Carcinogen Risk Assessment (2005b) recommend dose-response modeling and low dose extrapolation for chemicals described as likely to be carcinogenic. For chemicals with suggestive evidence of carcinogenicity, dose-response modeling and low dose extrapolation may be performed when data to support it are available. The guidelines recommend that the risk-based estimates for suggestive carcinogens be used to obtain “a sense of the magnitude and uncertainty of potential risks, ranking potential hazards, or setting research priorities.” Risk-based drinking water concentrations based on both non-carcinogenic and carcinogenic endpoints are presented below.

### **Potential Health-based MCLs based on non-carcinogenic endpoints**

#### **Selection of toxicological endpoints for consideration as basis for potential Health-based MCLs**

As reviewed in the Toxicology section above, PFOA causes numerous systemic effects in experimental animals. These include liver toxicity, immune system toxicity, adverse developmental effects, and other adverse effects. The Health Effects Subcommittee concluded that delayed mammary gland development and increased relative liver weight are the most sensitive systemic endpoints with data appropriate for dose-response modeling.

Delayed mammary gland development from perinatal exposure is the most sensitive systemic endpoint for PFOA with data appropriate for dose-response modeling. It is a well-established toxicological effect of PFOA that is considered to be adverse and relevant to humans for the purposes of risk assessment. An RfD based on this endpoint is presented below.

To the knowledge of the Health Effects Subcommittee, an RfD for delayed mammary gland development has not previously been used as the primary basis for health-based drinking water concentrations or other human

health criteria for environmental contaminants. Because the use of this endpoint as the basis for human health criteria is a currently developing topic, the Health Effects Subcommittee decided not to recommend a Health-based MCL with the RfD for delayed mammary gland development as its primary basis. However, the occurrence of this and other effects at doses far below those that cause increased relative liver weight (the endpoint used as the primary basis for the recommended Health-based MCL) clearly requires application of an uncertainty factor to protect for these more sensitive effects.

Increased relative liver weight is a well-established effect of PFOA that is more sensitive than most other toxicological effects such as immune system toxicity and most reproductive/developmental effects (Table 12 of Animal Toxicology section). A recommended Health-based MCL with increased liver weight as its primary basis is presented below.

#### Selection of studies and data for dose-response modeling

Only those studies that provide serum PFOA data were considered for dose-response modeling of non-carcinogenic effects. A risk assessment approach based on measured serum PFOA levels is less uncertain than one based on pharmacokinetic modeling of estimated serum PFOA levels or an approach in which interspecies extrapolations is based on interspecies half-life differences. For example, as discussed above, serum PFOA concentrations from the same administered dose vary among strains and even between animals of the same strain obtained from different sources. Available approaches based on pharmacokinetic modeling or interspecies half-life conversions do not account for these intra-strain differences.

In some studies, serum PFOA was measured only at time points well after dosing had ended. Serum data from these later time points are not appropriate for dose-response modeling because PFOA body burdens would have decreased, and the serum levels thus do not represent the maximum exposures during the study. Therefore, only studies which provide serum PFOA levels close to the end of the dosing period were considered for dose-response modeling. Use of the maximum serum levels that occurred during the study is a non-conservative approach (i.e. would result in a less stringent, rather than more stringent, risk assessment than other potential approaches such as area under the curve modeling), since the observed toxicological effects could have resulted from the lower average exposures experienced over the entire dosing and post-dosing time periods.

Benchmark dose (BMD) modeling is a quantitative approach commonly used to estimate the lower 95% confidence limit (the BMDL) on the dose corresponding to a minimal response (the benchmark response, BMR) that is consistent with the observed data. The BMDL is considered to be an estimate of the NOAEL, but it is based on the entire dose-response curve for the endpoint of interest rather than just the fixed doses administered in the study. When the necessary data are available, BMD modeling can be performed using serum concentrations instead of administered doses. Serum concentrations are preferable to administered doses as the basis for BMD modeling because they are a better representation of the shape of the internal dose response curve. BMD modeling based on serum PFOA data was used to determine BMDLs for serum PFOA concentrations used as the points of departure (PODs) to develop RfDs for both increased relative liver weight and delayed mammary gland development.

#### Reference Dose based on delayed mammary gland development

Delayed mammary gland development in mice from developmental exposures is a sensitive endpoint for PFOA's toxicity. This effect has been reported in nine separate studies presented in five publications (Table 14

of Toxicology section). Only one study (Albrecht et al., 2013), which has several general problematic issues (discussed in Toxicology section) did not find this effect. Gestational and/or lactational exposures to PFOA caused delayed mammary gland development in pregnant dams and/or female offspring in two strains of mice. In one study, this effect was statistically significant in mouse pups exposed to concentrations of 5000 ng/L (5 µg/L) in drinking water *in utero* and after birth. The serum PFOA levels (80 ng/ml in the dams and 20-70 ng/ml in the pups) that resulted in delayed mammary gland development in these mice are relevant to human serum PFOA levels from contaminated drinking water. Histological changes in the mammary glands of exposed offspring persisted until adulthood and were considered permanent. Delayed mammary gland development occurs in a dose-related fashion, and there is no information indicating it is not relevant to humans. For these reasons, delayed mammary gland development from developmental exposures to PFOA is considered a sensitive and relevant endpoint for dose-response modeling.

Selection of study and data for dose-response modeling of delayed mammary gland development

The late gestational exposure study conducted by Macon et al. (2011) is the only developmental exposure study of mammary gland development that provides serum PFOA data from the end of the dosing period (PND 1) that can be used for dose-response modeling. In this study, pregnant dams were dosed with PFOA (0.01 to 1 mg/kg/day) on GD 10-17. Mammary gland development was assessed on PND 1, 4, 7, 14, and 21, and delays in development were most evident on PND 21. Of the several endpoints related to mammary gland development reported by Macon et al. (2011), two endpoints (decreased mammary gland developmental score and decreased number of terminal end buds) showed a statistically significant dose-related decrease at PND 21 over the dose range studied. These endpoints were selected for dose-response modeling (Table 15).

Table 15. Mammary gland development parameters selected for dose-response modeling from PND 21 female offspring after exposure on GD 10-17 (Macon et al., 2011)

<b>Dose (mg/kg/day)</b>	<b>Pup Serum PFOA, PND 1 (ng/ml)</b>	<b>Developmental score (1-4)</b>	<b>Number of Terminal End Buds</b>
Control	22.6 ± 5.5	3.3 ± 0.3	40 ± 4
0.01	284.5 ± 21.0	2.2 ± 0.2	33 ± 4
0.1	2303.5 ± 114.1	1.8 ± 0.3	24 ± 4
1.0	16,305.5 ± 873.5	1.6 ± 0.1	15 ± 2

Determination of Point of Departure for delayed mammary gland development

USEPA Benchmark Dose Modeling Software 2.1.2 was used to perform BMD modeling of the data for mammary gland developmental score and number of terminal endbuds at PND 21 from Macon et al. (2011), using serum PFOA data from PND 1 as the dose. Continuous response models were used to obtain the BMD and the BMDL for a 10% change from the mean (the percent change typically used as the BMR) for the two endpoints. Modeling was based on serum levels at PND 1, since they were higher at this time than at later time points. In this study, the serum level in the control group was 22.6 ng/ml, indicating that some PFOA exposure occurred in these non-dosed animals. The BMD and BMDL values presented in Table 16 were derived using this value from the control group (22.6 ng/ml) as the baseline. The serum level BMDs and BMDLs may have been lower if the baseline serum level had been lower (Post et al., 2012).

Compared to controls, the developmental score at PND 21 significantly decreased at all three doses; the number of terminal end buds also decreased at all three doses, with significance at the two higher doses. The BMDLs

for the two endpoints, 24.9 and 22.9 ng/ml (Table 16), are close to the NOAEL of 28.5 ng/ml that is estimated by applying a standard uncertainty factor of 10 for LOAEL-to-NOAEL extrapolation to the serum level of 285 ng/ml at the LOAEL, 0.01 mg/kg/day. Outputs of the BMD modeling are provided in Appendix 6.

Table 16. Benchmark Dose modeling of serum PFOA data (PND1) for mammary gland developmental effects (PND 21) in CD-1 mouse pups (Macon et al., 2011) <sup>a</sup>				
Model	Chi-square p-value <sup>b</sup>	Akaike Information Criterion (AIC) <sup>c</sup>	BMD (Serum PFOA, ng/ml)	BMDL (Serum PFOA, ng/ml)
<b>Decreased Mammary Gland Developmental Score</b>				
Hill (non-logged concs.)	0.70	-4.28	57.4	28.1
Polynomial - 2 <sup>nd</sup> deg. (logged concs.)	0.83	-4.39	25.9	24.0
<b>Exponential -model 2 (logged concs.)</b>	<b>0.87</b>	<b>-36.86</b>	<b>25.7<sup>d</sup></b>	<b>24.7<sup>d</sup></b>
Linear (logged concs.)	0.83	-6.05	28.0	26.5
<b>Decreased Number of Terminal End Buds</b>				
Hill (non-logged concs.)	0.47	88.43	235.1	78.5
Exponential - model 4 (non-logged concs.)	0.30	88.97	399.8	110.5
Power (non-logged concs.)	0.62	88.15	64.8	23.4
Power (logged concs.)	0.81	87.96	87.2	29.0
Polynomial – 2 <sup>nd</sup> deg. (logged concs.)	0.84	87.94	96.6	28.1
Linear (logged concs.)	0.12	89.47	27.0	25.7
<b>Exponential – model 3 (logged concs.)</b>	<b>0.98</b>	<b>87.90</b>	<b>25.1<sup>d</sup></b>	<b>22.9<sup>d</sup></b>

<sup>a</sup> Results are shown for all models that gave an acceptable visual fit.

<sup>b</sup> A larger Chi-square p-value indicates a better fit to the data.

<sup>c</sup> AIC: A measure of information loss from a dose-response model that can be used to compare a specified set of models. The AIC is defined as  $-2 \times (\text{LL} - p)$ , where LL is the log-likelihood of the model given the data, and p is the number of parameters estimated in the model. When comparing models, a lower AIC is preferable to a higher one (USEPA, 2012a).

<sup>d</sup> BMDs and BMDLs from the models with the lowest AIC statistic for each endpoint.

#### Application of uncertainty factors for delayed mammary gland development

The choice of uncertainty factors is consistent with current USEPA IRIS guidance (USEPA, 2012c) and previous risk assessments developed by NJDEP and the DWQI.

The BMDL for decreased number of terminal endbuds of 22.9 ng/ml in serum (derived above) was used as the POD for RfD development. Uncertainty factors (UFs) were applied to the POD to obtain the Target Human Serum Level. The Target Human Serum Level (ng/ml in serum) is analogous to an RfD but is expressed in



terms of internal dose rather than administered dose.

The total of the uncertainty factors (UFs) applied to the POD serum level was 30, and included the following factors:

10 – UF for human variation, to account for variation in susceptibility across the human population and the possibility that the available data may not be representative of individuals who are most sensitive to the effect.

3 – UF for animal-to-human extrapolation, to account for toxicodynamic differences between humans and mice.

The typical uncertainty factor of 3 for toxicokinetic variability between species is not included because the risk assessment is based on comparison of internal dose (serum levels) rather than administered dose.

1 – UF for LOAEL to NOAEL.

The point of departure is a BMDL, not a LOAEL. Therefore, this uncertainty factor is not applied.

1 – UF for duration of exposure.

Delayed mammary gland development occurs from exposures during development. Therefore, an UF to account for effects from longer term exposures is not used.

1 – UF for more sensitive effects that are not considered (e.g. incomplete database).

Because delayed mammary gland development is a sensitive endpoint for PFOA toxicity, the UF is not applied.

The target human serum level is:  $\frac{22.9 \text{ ng/ml}}{30} = 0.8 \text{ ng/ml}$  (800 ng/L).

30

As discussed above, the most recent median and 95th percentile NHANES values for serum PFOA in the general population are 2.1 and 5.7 ng/ml (CDC, 2015). Therefore, the target human serum level for delayed mammary gland development, 0.8 ng/ml, is below the median serum PFOA level in the U.S. general population.

Development of Reference Dose based on delayed mammary gland development

USEPA (2016a) used a pharmacokinetic modeling approach to develop a species-independent clearance factor,  $1.4 \times 10^{-4}$  L/kg/day that relates serum PFOA level ( $\mu\text{g/L}$ ) to human PFOA dose ( $\mu\text{g/kg/day}$ ). As discussed in the Toxicokinetics section, this clearance factor predicts a serum:drinking water ration of 114:1 with average drinking water consumption, consistent with the empirically observed average serum:drinking water ratio of greater than 100:1 in human populations exposed to PFOA through drinking water. The clearance factor can be used to calculate the RfD, as follows:

$$800 \text{ ng/L} \times 1.4 \times 10^{-4} \text{ L/kg/day} = 0.11 \text{ ng/kg/day}$$

Where: 800 ng/L = Target Human Serum Level

$1.4 \times 10^{-4}$  L/kg/day = Clearance

0.11 ng/kg/day = RfD



### Potential Health-based MCL based on increased relative liver weight

Increased relative liver weight is a well-established toxicological effect of PFOA in both non-human primates and rodents and is more sensitive than most other toxicological effects. Increased liver weight occurs in newborn animals after *in utero* exposure, during early life from lactational exposure, and from exposures during adulthood. As discussed in the Mode of Action section, PFOA may cause increased relative liver weight through multiple biochemical and cellular pathways. Increased relative liver weight can co-occur with and/or progress to other types of hepatic toxicity and is considered relevant to humans for the purposes of risk assessment.

According to USEPA IRIS guidance (USEPA, 2012c), endpoints that are “adverse, considered to be adverse, or a precursor to an adverse effect” are appropriate as the basis for non-cancer risk assessment. The increased relative liver weight caused by PFOA is usually accompanied by hepatocellular hypertrophy, and it can co-occur with and/or progress to more severe hepatic effects including hepatocellular necrosis, fatty liver, increased serum liver enzymes, and hyperplastic nodules. Additionally, PFOA caused hepatocellular adenomas in chronically exposed male rats in the study conducted by Biegel et al. (2001). Although these tumors were not reported to be increased in males rats in the earlier chronic study (Sibinski, 1987), Butenhoff et al. (2012) noted that these lesions represent a regenerative process and that diagnostic criteria for hepatic hyperplastic nodules have changed since the livers from the study were evaluated in 1986.

Increased relative liver weight in mice can result either from *in utero* exposure during the prenatal period or from lactational exposure during the neonatal period (Wolf et al., 2007; White et al., 2009). In other studies, ultrastructural and/or histopathological changes indicative of liver toxicity persisted until adulthood (age 3 months, Quist et al., 2015; age 18 months, Filgo et al., 2015) in offspring of dams dosed with PFOA during gestation. Hepatocellular hypertrophy and periportal inflammation occurred at doses below those that caused increased liver weight (Quist et al., 2015). It is not known whether these sensitive hepatic effects resulted from *in utero* exposure, lactational exposure, or both. Additionally, results from offspring at age 18 months suggest the possibility of an increased incidence of liver tumors from developmental exposures to PFOA, although the study was not designed as a carcinogenicity bioassay (Filgo et al., 2015). Although data from these studies are not amenable dose-response modeling, they support the conclusions that liver toxicity is a sensitive endpoint for PFOA, that the developmental period is a sensitive lifestage for PFOA’s hepatic effects, and that increased relative liver weight is a relevant and appropriate endpoint for PFOA’s toxicity.

### Selection of study and data for dose-response modeling of increased liver weight

Increased relative liver weight has been observed in many studies of PFOA in both rodents and non-human primates. The five publications reporting studies of relative liver weight that were considered for dose-response modeling are summarized in the first part of Table 10 of the Animal Toxicology section. Studies were included if they provide serum PFOA data from the end of the dosing period, and, for rodent studies, include relatively low doses (1 mg/kg/day or less). Rodent studies that meet these criteria were reported in four publications. The 90-day cynomolgus monkey study in which the lowest dose was 3 mg/kg/day is also included in Table 10 of the Animal Toxicology section for comparison purposes, since it used a non-human primate species and has been the focus of risk assessments by other groups.

The 90 day cynomolgus monkey study (Thomford et al., 2001b; Butenhoff et al., 2002) was not considered appropriate for dose-response modeling for several reasons (discussed in detail in Appendix 3). The study does

not provide serum PFOA data that can be used for dose-response modeling because serum PFOA levels did not differ at the two lower doses (3 and 10 mg/kg/day); the high dose (30/20 mg/kg/day) group is excluded for use in dose-response modeling due to overt toxicity. Additionally, the death of one of four animals in the low dose group may have been due to PFOA toxicity. Aside from its lack of utility for dose-response modeling, this study provides no indication of the NOAEL for PFOA toxicity in this species because of the lack of a relationship between administered or internal dose and response, and because of the possibility of overt toxicity at the lowest dose.

Two of the four rodent studies (Loveless et al., 2006; Perkins et al., 2004) used adult male rats, and one of these (Loveless et al., 2006), also used adult male mice. Loveless et al. (2006) administered three different isomeric mixtures of PFOA (linear/branched, linear, and branched) to adult male mice and rats for 2 weeks, while Perkins et al. administered PFOA to adult male rats for 4, 7, or 13 weeks.

As discussed in the Toxicology section, increased relative liver weight associated with hepatocellular hypertrophy is an early manifestation of PFOA's hepatic toxicity. This effect does not appear to increase in magnitude over time, but rather it appears to progress over time to other more severe hepatic effects (Butenhoff et al., 2012). Relative liver weight data from male CD-1 mice after 14 day exposures (Loveless et al., 2006) and 29 day exposures (Loveless et al., 2008) were compared based on administered dose, as Loveless et al. (2008) does not provide serum PFOA levels. This comparison shows that the dose-response curves for increased relative liver weight are similar for the 14 day and 29 day exposure periods. Furthermore, dose-response curves for relative liver weight in male rats were similar after 4, 7, and 13 week exposures (Perkins et al., 2004).

Two additional developmental studies in mice (Lau et al., 2006; Macon et al., 2011) also met the criteria for inclusion in Table 10 of the Toxicology section. Lau et al. (2006) evaluated increased liver weight on GD 18 in pregnant mice dosed with PFOA on GD 1-18. The data for liver weight and serum PFOA levels in pregnant mice in this publication are not presented in a form that is appropriate for dose-response modeling of increased relative liver weight. Data on absolute liver weight and serum PFOA levels are presented in graphical form in the publication; numerical data for absolute liver weight, and liver weight relative to body weight minus weight of gravid uterus, were obtained from the investigator.

Macon et al. (2011) evaluated relative liver weight on PND 1 in female offspring exposed *in utero* on GD 10-17. Comparison of serum PFOA level LOAELs for increased relative liver weight in neonatal female mice in Macon et al. (2011) and in adult male mice (Loveless et al., 2006) suggest similar sensitivity to this effect at both life stages.

The relative liver weight data from male mice exposed to branched/linear PFOA for 14 days (Loveless et al., 2006) were selected for dose-response modeling. These data are shown in Table 17. The branched/linear isomeric mixture is relevant to environmental contamination and human exposure, and almost all toxicological studies of PFOA used the branched/linear isomeric mixture. An increasing response with dose was observed in mice for increased relative liver weight from branched/linear PFOA over the range of doses used in this study. Data from both the standard strain and PPAR-alpha null strains of mice demonstrate that increased liver weight and other types of hepatic toxicity occur through both PPAR-alpha dependent and independent modes of action in mice, and these effects are considered relevant to humans. As shown in Figure 13 in the Mode of Action

section, increased liver weight was not correlated with PPAR-alpha activity in mice in Loveless et al. (2006). As discussed above, relative liver weight does not appear to increase in magnitude with longer exposure durations. Therefore, 14 days is considered to be of sufficient duration, particularly since dose-response modeling is based on serum PFOA level, rather than administered dose, thus avoiding uncertainties about whether internal dose increases with exposures longer than 14 days.

Dose (mg/kg/day)	Serum PFOA (µg/ml)	Relative Liver Weight (g/100 g)
0	0.04±0.02	5.14±0.27
0.3	10±1.4	6.12±0.25
1	27±5.0	7.92±0.49
3	66±8.6	10.72±0.63
10	190±29	16.27±1.05
30	241±28	18.28±1.57

#### Determination of Point of Departure (POD) for increased relative liver weight

USEPA Benchmark Dose Modeling Software 2.6.0.88 was used to perform BMD modeling of the data on increased relative liver weight in male mice exposed to linear/branched PFOA from Loveless et al. (2006). BMD and BMDL serum levels were determined for a BMR of a 10% increase in mean relative liver weight from the control values. All models for continuous data included in the software were run.

Results of the BMD modeling are shown in Table 18, and a more detailed explanation and the complete output of the BMDS software for each model are presented in Appendix 7. Both of the exponential models (models 4 and 5) gave identical fits. These exponential models and the 3<sup>rd</sup>

degree polynomial model gave acceptable fits to these data. The 3<sup>rd</sup> degree polynomial model over-fits the data at the high dose, forcing a fit and resulting in a biologically unlikely fit in this area of the dose-response curve. However, the fit of the 3<sup>rd</sup> degree polynomial model at the lower doses (i.e., in the range of the BMD) is regular and biologically appropriate. It is unlikely that the forced fit at the high dose has any significant influence on the fit of the model at the BMD. Although the 3<sup>rd</sup> degree polynomial model gave a slightly better fit than the exponential models and also yielded a slightly lower BMDL, the exponential models produced a highly comparable fit and a similar BMDL. As neither model appears to have a claim to greater biological significance, it was recommended that the point-of-departure be derived as the average of the BMDLs for both of these models. **This yielded an average BMDL of 4,351 ng/ml.**

Table 18. Benchmark Dose analysis for a 10% increase in relative liver weight from linear/branched PFOA in male mice (Loveless et al., 2006) <sup>a</sup>				
Model	Chi-square p-value <sup>b</sup>	AIC <sup>c</sup>	BMD (Serum PFOA, ng/ml)	BMDL (Serum PFOA, ng/ml)
<b>Exponential (Models 4 and 5)</b>	<b>0.2636</b>	<b>2.12782</b>	<b>4,904<sup>d</sup></b>	<b>4,466<sup>d</sup></b>
Hill	-	-	-	-
Linear	-	-	-	-
Polynomial (2 <sup>nd</sup> degree)	0.03245 <sup>c</sup>	6.92134	5,317	4,896
<b>Polynomial (3<sup>rd</sup> degree)</b>	<b>0.4678</b>	<b>1.66669</b>	<b>4,682<sup>d</sup></b>	<b>4,236<sup>d</sup></b>
<i>Average of Exponential (Models 4 and 5) and Polynomial (3rd degree)</i>			<b>4,793</b>	<b>4,351</b>

<sup>a</sup> Results are shown for all models that gave an acceptable visual fit.

<sup>b</sup> A larger Chi-square p-value indicates a better fit to the data.

<sup>c</sup> AIC: A measure of information loss from a dose-response model that can be used to compare a specified set of models. The AIC is defined as  $-2 \times (\text{LL} - p)$ , where LL is the log-likelihood of the model given the data, and p is the number of parameters estimated in the model. When comparing models, a lower AIC is preferable to a higher one (USEPA, 2012a).

<sup>d</sup> BMDs and BMDLs from the models used to derive the point of departure, as discussed in text.

#### Application of uncertainty factors for increased relative liver weight

The choice of UFs is consistent with current USEPA IRIS guidance (USEPA, 2012c) and previous risk assessments developed by NJDEP and the DWQL.

The BMDL of 4,351 ng/ml was used as the POD for RfD development. UFs were applied to the POD serum level of 4,351 ng/ml to obtain the Target Human Serum Level. The Target Human Serum level (ng/ml serum) is analogous to the RfD but is expressed in terms of internal, rather than administered, dose.

The total of the UFs applied to the POD serum level was 300, and included the following factors:

- 10 - UF for human variation, to account for variation in susceptibility across the human population and the possibility that the available data may not be representative of individuals who are most sensitive to the effect.
- 3 - UF for animal-to-human extrapolation, to account for toxicodynamic differences between humans and mice.

The typical uncertainty factor of 3 for toxicokinetic variability between species is not included because the risk assessment is based on comparison of internal dose (serum levels) rather than administered dose.

1 - UF for LOAEL to NOAEL.

The point of departure is a BMDL, not a LOAEL. Therefore, an adjustment for use of a LOAEL is not necessary.

1 - UF for duration of exposure.

The POD is based on increased liver weight resulting from exposure for 2 weeks, while the Health-based MCL is intended to protect for chronic exposure. However, increased liver weight, usually associated with hepatocellular hypertrophy, is an early manifestation of PFOA's hepatic toxicity. Data from the relevant studies (reviewed above) indicate that the dose-response for this effect, on an internal dose (serum PFOA level) basis, is similar after 2 weeks of exposure and from longer exposures, and that this effect does not appear to occur at lower internal doses (serum PFOA levels) or increase in magnitude with chronic exposures. Rather, the initial effect (increased liver weight accompanied by hepatocellular hypertrophy) appears to progress over time to other more severe hepatic types of effects. Therefore, an adjustment based on duration of exposure is not necessary.

10 - UF for more sensitive effects that are not otherwise considered (e.g. incomplete database).

USEPA IRIS guidance (USEPA, 2012c) states that: "If an incomplete database raises concern that further studies might identify a more sensitive effect, organ system, or lifestage, the assessment may apply a database uncertainty factor." Adverse effects on mammary gland development occur at doses much more than 10-fold lower than those that cause increased relative liver weight. Additionally, hepatic toxicity not associated with increased liver weight occurs at similarly low doses after developmental exposures. Therefore, a UF of 10 to account for more sensitive effects was applied.

The target human serum level is:  $\frac{4351 \text{ ng/ml}}{300} = 14.5 \text{ ng/ml}$  (14,500 ng/L)

Development of Reference Dose for increased relative liver weight

As above, the clearance factor ( $1.4 \times 10^{-4}$  L/kg/day; USEPA, 2016a) was used to derive the RfD from the Target Human Serum Level. This factor was used to develop the RfD that is the basis for the recommended Health-based MCL. As discussed in the Toxicokinetics section, the clearance factor is consistent with empirical data on the serum:drinking water ratio from communities with contaminated drinking water. It should be noted that health-based drinking water values may also be developed from target human serum levels for PFOA and other PFCs using an approach based on this ratio.

$$14,500 \text{ ng/L} \times 1.4 \times 10^{-4} \text{ L/kg/day} = 2 \text{ ng/kg/day}$$

Where: 14,500 ng/L = Target Human Serum Concentration

$1.4 \times 10^{-4}$  L/kg/day = Clearance Factor

2 ng/kg/day = RfD

### Relative Source Contribution factor

A Relative Source Contribution (RSC) factor that accounts for non-drinking water sources including food, soil, air, water, and consumer products is used in the development of health-based drinking water concentrations based on non-carcinogenic effects. An RSC is used by the DWQI for Health-based MCLs, by USEPA for Maximum Contaminant Level Goals, and by other states in development of similar health-based drinking water values. The RSC is intended to prevent total exposure from all sources from exceeding the RfD (USEPA, 2000). When sufficient chemical-specific information on non-drinking water exposures is not available, a default RSC of 0.2 (20%) is used. This default value assumes that 20% of exposure comes from drinking water and 80% from other sources (USEPA, 2000). When sufficient chemical-specific exposure data are available, a less stringent chemical-specific RSC may be derived, with floor and ceiling RSC values of 20% and 80% (USEPA, 2000).

The Health Effects Subcommittee concluded that there are insufficient data to develop a chemical-specific RSC for PFOA. There are no New Jersey-specific biomonitoring data for PFOA, and its frequent occurrence in NJ PWS suggests that New Jersey residents may also have higher exposure from non-drinking sources than the U.S. general population (e.g. NHANES). Elevated levels of PFOA were detected in PWS located throughout NJ in USEPA UCMR3 and other monitoring studies; PFOA was detected much more frequently at > 20 ng/L in NJ PWS (10.5%) than nationwide (1.9%) in UCMR3 (discussed in the Drinking Water Occurrence section). Potential sources of this contamination have been identified in some instances, while sources are unknown in other locations. Environmental contamination with PFOA that results in its presence in drinking water can arise from a number of different types of sources (reviewed in Fate and Transport Relevant to Drinking Water Contamination). These include releases to air, soil, and water from fluoropolymer telomer manufacturing facilities, on-site and off-site disposal from smaller industrial facilities that make products from fluoropolymer dispersions containing PFOA, releases of aqueous firefighting foams, and land application of biosolids from wastewater treatment plants treating waste containing PFOA, among others. These various sources may potentially result in human exposures through contamination of nearby soils, house dust, or other environmental media. In communities with drinking water contamination, consumption of produce from home gardens or grown locally was associated with higher serum levels of PFOA (Emmett et al., 2006a; Holzer et al., 2008; Steenland et al., 2009a).

The exposure factors used to develop the Health-based MCL (below) are based on an adult drinking water consumption rate and body weight. The default RSC of 20%, while not explicitly intended for this purpose, also partially accounts for the higher PFOA exposures in infants. Exposures to infants, both breastfed and consuming formula prepared with contaminated drinking water, are much higher than in than older individuals. Infants consume much more fluid (breast milk or formula) than older individuals on a body weight basis; about 10-fold more from birth to 1 month of age, and 4 -6 fold more between ages 6-12 months. Additionally, PFOA concentrations in breast milk are similar or higher than in the mother's drinking water source (Post et al., 2012).

For these reasons, although serum levels in infants are similar to their mother's at birth (Post et al., 2012), they increase rapidly by several-fold shortly after birth for a period of at least several months. As shown in Figure 16, this increase was five-fold or greater in a considerable portion of infants evaluated in two studies (Fromme et al., 2010; Mogensen et al., 2015). Additionally, Monte Carlo simulations of results of a pharmacokinetic model predict median, 95<sup>th</sup> percentile, and maximum infant:mother plasma PFOA ratios of 4.5-fold, 7.8-fold,



and 15.3-fold, respectively, during the period of greatest infant exposure (Verner et al., 2016a; Figure 17).




Figure 16. Changes in PFOA levels in breast-fed infants from birth to later timepoints (Fromme et al., 2010; Mogensen et al., 2015)




Figure 17. Monte Carlo simulations of child/mother ratios of plasma PFOA levels (ng/ml) a breastfeeding period of 30 months. Black line - 50th percentile; blue line - 5th percentile; red line - 95th percentile; dotted lines - minimum and maximum values (Verner et al., 2016).

These higher infant exposures must be considered because the toxicological effects of concern (delayed mammary gland development and increased relative liver weight) occur from short term exposures relevant to elevated exposures in infancy. Cross-fostering studies (discussed in [Toxicology](#) section) show that lactational exposure causes increased relative liver weight and delayed mammary gland development (White et al., 2007; White et al., 2009) in animals with no *in utero* exposure. Additionally, hepatic toxicity that persists until adulthood occurs in offspring of dams exposed to low doses of PFOA during gestation (Quist et al., 2015). These effects could result from prenatal or lactational exposure, or both.



For the reasons discussed above, the default RSC of 20% is used to develop the Health-based MCL.

Development of potential Health-based MCL based on hepatic effects

$$\frac{2 \text{ ng/kg/day} \times 70 \text{ kg} \times 0.2}{2 \text{ L/day}} = 14 \text{ ng/L} \text{ (0.014 } \mu\text{g/L)}$$

Where:

- 2 ng/kg/day = Reference Dose
- 70 kg = assumed adult body weight
- 0.2 = Relative Source Contribution from drinking water
- 2 L/day = assumed adult daily drinking water intake

**Potential Health-based MCL based on carcinogenicity**

PFOA caused tumors in male rats in two chronic studies (Sibinski et al., 1987, Butenhoff et al., 2012; and Biegel et al., 2001). It caused a statistically significant increase in testicular Leydig cell tumors in both studies, as well as a statistically significant increase in liver tumors and pancreatic tumors in Biegel et al. (2001). The testicular tumor data from the chronic dietary exposure rat study reported by Sibinski et al. (1987) and Butenhoff et al. (2012) are appropriate for BMD modeling and can be used as the basis for development of a cancer potency factor. This study used two PFOA dose levels, and the incidence of testicular tumors increased in a dose-related fashion. Because Biegel et al. (2001) used only one dose, data from this study are not appropriate for dose-response modeling. As discussed above, the mode of action for rat testicular tumors has not been established and they are considered relevant to humans for the purposes of risk assessment. USEPA Guidelines for Carcinogen Risk Assessment (USEPA, 2005b) state that linear low-dose extrapolation should be used for dose-response modeling if the mode of action has not been established. Therefore, the linear low-dose extrapolation approach is appropriate for dose-response modeling of these testicular tumors. The linear low-dose extrapolation approach is based on the assumption that exposure to any dose of a carcinogen results in some risk of cancer.

The incidence of testicular tumors (Sibinski et al., 1987; Butenhoff et al., 2012) was 0/49, 2/50, and 7/50 in the control, 30 ppm (1.3 mg/kg/day), and 300 ppm (14.2 mg/kg/day) groups. Modeling was performed using EPA BMD software (version 2.6.0.86). Because serum PFOA levels were not measured in this study, the BMDL and slope factor were modeled in terms of dose administered to rats. The value based on administered dose to rats was then converted to the equivalent human dose, based on pharmacokinetic differences (ratio of half-lives) between rats and humans. A benchmark response (BMR) of 0.05 (5%) tumor incidence was selected for consistency with the recommendations for selection of the POD for cancer potency factor derivation in the USEPA (2005b) Guidance for Carcinogen Risk Assessment. This value is close to the 4% response at the lowest dose in this data set. Results of the modeling are shown in Table 21, and the complete output from the modeling is found in Appendix 8.

Table 19. BMD modeling (0.05 BMR; 5% response) of rat testicular tumor data (Butenhoff et al., 2012)<sup>a</sup>

<i>Model</i>	<i>Chi-square p-value</i> <sup>b</sup>	<i>AIC</i> <sup>c</sup>	<i>BMD (mg/kg/day)</i>	<i>BMDL (mg/kg/day)</i>	<i>Rat Cancer Potency Factor (mg/kg/day)<sup>-1</sup></i>	<i>Rat Dose at 1 x 10<sup>-6</sup> risk (mg/kg/day)</i>
<b>Gamma (power restricted to <math>\geq 1</math>)</b> <b>Multistage (betas <math>\geq 0</math>)</b> <b>Weibull (power restricted to <math>\geq 1</math>)</b> <b>Quantal linear</b>	<b>0.2292</b>	<b>62.6851</b>	<b>4.42913<sup>d</sup></b>	<b>2.50664<sup>d</sup></b>	<b>0.020</b>	<b>5.0 x 10<sup>-5</sup></b>
Gamma (power unrestricted)	1.00	61.2908	4.42913	1.36483e-6		
Log-logistic (power unrestricted)	1.00	61.2908	1.95859	2.00091e-6		
Logistic	0.1905	63.6843	8.85708	6.49805		
<b>Log-logistic (slope restricted to <math>\leq 1</math>)</b>	<b>0.2338</b>	<b>62.5526</b>	<b>4.02707<sup>d</sup></b>	<b>2.2101<sup>d</sup></b>	<b>0.023</b>	<b>4.3 x 10<sup>-5</sup></b>
Probit	0.1948	63.625	8.32341	5.95965		
Weibull (power unrestricted)	1.00	61.2908	1.97407	1.65976e-6		
<b>Average of Gamma (and other identical models) and Log-logistic (slope restricted to <math>\leq 1</math>)</b>				<b>2.36</b>	<b>0.021</b>	<b>4.8 x 10<sup>-5</sup></b>

<sup>a</sup> Results are shown for all models that gave an acceptable visual fit.

<sup>b</sup> A larger Chi-square p-value indicates a better fit to the data.

<sup>c</sup> AIC: A measure of information loss from a dose-response model that can be used to compare a specified set of models. The AIC is defined as  $-2 \times (\text{LL} - p)$ , where LL is the log-likelihood of the model given the data, and p is the number of parameters estimated in the model. When comparing models, a lower AIC is preferable to a higher one (USEPA, 2012a).

<sup>d</sup> BMDs and BMDLs from the models used to derive the potency factor, as discussed in the text.

The Gamma model with power restricted to  $\geq 1$  (and the other models shown in the same cell in Table 19) and the Log-logistic model with slope restricted to  $\leq 1$  fit the data very similarly and yielded very similar BMDLs. Because neither of these models has a form that is obviously more biologically accurate, it is appropriate to average their BMDLs. The average BMDL for these models is **2.36 mg/kg/day**. For a 5% BMR, the corresponding cancer potency factor in rats is **0.021 (mg/kg/day)<sup>-1</sup>**, and the dose in rats corresponding to a  $1 \times 10^{-6}$  risk is estimated as **4.8 x 10<sup>-5</sup> mg/kg/day**. These values are shown in the last row of Table 19.

As above, the dose-response modeling was based on administered PFOA dose to rats (mg/kg/day) instead of internal dose (serum PFOA level) since serum PFOA levels were not measured in the study. Thus, the rat doses derived through the modeling must be converted to equivalent human doses. As per USEPA (2005b) guidelines for carcinogen risk assessment, this adjustment is made based on pharmacokinetic differences between species instead of through the default adjustment based on body weight<sup>3/4</sup>. To make the interspecies adjustment, the dose in male rats corresponding to a  $1 \times 10^{-6}$  cancer risk is converted to the human equivalent dose based on the

ratio of half-lives in the two species. This approach accounts for the much longer half-life of PFOA in humans than male rats, although it is associated with more uncertainty than an approach using measured serum PFOA levels.

The half-lives used for this adjustment were 7 days for male rats and 2.3 years (840 days) for humans. The half-life in male Sprague-Dawley rats after a single gavage dose of 0.1 to 25 mg/kg PFOA was about 7 days and was independent of dose (Kemper et al., 2003). Bartell et al. (2010a) estimated a human half-life of 2.3 years for a one-year period after exposure to contaminated drinking water ceased; elimination rate was not affected by age or gender. The ratio of these human and rat half-lives (840 days/7 days) is 120.

Therefore, the human dose corresponding to a  $1 \times 10^{-6}$  lifetime cancer risk is estimated as:

$$(4.8 \times 10^{-5} \text{ mg/kg/day}) / 120 = 4 \times 10^{-7} \text{ mg/kg/day} \text{ (} 4 \times 10^{-4} \text{ } \mu\text{g/kg/day; } 0.4 \text{ ng/kg/day)}$$

This corresponds to a human cancer potency factor of  $2.52 \text{ (mg/kg/day)}^{-1}$  (i.e. rat cancer potency factor x ratio of human/rat half-lives;  $0.021 \text{ (mg/kg/day)}^{-1} \times 120$ ).

Using default drinking water assumptions (2 L/day water consumption; 70 kg body weight), the potential Health-based MCL at the  $1 \times 10^{-6}$  lifetime cancer risk level is:

$$\frac{0.4 \text{ ng/kg/day} \times 70 \text{ kg}}{2 \text{ L}} = 14 \text{ ng/L} \text{ (} 0.014 \text{ } \mu\text{g/L)}$$

This value is identical to the Health-based MCL based on non-cancer endpoints developed above.

### **Recommended Health-based MCL**

A potential Health-based MCL based on the RfD for delayed mammary gland development was not developed, for reasons discussed above. The potential Health-based MCL based on the RfD for increased relative liver weight is 14 ng/L (0.014  $\mu$ g/L). The potential Health-based MCL based on a lifetime carcinogenic risk one in one million ( $1 \times 10^{-6}$ ), the cancer risk goal for New Jersey MCLs, is also 14 ng/L.

Therefore, the recommended Health-based MCL is 14 ng/L (0.014  $\mu$ g/L).

### **DISCUSSION OF UNCERTAINTIES**

- PFOA is associated with multiple human health effects in epidemiology studies of the general population and communities with drinking water exposure. There is evidence to support multiple criteria for causality for some of these endpoints. Although causality cannot be definitively proven for these associations of PFOA with human health effects, these numerous findings indicate the need for caution about drinking water exposures that will increase serum PFOA to levels substantially higher than in the general population. This is particularly true because elevated serum PFOA levels persist for many years after exposure ends, due to its long human half-life (several years).

Ongoing exposure to the recommended Health-based MCL of 14 ng/L is expected to increase serum PFOA levels, on average, by about 1.6 ng/ml (ppb) with average daily water consumption and 2.8 ng/ml (ppb) with upper percentile daily water consumption in adults. Increases in serum PFOA levels are predicted to be several-

fold higher than in infants than in adults, including both breastfed infants whose mothers ingest PFOA in drinking water or from formula prepared with water contaminated with PFOA.

- The potential for prenatal and early life exposures to environmental contaminants to cause adverse health effects later in life is currently a focus of high interest in both epidemiology and toxicology (Boekelheide et al., 2012; Heindel and Vandenberg, 2015). Developmental exposures to PFOA caused effects in mice, with no threshold (NOAEL) identified, at doses far below those that caused effects in older animals. These effects include persistent changes in the mammary gland, persistent damage to hepatic cells, persistent neurobehavioral effects from a single relatively low dose to the pregnant dam, and obesity and metabolic changes in adulthood. Some of these effects were not evident until later in life and/or adulthood, long after the administered PFOA has been eliminated from the body. Some of these effects (obesity/overweight later in life after prenatal exposure; neurobehavioral effects) have been evaluated in humans, with both positive and negative findings among the studies. As discussed in the Development of Health-Based MCL section, the Target Human Serum Level based on delayed mammary gland development in mice is below the serum PFOA levels prevalent in the general population. The proposed Health-based MCL includes an uncertainty factor to protect for more sensitive developmental effects. However, there is still uncertainty about whether it is sufficiently protective for subtle effects later in life that may result from very low exposures during the developmental period.
- Chronic toxicity and carcinogenicity of PFOA have been studied only in the rat, a species in which PFOA is rapidly excreted by females. There is uncertainty about chronic effects including carcinogenicity in other species such as mice in which PFOA is persistent in both sexes. Furthermore, the chronic studies did not assess effects including carcinogenicity which might result from exposures during the critical developmental stages now known to be sensitive periods for PFOA toxicity.
- Uncertainties about the human relevance of effects seen in animals are inherent to all risk assessments based on animal data. As reviewed in detail in this document, the available information indicates that the effects of PFOA observed in experimental animals are relevant to humans for the purposes of risk assessment.
- Available information indicates that the target organs and modes of action are generally similar for PFOA and some other PFCs, including PFNA (DWQI, 2015c). Therefore, the toxicity of PFOA and other PFCs may be additive. Although PFOA and other PFCs, including PFNA, are known to co-occur in some NJ public water supplies, the potential for additive toxicity of PFOA and other PFCs was not considered in development of the Health-based MCL.

**CITATIONS**

Abbott, B. D., Wolf, C. J., Schmid, J. E., Das, K. P., Zehr, R. D., Helfant, L., Nakayama, S., Lindstrom, A. B., Strynar, M. J., Lau, C. (2007). Perfluorooctanoic acid induced developmental toxicity in the mouse is dependent on expression of peroxisome proliferator activated receptor-alpha. *Toxicol. Sci.* 98: 571–581.

Abbott, B.D. (2009). Review of the expression of peroxisome proliferator-activated receptors alpha (PPAR alpha), beta (PPAR beta), and gamma (PPAR gamma) in rodent and human development. *Reprod. Toxicol.* 27: 246-257.

Abbott, B.D., Wood, C.R., Watkins, A.M., Das, K.P., Lau, C.S. (2010). Peroxisome proliferator-activated receptors alpha, beta, and gamma mRNA and protein expression in human fetal tissues. *PPAR Res.* Volume 2010, Article ID 690907

Abbott, B.D., Wood, C.R., Watkins, A.M, Tatum-Gibbs, K., Das, K.P., Lau, C. (2012). Effects of perfluorooctanoic acid (PFOA) on expression of peroxisome proliferator-activated receptors (PPAR) and nuclear receptor-regulated genes in fetal and postnatal CD-1 mouse tissues. *Reprod Toxicol.* 33: 491-505

Abdellatif, A.G., Preat, V., Taper, H.S., Roberfroid, M. (1991). The modulation of rat liver carcinogenesis by perfluorooctanoic acid, a peroxisome proliferator. *Toxicol. Appl. Pharmacol.* 111: 530-537.

Abdelmegeed, M.A., Yoo, S.H., Henderson L.E., Gonzalez, F.J., Woodcroft, K.J., Song, B.J. (2011). PPAR-alpha expression protects male mice from high fat-induced nonalcoholic fatty liver. *J. Nutr.* 141: 603-10.

Albrecht, P. P., Torsell, N. E., Krishnan, P., Ehresman, D. J., Frame, S. R., Chang, S. C., Butenhoff, J. L., Kennedy, G. L., Gonzalez, F. J., Peters, J. M. (2013). A species difference in the peroxisome proliferator-activated receptor alpha-dependent response to the developmental effects of perfluorooctanoic acid. *Toxicol. Sci.* 131: 568-582.

Alexander, B.H., Olsen, G.W., Burriss, J.M., Mandel, J.H., Mandel, J.S. (2003). Mortality of employees of a perfluorooctanesulphonyl fluoride manufacturing facility. *Occup. Environ. Med.* 60: 722-729.

Alexander, B.H., Olsen, G.W. (2007). Bladder cancer in perfluorooctanesulfonyl fluoride manufacturing workers. *Ann. Epidemiol.* 17: 471-478.

Andersen, M.E., Clewell, H.J., Tan, Y., Butenhoff, J. L., Olsen, G. W. (2006). Pharmacokinetic modeling of saturable, renal resorption of Perfluoroalkyl acids in monkeys—Probing the determinants of long plasma half-lives. *Toxicology* 227: 156–164.

Andersen, C.S., Fei, C., Gamborg, M., Nohr, E.A., Sørensen, T.I., Olsen, J. (2010). Prenatal exposures to perfluorinated chemicals and anthropometric measures in infancy. *Am. J. Epidemiol.* 172: 1230-1337.

Andersen, C. S., Fei, C., Gamborg, M., Nohr, E. A., Sorensen, T. I., Olsen, J. (2013). Prenatal exposures to perfluorinated chemicals and anthropometry at 7 years of age. *Am. J. Epidemiol.* 178: 921-927.

Anderson-Mahoney, P., Kotlerman, J., Takhar, H., Gray, D., Dahlgren, J.C. (2008). Self-reported health effects among community residents exposed to perfluorooctanoate. *New Solut.* 18: 129-143.

Apel, P., Angerer, J., Wilhelm, M., Kolossa-Gehring, M. (2016). New HBM values for emerging substances, inventory of reference and HBM values in force, and working principles of the German Human Biomonitoring Commission. *Int. J. Hyg. Environ. Health* (in press).

Apelberg, B.J., Witter, F.R., Herbstman, J.B., Calafat, A.M., Halden, R.U., Needham, L.L., Goldman, L.R. (2007). Cord serum concentrations of perfluorooctane sulfonate (PFOS) and perfluorooctanoate (PFOA) in relation to weight and size at birth. *Environ. Health Perspect.* 115: 1670-1676.

Appleman, T.D., Higgins, C. P., Quinones, O., Vanderford, B.J, Kolstad, C., Zeigler-Holady, J.C., Dickenson, E.R. (2014). Treatment of poly- and perfluoroalkyl substances in U.S. full-scale water treatment systems. *Water Res.* 51: 246-255.

ATSDR (2013). Agency for Toxics Substances and Disease Registry. Health Consultation. Exposure Investigation Report. Perfluorochemical serum sampling in the vicinity of Decatur, Alabama. Morgan, Lawrence, and Limestone Counties. April 1, 2013.  
[http://www.atsdr.cdc.gov/HAC/pha/Decatur/Perfluorochemical\\_Serum%20Sampling.pdf](http://www.atsdr.cdc.gov/HAC/pha/Decatur/Perfluorochemical_Serum%20Sampling.pdf)

ATSDR (2015). Agency for Toxics Substances and Disease Registry. Toxicological Profile for Perfluoroalkyls. Draft for Public Comment. August 2015.

Backe W.J., Day, T.C., Field, J.A. (2013). Zwitterionic, cationic, and anionic fluorinated chemicals in aqueous film forming foam formulations and groundwater from U.S. military bases by nonaqueous large-volume injection HPLC-MS/MS. *Environ. Sci. Technol.* 47: 5226-34.

Balakumar, P. and Mahadevan, N. (2015). Interplay between statins and PPARs in improving cardiovascular outcomes: a double-edged sword? *Br. J. Pharmacol.* 165: 373-9.

Barouki, R., Gluckman, P.D., Grandjean, P., Hanson, M., Heindel, J.J. (2012). Developmental origins of non-communicable disease: implications for research and public health. *Environ. Health.* 11: 42.

Barry, V., Winquist, A., Steenland, K. (2013). Perfluorooctanoic acid (PFOA) exposures and incident cancers among adults living near a chemical plant. *Environ. Health Perspect.* 121: 1313-1318.

Barry, V., Darrow, L.A. Klein, M., Winquist, A. Steenland, K. (2014). Early life perfluorooctanoic acid (PFOA) exposure and overweight and obesity risk in adulthood in a community with elevated exposure. *Environ. Res.* 132: 62-69.

Bartell, S.M., Calafat, A.M., Lyu, C., Kato, K., Ryan, P.B., Steenland, K. (2010a). Rate of decline in serum PFOA concentrations after granular activated carbon filtration at two public water systems in Ohio and West Virginia. *Environ. Health Perspect.* 118: 222-8.

Bartell, S.M., Lyu, C., Ryan, P.B., Steenland, K. (2010b). Decline of perfluorooctanoic acid in human serum before and after granular activated carbon filtration in two public water supplies, and implications for half-life estimation. Presented at PFAA Days III, Research Triangle, Park, NC. June 2010.  
<http://www.health.state.mn.us/divs/eh/hazardous/topics/pfcs/pfaadays3.pdf> Accessed 1/17/12.

Beesoon, S., Webster G.M., Shoeib, M., Harner, T., Benskin, J.P., Martin, J.W. (2011). Isomer profiles of perfluorochemicals in matched maternal, cord and house dust samples: manufacturing sources and transplacental transfer. *Environ. Health Perspect.* 119: 1659-1664.

Beesoon, S., Martin, J.W. (2015). Isomer-specific binding affinity of perfluorooctanesulfonate (PFOS) and perfluorooctanoate (PFOA) to serum proteins. *Environ. Sci. Technol.* 49: 5722-31.

Benninghoff, A.D., Bisson, W.H., Koch, D.C., Ehresman, D.J., Kolluri, S.K., Williams, D.E. (2011). Estrogen-like activity of perfluoroalkyl acids in vivo and interaction with human and rainbow trout estrogen receptors in vitro. *Toxicol. Sci.* 120: 42-58.

Benninghoff A.D., Orner, G.A., Buchner, C.H., Hendricks, J.D., Duffy, A.M., Williams, D.E. (2012). Promotion of hepatocarcinogenesis by perfluoroalkyl acids in rainbow trout. *Toxicol Sci.* 125: 69-78.

Benskin, J.P., De Silva, A.O., Martin, L.J., Arsenault, G., McCrindle, R., Riddell, N., Mabury, S.A., Martin, J.W. (2009). Disposition of perfluorinated acid isomers in Sprague-Dawley rats; part 1: single dose. *Environ. Toxicol. Chem.* 28: 542-554.



- Berthiaume, J. and K. B. Wallace (2002). Perfluorooctanoate, perfluorooctanesulfonate, and N-ethyl perfluorooctanesulfonamido ethanol; peroxisome proliferation and mitochondrial biogenesis. *Toxicol. Lett.* 129: 23-32
- Biegel, L.B, Hurtt, M.E., Frame, S.R., O'Connor, J.C., Cook, J.C. (2001). Mechanisms of extrahepatic tumor induction by peroxisome proliferators in male CD rats. *Toxicol. Sci.* 60: 44-55.
- Black, S., Nicolay, U., Del Giudice, G., Rappuoli, R. (2016). Influence of statins on influenza vaccine response in elderly individuals. *J. Infect. Dis.* 213: 1224-8.
- Bloom, M. S., Kannan, K. Spliethoff, H. M., Tao, L., Aldous, K. M, Vena, J.E. (2010). Exploratory assessment of perfluorinated compounds and human thyroid function. *Physiol. Behav.* 99: 240-245.
- Boekelheide K, Blumberg B, Chapin R.E., Cote I., Graziano J.H., Janesick, A., Lane, R., Lillycrop, K, Myatt, L., States J.C., Thayer, K.A., Waalkes, M.P., Rogers, J.M. (2012). Predicting later-life outcomes of early-life exposures. *Environ. Health Perspect.* 120: 1353-61.
- Botelho S.C., Saghafian M, Pavlova S, Hassan M, DePierre J.W., Abedi-Valugerdi M. (2015). Complement activation is involved in the hepatic injury caused by high-dose exposure of mice to perfluorooctanoic acid. *Chemosphere* 129: 225-31.
- Braun, J.M., Chen, A., Romano, M.E., Calafat, A.M., Webster, G.M., Yolton, K., Lanphear, B.P. (2016). Prenatal perfluoroalkyl substance exposure and child adiposity at 8 years of age: The HOME study. *Obesity (Silver Spring)* 24: 231-7.
- Brede, E., Wilhelm, M., Göen, T., Müller, J., Rauchfuss, K., Kraft, M., Hölzer, J. (2010). Two-year follow-up biomonitoring pilot study of residents' and controls' PFC plasma levels after PFOA reduction in public water system in Arnsberg, Germany. *Int. J. Hyg. Environ. Health* 213: 217-223.
- Buck, R.C., Franklin, J., Berger, U., Conder, J.M., Cousins, I.T., de Voogt, P., Jensen, A.A., Kannan, K., Mabury, S.A., van Leeuwen, S.P. (2011). Perfluoroalkyl and polyfluoroalkyl substances in the environment: terminology, classification, and origins. *Integr. Environ. Assess. Manag.* 7: 513-541.
- Budd, A., Alleva, L., Alsharifi, M., Koskinen, A., Smythe, V., Müllbacher, A., Wood, J., Clark, I. (2007). Increased survival after gemfibrozil treatment of severe mouse influenza. *Antimicrob. Agents. Chemother.* 51: 2965-8.
- Buhrke, T., Krüger, E., Pevny, S., Röbller, M., Bitter, K., Lampen, A. (2015). Perfluorooctanoic acid (PFOA) affects distinct molecular signalling pathways in human primary hepatocytes. *Toxicology* 333: 53-62.
- Butenhoff, J., Costa, G., Elcombe, C., Farrar, D., Hansen, K., Iwai, H., Jung, R., Kennedy, G., Lieder, P., Olsen, G., Thomford, P. (2002). Toxicity of ammonium perfluorooctanoate in male cynomolgus monkeys after oral dosing for 6 months. *Toxicol. Sci.* 69: 244-257.
- Butenhoff, J.L., Kennedy, Jr, G.L., Hinderliter, P.M., Lieder, P.H., Jung, R., Hansen, K.J, Gorman, G.S., Noker, P.E., Thomford, P.J. (2004a). Pharmacokinetics of perfluorooctanoate in Cynomolgus monkeys. *Toxicol. Sci.* 82: 394-406.
- Butenhoff, J.L., Kennedy, G.L., Frame, S.R., O'Conner, J.C., York, R.G. (2004b). The reproductive toxicology of ammonium perfluorooctanoate (APFO) in the rat. *Toxicology* 196: 95-116.
- Butenhoff, J. L., Gaylor, D. W., Moore, J. A., Olsen, G. W., Rodricks, J., Mandel, J. H., Zobel, L. R. (2004c). Characterization of risk for general population exposure to perfluorooctanoate. *Regul. Tox. Pharmacol.* 39: 363-380.
- Butenhoff, J. L., Kennedy, G. L. Jr., Chang, S. C. Olsen, G. W. (2012). Chronic dietary toxicity and carcinogenicity study with ammonium perfluorooctanoate in Sprague-Dawley rats. *Toxicology* 298: 1-13.



- Butenhoff, J.L., Kennedy, G.L., Jung, R., Chang, S.C. (2014). Evaluation of perfluorooctanoate for potential genotoxicity. *Toxicology Reports* 1: 252-270.
- Butt, C.M., Berger, U., Bossi, R., Tomy, G.T. (2010). Review: Levels and trends of poly- and perfluorinated compounds in the arctic environment. *Sci. Total Environ.* 408: 2936-2965.
- Butt, C. M., Muir, D. C., Mabury, S. A. (2014). Biotransformation pathways of fluorotelomer-based polyfluoroalkyl substances: a review. *Environ. Toxicol. Chem.* 33: 243-267.
- C8 Science Panel (undated, a). Background Information on Lawsuit Settlement. [http://www.c8sciencepanel.org/panel\\_background.html](http://www.c8sciencepanel.org/panel_background.html) (accessed March 15, 2016).
- C8 Science Panel (undated, b). The Science Panel Website. <http://www.c8sciencepanel.org/> (Accessed March 15, 2016).
- C8 Science Panel. (2011). Probable Link Evaluation of Preterm Birth and Low Birthweight. [http://www.c8sciencepanel.org/pdfs/Probable\\_Link\\_C8\\_Preterm\\_and\\_LBW\\_birth\\_5Dec2011.pdf](http://www.c8sciencepanel.org/pdfs/Probable_Link_C8_Preterm_and_LBW_birth_5Dec2011.pdf), (accessed March 18, 2016)
- C8 Science Panel. (2012). "Probable Link Evaluation of Thyroid Disease." Retrieved February 12, 2016, [http://www.c8sciencepanel.org/pdfs/Probable\\_Link\\_C8\\_Thyroid\\_30Jul2012.pdf](http://www.c8sciencepanel.org/pdfs/Probable_Link_C8_Thyroid_30Jul2012.pdf) (accessed February 12, 2016)
- Calafat, A.M., Wong, L.Y., Kuklennyik, Z., Reidy, J.A., Needham, L.L. (2007). Polyfluoroalkyl chemicals in the U.S. population: data from the National Health and Nutrition Examination Survey (NHANES) 2003-2004 and comparisons with NHANES 1999-2000. *Environ. Health Perspect.* 115: 1596-1602.
- CDC (2015). Centers for Disease Control and Prevention. Fourth National Report on Human Exposure to Environmental Chemicals. [http://www.cdc.gov/biomonitoring/pdf/FourthReport\\_UpdatedTables\\_Feb2015.pdf](http://www.cdc.gov/biomonitoring/pdf/FourthReport_UpdatedTables_Feb2015.pdf).
- CDC (2016). Centers for Disease Control and Prevention. National Center for Health Statistics. Diet/Nutrition. Last updated April 27, 2016. <http://www.cdc.gov/nchs/fastats/diet.htm>
- Chan, E., Burstyn, I., Cherry, N., Bamforth, F., Martin, J. W. (2011). Perfluorinated acids and hypothyroxinemia in pregnant women. *Environ. Res.* 111: 559-564.
- Cheng, X., Klaassen, C. D. (2008). Critical role of PPAR-alpha in perfluorooctanoic acid- and perfluorodecanoic acid-induced downregulation of Oatp uptake transporters in mouse livers. *Toxicol. Sci.* 106: 37-45.
- Clarke, B.O., Smith, S.R. (2011). Review of 'emerging' organic contaminants in biosolids and assessment of international research priorities for the agricultural use of biosolids. *Environ. Int.* 37: 226-247.
- Clewell, H.J. (2006). Application of pharmacokinetic modeling to estimate PFOA exposures associated with measured blood concentrations in human populations. Society for Risk Analysis 2006 Annual Meeting (PowerPoint Presentation).
- Clewell, H. (2009). Pharmacokinetic modeling of PFOA and PFOS. PowerPoint presentation to USEPA, Washington DC, September 2009.
- Conder, J.M., Hoke, R.A., De Wolf, W., Russell, M.H., Buck, R.C. (2008). Are PFCA's bioaccumulative? A critical review and comparison with regulatory criteria and persistent lipophilic compounds. *Environ. Sci. Technol.* 42: 995-1003.
- Cornelis, C., D'Hollander, W., Roosens, L., Covaci, A., Smolders, R., Van Den Heuvel, R., Govarts, E., Van Campenhout, K., Reynders, H., Bervoets, L. (2012). First assessment of population exposure to perfluorinated compounds in Flanders, Belgium. *Chemosphere* 86: 308-314.

- Corsini, E., Avogadro, A. Galbiati, V., dell'Agli, M. Marinovich, M., Galli, C. L., Germolec, D. R. (2011). In vitro evaluation of the immunotoxic potential of perfluorinated compounds (PFCs). *Toxicol. Appl. Pharmacol.* 250: 108-116.
- Corton, J.C. (2010). Mode of action analysis and human relevance of liver tumors induced by PPAR-alpha activation. In: Hsu, C-H, Stedeford, T. (Eds.), *Cancer Risk Assessment: Chemical Carcinogenesis from Biology to Standards Quantification*, John Wiley & Sons, Inc., Hoboken, NJ.
- Costa, G., Sartori, S., Consonni, D. (2009). Thirty years of medical surveillance in perfluorooctanoic acid production workers. *J. Occup. Environ. Med.* 51: 364-372.
- Cui, L., Zhou, Q. F. Liao, C. Y. Fu, J. J., Jiang, G. B. (2009). Studies on the toxicological effects of PFOA and PFOS on rats using histological observation and chemical analysis. *Arch. Environ. Contam. Toxicol.* 56: 338-349.
- Cui, L., Liao, C. Y. Zhou, Q. F. Xia, T. M., Yun, Z. J., Jiang, G. B. (2010). Excretion of PFOA and PFOS in male rats during a subchronic exposure. *Arch. Environ. Contam. Toxicol.* 58: 205-213.
- Daniel, C.W., Silberstein, G.B. (1987). Chapter 1: Postnatal development of the rodent mammary gland. In: *The Mammary Gland Development, Regulation and Function*. Editors: Margaret C. Neville and Charles W. Daniel, Plenum Press, NY, London.
- Darrow, L. A., Groth, A. C., Winkquist, A. Shin, H. M., Bartell, S. M., Steenland, K. (2016). Modeled perfluorooctanoic acid (PFOA) exposure and liver function in a Mid-Ohio Valley community. *Environ. Health Perspect.* (in press).
- Das, K.P., Zehr, D., Strynar, M., Lindstrom, A., Wambaugh, J., Lau, C. (2010). Pharmacokinetic profiles of perfluorooctanoic acid in mice after chronic exposure. *Toxicologist* 114: 47.
- Davis, K.L., Aucoin, M.D., Larsen, B.S., Kaiser, M.A., Hartten, A.S. (2007). Transport of ammonium perfluorooctanoate in environmental media near a fluoropolymer manufacturing facility. *Chemosphere* 67: 2011-2019.
- de Cock, M., de Boer, M. R., Lamoree, M., Legler, J., van de Bor, M. (2014). Prenatal exposure to endocrine disrupting chemicals in relation to thyroid hormone levels in infants - a Dutch prospective cohort study. *Environ. Health* 13: 106
- D'eon, J.C., Crozier, P.W., Furdui, V.I., Reiner, E.J., Libelo, E.L., Mabury, S.A. (2009). Observation of a commercial fluorinated material, the polyfluoroalkyl phosphoric acid diesters, in human sera, wastewater treatment plant sludge, and paper fibers. *Environ. Sci. Technol.* 43: 4589-4594.
- D'eon, J.C., Mabury, S.A. (2011a). Exploring indirect sources of human exposure to perfluoroalkyl carboxylates (PFCAs): Evaluating uptake, elimination, and biotransformation of polyfluoroalkyl phosphate esters (PAPs) in the rat. *Environ. Health Perspect.* 119: 344-350.
- D'eon, J.C., Mabury, S.A. (2011b). Is indirect exposure a significant contributor to the burden of perfluorinated acids observed in humans? *Environ. Sci. Technol.* 45: 7974-7984.
- De Silva, A.O., Benskin, J.P., Martin, L.J., Arsenault, G., McCrindle, R., Riddell, N., Martin, J.W., Mabury, S.A. (2009b). Disposition of perfluorinated acid isomers in Sprague-Dawley rats; part 2: Subchronic dose. *Environ. Toxicol. Chem.* 28: 555-567.
- Dewitt, J.C., Copeland, C.B., Strynar, M.J., Luebke, R.W. (2008). Perfluorooctanoic acid-induced immunomodulation in adult C57BL/6J or C57BL/6N female mice. *Environ. Health Perspect.* 116: 644-650.
- Dewitt, J.C., Shnyra, A., Badr, M.Z., Loveless, S.E., Hoban, D., Frame, S.R., Cunard, R., Anderson, S.E., Meade, B.J., Peden-Adams, M.M., Luebke, R.W., Luster M.I. (2009a). Immunotoxicity of perfluorooctanoic

acid and perfluorooctane sulfonate and the role of peroxisome proliferator-activated receptor alpha. *Crit. Rev. Toxicol.* 39: 76-94.

DeWitt, J. C., Copeland, C. B., & Luebke, R. W. (2009b). Suppression of humoral immunity by perfluorooctanoic acid is independent of elevated serum cortisone concentration in mice. *Toxicol. Sci.*, 109: 106-112.

Dewitt, J.C., Peden-Adams, M.M., Keller, J.M., Germolec, D.R. (2012). Immunotoxicity of perfluorinated compounds: recent developments. *Toxicol. Pathol.* 40: 300-11.

DeWitt, J.C., Williams, W.C., Creech, N.J., Luebke, R.W. (2016). Suppression of antigen-specific antibody responses in mice exposed to perfluorooctanoic acid: Role of PPAR $\alpha$  and T- and B-cell targeting. *J. Immunotoxicol.* 13: 38-45.

D'Hollander, W., de Voogt, P., De Coen, W., Bervoets, L. (2010). Perfluorinated substances in human food and other sources of human exposure. *Rev. Environ. Contam. Toxicol.* 208: 179-215.

Dixon, D., Reed, C.E., Moore, A.B., Gibbs-Flournoy, E.A., Hines, E.P., Wallace, E.A., Stanko, J.P., Lu, Y., Jefferson, W.N., Newbold, R.R., Fenton, S.E. (2012). Histopathologic changes in the uterus, cervix and vagina of immature cd-1 mice exposed to low doses of perfluorooctanoic acid (PFOA) in a uterotrophic assay. *Reproductive Toxicology* 33:506-12

Domingo, J. L. (2012). Health risks of dietary exposure to perfluorinated compounds. *Environ. Int.* 40: 187-195.

DuPont and URS Diamond Corporate Remediation Group, 2008. Data Assessment Dupont Washington Works (OPPT-2004-0113 PFOA Site-Related Environmental Assessment Program). <http://itp-pfoa.ce.cmu.edu/docs/Data%20Assessment/DA%20Report-1%20100208%20Text%20and%20Tables.pdf>. Accessed 6/16/11.

DuPont (2009). Private Drinking Water Well Survey and Sampling Update. DuPont Chambers Works Facility, Deepwater, New Jersey (Table 1). Data submitted to NJDEP, May 12, 2009.

DWQI (1987). New Jersey Drinking Water Quality Institute. Maximum Contaminant Level Recommendations for Hazardous Contaminants in Drinking Water. March 26, 1987.

DWQI (1994). New Jersey Drinking Water Quality Institute. Maximum Contaminant Level Recommendations for Hazardous Contaminants in Drinking Water. March 26, 1987.

DWQI (2009). New Jersey Drinking Water Quality Institute. Maximum Contaminant Level Recommendations for Hazardous Contaminants in Drinking Water. March, 2009a.

DWQI (2009b). New Jersey Drinking Water Quality Institute. Minutes of January 27, 2009 meeting. <http://www.nj.gov/dep/watersupply/pdf/minutes090127.pdf>

(DWQI, 2010). New Jersey Drinking Water Quality Institute. Minutes of September 10, 2010 meeting. <http://www.nj.gov/dep/watersupply/pdf/minutes100910.pdf>

DWQI (2015a). New Jersey Drinking Water Quality Institute. Maximum Contaminant Level Recommendations for Perfluorononanoic Acid in Drinking Water. July 1, 2015. <http://www.nj.gov/dep/watersupply/pdf/pfna-recommend-final.pdf>

DWQI (2015b). New Jersey Drinking Water Quality Institute. Recommendation on Perfluorinated Compound Treatment Options for Drinking Water. New Jersey Drinking Water Quality Institute Treatment Subcommittee. June 2015. <http://www.nj.gov/dep/watersupply/pdf/pfna-pfc-treatment.pdf>

DWQI (2015c). New Jersey Drinking Water Quality Institute. Health-Based Maximum Contaminant Level Support Document: Perfluorononanoic Acid (PFNA). New Jersey Drinking Water Quality Institute Health Effects Subcommittee. June 22, 2015. <http://www.nj.gov/dep/watersupply/pdf/pfna-health-effects.pdf>

- ECHA (2013). European Chemical Agency. Member State Committee Support Document for Identification of Pentadecafluorooctanoic Acid (PFOA) as a Substance of Very High Concern Because of its CMR1 and PBT2 Properties. June 14, 2013. <http://echa.europa.eu/documents/10162/8059e342-1092-410f-bd85-80118a5526f5>
- ECHA (2015). European Chemical Agency. RAC concludes on PFOA restriction. September 30, 2015. [http://echa.europa.eu/view-article/-/journal\\_content/title/rac-concludes-on-pfoa-restriction](http://echa.europa.eu/view-article/-/journal_content/title/rac-concludes-on-pfoa-restriction)
- EFSA (2008) European Food Safety Authority. Opinion of the Scientific Panel on Contaminants in the Food Chain on Perfluorooctane sulfonate (PFOS) and Perfluorooctanoic acid (PFOA) and their Salts. EFSA Journal, 2008, Journal number 653: 1-131; available at [http://www.efsa.europa.eu/EFSA/efsa\\_locale-1178620753812\\_1211902012410.htm](http://www.efsa.europa.eu/EFSA/efsa_locale-1178620753812_1211902012410.htm).
- Eggen, T., Moeder, M., Arukwe, A. (2010). Municipal landfill leachates: a significant source for new and emerging pollutants. *Sci. Total. Environ.* 408: 5147-5157.
- Elcombe, C.R., Elcombe, B.M, Foster, J.R., Farrar, D.G., Jung, R., Chang, S.C., Kennedy, G.L., Butenhoff, J.L. (2010). Hepatocellular hypertrophy and cell proliferation in Sprague-Dawley rats following dietary exposure to ammonium perfluorooctanoate occurs through increased activation of the xenosensor nuclear receptors PPARalpha and CAR/PXR. *Arch. Toxicol.* 84: 787-798.
- Emmett, E.A., Shofer, F.S., Zhang, H., Freeman, D., Desai, C., Shaw, L.M. (2006a). Community exposure to perfluorooctanoate: Relationships between serum concentrations and exposure sources. *J. Occ. Environ. Med.* 48: 759-770.
- Emmett, E. A., Zhang, H., Shofer, F. S., Freeman, D., Rodway, N. V., Desai, C., Shaw, L. M. (2006b). Community exposure to perfluorooctanoate: relationships between serum levels and certain health parameters. *J. Occup. Environ. Med.* 48: 771-779.
- Eriksen, K. T., Raaschou-Nielsen, O., McLaughlin, K., Lipworth, L., Tjønneland, A., Overvad, K., Sørensen, M. (2013). Association between plasma PFOA and PFOS levels and total cholesterol in a middle-aged Danish population. *PLoS One* 8: e56969.
- Eschauzier, C., Beerendonk, E., Scholte-Veenendaal, P., De Voogt, P. (2012). Impact of treatment processes on the removal of perfluoroalkyl acids from the drinking water production chain. *Environ. Sci. Technol.* 46: 1708-1715.
- Fang, J., Alderman, M. H. (2000). Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. *JAMA* 283: 2404-2410.
- Fairley, K.J., Purdy, R., Kearns, S., Anderson, S.E., Meade, B.J. (2007). Exposure to the immunosuppressant, perfluorooctanoic acid, enhances the murine IgE and airway hyperreactivity response to ovalbumin. *Toxicol. Sci.* 97: 375-383.
- Fasano, W.J., Kennedy, G.L., Szostek, B., Farrar, D.G., Ward, R.J., Haroun, L., Hinderliter, P.M. (2005). Penetration of ammonium perfluorooctanoate through rat and human skin in vitro. *Drug Chem. Toxicol.* 28: 79-90.
- Fei, C., McLaughlin, J.K., Tarone, R.E., Olsen, J. (2007). Perfluorinated chemicals and fetal growth: a study within the Danish National Birth Cohort. *Environ. Health Perspect.* 115: 1677-1682.
- Fei, C., McLaughlin, J. K., Lipworth, L., Olsen, J. (2010). Maternal concentrations of perfluorooctanesulfonate (PFOS) and perfluorooctanoate (PFOA) and duration of breastfeeding. *Scand. J. Work Environ. Health* 36: 413-421.
- Fenton, S.E. (2006). Endocrine-disrupting compounds and mammary gland development: early exposure and later life consequences. *Endocrinology* 147: 518-524.

- Fenton, S.E., Reiner, J.L., Nakayama, S.F., Delinsky, A.D., Stanko, J.P., Hines, E.P., White, S.S., Lindstrom, A.B., Strynar, M.J., Petropoulou, S.S. (2009). Analysis of PFOA in dosed CD-1 mice. Part 2. Disposition of PFOA in tissues and fluids from pregnant and lactating mice and their pups. *Reprod. Toxicol.* 27: 365-732.
- Fenton, S.E., Reed, C., Newbold, R.R. (2012). Perinatal environmental exposures affect mammary development, function, and cancer risk in adulthood. *Annu. Rev. Pharmacol. Toxicol.* 52: 455-79.
- Fenton, S.E., Birnbaum, L.S. (2015). Timing of environmental exposures as a critical element in breast cancer risk. *J. Clin. Endocrinol. Metab.* 100: 3245-50.
- Filgo, A.J., Quist, E.M., Hoenerhoff, M.J., Brix, A.E., Kissling, G.E., Fenton, S.E. (2015). Perfluorooctanoic acid (PFOA)-induced liver lesions in two strains of mice following developmental exposures: PPAR $\alpha$  is not required. *Toxicol. Pathol.* 43:558-68.
- Fisher, M., Arbuckle, T. E., Wade, M., Haines, D. A. (2013). Do perfluoroalkyl substances affect metabolic function and plasma lipids?--Analysis of the 2007-2009, Canadian Health Measures Survey (CHMS) Cycle 1. *Environ. Res.* 121: 95-103.
- Fitz-Simon, N., Fletcher, T., Luster, M. I., Steenland, K. Calafat, A. M., Kato, K., Armstrong, B. (2013). Reductions in serum lipids with a 4-year decline in serum perfluorooctanoic acid and perfluorooctanesulfonic acid. *Epidemiology* 24: 569-576.
- Fletcher, T., Steenland, K., Savitz, D. (2009). Status Report: PFOA and immune biomarkers in adults exposed to PFOA in drinking water in the Mid Ohio Valley. [http://www.c8sciencepanel.org/pdfs/Status\\_Report\\_C8\\_and\\_Immune\\_markers\\_March2009.pdf](http://www.c8sciencepanel.org/pdfs/Status_Report_C8_and_Immune_markers_March2009.pdf). Accessed April 12, 2016.
- Fletcher, T., Galloway, T. S., Melzer, D., Holcroft, P., Cipelli, R. Pilling, L. C., Mondal, D., Luster, M., Harries, L. W. (2013). Associations between PFOA, PFOS and changes in the expression of genes involved in cholesterol metabolism in humans. *Environ. Int.* 57-58: 2-10.
- Frame, S.R., McConnell, E.E. (2003). Review of proliferative lesions of the exocrine pancreas in two chronic studies in rats with ammonium perfluorooctanoate. DuPont-13788. Oct. 16, 2003. (Cited in USEPA, 2005a).
- Franko J., Meade, B.J., Frasc, H.F., Barbero, A.M., Anderson, S.E. (2012). Dermal penetration potential of perfluorooctanoic acid (PFOA) in human and mouse skin. *J. Toxicol. Environ. Health A* 75: 50-62.
- Fraser, A.J., Webster, T.F., Watkins, D.J., Nelson, J.W., Stapleton, H.M., Calafat, A.M., Kato, K., Shoeib, M., Vieira, V.M., McClean, M.D. (2012). Perfluorinated compounds in serum linked to indoor air in office environments. *Environ. Sci. Technol.* 46: 1209-1215.
- Fraser, A. J., Webster, T. F., Watkins, D. J., Strynar, M. J. Kato, K., Calafat, A. M., Vieira, V. M. McClean, M. D. (2013). Polyfluorinated compounds in dust from homes, offices, and vehicles as predictors of concentrations in office workers' serum. *Environ. Int.* 60: 128-136.
- Freberg, B.I., Haug, L.S., Olsen, R., Daae, H.L., Hersson, M., Thomsen, C., Thorud, S., Becher, G., Molander, P., Ellingsen, D.G. (2010). Occupational exposure to airborne perfluorinated compounds during professional ski waxing. *Environ. Sci. Technol.* 44: 7723-7728.
- Freedman, D. S., Williamson, D. F., Gunter, E. W., Byers, T. (1995). Relation of serum uric acid to mortality and ischemic heart disease. The NHANES I Epidemiologic Follow-up Study. *Am. J. Epidemiol.* 141: 637-644.
- Frisbee, S. J., Brooks, Jr., A. P., Maher, A., Flensburg, P., Arnold, S., Fletcher, T., Steenland, K., Shankar, A., Knox, S. S., Pollard, C., Halverson, J. A., Vieira, V. M., Jin, C., Leyden, K. M., Ducatman, A. M. (2009). The C8 health project: design, methods, and participants. *Environ. Health Perspect.* 117: 1873-1882.
- Frisbee, S. J., Shankar, A., Knox, S. S., Steenland, K. D., Savitz, A., Fletcher, T., Ducatman, A. M. (2010). Perfluorooctanoic acid, perfluorooctanesulfonate, and serum lipids in children and adolescents: results from the C8 Health Project. *Arch. Pediatr. Adolesc. Med.* 164: 860-869.



- Fromme, H., Tittlemier, S.A., Völkel, W., Wilhelm, M., Twardella, D. (2009). Perfluorinated compounds-exposure assessment for the general population in Western countries. *Int. J. Hyg. Environ. Health.* 212: 239-270.
- Fromme, H., Mosch, C., Morovitz, M., Alba-Alejandre, I., Boehmer, S., Kiranoglu, M., Faber, F., Hannibal, I., Genzel-Boroviczény, O., Koletzko, B., Völkel, W. (2010). Pre- and postnatal exposure to perfluorinated compounds (PFCs). *Environ. Sci. Technol.* 44: 7123-7129.
- Fujii, Y., Harada, K. H., Koizumi, A. (2013). Occurrence of perfluorinated carboxylic acids (PFCAs) in personal care products and compounding agents. *Chemosphere* 93: 538-544.
- Fu, Y., Wang, T., Fu, Q., Wang, P., Lu, Y. (2014). Associations between serum concentrations of perfluoroalkyl acids and serum lipid levels in a Chinese population. *Ecotoxicol. Environ. Saf.* 106: 246-252.
- Fujii, Y., Niisoe, T., Harada, K. H., Uemoto, S., Ogura, Y., Takenaka, K., A. Koizumi, K. (2015). Toxicokinetics of perfluoroalkyl carboxylic acids with different carbon chain lengths in mice and humans. *J. Occup. Health* 57: 1-12.
- Gallo, V., Leonardi, G., Genser, B., Lopez-Espinosa, M. J., Frisbee, S. J., Karlsson, L., Ducatman, A. M., Fletcher, T. (2012). Serum perfluorooctanoate (PFOA) and perfluorooctane sulfonate (PFOS) concentrations and liver function biomarkers in a population with elevated PFOA exposure. *Environ. Health Perspec.* 120: 655-660.
- Gao, Y, Fu, J., Cao, H, Wang, Y, Zhang A, Liang Y, Wang, T., Zhao, C, Jiang, G. (2015). Differential accumulation and elimination behavior of perfluoroalkyl Acid isomers in occupational workers in a manufactory in China. *Environ. Sci. Technol.* 49: 6953-62.
- Gebbink, W. A., Glynn, A, Darnerud, P. O., Berger, U. (2015a). Perfluoroalkyl acids and their precursors in Swedish food: The relative importance of direct and indirect dietary exposure. *Environ. Pollut.* 198: 108-115.
- Gebbink, W. A., Berger, U., Cousins, I. T. (2015b). Estimating human exposure to PFOS isomers and PFCA homologues: the relative importance of direct and indirect (precursor) exposure. *Environ. Int.* 74: 160-169.
- Geiger, S. D., Xiao, J., Ducatman, A., Frisbee, S., Innes, K., Shankar, A. (2014). The association between PFOA, PFOS and serum lipid levels in adolescents. *Chemosphere* 98: 78-83.
- Geiger, S. D., Xiao, J., Shankar, A. (2013). Positive association between perfluoroalkyl chemicals and hyperuricemia in children. *Am. J. Epidemiol.* 177: 1255-1262.
- Genser, B., Teles C.A., Barreto M.L., Fischer, J.E. (2015). Within- and between-group regression for improving the robustness of causal claims in cross-sectional analysis. *Environ. Health* 10: 14:60.
- Gewurtz, S.B., Bhavsar, S.P., Crozier, P.W., Diamond, M.L., Helm, P.A., Marvin, C.H. Reiner, E.J. (2009). Perfluoroalkyl contaminants in window film: indoor/outdoor, urban/rural, and winter/summer contamination and assessment of carpet as a possible source. *Environ. Sci. Technol.* 43: 7317-7323.
- Gibson, H. M. (1973) Plasma volume and glomerular filtration rate in pregnancy and their relation to differences in fetal growth. *J. Obstet. Gynaecol. Br. Commonw.* 80: 1067-1074.
- Gibson, S.J., Johnson, J.D. (1983). Extent and route of excretion of total carbon-14 in pregnant rats after a single oral dose of ammonium 14C-PFOA. Riker Laboratories, St. Paul, MN. USEPA AR-226-0458. (Cited in Hinderliter et al., 2005).
- Gilliland, F. D., Mandel, J. S. (1996). Serum perfluorooctanoic acid and hepatic enzymes, lipoproteins, and cholesterol: a study of occupationally exposed men. *Am. J. Ind. Med.* 29: 560-568.

- Gleason, J. A., Post, G. B., Fagliano, J. A. (2015). Associations of perfluorinated chemical serum concentrations and biomarkers of liver function and uric acid in the US population (NHANES), 2007-2010. *Environ. Res.* 136: 8-14.
- Goldenthal, E.I. (1978). Final report. Ninety day subacute rhesus monkey toxicity study. International Research and Development Corporation. Study No. 137-090. November 10, 1978. USEPA AR226-0447 (Cited in USEPA, 2005a).
- Gore, A.C., Chappell, V.A., Fenton, S.E., Flaws, J.A., Nadal, A., Prins, G.S., Toppari J., Zoeller, R.T. (2015). EDC-2: The Endocrine Society's Second Scientific Statement on Endocrine-Disrupting Chemicals. *Endocr Rev.* 36: E1-E150.
- Gortner, E.G. (1981). Oral teratology study of T-2998CoC in rats. Safety Evaluation Laboratory and Riker Laboratories, Inc. Experiment Number: 0681TR0110, December 1981 (Cited in USEPA, 2005).
- Gortner, E.G. (1982). Oral teratology study of T-3141CoC in rabbits. Safety Evaluation Laboratory and Riker Laboratories, Inc. Experiment Number: 0681TB0398, February 1982 (Cited in USEPA, 2005).
- Goss, K.U. (2008). The pKa values of PFOA and other highly fluorinated carboxylic acids. *Environ. Sci. Technol.* 42: 456–458.
- Grandjean, P., E. Andersen, W., Budtz-Jorgensen, E., Nielsen, F., Molbak, K., Weihe, P. Heilmann, C. (2012). Serum vaccine antibody concentrations in children exposed to perfluorinated compounds. *JAMA* 307: 391-397.
- Granum, B., L. Haug, S. Namork, E. Stolevik, S. B., Thomsen, C., Aaberge, I. S., H. van Loveren, I. S., Lovik, M., Nygaard, U. C. (2013). Pre-natal exposure to perfluoroalkyl substances may be associated with altered vaccine antibody levels and immune-related health outcomes in early childhood. *J. Immunotoxicol.* 10: 373-379.
- Griffith, F.D., Long, J.E. (1980). Animal toxicity studies with ammonium perfluorooctanoate. *Am. Ind. Hyg. Assoc. J.* 41: 576-583.
- Guo, Z., Lin, X., Krebs, K.A., Roache, N. (2009). Perfluorocarboxylic acid content in 116 articles of commerce. ORD, USEPA, RTP, NC. EPA/600/R-09/033. March 2009. <http://www.oecd.org/dataoecd/47/50/48125746.pdf> Accessed 1/17/12.
- Guruge, K.S., Taniyasu, S., Yamashita, N., Wijeratna, S., Mohotti, K.M., Seneviratne, H.R., Kannan, K., Yamanaka, N., Miyazaki, S. (2005). Perfluorinated organic compounds in human blood serum and seminal plasma: a study of urban and rural tea worker populations in Sri Lanka. *J. Environ. Monit.* 7: 371-7.
- Gützkow, K.B., Haug, L.S., Thomsen, C., Sabaredzovic, A., Becher, G., Brunborg, G. (2012). Placental transfer of perfluorinated compounds is selective - A Norwegian Mother and Child sub-cohort study. *Int. J. Hyg. Environ. Health* 215: 216-19.
- Guyton, K.Z., Chiu, W.A., Bateson, T. F., Jinot, J., Scott, C.S., Brown, R.C., Caldwell., J. C. (2009). A reexamination of the PPAR- $\alpha$  activation mode of action as a basis for assessing human cancer risks of environmental contaminants. *Environ. Health Perspect.* 117: 1664–1672.
- Halldorsson, T.I., Rytter, D., Haug, L.S., Bech, B.H., Danielsen, I., Becher, G., Henriksen, T.B., Olsen, S.F. (2012). Prenatal exposure to perfluorooctanoate and risk of overweight at 20 years of age: a prospective cohort study. *Env. Health Perspect.* 120: 668-673.
- Hamm, M.P., Cherry, N.M., Chan, E., Martin, J.W., Burstyn, I. (2010). Maternal exposure to perfluorinated acids and fetal growth. *J. Expo. Sci. Environ. Epidemiol.* 20: 589-597.
- Han, H., Snow, T.A., Kemper, R.A., Jepson, G.W. (2003). Binding of perfluorooctanoic acid to rat and human plasma proteins. *Chem. Res. Toxicol.* 16: 775-781.



- Han, X, Kemper, R.A, Jepson, G.W. (2005). Subcellular distribution and protein binding of perfluorooctanoic acid in rat liver and kidney. *Drug Chem. Toxicol.* 28: 197-209.
- Han, X., Nabb, D.L., Russell, M.H., Kennedy, G.L., Rickard, R.W. (2012). Renal elimination of perfluorocarboxylates (PFCAs). *Chem. Res. Toxicol.* 25: 35-46.
- Hanhijarvi, H., Ylinen, M., Haaranen, T., Nevalainen, T. (1988). A proposed species difference in the renal excretion of perfluorooctanoic acid in the beagle dog and rat. In: Beynen, A.C. Solleveld, H.A. (Eds.), *New Development in Biosciences: Their Implications for Laboratory Animal Sciences*, Martinus Nijhoff Publishers, Dordrecht, The Netherlands, pp. 409–412. (Cited in Lau et al., 2007).
- Hansen, K.J., Johnson, H.O., Eldridge, J.S., Butenhoff, J.L., Dick, L.A. (2002). Quantitative characterization of trace levels of PFOS and PFOA in the Tennessee River. *Environ. Sci. Technol.* 36: 1681-1685.
- Hanssen, L., Röllin, H., Odland, J.O., Moe, M.K., Sandanger, T.M. (2010). Perfluorinated compounds in maternal serum and cord blood from selected areas of South Africa: results of a pilot study. *J. Environ. Monit.* 12: 1355 – 1361.
- Harada, K.H., Koizumi, A. (2009). Environmental and biological monitoring of persistent fluorinated compounds in Japan and their toxicities. *Environ Health Prev Med.* 14, 7-19.
- Hardisty, J.F., Willson, G.A., Brown, W.R., McConnell, E.E., Frame, S.R., Gaylor, D.W., Kennedy, G.L., Butenhoff, J.L. 2010. Pathology Working Group review and evaluation of proliferative lesions of mammary gland tissues in female rats fed ammonium perfluorooctanoate (APFO) in the diet for 2 years. *Drug Chem. Toxicol.* 33: 131-137.
- Haug, L.S., Thomsen, C., Becher, G. (2009). Time trends and the influence of age and gender on serum concentrations of perfluorinated compounds in archived human samples. *Environ. Sci. Technol.* 43: 2131-2136.
- Haug, L.S., Salihovic, S., Jogsten, I.E., Thomsen, C., van Bavel, B, Lindström, G., Becher, G., (2010a). Levels in food and beverages and daily intake of perfluorinated compounds in Norway. *Chemosphere* 80: 1137-1143.
- Haug, L.S., Thomsen, C., Brantsaeter, A.L., Kvalem, H.E., Haugen, M., Becher, G., Alexander, J., Meltzer, H.M., Knutsen, H.K. (2010b). Diet and particularly seafood are major sources of perfluorinated compounds in humans. *Environ. Int.* 36: 772-778.
- Haughom, B., Spydevold, O. (1992). The mechanism underlying the hypolipemic effect of perfluorooctanoic acid (PFOA), perfluorooctane sulphonic acid (PFOSA) and clofibrac acid. *Biochim. Biophys. Acta* 1128: 65-72.
- Haug, L.S., Huber, S., Becher, G., Thomsen, C. (2011). Characterisation of human exposure pathways to perfluorinated compounds - comparing exposure estimates with biomarkers of exposure. *Environ. Int.* 37: 687-693.
- Heindel, J.J., Vandenberg, L.N. (2015) Developmental origins of health and disease: a paradigm for understanding disease cause and prevention. *Curr. Opin. Pediatr.* 27: 248-53.
- Hemat, H., Wilhelm, M., Völkel, W., Mosch, C., Fromme, H., Wittsiepe, J. (2010). Low serum levels of perfluorooctanoic acid (PFOA), perfluorooctane sulfonate (PFOS) and perfluorohexane sulfonate (PFHxS) in children and adults from Afghanistan. *Sci. Total Environ.* 408: 3493-3495.
- Hinderliter, P.M., Mylchreest, E., Gannon, S.A., Butenhoff, J.L., Kennedy, G.L. Jr. (2005). Perfluorooctanoate: Placental and lactational transport pharmacokinetics in rats. *Toxicology.* 211: 139-48.
- Hinderliter, P.M., Han, X., Kennedy, G.L., Butenhoff, J.L. (2006). Age effect on perfluorooctanoate (PFOA) plasma concentration in post-weaning rats following oral gavage with ammonium perfluorooctanoate (APFO). *Toxicology* 225: 195-203.

- Hines, E.P., White, S.S., Stanko, J.P., Gibbs-Flournoy, E.A., Lau, C., Fenton, S.E. (2009). Phenotypic dichotomy following developmental exposure to perfluorooctanoic acid (PFOA) in female CD-1 mice: Low doses induce elevated serum leptin and insulin, and overweight in mid-life. *Mol. Cell. Endocrinol.* 304: 97-105.
- Hoffman, K., Webster, T.F., Weisskopf, M.G., Weinberg, J., Vieira, V.M. (2010). Exposure to polyfluoroalkyl chemicals and attention deficit/hyperactivity disorder in U.S. children aged 12-15 years. *Environ. Health Perspect.* 118: 1762-1767.
- Hoffman, K., Webster, T.F., Bartell, S.M., Weisskopf, M.G., Fletcher, T., Vieira, V.M. (2011). Private drinking water wells as a source of exposure to PFOA in communities surrounding a fluoropolymer production facility. *Environ. Health Perspect.* 119: 92-97.
- Hölzer, J., Midasch, O., Rauchfuss, K., Kraft, M., Reupert, R., Angerer, J., Kleeschulte, P., Marschall, N., Wilhelm, M. (2008). Biomonitoring of perfluorinated compounds in children and adults exposed to perfluorooctanoate-contaminated drinking water. *Environ. Health Perspect.* 116: 651-657.
- Hölzer, J., Göen T, Just, P., Reupert, R., Rauchfuss, K., Kraft, M., Müller, J., Wilhelm, M. (2011). Perfluorinated compounds in fish and blood of anglers at Lake Möhne, Sauerland area, Germany. *Environ. Sci. Technol.* 45: 8046-8052.
- Howard, B.A., Gusterson, B.A. (2000). Human breast development. *J Mammary Gland Biol Neoplasia.* 5: 119-37.
- Hu, Q., Strynar, M. J., DeWitt, J. C. (2010). Are developmentally exposed C57BL/6 mice insensitive to suppression of TDAR by PFOA? *J. Immunotoxicol.* 7: 344-349.
- Hu, Q., Franklin, J. N., Bryan, I., Morris, E., Wood, A., DeWitt, J. C. (2012). Does developmental exposure to perfluorooctanoic acid (PFOA) induce immunopathologies commonly observed in neurodevelopmental disorders? *Neurotoxicology* 33: 1491-1498.
- Hundley, S.G., Sarrif, A.M., Kennedy, G.L. (2006). Absorption, distribution, and excretion of ammonium perfluorooctanoate (APFO) after oral administration to various species. *Drug Chem. Toxicol.* 29: 137-145.
- Hurley, S., Houtz, E., Goldberg, D., Wang, M., Park, J-S., Nelson, D.O., Reynolds, P., Bernstein, L., Anton-Culver, H., Horn-Ross, P., Petreas, M. (2016). Preliminary associations between the detection of perfluoroalkyl acids (PFAAs) in drinking water and serum concentrations in a sample of California women. In press. DOI: 10.1021/acs.estlett.6b00154
- IARC (2016). International Agency for Research on Cancer. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Volume 110. Perfluorooctanoic acid. p. 37-110.
- IOM (2011). *Breast Cancer and the Environment: A Life Course Approach*. Institute of Medicine of the National Academies. The National Academies Press, Washington, DC. Prepublication copy, December 7, 2011. [https://download.nap.edu/catalog.php?record\\_id=13263](https://download.nap.edu/catalog.php?record_id=13263). Accessed December 7, 2011.
- Iwai, H., Yamashita, K. (2006). A fourteen-day repeated dose oral toxicity study of APFO in rats. *Drug Chem. Toxicol.* 29: 323-332.
- Jain, R. B. (2013). Association between thyroid profile and perfluoroalkyl acids: data from NHNAES 2007-2008. *Environ. Res.* 126: 51-59.
- Ji, K., Kim, S., Kho, Y., Paek, D., Sakong, J., Ha, J., Kim, S., Choi, K. (2012). Serum concentrations of major perfluorinated compounds among the general population in Korea: dietary sources and potential impact on thyroid hormones." *Environ. Int.* 45: 78-85.
- Jiang, W., Zhang, Y., Zhu, L., Deng, J. (2014). Serum levels of perfluoroalkyl acids (PFAAs) with isomer analysis and their associations with medical parameters in Chinese pregnant women. *Environ. Int.* 64: 40-47.

- Joensen, U.N., Bossi, R., Leffers, H., Jensen, A.A., Skakkebaek, N.E., Jørgensen N. (2009). Do perfluoroalkyl compounds impair human semen quality? *Environ. Health Perspect.* 117: 923-927.
- Johansson, N., Fredriksson, A., Eriksson, P. (2008). Neonatal exposure to perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA) causes neurobehavioural defects in adult mice. *Neurotoxicology* 29: 160-169.
- Johansson, N., Eriksson, P., Viberg, H. (2009). Neonatal exposure to PFOS and PFOA in mice results in changes in proteins which are important for neuronal growth and synaptogenesis in the developing brain. *Toxicol. Sci.* 108: 412-418.
- Johnson, J. D., Gibson, S. J., Ober, R. E. (1979). Extent and route of excretion and tissue distribution of total carbon-14 in rats after a single i.v. dose of FC-95-14C. Riker Laboratories, Inc., St Paul, MN, US EPA Administrative Record, 8EHQ-1180-00374 (Cited in Lau et al., 2007).
- Johnson, J.D., Gibson, S.J., Ober, R.E. (1984). Cholestyramine-enhanced fecal elimination of carbon-14 in rats after administration of ammonium [<sup>14</sup>C]perfluorooctanoate or potassium [<sup>14</sup>C]perfluorooctanesulfonate. *Fundam. Appl. Toxicol.* 4: 972-976.
- Johnson, P.I., Sutton, P., Atchley, D.S., Koustas, E., Lam, J., Sen, S., Robinson, K.A., Axelrad, D.A., Woodruff, T.J. (2014). The Navigation Guide - evidence-based medicine meets environmental health: systematic review of human evidence for PFOA effects on fetal growth. *Environ. Health Perspect.* 122: 1028-39.
- Kataria, A., Trachtman, H., Malaga-Dieiguez, L., Trasande, L. (2015). Association between perfluoroalkyl acids and kidney function in a cross-sectional study of adolescents. *Environ. Health* 14: 89.
- Kato, K., Calafat, A.M., Wong, L.Y., Wanigatunga, A.A., Caudill, S.P., Needham, L.L. (2009). Polyfluoroalkyl compounds in pooled sera from children participating in the National Health and Nutrition Examination Survey 2001-2002. *Environ. Sci. Technol.* 43: 2641-2647.
- Kato, K., Wong, L.Y., Jia, L.T., Kuklennyik, Z., Calafat, A.M. (2011). Trends in exposure to polyfluoroalkyl chemicals in the U.S. population: 1999-2008. *Environ. Sci. Technol.* 45: 8037-8045.
- Kato, K., Ye, X., Calafat, A.M. (2015). PFASs in the general population. In: *Toxicological Effects of Perfluoroalkyl and Polyfluoroalkyl Substances*. J.D. DeWitt, Editor. Humana Press. pp. 51-76.
- Kawashima, Y., Kobayashi, H., Miura, H., Kozuka, H. (1995). Characterization of hepatic responses of rat to administration of perfluorooctanoic and perfluorodecanoic acids at low levels. *Toxicology* 99: 169-178.
- Kemper, R.A. (2003). Perfluorooctanoic acid: Toxicokinetics in the rat. Association of Plastics Manufactures of Europe. Submitted to the U.S. Environmental Protection Agency's Administrative Record. AR226-1499. Cited in USEPA, 2005a.
- Kemper, R.A., Jepson, G.W. (2003). Pharmacokinetics of PFOA in male and female rats. *Toxicologist* 72: 148.
- Kennedy, G.L. (1985). Dermal toxicity of ammonium perfluorooctanoate. *Toxicol. Appl. Pharmacol.* 81: 348-355.
- Kennedy, G.L. Jr., Hall, G.T., Brittelli, M.R., Barnes, J.R., Chen, H.C. (1986). Inhalation toxicity of ammonium perfluorooctanoate. *Food Chem. Toxicol.* 24: 1325-1329.
- Kennedy, G.L., Butenhoff, J.L., Olsen, G.W., O'Connor, J.C., Seacat, A.M., Perkins, R.G., Biegel, L.B., Murphy, S.R., Farrar, D.G. (2004). The toxicology of perfluorooctanoate. *Crit. Rev. Toxicol.* 34: 351-384.
- Kielsen, K., Shamim, Z., Ryder, L. P., Nielsen Z. F., Grandjean, P., Budtz-Jorgensen, E., Heilmann, C. (2015). Antibody response to booster vaccination with tetanus and diphtheria in adults exposed to perfluorinated alkylates. *J. Immunotoxicol.* 13: 270-273.

Kim, S.K., Kannan, K. (2007). Perfluorinated acids in air, rain, snow, surface runoff, and lakes: relative importance of pathways to contamination of urban lakes. *Env. Sci. Technol.* 41: 8328–8334.

Kim, S.K., Lee, K.T., Kang, C.S., Tao, L., Kannan, K., Kim, K.R., Kim, C.K., Lee, J.S., Park, P.S., Yoo, Y.W., Ha, J.Y., Shin, Y.S., Lee, J.H. (2011). Distribution of perfluorochemicals between sera and milk from the same mothers and implications for prenatal and postnatal exposures. *Environ. Pollut.* 159: 169-174.

Kjeldsen L.S., Bonefeld-Jørgensen E.C. (2013). Perfluorinated compounds affect the function of sex hormone receptors. *Environ. Sci. Pollut. Res. Int.* 20: 8031-44.

Klaunig, J.E., Babich, M.A., Baetcke, K.P., Cook, J.C., Corton, J.C., David, R.M., DeLuca, J.G., Lai, D.Y., McKee, R.H., Peters, J.M., Roberts, R.A., Fenner-Crisp, P.A. (2003). PPAR alpha agonist-induced rodent tumors: modes of action and human relevance. *Crit. Rev. Toxicol.* 33: 655-780.

Klaunig, J. E., Hocevar, B. A., Kamendulis, L. M. (2012). Mode of Action analysis of perfluorooctanoic acid (PFOA) tumorigenicity and human relevance. *Reprod. Toxicol.* 33: 410-418.

Kleemann, R., Gervois, P.P., Verschuren, L., Staels, B., Princen, H.M., Kooistra, T. (2003). Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFkappa B-C/EBP-beta complex formation. *Blood.* 101: 545-551.

Klein, R., Klein, B. E., Cornoni, J. C., Maready, J., Cassel, J. C., Tyroler, H. A. (1973). Serum uric acid. Its relationship to coronary heart disease risk factors and cardiovascular disease, Evans County, Georgia. *Arch. Intern. Med.* 132: 401-410.

Knobeloch, L., Imm, P., Anderson, H. (2012). Perfluoroalkyl chemicals in vacuum cleaner dust from 39 Wisconsin homes. *Chemosphere* 88: 779-783.

Knox, S. S., Jackson, T., Frisbee, S. J. Javins, B., Ducatman, A. M. (2011). Perfluorocarbon exposure, gender and thyroid function in the C8 Health Project. *J. Toxicol. Sci.* 36: 403-410.

Konwick, B.J., Tomy, G.T., Ismail, N., Peterson, J.T., Fauver, R.J., Higginbotham, D., Fisk, A.T. (2008). Concentrations and patterns of perfluoroalkyl acids in Georgia, USA surface waters near and distant to a major use source. *Environ. Toxicol. Chem.* 27: 2011-2018.

Koskela, A., Finnilä, M.A., Korkalainen, M., Spulber, S., Koponen, J., Håkansson, H., Tuukkanen, J., Viluksela, M. (2016). Effects of developmental exposure to perfluorooctanoic acid (PFOA) on long bone morphology and bone cell differentiation. *Toxicol. Appl. Pharmacol.* 301:14-21.

Kotthoff, M., Müller, J., Jüriling, H., Schlummer, M., Fiedler, D. (2015). Perfluoroalkyl and polyfluoroalkyl substances in consumer products. *Environ. Sci. Pollut. Res. Int.* 22: 14546-59.

Koustaas E, Lam, J., Sutton, P., Johnson, P.I., Atchley, D.S., Sen, S., Robinson, K.A., Axelrad, D.A., Woodruff, T. J. (2014). The Navigation Guide - evidence-based medicine meets environmental health: systematic review of nonhuman evidence for PFOA effects on fetal growth. *Environ. Health Perspect.* 122: 1015-27.

Kudo, N., Kawashima, Y. (1997). Fish oil-feeding prevents perfluorooctanoic acid-induced fatty liver in mice. *Toxicol. Appl. Pharmacol.* 145: 285-293.

Kudo, N., Katakura, M., Sato, Y., Kawashima, Y. (2002). Sex hormone-regulated renal transport of perfluorooctanoic acid. *Chem. Biol. Interact.* 139: 301-316.

Kudo, N., Kawashima, Y. (2003). Toxicity and toxicokinetics of perfluorooctanoic acid in humans and animals. *J. Toxicol. Sci.* 28: 49-57.

- Kudo, N., Sakai, A., Mitsumoto, A., Hibino, Y., Tsuda, T., Kawashima, Y. (2007). Tissue distribution and hepatic subcellular distribution of perfluorooctanoic acid at low dose are different from those at high dose in rats. *Biol. Pharm. Bull.* 30: 1535-40.
- Kummu, M., Sieppi, E., Koponen, J., Laatio, L., Vähäkangas, K., Kiviranta, H., Rautio, A., Myllynen, P. (2015). Organic anion transporter 4 (OAT 4) modifies placental transfer of perfluorinated alkyl acids PFOS and PFOA in human placental ex vivo perfusion system. *Placenta* 36: 1185-91.
- LabDiet. Laboratory Rodent Diet 5001.  
[http://www.labdiet.com/cs/groups/lolweb/@labdiet/documents/web\\_content/mdrf/mdi4/~edisp/ducum04\\_028021.pdf](http://www.labdiet.com/cs/groups/lolweb/@labdiet/documents/web_content/mdrf/mdi4/~edisp/ducum04_028021.pdf) Accessed April 10, 2016.
- Lam, J., Koustas, E., Sutton, P., Johnson, P. I., Atchley, D. S., Sen, S., Robinson, K. A., Axelrad, D. A., Woodruff, T. J. (2014). The Navigation Guide - evidence-based medicine meets environmental health: integration of animal and human evidence for PFOA effects on fetal growth. *Environ. Health Perspect.* 122: 1040-1051.
- Landsteiner, A., Huset, C., Johnson, J., Williams, A. (2014). Biomonitoring for perfluorochemicals in a Minnesota community with known drinking water contamination. *J. Environ. Health* 77: 14-19.
- Lau, C., Strynar, M.J., Lindstrom, A.B., Hanson, R.G., Thibodeaux, J.R., Barton, H.A. (2005). Pharmacokinetic evaluation of perfluorooctanoic acid in the mouse. *Toxicologist* 84: 252.
- Lau, C., Thibodeaux, J. R., Hanson, R. G., Narotsky, M. G., Rogers, J. M., Lindstrom, A. B., Strynar, M. J. (2006). Effects of perfluorooctanoic acid exposure during pregnancy in the mouse. *Toxicol. Sci.* 90: 510–518.
- Lau, C., Anitole, K., Hodes, C., Lai, D., Pfahles-Hutchens, A., Seed, J. (2007). Perfluoroalkyl acids: a review of monitoring and toxicological findings. *Toxicol. Sci.* 99: 366-394.
- Lau, C. (2012). Perfluorinated compounds. *EXS* 101, 47–86
- Lechner, M., Knapp, H. (2011). Carryover of perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate (PFOS) from soil to plant and distribution to the different plant compartments studied in cultures of carrots (*Daucus carota* ssp. *Sativus*), potatoes (*Solanum tuberosum*), and cucumbers (*Cucumis Sativus*). *J. Agric. Food Chem.* 59: 11011-11018.
- Lee, S.S., Pineau, T., Drago, J., Lee, E.J., Owens, J.W., Kroetz, D.L., Fernandez-Salguero, P.M., Westphal, H., Gonzalez, F.J. (1995). Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. *Mol. Cell. Biol.* 15: 3012-3022.
- Lee, H., D'eon, J., Mabury, S.A., (2010). Biodegradation of polyfluoroalkyl phosphates as a source of perfluorinated acids to the environment. *Env. Sci. Technol.* 44: 3305-3310.
- Lee, H., Mabury, S.A. (2011). A pilot survey of legacy and current commercial fluorinated chemicals in human sera from United States donors in 2009. *Environ. Sci. Technol.* 45: 8067-8074.
- Leonard, R. C. (2003). Epidemiology Surveillance Program. Cancer Incidence Report 1959-2001 and All-Case Mortality Report 1957-2000 at the Washington Works, Parkersburg, WV. DuPont. USEPA. AR226-1307-6.
- Leonard, R. C., Kreckmann, K. H., Sakr, C. J., Symons, J. M. (2008). Retrospective cohort mortality study of workers in a polymer production plant including a reference population of regional workers. *Ann. Epidemiol.* 18: 15-22.
- Li, Y., Ramdhan, D. H., Naito, H., Yamagishi, N., Ito, Y., Hayashi, Y., Yanagiba, Y., Okamura, A., Tamada, H., Gonzalez, F. J., Nakajima, T. (2011). Ammonium perfluorooctanoate may cause testosterone reduction by adversely affecting testis in relation to PPARalpha. *Toxicol. Lett.* 205: 265-272.



- Lien, G.W., Wen, T.W., Hsieh, W.S., Wu, K.Y., Chen, C.Y., Chen, P.C. (2011). Analysis of perfluorinated chemicals in umbilical cord blood by ultra-high performance liquid chromatography/tandem mass spectrometry. *J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.* 879: 641-646.
- Lin, C. Y., Lin, L. Y., Chiang, C. K., Wang, W. J., Su, Y. N., Hung, K. Y., Chen, P. C. (2010). Investigation of the associations between low-dose serum perfluorinated chemicals and liver enzymes in US adults. *Am. J. Gastroenterol.* 105: 1354-1363.
- Lin, C. Y., Lin, L. Y., Wen, T. W., Lien, G. W., Chien, K. L., Hsu, S. H., Liao, C. C., Sung, P., Chen, C., Su, C. (2013). Association between levels of serum perfluorooctane sulfate and carotid artery intima-media thickness in adolescents and young adults. *Int. J. Cardiol.* 168: 3309-3316.
- Lin, C. Y., Wen, L. L., Lin, L. Y., Wen, T. W., Lien, G. W., Chen, C. Y., Hsu, S. H., Chien, K. L., Sung, F. C., Chen, P. C., Su, T. C. (2011). Associations between levels of serum perfluorinated chemicals and adiponectin in a young hypertension cohort in Taiwan. *Environ. Sci. Technol.* 45: 10691-10698.
- Lin, C. Y., Wen, L. L., Lin, L. Y., Wen, T. W., Lien, G. W., Hsu, S. H., Chien, K. L., Liao, C.C., Sung, F.C., Chen, P. C. and Su, T. C. (2013). The associations between serum perfluorinated chemicals and thyroid function in adolescents and young adults. *J. Hazard. Mater.* 244-245: 637-644.
- Lindstrom, A.B., Strynar, M.J., Libelo, E.L. (2011a). Polyfluorinated compounds: Past, present, and future. *Environ. Sci. Technol.* 45: 7954-7961.
- Lindstrom, A.B., Strynar, M.J., Delinsky, A.D., Nakayama, S.F., McMillan, L., Libelo, E.L., Neill, M., Thomas, L. (2011b). Application of WWTP biosolids and resulting perfluorinated compound contamination of surface and well water in Decatur, Alabama, USA. *Environ. Sci. Technol.* 45: 8015-8021.
- Liu, J., Li, J. Zhao, Y., Wang, X., Zhang, L., Wu, Y. (2010). The occurrence of perfluorinated alkyl compounds in human milk from different regions of China. *Environ. Int.* 36: 433-438.
- Liu, J., Li, J., Liu, Y., Chan, H.M., Zhao, Y., Cai, Z., Wu, Y. (2011). Comparison on gestation and lactation exposure of perfluorinated compounds for newborns. *Environ Int.* 37: 1206-1212.
- Liu, W, Yang, B, Wu, L, Zou, W, Pan, X, Zou, T, Liu, F, Xia, L, Wang, X, Zhang, D. (2015). Involvement of NRF2 in Perfluorooctanoic Acid-Induced Testicular Damage in Male Mice. *Biol. Reprod.* 93: 41.
- Llorca, M., Farré, M., Picó, Y., Teijón, ML., Alvarez, J.G., Barceló, D. (2010). Infant exposure of perfluorinated compounds: levels in breast milk and commercial baby food. *Environ. Int.* 36: 584-592.
- Looker, C., Luster, M. I., Calafat, A. M., Johnson, V. J., Burleson, G. R., Burleson, F. G., Fletcher, T. (2014). Influenza vaccine response in adults exposed to perfluorooctanoate and perfluorooctanesulfonate. *Toxicol. Sci.* 138: 76-88.
- Lopez-Espinosa, M. J., Mondal, D., Armstrong, B., Bloom, M. S., Fletcher, T. (2012). Thyroid function and perfluoroalkyl acids in children living near a chemical plant. *Environ Health Perspect* 120: 1036-1041.
- Lorber, M., Egeghy, P. P. (2011). Simple intake and pharmacokinetic modeling to characterize exposure of Americans to perfluorooctanoic acid, PFOA. *Environ. Sci. Technol.* 45: 8006-8014.
- Lorber, M., Eaglesham, G.E., Hobson, P., Toms, L.M., Mueller, J.F., Thompson, J.S. (2015). The effect of ongoing blood loss on human serum concentrations of perfluorinated acids. *Chemosphere* 118: 170-177.
- Lou, I., Wambaugh, J.F., Lau, C., Hanson, R.G., Lindstrom, A.B., Strynar, M.J., Zehr, R.D., Setzer, R.W., Barton, H.A. (2009). Modeling single and repeated dose pharmacokinetics of PFOA in mice. *Toxicol. Sci.* 107: 331-341.

- Loveless, S.E., Finlay, C., Everds, N.E., Frame, S.R., Gillies, P.J., O'Connor, J.C., Powley, C.R., Kennedy, G.L. (2006). Comparative responses of rats and mice exposed to linear/branched, linear, or branched ammonium perfluorooctanoate (APFO). *Toxicology* 220: 203–217.
- Loveless, S.E., Hoban, D., Sykes, G., Frame, S.R., Everds, N.E. (2008). Evaluation of the immune system in rats and mice administered linear ammonium perfluorooctanoate. *Toxicol. Sci.* 105: 86-96.
- Lu, Y., Luo, B., Li, J., Dai, J. (2015). Perfluorooctanoic acid disrupts the blood-testis barrier and activates the TNFalpha/p38 MAPK signaling pathway in vivo and in vitro. *Arch. Toxicol.* 90: 971-83.
- Macon, M.B., Villanueva, L.R., Tatum-Gibbs, K., Zehr, R.D., Strynar, M.J., Stanko, J.P., White, S.S., Helfant, L., Fenton, S.E. (2011). Prenatal perfluorooctanoic acid exposure in CD-1 mice: low dose developmental effects and internal dosimetry. *Toxicol. Sci.* 122: 134-45.
- Macon, M.B., Fenton, S.E. (2013). Endocrine disruptors and the breast: early life effects and later life disease. *J. Mammary Gland Biol. Neoplasia.* 18: 43-61.
- Maher, J. M., Aleksunes, L. M., Dieter, M. Z. Tanaka, Y., Peters, J. M., Manautou, J. E., Klaassen, C. D. (2008). Nrf2- and PPAR alpha-mediated regulation of hepatic Mrp transporters after exposure to perfluorooctanoic acid and perfluorodecanoic acid. *Toxicol. Sci.* 106: 319-328.
- Maine DHHS (2014). Maine Department of Health and Human Services. Maximum Exposure Guideline for Perfluorooctanoic Acid in Drinking Water. CAS Registry Number (Free Acid): 335-67-1. March 17th, 2014. [http://www.bennington.edu/docs/default-source/docs-pfoa/me\\_pfoameg.pdf?sfvrsn=4](http://www.bennington.edu/docs/default-source/docs-pfoa/me_pfoameg.pdf?sfvrsn=4)
- Maisonet, M., Terrell, M. L., McGeehin, M. A, Christensen, K. Y, Holmes, A., Calafat, A. M. Marcus, M. (2012). Maternal concentrations of polyfluoroalkyl compounds during pregnancy and fetal and postnatal growth in British girls. *Environ. Health Perspect.* 120: 1432-1437.
- Mak, Y.L., Taniyasu, S., Yeung, L.W.Y., Lu, G., Jin, L., Yang, Y., Lam, P.K.S., Kannan, K., Yamashita, N. (2009). Perfluorinated compounds in tap water from China and several other countries. *Environ. Sci. Technol.* 43: 4824–4829.
- Maloney, E. K., Waxman, D. J. (1999). trans-Activation of PPARalpha and PPARgamma by structurally diverse environmental chemicals. *Toxicol. Appl. Pharmacol.* 161: 209-218.
- Mann, P., Frame, S.R. (2004). FC-143: Two year oral toxicity-oncogenicity study in rats. Peer review of ovaries. Submitted by E.I du Pont de Nemours and Company. USEPA Docket AR-226-1921.
- Mann, P.C., Vahle, J., Keenan, C.M., Baker, J.F., Bradley, A.E., Goodman, D.G., Harada, T., Herbert, R., Kaufmann, W., Kellner, R., Nolte, T., Rittinghausen, S., Tanaka, T. (2012). International harmonization of toxicologic pathology nomenclature: an overview and review of basic principles. *Toxicol. Pathol.* 40: 7S-13S.
- Martin, J.W., Mabury, S.A., Solomon, K.R., Muir, D.C. (2003). Bioconcentration and tissue distribution of perfluorinated acids in rainbow trout (*Oncorhynchus mykiss*). *Environ. Toxicol. Chem.* 22: 196-204.
- Martin, M. T., Brennan, R. J., Hu, W., Ayanoglu, E., Lau, C., Ren, H., Wood, C. R., Corton, J. C., Kavlock, R. J., Dix, D. J. (2007). Toxicogenomic study of triazole fungicides and perfluoroalkyl acids in rat livers predicts toxicity and categorizes chemicals based on mechanisms of toxicity. *Toxicol. Sci.* 97: 595-613.
- MDH (2008). Minnesota Department of Health. Health Risk Limits for Groundwater 2008 Rule Revision. Perfluorooctanoic Acid. <http://www.health.state.mn.us/divs/eh/risk/guidance/gw/pfoa.pdf>
- MDH (2009). Minnesota Department of Health. East Metro Perfluorochemical Biomonitoring Pilot Project. July 21, 2009. <http://www.health.state.mn.us/divs/eh/tracking/finalpfcprpt.pdf>



- Melzer, D., Rice, N., Depledge, M. H., Henley, W. E., Galloway, T. S. (2010). Association between serum perfluorooctanoic acid (PFOA) and thyroid disease in the U.S. National Health and Nutrition Examination Survey. *Environ. Health Perspect.* 118: 686-692.
- Michalik, L., Auwerx, J., Berger, J.P., Chatterjee, V.K., Glass, C.K., Gonzalez, F.J., Grimaldi, P.A., Kadowaki, T., Lazar, M.A., O'Rahilly, S., Palmer, C.N., Plutzky J., Reddy, J.K., Spiegelman, B.M., Staels, B., Wahli, W. (2006). International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. *Pharmacol. Rev.* 58: 726-41.
- Midasch, O., Drexler, H., Hart, N., Beckmann, M.W., Angerer, J. (2007). Transplacental exposure of neonates to perfluorooctanesulfonate and perfluorooctanoate: a pilot study. *Int. Arch. Occup. Environ. Health* 80: 643-648.
- Minata, M., Harada, K.H., Kärrman, A., Hitomi, T., Hirosawa, M., Murata, M., Gonzalez, F.J., Koizumi, A. (2010). Role of peroxisome proliferator-activated receptor- $\alpha$  in hepatobiliary injury induced by ammonium perfluorooctanoate in mouse liver. *Ind. Health* 48: 96-107.
- Mogensen, U.B., Grandjean, P., Nielsen, F., Weihe, P., Budtz-Jørgensen, E. (2015). Breastfeeding as an exposure pathway for perfluorinated alkylates. *Environ. Sci. Technol.* 49: 10466-73.
- Mondal, D., Lopez-Espinosa, M-J., Armstrong, B., Stein, C.R., Fletcher, T. (2012). Relationships of perfluorooctanoate and perfluorooctane sulfonate serum concentrations between child-mother pairs in a population with perfluorooctanoate exposure from drinking water. *Environ. Health Perspect.* 120: 752-757.
- Mondal, D., Weldon, R. H., Armstrong, B. G., Gibson, L. J., Lopez-Espinosa, M. J., Shin, H. M., Fletcher, T. (2014). Breastfeeding: a potential excretion route for mothers and implications for infant exposure to perfluoroalkyl acids. *Environ. Health Perspect.* 122: 187-192.
- Monroy, R., Morrison, K., Teo, K., Atkinson, S., Kubwabo, C., Stewart, B., Foster, W.G. (2008). Serum levels of perfluoroalkyl compounds in human maternal and umbilical cord blood samples. *Environ. Res.* 108: 56-62.
- Moody, C.A., Hebert, G.N., Strauss, S.H., Field, J.A. (2003). Occurrence and persistence of perfluorooctanesulfonate and other perfluorinated surfactants in groundwater at a fire-training area at Wurtsmith Air Force Base, Michigan, USA. *J. Environ. Monit.* 5: 341-345.
- Morel-Symons, J., Sakr, C.J., Kreckmann, K.H., Leonard, R.C. (2007). Addendum report on confirmed and potential carcinoid tumor cases in the DuPont Cancer Registry. D. E. Program. Newark, DE. DuPont-24117-Addendum. EPA Docket AR, 226.
- Morken, N.-H., Travlos, G. S., Wilson, R. E., Eggesbø, M., Longnecker, M. P. (2014). Maternal glomerular filtration rate in pregnancy and fetal size. *PLoS ONE* 9: e101897.
- Murakami, M., Shinohara, H., Takada, H. (2009). Evaluation of wastewater and street runoff as sources of perfluorinated surfactants (PFSS). *Chemosphere* 74: 487-493.
- Mylchreest, E. (2003). PFOA: Lactational and placental transport pharmacokinetic study in mice. Laboratory Project ID: DuPont-13309. December 19, 2003. US EPA AR226-1551.
- Nakagawa, T., Ramdhan, D.H., Tanaka, N., Naito, H., Tamada, H., Ito, Y., Li, Y., Hayashi, Y., Yamagishi, N., Yanagiba, Y., Aoyama, T., Gonzalez, F.J., Nakajima, T. (2011). Modulation of ammonium perfluorooctanoate-induced hepatic damage by genetically different PPAR $\alpha$  in mice. *Arch. Toxicol.* 86: 63-74.
- Nakayama, S., Strynar, M.J., Helfant, L., Egeghy, P., Ye, X., Lindstrom, A.B. (2007). Perfluorinated compounds in the Cape Fear drainage basin in North Carolina. *Environ. Sci. Technol.* 41: 5271-5276.
- Nakayama, S.F., Strynar, M.J., Reiner, J.L., Delinsky, A.D., Lindstrom, A.B. (2010). Determination of perfluorinated compounds in the Upper Mississippi river basin. *Environ. Sci. Technol.* 44: 4103-4109.

Needham, L.L., Grandjean, P., Heinzow, B., Jørgensen, P.J., Nielsen, F., Patterson, D.G. Jr., Sjödin, A., Turner, W.E., Weihe, P. (2011). Partition of environmental chemicals between maternal and fetal blood and tissues. *Environ. Sci. Technol.* 45: 1121-1126.

Nelson, J.W., Hatch, E.E., Webster, T.F. (2010). Exposure to polyfluoroalkyl chemicals and cholesterol, body weight, and insulin resistance in the general US population. *Environ. Health Perspect.* 118: 197–202.

Ngo, H. T., Hetland, R. B., Sabaredzovic, A, Haug, L. S., Steffensen, I. L. (2014). In utero exposure to perfluorooctanoate (PFOA) or perfluorooctane sulfonate (PFOS) did not increase body weight or intestinal tumorigenesis in multiple intestinal neoplasia (Min/+) mice. *Environ Res* 132: 251-263.

NH (2017). New Hampshire Code of Administrative Rules. Chapter Env-Or 600. Contaminated Site Management.

NH DES (2016). New Hampshire Department of Environmental Services. Letter from John M. Regan. 11/22/16. <http://www.des.nh.gov/organization/divisions/waste/hwrp/documents/pfc-stakeholder-notification-20161122.pdf>

NH DHHS (2015). New Hampshire Department of Health & Human Services. Perfluorochemical (PFC) Testing Program: Summary of test results for children <12 y.o. September 9, 2015. <http://www.dhhs.nh.gov/dphs/documents/pediatric-results-presentation.pdf>

Nilsson, R., Beije, B., Pr at, V., Erixon, K., Ramel, C. (1991). On the mechanism of the hepatocarcinogenicity of peroxisome proliferators. *Chem. Biol. Interact.* 78: 235-250.

Nilsson, H., K arrman, A., Westberg, H., Rotander, A., van Bavel, B., Lindstr om, G. (2010). A time trend study of significantly elevated perfluorocarboxylate levels in humans after using fluorinated ski wax. *Environ. Sci. Technol.* 44: 2150-2155.

NJDEP (2007a). Guidance for PFOA in drinking water at Pennsgrove Water Supply Company. Division of Science, Research, and Technology. February 13, 2007. [http://www.nj.gov/dep/watersupply/pdf/pfoa\\_dwguidance.pdf](http://www.nj.gov/dep/watersupply/pdf/pfoa_dwguidance.pdf)

NJDEP (2007b). Determination of Perfluorooctanoic Acid (PFOA) in Aqueous Samples, Final Report, January 2007. [http://www.nj.gov/dep/watersupply/final\\_pfoa\\_report.pdf](http://www.nj.gov/dep/watersupply/final_pfoa_report.pdf)

NJDEP (2010). New Jersey Department of Environmental Protection. Letter to Reginald C. Jordan, Ph.D., CIH. NC Division of Air Quality. June 1, 2010.

NJDEP (2014). New Jersey Department of Environmental Protection. Occurrence of Perfluorinated Chemicals in Untreated New Jersey Drinking Water Sources Final Report. April 2014. <http://www.nj.gov/dep/watersupply/pdf/pfc-study.pdf>

NJDHSS (2010). New Jersey Department of Health and Senior Services. Letter to Reginald C. Jordan, Ph.D., CIH. NC Division of Air Quality. June 1, 2010.

NJDOH (2014). New Jersey Department of Health. ATSDR Technical Assistance Form. NJDOH response to NJDEP request for evaluation of showering/bathing exposure to PFNA.

Noorlander, C.W., van Leeuwen, S.P., Te Biesebeek, J.D., Mengelers, M.J., Zeilmaker, M.J. (2011). Levels of perfluorinated compounds in food and dietary intake of PFOS and PFOA in the Netherlands. *J. Agric. Food Chem.* 59: 7496-7505.

NRC (2006). National Research Council. Assessing the human health risk of trichloroethylene. Appendix E: Peroxisome proliferators and liver cancer. National Academies Press, Washington, DC.

NTP (1997). National Toxicology Program. NTP Toxicology and Carcinogenesis Studies of Tetrafluoroethylene (CAS No. 116-14-3) in F344/N Rats and B6C3F1 Mice (Inhalation Studies). Research Triangle Park, N.C., National Institute of Environmental Health Sciences.

NTP (2016). National Toxicology Program. Systematic review of immunotoxicity associated with exposure to perfluorooctanoic acid (PFOA) or perfluorooctane sulfonate (PFOS). September 2016. [https://ntp.niehs.nih.gov/ntp/ohat/pfoa\\_pfos/pfoa\\_pfosmonograph\\_508.pdf](https://ntp.niehs.nih.gov/ntp/ohat/pfoa_pfos/pfoa_pfosmonograph_508.pdf) Accessed January 24, 2017.

NYS DOH (2016). New York State Department of Health. Information Sheet. PFOA Biomonitoring Group-Level Results. June 2, 2016.

<https://www.health.ny.gov/environmental/investigations/hoosick/docs/infosheetshortgroupresults.pdf> Accessed June 9, 2016.

Ode, A., Kallen, K., Gustafsson, P., Rylander, L., Jonsson, B. A., Olofsson, P., Ivarsson, S. A., Lindh, C. H., Rignell-Hydbom, A. (2014). Fetal exposure to perfluorinated compounds and attention deficit hyperactivity disorder in childhood. *PLoS One* 9: e95891.

OECD (2015). Organisation for Economic Cooperation and Development. Working Towards a Global Emission Inventory of PFASs: Focus on PFCAs - Status Quo and the Way Forward. Paris, 2015. <https://www.oecd.org/chemicalsafety/risk-management/Working%20Towards%20a%20Global%20Emission%20Inventory%20of%20PFASS.pdf>

Olsen, G. W., Lange, C. C., Ellefson, M. E., Mair, D. C., Church, T. R., Goldberg, C. L., Herron, R. M., Medhdizadehkashi, Z. Nobiletti, J. B., Rios, J. A., Reagen, W. K., Zobel, L. R. (2012). Temporal trends of perfluoroalkyl concentrations in American Red Cross adult blood donors, 2000-2010. *Environ. Sci. Technol.* 46: 6330-6338.

Olsen, G. W., Ehresman, D. J., Buehrer, B. D., Gibson, B. A., Butenhoff, J. L., Zobel, L. R., (2012). Longitudinal assessment of lipid and hepatic clinical parameters in workers involved with the demolition of perfluoroalkyl manufacturing facilities. *J. Occup. Environ. Med.* 54: 974-983.

Olsen, G. W., Gilliland, F. D., Burlew, M. M., Burriss, J. M., Mandel, J. S., Mandel, J. H. (1998). An epidemiologic investigation of reproductive hormones in men with occupational exposure to perfluorooctanoic acid. *J. Occup. Environ. Med.* 40: 614-622.

Olsen, G. W., Burriss, J. M., Burlew, M. M., Mandel, J. H. (2000). Plasma cholecystokinin and hepatic enzymes, cholesterol and lipoproteins in ammonium perfluorooctanoate production workers. *Drug Chem. Toxicol.* 23: 603-620.

Olsen, G. W., Burriss, J. M., Burlew, M. M., Mandel, J. H. (2003). Epidemiologic assessment of worker serum perfluorooctanesulfonate (PFOS) and perfluorooctanoate (PFOA) concentrations and medical surveillance examinations. *J. Occup. Environ. Med.* 45: 260-270.

Olsen, G. W., Zobel, L. R. (2007). Assessment of lipid, hepatic, and thyroid parameters with serum perfluorooctanoate (PFOA) concentrations in fluorochemical production workers. *Int Arch. Occup. Environ. Health* 81: 231-246.

Olsen, G.W. (2015). PFAS biomonitoring in higher exposed populations. In: *Toxicological Effects of Perfluoroalkyl and Polyfluoroalkyl Substances*. J.D. DeWitt, Editor. Humana Press. pp. 77-126.

Omer, S.B., Phadke, V.K., Bednarczyk, R.A., Chamberlain, A.T., Brosseau, J.L., Orenstein, W.A. (2016). Impact of statins on influenza vaccine effectiveness against medically attended acute respiratory illness. *J. Infect. Dis.* 213: 1216-23.

Onishchenko, N., Fischer, C., Wan Ibrahim, W.N., Negri, S., Spulber, S., Cottica, D., Ceccatelli, S. (2010). Prenatal exposure to PFOS or PFOA alters motor function in mice in a sex-related manner. *Neurotox. Res.* 19: 452-461.

Osborne, G, Rudel, R., Schwarzman, M. (2015). Evaluating chemical effects on mammary gland development: A critical need in disease prevention. *Reprod. Toxicol.* 54: 148-55.

Palkar, P.S., Anderson, C.R., Ferry, C.H., Gonzalez, F.J., Peters, J.M. (2010). Effect of prenatal peroxisome proliferator-activated receptor alpha (PPARalpha) agonism on postnatal development. *Toxicology* 276: 79-84.

Perkins, R.G., Butenhoff, J.L., Kennedy, G.L., Palazzolo, M.J. (2004). 13-Week dietary toxicity study of ammonium perfluorooctanoate (APFO) in male rats. *Drug Chem. Toxicol.* 27: 361-378.

Peters, J.M., Gonzalez, F.J. (2011). Why toxic equivalency factors are not suitable for perfluoroalkyl chemicals. *Chem. Res. Toxicol.* 24: 1601-1609.

Post, G.B., Louis, J.B., Cooper, K.R., Boros-Russo, B.J., Lippincott, R.L. (2009a). Occurrence and potential significance of perfluorooctanoic acid (PFOA) detected in New Jersey public drinking water systems. *Environ. Sci. Technol.* 43: 4547–4554.

Post, G.B., Louis, J.B., Cooper, K.R., Lippincott, R.L. (2009b). Response to Comment on Occurrence and potential significance of perfluorooctanoic acid (PFOA) detected in New Jersey public drinking water systems. *Environ. Sci. Technol.* 43: 8699–8700.

Post, G.B., Cohn, P.D., Atherholt, T.A. (2011). Health and aesthetic aspects of water quality. In: J. Edzwald (Ed.), *Water Quality and Treatment: A Handbook of Community Water Supplies*, American Water Works Association, 6th edition. McGraw-Hill, New York. pp. 2.1-2.100.

Post, G.B., Cohn, P.D., Cooper, K.R. (2012). Perfluorooctanoic acid (PFOA), an emerging drinking water contaminant: a critical review of recent literature. *Env. Res.* 116: 93-117.

Post, G.B., Louis, J.B., Lippincott, R.L., Procopio, N.A. (2013). Occurrence of perfluorinated chemicals in raw water from New Jersey public drinking water systems. *Environ. Sci. Technol.* 47: 13266-75.

Prevedouros, K., Cousins, I.T., Buck, R.C., Korzeniowski, S.H. (2006). Sources, fate and transport of perfluorocarboxylates. *Environ. Sci. Technol.* 40: 32–44.

PubChem (2016). Pefluorooctanoic acid. Accessed May 15, 2016.

Qazi, M. R., Bogdanska, J., Butenhoff, J. L., Nelson, B. D., DePierre, J. W., Abedi-Valugerdi, M. (2009a). High-dose, short-term exposure of mice to perfluorooctanesulfonate (PFOS) or perfluorooctanoate (PFOA) affects the number of circulating neutrophils differently, but enhances the inflammatory responses of macrophages to lipopolysaccharide (LPS) in a similar fashion. *Toxicology* 262: 207-214.

Qazi, M. R., Xia, Z., Bogdanska, J., Chang, S. C., Ehresman, D. J., Butenhoff, J. L., Nelson, B. D., DePierre, J. W., Abedi-Valugerdi, M. (2009b). The atrophy and changes in the cellular compositions of the thymus and spleen observed in mice subjected to short-term exposure to perfluorooctanesulfonate are high-dose phenomena mediated in part by peroxisome proliferator-activated receptor-alpha (PPARalpha). *Toxicology* 260: 68-76.

Qazi, M. R., Abedi, M. R., Nelson, B. D., DePierre, J. W., Abedi-Valugerdi, M. (2010). Dietary exposure to perfluorooctanoate or perfluorooctane sulfonate induces hypertrophy in centrilobular hepatocytes and alters the hepatic immune status in mice. *Int. Immunopharmacol.* 10: 1420-1427.

Qazi, M. R., Nelson, B. D., DePierre, J. W., Abedi-Valugerdi, M. (2012). High-dose dietary exposure of mice to perfluorooctanoate or perfluorooctane sulfonate exerts toxic effects on myeloid and B-lymphoid cells in the bone marrow and these effects are partially dependent on reduced food consumption. *Food. Chem. Toxicol.* 50: 2955-2963.

Qazi, M. R., Hassan, M., Nelson, B. D., Depierre, J. W., Abedi-Valugerdi, M. (2013). Sub-acute, moderate-dose, but not short-term, low-dose dietary pre-exposure of mice to perfluorooctanoate aggravates concanavalin A-induced hepatitis. *Toxicol. Lett.* 219: 1-7.

Quist, E.M., Filgo, A.J., Cummings, C.A., Kissling, G.E., Hoenerhoff, M.J., Fenton, S.E. (2015). Hepatic mitochondrial alteration in CD-1 mice associated with prenatal exposures to low doses of perfluorooctanoic acid (PFOA). *Toxicol. Pathol.* 43: 546-57.

Rayne, S., Forest, K. (2010). Theoretical studies on the pKa values of perfluoroalkyl carboxylic acids. *J. Mol. Struct. (Theochem)* 949: 60–69.

Raleigh, K.K., Alexander, B.H., Olsen, G.W., Ramachandran, G., Morey, S.Z., Church, T.R., Logan, P.W., Scott, L.L.F., Allen, E.M. (2014). Mortality and cancer incidence in ammonium

perfluorooctanoate production workers. *Occup. Environ. Med.* 71:500–506

Rayne, S., Forest, K. (2010). Theoretical studies on the pKa values of perfluoroalkyl carboxylic acids. *J. Mol. Struct. (Theochem)* 949: 60–69.

Rebholz S.L., Jones, T., Herrick, R.L., Xie, C., Calafat, A.M., Pinney, S.M., Woollett, L.A. (2016). Hypercholesterolemia with consumption of PFOA-laced Western diets is dependent on strain and sex of mice. *Toxicol. Rep.* 3: 46-54.

Reiner, J.L., Nakayama, S.F., Delinsky, A.D., Stanko, J.P., Fenton, S.E., Lindstrom, A.B., Strynar, M.J. (2009). Analysis of PFOA in dosed CD1 mice. Part 1. Methods development for the analysis of tissues and fluids from pregnant and lactating mice and their pups. *Reprod. Toxicol.* 27: 360-4.

Romano, M.E., Xu, Y., Calafat, A.M., Yolton, K., Chen, A., Webster, G.M., Eliot, M.N., Howard, C.R., Lanphear, B.P., Braun, J.M. (2016). Maternal serum perfluoroalkyl substances during pregnancy and duration of breastfeeding. *Env. Research* 149: 239-46.

Roosens, L., D'Hollander, W., Bervoets, L., Reynders, H., Van Campenhout, K., Cornelis, C., Van Den Heuvel, R., Koppen, G., Covaci, A. (2010). Brominated flame retardants and perfluorinated chemicals, two groups of persistent contaminants in Belgian human blood and milk. *Environ. Pollut.* 158: 2546–2552.

Rosen, M.B., Thibodeaux, J.R., Wood, C.R., Zehr, R.D., Schmid, J.E., Lau, C. (2007). Gene expression profiling in the lung and liver of PFOA-exposed mouse fetuses. *Toxicology* 239: 15-33.

Rosen, M.B., Abbott, B.D., Wolf, D.C., Corton, J.C., Wood, C.R., Schmid, J.E., Das, K.P., Zehr, R.D., Blair, E.T., Lau, C. (2008a). Gene profiling in the livers of wild-type and PPAR alpha-null mice exposed to perfluorooctanoic acid. *Toxicol. Pathol.* 36: 592-607.

Rosen, M.B., Lee, J.S., Ren, H., Vallanat, B., Liu, J., Waalkes, M.P., Abbott, B.D., Lau, C., Corton, J.C. (2008b). Toxicogenomic dissection of the perfluorooctanoic acid transcript profile in mouse liver: evidence for the involvement of nuclear receptors PPAR alpha and CAR. *Toxicol. Sci.* 103: 46-56.

Roth, M., Obaidat, A., Hagenbuch, B. (2012). OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies. *Br. J. Pharmacol.* 165: 1260-87.

Rudel, R.A., Fenton, S.E., Ackerman, J.M., Euling, S.Y., Makris, S.L. (2011). Environmental exposures and mammary gland development: state of the science, public health implications, and research recommendations. *Environ. Health Perspect.* 119: 1053-1061.

Rumsby, P.C., McLaughlin, C.L., Hall, T. (2009). Perfluorooctane sulphonate and perfluorooctanoic acid in drinking and environmental waters. *Philos. Transact. A Math. Phys. Eng. Sci.* 367: 4119-4136.

Rusiecka, I., Składanowski, A.C. (2008). Induction of the multixenobiotic/multidrug resistance system in various cell lines in response to perfluorinated carboxylic acids. *Acta Biochim. Pol.* 55: 329-37.

Russell, M.H., Berti, W.R., Szostek, B., Buck, R.C. (2008). Investigation of the biodegradation potential of a fluoroacrylate polymer product in aerobic soils. *Environ. Sci. Technol.* 42: 800-807.

Sakr, C. J., Kreckmann, K. H., Green, J. W., Gillies, P. J., Reynolds, J. L., Leonard, R. C. (2007). Cross-sectional study of lipids and liver enzymes related to a serum biomarker of exposure (ammonium perfluorooctanoate or APFO) as part of a general health survey in a cohort of occupationally exposed workers. *J. Occup. Environ. Med.* 49: 1086-1096.

Sakr, C. J., Leonard, R. C., Kreckmann, K. H., Slade, M. D., Cullen, M. R. (2007). Longitudinal study of serum lipids and liver enzymes in workers with occupational exposure to ammonium perfluorooctanoate. *J. Occup. Environ. Med.* 49: 872-879.



- Savitz, D. A., Stein, C. R., Elston, B., Wellenius, G. A., Bartell, S. M., Shin, H. M., Vieira, V. M. Fletcher, T. (2012). Relationship of perfluorooctanoic acid exposure to pregnancy outcome based on birth records in the mid-Ohio Valley. *Environ. Health Perspect.* 120: 1201-1207.
- Schechter, A., Malik-Bass, N., Calafat, A.M., Kato, K., Colacino, J.A., Gent, T.L., Hynan, L.S., Harris, T.R., Malla, S., Birnbaum, L.S. (2011). Polyfluoroalkyl compounds in Texas children from birth through 12 years of age. *Environ. Health Perspect.* (in press).
- Schlummer, M., Gruber, L., Fiedler, D., Kizlauskas, M., Muller, J. (2013). Detection of fluorotelomer alcohols in indoor environments and their relevance for human exposure. *Environ. Int.* 57-58: 42-49.
- Seals, R., Bartell, S.M., Steenland, K. (2011). Accumulation and clearance of perfluorooctanoic acid (PFOA) in current and former residents of an exposed community. *Environ. Health Perspect.* 119: 119-124.
- Sepulvado, J.G., Blaine, A.C., Hundal, L.S., Higgins, C.P. (2011). Occurrence and fate of perfluorochemicals in soil following the land application of municipal biosolids. *Environ. Sci. Technol.* 45: 8106-8112.
- Shah, D. (2009). Healthy worker effect phenomenon. *Indian J. Occup. Environ. Med.* 13: 77-79.
- Shankar, A., Xiao, J., Ducatman, A. (2011). Perfluoroalkyl chemicals and elevated serum uric acid in US adults. *Clin. Epidemiol.* 3: 251-258.
- Shin, H.M., Vieira, V.M., Ryan, P.B., Steenland, K., Bartell, S.M. (2011). Retrospective exposure estimation and predicted versus observed serum perfluorooctanoic acid concentrations for participants in the C8 Health Project. *Environ. Health Perspect.* 119: 1760-1765.
- Shrestha, S., Bloom, M. S., Yucel, R., Seegal, R. F., Wu, Q., Kannan, K., Rej, R., Fitzgerald, E. F. (2015). Perfluoroalkyl substances and thyroid function in older adults. *Environ. Int.* 75: 206-214.
- Shoeib, M., Harner, T.M., Webster, G., Lee, S.C., (2011). Indoor sources of poly- and perfluorinated compounds (PFCS) in Vancouver, Canada: implications for human exposure. *Environ. Sci. Technol.* 45: 7999-8005.
- Sibinski, L.J. (1987). Final report of a two year oral (diet) toxicity and carcinogenicity study of fluorochemical FC-143 (perfluorooctanoate ammonium carboxylate) in rats. Vol. 1-4, 3M Company/RIKER. No.0281CR0012; 8EHQ-1087-0394, October 16, 1987.
- Sinclair, E., Kannan, K. (2006). Mass loading and fate of perfluoroalkyl surfactants in wastewater treatment plants. *Env. Sci. Technol.* 40: 1408-1414.
- Skutlarek, D., Exner, M., Färber, H. (2006). Perfluorinated surfactants in surface and drinking waters. *Environ. Sci. Pollut. Res. Int.* 13: 299-307.
- So, M.K., Yamashita, N., Taniyasu, S., Jiang, Q., Giesy, J.P., Chen, K., Lam, P.K. (2006). Health risks in infants associated with exposure to perfluorinated compounds in human breast milk from Zhoushan, China. *Environ. Sci. Technol.* 40: 2924-2929.
- Sobolewski, M., Conrad, K., Allen, J. L., Weston, H., Martin, K., Lawrence, B. P., Cory-Slechta, D. A. (2014). Sex-specific enhanced behavioral toxicity induced by maternal exposure to a mixture of low dose endocrine-disrupting chemicals. *Neurotoxicology* 45: 121-130.
- Son, H.Y., Kim, S.H., Shin, H.I., Bae, H.I., Yang, J.H. (2008). Perfluorooctanoic acid-induced hepatic toxicity following 21-day oral exposure in mice. *Arch. Toxicol.* 82: 239-246.
- Son, H.Y., Lee, S., Tak, E.N., Cho, H.S., Shin H.I., Kim, S.H., Yang, J.H. (2009). Perfluorooctanoic acid alters T lymphocyte phenotypes and cytokine expression in mice. *Environ. Toxicol.* 24: 580-588.

- SRI. Southern Research Institute (2003). Protein binding of perfluorohexane sulfonate, perfluorooctane sulfonate and perfluorooctanoate to plasma (human, rat and monkey), and various human derived plasma protein fractions. Study ID: 9921.7. US EPA AR226-1354. Cited in USEPA (2005a).
- Stahl, T., Heyn, J., Thiele, H., Hüther, J., Failing, K., Georgii, S., Brunn, H. (2009). Carryover of perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate (PFOS) from soil to plants. *Arch. Environ. Contam. Toxicol.* 57: 289-298.
- Starkov, A. A., Wallace, K. B. (2002). Structural determinants of fluorochemical-induced mitochondrial dysfunction. *Toxicol Sci* 66: 244-252.
- Starling, A. P., Engel, S. M., Whitworth, K. W., Richardson, D. B., Stuebe, A. M., Daniels, J. L., Haug, L. S., Eggesbo, M., Becher, G., Sabaredzovic, A., Thomsen, C., Wilson, R. E., Travlos, G. S., Hoppin, J. A., Baird, D. D., Longnecker, M. P. (2014). Perfluoroalkyl substances and lipid concentrations in plasma during pregnancy among women in the Norwegian Mother and Child Cohort Study. *Environ. Int.* 62: 104-112.
- Steenland, K., Jin, C., MacNeil, J., Lally, C., Ducatman, A., Vieira V., Fletcher, T. (2009a). Predictors of PFOA levels in a community surrounding a chemical plant. *Environ. Health Perspect.* 117: 1083-1088.
- Steenland, K., Tinker, S., Frisbee, S., Ducatman, A., Vaccarino, V. (2009b). Association of perfluorooctanoic acid and perfluorooctane sulfonate with serum lipids among adults living near a chemical plant. *Am. J. Epidemiol.* 170: 1268-1278.
- Steenland K., Fletcher T., Savitz D.A. (2010a). Epidemiologic evidence on the health effects of perfluorooctanoic acid (PFOA). *Environ. Health Perspect.* 118: 1100-1108.
- Steenland, K., Tinker, S., Shankar, A., Ducatman, A. (2010b). Association of perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate (PFOS) with uric acid among adults with elevated community exposure to PFOA. *Environ. Health Perspect.* 118: 229-233.
- Steenland K., Savitz, D.A., Fletcher, T. (2014). Commentary: Class action lawsuits: can they advance epidemiologic research? *Epidemiology* 25: 167-9.
- Steenland, K., Zhao, L., Winqvist, A. (2015). A cohort incidence study of workers exposed to perfluorooctanoic acid (PFOA). *Occup. Environ. Med.* 72: 373-380.
- Stein, C. R., Savitz, D. A., Dougan, M. (2009). Serum levels of perfluorooctanoic acid and perfluorooctane sulfonate and pregnancy outcome. *Am. J. Epidemiol.* 170: 837-846.
- Stein, C. R., McGovern, K. J., Pajak, A. M., Maglione, P. J., Wolff, M. S. (2016). Perfluoroalkyl and polyfluoroalkyl substances and indicators of immune function in children aged 12-19 y: National Health and Nutrition Examination Survey. *Pediatr. Res.* 79: 348-357.
- Stein, C.R., Savitz, D.A., (2011). Serum perfluorinated compound concentration and Attention Deficit/Hyperactivity Disorder in children 5–18 years of age. *Environ. Health. Perspect.* 119: 1466-1471.
- Stein, C. R., Wolff, M. S., Calafat, A. M., Kato, K., Engel, S. M. (2012). Comparison of polyfluoroalkyl compound concentrations in maternal serum and amniotic fluid: a pilot study. *Reprod. Toxicol.* 34: 312-316.
- Suh, C.H., Cho, N.K., Lee, C.K., Lee, C.H., Kim, D.H., Kim, J.H., Son, B.C., Lee, J.T. (2011). Perfluorooctanoic acid-induced inhibition of placental prolactin-family hormone and fetal growth retardation in mice. *Mol. Cell. Endocrinol.* 337: 7-15.
- Sundström, M., Ehresman, D.J., Bignert, A., Butenhoff, J.L., Olsen, G.W., Chang, S.C., Bergman, A. (2011). A temporal trend study (1972-2008) of perfluorooctanesulfonate, perfluorohexanesulfonate, and perfluorooctanoate in pooled human milk samples from Stockholm, Sweden. *Environ. Int.* 37: 178-183.



- Takagi, A., Sai, K., Umemura, T., Hasegawa, R., Kurokawa, Y. (1991). Short-term exposure to the peroxisome proliferators, perfluorooctanoic acid and perfluorodecanoic acid, causes significant increase of 8-hydroxydeoxyguanosine in liver DNA of rats. *Cancer Lett.* 57: 55-60.
- Takagi, S., Adachi, F., Miyano, K., Koizumi, Y., Tanaka, H., Watanabe, I., Tanabe, S., Kannan, K. (2011). Fate of perfluorooctanesulfonate and perfluorooctanoate in drinking water treatment processes. *Water Res.* 45: 3925-3932
- Tan, X., Xie, G., Sun, X., Li, Q., Zhong, W., et al. (2013). High Fat Diet Feeding Exaggerates Perfluorooctanoic acid-induced liver injury in mice via modulating multiple metabolic pathways. *PLoS ONE* 8: e61409.
- Tao, L., Kannan, K., Wong, C.M., Arcaro, K.F., Butenhoff, J.L. (2008a). Perfluorinated compounds in human milk from Massachusetts, U.S.A. *Environ. Sci. Technol.* 42: 3096-3101.
- Tao, L., Ma, J., Kunisue, T., Libelo, E.L., Tanabe, S., Kannan, K. (2008b). Perfluorinated compounds in human breast milk from several Asian countries, and in infant formula and dairy milk from the United States. *Environ. Sci. Technol.* 42: 8597-8602.
- Tardiff, R.G., Carson, M.L., Sweeney, L.M., Kirman, C.R., Tan, Y.-M., Andersen, M., Bevan, C., Gargas, M.L. (2009). Derivation of a drinking water equivalent level (DWEL) related to the maximum contaminant level goal for perfluorooctanoic acid (PFOA), a persistent water soluble compound. *Food Chem. Toxicol.* 47: 2557-2589.
- Taylor, K.W., Hoffman, K., Thayer, K.A., Daniels, J.L. (2014). Polyfluoroalkyl chemicals and menopause among women 20-65 years of age (NHANES). *Environ. Health Perspect.* 122: 145- 50.
- Thomford, P.J. (2001a). 4-Week capsule toxicity study with ammonium perfluorooctanoate (APFO) in cynomolgus monkeys. Covance Laboratories Inc., Madison, WI. Covance 6329-230. December 18, 2001.
- Thomford, P.J. (2001b). 26-Week capsule toxicity study with ammonium perfluorooctanoate (APFO) in cynomolgus monkeys. Covance Laboratories Inc., Madison WI. Covance 6329-231. December 18, 2001.
- Thompson, J., Lorber, M., Toms, L. M. L., Kato, K.; Calafat, A. M., Mueller, J. F. (2010). Use of simple pharmacokinetic modeling to characterize exposure of Australians to perfluorooctanoic acid and perfluorooctane sulfonic acid. *Environ. Int.* 36: 390–397.
- Thompson, J., Eaglesham, G., Mueller, J., (2011). Concentrations of PFOS, PFOA and other perfluorinated alkyl acids in Australian drinking water. *Chemosphere* 83: 1320-1325.
- Thomsen, C., Haug, L.S., Stigum, H., Frøshaug, M., Broadwell, S.L., Becher, G. (2010). Changes in concentrations of perfluorinated compounds, polybrominated diphenyl ethers, and polychlorinated biphenyls in Norwegian breast-milk during twelve months of lactation. *Environ. Sci. Technol.* 44: 9550-9556.
- Tilton, S.C., Orner, G.A., Benninghoff, A.D., Carpenter, H.M., Hendricks, J.D., Pereira, C.B., Williams, D.E. (2008). Genomic profiling reveals an alternate mechanism for hepatic tumor promotion by perfluorooctanoic acid in rainbow trout. *Environ. Health Perspect.* 116: 1047-1055.
- Timmermann, C.A., Budtz-Jørgensen, E., Petersen, M.S., Weihe, P., Steuerwald, U., Nielsen, F., Jensen, T.K., Grandjean, P. (2016). Shorter duration of breastfeeding at elevated exposures to perfluoroalkyl substances. *Reprod Toxicol.* (in press).
- Tittlemier, S.A., Pepper, K., Seymour, C., Moisey, J., Bronson, R., Cao, X.L., Dabeka, R.W. (2007). Dietary exposure of Canadians to perfluorinated carboxylates and perfluorooctane sulfonate via consumption of meat, fish, fast foods, and food items prepared in their packaging. *J. Agric. Food Chem.* 18: 3203-3210.
- Toms, L.M., Calafat, A.M, Kato, K., Thompson, J., Harden, F., Hobson, P., Sjödin, A., Mueller, J.F. (2009). Polyfluoroalkyl chemicals in pooled blood serum from infants, children, and adults in Australia. *Environ. Sci. Technol.* 43: 4194-4199.

Trudel, D., Horowitz, L., Wormuth, M., Scheringer, M., Cousins, I.T., Hungerbuheler, K. (2008). Estimating consumer exposure to PFOS and PFOA. *Risk Anal.* 28: 251-269.

Tucker, D. K., Macon, M. B., Strynar, M. J., Dagnino, S., Andersen, E., Fenton, S. E. (2015). The mammary gland is a sensitive pubertal target in CD-1 and C57Bl/6 mice following perinatal perfluorooctanoic acid (PFOA) exposure. *Reprod. Toxicol.* 54: 26-36.

Upham, B.L., Deocampo, N.D., Wurl, B., et al. (1998). Inhibition of gap junctional intercellular communication by perfluorinated fatty acids is dependent on the chain length of the fluorinated tail. *Int. J. Cancer* 78: 491-495.

Upham, B.L., Park, J.S., Babica, P., Sovadinova, I., Rummel, A.M., Trosko, J.E., Hirose, A., Hasegawa, R., Kanno, J., Sai, K. (2009). Structure-activity-dependent regulation of cell communication by perfluorinated fatty acids using in vivo and in vitro model systems. *Environ. Health Perspect.* 117: 545-51.

USEPA (2000). Methodology for Deriving Ambient Water Quality Criteria for the Protection of Human Health. Office of Science and Technology. Office of Water. Washington, DC. EPA 822-B-00-004. October 2000. [http://water.epa.gov/scitech/swguidance/standards/upload/2005\\_05\\_06\\_criteria\\_humanhealth\\_method\\_complete.pdf](http://water.epa.gov/scitech/swguidance/standards/upload/2005_05_06_criteria_humanhealth_method_complete.pdf)

USEPA (2005a). United States Environmental Protection Agency. Draft Risk Assessment of the Potential Human Health Effects Associated with Exposure to Perfluorooctanoic Acid and Its Salts. Office of Pollution Prevention and Toxics, January 4, 2005. <http://www.epa.gov/oppt/pfoa/pubs/pfoarisk.pdf>. Accessed August 16, 2011.

USEPA (2005b). United States Environmental Protection Agency. Guidelines for Carcinogen Risk Assessment. Risk Assessment Forum, USEPA, Washington, DC. EPA/630.P-03/001F, March 2005.

USEPA (2006). United States Environmental Protection Agency. Science Advisory Board Review of EPA's Draft Risk Assessment of Potential Human Health Effects Associated with PFOA and Its Salts, May 30, 2006. [http://www.epa.gov/sab/pdf/sab\\_06\\_006.pdf](http://www.epa.gov/sab/pdf/sab_06_006.pdf). Accessed August 16, 2011.

USEPA (2008a). United States Environmental Protection Agency. Child-Specific Exposure Factors Handbook. EPA/600/R-06/096F. National Center for Environmental Assessment, Washington, DC. September 2008. <http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=199243> Accessed 1/17/12.

USEPA (2008b). Toxicological Review of 2,2',4,4',5-Pentabromodiphenyl Ether (BDE-99) (CAS No. 60348-60-9). June 2008. EPA/635/R-07/006F.

USEPA (2008c). Toxicological Review of 2,2',4,4'-Tetrabromodiphenyl Ether (BDE-47) (CAS No. 5436-43-1). June 2008. EPA/635/R-07/005F.

USEPA (2009a). United States Environmental Protection Agency. Long-Chain Perfluorinated Chemicals (PFCs) Action Plan. Office of Pollution Prevention and Toxics. December 30, 2009.

USEPA (2009b). Provisional Health Advisories for Perfluorooctanoic Acid (PFOA) and Perfluorooctane Sulfonate (PFOS). USEPA Office of Water, Jan. 8, 2009. [http://www.epa.gov/waterscience/criteria/drinking/pha-PFOA\\_PFOS.pdf](http://www.epa.gov/waterscience/criteria/drinking/pha-PFOA_PFOS.pdf)

USEPA (2009c). Toxicological Review of Trichloroethylene (CAS No. 79-01-6) In Support of Summary Information on the Integrated Risk Information System (IRIS), External Review Draft. October 2009. EPA/635/R-09/011A.

USEPA (2011a). United States Environmental Protection Agency. Integrated Risk Information System (IRIS) Glossary. Last updated August 21, 2011. [https://ofmpub.epa.gov/sor\\_internet/registry/termreg/searchandretrieve/glossariesandkeywordlists/search.do?details=&glossaryName=IRIS%20Glossary#formTop](https://ofmpub.epa.gov/sor_internet/registry/termreg/searchandretrieve/glossariesandkeywordlists/search.do?details=&glossaryName=IRIS%20Glossary#formTop) Accessed May 10, 2016.

USEPA (2011b). Exposure Factors Handbook 2011 Edition (Final). U.S. Environmental Protection Agency, Washington, DC, EPA/600/R-09/052F.

USEPA (2012a). United States Environmental Protection Agency. Benchmark Dose Technical Guidance. Risk Assessment Forum. June 2012. EPA/100/R-12/001. [https://www.epa.gov/sites/production/files/2015-01/documents/benchmark\\_dose\\_guidance.pdf](https://www.epa.gov/sites/production/files/2015-01/documents/benchmark_dose_guidance.pdf)

USEPA (2012b). United States Environmental Protection Agency. Revisions to the unregulated contaminant monitoring regulation (UCMR 3) for public water systems, final rule. Fed. Regist. 77, 26072–26101.

USEPA (2012c). United States Environmental Protection Agency. “Preamble to IRIS Toxicological Reviews” in: Toxicological Review of Ammonia (CAS No. 7664-41-7) in Support of Summary Information on the Integrated Risk Information System (IRIS). June 2012. EPA/635/R-11/013A.

USEPA (2014). United States Environmental Protection Agency. Draft Health Effects Document for Perfluorotanoic Acid (PFOA). Office of Water. EPA Document Number: 822R14001. February 2014

USEPA (2016a). United States Environmental Protection Agency. Drinking Water Health Advisory for Perfluorooctanoic Acid (PFOA). Office of Water. EPA 822-R-16-005. May 2016. [https://www.epa.gov/sites/production/files/2016-05/documents/pfoa\\_health\\_advisory\\_final-plain.pdf](https://www.epa.gov/sites/production/files/2016-05/documents/pfoa_health_advisory_final-plain.pdf)

USEPA (2016b). United States Environmental Protection Agency. Office of Pollution Prevention and Toxics. 2010/2015 PFOA Stewardship Program. <https://www.epa.gov/assessing-and-managing-chemicals-under-tsca/20102015-pfoa-stewardship-program> Accessed May 15, 2016.

USEPA (2016c). United States Environmental Protection Agency. Drinking Water Health Advisory for Perfluorooctane Sulfonate (PFOS). Office of Water. EPA 822-R-16-005. May 2016. [https://www.epa.gov/sites/production/files/2016-05/documents/pfos\\_health\\_advisory\\_final\\_508.pdf](https://www.epa.gov/sites/production/files/2016-05/documents/pfos_health_advisory_final_508.pdf)

USEPA (2016d). United States Environmental Protection Agency. Fact Sheet: PFOA & PFOS Drinking Water Health Advisories. Office of Water. May 2016.

USEPA (2016e). United States Environmental Protection Agency. Hoosick Falls, New York. Drinking Water and Groundwater Contamination. Frequently Asked Questions. [https://www.epa.gov/sites/production/files/2016-01/documents/hoosickfalls\\_faqs.pdf](https://www.epa.gov/sites/production/files/2016-01/documents/hoosickfalls_faqs.pdf)

USEPA (2016f). United States Environmental Protection Agency. Occurrence Data for the Unregulated Contaminant Monitoring Rule. Data posted through January 2016. <https://www.epa.gov/dwucmr/occurrence-data-unregulated-contaminant-monitoring-rule> Accessed March 3, 2016.

USEPA (2016f). United States Environmental Protection Agency. Health Effects Support Document for Perfluorooctanoic Acid (PFOA). Office of Water. EPA 822-R-16-003. May 2016. [https://www.epa.gov/sites/production/files/2016-05/documents/pfoa\\_hesd\\_final\\_508.pdf](https://www.epa.gov/sites/production/files/2016-05/documents/pfoa_hesd_final_508.pdf)

Vaalgamaa, S., Vähätalo, A.V., Perkola, N., Huhtala, S. (2011). Photochemical reactivity of perfluorooctanoic acid (PFOA) in conditions representing surface water. *Sci. Total Environ.* 409: 3043-3048.

van Esterik, J.C., Sales, L.B., Dollé, M.E., Håkansson, H., Herlin, M., Legler, J., van der Ven, L.T. (2016). Programming of metabolic effects in C57BL/6JxFVB mice by in utero and lactational exposure to perfluorooctanoic acid. *Arch. Toxicol.* 90: 701-15.

Vanden Heuvel, J.P., Kuslikis, B.I., Van Rafelghem, M.J., Peterson, RE. (1991). Tissue distribution, metabolism, and elimination of perfluorooctanoic acid in male and female rats. *J. Biochem. Toxicol.* 6: 83-92.

Vanden Heuvel, J. P., Thompson, J. T., Frame, S. R., Gillies, P. J. (2006). Differential activation of nuclear receptors by perfluorinated fatty acid analogs and natural fatty acids: a comparison of human, mouse, and rat peroxisome proliferator-activated receptor- $\alpha$ , - $\beta$ , and - $\gamma$ , liver X receptor- $\beta$ , and retinoid X receptor- $\alpha$ . *Toxicol. Sci.* 92: 476-489.

Vermont DEC (2016a). Vermont Department of Environmental Conservation. Environmental Protection Rules. Chapter 12. Groundwater Protection Rule and Strategy. Adopted: December 16, 2016. [http://dec.vermont.gov/sites/dec/files/documents/2016\\_12\\_16\\_GWPR%26Sadopted.pdf](http://dec.vermont.gov/sites/dec/files/documents/2016_12_16_GWPR%26Sadopted.pdf)

Vermont DEC (2016b). Vermont Department of Environmental Conservation. Environmental Protection Rules. Chapter 21. Water Supply Rule. Original Effective Date: September 24, 1992. Revision Date: December 1, 2010

Vermont DOH (2016). Vermont Department of Health. Memorandum from Sarah Vose to Chuck Schwer, Vermont DEC. <http://dec.vermont.gov/sites/dec/files/documents/2016.03.16.PFOA-interim-groundwater-enforcement-standard-1.pdf>

Verner, M.-A., Loccisano, A. E., Morken, N.-H., Yoon, M., Wu, H., McDougall, R., Maisonet, M., Marcus, M., Kishi, R., Miyashita, C., Chen, M.-H., Hsieh, W.-S., Andersen, M. E., Clewell, H. J., Longnecker, M. P. (2015). Associations of perfluoroalkyl substances (PFAS) with lower birth weight: an evaluation of potential confounding by glomerular filtration rate using a physiologically based pharmacokinetic model (PBPK). *Environ. Health Perspect.* 123: 1317-1324.

Verner, M.A., Ngueta, G., Jensen, E.T., Fromme, H., Völkel, W., Nygaard, U.C., Granum, B., Longnecker, M.P. (2016a). A simple pharmacokinetic model of prenatal and postnatal exposure to perfluoroalkyl substances (PFASs). *Environ. Sci. Technol.* 50: 978-86.

Verner, M.A., Ngueta, G., Jensen, E.T., Fromme, H., Völkel, W., Nygaard, U.C., Granum, B., Longnecker, M.P. (2016b). Correction to A Simple Pharmacokinetic Model of Prenatal and Postnatal Exposure to Perfluoroalkyl Substances (PFASs). *Environ. Sci. Technol.* 50:5420-1.

Vestergren, R., Cousins, I.T. (2009). Tracking the pathways of human exposure to perfluorocarboxylates. *Environ. Sci. Technol.* 43: 5565-5575.

Vesterinen, H. M., Johnson, P. I., Atchley, D. S., Sutton, P., Lam, J., Zlatnik, M. G., Sen, S., Woodruff, T. J. (2015). Fetal growth and maternal glomerular filtration rate: a systematic review. *J. Matern. Fetal Neonatal Med.* 28: 2176-2181.

Vieira, V. M., Hoffman, K., Shin, H. M., Weinberg, J. M., Webster, T. F., Fletcher, T. (2013). Perfluorooctanoic acid exposure and cancer outcomes in a contaminated community: a geographic analysis. *Environ. Health Perspect.* 121: 318-323.

von Ehrenstein, O.S., Fenton, S.E., Kato, K., Kuklennyik, Z., Calafat, A.M., Hines, E.P. (2009). Polyfluoroalkyl chemicals in the serum and milk of breastfeeding women. *Reprod. Toxicol.* 27: 239-245.

Wagner, A.M., Sánchez-Quesada, J.L., Benítez, S., Bancells, C., Ordóñez-Llanos, J., Pérez (2011). Effect of statin and fibrate treatment on inflammation in type 2 diabetes. A randomized, cross-over study. *Diabetes Res. Clin. Pract.* 93: e25-8.

Walters, M. W., Bjork, J. A., Wallace, K. B. (2009). Perfluorooctanoic acid stimulated mitochondrial biogenesis and gene transcription in rats. *Toxicology* 264: 10-15.

Wang, M., Park, J.S., Petreas, M. (2011a). Temporal changes in the levels of perfluorinated compounds in California women serum over the past 50 years. *Environ. Sci. Technol.* 45: 7510-7516.

Wang, J., Zhang, Y., Zhang, W., Jin, Y., Dai, J. (2012). Association of perfluorooctanoic acid with HDL cholesterol and circulating miR-26b and miR-199-3p in workers of a fluorochemical plant and nearby residents. *Environ. Sci. Technol.* 46: 9274-9281.

Wang, L., Wang, Y., Liang, Y., Li, J., Liu, Y., Zhang, J., Zhang, A., Fu, J., Jiang, G. (2013). Specific accumulation of lipid droplets in hepatocyte nuclei of PFOA-exposed BALB/c mice. *Sci. Rep.* 3: 2174.

- Wang, Y., Rogan, P. C., Chen, G. W., Lien, H. Y., Chen, Y. C., Tseng, M. P., Longnecker, Wang, S. L. (2014). Association between maternal serum perfluoroalkyl substances during pregnancy and maternal and cord thyroid hormones: Taiwan maternal and infant cohort study. *Environ. Health Perspect.* 122: 529-534.
- Washburn, S.T., Bingman, T.S., Braithwaite, S.K., Buck, R.C., Buxton, L.W., Clewell, H.J., Haroun, L.A., Kester, J.E., Rickard, R.W., Shipp, A.M. (2005). Exposure assessment and risk characterization for perfluorooctanoate in selected consumer articles. *Environ. Sci. Technol.* 39: 3904-3910.
- Washington, J.W., Ellington, J., Jenkins, T.M., Evans J.J., Yoo, H., Hafner, S.C. (2009). Degradability of an acrylate-linked, fluorotelomer polymer in soil. *Environ. Sci. Technol.* 43: 6617-6623.
- Weaver, Y.M., Ehresman, D.J., Butenhoff, J.L., Hagenbuch, B. (2010). Roles of rat renal organic anion transporters in transporting perfluorinated carboxylates with different chain lengths. *Toxicol. Sci.* 113: 305-314.
- Wang, Y., Rogan, W. J., Chen, P. C., Lien, G. W., Chen, H. Y., Tseng, Y. C., Longnecker, M. P., Wang, S. L. (2014). Association between maternal serum perfluoroalkyl substances during pregnancy and maternal and cord thyroid hormones: Taiwan maternal and infant cohort study. *Environ. Health Perspect.* 122: 529-534.
- Wei, Y., Dai, J., Liu, M., Wang, J., Xu, M., Zha, J., Wang, Z. (2007). Estrogen-like properties of perfluorooctanoic acid as revealed by expressing hepatic estrogen-responsive genes in rare minnows (*Gobiocypris rarus*). *Environ. Toxicol. Chem.* 26: 2440-2447.
- Wen, L. L., Lin, L. Y., Su, T. C., Chen, P. C., Lin, C. Y. (2013). Association between serum perfluorinated chemicals and thyroid function in U.S. adults: the National Health and Nutrition Examination Survey 2007-2010. *J. Clin. Endocrinol. Metab.* 98: E1456-1464.
- White, S.S., Calafat, A.M., Kuklennyik, Z., Villanueva, L., Zehr, R.D., Helfant, L., Strynar, M.J., Lindstrom, A.B., Thibodeaux, J.R., Wood, C., Fenton, S.E. (2007). Gestational PFOA exposure of mice is associated with altered mammary gland development in dams and female offspring. *Toxicol. Sci.* 96: 133-144.
- White, S.S., Kato, K., Jia, L.T., Basden, B.J., Calafat, A.M., Hines, E.P., Stanko, J.P., Wolf, C.J., Abbott, B.D., Fenton, S.E. (2009). Effects of perfluorooctanoic acid on mouse mammary gland development and differentiation resulting from cross-foster and restricted gestational exposures. *Reprod. Toxicol.* 27: 289-298.
- White, S.S., Fenton, S.E., Hines, E.P. (2011a). Endocrine disrupting properties of perfluorooctanoic acid. *J. Steroid Biochem.* 127: 16-26.
- White, S.S., Stanko, J.P., Kato, K., Calafat, A.M., Hines, E.P., Fenton, S.E. (2011b). Gestational and chronic low-dose PFOA exposures and mammary gland growth and differentiation in three generations of CD-1 Mice. *Environ. Health Perspect.* 119: 1070-1076.
- Winqvist, A., Steenland, K. (2014a). Modeled PFOA exposure and coronary artery disease, hypertension, and high cholesterol in community and worker cohorts. *Environ. Health Perspect.* 122: 1299-1305.
- Winqvist, A., Steenland, K. (2014b). Perfluorooctanoic acid exposure and thyroid disease in community and worker cohorts. *Epidemiology* 25: 255-264.
- Wolf, C.J., Fenton, S.E., Schmid, J.E., Calafat, A.M., Kuklennyik, Z., Bryant, X.A., Thibodeaux, J., Das, K.P., White, S.S., Lau, C.S., Abbott, B.D. (2007). Developmental toxicity of perfluorooctanoic acid in the CD-1 mouse after cross-foster and restricted gestational exposures. *Toxicol. Sci.* 95: 462-473.
- Wolf, C.J., Zehr, R.D., Schmid, J.E., Lau, C., Abbott, B.D. (2010). Developmental effects of perfluorononanoic acid in the mouse are dependent on peroxisome proliferator-activated receptor-alpha. *PPAR Res.* 2010, pii: 282896.



- Wolf, C.J., Schmid, J.E., Lau, C., Abbott, B.D. (2012). Activation of mouse and human peroxisome proliferator-activated receptor-alpha (PPAR $\alpha$ ) by perfluoroalkyl acids (PFAAs): Further investigation of C4-C12 compounds. *Reprod Toxicol.* 33: 546-551.
- Wolf, D.C., Moore, T., Abbott, B.D., Rosen, M.B., Das, K.P., Zehr, R.D., Lindstrom, A.B., Strynar, M.J., Lau, C. (2008). Comparative hepatic effects of perfluorooctanoic acid and WY 14,643 in PPAR-alpha knockout and wild-type mice. *Toxicol. Pathol.* 36: 632-639.
- Woodruff, T.J. and Sutton, P. (2014). The Navigation Guide systematic review methodology: a rigorous and transparent method for translating environmental health science into better health outcomes. *Environ. Health Perspect.* 122:1007–1014.
- Yahia, D., El-Nasser, M. A., Abedel-Latif, M., Tsukuba, C., Yoshida, M., Sato, I., Tsuda, S., (2010). Effects of perfluorooctanoic acid (PFOA) exposure to pregnant mice on reproduction. *J Toxicol. Sci.* 35: 527-533.
- Yamaguchi, M., Arisawa, K., Uemura, H., Katsuura-Kamano, S., Takami, H., Sawachika, F., Nakamoto, M., Juta, T., Toda, E., Mori, K., Hasegawa, M., Tanto, M., Shima, M., Sumiyoshi, Y., Morinaga, K., Kodama, K., Suzuki, T., Nagai, M., Satoh, H. (2013). Consumption of seafood, serum liver enzymes, and blood levels of PFOS and PFOA in the Japanese population. *J. Occup. Health* 55: 184-194.
- Yan, S., Wang, J., Zhang, W., Dai, J. (2014). Circulating microRNA profiles altered in mice after 28 d exposure to perfluorooctanoic acid. *Toxicol. Lett.* 224: 24-31.
- Yang, Q., Xie, Y. Depierre, W. (2000). Effects of peroxisome proliferators in the thymus and spleen of mice. *Clin. Exp. Immunol.* 122: 219-226.
- Yang, Q., Abedi-Valugerdi, M., Xie, Y., Zhao, X., Moller, G., Nelson, B.D., DePierre, J.W. (2002a). Potent suppression of the adaptive immune response in mice upon dietary exposure to the potent peroxisome proliferator, perfluorooctanoic acid. *Internat. Immunopharmacol.* 2: 389-397.
- Yang, Q., Xie, Y., Alexson, S. E., Nelson, B. D. DePierre, J. W. (2002b). Involvement of the peroxisome proliferator-activated receptor alpha in the immunomodulation caused by peroxisome proliferators in mice. *Biochem. Pharmacol.* 63: 1893-1900.
- Yang, Q., Kurotani, R., Yamada, A., Kimura, S., Gonzalez, F.J. (2006). Peroxisome proliferator-activated receptor alpha activation during pregnancy severely impairs mammary lobuloalveolar development in mice. *Endocrinology* 147: 4772-4780.
- Yang, C., Tan, Y.S., Harkema, J.R., Haslam, S.Z. (2009a). Differential effects of peripubertal exposure to perfluorooctanoic acid on mammary gland development in C57Bl/6 and Balb/c mouse strains. *Reprod. Toxicol.* 27: 299-306.
- Yang, C. H., Glover, K. P., Han, X. (2009b). Organic anion transporting polypeptide (Oatp) 1a1-mediated perfluorooctanoate transport and evidence for a renal reabsorption mechanism of Oatp1a1 in renal elimination of perfluorocarboxylates in rats. *Toxicol. Lett.* 190: 163-171.
- Yang, C. H., Glover, K. P., Han, X. (2010). Characterization of cellular uptake of perfluorooctanoate via organic anion-transporting polypeptide 1A2, organic anion transporter 4, and urate transporter 1 for their potential roles in mediating human renal reabsorption of perfluorocarboxylates. *Toxicol. Sci.* 117: 294-302.
- Yang, B., Zou, W., Hu, Z., Liu, F., Zhou, L., Yang, S., Kuang, H., Wu, L., Wei, J. Wang, J., Zou, T., Zhang, D. (2014). Involvement of oxidative stress and inflammation in liver injury caused by perfluorooctanoic acid exposure in mice. *Biomed. Res. Int.* 2014: 409837.
- Yao, X., Zhong, L. (2005). Genotoxic risk and oxidative DNA damage in HepG2 cells exposed to perfluorooctanoic acid. *Mutat. Res.* 587: 38-44.

Yao, P. L., Ehresman, D. J., Rae, J. M., Chang, S. C., Frame, S. R., Butenhoff, J. L., Kennedy, G. L., Peters, J. M. (2014). Comparative in vivo and in vitro analysis of possible estrogenic effects of perfluorooctanoic acid. *Toxicology* 326: 62-73.

Ylinen, M., Kojo, A., Hanhijdrvi, H., Peura, P. (1990). Disposition of perfluorooctanoic acid in the rat after single and subchronic administration. *Bull. Environ. Contam. Toxicol.* 44: 46-53.

Yoo, H., Washington, J.W., Jenkins, T.M., Ellington, J.J. (2011). Quantitative determination of perfluorochemicals and fluorotelomer alcohols in plants from biosolid-amended fields using LC/MS/MS and GC/MS. *Environ. Sci. Technol.* 45: 7985-7990.

York, R.G. (2002). Oral (gavage) two-generation (one litter per generation) reproduction study of ammonium perfluorooctanoic (APFO) in rats. Argus Research Laboratories, Inc. Protocol Number: 418-020, Sponsor Study Number: T-6889.6, March 26, 2002. USEPA AR226-1092.

Zeng, X. W., Qian, Z., Emo, B., Vaughn, M., Bao, J., Qin, X. D., Zhu, Y., Li, J., Lee, Y. L., Dong, G. H. (2015). Association of polyfluoroalkyl chemical exposure with serum lipids in children. *Sci. Total Environ.* 512-513: 364-370.

Zhang, T., Sun, H., Lin, Y., Wang, L., Zhang, X., Liu, Y., Geng, X., Zhao, L., Li, F., Kannan, K. (2011). Perfluorinated compounds in human blood, water, edible freshwater fish, and seafood in China: daily intake and regional differences in human exposures. *J. Agric. Food Chem.* 59: 11168-11176.

Zhang, Y., Beesoon, S., Zhu, L., Martin, J.W. (2013). Biomonitoring of perfluoroalkyl acids in human urine and estimates of biological half-life. *Environ. Sci. Technol.* 47: 10619-27.

Zhang, H., Lu, Y., Luo, B., Yan, S., Guo, X., Dai, J. (2014). Proteomic analysis of mouse testis reveals perfluorooctanoic acid-induced reproductive dysfunction via direct disturbance of testicular steroidogenic machinery. *J. Proteome Res.* 13: 3370-85.

Zhao, Y., Tan, Y.S., Haslam, S.Z., Yang, C. (2010). Perfluorooctanoic acid effects on steroid hormone and growth factor levels mediate stimulation of peripubertal mammary gland development in C57BL/6 mice. *Toxicol. Sci.* 115: 214-224.

Zhao, Y., Tan, Y. S., Strynar, M. J., Perez, G., Haslam, S. Z., Yang, C. (2012). Perfluorooctanoic acid effects on ovaries mediate its inhibition of peripubertal mammary gland development in Balb/c and C57Bl/6 mice. *Reprod. Toxicol.* 33: 563-576.



**APPENDICES TO**  
**HEALTH-BASED MAXIMUM CONTAMINANT LEVEL**  
**SUPPORT DOCUMENT:**  
**PERFLUOROCTANOIC ACID (PFOA)**

**New Jersey Drinking Water Quality Institute**  
**Health Effects Subcommittee**  
**February 15, 2017**

***Subcommittee Members:***  
**Jessie A. Gleason, M.S.P.H., Chair**  
**Keith R. Cooper, Ph.D.**  
**Judith B. Klotz, M.S., Dr.P.H.**  
**Gloria B. Post, Ph.D., DABT**  
**George Van Orden, Ph.D.**

**TABLE OF CONTENTS**

Appendix 1 - Literature Search Criteria and Documentation – PFOA.....3

Appendix 2 – Comparison of USEPA Office of Water Health Advisory and DWQI recommended Health-based MCL for PFOA.....5

Appendix 3 - Risk Assessment Considerations for Butenhoff et al. (2002) Subchronic Cynomolgus Monkey Study.....18

Appendix 4 - Individual Tables for Epidemiology Studies.....21

Appendix 5 - Individual Tables for Toxicology Studies.....78


Appendix 6- Outputs of Benchmark Dose Modeling for Mammary Gland Development Endpoints .....112

Appendix 7 - Benchmark Dose Analysis of Relative Liver Weight in Response to PFOA (Linear/Branched) using BMR of 10% Increase Relative to Controls .....162

Appendix 8 - Benchmark dose analysis of testicular tumor data in response to PFOA using BMR of 5% tumor incidence .....176

## APPENDIX 1. Literature Search Criteria and Documentation - PFOA

1159 citations (2010 to present) and 857 citations (pre-2010) from PubMed (April 13, 2015): search "(pfoa OR (PFO AND (perfluoroalk\* OR perfluorocarb\* OR perfluorinat\* OR perfluoroc\*)) OR (C8 AND (perfluoroalk\* OR perfluorocarb\* OR perfluorinat\* OR perfluoroc\*)) OR apfo OR (perfluorooctanoic AND acid) OR (pentadecafluorooctanoic AND acid) OR (perfluoroheptanecarboxylic AND acid) OR (ammonium AND perfluorooctanoate) OR (ammonium AND pentadecafluorooctanoate) OR (fluorad) OR (ammonium AND perfluorocaprilate) OR (pentadecafluorooctanoic AND acid AND ammonium AND salt) OR (sodium AND perfluorooctanoate) OR (sodium AND pentadecafluorooctanoate) OR (sodium AND perfluorocaprylate) OR (perfluorooctanoic AND acid AND sodium AND salt) OR (potassium AND perfluorooctanoate) OR (potassium AND perfluoroacrylate) OR (perfluorooctanoic AND acid AND potassium AND salt) OR FC-143 OR (335-67-1[EC/RN Number]) OR (3825-26-1[EC/RN Number]) OR (335-95-5[EC/RN Number]) OR (2395-00-8[EC/RN Number])"; Limits: none



<sup>1</sup>Totals exceed number of imported files if articles are placed into more than one category. Additional studies were added via backward searching, relevant citations from earlier review by the Health Effects Subcommittee, and article title review of monthly PubMed key word searches.

<sup>2</sup>Title and/or abstract review

<sup>3</sup>Abstracts and/or text reviewed to be sorted into selected endpoints.

<sup>4</sup>Authors evaluated full text of each article to determine whether mammalian toxicology or human health effects were investigated in studies.

<sup>5</sup>This number does not represent unique studies.

<sup>6</sup>Some studies in this category are discussed in the text and others are not.

<sup>7</sup>Studies included in summary tables and/or individual study tables.

## APPENDIX 2: Comparison of USEPA Office of Water Health Advisory and DWQI recommended Health-based MCL for PFOA

The basis for the USEPA (2016a) Health Advisory and the recommended DWQI Health-based MCL, and other relevant information about these two drinking water values, are compared in the table below. Additional information is provided in the text that follows the table.

Parameter	USEPA Office of Water Health Advisory	DWQI Recommended Health-based MCL
<i>Value</i>	70 ng/L	14 ng/L
<i>General statement</i>	<p>“Protects the most sensitive populations, with a margin of protection from a lifetime of exposure.”</p>	<p>“Developed using a risk assessment approach intended to be protective for chronic (lifetime) exposure.”</p>
	<p>As discussed in this document, PFOA is associated with several human health effects, some with evidence supporting multiple criteria for causality, within the general population exposure range even without additional exposure from drinking water. Furthermore, the Reference Dose (RfD) for mammary gland effects in mice is below the average exposure level in the general population, and other toxicological effects occurred at similarly low doses in animal studies. Therefore, the Health Effects Subcommittee concluded that additional exposure from drinking water may potentially pose some risk of health effects. For this reason, it cannot be definitively concluded that lifetime exposure to these drinking water concentrations is protective of sensitive subpopulations with a margin of exposure.</p> <p>USEPA recognizes that human studies provide evidence of associations of several health effects with PFOA. However, USEPA concludes that the human studies do not provide quantitative information on the exposure levels or serum levels associated with these health effects. Therefore, USEPA did not consider the possibility that health effects may result from exposures within the general population range, even with no additional exposure from drinking water. USEPA also dismissed the low dose toxicological effects in animal studies from consideration in risk assessment. See discussion of these points below.</p>	

Parameter (cont.)	USEPA (cont.)	DWQI (cont.)
Reference Dose (RfD)	20 ng/kg/day	2 ng/kg/day
	<ul style="list-style-type: none"> <li>Based on delayed ossification of phalanges and accelerated male puberty after developmental exposures to mice (Lau et al., 2006).</li> <li>Data do not follow typical dose-response of greater response as dose increases. (See figures below.) An uncertainty factor of 10 was applied for LOAEL-to-NOAEL extrapolation. The basis and precedent for this approach with dose-response curves of this type is uncertain and may be subject to debate.</li> </ul>	Based on Benchmark Dose modeling of increased liver weight in mice, with additional uncertainty factor for more sensitive developmental effects at much lower doses (delayed mammary gland development, persistent liver toxicity, and others).
Interspecies conversion in RfD development	Note: USEPA and DWQI RfDs are <b>identical numerically</b> , with the exception of application of an additional uncertainty factor of 10 in the DWQI RfD to account for more sensitive developmental endpoints. These more sensitive endpoints were not considered in development of the USEPA RfD. Issues related to endpoints selected as the basis for RfDs by DWQI and USEPA are further discussed below.	
	Pharmacokinetic modeling was used to predict average serum PFOA concentrations at the NOAELs and/or LOAELs in toxicological studies. A clearance factor that relates serum PFOA level to human administered dose (applicable to serum PFOA data from any species) was used to obtain the Human Equivalent Doses (HEDs) at the modeled average serum levels. Uncertainty factors were applied to the HEDs to obtain potential RfDs.	Benchmark Dose modeling was performed on measured serum PFOA concentrations at each dose from the end of the dosing period to derive a serum level Benchmark Dose (BMD). This approach has less uncertainty than use of modeled serum PFOA data. Uncertainty factors were applied to the BMD serum level to obtain the Target Human Serum Level (i.e. the RfD in terms of serum PFOA level). The same clearance factor used by USEPA was applied to the Target Human Serum Level to obtain the RfD.

<b>Parameter (cont.)</b>	<b>USEPA (cont.)</b>	<b>DWQI (cont.)</b>
<i>Drinking water concentration estimated to result in one in one million (<math>10^{-6}</math>) lifetime cancer risk</i>	500 ng/L. Predicted risk at this concentration based on the DWQI evaluation is about $4 \times 10^{-5}$ (i.e. 40-fold higher than 1 in 1 million).	14 ng/L (Identical to the value based on non-cancer effects)
	USEPA and DWQI cancer assessments are both based on increased incidence of testicular tumors in a chronic rat study (Butenhoff et al., 2012), and the Benchmark Doses developed by USEPA and DWQI for these tumors are almost identical. The two assessments differ in the approach used for animal-to-human conversion. DWQI used the ratio of half-lives to account for interspecies pharmacokinetic differences, since serum PFOA data are not provided in this study. Although USEPA considered interspecies pharmacokinetic differences in animal-to-human conversion for non-cancer effects, the default animal-to-human extrapolation (ratio of body weights to the $\frac{3}{4}$ power) was used by USEPA for cancer risk assessment. This default approach does not account for interspecies pharmacokinetic differences. USEPA's use of an approach that does not account for pharmacokinetic differences for cancer risk assessment, although pharmacokinetic differences were considered for non-cancer risk assessment, does not appear to be logical or consistent.	
<i>Relative Source Contribution Factor</i>	20%. To account for non-drinking water exposures.	20%. To account for non-drinking water exposures. Also implicitly accounts for greater exposures to breastfed and formula fed infants than older individuals.
<i>Assumed Drinking Water Consumption</i>	0.054 L/kg/day. Based on 90 <sup>th</sup> percentile for lactating woman.  USEPA also developed an alternative Health Advisory of 100 ng/L that applies to adults in the general population based on standard adult exposure assumptions (2.5 L/day water consumption; 80 kg body weight). More information is provided below under <u>Sensitive Subpopulations</u> .	0.029 L/kg/day. Based on default upper percentile adult exposure assumptions (2 L/day water consumption, 70 kg body weight).



Parameter (cont.)	USEPA (cont.)	DWQI (cont.)
<p><i>Increase in serum PFOA concentration predicted from ongoing exposure to USEPA Health Advisory and DWQI recommended Health-based MCL (see <a href="#">bar graph</a> below)</i></p>	<ul style="list-style-type: none"> <li>• With average water consumption: 8.0 ng/ml; 4.8-fold increase from U.S. general population median of 2.1 ng/ml (CDC, 2015).</li> <li>• With upper percentile water consumption: 14 ng/ml; 7.7-fold increase from U.S. general population median.</li> </ul> <p>Note: A clearance factor that relates human PFOA exposures to human PFOA serum levels was developed by USEPA scientists (Lorber and Egeghy, 2011). This factor can be used to predict increases in serum PFOA from drinking water exposures. Although this factor was used in another part of the USEPA (2016a) assessment (to convert serum levels from laboratory animals to human doses, discussed above), USEPA does not acknowledge that it is possible to predict the increase in serum PFOA that will result from ongoing exposure to a given concentration of PFOA in drinking water (ASDWA, 2016; USEPA, 2016c; USEPA, 2016d).</p>	<ul style="list-style-type: none"> <li>• With average water consumption: 1.6 ng/ml; 1.8-fold increase from U.S. general population median.</li> <li>• With upper percentile water consumption: 2.8 ng/ml; 2.3-fold increase from U.S. general population median.</li> </ul>
<p><i>Sensitive Subpopulations</i></p>	<p>Pregnant and lactating women; bottle fed infants.</p> <p>USEPA does not include women who plan to become pregnant in its definition of sensitive subpopulations, but states that states may choose to expand the sensitive subgroups to include women of child-bearing age (ASDWA, 2016). This exclusion does not appear to be supportable because the body burden of PFOA remains elevated for many years after exposure ceases. Therefore, if body burden is elevated prior to pregnancy, it will remain elevated during pregnancy and lactation.</p> <p>USEPA (2016a) also calculated a lifetime HA value for alternative exposure scenarios for the general population (adults age 21 and older) of 100 ng/L based on standard adult exposure assumptions. USEPA states that the Lifetime Health Advisory of 70 ng/L is protective for effects other than developmental toxicity, such as testicular and kidney cancer, liver damage, and immune effects.</p> <p>However, it has been reported in the news media that some states have interpreted the USEPA designation of sensitive subgroups to mean that those not in these sensitive subpopulations may continue to drink water exceeding the USEPA Health Advisory (e.g. WAAYTV, 2016).</p>	<p>As is the case for all Health-based MCLs developed by the DWQI, the Health-based MCL recommended for PFOA is intended to be protective of all individuals, including sensitive subpopulations.</p> <p>Sensitive subpopulations for health effects of PFOA include women who plan to become pregnant, pregnant women, lactating women, and breast-fed and bottle-fed infants.</p>

Endpoints used as basis of DWQI recommended Health-based MCL

The primary basis for the recommended Health-based MCL is an RfD based on increased relative liver weight in mice (Loveless et al., 2006). As discussed elsewhere in this document, the Health Effects Subcommittee conducted an extensive and detailed review of the hepatic effects of PFOA. It was concluded that increased relative liver weight in animal studies is a sensitive and well established effect of PFOA which is accompanied by and/or can progress to more severe forms of liver toxicity, and that it should be considered relevant to humans. Additionally, human exposure to PFOA in the general population and in communities with contaminated drinking water is associated with increased serum levels of liver enzymes, strongly suggesting that low exposures to PFOA affect liver function in humans.

The Health Effects Subcommittee also conducted an extensive review of delayed mammary gland development in mice from developmental exposure to PFOA. This effect was observed in 9 separate studies from 5 publications and follows a typical (monotonic) dose-response curve, with greater effects at higher doses. The Health Effects Subcommittee concluded that this effect is adverse, results in persistent structural changes that are considered to be permanent, and should be considered relevant to humans. Additionally, recent human studies (Fei et al., 2010; Romano et al., 2016; Timmermann et al., 2016) suggest an association of PFOA exposure with decreased duration of breast feeding, an effect which may potentially be relevant to effects on mammary gland development.

The Health Effects Subcommittee developed an RfD for delayed mammary gland development (Macon et al., 2011) based on the Benchmark Dose presented in Post et al. (2012). A Health-based MCL based on this RfD would be 1 ng/L or less. The Health Effects Subcommittee chose not to use this RfD as the basis for a recommended Health-based MCL, not because of uncertainty about the scientific validity of doing so, but rather because of lack of precedent for use of this endpoint as the primary basis for health-based criteria for environmental contaminants. However, the Health Effects Subcommittee concluded that an additional uncertainty factor to protect for developmental effects (delayed mammary gland development; persistent liver toxicity) at much lower doses than those that caused increased liver weight should be incorporated into the RfD.

USEPA (2016a) provides a detailed summary of studies of mammary gland development in mice but chose not to consider this effect in risk assessment. The reasons provided by USEPA for not considering this endpoint (mode of action not known, effects occurred only at higher doses in a second strain of mice, functional significance is unclear) do not appear to be scientifically valid and/or are also equally or more applicable to the endpoints selected by USEPA as the basis for its Health Advisory (discussed further below in the section on Endpoints used as basis of EPA Health Advisory).

In regard to the issue of strain difference in susceptibility, it should be noted that almost all of the studies of developmental exposures to PFOA and mammary gland development were conducted in CD-1 mice. A second strain of mice (C57/B16) was included in only one study in which a very small number of mice of this strain were used in each dose group (Tucker et al., 2015). USEPA (2016a) does not discuss that the higher LOAEL for effects on the mammary gland in C57B1/6 mice as compared to CD-1 mice may potentially be explained by pharmacokinetic

differences (lower serum PFOA concentrations from the same dose of PFOA in the C57/B16 strain) and/or the very small number of C57/B16 mice per dose group, limiting the ability to achieve statistical significance (Tucker et al., 2015).

The Health Effects Subcommittee also considered persistent liver toxicity from developmental exposures to very low doses of PFOA (Quist et al., 2015). Although these effects cannot be used as the basis for an RfD because the serum PFOA data needed for dose-response modeling are not provided, they give further indication of effects at much lower doses than those that cause increased liver weight, the primary basis for the recommended RfD. The low doses at which these persistent hepatic effects from developmental exposures occurred were not considered by USEPA in developing its Health Advisory.

#### Endpoints used as basis of USEPA Health Advisory


The USEPA Health Advisory is based on an RfD for delayed ossification (conversion of cartilage to bone during development) of proximal phalanges and accelerated male puberty in offspring in a developmental study of CD-1 mice (Lau et al., 2006).

USEPA states that these effects have lifelong consequences. However, delayed ossification in Lau et al. (2006) represents a delay in timing of development rather than a permanent structural change, because the phalanges developed normally in mice treated with PFOA that were not sacrificed prior to delivery in this study (personal communication with C. Lau). Therefore, the long term consequences and functional significance of this effect are unclear. Similarly, the long term consequences and functional significance of accelerated puberty are unclear. This is particularly noteworthy because one of the reasons provided by USEPA for not considering delayed mammary gland development in risk assessment is that its functional significance is unclear, although developmental exposures to PFOA cause structural and/or histopathological changes that persist until adulthood in the mammary gland.

In regard to differences in strain sensitivity, there is a major difference in sensitivity to effects of gestational PFOA exposure on delayed ossification in ICR mice (Yahia et al., 2010) as compared to the CD-1 mice used by Lau et al. (2006). The LOAEL (10 mg/kg/day) and NOAEL (5 mg/kg/day) for delayed ossification in the ICR mice were much higher than the LOAEL (1 mg/kg/day) in CD-1 mice. In ICR mice, delayed ossification occurred only at a dose at or above the doses that caused maternal toxicity, decreased fetal weight, and decreased pup survival; no pups survived until 4 days of age at 10 mg/kg/day, the LOAEL for delayed ossification. This large difference in strain sensitivity is especially noteworthy because one of USEPA's reasons for dismissing effects on mammary gland development for consideration in risk assessment is the strain difference observed by Tucker et al. (2015), which may be explained by factors other than differences in intrinsic sensitivity (discussed above).

Accelerated puberty in male animals has not been reported in studies of PFOA other than Lau et al. (2006). To the knowledge of the Health Effects Subcommittee, this effect was not assessed in developmental studies of mice other than Lau et al. (2006). Timing of puberty in offspring was assessed in a two generation rat study (Butenhoff et al., 2004), and accelerated puberty was not observed in male offspring in this study.

The endpoints selected by USEPA (2016a) as the basis for the Health Advisory do not follow a typical (monotonic) dose-response in which greater effects occur with increasing dose (see graphs of data from Lau et al., 2006, below). In Lau et al. (2006), delayed ossification occurred at the lowest dose (1 mg/kg/day) but was not significantly increased at some of the higher doses. Acceleration of puberty in males in Lau et al. (2006) was greatest at the lowest dose (1 mg/kg/day), with a lesser effect with each increasing dose, and puberty was delayed rather than accelerated at the highest dose. USEPA (2016a) did not mention the shapes of these dose-response curves in its discussions of these endpoints. They considered the lowest dose to be the LOAEL for both of these effects and applied an uncertainty factor of 10 for extrapolation from LOAEL-to-NOAEL. However, the Health Effects Subcommittee is not aware of any precedent for use of an uncertainty factor for extrapolation from LOAEL-to-NOAEL for these types of dose response curves. The basis for application of this uncertainty factor, based on the assumption that the NOAEL is 10-fold lower than the lowest dose, is uncertain and may be subject to debate for dose-response curves of this type. In contrast, effects considered by the Health Effects Subcommittee for dose-response modeling (increased relative liver weight and delayed mammary gland development) follow typical monotonic dose-response curves and provide data appropriate for Benchmark Dose modeling.



Finally, the modes of action for delayed ossification and accelerated puberty in males are not known. This is noteworthy because one of the reasons provided by USEPA for not considering effects on mammary gland development in risk assessment is that the mode of action is not known.

#### Consideration of data from human epidemiological studies

As discussed in detail in the Epidemiology section of this document, PFOA is associated with several human health effects, some with evidence supporting multiple criteria for causality, in the general population exposure and in communities with exposure from contaminated drinking water. USEPA (2016a) acknowledges that associations of PFOA and numerous health endpoints

are observed in these human populations and that associations with some effects have consistently been found in multiple human studies.

However, USEPA states that, while these human studies are useful for hazard identification, they cannot be used quantitatively because the PFOA exposures at which the associations were observed are unknown or highly uncertain. Although the Health Effects Subcommittee agrees that the human data have limitations that preclude their use as the primary basis for risk assessment, it does not agree with USEPA that the serum PFOA concentrations and PFOA exposures associated with human health effects are highly uncertain or unknown.

Relevant to this point, it is noted that the German Human Biomonitoring Commission recently developed a Human Biomonitoring Level I (the serum level below which adverse health effects are not expected) for PFOA of 2 ng/ml, close to the current median PFOA serum level in the U.S. general population. This HBM I is based on the serum PFOA levels associated with increased time to pregnancy, decreased fetal growth, increased serum cholesterol, and decreased immune response in humans, and with delayed mammary gland development in mice (Apel et al., 2016).

USEPA (2016a) provides the following reasons for its conclusions:

- Serum levels may have decreased (in both the general population and in communities with drinking water exposure) prior to when the blood sample was taken. Therefore, the effects may have been due to earlier exposures that were higher than indicated by the measured serum PFOA levels.

It is unlikely that this is a major source of uncertainty in evaluation of exposure since PFOA serum levels decrease slowly (half-life of several years) and are generally stable over time. In the C8 Health Study, blood samples were taken before or soon after the installation of treatment to remove PFOA from drinking water. Participants' blood was drawn between August 2005 and August 2006, with over 80% of samples taken in March 2006 or earlier, and treatment removal began between March 2006 and September 2008 (WVU School of Medicine, 2008; Frisbee et al., 2009; Fitz-Simons et al, 2013). Additionally, if effects were actually due to previous exposures that were higher than those at the time of blood sampling, it would mean that the detrimental effects of PFOA are persistent and do not resolve when exposures decrease, which would increase the level of concern about the effects.

- PFOA measured in serum may result from metabolism of precursors to PFOA rather than direct exposure to PFOA itself.

This does not appear to be a valid reason to dismiss consideration of serum PFOA levels as a measure of PFOA exposure. Effects of PFOA would be the same regardless of whether the source of exposure is PFOA itself or metabolism of precursors to PFOA.

- Co-exposure to other PFCs, even if accounted for as a potential confounding factor in the statistical analysis, increase uncertainty about observed associations of health endpoints with PFOA.

However, co-exposure to other chemicals is a general issue for all human studies of exposure to environmental contaminants and does not preclude evaluation of the levels of PFOA exposure associated with health endpoints.




Consideration of increases in serum PFOA levels from exposure to PFOA in drinking water

As noted in the table at the beginning of this Appendix, a clearance factor developed by USEPA scientists (Lorber and Egeghy, 2011) relates human PFOA exposures to human PFOA serum levels. This factor can be used to predict increases in serum PFOA from ongoing drinking water exposures. The bar graph below shows the predicted increases in serum PFOA levels from ongoing exposure in drinking water at the USEPA (2016a) Health Advisory (70 ng/L), the NJDEP (2007) guidance (40 ng/L), and the DWQI recommended Health-based MCL (14 ng/L). Predictions based on both average and upper percentile drinking water ingestion rates are shown.

USEPA (2016a) used the clearance factor to convert NOAEL and LOAEL serum levels from laboratory animals to human equivalent doses (p. 4-13 of USEPA, 2016a) and discusses that it relates human PFOA dose to human PFOA serum level, including from drinking water exposure (p. 2-51 of USEPA, 2016b). However, USEPA does not acknowledge that it is possible to predict increases in serum PFOA levels from exposures to PFOA at 70 ng/L, the Health Advisory concentration (ASDWA, 2016; USEPA, 2016c; USEPA, 2016d). The Health Effects Subcommittee has evaluated this question and concludes that the use of the clearance factor to predict increases in serum PFOA levels from drinking water exposures is technically sound and is not subject to debate.

Several health effects, some with evidence supporting multiple criteria for causality, are associated with PFOA exposures at serum levels well below those that would result from exposure to 70 ng/L in drinking water. The Health Effects Subcommittee therefore concludes that elevations in serum PFOA levels of the magnitude expected from ongoing exposure to 70 ng/L (the USEPA Health Advisory) in drinking water are not desirable and may not be protective of public health.




14 ng/L – Health-based MCL recommended by DWQI Health Effects Subcommittee

40 ng/L – NJDEP drinking water guidance (2007) based on older toxicology data

70 ng/L – USEPA Lifetime Health Advisory

Finally, as discussed elsewhere in this document, several studies have shown that serum PFOA concentrations in breastfed infants increase several fold from levels at birth (which are similar to maternal levels) within the first few months of life (see figure below). Exposures to infants who consume formula prepared with contaminated water are also highest during this time period, and serum PFOA levels remain elevated for the first several years of life (see figure below). Therefore, increases in blood serum levels in infants and children from exposure to PFOA in drinking water are expected to be several-fold higher than those shown in the bar graph above.

USEPA recognizes that lactating women and bottle-fed infants are sensitive subpopulations for exposure to PFOA in drinking water. The Health Effects Subcommittee also concludes that the elevated exposures during infancy and early childhood are of particular concern because early life effects are sensitive endpoints for the toxicity of PFOA. Additionally, the Health Effects Subcommittee concludes women who may become pregnant should also be included as sensitive subpopulations, because the body burden of PFOA remains elevated for many years after exposure ceases. Therefore, if serum PFOA levels are elevated when a woman becomes pregnant, they will remain elevated during pregnancy and lactation.



From Verner et al. (2016). Modeling simulation of the ratio of PFOA in blood plasma in breast fed infants/children to plasma concentration in mother.

Black line - 50th percentile. Blue line - 5th percentile. Red line - 95th percentile. Dotted lines - minimum and maximum values.

### Citations

Apel, P., Angerer, J., Wilhelm, M., Kolossa-Gehring, M. (2016). New HBM values for emerging substances, inventory of reference and HBM values in force, and working principles of the German Human Biomonitoring Commission. *Int. J. Hyg. Environ. Health* (in press).

ASDWA (2016). Association of State Drinking Water Administrators. Information for States about the New Health Advisories for PFOA and PFOS. Presented by USEPA Office of Water. May 23, 2016. [https://www.youtube.com/watch?v=QoBBjLeOi\\_s&feature=youtu.be](https://www.youtube.com/watch?v=QoBBjLeOi_s&feature=youtu.be)



Butenhoff, J.L., Kennedy, G.L., Frame, S.R., O'Conner, J.C., York, R.G., 2004b. The reproductive toxicology of ammonium perfluorooctanoate (APFO) in the rat. *Toxicology* 196, 95-116.

Butenhoff, J. L., G. L. Kennedy, Jr., S. C. Chang and G. W. Olsen (2012). Chronic dietary toxicity and carcinogenicity study with ammonium perfluorooctanoate in Sprague-Dawley rats. *Toxicology* 298: 1-13.

CDC (2015). Centers for Disease Control and Prevention. Fourth National Report on Human Exposure to Environmental Chemicals.

[http://www.cdc.gov/biomonitoring/pdf/FourthReport\\_UpdatedTables\\_Feb2015.pdf](http://www.cdc.gov/biomonitoring/pdf/FourthReport_UpdatedTables_Feb2015.pdf)

Fei, C., McLaughlin, J. K., Lipworth, L., Olsen, J. (2010). Maternal concentrations of perfluorooctanesulfonate (PFOS) and perfluorooctanoate (PFOA) and duration of breastfeeding. *Scand. J. Work Environ. Health* 36: 413-421.

Filgo AJ, Quist EM, Hoenerhoff MJ, Brix AE, Kissling GE, Fenton SE. 2015. Perfluorooctanoic Acid (PFOA)-induced Liver Lesions in Two Strains of Mice Following Developmental Exposures: PPAR $\alpha$  Is Not Required. *Toxicol Pathol.* 43(4):558-68.

Fitz-Simon, N., T. Fletcher, M. I. Luster, K. Steenland, A. M. Calafat, K. Kato and B. Armstrong (2013). "Reductions in serum lipids with a 4-year decline in serum perfluorooctanoic acid and perfluorooctanesulfonic acid." *Epidemiology* 24(4): 569-576.

Frisbee, S. J., A. P. Brooks, Jr., A. Maher, P. Flensburg, S. Arnold, T. Fletcher, K. Steenland, A. Shankar, S. S. Knox, C. Pollard, J. A. Halverson, V. M. Vieira, C. Jin, K. M. Leyden and A. M. Ducatman (2009). "The C8 health project: design, methods, and participants." *Environ Health Perspect* 117(12): 1873-1882.

Lau, C.; Thibodeaux, J. R.; Hanson, R. G.; Narotsky, M. G.; Rogers, J. M.; Lindstrom, A. B.; Strynar, M. J., 2006. Effects of perfluorooctanoic acid exposure during pregnancy in the mouse. *Toxicol. Sci.* 90: 510–518.

Lorber, M. and P. P. Egeghy (2011). "Simple intake and pharmacokinetic modeling to characterize exposure of Americans to perfluorooctanoic acid, PFOA." *Environ Sci Technol* 45(19): 8006-8014.

Loveless, S.E., Finlay, C., Everds, N.E., Frame, S.R., Gillies, P.J., O'Connor, J.C., Powley, C.R., Kennedy, G.L. (2006). Comparative responses of rats and mice exposed to linear/branched, linear, or branched ammonium perfluorooctanoate (APFO). *Toxicology* 220: 203–217.

Macon, M.B., Villanueva, L.R., Tatum-Gibbs, K., Zehr, R.D., Strynar, M.J., Stanko, J.P., White, S.S., Helfant, L., Fenton, S.E. (2011). Prenatal perfluorooctanoic acid exposure in CD-1 mice: low dose developmental effects and internal dosimetry. *Toxicol. Sci.* 122: 134-45.

NJDEP. 2007a. Guidance for PFOA in drinking water at Pennsgrove Water Supply Company. Division of Science, Research, and Technology. February 13, 2007.  
[http://www.nj.gov/dep/watersupply/pdf/pfoa\\_dwguidance.pdf](http://www.nj.gov/dep/watersupply/pdf/pfoa_dwguidance.pdf)

Post, G.B., Cohn, P.D., and Cooper, K.R. (2012). Perfluorooctanoic acid (PFOA), an emerging drinking water contaminant: a critical review of recent literature. *Env. Res.* 116, 93-117.

Quist, E.M., Filgo, A.J., Cummings, C.A., Kissling, G.E., Hoenerhoff, M.J., Fenton, S.E. (2015). Hepatic mitochondrial alteration in CD-1 mice associated with prenatal exposures to low doses of perfluorooctanoic acid (PFOA). *Toxicol. Pathol.* 43:546-57

Romano, M.E., Xu, Y., Calafat, A.M., Yolton, K., Chen, A., Webster, G.M., Eliot, M.N., Howard, C.R., Lanphear, B.P., Braun, J.M. (2016). Maternal serum perfluoroalkyl substances during pregnancy and duration of breastfeeding. *Env. Research* (in press).

Tucker, D. K., M. B. Macon, M. J. Strynar, S. Dagnino, E. Andersen and S. E. Fenton (2015). "The mammary gland is a sensitive pubertal target in CD-1 and C57Bl/6 mice following perinatal perfluorooctanoic acid (PFOA) exposure." *Reprod Toxicol.* 54:26-36.

USEPA (2016a). United States Environmental Protection Agency. Drinking Water Health Advisory for Perfluorooctanoic Acid (PFOA). Office of Water. May 2016.

USEPA (2016b). United States Environmental Protection Agency. Fact Sheet: PFOA & PFOS Drinking Water Health Advisories. Office of Water. May 2016.

USEPA (2016c). United States Environmental Protection Agency. Health Effects Support Document for Perfluorooctanoic Acid (PFOA). Office of Water. May 2016.

USEPA (2016d). Response to New Jersey Drinking Water Quality Institute (DWQI) Health Effects Subcommittee Draft Health-Based Maximum Contaminant Level Support Document: Perfluorooctanoic Acid (PFOA). Appendix 2 – Comparison of USEPA Office of Water Health Advisory and DWQI Recommended Health-Based MCL for PFOA. November 21, 2016.  
<http://www.nj.gov/dep/watersupply/pdf/comment5.pdf>

Verner MA, Ngueta G, Jensen ET, Fromme H, Völkel W, Nygaard UC, Granum B, Longnecker MP (2016). A Simple Pharmacokinetic Model of Prenatal and Postnatal Exposure to Perfluoroalkyl Substances (PFASs). *Environ Sci Technol.* 50:978-86.

WAAYTV (2016). ADPH Says Health Advisory Only Affects Pregnant and Breastfeeding Women. June 6, 2016. [http://www.waaytv.com/appnews/adph-says-health-advisory-onlyaffects-pregnant-and-breastfeeding-women/article\\_79f0e016-29dd-11e6-8842-57daea17923d.html](http://www.waaytv.com/appnews/adph-says-health-advisory-onlyaffects-pregnant-and-breastfeeding-women/article_79f0e016-29dd-11e6-8842-57daea17923d.html) Accessed June 6, 2016.

WVU School of Medicine (2008). West Virginia University School of Medicine. C8 Health Project. Demographic Characteristics. Number of Participants in the C8 Health Project.  
<http://www.hsc.wvu.edu/media/4583/demograhpics-number-of-participants.pdf> Accessed June 6, 2016.

Yahia, D., M. A. El-Nasser, M. Abedel-Latif, C. Tsukuba, M. Yoshida, I. Sato and S. Tsuda (2010). "Effects of perfluorooctanoic acid (PFOA) exposure to pregnant mice on reproduction." *J Toxicol Sci* 35(4): 527-533.

### **APPENDIX 3: Risk Assessment Considerations for Butenhoff et al. (2002) Subchronic Cynomolgus Monkey Study**

The Butenhoff et al. (2002) six month study in male cynomolgus monkeys is described in detail in the Toxicology section of this document. As discussed in the Toxicology section, only 3 of 4 of the low dose monkeys and 2 of 6 of the high dose monkeys tolerated the administered dose well enough to complete the study, while all 6 animals in the mid-dose group (10 mg/kg/day) completed the study. The LOAEL in this study was 3 mg/kg/day based on mortality (25%) possibly attributed to treatment and increased liver weight, and the NOAEL was not identified. Furthermore, it is important to note that 6 months represents less than 2% of the lifespan of this species of monkey, which is about 30 years. It is not known whether additional or more severe effects would have occurred with continued dosing of the monkeys that were able to tolerate dosing for the full 6 months of the study. Therefore, if this study were to be used as the basis for risk assessment, an uncertainty factor (UF) for less than chronic exposure duration should be included.

In the study, serum PFOA levels were analyzed every 2 weeks, and it appeared that steady state was reached after 2 to 4 weeks of dosing. Importantly, the serum levels were highly variable between animals and over time in the same animal, and they did not increase proportionally with dose. The average serum levels in the 0, 3, 10, 30/20 mg/kg/day groups, respectively, were: 134 ±113, 81,000±40,000, 99,000±50,000 ug/ml, and 156,000 ±103,000 ng/ml (Butenhoff et al., 2004a). The PFOA concentrations in liver also did not appear to increase with dose or time, and the highest concentration in the liver was in a high dose animal sacrificed at week 5.

Butenhoff et al. (2004b) reported benchmark dose modeling of the liver-to-brain weight data from this study. A BMIC<sub>10</sub> (maximum likelihood estimate of PFOA serum concentration at 10% effect level) of 40,000 ng/ml and a LBMIC<sub>10</sub> (lower bound estimate of serum concentration at 10% effect level) of 23,000 ng/ml were derived. The data on liver-to-brain weight ratio versus serum PFOA concentration are shown in Figure A-1 (below).


As can be seen from the graph in Figure A-1, Benchmark Dose (BMD) modeling of these data is not appropriate for the following reasons: The dose-response relationship needed to support BMD modeling does not exist, since (as stated by Butenhoff et al. (2002) the liver-to-brain weight ratio did not increase with dose. Additionally, there are an insufficient number of data points for BMD modeling. In the modeling conducted by Butenhoff et al. (2004b), the highest dose group was dropped, leaving only two data points for dosed groups plus the control group. It should be noted that the reported LBMIC<sub>10</sub> of 23,000 ng/L is within the same range as the serum PFOA concentration in the low dose monkey that was sacrificed in moribund condition during the weeks prior to its sacrifice.

Based on the above considerations, this study does not appear to be appropriate as the basis for a health-based drinking water concentration. In addition to the lack of dose response, a very small number of animals completed the study, and there was a wide variation in the responses of the individual animals.

If a risk assessment were to be developed based on this study, in spite of its numerous limitations, the following point of departure (POD) and UFs appear to be appropriate:

- The serum level at the low dose, 3 mg/kg/day should be used as the POD. This dose was the LOAEL for both increased liver weight and increased mortality.
- In addition to the standard UFs for intraspecies (10) and interspecies toxicodynamic (3) variability used in risk assessments based on serum levels, a UF of 10 for extrapolation of a LOAEL to NOAEL and a UF of 10 for a study of less than chronic study duration, should be applied. These UFs combine to give a total UF of 3000.
- An additional UF for database limitations appears to be warranted due to the very small number of animals that completed the study, because mortality possibly related to treatment occurred in the low dose group, and because potentially more sensitive developmental endpoints were not evaluated.

**Figure A-1: Cynomolgus Monkey  
PFOA Serum Levels vs. Liver/Brain Weight Ratio**



Citations:

Butenhoff, J., Costa, G., Elcomebe, C., Farrar, D., Hansen, K., Iwai, H., Jung, R., Kennedy, G., Lieder, P., Olsen, G., and Thomford, P. (2002). Toxicity of ammonium perfluorooctanoate in male cynomolgus monkeys after oral dosing for 6 months. *Toxicol. Sci.* 69: 244-257.

Butenhoff, J.L., Kennedy, G.L., Jr, Hinderliter, P.M., Lieder, P.H., Jung, R., Hansen, K.J., Gorman, G.S., Noker, P.E., and Thomford, P.J. (2004a). Pharmacokinetics of perfluorooctanoate in Cynomolgus monkeys. *Toxicol. Sci.* 82: 394-406

Butenhoff, J. L., Gaylor, D. W., Moore, J. A., Olsen, G. W., Rodricks, J., Mandel, J. H., & Zobel, L. R. (2004b). Characterization of risk for general population exposure to perfluorooctanoate. *Regul. Tox. Pharmacol.* 39: 363-380.

## APPENDIX 4. Individual tables for epidemiology studies

Reference and Study Design	Exposure Measures	Results	Comment
<p>(Bloom, Kannan et al. 2010)</p> <p><b>Study Design:</b> Cross-sectional</p> <p><b>Location:</b> New York, USA</p> <p><b>Population:</b> Licensed anglers in NYS, n=31. Participants are as subgroup of NYSACS participants (licensed anglers in New York state and their partners)</p> <p><b>Outcome Definition:</b> Serum samples</p>	<p><b>Exposure Assessment:</b> Serum concentrations</p> <p><b>Population-Level Exposure:</b> Geometric mean = 1.33 95% CI 1.15-1.53 ng/mL</p>	<p><b>Stat Method:</b> Linear regression, covariates and confounders considered included age, gender, BMI, smoking, goiter or thyroid condition, race/ethnicity, use of thyroid medication, and self-reported consumption of sportfish caught from NY waters</p> <p>PFCs and TSH log transformed.</p> <p><b>Outcome:</b> ln-TSH <b>Major Findings:</b> NS <math>\beta = -0.06</math> (95% CI -0.78, 0.67)</p> <p><b>Outcome:</b> FT4 <b>Major Findings:</b> NS <math>\beta = -0.01</math> (95% CI -0.16, 0.14)</p>	<p><b>Major Limitations:</b> Power analyses = would require 408-fold increase in sample size to see statistically significant associations with 80% power at observed effect sizes.</p> <p>Small sample size limited ability to control for potential covariates and confounders simultaneously, or other potential environmental compounds of interest or other PFCs.</p> <p>Cross-sectional design prevents causal inference.</p> <p>High proportion of values measured below the LODs for these compounds.</p> <p><b>Funding Source:</b> Agency for Toxic Substances and Disease Registry (ATSDR), Grant H75-ATH 298338, the Great Lakes Protection Fund, Grant RM 791-3021, and the Centers for Disease Control and Prevention (CDC) National Center for Environmental Health (NCEH), Grant U59CCU22339202</p>



Reference and Study Design	Exposure Measures	Results	Comment
<p>(Chan, Burstyn et al. 2011)</p> <p><b>Study Design:</b> Matched case-control</p> <p><b>Location:</b> Edmonton, Alberta, Canada</p> <p><b>Population:</b> Hypothyroxemic pregnant women at 15-20 weeks gestation, N=96 + 175 nonhypothyroxemic pregnant controls, matched on age and referring physician (Total N = 271), years 2005-2006</p> <p><b>Outcome Definition:</b> Hypothyroxinemic cases defined as (normal TSH, the lowest 10<sup>th</sup> percentile of ft4 – measured in serum)</p>	<p><b>Exposure Assessment:</b> Serum PFOA</p> <p><b>Population-Level Exposure:</b> Geometric mean (SD) nmol/mL Cases - 3.10 (3.10) Controls - 3.32 (2.72)</p> <p>Median nmol/L Cases – 3.94 Controls – 3.62</p>	<p><b>Stat Method:</b> Student's t-test and chi-square were used to calculate differences in means between cases and controls by maternal age, maternal weight, gestation age at blood draw, and maternal race.</p> <p>Conditional logistic regression, covariates and confounders considered include maternal age, maternal weight, and gestational age at blood draw on mother.</p> <p>Each PFA was modelled separately and with three in a model (PFOA, PFOS, PFHxS).</p> <p>Adjusted analyses shown below.</p> <p><b>Outcome:</b> maternal hypothyroxemia</p> <p><b>Major Findings:</b> PFOA only OR = 0.94 (95% CI 0.74, 1.18)</p> <p>All PFCs in model OR=0.87 (95% CI 0.63,1.19)</p>	<p><b>Major Limitations:</b></p> <p>Small sample size.</p> <p>There are no known confounders to be accounted for in the study design.</p> <p>Possibility of confounding by socioeconomic or geographic factors</p> <p>Potential outcome misclassification due to timing of the blood draw.</p> <p><b>Funding Source:</b> University Hospital Foundation (U of Alberta) and Alberta Health and Wellness.</p>

Reference and Study Design	Exposure Measures	Results	Comment
<p>(Costa, Sartori et al. 2009)</p> <p><b>Study Design:</b> Case-control, cross-sectional</p> <p><b>Location:</b> Miteni, Trissino, Italy</p> <p><b>Population:</b> Cases (exposed): Workers (all male aged 20-63 years) engaged in the PFOA production department (n= 53). As of 2007,</p>	<p><b>Exposure Assessment:</b> Serum PFOA (monitoring 2000-2007)</p> <p><b>Population-Level Exposure:</b> Year 2007:</p> <p>Geometric mean (SD) µg/mL Currently Exposed – 4.02 (14.43) Formerly Exposed – 3.76 (6.06)</p> <p>Median (SD) µg/mL Currently Exposed – 5.71 (14.43) Formerly Exposed – 4.43 (6.06)</p>	<p><b>Stat Method:</b> ANOVA, t test, multiple linear regression models, multivariate GEE models controlling for within-subject correlations, covariates and confounders considered include age, years of exposure, year of PFOA sampling, BMI, smoking, and alcohol consumption.</p> <p>People under treatment of primary hyperlipidemias and with a history of chronic hepatitis were excluded. Natural log transformation was performed where appropriate.</p> <p>The following chemical chemistry was compared among exposed and non-exposed: BMI, glucose, urea nitrogen,</p>	<p><b>Major Limitations:</b> Small sample size</p> <p>Healthy worker effect</p> <p>Other environmental contaminants were not controlled for.</p> <p>Cross-sectional design prevents causal inference.</p> <p><b>Funding Source:</b> not specified. Authors are</p>

<p>37 were active workers and 16 unexposed.</p> <p>Controls (unexposed): Other male workers never exposed to PFOA (n= 107) (12 executive clerks and 95 blue collar workers from other departments)</p> <p>Matched on age, time of shift, area of residence and job seniority</p> <p><b>Outcome Definition:</b> Physical examination including blood chemical chemistry tests over 30 years (1978-2007)</p>	<p>Geometric Mean in Production Workers</p> <p><u>Year</u></p> <p>2000 = 11.7</p> <p>2001 = 10.2</p> <p>2002 = 9.3</p> <p>2003 = 6.9</p> <p>2004 = 6.5</p> <p>2006 = 5.8</p> <p>2007 = 5.4</p> <p>*renovation happened in the plant in 2002 partially automating the process</p>	<p>creatinine, uric acid, total cholesterol, HDL, triglycerides, total bilirubin, AST, ALT, GGT, ALP, proteins, albumin, <math>\alpha</math>1 globulins (large proteins found in the blood), <math>\alpha</math>2 globulins, <math>\beta</math> globulins, <math>\gamma</math> globulins, WBC, RBC, Haemoglobin, Haematocrit, platelets.</p> <p><b>Outcome:</b> Chemical chemistry</p> <p><b>Major Findings:</b> All the biochemical parameters turned out to be on average within the laboratory reference ranges.</p> <p>As compared with the control group some differences, both in terms of mean values and number of persons above the upper reference limited, were noted for some parameters such as uric acid, cholesterol, triglycerides, and liver enzymes.</p> <p><u>Analysis#1: T-test (Nonexposed (34 controls) v. 34 exposed)</u> <b>Uric acid – p-value= 0.039</b> <b>Total cholesterol – p-value=0.003</b></p> <p>All other findings are not significant.</p> <p><u>Analysis#2: Multiple regression analysis (34 Exposed v. 107 controls)</u> <b>Uric acid – p-value= 0.027</b> <b>Total cholesterol – p-value=0.005</b></p> <p>All other findings are not significant.</p> <p><u>Analysis#3: GEE Model (subjects regardless of exposure status with concurrent outcome and PFOA in the last 6 years)</u> <b>Uric acid – p-value &lt;0.05</b> <b>Total cholesterol – p-value &lt;0.05</b> <b>Total bilirubin - p-value &lt;0.01 (inversely)</b> <b>ALT - p-value &lt;0.01</b> <b>GGT - p-value &lt;0.01</b> <b>ALP - p-value &lt;0.05</b> <b><math>\alpha</math>2 globulins – p-value &lt;0.05</b></p> <p>All other findings are not significant.</p>	<p>employed by Department of Occupational and Environmental Health (Costa, Sartori), University of Milano, Italy; Unit of Epidemiology (Consonni), IRCCS Maggiore Hospital, Mangiagalli and Regina Elena Foundation, Milano, Italy; and Institute of Medical Statistics (Sartori)</p>
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Reference and Study Design	Exposure Measures	Results	Comment
<p>Darrow et al., 2016</p> <p><b>Study Design:</b> Cross-sectional; and a subanalysis with prospective analysis among those reporting liver disease in 2005/2006.</p> <p><b>Location:</b> United States – West Virginia and Ohio</p> <p><b>Population:</b> Adults (&gt; 20 years); liver biomarkers (n=30,726, including 1,892 workers) and liver disease (n=32,254, including 3,713 workers)</p> <p><b>Outcome Definition:</b> Alanine aminotransferase (ALT), <math>\gamma</math>-glutamyltransferase (GGT) and direct bilirubin, markers of liver toxicity (measures in 2005-2006) and self-reported liver disease (from surveys administered 2008 and 2011) which were medically reviewed. Liver disease was categorized as any medically-validated liver disease and liver disease restricted to medically-validated enlarged liver, fatty liver, or cirrhosis.</p>	<p><b>Exposure Assessment:</b> Historically modeled yearly PFOA exposure estimated using environmental fate and transport models and participant residential histories, a measure of cumulative serum PFOA exposure was calculated by summing all previous yearly estimates</p> <p><b>Population-Level Exposure:</b> Median estimated PFOA serum concentration in 2005-2006, 16.5 ng/mL (range 2.6 – 3559 ng/mL).</p>	<p><b>Stat Method:</b> In linear regression models, natural log-transformed liver function markers were analyzed in relation to estimated cumulative PFOA serum concentrations through 2005 or 2006 and estimated year-specific PFOA serum concentration in 2005 or 2006. Logistic regression was used to model dichotomized measures of the liver function measures. PFOA was analyzed continuously (log-transformed) and by quintiles.</p> <p>Covariates and confounders considered include age, sex, BMI, alcohol consumption, race, regular exercise, smoking status, education, household income, fasting status, history of working at DuPont plant, and insulin resistance (HOMA-IR).</p> <p>Stratified Cox proportional hazard models with age as the time scale, time-varying cumulative serum PFOA as a predictor and stratified by birth year to control for any birth cohort trends used to analyzed liver disease. Covariates and confounders considered include sex, years of schooling, race, smoking, regular alcohol consumption, and BMI. A 10-year lag was also investigated. Stratified by history of working in PFOA plant, gender, and age.</p> <p><b>Outcome:</b> Liver biomarkers</p> <p><b>Major Findings:</b> <i>Cumulative PFOA (these findings are reflective of 2005/2006 PFOA results)</i></p> <p><u>ALT:</u> <b>Contin.:</b> <math>\beta=0.012</math> (95% CI 0.008, 0.016) <b>Q2 v. Q1:</b> <math>\beta=0.023</math> (95% CI 0.006, 0.040) <b>Q3 v. Q1:</b> <math>\beta=0.035</math> (95% CI 0.018, 0.052) <b>Q4 v. Q1:</b> <math>\beta=0.039</math> (95% CI 0.022, 0.056) <b>Q5 v. Q1:</b> <math>\beta=0.058</math> (95% CI 0.040, 0.076)</p> <p><b>Trend:</b> p-value &lt;0.001</p> <p><u>GGT:</u> Contin.: <math>\beta=0.003</math> (95% CI -0.003, 0.008) Q2 v. Q1: <math>\beta=0.009</math> (95% CI -0.014, 0.031) Q3 v. Q1: <math>\beta=0.025</math> (95% CI 0.003, 0.047) Q4 v. Q1: <math>\beta=0.011</math> (95% CI -0.011, 0.033) Q5 v. Q1: <math>\beta=0.020</math> (95% CI -0.004, 0.044)</p> <p>Trend: p-value 0.1021</p> <p><u>Direct Bilirubin:</u> <b>Contin.:</b> <math>\beta=-0.005</math> (95% CI -0.008, -0.002) Q2 v. Q1: <math>\beta=0.012</math> (95% CI -0.002, 0.026)</p>	<p><b>Major Limitations:</b> Cross-sectional design prevents causal inference.</p> <p>Other environmental contaminants were not controlled for.</p> <p><b>Funding Sources:</b> C8 Class Action Settlement Agreement between DuPont and Plaintiffs</p>

		<p>Q3 v. Q1: <math>\beta=-0.003</math> (95% CI -0.017, 0.011)                  Q4 v. Q1: <math>\beta=-0.007</math> (95% CI -0.021, 0.007)  <b>Q5 v. Q1: <math>\beta=-0.017</math> (95% CI -0.032, -0.001)</b></p> <p><b>Trend: p-value 0.0029</b>  <b>Outcome:</b> Liver disease  <b>Major Findings:</b>  <u>Any liver disease (no lag):</u>                  Contin.: HR=0.97 (95% CI 0.92, 1.03)                  Q2 v. Q1: HR=1.19 (95% CI 0.88, 1.59)                  Q3 v. Q1: HR=1.08 (95% CI 0.81, 1.45)                  Q4 v. Q1: HR=1.04 (95% CI 0.78, 1.40)                  Q5 v. Q1: HR=0.95 (95% CI 0.70, 1.27)</p> <p><u>Enlarged liver, fatty liver, cirrhosis</u>                  Contin.: HR=0.97 (95% CI 0.91, 1.04)                  Q2 v. Q1: HR=0.90 (95% CI 0.65, 1.25)                  Q3 v. Q1: HR=0.83 (95% CI 0.60, 1.15)                  Q4 v. Q1: HR=0.75 (95% CI 0.54, 1.03)                  Q5 v. Q1: HR=0.83 (95% CI 0.60, 1.16)</p>	
--	--	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--

Reference and Study Design	Exposure Measures	Results	Comment
<p>(de Cock, de Boer et al. 2014)</p> <p><b>Study Design:</b> Cross-sectional</p> <p><b>Location:</b> Six midwifery clinics in Netherlands</p> <p><b>Population:</b> Mother-child cohort through neonatal screening programs, n=83 pairs</p> <p><b>Outcome Definition:</b> Blood levels of thyroxine (T4) in cord plasma (immediately after birth) screening and heel prick blood spots (between day 4 and day 7 after birth)</p>	<p><b>Exposure Assessment:</b> Cord plasma concentration</p> <p><b>Population-Level Exposure:</b> Cord plasma: Median = 885 ng/L = 0.89 ng/mL Range 200-2700 ng/L = 0.2-2.7 ng/mL</p>	<p><b>Stat Method:</b> Linear regression models (separate for each exposure). Models were stratified for gender.</p> <p>Covariates and confounders considered included health problems related to the thyroid gland, use of thyroid medication, birth weight, C-section, gestational weight gain, gestational age, parity, smoking, alcohol, maternal BMI, and maternal age at birth.</p> <p>Chemical compounds were analyzed as quartiles (after no linear associations were noted)</p> <p>Results reported for most adjusted model</p> <p><b>Outcome:</b> T4  <b>Major Findings:</b>  <i>In boys:</i>                  Q2 v. Q1, <math>\beta=7.9</math> (95% CI -18.0, 33.9)                  Q3 v. Q1, <math>\beta=-2.1</math> (95% CI -20.9, 19.8)                  Q4 v. Q1, <math>\beta=6.2</math> (95% CI -16.1, 28.5)</p>	<p><b>Major Limitations:</b> Homogenous w/r/t nationality and education level</p> <p>No adjustment for time of heel prick (between 4 and 7 days after birth),</p> <p>Small sample size</p> <p>Cross-sectional design prevents causal inference.</p> <p>Power decreased by quartile formation and stratifying, though there was justification for both practices.</p> <p><b>Funding Sources:</b> the European Community's Seventh Framework Programme [FP7/2007-2013] under grant agreement OBELIX n° 227391.</p>

		<p><i>In girls:</i>                  Q2 v. Q1, <math>\beta</math>=-5.9 (95% CI -26.8, 14.9)                  Q3 v. Q1, <math>\beta</math>=11.8 (95% CI -19.1, 42.7)  <b>Q4 v. Q1, <math>\beta</math>=38.6 (95% CI 13.3, 63.8)</b></p> <p>No linear associations found for any compound studied.</p>	
--	--	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--

Reference and Study Design	Exposure Measures	Results	Comment
<p>(Emmett, Zhang et al. 2006)</p> <p><b>Study Design:</b> Cross-sectional</p> <p><b>Location:</b> Little Hocking water district in SE Ohio</p> <p><b>Population:</b> Stratified random sample of residents (<math>\geq 2</math> year residence) of district (N=371, 317 randomly selected, 54 volunteer (18 occupationally exposed)), age range 2.5-89 years</p> <p><b>Outcome Definition:</b> Serum biomarkers and questionnaire of previous clinical diagnoses of liver or thyroid disease.</p>	<p><b>Exposure Assessment:</b> Serum concentrations</p> <p><b>Population-Level Exposure:</b> Median PFOA: 354 ng/mL, IQR 181 ng/mL to 571 ng/mL</p>	<p><b>Stat Method:</b> Simple regression (liver function/hematologic parameters), binary t-test (normal v. abnormal) blood chemistries or history of clinical diagnoses of interest</p> <p><b>Outcome:</b> Serum chemistry ( BUN, creatinine, total protein, albumin, total bilirubin, ASP, AST, ALT, GGR, total cholesterol, TSH)</p> <p><b>Major Findings:</b> No significant positive linear relationships (<math>p &gt; 0.05</math>)</p> <p><b>Outcome:</b> Hematologic parameters (WBC, RBC, hemoglobin, hematocrit, MCV, MCH, MCHC, RDW, Platelets, neutrophils, lymphocytes, monocytes, eosinophils, basophils, neutrophils, lymphocytes, monocytes, eos, basos)</p> <p><b>Major Findings:</b>  <b>Monocyte (linear) – <math>r=0.13</math>, <math>p</math>-value=0.01</b>  <b>AST (binary) – <math>p</math>-value=0.03 (inversely)</b>  <b>% neutrophils (binary) – <math>p</math>-value=0.02 (inversely)</b>  <b>% lymphocytes (binary) – <math>p</math>-value=0.01 (inversely)</b></p> <p>No other significant positive relationships (<math>p &gt; 0.05</math>)</p> <p><b>Outcome:</b> Liver disease  <b>Major Findings:</b> <math>p</math>-value=0.50                      Disease (n=13), PFOA=527 ng/mL vs.                      No disease, PFOA=441 ng/mL</p> <p><b>Outcome:</b> Thyroid disease  <b>Major Findings:</b> <math>p</math>-value=0.3                      Disease (n=40), PFOA=387 ng/mL vs.                      No disease, PFOA=451 ng/mL</p>	<p><b>Major Limitations:</b> Potential volunteer bias from volunteer group,</p> <p>Cross sectional design precludes causal inference</p> <p>No confounders or covariates were considered beyond stratified analyses by age.</p> <p>Other environmental or lifestyle confounder may be clouding true relationship between exposure and endpoints.</p> <p><b>Funding Source:</b> Grant ES12591 from the Environmental Justice Program and by grant number 1P30 ES013508-01A1 from the National Institute of Environmental Health.</p>

Reference and Study Design	Exposure Measures	Results	Comment
<p>(Eriksen, Raaschou-Nielsen et al. 2013)</p> <p><b>Study Design:</b> Cross-sectional</p> <p><b>Location:</b> Denmark</p> <p><b>Population:</b> Middle aged (50-65 years of age), N=753 (663 male, 90 female) Nested within a larger Danish Diet, Cancer, and Health cohort</p> <p><b>Outcome Definition:</b> Serum, questionnaires</p>	<p><b>Exposure Assessment:</b> Serum concentrations</p> <p><b>Population-Level Exposure:</b> Mean: 7.1 ng/mL</p>	<p><b>Stat Method:</b> Generalized linear models (crude adjusted for sex only and adjusted). Covariates and confounders considered included sex, age, education, BMI, smoking status, alcohol intake, egg intake, animal fat intake, physical activity.</p> <p>Primary analyses treated PFCs continuously. Additionally, investigated as 8 exposure groups (100 per group), with lowest group as reference.</p> <p><b>Outcome:</b> total cholesterol</p> <p><b>Major Findings:</b> <math>\beta_{unadj} = 4.1</math> (95% CI 0.8, 7.4) <math>\beta_{adj} = 4.4</math> (95% CI 1.1, 7.8)</p> <p>Using the lowest exposure group as a referent group, the level of total cholesterol appears to be higher with higher PFOA plasma levels with a borderline significant p value for trend.</p>	<p><b>Major Limitations:</b> Cross-sectional design precludes causal inference.</p> <p>Other unidentified confounders may exist</p> <p><b>Funding Sources:</b> Danish Cancer Society and the International Epidemiology Institute (IEI), which received an unrestricted research grant from the 3M Company.</p>

Reference and Study Design	Exposure Measures	Results	Comment
<p>(Fisher, Arbuckle et al. 2013)</p> <p><b>Study Design:</b> Cross-sectional</p> <p><b>Location:</b> Canada</p> <p><b>Population:</b> CHMS (Canadian Health Measures Survey, 2007-2009) N=5604, 6-79 year olds</p> <p><b>Outcome Definition:</b> Serum measures and questionnaires</p>	<p><b>Exposure Assessment:</b> Serum concentration</p> <p><b>Population-Level Exposure:</b> Geometric mean = 2.46 <math>\mu\text{g/L}</math> (ng/mL)</p>	<p><b>Stat Method:</b> Multivariate linear and logistic regression models, covariates and confounders considered include cholesterol lowering medications, sampling weights, age, gender, marital status, income adequacy, race, education, BMI, physical activity index, smoking status and alcohol consumption.</p> <p>PFOA analyzed in quartiles, reference=1 ng/mL and dichotomous</p> <p>Outcomes and exposures were log transformed</p> <p>Results shown for most adjusted models by unweighted and weighted.</p>	<p><b>Major Limitations:</b> Cross sectional design precludes causal inference.</p> <p>Reverse causality or unexplored confounder may exist</p> <p>Excluded those on cholesterol-lowering medication, removing some of diseased population</p> <p>Other unidentified confounders may exist. No adjustment for albumin (possible non-casual positive correlation between PFCs and cholesterol)</p>

For all clinical outcomes non-pregnant adults ( $\geq 18$  years of age)

**Outcome:** Cholesterol outcomes

**Major Findings:**

Linear - unweighted

HDL –  $\beta=0.007$ , p-value=0.45

TC/HDL –  $\beta=0.02$ , p-value=0.11

LDL –  $\beta=0.008$ , p-value=0.64

**Non-HDL –  $\beta=0.03$ , p-value=0.003**

**TC –  $\beta=0.02$ , p-value=0.001**

Triglycerides –  $\beta=0.02$ , p-value=0.49

Linear - weighted

HDL –  $\beta=0.009$ , p-value=0.96

TC/HDL –  $\beta=0.02$ , p-value=0.22

LDL –  $\beta=0.02$ , p-value=0.63

Non-HDL –  $\beta=0.036$ , p-value=0.13

TC –  $\beta=0.03$ , p-value=0.22

Triglycerides –  $\beta=-0.003$ , p-value=0.94

(High cholesterol)

Quartiles – unweighted

Q2 v. Q1, OR=1.26 (95% CI 0.98, 1.62)

Q3 v. Q1, OR=1.18 (95% CI 0.91, 1.52)

**Q4 v. Q1, OR=1.46 (95% CI 1.13, 1.89)**

**P for Trend=0.01**

Quartiles - weighted

**Q2 v. Q1, OR=1.61 (95% CI 1.02, 2.53)**

Q3 v. Q1, OR=1.26 (95% CI 0.76, 2.07)

Q4 v. Q1, OR=1.5 (95% CI 0.86, 2.62)

P for Trend=0.10

High cholesterol (dichotomous)

**Unweighted OR=1.20 (95% CI 1.03, 1.40)** Weighted

OR=1.22 (85% CI 0.89, 1.67)

**Outcome:** Metabolic outcomes

**Major Findings:**

Linear - unweighted

Insulin –  $\beta=-0.003$ , p-value=0.91

Glucose –  $\beta=-0.01$ , p-value=0.06

HOMA-IR –  $\beta=-0.01$ , p-value=0.63

85% of participants were Caucasian, 60% with post-secondary education, and close to half were in the highest income adequacy category.

**Funding Source:** unspec, Authors are employed by Health Canada.



	<p><u>Linear - weighted</u>                  Insulin – <math>\beta</math>=-0.071, p-value=0.12                  Glucose – <math>\beta</math>=-0.04, p-value=0.17                  HOMA-IR – <math>\beta</math>=-0.1, p-value=0.10</p> <p><u>Metabolic syndrome (dichotomous)</u>                  Unweighted OR=1.26 (95% CI 0.92, 1.73) Weighted                  OR=1.13 (85% CI 0.46, 2.77)</p>	
--	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--

Reference and Study Design	Exposure Measures	Results	Comment
<p>(Fitz-Simon, Fletcher et al. 2013)</p> <p><b>Study Design:</b> Cohort, Longitudinal, over a 4.4-year period</p> <p><b>Location:</b> Ohio and West Virginia, USA</p> <p><b>Population:</b> n=560, living in areas with PFOA contaminated drinking water (sample derived from C8 short term follow up study), 2005-2006 followed through 2010 [C8 Short-Term Follow-up Study], 20-60 years</p> <p><b>Outcome Definition:</b> Serum concentration (LDL, HDL, total cholesterol, triglycerides)</p>	<p><b>Exposure Assessment:</b> Serum concentration</p> <p><b>Population-Level Exposure:</b> (ng/mL)</p> <p><u>Baseline (2005/06)</u> Geometric Mean=74.8; Arithmetic Mean=140.1</p> <p><u>Follow-up (2010)</u> Geometric Mean=30.8 Arithmetic Mean=68.2</p>	<p><b>Stat Method:</b> adjusted linear regression models. Change-vs-change model, in which the cross-sectional model as baseline is subtracted from the cross-sectional model at follow-up. Covariates and confounders considered include age at baseline, time between measurements, sex, and fasting status (from both baseline and follow-up). PFOS also controlled for in PFOA model.</p> <p>Sensitivity analysis adjusted for baseline BMI, years of schooling, change in smoking, and baseline and changes in GFR. Additionally, a ratio of baseline to follow-up and PFOA tertiles are ordered by decrease.</p> <p>PFOA log transformed. Findings shown below are for most adjusted model and model adjusting for PFOS. Effect estimates are percentage decrease in serum lipid based on halving of PFOA.</p> <p>Estimates are shown as percent decrease.</p> <p><b>Outcome:</b> LDL  <b>Major Findings:</b>                  % ↓=3.58 (95% CI 1.47, 5.66)                  % ↓<sub>(PFOS)</sub>=2.92 (95% CI 0.71, 5.09)</p> <p><b>Outcome:</b> Total cholesterol  <b>Major Findings:</b>                  % ↓=1.65 (95% CI 0.32, 2.97)                  % ↓<sub>(PFOS)</sub>= 0.63(95% CI -0.88, 2.12)</p>	<p><b>Major Limitations:</b> Joint models should be assessed with caution because PFOA and PFOS are highly correlated.</p> <p>Only two time points from which to estimate relationship</p> <p>Lag uncertainty</p> <p>Cannot detect any possible irreversible effects of PFOA on serum lipids Low power in LDL analysis – n=56</p> <p>Exact mechanism unknown – limits causal explanation</p> <p>Caution when extrapolating to general population – this is a highly exposed population</p> <p><b>Funding Source:</b> C8 Class Action Settlement Agreement between DuPont and Plaintiffs</p>

	<p><b>Outcome:</b> HDL  <b>Major Findings:</b>                  % ↓ =1.33 (95% CI -0.21, 2.85)                  % ↓<sub>(PFOS)</sub>=1.24 (95% CI -0.34, 279)</p> <p><b>Outcome:</b> Triglycerides  <b>Major Findings:</b>                  % ↓ =-0.78 (95% CI -5.34, 3.58)                  % ↓<sub>(PFOS)</sub>=-1.16 (95% CI -5.85, 3.33)</p>	
--	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--

Reference and Study Design	Exposure Measures	Results	Comment																
<p>(Fletcher, Galloway et al. 2013)</p> <p><b>Study Design:</b> Cross-sectional</p> <p><b>Location:</b> Parkersburg, WV, USA</p> <p><b>Population:</b> Residents for at least one year, 20-60 year olds, N=290</p> <p><b>Outcome definition:</b> Changes in the expression of genes (13 target genes) involves in cholesterol metabolism in humans. Genes were selected on the basis of roles in cholesterol biogenesis (HMGCR), peroxisome proliferation (PPARA, PPARD, PPARG, and PGC1A), cholesterol transport (ABCA1, ABCG1, and APOA1), downstream transcriptional activation of PPARA (NR1H1, NR1H2, and mobilization of cholesterol (NPC1, ACAT1, and NCEH1)</p>	<p><b>Exposure Assessment:</b> Serum concentrations</p> <p><b>Population-Level Exposure:</b> Median = 30.1 ng/mL</p>	<p><b>Stat Method:</b> Adjusted linear regression, some models stratify by gender and menopausal status. Covariates and confounders considered include age, sex, BMI, average household income, and smoking status</p> <p>Expression value of each of the target genes and for PFOA/PFOS levels were log transformed.</p> <p><b>Outcome:</b> Candidate gene transcript levels  <b>Major Findings:</b>                      Following are statistically significant:  <b>significant:</b></p> <table border="1"> <thead> <tr> <th>Gene</th> <th>Coeff</th> <th>95% CI</th> <th>P</th> </tr> </thead> <tbody> <tr> <td><b>ABCG1</b></td> <td><b>-0.29</b></td> <td><b>-0.51, -0.06</b></td> <td><b>0.014</b></td> </tr> <tr> <td><b>NPC1</b></td> <td><b>-0.34</b></td> <td><b>-0.63, -0.04</b></td> <td><b>0.026</b></td> </tr> <tr> <td><b>NR1H2 (LXRB)</b></td> <td><b>-0.55</b></td> <td><b>-0.90, -0.20</b></td> <td><b>0.002</b></td> </tr> </tbody> </table> <p>ABCA1, ACAT1, APOA1, HMGCR, NCEH1, NR1H3, PPARA, PPARD, PPARGC1A, PPARG – were not statistically significant</p>	Gene	Coeff	95% CI	P	<b>ABCG1</b>	<b>-0.29</b>	<b>-0.51, -0.06</b>	<b>0.014</b>	<b>NPC1</b>	<b>-0.34</b>	<b>-0.63, -0.04</b>	<b>0.026</b>	<b>NR1H2 (LXRB)</b>	<b>-0.55</b>	<b>-0.90, -0.20</b>	<b>0.002</b>	<p><b>Major Limitations:</b> Restriction on examining expression in whole blood only – may not correlate with expression in target organs.</p> <p>Limited size of population, power concerns.</p> <p>Cross sectional design precludes causal inference.</p> <p><b>Funding Source:</b> C8 Class Action Settlement Agreement between DuPont and Plaintiffs, funds administered by Garden City Group</p>
Gene	Coeff	95% CI	P																
<b>ABCG1</b>	<b>-0.29</b>	<b>-0.51, -0.06</b>	<b>0.014</b>																
<b>NPC1</b>	<b>-0.34</b>	<b>-0.63, -0.04</b>	<b>0.026</b>																
<b>NR1H2 (LXRB)</b>	<b>-0.55</b>	<b>-0.90, -0.20</b>	<b>0.002</b>																

		<p><b>Men:</b></p> <table border="1"> <thead> <tr> <th>Gene</th> <th>Coeff</th> <th>95%CI</th> <th>P</th> </tr> </thead> <tbody> <tr> <td>ABCG1</td> <td>-0.34</td> <td>-0.64, 0.047</td> <td>0.024</td> </tr> <tr> <td>NPC1</td> <td>-0.53</td> <td>-0.99, -0.06</td> <td>0.025</td> </tr> <tr> <td>PPARA</td> <td>-0.38</td> <td>-0.68, 0.07</td> <td>0.012</td> </tr> <tr> <td>NR1H2</td> <td>-0.71</td> <td>-1.29, -0.12</td> <td>0.019</td> </tr> </tbody> </table> <p><b>Women:</b></p> <table border="1"> <thead> <tr> <th>Gene</th> <th>Coeff</th> <th>95% CI</th> <th>P</th> </tr> </thead> <tbody> <tr> <td><b>NCEH1</b></td> <td><b>0.44</b></td> <td><b>0.03, 0.85</b></td> <td><b>0.036</b></td> </tr> </tbody> </table> <p><b>Premenopausal (inverse effects):</b></p> <table border="1"> <thead> <tr> <th>Gene</th> <th>Coeff</th> <th>95%CI</th> <th>P</th> </tr> </thead> <tbody> <tr> <td><b>NR1H2</b></td> <td><b>-1.47</b></td> <td><b>-2.63, -0.32</b></td> <td><b>0.013</b></td> </tr> <tr> <td><b>PPARD</b></td> <td><b>-1.06</b></td> <td><b>-2.05, -0.07</b></td> <td><b>0.036</b></td> </tr> </tbody> </table> <p><b>Postmenopausal (positive effects):</b></p> <table border="1"> <thead> <tr> <th>Gene</th> <th>Coeff</th> <th>96% CI</th> <th>P</th> </tr> </thead> <tbody> <tr> <td><b>APOA1</b></td> <td><b>0.051</b></td> <td><b>0.11, 0.90</b></td> <td><b>0.013</b></td> </tr> </tbody> </table> <p>Provides evidence from a human population that PFOA are associated with alterations in the levels of gene transcripts involves in cholesterol transport or mobilization, which appear consistent with PFOA promoting a hypercholesteroleamic environment.</p>	Gene	Coeff	95%CI	P	ABCG1	-0.34	-0.64, 0.047	0.024	NPC1	-0.53	-0.99, -0.06	0.025	PPARA	-0.38	-0.68, 0.07	0.012	NR1H2	-0.71	-1.29, -0.12	0.019	Gene	Coeff	95% CI	P	<b>NCEH1</b>	<b>0.44</b>	<b>0.03, 0.85</b>	<b>0.036</b>	Gene	Coeff	95%CI	P	<b>NR1H2</b>	<b>-1.47</b>	<b>-2.63, -0.32</b>	<b>0.013</b>	<b>PPARD</b>	<b>-1.06</b>	<b>-2.05, -0.07</b>	<b>0.036</b>	Gene	Coeff	96% CI	P	<b>APOA1</b>	<b>0.051</b>	<b>0.11, 0.90</b>	<b>0.013</b>	
Gene	Coeff	95%CI	P																																																
ABCG1	-0.34	-0.64, 0.047	0.024																																																
NPC1	-0.53	-0.99, -0.06	0.025																																																
PPARA	-0.38	-0.68, 0.07	0.012																																																
NR1H2	-0.71	-1.29, -0.12	0.019																																																
Gene	Coeff	95% CI	P																																																
<b>NCEH1</b>	<b>0.44</b>	<b>0.03, 0.85</b>	<b>0.036</b>																																																
Gene	Coeff	95%CI	P																																																
<b>NR1H2</b>	<b>-1.47</b>	<b>-2.63, -0.32</b>	<b>0.013</b>																																																
<b>PPARD</b>	<b>-1.06</b>	<b>-2.05, -0.07</b>	<b>0.036</b>																																																
Gene	Coeff	96% CI	P																																																
<b>APOA1</b>	<b>0.051</b>	<b>0.11, 0.90</b>	<b>0.013</b>																																																
<p><b>Reference and Study Design</b> (Frisbee, Shankar et al. 2010)</p> <p><b>Study Design:</b> Cross-sectional</p> <p><b>Location:</b> Mid-Ohio river</p>	<p><b>Exposure Measures</b></p> <p><b>Exposure Assessment:</b> Serum concentration</p> <p><b>Population-Level Exposure:</b> Mean = 69.2 ng/mL (SD = 111.9)</p>	<p><b>Results</b></p> <p><b>Stat Method:</b> Multiple linear regressions with GLM ANCOVA analysis to estimate predicted lipids with PFOA as quintile. To assess the linearity/nonlinearity of associations, population median for 20-group quantiles were plotted again the PFOA median. Binary</p>	<p><b>Comment</b></p> <p><b>Major Limitations:</b> Cross sectional design precludes causal inference.</p> <p>Self-reported survey data not uniformly reliable</p>																																																

<p>valley (OH and WV, USA)</p> <p><b>Population:</b> Children included in C8 Health Project N=12,476, 1-17.9 years</p> <p><b>Outcome Definition:</b> Serum lipids (LDL, total cholesterol, HDL, fasting triglycerides)</p>	<p>logistic regression analysis with outcomes as ‘high’ or ‘low’ and PFCs as quintiles. Covariates and confounders considered include age, gender, BMI, time of fasting, and exercise, and sensitivity analyses of fasting and socioeconomic status. Age and gender specific quantiles were created.</p> <p>PFOA was log-transformed. Interaction between PFOA and PFOA was assessed.</p> <p><b>Outcome:</b> Total cholesterol <b>Major Findings:</b> *Results not shown but after adjustment <b>PFOA linearly/positively associated (p&lt;0.0001)</b></p> <p>Q2 v. Q1, OR=1.1 (95% CI 1.0,1.3) Q3 v. Q1, OR=1.2 (95% CI 1.0, 1.4) <b>Q4 v. Q1, OR=1.2 (95% CI 1.1, 1.4)</b> <b>Q5 v. Q1, OR=1.2 (95% CI 1.1, 1.4)</b></p> <p><b>Outcome:</b> LDL <b>Major Findings:</b> *Results not shown but after adjustment <b>PFOA linearly/positively associated (p&lt;0.0001)</b></p> <p>Q2 v. Q1, OR=1.2 (95% CI 1.0,1.5) Q3 v. Q1, OR=1.2 (95% CI 1.0, 1.4) Q4 v. Q1, OR=1.2 (95% CI 1.0, 1.4) <b>Q5 v. Q1, OR=1.4 (95% CI 1.1, 1.7)</b></p> <p><b>Outcome:</b> Triglycerides <b>Major Findings:</b> *Results not shown but after adjustment <b>PFOA linearly/positively associated (p=0.019)</b></p> <p>Q2 v. Q1, OR=1.0 (95% CI 0.7,1.5) Q3 v. Q1, OR=1.3 (95% CI 0.9, 1.9) Q4 v. Q1, OR=1.6 (95% CI 1.1, 2.3) Q5 v. Q1, OR=1.0 (95% CI 0.7, 1.6)</p>	<p>Limited availability of known covariates</p> <p><b>Funding Source:</b> C8 Class Action Settlement Agreement between DuPont and Plaintiffs, and contractual relationship between Brookmar, INC. and West Virginia University. Authors are members of the separate C8 Science Panel.</p>
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

		<p><b>Outcome:</b> HDL</p> <p><b>Major Findings:</b> *Results not shown but after adjustment PFOA not linearly associated</p> <p>Q2 v. Q1, OR=1.0 (95% CI 0.8,1.2) Q3 v. Q1, OR=1.0 (95% CI 0.8, 1.2) Q4 v. Q1, OR=1.0 (95% CI 0.9, 1.2) Q5 v. Q1, OR=0.9 (95% CI 0.8, 1.1)</p>	
--	--	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--

Reference and Study Design	Exposure Measures	Results	Comment										
<p>(Fu, Wang et al. 2014)</p> <p><b>Study Design:</b> Cross-sectional</p> <p><b>Location:</b> Henan, China</p> <p><b>Population:</b> Random selection of people coming in for health check-up at Yuanyang hospital, N=133, aged 0-88 years</p> <p><b>Outcome Definition:</b> Serum lipids</p>	<p><b>Exposure Assessment:</b> Serum concentrations</p> <p><b>Population-Level Exposure:</b> Median = 1.43 ng/mL</p> <table border="1"> <thead> <tr> <th>Quartile</th> <th>Mean (ng/mL)</th> </tr> </thead> <tbody> <tr> <td>1</td> <td>0.71</td> </tr> <tr> <td>2</td> <td>1.24</td> </tr> <tr> <td>3</td> <td>1.97</td> </tr> <tr> <td>4</td> <td>4.88</td> </tr> </tbody> </table>	Quartile	Mean (ng/mL)	1	0.71	2	1.24	3	1.97	4	4.88	<p><b>Stat Method:</b> Linear regression, exposure modeled in quartiles with 1<sup>st</sup> quartile serving as the referent group. Binary logistic regression of abnormal lipids by PFC quartile. Covariates and confounders considered include age, gender, and BMI.</p> <p>Outcomes are based on a change in values.</p> <p><b>Outcome:</b> Total cholesterol <b>Major Findings:</b> ↑ (p-value for trend 0.015)</p> <p><b>Outcome:</b> Triglycerides <b>Major Findings:</b> NS (p-value for trend 0.298)</p> <p><b>Outcome:</b> HDLC <b>Major Findings:</b> NS (p-value for trend 0.260)</p> <p><b>Outcome:</b> LDLC <b>Major Findings:</b> ↑ (p-value for trend 0.022)</p> <p>*For each of these outcomes there were also binary logistic regression results; however, no results were statistically significant for any level of PFC or outcome.</p>	<p><b>Major Limitations:</b> Cross sectional design precludes causal inference.</p> <p>Did not take into account cholesterol-lowering medications or other environmental factors and contaminants including other co-occurring PFCs.</p> <p>Convenience sample – possible bias.</p> <p>Small sample size.</p> <p><b>Funding Source:</b> National Natural Science Foundation of China (Grant nos. 41371488 and 41071355, the International Scientific Cooperation Program (Grant no. 2012DFA91150), and Key Project of the Chinese Academy of Sciences (Grant no. KZZD-EW-TZ-12).</p>
Quartile	Mean (ng/mL)												
1	0.71												
2	1.24												
3	1.97												
4	4.88												

Reference and Study Design	Exposure Measures	Results	Comment
<p>(Gallo, Leonardi et al. 2012)</p> <p><b>Study Design:</b> Cross-sectional</p> <p><b>Location:</b> United States – West Virginia and Ohio</p> <p><b>Population:</b> Adults (18 years or older). Consumed water for at least 1 year from a water district with known PFOA contamination, n=47,092</p> <p><b>Outcome Definition:</b> Serum biomarkers of liver function: ALT (alanine transaminase), GGT (gamma-glutamyltransferase), direct bilirubin</p>	<p><b>Exposure Assessment:</b> Serum concentrations</p> <p><b>Population-Level Exposure:</b> Median: 23.1 ng/mL, IQR 11.3-58.2</p>	<p><b>Stat Method:</b> Linear regression of ln-transformed values, logistic regression fitted (reference levels as cut-offs for outcomes) comparing deciles of exposure, multilevel analysis comparing individual-level associations to population-level associations. Covariates and confounders considered include age, physical activity, BMI, average household income, educational level, alcohol consumption, cigarette smoking, fasting status, SES, race, and month of blood sample collection, and insulin resistance.</p> <p>Results for most adjusted models are presented.</p> <p><b>Outcome:</b> ln-ALT <b>Major Findings:</b> <math>\beta = 0.022</math> (95% CI 0.018, 0.025) p-value for trend &lt; 0.001 ln-Unit OR=1.10 (95% CI 1.01, 1.13)</p> <p><b>Relationship consistent for both between water districts and among individuals within districts increases strength of evidence for casual association.</b></p> <p><b>Outcome:</b> ln-GGT <b>Major Findings:</b> <math>\beta = 0.015</math> (95% CI 0.010, 0.019) p-value for trend = 0.213 ln-Unit OR=1.01 (95% CI 0.99, 1.04)</p> <p>Absence of trend across districts might be indicative of some confounding factor at the individual level.</p> <p><b>Outcome:</b> ln-Direct bilirubin <b>Major Findings:</b> <math>\beta = 0.001</math> (95% CI -0.002, 0.014) p-value for trend 0.496 ln-Unit OR=0.97 (95% CI 0.90, 1.15)</p> <p>Some evidence of geographic confounding.</p>	<p><b>Major Limitations:</b> Cross sectional design precludes causal inference.</p> <p>Self-reported data of lifestyle characteristics strongly associated with exposures of interest – can hamper confounder adjustment</p> <p>Possible confounding due to unmeasured variables, and other environmental contaminants, including other PFCs.</p> <p><b>Funding Source:</b> C8 Class Action Settlement Agreement between DuPont and Plaintiffs</p>

Reference and Study Design	Exposure Measures	Results	Comment
(Geiger, Xiao et al. 2013)  <b>Study Design:</b> Cross-sectional  <b>Location:</b> United States  <b>Population:</b> NHANES 1999-2000 and 2003-2008, ≤18 years of age, n=1,772  <b>Outcome Definition:</b> Hyperuricemia (serum uric acid levels >6 mg/dL)	<b>Exposure Assessment:</b> Serum concentrations  <b>Population-Level Exposure:</b> Mean = 4.3 ng/mL (SE 0.1)	<b>Stat Method:</b> Linear regression models, and multivariable logistic regression. Covariates and confounders considered include age, sex, race/ethnicity, BMI, annual household income, physical activity, total cholesterol, and serum cotinine levels.  PFCs were log-transformed in continuous analyses and categorized into quartiles for categorical analysis.  Results shown for most adjusted models.  <b>Outcome:</b> Uric Acid <b>Major Findings:</b> <b>Ln-Unit, mean change=0.20 (0.11, 0.29)</b>  Q2 v. Q1, mean change=0.02 (95% CI -0.10, 0.14) Q3 v. Q1, mean change=0.03 (95% CI -0.11, 0.17) <b>Q4 v. Q1, mean change=0.30 (95% CI 0.17, 0.43)</b>  <b>P-value for trend=0.0001</b>  <b>Outcome:</b> Hyperuricemia <b>Major Findings:</b> <b>Ln-Unit, OR=1.59 (1.19, 2.13)</b>  Q2 v. Q1, OR=0.94 (95% CI 0.58, 1.53) Q3 v. Q1, OR=1.01 (95% CI 0.62, 1.63) <b>Q4 v. Q1, OR=1.62 (95% CI 1.10, 0.43)</b>  <b>P-value for trend=0.0071</b>	<b>Major Limitations:</b> Cross-sectional design precludes causal inference.  Spot samples of urinalysis cannot detect changes in response to recent changes in exposure,  Possible confounding due to unmeasured variables, and other environmental contaminants, including other PFCs.

Reference and Study Design	Exposure Measures	Results	Comment
(Geiger, Xiao et al. 2014)  <b>Study Design:</b> Cross-sectional  <b>Location:</b> United States	<b>Exposure Assessment:</b> Serum concentrations  <b>Population-Level Exposure:</b> Mean: 4.2 (SE = 0.2) ng/mL	<b>Stat Method:</b> Linear regression models, and multivariable logistic regression. Covariates and confounders considered includes age, sex, race/ethnicity, BMI categories, annual household incomes, moderate activity, and serum cotinine.	<b>Major Limitations:</b> Cross sectional design precludes causal inference.  Possible confounding due to unmeasured variables, and other environmental contaminants, including other PFCs.



<p><b>Population:</b> NHANES 1999-2000 and 2003-2008, ≤18 years of age, n=815</p> <p><b>Outcome Definition:</b> Dyslipidemia (TC &gt; 170 mg/dL, HDL &lt; 40 mg/dL, LDL &gt;110 mg/dL, or triglycerides &gt;150 mg/dL)</p>		<p>PFCs were log-transformed in continuous analyses and categorized into tertiles for both continuous and categorical analysis.</p> <p>Results shown for most adjusted models.</p> <p><b>Outcome:</b> Total cholesterol <b>Major Findings:</b> Ln-Unit, OR=4.55 (95% CI 0.90, 8.20)</p> <p>Q2 v. Q1, OR=4.72 (95% CI -1.23, 10.67) <b>Q3 v. Q1, OR=7.00 (95% CI 1.40, 12.60)</b></p> <p><b>P-value for trend=0.017</b></p> <p><b>Outcome:</b> LDL <b>Major Findings:</b> <b>Ln-Unit, OR=5.75 (95% CI 2.16, 9.33)</b></p> <p>Q2 v. Q1, OR=3.61 (95% CI -1.13, 8.36) <b>Q3 v. Q1, OR=8.18 (95% CI 3.04, 13.32)</b></p> <p><b>P-value for trend=0.0027</b></p> <p><b>Outcome:</b> HDL <b>Major Findings:</b> Ln-Unit, OR=-1.52 (95% CI -3.02, -0.03)</p> <p>Q2 v. Q1, OR=0.53 (95% CI -1.23, 2.30) Q3 v. Q1, OR=-1.19 (95% CI -2.94, 0.56)</p> <p>P-value for trend=0.1769</p> <p><b>Outcome:</b> Triglycerides <b>Major Findings:</b> Ln-Unit, OR=1.74 (95% CI -2.88, 11.68)</p> <p>Q2 v. Q1, OR=3.00 (95% CI -5.68, 11.68) Q3 v. Q1, OR=0.09 (95% CI -6.11, 6.30)</p> <p>P-value for trend=0.9943</p>	<p><b>Funding Source:</b> Grant numbers 5T32HL090610-04, 1R01ES021825-01 and 5R03ES018888-02 from the National Institutes of Health.</p>
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	------------------------------------------------------------------------------------------------------------------------------------------

	<p><b>Outcome:</b> Dyslipidemia  <b>Major Findings:</b>                  Findings consistent with findings from linear regression analyses. Positive association between PFOA exposures and high total cholesterol and high LDL, but not with low HDL or high triglycerides.</p>	
--	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--

Reference and Study Design	Exposure Measures	Results	Comment
<p>(Gilliland and Mandel 1996)</p> <p><b>Study Design:</b> Cross-sectional</p> <p><b>Location:</b> 3M Chemolite plant (PFOA production plant), Cottage Grove, MN</p> <p><b>Population:</b> Occupationally exposed men (currently employed), 1985-1989, n=115</p> <p><b>Outcome Definition:</b> Hepatic enzyme and serum lipids: Serum glutamyl oxaloacetic transaminase (SGOT), serum glutamyl pyruvic transaminase (SGPT), gamma glutamyl transferase (GGT), cholesterol, low-density lipoproteins (LDL), high-density lipoproteins (HDL)</p> <p><b>Related Studies:</b> Gilliland and Mandel, 1993</p>	<p><b>Exposure Assessment:</b> Workers with jobs involving direct contact with PFOA = highly exposed. Workers without direct contact with PFOA for at least 5 years = low exposure. Job metrics were not used once determine 'unexposed' groups had levels 20-50 times higher than levels reported for general population.</p> <p>Total serum fluorine used as a surrogate.</p> <p><b>Population-Level Exposure:</b> Mean= 3.3ppm (mg/L)=3300 ng/mL Range 0 – 26 ppm</p>	<p><b>Stat Method:</b> Stratified analysis using ANOVA procedures to assess differences in mean values. Total fluorine divided into 5 groups. Pearson correlation coefficient (univariate), linear multivariate regression. Covariates and confounders considered include age, BMI, alcohol use, and tobacco use.</p> <p><b>Outcome:</b> Serum lipids  <b>Major Findings:</b>                  Cholesterol, r=0.07 (NS)                  LDL, r=0.02 (NS)                  HDL, r=-0.01 (NS)</p> <p><b>HDL, <math>\beta=-1.61</math>, p-value=0.04</b>                  Cholesterol and LDL (NS), results not shown</p> <p><b>Outcome:</b> Hepatic enzymes  <b>Major Findings:</b> NS                  SGOT (AST), r=0.01 (NS)                  SGPT (ALT), r=0.01 (NS)                  GGT, r=-0.04 (NS)</p> <p><b>SGOT (AST), <math>\beta=-3.23</math>, p-value=0.02</b>  <b>SGPT (ALT), <math>\beta=-15.8</math>, p-value=0.0008</b>                  GGT, <math>\beta=-1.93</math>, p-value=0.36</p> <p>Note: subclinical hepatic toxic effects in obese workers, drinkers and smokers. PFOA may be modulating these effects, i.e. "endocrine disruptor"</p>	<p><b>Major Limitations:</b> Healthy worker effect</p> <p>Cross sectional design precludes causal inference.</p> <p>Self-reported smoking and drinking status – not uniformly reliable</p> <p>Duration of exposure information not available</p> <p>Concerns with using serum fluorine rather than direct PFOA,</p> <p><b>Funding Source:</b> NIOSH grant T150H07098-16 and the 3M Medical Department</p>

Reference and Study Design	Exposure Measures	Results	Comment
<p>(Gleason, Post et al. 2015)</p> <p><b>Study Design:</b> Cross-sectional</p> <p><b>Location:</b> United States</p> <p><b>Population:</b> NHANES 2007-2010, individuals &gt; 12 years of age, n=4,333</p> <p><b>Outcome Definition:</b> Clinical biomarkers of liver function and uric acid</p>	<p><b>Exposure Assessment:</b> Serum concentrations</p> <p><b>Population-Level Exposure:</b> Geometric mean=3.5 ng/mL Median=3.7</p>	<p><b>Stat Method:</b> Linear regression, covariates and confounders considered include age, gender, race/ethnicity, BMI group, poverty, smoking, serum creatinine, and/or alcohol consumption. PFCs were natural log transformed. Logistic regression in exposure quartiles.</p> <p>Results are presented for models with most adjustment.</p> <p><b>Outcome:</b> Uric acid (mg/dL) <b>Major Findings:</b> LinR: <math>\beta = .303</math> (95% CI .238, .367) LogR: p-value for trend &lt;.001</p> <p><b>Outcome:</b> alanine transferase (ALT) (ppb) <b>Major Findings:</b> LinR: <math>\beta = .038</math> (95% CI .014, .062) LogR: p-value for trend =.007</p> <p><b>Outcome:</b> gamma-glutamyl transferase (GGT) (ppb) <b>Major Findings:</b> LinR: <math>\beta = .058</math> (95% CI .021, .096) LogR: p-value for trend =.042</p> <p><b>Outcome:</b> Total bilirubin (mg/dL) <b>Major Findings:</b> LinR: <math>\beta = .048</math> (95% CI .016, .081) LogR: p-value for trend &lt;.001</p> <p><b>Outcome:</b> asparate aminotransferase (AST) (ppb) <b>Major Findings:</b> LinR: <math>\beta = .025</math> (95% CI .007, .043) LogR: p-value for trend=.058</p> <p><b>Outcome:</b> alkaline phosphate (ALP) (ppb) <b>Major Findings:</b> LinR: <math>\beta = -.003</math> (95% CI -.023, .016) LogR: p-value for trend=.528</p>	<p><b>Major Limitations:</b> Modeling techniques may result in model- dependent estimates.</p> <p>PFCs appear to be correlated with each other, making it difficult to clearly distinguish the effects of individual PFCs.</p> <p>Cross sectional design precludes causal inference.</p> <p><b>Funding Source:</b> None, authors employed by NJDEP and NJDOH.</p>

Reference and Study Design	Exposure Measures	Results	Comment
<p>(Grandjean, Andersen et al. 2012)</p> <p><b>Study Design:</b> Prospective birth cohort</p> <p><b>Location:</b> Faroe Islands (National Hospital)</p> <p><b>Population:</b> n=656 consecutive singleton births recruited 1997-2000 and 587 followed-up through 2008.</p> <p><b>Outcome Definition:</b> Serum antibody concentrations against tetanus and diphtheria toxoids at ages 5 years prebooster, approximately 4 weeks after the booster, and at age 7 years.</p>	<p><b>Exposure Assessment:</b> Prenatal exposures to PFCs at week 32 of pregnancy, postnatal exposure at child age 5 years.</p> <p><b>Population-Level Exposure:</b> Geometric means: Maternal PFOA – 3.20 ng/mL Child (age 5) PFOA – 4.06</p>	<p><b>Stat Method:</b> Correlations were determined by pairwise Pearson correlation coefficients. Linear regression, covariates and confounders considered include sex and age. For 5-year pre-booster data models adjusted for time since vaccination, possible PCB exposure, birth weight, maternal smoking during pregnancy, and duration of breastfeeding, and booster type. Structural equation models were generated to determine the joint association of PFCs with the overall antibody concentrations. Also controlled for PFCs in maternal pregnancy serum in some of these structural models.</p> <p>PFCs were also categorized when greater than 0.1 IU/mL – and odds ratios were estimated.</p> <p>PFCs and antibodies were log-transformed.</p> <p><b>Outcome:</b> <b>Major Findings:</b> <b><u>Tetanus % difference (2-fold)</u></b> <b><u>Maternal PFC</u></b> (Year 5 Pre): -10.5 (95% CI -28.2, 11.7) (Year 5 Post): 14.5 (95% CI -10.4, 46.4) (Year 7): 7.4 (95% CI -17.1, 39.0) (Year 7 adj. for 5): 12.3 (95% CI -8.6, 38.1)</p> <p><i>Structural Eq.</i> (Year 5 Pre): -20.2 (95% CI -49.2, 25.2) (Age 7): 35.1 (95% CI -25.4, 144.6)</p> <p><i>Child (age 5) PFC</i> (Year 5 Pre): -13.3 (95% CI -31.6, 9.9) (Year 5 Post): -9.7 (95% CI -30.7, 17.7) <b>(Year 7): -35.8 (95% CI -51.9,-14.2); OR=3.27 (95% CI 1.43, 7.51)</b> <b>(Year 7 adj for 5): -28.8 (95% CI -42.7, -10.1)</b></p> <p><i>Structural Eq.</i> (Year 5 Pre): -20.5 (95% CI -44.4, 13.6) (Age 7): -55.2 (95% CI -73.3, 25.0)</p> <p><i>Child (age 5 adj.) PFC:</i> <i>Structural Eq.</i> (Year 5 Pre): -17.2 (95% CI -42.1, 18.5) <b>(Year 7): -58.8 (95% CI -76.0, 29.3)</b></p>	<p><b>Major Limitations:</b> Possible confounding due to unmeasured variables, and other environmental contaminants, including other PFCs.</p>

		<p><b><u>Diphtheria % difference (2-fold)</u></b></p> <p><u>Maternal PFC</u>          (Year 5 Pre): -16.2 (95% CI -34.2, 6.7)          (Year 5 Post): -6.2 (95% CI -22.4, 13.3)  <b>(Year 7): -22.8 (95% CI -39.4, -1.7)</b>  <b>(Year 7 adj. for 5): -16.8 (95% CI -32.9, 3.8)</b></p> <p><u>Structural Eq.</u>  <b>(Year 5 Pre): -47.9 (95% CI -67.7, -15.9)</b>  <b>(Age 7): -42.0 (95% CI -66.1, -0.8)</b></p> <p><u>Child (age 5) PFC</u>          (Year 5 Pre): -6.8 (95% CI -28.3, 21.0)          (Year 5 Post): -6.1 (95% CI -23.6, 15.5)  <b>(Year 7): -25.2 (95% CI -42.9, -2.0); OR=4.20 (95% CI 1.54, 11.44)</b>  <b>(Year 7 adj for 5): -23.4 (95% CI -39.3, -3.4)</b></p> <p><u>Structural Eq.</u>          (Year 5 Pre): -7.9 (95% CI -88.0, 37.0)  <b>(Age 7): -44.4 (95% CI -65.5, -10.5)</b></p> <p><u>Child (age 5 adj.) PFC:</u>  <u>Structural Eq.</u>          (Year 5 Pre): -1.2 (95% CI -33.6, 46.8)  <b>(Year 7): -45.5 (95% CI -66.9, 10.3)</b></p> <p><b>For the structural equation model the joint change in antibody showed statistical significance with PFCs at age 5 and at age 5 with adjustment for PFC in maternal pregnancy serum.</b></p>	
--	--	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--

Reference and Study Design	Exposure Measures	Results	Comment
<p>(Granum, Haug et al. 2013)</p> <p><b>Study Design:</b> Prospective birth cohort</p> <p><b>Location:</b> Oslo and Akershus, Norway</p> <p><b>Population:</b> Sub-cohort from Norwegian Mother and Child Cohort Study recruited 2007-2008, n=49-99.</p> <p><b>Outcome Definition:</b> Three annual questionnaire-based follow-ups (infectious diseases, allergies, and asthma) and blood samples collect from the mothers at the time of delivery and from the children at the age of 3 years.</p> <p>Serological outcomes: antibody levels specific for four vaccines (measles, rubella, tetanus, and HiB)</p>	<p><b>Exposure Assessment:</b> Maternal serum concentrations collected at time of delivery.</p> <p><b>Population-Level Exposure:</b> Median 1.1 ng/mL</p>	<p><b>Stat Method:</b> Poisson regression used for health outcomes with count data, otherwise logistic or linear regression analyses were applied. Confounders and covariates considered include maternal allergy, paternal allergy, maternal education, child's gender, and/or age at 3-year follow-up.</p> <p>PFCs categorized into quartiles.</p> <p><b>Outcome:</b> Anti-vaccine antibody levels <b>Major Findings:</b> <b>Rubella: (Bivariate) <math>\beta=-0.40</math> (95% CI -0.64, -0.17);</b> Measles: <math>\beta=-0.13</math> (95% CI -0.35, 0.09) Hib: <math>\beta=-0.05</math> (95% CI -3.85, 3.74) Tetanus: <math>\beta=0.01</math> (95% CI -0.09, 0.10)</p> <p><b>(Multivariate) <math>\beta=-0.40</math> (-0.64, -0.17)</b></p> <p><b>Outcome:</b> Health outcomes <b>Major Findings:</b> <u>Common Cold</u> (No. of episodes) <b>3<sup>rd</sup> year: <math>\beta=0.42</math> (95% CI 0.16, 0.72)</b> <b>All 3 years: <math>\beta=0.17</math> (95% CI 0.01, 0.33)</b> (Dichotomous) 3<sup>rd</sup> year: OR=1.24 (95% CI 0.32, 4.83)</p> <p><u>Gastroenteritis</u> (No. of episodes) 3<sup>rd</sup> year: <math>\beta=0.21</math> (95% CI -0.21, 0.64) <b>All 3 years: <math>\beta=0.31</math> (95% CI 0.002, 0.61)</b> (Dichotomous) 3<sup>rd</sup> year: OR=1.16 (95% CI 0.37, 3.65) All 3 years: OR=3.13 (95% CI 0.37, 3.65)</p>	<p><b>Major Limitations:</b></p> <p>No direct measures of fetal exposure without cord blood PFCs. Also can not differentiate from prenatal v. postnatal exposure.</p> <p>Possible selection bias due to the low recruitment rate in the original cohort (authors suggest selection bias between participants and non-participants due to self-selection has been evaluated and not likely to be a problem).</p> <p>Small study size.</p> <p>Possible confounding due to unmeasured variables, and other environmental contaminants, including other PFCs.</p>

Reference and Study Design	Exposure Measures	Results	Comment
<p>(Jain 2013)</p> <p><b>Study Design:</b> Cross-sectional</p> <p><b>Location:</b> United States</p> <p><b>Population:</b> NHANES 2007-08, &gt;12 years of age. n=1,540</p> <p><b>Outcome Definition:</b> Six thyroid function variables (TSH, FT4, TT4, FT3, TT3, thyroglobulin)</p>	<p><b>Exposure Assessment:</b> Serum concentrations</p> <p><b>Population-Level Exposure:</b> 4.1 ng/mL</p> <p>1<sup>st</sup> tertile <math>\leq</math>3.3 ng/mL 3<sup>rd</sup> tertile <math>\geq</math>5.1 ng/mL</p>	<p><b>Stat Method:</b> Linear regression, covariates and confounders considered included age, gender, race/ethnicity, smoking, iodine status, C-reactive proteins, BMI, fasting time, and caloric intake. Only select PFCs and outcomes are analyzed following some modeling selection criteria.</p> <p>PFCs and thyroid parameters were log transformed.</p> <p><b>Outcome:</b> TSH <b>Major Findings:</b> positively associated <math>\beta=0.053</math>, p-value=0.098 <math>\uparrow</math>(tertile) p-value &lt;0.01</p> <p><b>Outcome:</b> TT3 <b>Major Findings:</b> positively associated <math>R^2 = 17.3\%</math> <math>\beta=0.032</math>, p-value=0.013</p> <p><b>Outcome:</b> FT3, FT4, TT4, TGN <b>Major Findings:</b> FT3: <math>\beta=0.012</math>, p-value=0.09 FT4: <math>\beta=0.003</math>, p-value=0.83 TT4: <math>\beta=0.012</math>, p-value=0.43 TGN: <math>\beta=0.057</math>, p-value=0.17</p>	<p><b>Major Limitations:</b> 88 participants were on thyroid medication or reported a current thyroid problem (small compared to overall N),  Combined effect of persistent organic pollutants not known,  Cross sectional design precludes causal inference.</p> <p><b>Funding Source:</b> unspec - Author was publishing regularly for CDC until 2011, then seemed to be researching independently. Address on paper is a residential property in GA. Author subsequently worked for Fort Bragg in NC in 2014 before moving to an independent biostatistics consulting firm, empiristat, in January 2015.</p>

Reference and Study Design	Exposure Measures	Results	Comment
<p>(Ji, Kim et al. 2012)</p> <p><b>Study Design:</b> Cross-sectional</p> <p><b>Location:</b> Sigeung, Korea</p> <p><b>Population:</b> Recruited from cohort, aged greater than 12 years, n = 633</p> <p><b>Outcome Definition:</b> Thyroid hormones</p>	<p><b>Exposure Assessment:</b> Serum concentrations</p> <p><b>Population-Level Exposure:</b> 2.74 ng/mL IQR=2.04-3.64</p>	<p><b>Stat Method:</b> Linear regression, covariates and confounders considered include age and BMI.</p> <p><b>Outcome:</b> T4 <b>Major Findings:</b> <math>\beta=-0.007</math> (95% CI -0.029,0.015)</p> <p><b>Outcome:</b> TSH <b>Major Findings:</b> <math>\beta=-0.066</math> (95% CI -0.220,0.089)</p>	<p><b>Major Limitations:</b> One city not representative of all of Korea – very homogenous.  Cross sectional design precludes causal inference. Unknown  Did not control other environmental pollutants, including other PFCs.</p> <p><b>Funding Sources:</b> This research was supported by Korea Food &amp; Drug Administration (08182KFDA499).</p>



Reference and Study Design	Exposure Measures	Results	Comment
<p>(Jiang, Zhang et al. 2014)</p> <p><b>Study Design:</b> Cross-sectional</p> <p><b>Location:</b> Tianjin, China</p> <p><b>Population:</b> Pregnant women, n=141</p> <p><b>Outcome Definition:</b> White blood cells, red blood cells, hemoglobin, and platelet, total bilirubin, total protein, albumin, glucose, AST, and ALT.</p>	<p><b>Exposure Assessment:</b> Serum concentrations</p> <p><b>Population-Level Exposure:</b> Geo Mean n-PFOA = 4.18 ng/mL iso-PFOA = 0.04 ng/mL 5m-PFOA = 0.002 ng/mL</p> <p>Total=4.22</p>	<p><b>Stat Method:</b> Pearson rank-order correlations, PFCs and outcomes were log transformed.</p> <p>Results shown here for total PFOA.</p> <p><b>Outcome:</b> <b>Major Findings:</b></p> <p>WBC, <math>r=-0.042</math> (NS) RBC, <math>r=0.061</math> (NS) <b>Hemo, <math>r=0.192</math>, <math>p&lt;0.05</math></b> Platelet, <math>r=-0.004</math> (NS) Glucose, <math>r=0.103</math> (NS) Total protein, <math>r=0.092</math> (NS) <b>Albumin, <math>r=0.251</math>, <math>p&lt;0.01</math></b> Total bilirubin, <math>r=0.135</math> (NS) AST, <math>r=0.041</math> (NS) ALT, <math>r=-0.071</math> (NS)</p>	<p><b>Major Limitations:</b> Cross sectional design precludes causal inference.</p> <p>Third party confounders may exist</p> <p><b>Funding Source:</b> Natural Science Foundation of China (NSFC 21077060, 21325730, 21050110427), Ministry of Education (20130031130005), and the Ministry of Environmental Protection (201009026).</p>

Reference and Study Design	Exposure Measures	Results	Comment
<p>(Kielsen et al., 2015)</p> <p><b>Study Design:</b> Prospective cohort</p> <p><b>Location:</b> Denmark</p> <p><b>Population:</b> Healthy adults (n=12) without a history of tetanus-diphtheria booster vaccination in the past 5, recruited among staff at a hospital, 23 to 66 years of age</p> <p><b>Outcome Definition:</b> Antibody responses followed for 30 days after a booster vaccination (days 2,4,7,10,14 and 30) with diphtheria and</p>	<p><b>Exposure Assessment:</b> Serum PFOA measured prospectively for 30 days after booster vaccination (days 2,4,7,10,14 and 30).</p> <p><b>Population-Level Exposure:</b> Median 1.69 ng/mL, range 1.30-2.79</p>	<p><b>Stat Method:</b> Modeling which assumed a constant concentration level until Day 4 followed by a linear increase between days 4-10 after which the concentration was assumed to be constant, allowing the PFOA concentration to especially affect the intercept of the curve on those days. The analyses estimate how much this factor change, in percent, when the PFOA concentration doubled.</p> <p>Effects were adjusted for sex and age.</p> <p>PFOA and antibody concentrations were log transformed.</p> <p><b>Outcome:</b> Diphtheria Antibody Concentration <b>Major Findings:</b> % Change (Day 4-10)=-8.22 (95% CI 6.44, -20.85)</p>	<p><b>Major Limitations:</b> Small sample size</p> <p>Possible confounding due to unmeasured variables, including other environmental contaminant as well as other PFCs.</p>

<p>tetanus.</p> <p>Median antibody concentration pre-vaccination: Diphtheria 1.00 IU/ml Tetanus 4.03 IU/ml</p>		<p>Effects were stronger for diphtheria in general than compared with tetanus, and affects were statistically significant for PFOS, PFNA, and PFDA</p> <p><b>Outcome:</b> Tetanus Antibody Concentration <b>Major Findings:</b> % Change (Day 4-10)=0.23 (95% CI 12.1, -10.40)</p>	
------------------------------------------------------------------------------------------------------------------------	--	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--

Reference and Study Design	Exposure Measures	Results	Comment
<p>(Kim, Choi et al. 2011)</p> <p><b>Study Design:</b> Prospective birth cohort (matching prepartum blood – cord blood- postpartum breast milk)</p> <p><b>Location:</b> Seoul, Cheongju, and Gumi, South Korea</p> <p><b>Population:</b> Pregnant women recruited from three hospitals (n=44), age &gt; 25 years. Paired samples available for n=26 mother-infant pairs.</p> <p><b>Outcome Definition:</b> Serum concentrations mostly sampled in third trimester but some earlier (n=7, week 20-25), cord blood at delivery, and breast milk during mother checkup visit.</p>	<p><b>Exposure Assessment:</b> Maternal blood serum (n=44), fetal cord blood serum (n=43), and breast milk (n=35)</p> <p><b>Population-Level Exposure:</b></p> <p>Median (maternal prepartum blood serum) = 1.46 ng/mL</p> <p>Median (cord serum) = 1.15 ng/mL</p> <p>Median (breast milk) = 0.05 ng/mL</p>	<p><b>Stat Method:</b> Correlations between exposure and outcomes using Pearson correlation testes performed using the log of thyroid hormones and PFCs with and with-out adjustment for influential covariates. The following covariates and confounders were considered maternal age, gestational age, and maternal BMI.</p> <p>Results shown for adjusted correlations.</p> <p><b>Outcome:</b> fetal cord blood total T3 <b>Major Findings:</b> Fetal, r=-0.210 (NS) Maternal, r=-0.238 (NS)</p> <p><b>Outcome:</b> fetal cord blood total T4 <b>Major Findings:</b> Fetal, r=-0.157 (NS) Maternal, r=-0.071 (NS)</p> <p><b>Outcome:</b> fetal cord blood TSH <b>Major Findings:</b> Fetal, r=0.089 (NS) <b>Maternal, r=0.443 p&lt;0.05</b></p> <p>No significant association with birth weight and length for any measures of PFOA.</p>	<p><b>Major Limitations:</b> Possible confounding due to unmeasured variables, including other PFCs.</p> <p>Plausible competing mechanism involved in transplacental transfer.</p> <p>Cross-sectional design prevents causal inference.</p> <p>Small sample size.</p> <p><b>Funding Source:</b> This research was supported by Korea Food &amp; Drug Administration (08182KFDA499). The research was also supported by a Discovery Grant from the National Science and Engineering Research Council of Canada (Project # 326415-07) and a grant from the Western Economic Diversification Canada (Project # 6578 and 6807). The authors wish to acknowledge the support of an instrumentation grant from the Canada Foundation for Infrastructure.</p>

Reference and Study Design	Exposure Measures	Results	Comment
<p>(Knox, Jackson et al. 2011)</p> <p><b>Study Design:</b> Cross-sectional</p> <p><b>Location:</b> United States – West Virginia and Ohio</p> <p><b>Population:</b> Adults (20 years or older) without thyroid disease, consumed water for at least 1 year from a water district with known PFOA contamination, n=50,113 members of the class of those affected by C8 spill</p> <p><b>Outcome Definition:</b> thyroxine, T3 uptake, TSH,</p>	<p><b>Exposure Assessment:</b> Serum concentrations</p> <p><b>Population-Level Exposure:</b></p> <p>PFOA (ng/mL) Means by age group  Women 20-50=52.6  Men 20-50=91.0  Women &gt; 50=98.6  Men &gt; 50=124.3</p> <p>Total Mean = 86.57 ng/mL</p>	<p><b>Stat Method:</b> Linear regression and ANOVA to estimate gender differences, covariates and confounders considered include age, serum estradiol, and alcohol.</p> <p><b>Outcome:</b> TSH  <b>Major Findings:</b>  No significant associations, results not shown</p> <p><b>Outcome:</b> Thyroxine (T4)  <b>Major Findings:</b>  <b>Women 20-50, <math>\beta=0.05</math>, <math>p&lt;0.0001</math></b>  Men 20-50, (NS) results not provided  <b>Women &gt; 50, <math>\beta=0.08</math>, <math>p&lt;0.0001</math></b>  <b>Men &gt; 50, <math>\beta=0.06</math>, <math>p=0.0001</math></b></p> <p><b>Outcome:</b> T3  <b>Major Findings:</b>  <b>Women 20-50, <math>\beta=-0.08</math>, <math>p=0.0001</math></b>  Men 20-50, (NS) results not provided  <b>Women &gt; 50, <math>\beta=-0.07</math>, <math>p&lt;0.005</math></b>  <b>Men &gt; 50, <math>\beta=-0.04</math>, <math>p=0.037</math></b></p> <p><b>Outcome:</b> albumin  <b>Major Findings:</b>  <b>Women 20-50, <math>\beta=0.02</math>, <math>p&lt;0.0001</math></b>  <b>Men 20-50, <math>\beta=0.02</math>, <math>p&lt;0.0001</math></b>  <b>Women &gt; 50, <math>\beta=0.02</math>, <math>p&lt;0.0001</math></b>  <b>Men &gt; 50, <math>\beta=0.02</math>, <math>p&lt;0.0001</math></b></p>	<p><b>Major Limitations:</b>  Thyroxin-Binding Globulin production not measured, albumin used instead,    Cross sectional design precludes causal inference.    Possible confounding due to unmeasured variables, including other PFCs.</p> <p><b>Quality of study:</b> previously unreported gender differences in thyroxine and T3 uptake</p> <p><b>Funding Source:</b> unspec, All authors employed by WVU School of Medicine.</p>

Reference and Study Design	Exposure Measures	Results	Comment						
<p>(Lin, Lin et al. 2010)</p> <p><b>Study Design:</b> Cross-sectional</p> <p><b>Location:</b> United States</p> <p><b>Population:</b> NHANES 1999-2000 &amp; 2003-2004, n=2,216, 18 years of age or older</p>	<p><b>Exposure Assessment:</b> Serum concentrations</p> <p><b>Population-Level Exposure:</b></p> <table border="1"> <thead> <tr> <th>Gender</th> <th>Mean PFOA (ng/mL)</th> </tr> </thead> <tbody> <tr> <td>Male</td> <td>5.05</td> </tr> <tr> <td>Female</td> <td>4.06</td> </tr> </tbody> </table> <p>Population Mean: 4.54 ng/mL</p>	Gender	Mean PFOA (ng/mL)	Male	5.05	Female	4.06	<p><b>Stat Method:</b> Linear regression, covariates and confounders considered include age, gender, race/ethnicity, smoking, alcohol consumption, education level, BMI, HOMA-IR, metabolic syndrome, and iron saturation. PFCs assessed as quartiles and natural log transformed. Model estimates are shown for most adjusted.</p> <p>PFCs modeled separately and included in a composite analysis with PFOS, PFNA, and PFHxS.</p>	<p><b>Major Limitations:</b>  Cross sectional design precludes causal inference.</p> <p>No other environmental chemicals were included, may be important covariates</p> <p>Did not take into account any medications that may cause elevated ALT or GGT</p> <p>Common physiology could influence both serum PFCs and liver enzymes</p>
Gender	Mean PFOA (ng/mL)								
Male	5.05								
Female	4.06								

<p><b>Outcome Definition:</b> Serum liver enzymes: ALT (alanine transaminase), GGT (gamma-glutamyltransferase), total bilirubin</p>		<p><b>Outcome:</b> ALT <b>Major Findings:</b> <b>Quartiles of PFOA (unadj.), increasing trend (p&lt;0.001)</b> <b>Separate, <math>\beta = 1.86, p=0.005</math>.</b> <b>Composite, <math>\beta = 2.19, p=0.009</math>.</b></p> <p><b>Outcome:</b> GGT <b>Major Findings:</b> <b>Quartiles of PFOA (unadj.), increasing trend (p&lt;0.001)</b> <b>Separate, <math>\beta = 0.08, p=0.019</math>.</b> <b>Composite, <math>\beta = 0.15, p=0.001</math>.</b></p> <p><b>Outcome:</b> Total bilirubin <b>Major Findings:</b> Quartiles of PFOA (Unadj), no trend (p=0.638) Separate, <math>\beta = -0.09, p=0.645</math>. Composite, <math>\beta = -0.20, p=0.378</math>.</p>	<p>Status of liver tissue was not available to determine hepatic steatosis, inflammation, or fibrosis.</p> <p><b>Funding Source:</b> This was an investigator-initiated unfunded study. All authors had access to the data and the statistical analysis report. Pau-Chung Chen was the guarantor of the article, from the institute of Occupational Medicine and Industrial Hygiene, National Taiwan University College of Public Health.</p>
-----------------------------------------------------------------------------------------------------------------------------------------	--	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Reference and Study Design	Exposure Measures	Results	Comment										
<p>(Lin, Wen et al. 2011)</p> <p><b>Study Design:</b> Cross-sectional</p> <p><b>Location:</b> Taipei, Taiwan</p> <p><b>Population:</b> 287 adolescents and young adults, aged 12-30 years of age recruited from a hypertension cohort.</p> <p><b>Outcome Definition:</b> Serum measures</p> <p>Adiponectin is a protein hormone that modulates a number of metabolic processes, including glucose regulation and fatty acid catabolism.</p>	<p><b>Exposure Assessment:</b> Screening of school-age children via urine with subsequent blood serum tests,</p> <p><b>Population-Level Exposure:</b> Median: 2.39 ng/mL</p> <table border="1" data-bbox="478 987 747 1182"> <thead> <tr> <th>Percentile</th> <th>Median (ng/mL)</th> </tr> </thead> <tbody> <tr> <td>&lt;50<sup>th</sup></td> <td>0.75</td> </tr> <tr> <td>50-74<sup>th</sup></td> <td>3.86</td> </tr> <tr> <td>75<sup>th</sup>-89<sup>th</sup></td> <td>7.89</td> </tr> <tr> <td>≥ 90<sup>th</sup></td> <td>11.54</td> </tr> </tbody> </table>	Percentile	Median (ng/mL)	<50 <sup>th</sup>	0.75	50-74 <sup>th</sup>	3.86	75 <sup>th</sup> -89 <sup>th</sup>	7.89	≥ 90 <sup>th</sup>	11.54	<p><b>Stat Method:</b> The relation of PFC variables to categorical variables was tested using the Mann-Whitney U test or Kruskal-Wallis test.</p> <p>Linear regression with adiponectin, glucose homeostasis, lipid profile, inflammatory markers</p> <p>Covariates and confounders: Model 1 (age and gender), Model 2 (age, gender, lifestyle factors), Model 3 (Model 2 + measurement data).</p> <p>Significant only if significant in all models.</p> <p><b>Outcome:</b> Serum adiponectin, glucose, insulin, triglycerides, CRP, HDL <b>Major Findings:</b> PFOA levels were significantly lower in subjects with metabolic syndrome (p=0.009)</p>	<p><b>Major Limitations:</b> Cross sectional design precludes causal inference.</p> <p>No inclusion of other environmental chemicals which may be important covariates</p> <p>The study population is made up of adolescents and young adults with abnormal urinalysis results.</p> <p>Study population only adolescents and young adults – not generalizable to larger population</p> <p>Common physiology could influence both serum PFCs and outcome measures</p> <p><b>Funding Source:</b> This study was supported by grants from the National Health Research Institute of Taiwan (NHRI-EX97-9721PC, EX97-9821P C,</p>
Percentile	Median (ng/mL)												
<50 <sup>th</sup>	0.75												
50-74 <sup>th</sup>	3.86												
75 <sup>th</sup> -89 <sup>th</sup>	7.89												
≥ 90 <sup>th</sup>	11.54												

		<p>Results in Supporting Information Tables – reported as all non-significant for all 3 model types.</p>	<p>and X97 -9921PC ) and (NHRI-EX95-953 I PI, EX95 - 9631PI, and EX95-9731PI) and from the National Science Council of Taiwan (99-2314-B-385 001-MY3).</p>
--	--	----------------------------------------------------------------------------------------------------------	------------------------------------------------------------------------------------------------------------------------------------------------------------

Reference and Study Design	Exposure Measures	Results	Comment										
<p>(Lin, Wen et al. 2013)</p> <p><b>Study Design:</b> Cross sectional</p> <p><b>Location:</b> Taipei, Taiwan</p> <p><b>Population:</b> Young adults with abnormal urinalysis in childhood, 12-30 years old, N=551 (510 with normal blood pressure and 41 hypertensive)</p> <p><b>Outcome Definition:</b> Laboratory, examination, and survey information.</p>	<p><b>Exposure Assessment:</b> Serum concentrations</p> <p><b>Population-Level Exposure:</b> Geometric mean = 2.67 ng/mL</p> <table border="1" data-bbox="478 586 739 777"> <thead> <tr> <th>Quartile</th> <th>Levels ng/mL</th> </tr> </thead> <tbody> <tr> <td>&lt; 50<sup>th</sup></td> <td>&lt;3.64</td> </tr> <tr> <td>50<sup>th</sup>-75<sup>th</sup></td> <td>≤6.66</td> </tr> <tr> <td>75<sup>th</sup> – 90<sup>th</sup></td> <td>≤9.71</td> </tr> <tr> <td>&gt; 90<sup>th</sup></td> <td>&gt;9.71</td> </tr> </tbody> </table>	Quartile	Levels ng/mL	< 50 <sup>th</sup>	<3.64	50 <sup>th</sup> -75 <sup>th</sup>	≤6.66	75 <sup>th</sup> – 90 <sup>th</sup>	≤9.71	> 90 <sup>th</sup>	>9.71	<p><b>Stat Method:</b> Linear and logistic regression for categories of PFCs (≤50<sup>th</sup>, ≤50<sup>th</sup>-75<sup>th</sup>, ≤75<sup>th</sup>- 90<sup>th</sup>, &gt;90<sup>th</sup>), covariates and confounders considered include age, gender, smoking, and alcohol consumption.</p> <p>TSH was natural log transformed.</p> <p><b>Outcome:</b> Free T4 (ng/dL) <b>Major Findings:</b> Means=1.07, 1.08, 1.10, 1.06 (P for Trend NS)</p> <p><b>Outcome:</b> log TSH (m IU/l) <b>Major Findings:</b> Means=0.48, 0.45, 0.36, 0.41 (P for Trend NS)</p>	<p><b>Major Limitations:</b> Cross sectional design precludes causal inference.</p> <p>Population is not generalizable – very specific,</p> <p>Did not take into account all medications that may have impact on thyroid functioning,</p> <p>Unmeasured confounders possible,</p> <p>Status of thyroid tissue unavailable to determine thyroid pathology.</p> <p><b>Funding Source:</b> This study was supported by grants from National Health Research Institute of Taiwan (EX97-9721PC, EX97-9821PC, X97-9921PC, EX95-9531PI, EX95-9631PI and EX95-9731PI) and from National Science Council of Taiwan (99-2314-B-385-001-MY3).</p>
Quartile	Levels ng/mL												
< 50 <sup>th</sup>	<3.64												
50 <sup>th</sup> -75 <sup>th</sup>	≤6.66												
75 <sup>th</sup> – 90 <sup>th</sup>	≤9.71												
> 90 <sup>th</sup>	>9.71												

Reference and Study Design	Exposure Measures	Results	Comment
<p>(Lin, Lin et al. 2013)</p> <p><b>Study Design:</b> Cross-sectional</p> <p><b>Location:</b> Taipei area, Taiwan</p> <p><b>Population:</b> Taiwanese young adults with abnormal urinalysis in childhood, 12-30 years old, N=664 (246 with elevated blood pressure and 398 with normal blood pressure)</p> <p><b>Outcome Definition:</b> Serum samples, sociodemographic data collected during interview. Clinical outcomes were determined from clinical serum measures.</p> <p>Carotid intima-media thickness (CIMT) is a marker of subclinical atherosclerosis.</p>	<p><b>Exposure Assessment:</b> Serum concentrations</p> <p><b>Population-Level Exposure:</b> Median: 3.49 ng/mL Range: 0.75-52.2</p>	<p><b>Stat Method:</b> Linear regression and logistic regression for categories of PFCs (<math>\leq 50^{\text{th}}</math>, <math>\leq 50^{\text{th}}-75^{\text{th}}</math>, <math>\leq 75^{\text{th}}-90^{\text{th}}</math>, <math>&gt;90^{\text{th}}</math>) covariates and confounders considered include age, gender, smoking status, alcohol consumption, and BMI to estimate association with cardiovascular risk factors, and additionally sBP, BMI, LDL, CRP, TG, and HOMA-IR for CIMT.</p> <p>Logistic regression analysis was conducted to examine the odds ratios of thicker CIMT for PFOS only. Investigators performed a composite analysis with four PFCs modeled together.</p> <p><b>Outcome:</b> Cardiovascular risk factors</p> <p><b>Major Findings:</b> SBP - ↓ (P for trend=0.177) BMI - ↓ (P for trend=0.130) LDL-C - ↓ (P for trend=0.117) <b>Log-TG - ↓ (P for trend=0.015)</b> UA - ↑ (P for trend=0.983) Log-HOMA-IR - ↑/↓ (P for trend=0.694)</p> <p><b>Outcome:</b> CIMT <b>Major Findings:</b> NS (findings in paper are only PFOS-relevant)</p>	<p><b>Major Limitations:</b> Cross sectional design precludes causal inference.</p> <p>Did not include other environmental factors (ie particulate matter air pollution)</p> <p>Tenuous generalizability due to sample</p> <p>Did not take into account medicines which may affect CIMT</p> <p>Common physiology could influence both things.</p> <p><b>Funding Source:</b> This study was supported by grants from the National Health Research Institute of Taiwan (NHRI EX97-9721PC, EX98-9721PC, EX99-9721PC, and EX100-9721PC; EX95-9531PI, EX96-9531PI and EX95-9731PI) and from the National Science Council of Taiwan (NSC 99-2314-B-385-001-MY3 and NSC 101-2314-B-002-184-MY3).</p>

Reference and Study Design	Exposure Measures	Results	Comment
<p>(Looker, Luster et al. 2014)</p> <p><b>Study Design:</b> Prospective cohort</p> <p><b>Location:</b> U.S., mid-Ohio region of Ohio and West Virginia</p> <p><b>Population:</b> Adults who consumed water (for at least 1 year) from a water district with</p>	<p><b>Exposure Assessment:</b> Serum concentrations at time of vaccination.</p> <p><b>Population-Level Exposure:</b> Median, 31.5 ng/mL</p>	<p><b>Stat Method:</b> Linear regression for PFC (log transformed and quartiles), covariates and confounders considered include age and gender, smoking status, any previous influenza vaccination, specific H1N1 vaccination in previous year, day of serum sample collection, coexisting medical conditions, and common anti-inflammatory, and pain relief medications, as well as mobility. Logistic regression also utilized for dichotomized outcomes.</p> <p>Differences and ratios of antibody titers were log transformed. Titers also dichotomized into seroconversions (4-fold or greater increase in antibody titer following vaccination) and seroprotection (HI titer &gt;</p>	<p><b>Major Limitations:</b> Reporting of previous – potential of recall bias</p> <p>Given the high background rate of respiratory infection, there is not much scope to detect an increase in infections.</p> <p>Not a longitudinal analysis. No vaccination information</p>



<p>known PFOA contamination, n=411. Initial recruitment was 2005-06 and were followed-up in 2010.</p> <p><b>Outcome Definition:</b> Hemagglutination inhibition tests were conducted on serum samples collected preinfluenza vaccination and 21± 3 postvaccination in 2010.</p> <p>Questionnaires were conducted regarding the occurrence and frequency of recent (last 12 months) of respiratory infections.</p>	<p>1:40).</p> <p>PFCs were untransformed, log transformed, and categorized into quartiles.</p> <p><b>Outcome: Geometric Mean antibody titer (GMT) Rise Following Vaccination</b></p> <p><b>Major Findings:</b> <u>Influenza Type B</u> Q1: 49.46 (95% CI 38.14, 64.12) Q2: 46.00 (95% CI 35.28, 59.97) Q3: 43.55 (95% CI 33.08, 57.33) <b>Q4: 20.90 (95% CI 16.58, 28.24)</b></p> <p>Titer Rise: Linear - <math>\beta(\text{adj.})=-0.2</math> (95% CI -0.13, 0.09) Q2 v. Q1 - <math>\beta(\text{adj.})=-0.3</math> (95% CI -0.19, 0.13) Q3 v. Q1 - <math>\beta(\text{adj.})=-0.2</math> (95% CI -0.19, 0.15) Q4 v. Q1 - <math>\beta(\text{adj.})=-0.7</math> (95% CI -0.24, 0.10)</p> <p>Titer Ratio: Linear - <math>\beta(\text{adj.})=-0.2</math> (95% CI -0.11, 0.08) Q2 v. Q1 - <math>\beta(\text{adj.})=0.5</math> (95% CI -0.09, 0.19) Q3 v. Q1 - <math>\beta(\text{adj.})=0.7</math> (95% CI -0.07, 0.22) Q4 v. Q1 - <math>\beta(\text{adj.})=-0.3</math> (95% CI -0.17, 0.12)</p> <p>No statistically significant ORs for seroconversions or seroprotection.</p> <p><u>Influenza Type A H1N1</u> 476.23 (360.77, 628.65) 352.22 (255.33, 485.88) 306.32 (232.58, 403.44) 274.79 (202.85, 372.23)</p> <p>Titer Rise: Linear - <math>\beta(\text{adj.})=-0.3</math> (95% CI -0.14, 0.09) Q2 v. Q1 - <math>\beta(\text{adj.})=-0.9</math> (95% CI -0.27, 0.08) Q3 v. Q1 - <math>\beta(\text{adj.})=-0.10</math> (95% CI -0.28, 0.09) Q4 v. Q1 - <math>\beta(\text{adj.})=-0.12</math> (95% CI -0.30, 0.06)</p> <p>Titer Ratio: Linear - <math>\beta(\text{adj.})=-0.7</math> (95% CI -0.06, 0.21) Q2 v. Q1 - <math>\beta(\text{adj.})=-0.8</math> (95% CI -0.29, 0.12) Q3 v. Q1 - <math>\beta(\text{adj.})=-0.04</math> (95% CI -0.25, 0.18) Q4 v. Q1 - <math>\beta(\text{adj.})=0.7</math> (95% CI -0.14, 0.29)</p>	<p>for 2005/2006 such that persons could have been followed as the PFC levels decreased.</p>
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	----------------------------------------------------------------------------------------------



	<p>No statistically significant ORs for seroconversions or seroprotection.</p> <p><u>Influenza A H3N2</u>                  228.86 (161.53, 324.27)                  125.36 (86.01, 182.73)                  104.13 (72.47, 149.64)                  183.73 (127.28, 265.23)</p> <p>Titer Rise:                  Linear - <math>\beta(\text{adj.})=-0.1</math> (95% CI -0.17, 0.14)  <b>Q2 v. Q1 - <math>\beta(\text{adj.})=-0.28</math> (95% CI -0.51, -0.06)</b>  <b>Q3 v. Q1 - <math>\beta(\text{adj.})=-0.37</math> (95% CI -0.60, -0.13)</b>                  Q4 v. Q1 - <math>\beta(\text{adj.})=-0.12</math> (95% CI -0.36, 0.13)</p> <p>Titer Ratio:                  Linear - <math>\beta(\text{adj.})=-0.127</math> (95% CI -0.25, 0.02)                  Q2 v. Q1 - <math>\beta(\text{adj.})=-0.10</math> (95% CI -0.30, 0.10)                  Q3 v. Q1 - <math>\beta(\text{adj.})=-0.07</math> (95% CI -0.28, 0.14)  <b>Q4 v. Q1 - <math>\beta(\text{adj.})=-0.22</math> (95% CI -0.43, -0.01)</b></p> <p>No statistically significant seroconversions.</p> <p><u>Seroprotection</u>  <b>Q2 v. Q1 - OR=0.34 (95% CI 0.14, 0.83)</b>  <b>Q3 v. Q1 - OR=0.28 (95% CI 0.11, 0.70)</b>  <b>Q4 v. Q1 - OR=0.39 (95% CI 0.15, 0.99)</b></p> <p>*No statistically significant associations between self-reported colds or influenza and PFOA levels.</p>	
--	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--

Reference and Study Design	Exposure Measures	Results	Comment
<p>(Lopez-Espinosa, Mondal et al. 2012)</p> <p><b>Study Design:</b> Cross-sectional and birth cohort</p> <p><b>Location:</b> mid-Ohio valley, USA</p>	<p><b>Exposure Assessment:</b> Serum PFOA and modeled in utero PFOA (information on historical releases, environmental distribution, pharmacokinetic modeling, residential histories)</p> <p><b>Population-Level Exposure:</b> Median in utero: 12 ng/mL Median serum PFOA: 29 ng/mL</p>	<p><b>Stat Method:</b> Linear and logistic regression, covariates and confounders considered include age, sex, race/ethnicity, BMI, month of sampling, average household family income, smoking, and alcohol consumption.</p> <p><b>Outcome:</b> ln-TSH</p> <p><b>Major Findings:</b> Modeled (% change 1-17 years old, IQR): %=-0.5 (95% CI -2.4, 1.5)</p>	<p><b>Major Limitations:</b> Mostly cross-sectional design precludes much causal inference,  Absence of measurements of child triiodothyronine,  Reliance on recall for thyroid diagnosis (though a more stringent case definition produced similar results).</p>

<p><b>Population:</b> Children (age 1-17) who consumed water (for at least 1 year) from a water district with known PFOA contamination, n=10,725 were included in the analysis. Subsample of children matched to mothers for model in utero PFOA exposure, n=4,713 (pregnancies from 1987-2005)</p> <p><b>Outcome Definition:</b> Serum samples of TSH, TT4, categorized into subclinical hypothyroidism and hyperthyroidism. Also parent self-reported thyroid disease and thyroid disease related medication use.</p>	Years	Model	Measure	<p>Measure (%change 1-17 years old, IQR): %=1.0 (95% CI -0.5, 2.7)</p> <p><b>Outcome:</b> TT4 <b>Major Findings:</b> Modeled (% change 1-17 years old, IQR): %=-0.1 (95% CI -0.8, 0.6)</p> <p>Measure (%change 1-17 years old, IQR): %=0.1 (95% CI -0.5, 0.6)</p> <p><b>Outcome:</b> Thyroid disease <b>Major Findings:</b> Modeled, Reported OR=1.47 (95% CI 0.95, 2.27) <b>Measured, Reported</b> <b>OR=1.44 (95% 1.02, 2.03)</b></p> <p><b>Outcome:</b> Hypothyroidism <b>Major Findings:</b> Modeled, Reported OR=1.61 (95% CI 0.96, 2.63) <b>Measured, Reported</b> <b>OR=1.54 (95% 1.00, 2.37)</b> Modeled (in utero), Subclinical OR=0.94 (95% CI 0.76, 1.16) Measure, Subclinical OR=0.98 (95% CI 0.86, 1.15)</p> <p><b>Outcome:</b> Hyperthyroidism <b>Major Findings:</b> Modeled, Subclinical OR=1.10 (95% CI 0.69, 1.74) Measure, Subclinical OR=0.81 (95% CI 0.58, 1.15)</p>
	1-5	23.8	33.8	
	6-10	14.5	32.2	
	> 10	9.32	26.9	
	1-17	11.5	29.3	
				<p>No control for other environmental chemicals including other PFCs.</p> <p>Reliant of modeled in utero PFOA exposure for birth cohort.</p> <p><b>Quality of study:</b> first large scale report in children suggesting associations of serum PFOA and hypothyroidism</p> <p><b>Funding Source:</b> C8 class action settlement agreement between DuPont and plaintiffs</p>

Reference and Study Design	Exposure Measures	Results	Comment
<p>(Melzer, Rice et al. 2010)</p> <p><b>Study Design:</b> Cross-sectional</p> <p><b>Location:</b> United States</p>	<p><b>Exposure Assessment:</b> Serum PFOA</p> <p><b>Population-Level Exposure:</b> Geo mean men = 4.91 ng/mL  Geo mean women = 3.77 ng/mL</p>	<p><b>Stat Method:</b> Multivariate logistic regression of thyroid disease by PFC quartile. Sex specific models were used. Covariates and confounders considered include year of NHANES cycle, age, sex, race/ethnicity, education, smoking status, BMI, and alcohol intake.</p>	<p><b>Major Limitations:</b> Investigators based PFOA on a single serum sample, likely to represent medium-term internal dose, samples taken at several time points might be more accurate in classifying exposure. Any misclassification from single measures</p>

<p><b>Population:</b> NHANES 1999-2000, 2003-2004, and 2005-2006 N=3974; ≥ 20 years of age</p> <p><b>Outcome Definition:</b> Thyroid disease= ever self-reported health professional diagnosis and current diagnosis and currently taking medication for the disease (CURRENT).</p> <p>Also examined other self-reported diseases.</p>		<p>Results shown for most adjusted models.</p> <p><b>Outcome:</b> Thyroid disease <b>Major Findings:</b> EVER: Women, Q2 v. Q1, OR=0.95 (95% CI 0.62,1.47) Q3 v. Q1, OR=1.11 (95% CI 0.67, 1.83) <b>Q4 v. Q1, OR= 1.64 (95% CI 1.09, 2.46)</b></p> <p>Men, Q2 v. Q1, OR=1.11 (95% CI 0.62,1.99) Q3 v. Q1, OR=0.57 (95% CI 0.19, 1.66) Q4 v. Q1, OR= 1.58 (95% CI 0.74, 3.39)</p> <p>CURRENT: Women Q2 v. Q1, OR=0.89 (95% CI 0.49,1.59) <b>Q3 v. Q1, OR=1.86 (95% CI 1.12, 3.09)</b> <b>Q4 v. Q1, OR=2.24 (95% CI 1.38, 3.65)</b></p> <p>Men, Q2 v. Q1, OR=1.12 (95% CI 0.52, 2.39) Q3 v. Q1, OR=0.49 (95% CI 0.18, 1.38) Q4 v. Q1, OR=1.89 (95% CI 0.60, 5.90)</p> <p><b>Outcome:</b> Arthritis ever, asthma ever, COPD ever, Diabetes ever, Heart disease ever, Liver disease current <b>Major Findings:</b> Some evidence of positive association with arthritis (Q2 v. Q1 and Q3 v. Q1 P &lt;0.05, but not Q4). For asthma ever Q2 v. Q1 is statistically significant (p&lt;0.05) but not for other quartile. For other disease in which the percentage of ‘disease’ become increasingly minimal: COPD (11.2-11.9%), Diabetes (7.0-10.9%), Heart disease (5.4-5.7%), and Liver disease (0.8-1.4%) there are no significant findings.</p>	<p>would tend to decrease power and underestimate the real strengths of association.</p> <p>Cross sectional design precludes causal inference.</p> <p>Confounding is also possible but unlikely.</p> <p>Since associations reported were in people on thyroid medications, which mimic normal thyroid function, reverse causation implausible.</p> <p><b>Funding Source:</b> Peninsula Medical School and University of Exeter</p>
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Reference and Study Design	Exposure Measures	Results	Comment
<p>(Nelson, Hatch et al. 2010)</p> <p><b>Study Design:</b> Cross-sectional</p> <p><b>Location:</b> United States</p> <p><b>Population:</b> NHANES 2003-2004, 12-80 year olds, N=416-860 depending on parameter</p> <p><b>Outcome Definition:</b> Serum samples and anthropometric measurements: cholesterol, body weight, insulin resistance</p>	<p><b>Exposure Assessment:</b> Serum concentrations</p> <p><b>Population-Level Exposure:</b> Median = 3.8 µg/L (ng/mL)</p>	<p><b>Stat Method:</b> Linear regression, covariates and confounders considered include age, sex, race/ethnicity, socioeconomic status, saturated fat intake, exercise, TV time, alcohol consumption, smoking, and parity in women. Also examined PFCs as quartile and performed test for trend.</p> <p>Effect estimates of each quartile to the lowest quartile, Test for trend performed.</p> <p><b>Outcome:</b> Total &amp; non-HDL cholesterol (70-80% of TC)</p> <p><b>Major Findings:</b> <b>TC, β=1.22 (95% CI 0.04, 2.40)</b> P for Trend=0.07 <b>Non-HDL, β=1.38 (95% 0.12, 2.65)</b> <b>P for Trend=0.05</b></p> <p><b>Outcome:</b> HDL <b>Major Findings:</b> β=-0.12 (95% -0.41, 0.16) P for Trend=0.34</p> <p><b>Outcome:</b> LDL <b>Major Findings:</b> β=-0.21 (95% -1.91, 1.49) P for Trend=0.84</p> <p><b>Outcome:</b> Anthropometric measures <b>Major Findings:</b> BMI, P for Trend=0.96 Waist Circumference, P for Trend=0.84 Log-HOMA, P for Trend=0.31</p>	<p><b>Major Limitations:</b> Cross sectional design precludes causal inference.</p> <p>Differing physiology might affect PFOA behavior (PFCs may bind to beta-lipoproteins and albumin in the blood)</p> <p>Only one measurement of PFCs and cholesterol concentrations</p> <p>Unable to consider other environmental contaminants</p> <p><b>Quality of study:</b> large sample size, ability to account for key covariates like alcohol and cholesterol lowering medications, and consideration of modification by age and/or gender.</p> <p><b>Funding Source:</b> This work was supported in part by grant R21ES013724 from the National Institute of Environmental Health Sciences (NIEHS). J.W.N. was supported in part by award T32ES014562 from NIEHS.</p>

Reference and Study Design	Exposure Measures	Results	Comment
<p>(Olsen, Gillilan et al. 1998)</p> <p><b>Study Design:</b> Two cross-sectional studies (1993 &amp; 1995)</p> <p><b>Location:</b> U.S. – 3M Plant</p> <p><b>Population:</b> 111 and 80 male production workers (68 workers participated in both years)</p> <p><b>Outcome Definition:</b> Eleven hormones were assayed: cortisol, dehydroepiandrosterone sulfate (CHEAS), estradiol, FSH, 17<math>\alpha</math>-hydroxyprogesterone (17-HP), free testosterone, LH, prolactin, thyroid-stimulating hormone (TSH), and sex hormone-binding globulin (SHBG)</p>	<p><b>Exposure Assessment:</b> PFOA serum concentrations</p> <p><b>Population-Level Exposure:</b> Mean by PFOA category</p> <p>1993 (ppm): 0-1: 0.48 1-&lt;10: 3.34 10-&lt;30: 16.26 &gt;=30: 60.13</p> <p>1995 (ppm): 0-1: 0.31 1-&lt;10: 3.03 10-&lt;30: 17.11 &gt;=30: 55.96</p>	<p><b>Stat Method:</b> Simple and stratified analyses, analysis of variance (ANOVA), Pearson correlation coefficients, and ordinary multivariable regression were used to evaluate associations between PFOA and each hormone, with adjustment for potential confounding variables. Covariates and confounders considered include age, BMI, alcohol use, and cigarette use.</p> <p>PFOA serum concentrations were divided into four categories (0-1, 1-&lt;10, 10-&lt;30, and &gt;=30 ppm).</p> <p><b>Outcome:</b> Hormones (reproductive mainly) <b>Major Findings:</b> (Description is limited since endpoints are not being comprehensively reviewed).</p> <p>“Simple linear regression of the natural log of each hormone with PFOA, treated as a continuous variable, resulted in no statistically significant coefficients in 1993 for any hormone and only one in 1995 (17-HP). “</p> <p>These findings were the same for the multivariable regression also.</p> <p>Univariate analysis (1995) - Statistically increased mean for TSH between 1-&lt;10 and 10-&lt;30 ppm groups (p=0.002), but not for highest PFOA category. Findings were not statistically significant for 1993 but mean TSH increased for the 10-&lt;30 category compared to the lower two categories.</p>	<p><b>Major Limitations:</b> Cross sectional design precludes causal inference.</p> <p>Healthy worker effect</p> <p>Few subjects exposed at highest and lowest levels</p> <p>No females included.</p> <p><b>Funding Source:</b> Not explicitly stated but 3M – corresponding (lead) author is employee of 3M Company</p>

Reference and Study Design	Exposure Measures	Results	Comment																																																																																				
<p>(Olsen, Burris et al. 2000)</p> <p><b>Study Design:</b> Cross-sectional</p> <p><b>Location:</b> U.S. – 3M Plant</p> <p><b>Population:</b> Male workers involved in ammonium perfluorooctanate production in 1993 (n=111), 1995 (n=80), and 1997 (n=74); N total=265</p> <p><b>Outcome Definition:</b> serum hepatic enzymes, cholesterol, lipoproteins, serum cholecystokinin (CCK, a peptide hormone of the gastrointestinal system responsible for stimulating the digestion of fat and protein) - 1997 only</p>	<p><b>Exposure Assessment:</b> serum concentrations</p> <p><b>Population-Level Exposure:</b> (ppm)</p> <table border="1" data-bbox="478 245 870 464"> <thead> <tr> <th>Year</th> <th>Mean</th> <th>Median</th> <th>Range</th> </tr> </thead> <tbody> <tr> <td>1993</td> <td>5.0</td> <td>1.1</td> <td>0.0-80.0</td> </tr> <tr> <td>1995</td> <td>6.8</td> <td>1.2</td> <td>0.0-114.1</td> </tr> <tr> <td>1997</td> <td>6.4</td> <td>1.3</td> <td>0-81.3</td> </tr> </tbody> </table> <p>Median PFOA: 1.19 ppm Mean PFOA: 5.93 ppm</p>	Year	Mean	Median	Range	1993	5.0	1.1	0.0-80.0	1995	6.8	1.2	0.0-114.1	1997	6.4	1.3	0-81.3	<p><b>Stat Method:</b> Simple and stratified analyses, ANOVA, multivariable regression (linear and nonlinear). Covariates and confounders considered include age, BMI, alcohol use, and cigarette use.</p> <p>Participants were stratified into 3 categories of PFOA (0-&lt;1ppm), (1-&lt;10ppm), (≥10ppm).</p> <p><b>Outcome:</b> Hepatic enzymes</p> <p><b>Major Findings:</b> Simple analysis (p-values)</p> <table border="1" data-bbox="913 459 1400 683"> <thead> <tr> <th></th> <th>1993</th> <th>1995</th> <th>1997</th> </tr> </thead> <tbody> <tr> <td>ALP</td> <td>0.52</td> <td>0.25</td> <td>0.28</td> </tr> <tr> <td>GGT</td> <td>0.24</td> <td>0.41</td> <td>0.78</td> </tr> <tr> <td>AST</td> <td>0.33</td> <td>0.45</td> <td>0.83</td> </tr> <tr> <td>ALT</td> <td>0.82</td> <td>0.30</td> <td>0.73</td> </tr> <tr> <td>T. Bilir</td> <td>0.48</td> <td>0.11</td> <td>0.58</td> </tr> <tr> <td>D. Bilir</td> <td>0.82</td> <td>0.05</td> <td>0.74</td> </tr> </tbody> </table> <p>Multivariate (β / p-value)</p> <table border="1" data-bbox="913 743 1400 841"> <thead> <tr> <th></th> <th>1990</th> <th>1993</th> <th>1995</th> <th>1997</th> </tr> </thead> <tbody> <tr> <td>ALT</td> <td>-15.8/ 0.0008</td> <td>0.89/ 0.76</td> <td>0.81/ 0.75</td> <td>2.77/ 0.03</td> </tr> </tbody> </table> <p><b>Outcome:</b> Serum lipids</p> <p><b>Major Findings:</b> Simple analysis (p-values)</p> <table border="1" data-bbox="913 963 1400 1122"> <thead> <tr> <th></th> <th>1993</th> <th>1995</th> <th>1997</th> </tr> </thead> <tbody> <tr> <td>Choles</td> <td>0.45</td> <td>0.48</td> <td>0.08</td> </tr> <tr> <td>HDL</td> <td>0.32</td> <td>0.70</td> <td>0.40</td> </tr> <tr> <td>LDL</td> <td>0.84</td> <td>0.96</td> <td>0.11</td> </tr> <tr> <td>Trigly</td> <td>0.77</td> <td>0.07</td> <td>0.13</td> </tr> </tbody> </table> <p>Multivariate (β / p-value)</p> <table border="1" data-bbox="913 1182 1400 1279"> <thead> <tr> <th></th> <th>1990</th> <th>1993</th> <th>1995</th> <th>1997</th> </tr> </thead> <tbody> <tr> <td>HDL</td> <td>-1.61/ 0.04</td> <td>-0.14/ 0.67</td> <td>-0.10/ 0.08</td> <td>-0.19/ 0.16</td> </tr> </tbody> </table> <p><b>Outcome:</b> CCK (1997 only) <b>Major Findings:</b> β=-0.008, p-value=0.07</p>		1993	1995	1997	ALP	0.52	0.25	0.28	GGT	0.24	0.41	0.78	AST	0.33	0.45	0.83	ALT	0.82	0.30	0.73	T. Bilir	0.48	0.11	0.58	D. Bilir	0.82	0.05	0.74		1990	1993	1995	1997	ALT	-15.8/ 0.0008	0.89/ 0.76	0.81/ 0.75	2.77/ 0.03		1993	1995	1997	Choles	0.45	0.48	0.08	HDL	0.32	0.70	0.40	LDL	0.84	0.96	0.11	Trigly	0.77	0.07	0.13		1990	1993	1995	1997	HDL	-1.61/ 0.04	-0.14/ 0.67	-0.10/ 0.08	-0.19/ 0.16	<p><b>Major Limitations:</b> Cross sectional design precludes causal inference.</p> <p>Healthy worker effect</p> <p>Only 17 subjects were common in all 3 study years.</p> <p>Voluntary participation, 50-70% participation</p> <p>Turnover of employees prevented longitudinal assessment</p> <p>Changes in laboratory procedures between 1995 and 1997 may have disguised lower exposure doses in earlier years.</p> <p>Male only</p> <p>Unable to consider other environmental contaminants</p> <p><b>Funding Source:</b> 3M</p>
Year	Mean	Median	Range																																																																																				
1993	5.0	1.1	0.0-80.0																																																																																				
1995	6.8	1.2	0.0-114.1																																																																																				
1997	6.4	1.3	0-81.3																																																																																				
	1993	1995	1997																																																																																				
ALP	0.52	0.25	0.28																																																																																				
GGT	0.24	0.41	0.78																																																																																				
AST	0.33	0.45	0.83																																																																																				
ALT	0.82	0.30	0.73																																																																																				
T. Bilir	0.48	0.11	0.58																																																																																				
D. Bilir	0.82	0.05	0.74																																																																																				
	1990	1993	1995	1997																																																																																			
ALT	-15.8/ 0.0008	0.89/ 0.76	0.81/ 0.75	2.77/ 0.03																																																																																			
	1993	1995	1997																																																																																				
Choles	0.45	0.48	0.08																																																																																				
HDL	0.32	0.70	0.40																																																																																				
LDL	0.84	0.96	0.11																																																																																				
Trigly	0.77	0.07	0.13																																																																																				
	1990	1993	1995	1997																																																																																			
HDL	-1.61/ 0.04	-0.14/ 0.67	-0.10/ 0.08	-0.19/ 0.16																																																																																			

Reference and Study Design	Exposure Measures	Results	Comment																																			
<p>(Olsen, Burris et al. 2003)</p> <p><b>Study Design:</b> Cross sectional and longitudinal</p> <p><b>Location:</b> Antwerp, Belgium, and Decatur, AL, USA</p> <p><b>Population:</b> Cross Sectional: male and female workers at PFC manufacturing locations N=263 in Decatur N= 255 in Antwerp Total N = 421 male, 97 female Year: 2000</p> <p>Longitudinal: male workers, both locations n=174 6 year time period</p> <table border="1"> <thead> <tr> <th>Worker Cohort</th> <th>% involved in production activities</th> </tr> </thead> <tbody> <tr> <td>Total Antwerp</td> <td>73</td> </tr> <tr> <td>Female Antwerp</td> <td>12</td> </tr> <tr> <td>Total Decatur</td> <td>75</td> </tr> <tr> <td>Female Decatur</td> <td>63</td> </tr> </tbody> </table> <p><b>Outcome Definition:</b> hematological, lipid, hepatic, thyroid, urinary parameters: Cholesterol, HDL, Triglycerides, ALP, GGT, AST, ALT, total bilirubin, TSH, T4, Free T4, T3</p>	Worker Cohort	% involved in production activities	Total Antwerp	73	Female Antwerp	12	Total Decatur	75	Female Decatur	63	<p><b>Exposure Assessment:</b> Serum concentrations</p> <p><b>Population-Level Exposure:</b></p> <p>Cross-sectional (ppm):</p> <table border="1"> <thead> <tr> <th>Site</th> <th>Mean (range)</th> <th>GeoMean (95%CI)</th> </tr> </thead> <tbody> <tr> <td>Antwerp</td> <td>0.84 (0.01-7.04)</td> <td>0.33 (0.27-0.40)</td> </tr> <tr> <td>Decatur</td> <td>1.78 (0.04-12.70)</td> <td>1.13 (0.99-1.30)</td> </tr> </tbody> </table> <p>Longitudinal (ppm): means</p> <table border="1"> <thead> <tr> <th>Subgroup</th> <th>1994-95</th> <th>1997</th> <th>2000</th> </tr> </thead> <tbody> <tr> <td>A</td> <td>1.36</td> <td>-</td> <td>1.72</td> </tr> <tr> <td>B</td> <td>-</td> <td>1.22</td> <td>1.49</td> </tr> <tr> <td>C</td> <td>1.41</td> <td>1.90</td> <td>1.77</td> </tr> </tbody> </table> <p>Range: 1,220-1,900 ng/mL</p>	Site	Mean (range)	GeoMean (95%CI)	Antwerp	0.84 (0.01-7.04)	0.33 (0.27-0.40)	Decatur	1.78 (0.04-12.70)	1.13 (0.99-1.30)	Subgroup	1994-95	1997	2000	A	1.36	-	1.72	B	-	1.22	1.49	C	1.41	1.90	1.77	<p><b>Stat Method:</b> ANOVA, multivariable for cross-sectional analyses. Logistic regression for PFOS quartile distribution for those with elevated liver function tests. And linear regression with parameters as continuous.</p> <p>For longitudinal assessment, repeated measures incorporating the random subject's effect fitted to a mixed model. Covariates and confounders considered include years of observation, the interaction term of PFOS and years of observation, age, BMI, cigarettes smoked per day, alcohol drinks per day, location, year at first entry, and baseline years worked.</p> <p><b>Outcome:</b> Serum lipids <b>Major Findings:</b> <u>Longitudinal (n=174 male employees):</u> <b>Cholesterol</b> <math>\beta=0.032</math> (95% CI 0.013, 0.051) <b>Triglycerides</b> <math>\beta=0.094</math> (95% CI 0.045, 0.144)</p> <p>“There were no significant [PFOA] coefficients associated with changes in HDL”</p> <p><b>Outcome:</b> Liver function <b>Major Findings:</b> “There were no significant [PFOA] coefficients associated with changes in various liver function tests (data not shown) adjusted for potential confounders”.</p> <p><b>Outcome:</b> Thyroid hormones <b>Major Findings:</b> Results not provided, following description in report: “Multivariate regression analyses of the thyroid hormones resulted in no significant associations with [PFOS or] PFOA except for a positive association with the natural log of T3 (<math>\beta=0.016</math>, p-value=0.01)</p>	<p><b>Major Limitations:</b> Voluntary participation, volunteer bias</p> <p>Potential environmental confounders Only 41 employees completed all 3 testing dates (subgroup C)</p> <p>Healthy worker effect</p> <p>Cross sectional design of one section precludes causal inference for that section.</p> <p>Low participation rate in first years of study, participation rates in earlier years were lower, participation rate and date could be related to QC procedures</p> <p>Unclear mechanisms for PFOA/triglycerides</p> <p>Unable to consider other environmental contaminants</p> <p><b>Funding Source:</b> DuPont/3M</p>
Worker Cohort	% involved in production activities																																					
Total Antwerp	73																																					
Female Antwerp	12																																					
Total Decatur	75																																					
Female Decatur	63																																					
Site	Mean (range)	GeoMean (95%CI)																																				
Antwerp	0.84 (0.01-7.04)	0.33 (0.27-0.40)																																				
Decatur	1.78 (0.04-12.70)	1.13 (0.99-1.30)																																				
Subgroup	1994-95	1997	2000																																			
A	1.36	-	1.72																																			
B	-	1.22	1.49																																			
C	1.41	1.90	1.77																																			



Reference and Study Design	Exposure Measures	Results	Comment															
<p>(Olsen and Zobel 2007)</p> <p><b>Study Design:</b> Cross-sectional</p> <p><b>Location:</b> Antwerp, Belgium; Decatur, AL; Cottage Grove,, MN</p> <p><b>Population:</b> Voluntary participation of male employees (PFOA production), n=506, from three locations. Exclusion of those taking lipid-lowering medications</p> <p><b>Outcome Definition:</b> lipid, hepatic, thyroid parameters: Cholesterol, HDL, Triglycerides, ALP, GGT, AST, ALT, total bilirubin, TSH, T4, Free T4, T3</p>	<p><b>Exposure Assessment:</b> Serum concentrations</p> <p><b>Population-Level Exposure:</b></p> <p>ug/mL (ppm)</p> <table border="1" data-bbox="443 375 811 605"> <thead> <tr> <th>Site</th> <th>Mean</th> <th>Median</th> </tr> </thead> <tbody> <tr> <td>Antwerp</td> <td>1.02</td> <td>0.65</td> </tr> <tr> <td>Cottage Grove</td> <td>4.63</td> <td>0.95</td> </tr> <tr> <td>Decatur</td> <td>1.89</td> <td>1.51</td> </tr> <tr> <td>Total</td> <td>2.21</td> <td>1.10</td> </tr> </tbody> </table>	Site	Mean	Median	Antwerp	1.02	0.65	Cottage Grove	4.63	0.95	Decatur	1.89	1.51	Total	2.21	1.10	<p><b>Stat Method:</b> Multiple and logistic regression and analysis of covariance. Covariates and confounders considered are age, BMI, and alcohol usage, and serum triglycerides for analysis of hepatic enzymes.</p> <p>Results shown for most adjusted models (age, BMI, alcohol), and all locations combined.</p> <p><b>Outcome:</b> Serum lipids</p> <p><b>Major Findings:</b> <u>All locations</u> Cholesterol: <math>\beta=0.0076</math>, p-value=0.20 LDL: <math>\beta=0.0021</math>, p-value=0.81 <b>HDL:</b> <math>\beta=-0.0183</math>, p-value=0.01 <b>Triglycerides:</b> <math>\beta=0.0711</math>, p-value&lt;0.0001</p> <p>Findings from cholesterol and LDL were similar for the three locations. HDL associations were not found in any of the other locations. Triglycerides associations only for Antwerp location and Decatur (borderline nonsignificant). Decile analyses suggest decreasing HDL and increasing triglycerides with increasing PFOA.</p> <p><b>Outcome:</b> Hepatic enzymes</p> <p><b>Major Findings:</b> <u>All locations</u> ALP: <math>\beta=0.0093</math>, p-value=0.25 AST: <math>\beta=-0.0051</math>, p-value=0.55 ALT: <math>\beta=0.0249</math>, p-value=0.06 <b>GGT: <math>\beta=0.0326</math>, p-value=0.05</b> <b>Total Bili: <math>\beta=-0.0325</math>, p-value=0.001</b> Direct Bili: not shown</p> <p>ALP significant in Decatur, AST borderline insignificant in Cottage Grove, ALT highly significant for unadjusted models for all locations and significant in Decatur, bilirubin significance appears to be driven by Decatur. Decile analyses suggest some</p>	<p><b>Major Limitations:</b> Voluntary participation, 50-65% participation, Demographics of nonparticipants unknown.</p> <p>They talk about lots of residual confounding when putting locations together – use to explain away HDL effect</p> <p>Healthy worker effect</p> <p>Unable to consider other environmental contaminants</p> <p><b>Funding Source:</b> unspec, authors employed by 3M Medical Department</p>
Site	Mean	Median																
Antwerp	1.02	0.65																
Cottage Grove	4.63	0.95																
Decatur	1.89	1.51																
Total	2.21	1.10																

increase in ALT levels with increasing PFOA deciles. There is an inverse association (NS) for GGT in Cottage Grove while other findings suggest a positive association. Model results are not shown for direct bilirubin but decile analyses don't suggest a trend.

**Outcome:** Thyroid hormones  
**Major Findings:**  
 TSH:  $\beta=0.0360$ , p-value=0.08  
 T4:  $\beta=-0.0057$ , p-value=0.29  
**Free T4:  $\beta=-0.0117$ , p-value=0.01**  
**T3:  $\beta=0.0105$ , p-value=0.05**

No significant findings for any of three locations for TSH, TT4 has no significance, FT4 association only overall but Antwerp and Decatur almost reaches significance, and T3 significant except for Cottage Grove. TT4 appears to decrease with increasing deciles of PFOA; no other consistent differences seem to be meaningful for the other thyroid hormones.

Reference and Study Design	Exposure Measures	Results	Comment									
<p>(Olsen, Ehresman et al. 2012)</p> <p><b>Study Design:</b> Longitudinal</p> <p><b>Location:</b> Cottage Grove MN, Decatur AL</p> <p><b>Population:</b> n=204, analyses restricted to 98 to 179 workers not on lipid lowering medication</p> <p>In 2008-2010, 3M employees – general management tasks and Non-3M employees (Contract workers) – specific demolition tasks, demolished a building where 3M produced PFOA.</p> <p><b>Outcome Definition:</b> lipids and hepatic clinical chemistries at baseline and end-of-project</p>	<p><b>Exposure Assessment:</b> Serum concentrations</p> <p><b>Population-Level Exposure:</b> (ng/mL)</p> <table border="1" data-bbox="478 865 857 1084"> <thead> <tr> <th></th> <th>Baseline</th> <th>Mean Change</th> </tr> </thead> <tbody> <tr> <td>Mean 3M employee</td> <td>881</td> <td>-218.3</td> </tr> <tr> <td>Mean contract worker</td> <td>28.9</td> <td>32.1</td> </tr> </tbody> </table> <p>Mean time interval between baseline and endpoint assessments:                      3M workers = 306 days                      Contract workers = 152 days</p>		Baseline	Mean Change	Mean 3M employee	881	-218.3	Mean contract worker	28.9	32.1	<p><b>Stat Method:</b> Matched-pair and linear regression analyses. Covariates and confounders considered include sex, baseline age, BMI, and alcohol consumption, and time interval between assessments.</p> <p>Stratified by magnitude of change</p> <p>Linear regression results shown for entire database, and adjusted models.</p> <p><b>Outcome:</b> Serum lipids  <b>Major Findings:</b>                      Cholesterol: <math>\beta=-0.003</math>, p-value=0.79                      Non-HDL: <math>\beta=-0.006</math>, p-value=0.54                      HDL: <math>\beta=0.004</math>, p-value=0.35  <b>Choles/HDL ratio: <math>\beta=-0.00097</math>, p-value=0.03</b></p> <p><b>Outcome:</b> Liver enzymes  <b>Major Findings:</b>                      ALP: <math>\beta=-0.002</math>, p-value=0.67                      AST: <math>\beta=-0.003</math>, p-value=0.29  <b>ALT: <math>\beta=-0.0097</math>, p-value=0.05</b>                      T. Bilirubin: <math>\beta=-0.000</math>, p-value=0.60</p>	<p><b>Major Limitations:</b>                      Healthy worker effect,                      Exclusion of persons on lipid-lowering medications,                      Time period of study,                      Inclusion of largely managerial 3M workers in sample                      Unable to consider other environmental contaminants</p> <p><b>Funding Source:</b> unspec, authors employed by 3M Medical Department</p>
	Baseline	Mean Change										
Mean 3M employee	881	-218.3										
Mean contract worker	28.9	32.1										

Reference and Study Design	Exposure Measures	Results	Comment
<p>(Sakr, Kreckmann et al. 2007)</p> <p><b>Study Design:</b> Cross-sectional</p> <p><b>Location:</b> Washington Works production site, WV, U.S.A</p> <p><b>Population:</b> Active workers with potential exposure to APFO, N=1025-excluding those on lipid-lowering medications = 840</p> <p><b>Outcome Definition:</b> Serum lipids and liver enzymes and other outcomes:</p> <p>Cholesterol, HDL, LDL, triglyceride VLDL, AST, ALT&lt; GGT, CBC (complete blood count), glucose, blood urea nitrogen, creatinine, iron, uric acid, electrolytes, creatinine kinase, lactate dehydrogenase, ALP, protein, albumin, and c-reactive protein, serum PSA in men, and serum hormonal levels TSH, T4, T3 uptake, estradiol, and testosterone.</p>	<p><b>Exposure Assessment:</b> Serum concentrations</p> <p><b>Population-Level Exposure:</b> Mean = 0.428 ppm = 428 ppb (µg/L)</p> <p>Median = 0.189 ppm (IQR = 0.099-0.381)</p> <p>Range= 0.005-9.55 ppm</p>	<p><b>Stat Method:</b> Linear regression. Covariates and confounders considered include age, BMI, gender, and alcohol consumption, parental history of heart attack, and use of lipid-lowering medication.</p> <p>Log transformation of outcomes as required.</p> <p><b>Outcome:</b> Serum lipids <b>Major Findings:</b> <b>Cholesterol: <math>\beta=4.04</math>, p-value=0.002</b> <b>LDL: <math>\beta=2.834</math>, p-value=0.005</b> HDL: <math>\beta=-0.178</math>, p-value=0.680 <b>VLDL: <math>\beta=0.045</math>, p-value=0.031</b> Triglycerides: <math>\beta=0.018</math>, p-value=0.384</p> <p>*findings remained similar with exclusion for lipid-lowering medication use.</p> <p><b>Outcome:</b> Liver enzymes <b>Major Findings:</b> AST: <math>\beta=0.012</math>, p-value=0.317 ALT: <math>\beta=0.023</math>, p-value=0.124 <b>GGT: <math>\beta=0.048</math>, p-value=0.016</b> Bilirubin: <math>\beta=0.008</math>, p-value=0.590</p> <p>*findings remained similar with exclusion for lipid-lowering medication use.</p> <p><b>Outcome: others</b> <b>Major Findings:</b> <b>“Uric acid, iron, lactate dehydrogenase, calcium, and potassium showed statistically significant associations with serum PFOA in linear regression models. In men estradiol and testosterone were significantly associated with serum PFOA.: DuPont – 22458, 2007, internal report.</b></p>	<p><b>Major Limitations:</b> Cross sectional design precludes causal inference.</p> <p>55% voluntary participation rate</p> <p>Healthy worker effect</p> <p>Biological factors not taken into account</p> <p>Unable to consider other environmental contaminants</p> <p><b>Funding Source:</b> DuPont</p>

Reference and Study Design	Exposure Measures	Results	Comment
<p>(Sakr, Leonard et al. 2007)</p> <p><b>Study Design:</b> Longitudinal</p> <p><b>Location:</b> Washington Works site, WV, USA</p> <p><b>Population:</b> n=454 workers with two or more measures of PFOA unless outcomes measures were taken in the same year</p> <p><b>Outcome Definition:</b> Serum lipids and liver enzymes, calculation of LDL based on Friedewald formula</p>	<p><b>Exposure Assessment:</b> Serum concentrations</p> <p><b>Population-Level Exposure:</b> Overall mean: 1.13 ppm Mean first measurement: 1.04 ppm Mean last measurement: 1.16 ppm</p>	<p><b>Stat Method:</b> Linear mixed effect model including a random effect for subject and fixed effects for age, and other potential confounders. An interaction term gender X age was included. Used a spatial Gaussian covariance structure. Covariates and confounders considered include age, age-squared, gender, BMI, and decade of hire along with all interactions.</p> <p>Number of observations differed for each outcome analyzed.</p> <p><b>Outcome:</b> Serum lipids <b>Major Findings:</b> <b>Choles:</b> <math>\beta=1.06</math>, (95% CI 0.24, 1.88) Trigly: <math>\beta=0.79</math>, (95% CI -5.99, 7.57) HDL: <math>\beta=0.16</math>, (95% CI -0.39, 0.71) LDL: <math>\beta=0.46</math>, (95% Ci -0.87, 1.79)</p> <p><b>Outcome:</b> Liver enzymes <b>Major Findings:</b> <b>T. Bilir:</b> <math>\beta=-0.008</math>, (95% CI -0.0138, -0.0021) GGT: <math>\beta=1.24</math>, (95% CI -1.09, 3.57) ALP: <math>\beta=-0.21</math>, (95% CI -0.60, 0.18) <b>AST:</b> <math>\beta=0.35</math>, (95% CI 0.10, 0.60) ALT: <math>\beta=0.54</math>, (95% CI -0.46, 1.54)</p>	<p><b>Major Limitations:</b> Healthy worker effect</p> <p>Sample is only 16% of all workers who had ever worked at plant, 10% of workers for over one year.</p> <p>No info on lipid lowering medications or alcohol intake.</p> <p>Exposure and outcome were not measured on same date.</p> <p>LDL calculated based on outdated Friedewald formula (except for 2004 data).</p> <p>Other environmental contaminants, including other PFCs, were not considered.</p> <p><b>Funding Source:</b> DuPont</p>

Reference and Study Design	Exposure Measures	Results	Comment															
<p>(Shankar, Xiao et al. 2011)</p> <p><b>Study Design:</b> Cross-sectional</p> <p><b>Location:</b> USA</p> <p><b>Population:</b> NHANES 1999-2000 &amp; 2003-2006, &gt; 20 years of age, n=3883</p> <p><b>Outcome Definition:</b> Hyperuricemia (serum uric acid levels &gt;6.8mg/dL in men and &gt;6.0 mg/dL in women)</p>	<p><b>Exposure Assessment:</b> Plasma concentrations</p> <p><b>Population-Level Exposure:</b> Median = 3.5 ppb (women), 4.6 ppb (men)</p>	<p><b>Stat Method:</b> Linear regression models with continuous log-transformed PFOA and quartile PFOA. Multivariable logistic regression with PFOA quartiles. Covariates and confounders considered include age, gender, race/ethnicity, education, smoking, alcohol consumption,</p> <p>Results presented for most adjusted models.</p> <p><b>Outcome:</b> Uric Acid</p> <p><b>Major Findings:</b> <b>Mean Change-</b> <b>Q2 v. Q1: 0.14 (95% CI 0.04, 0.25)</b> <b>Q3 v. Q1: 0.37 (95% CI 0.25, 0.49)</b> <b>Q4 v. Q1: 0.44 (95 % CI 0.32, 0.56)</b> <b>P for Trend &lt; 0.0001</b></p> <p><b>PFOA log transformed: 0.22 (95% CI 0.15, 0.30)</b></p> <p><b>Outcome:</b> Hyperuricemia</p> <p><b>Major Findings:</b></p> <table border="1" data-bbox="881 764 1392 922"> <thead> <tr> <th>Quartile</th> <th>OR</th> <th>95% CI</th> </tr> </thead> <tbody> <tr> <td>1</td> <td>1</td> <td>referent</td> </tr> <tr> <td>2</td> <td>1.14</td> <td>0.78, 1.67</td> </tr> <tr> <td>3</td> <td><b>1.90</b></td> <td><b>1.35, 2.69</b></td> </tr> <tr> <td>4</td> <td><b>1.97</b></td> <td><b>1.44, 2.70</b></td> </tr> </tbody> </table> <p><b>P for Trend &lt;0.0001</b></p> <p><b>PFOA log transformed OR=1.43 (95% CI 1.16, 1.76)</b></p>	Quartile	OR	95% CI	1	1	referent	2	1.14	0.78, 1.67	3	<b>1.90</b>	<b>1.35, 2.69</b>	4	<b>1.97</b>	<b>1.44, 2.70</b>	<p><b>Major Limitations:</b> Cross sectional design precludes causal inference.</p> <p>Unclear biological mechanism,</p> <p>Over-adjustment for mediators may have underestimated true association between PFOA and hyperuricemia</p> <p>Other environmental contaminants, including other PFCs, were not considered.</p> <p><b>Funding Source:</b> American Heart Association National Clinical Research Program award and a National Institutes of Health/National Institute of Environmental Health Sciences grant (NIH/NIEHS 5R03ES018888-02)</p>
Quartile	OR	95% CI																
1	1	referent																
2	1.14	0.78, 1.67																
3	<b>1.90</b>	<b>1.35, 2.69</b>																
4	<b>1.97</b>	<b>1.44, 2.70</b>																

Reference and Study Design	Exposure Measures	Results	Comment
<p>(Shrestha, Bloom et al. 2015)</p> <p><b>Study Design:</b> Cross sectional</p> <p><b>Location:</b> Upper Hudson River communities, NY</p> <p><b>Population:</b> Older adults 55-74 years of age who lived in three communities adjacent to the Hudson River for 25 years or more, without clinically diagnosed thyroid disease and did not work in PCB related job for a year or more, and other health conditions, n=87</p> <p><b>Outcome Definition:</b> Thyroid function as measured by serum thyrotropin, free thyroxine, total thyroxine, and total triiodothyronine</p>	<p><b>Exposure Assessment:</b> Serum concentrations</p> <p><b>Population-Level Exposure:</b>  Median = 9.32 ng/mL</p>	<p><b>Stat Method:</b> Multivariable linear regression analyses. Covariates and confounders considered include age, sex, years of education, and serum PCBs</p> <p>PFOA was log transformed. Effects were reported as the changed in thyroid hormone level per interquartile range increase in ln-PFOA.</p> <p>Looked at interactions with other environmental contaminants.</p> <p><b>Outcome: Thyroid hormones</b> <b>Major Findings:</b> TSH: <math>\beta=0.102</math> (95% -0.023, 0.281) FT4: <math>\beta=0.016</math> (95% CI -0.036, 0.069) T4: <math>\beta=0.380</math> (95% CI -0.070, 0.830) T3: <math>\beta=3.032</math> (95% CI -1.725, 7.789)</p> <p>Statistical interactions between age and PFOA for effect of FT4 and T4 (<math>p&lt;0.05</math>).</p> <p>The joint effect of age and PFOA = 7% increase in T4 and 3% for FT4.</p>	<p><b>Major Limitations:</b> Cross sectional design precludes causal inference.</p> <p>No information on serum albumin and TBG</p> <p>Multiple statistical analyses increase probability of chance findings,</p> <p>Small n</p> <p>Unable to analyze joint effects of age and sex,</p> <p>Used archived sera to estimate thyroid biomarkers and PFOA, raising possibility for sample degradation over time (not likely a concern).</p> <p><b>Funding Source:</b> grants provided by the National Institute on Aging (Grant # R15/AG0333700A1) and the Agency for Toxic Substances and Disease Registry (Grant # H75/ATH298312)</p>

Reference and Study Design	Exposure Measures	Results	Comment
<p>(Starling, Engel et al. 2014)</p> <p><b>Study Design:</b> Cross-sectional</p> <p><b>Location:</b> Norway</p> <p><b>Population:</b> Pregnant women enrolled in the Norwegian Mother and Child Cohort Study 2003-04 (n= 891)</p>	<p><b>Exposure Assessment:</b> Plasma concentrations taken at mid-pregnancy</p> <p><b>Population-Level Exposure:</b>  Median: 2.25 ng/mL</p>	<p><b>Stat Method:</b> Weighted linear regression + multiple PFAS model, spearman rank-order correlations. Covariates and confounders considered include maternal age, pre=pregnancy BMI, nulliparous or most recent inter-pregnancy interval, duration of breastfeeding most recent child, maternal years of education, current smoking at mid-pregnancy, gestational weeks at blood draw, and amount of oily fish consumed daily, and weight gain, and albumin.</p> <p>PFOA natural log transformed and categorized into quartiles. Results reported for IQR change increase. Outcome log transformed as needed.</p>	<p><b>Major Limitations:</b> Cross sectional design precludes causal inference. Use of nonfasting plasma lipid measurements,  No measurement of other environmental contaminants,</p> <p><b>Funding Source:</b> in part by the Intramural Research Program of the NIH, National Institute of Environmental Health Sciences. A.P. Starling was</p>

<p><b>Outcome Definition:</b> Serum measurements of lipids – measured from same exposure assessment sample.</p>	<p><b>Outcome:</b> Serum lipids</p> <p><b>Major Findings:</b></p> <p><u>Total cholesterol</u>                  Q2 v. Q1 <math>\beta=1.49</math> (95% CI -6.49, 9.48)                  Q3 v. Q1 <math>\beta=3.54</math> (95% CI -4.51, 11.59)                  Q4 v. Q1 <math>\beta=3.90</math> (95% CI -5.00, 12.80)                  Ln-unit <math>\beta=2.58</math> (95% CI -4.32, 9.47)                  IQR <math>\beta=1.55</math> (95% CI -2.60, 5.69)</p> <p>Multi-pollutant model brought the already non-significant relationship even closer to the null.</p> <p><u>HDL</u>                  Q2 v. Q1 <math>\beta=0.22</math> (95% CI -2.38, 2.83)                  Q3 v. Q1 <math>\beta=2.31</math> (95% CI -0.59, 5.20)                  Q4 v. Q1 <math>\beta=3.42</math> (95% CI 0.56, 6.28)                  Ln-unit <math>\beta=2.13</math> (95% CI -0.26, 4.51)                  IQR <math>\beta=1.28</math> (95% CI -0.15, 2.71)</p> <p><u>LDL</u>                  Q2 v. Q1 <math>\beta=0.94</math> (95% CI -6.08, 7.96)                  Q3 v. Q1 <math>\beta=4.16</math> (95% CI -3.19, 11.50)                  Q4 v. Q1 <math>\beta=3.35</math> (95% CI -4.35, 11.06)                  Ln-unit <math>\beta=2.25</math> (95% CI -3.97, 8.48)                  IQR <math>\beta=1.36</math> (95% CI -2.38, 5.10)</p> <p><u>Ln-triglycerides</u>                  Q2 v. Q1 <math>\beta=0.03</math> (95% CI -0.04, 0.11)                  Q3 v. Q1 <math>\beta=0.01</math> (95% CI -0.08, 0.09)                  Q4 v. Q1 <math>\beta=-0.04</math> (95% CI -0.12, 0.04)                  Ln-unit <math>\beta=0.00</math> (95% CI -0.07, 0.06)                  IQR <math>\beta=0.00</math> (95% CI -0.04, 0.04)</p>	<p>supported by an extramural award (1-F30-ES022126-01) from the National Institute of Environmental Health Sciences.</p>
---------------------------------------------------------------------------------------------------------------------	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	---------------------------------------------------------------------------------------------------------------------------



Reference and Study Design	Exposure Measures	Results	Comment															
<p>(Steenland, Tinker et al. 2009)</p> <p><b>Study Design:</b> Cross-sectional</p> <p><b>Location:</b> OH and WV, USA</p> <p><b>Population:</b> Residents 18 years of age and older who drank water contaminated by nearby plant, for at least one year, n= 46,294</p> <p><b>Outcome Definition:</b> Serum lipids; High cholesterol (&gt;240 mg/dL), serum lipids</p>	<p><b>Exposure Assessment:</b> Serum PFOA</p> <p><b>Population-Level Exposure:</b> Mean: 80 ng/mL Median: 27 ng/mL</p>	<p><b>Stat Method:</b> Linear regression (continuous and categorical PFOA) and logistic model for “high cholesterol” with PFOA in quartiles. Covariates and confounders considered include age, gender, BMI, education, smoking, regular exercise, and current alcohol consumption, and fasting and PFOS.</p> <p>Outcomes were natural log transformed.</p> <p><b>Outcome:</b> Serum lipids <b>Major Findings:</b> <b>A largely monotonic increase in log cholesterol with each decile of PFOA (p&lt;0.0001). Tests for linear trend were highly significant.</b></p> <p><b>Trends for LDL cholesterol, non-HDL cholesterol, and the ratio of total cholesterol to HDL were similar to the nearly monotonic trends for total cholesterol. Therefore was a positive trend with triglycerides but little association with HDL.</b></p> <p><b>The results for unlogged PFOA are test for linear trend for the categorical models; all such linear trends were positive (total cholesterol, LDL, Triglycerides, TC/HDL ratio, non-HDL-C) and significant (p&lt;0.05) except for HDL.</b></p> <p><b>Outcome:</b> “High cholesterol” <b>Major Findings:</b></p> <table border="1" data-bbox="819 974 1451 1136"> <thead> <tr> <th>Quartile</th> <th>OR</th> <th>95% CI</th> </tr> </thead> <tbody> <tr> <td>1</td> <td>1</td> <td>Referent</td> </tr> <tr> <td>2</td> <td>1.21</td> <td>1.12,1.31</td> </tr> <tr> <td>3</td> <td>1.33</td> <td>1.23,1.43</td> </tr> <tr> <td>4</td> <td>1.4</td> <td>1.28,1.50</td> </tr> </tbody> </table> <p><b>P for trend &lt;0.0001</b></p>	Quartile	OR	95% CI	1	1	Referent	2	1.21	1.12,1.31	3	1.33	1.23,1.43	4	1.4	1.28,1.50	<p><b>Major Limitations</b> Cross-sectional design precludes causal inference.</p> <p>Lack of a measure of cumulative exposure</p> <p>Did not control for other environmental contaminants (did control for PFOS).</p> <p><b>Funding Source:</b> C8 Class Action Settlement between DuPont and Plaintiffs</p>
Quartile	OR	95% CI																
1	1	Referent																
2	1.21	1.12,1.31																
3	1.33	1.23,1.43																
4	1.4	1.28,1.50																

Reference and Study Design	Exposure Measures	Results	Comment																		
<p>(Steenland, Tinker et al. 2010)</p> <p><b>Study Design:</b> Cross-sectional</p> <p><b>Location:</b> OH and WV, USA</p> <p><b>Population:</b> Residents 20 years of age and older who drank water contaminated by nearby plant, for at least one year, n= 54,591</p> <p><b>Outcome Definition:</b> Uric acid; hyperuricemia (serum uric acid &gt; 6 mg/dL for women and &gt;6.8 mg/dL for men.</p>	<p><b>Exposure Assessment:</b> Serum concentrations</p> <p><b>Population-Level Exposure:</b> (ng/mL) Mean: 86.4 SD: 261.3 IQR: 13.5 – 71.4 Median: 27.9</p>	<p><b>Stat Method:</b> Linear regression, some analyses log transformed PFOA, others treated as categorical. Logistic regression for hyperuricemia, PFOA in quintiles.</p> <p>Covariates and confounders considered include age, sex, BMI, education, smoking, alcohol consumption, serum creatinine (log), and control for PFOS.</p> <p>Sensitivity analysis – restricting elevated serum creatinine (indicator of kidney disease)</p> <p><b>Outcome:</b> Uric acid <b>Major findings:</b> <b>Test for linear trend was highly significant (p&lt;0.001).</b></p> <p><b>A close to monotonic increase in uric acid with an increase in PFOA. There is an increase in uric acid of 0.2-0.3 from the lowest to the heist decile for PFOA.</b></p> <p><b>Outcome:</b> Hyperuricemia <b>Major Findings:</b></p> <table border="1" data-bbox="881 852 1392 1047"> <thead> <tr> <th>Quintile</th> <th>OR</th> <th>95% CI</th> </tr> </thead> <tbody> <tr> <td>1</td> <td>1</td> <td>Referent</td> </tr> <tr> <td>2</td> <td>1.33</td> <td>1.24-1.43</td> </tr> <tr> <td>3</td> <td>1.35</td> <td>1.26-1.45</td> </tr> <tr> <td>4</td> <td>1.47</td> <td>1.37-1.58</td> </tr> <tr> <td>5</td> <td>1.47</td> <td>1.37-1.58</td> </tr> </tbody> </table> <p><b>P for Trend &lt;0.0001</b></p> <p>More consistent linear relationship for women than for men.</p>	Quintile	OR	95% CI	1	1	Referent	2	1.33	1.24-1.43	3	1.35	1.26-1.45	4	1.47	1.37-1.58	5	1.47	1.37-1.58	<p><b>Major Limitations:</b> Cross sectional design precludes causal inference.</p> <p>Mechanism unknown – may have unknown confounder,</p> <p>No data on blood pressure for population,</p> <p><b>Funding Source:</b> C8 Class Action Settlement between DuPont and Plaintiffs</p>
Quintile	OR	95% CI																			
1	1	Referent																			
2	1.33	1.24-1.43																			
3	1.35	1.26-1.45																			
4	1.47	1.37-1.58																			
5	1.47	1.37-1.58																			

Reference and Study Design	Exposure Measures	Results	Comment
<p>(Steenland, Zhao et al. 2015)</p> <p><b>Study Design:</b> Retrospective occupational cohort</p> <p><b>Location:</b> Washington Works plant, DuPont – WV, USA</p> <p><b>Population:</b> Workers or next of kin in 2008-20011, n=3713.</p> <p>Original DuPont Cohort included 6026 workers with at least 1 day of work between 1948 and 2002.</p> <p><b>Outcome Definition:</b> Self-reported disease – validated by medical record abstraction: all but three.</p>	<p><b>Exposure Assessment:</b> Historical estimates of serum PFOA levels based on job history + nonoccupational exposures → lifetime serum cumulative dose.</p> <p>Investigators used a job exposure matrix validated using worker serum samples from 1979-2004.</p> <p><b>Population-Level Exposure:</b> In 2005, median measured serum level was 113 ng/mL (n=1881)</p>	<p><b>Stat Method:</b> Cox regression models with age as the time scale and time-varying exposure and covariates. Additionally performed parametric tests for trend, categorical trend tests.</p> <p>Looked at lag and 10-year lag.</p> <p>Coronary heart disease, stroke, chronic obstructive pulmonary disease, autoimmune disease, type 2 diabetes, liver disease (hepatitis and non-hepatitis), Parkinson’s disease, Alzheimer’s disease, thyroid disease, asthma with reported current medication, and cancer. And three self-reported outcomes: osteoarthritis, hypertension, and high cholesterol.</p> <p>All statistically significant results are listed below (<math>p &lt; 0.05</math>). Those not listed mean that outcomes were not significant.</p> <p><b>Outcome:</b> <b>Major Findings:</b> <b>Ulcerative colitis – positive trend using the log cumulative exposure for no lag and a 10-year lag. For 10-year the highest exposure category for had a RR relative to the first quartile of 6.57 (95% CI 1.47, 29.40).</b></p> <p><b>No other disease showed a statistically significant positive trend using the log transform trend test.</b></p> <p><b>Rheumatoid arthritis showed a significant positive trend using the trend test based on the quartile midpoints (<math>p=0.04</math>). The highest exposure category (no lag) had a RR relative to the first quartile of 4.45 (95% CI 0.99, 19.9) – <math>p=0.05</math>.</b></p> <p><b>Type II diabetes (10 year lag) had a significant trend using the categorical trend test.</b></p>	<p><b>Major Limitations:</b> Small n compared to whole C8 cohort under representation of hard to trace decedents.</p> <p>Few low-exposed referents.</p> <p>Largely confined to men.</p> <p>Healthy worker effect.</p> <p>Limited sample size for some outcomes.</p> <p>62% of target population.</p> <p>Failure to obtain medical records for 17% of those self-reporting disease.</p> <p>Survival bias</p> <p>Truncated residential histories at 1970 - underestimated exposures for some participants.</p> <p><b>Funding Source:</b> C8 Class Action Settlement between DuPont and Plaintiffs</p>

		<p><b>Bladder cancer showed a negative trend using log cumulative dose (for the analysis with no lag) and the categorical trend test (for the analysis with a 10-year lag).</b></p> <p><b>Negative trend for asthma with medication (no lag) in the categorical trend test</b></p>	
--	--	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--

Reference and Study Design	Exposure Measures	Results	Comment
<p>(Stein et al., 2016)</p> <p><b>Study Design:</b> Cross-sectional</p> <p><b>Location:</b> U.S. general population</p> <p><b>Population:</b> NHANES (1999-2000 and 2003-2005), n=1,191 and (2005-2006), n=640; adolescents aged 12 to 19 years.</p> <p><b>Outcome Definition:</b> Measles, mumps, and rubella antibody concentrations (1999-2000 and 2003-2004 cycles) and allergic conditions and allergic sensitization (2005-2006 cycles).</p> <p>Allergic sensitization defined as sIgE ≥0.35 kU/L</p>	<p><b>Exposure Assessment:</b> PFOA serum concentrations</p> <p><b>Population-Level Exposure:</b></p> <p>Geometric Mean= 4.13 ng/mL (cycles 1999-2000 and 2003-2005)</p> <p>Geometric Mean=3.59 ng/mL (cycles 2005-2006)</p>	<p><b>Stat Method:</b> Adjusted, survey-weighted regression models. Covariates and confounders considered include age, sex, and race/ethnicity, serum cotinine, BMI, and others.</p> <p>Linear regression was used for the vaccine study with PFC treated continuously and as quartiles. Exposures and outcomes were natural log transformed. All models were run for full population and run again restricted to the seropositive population. Logistic regression for estimates for the allergy study. Odds ratios based on an IQR shift and for quartiles of PFOA and linear regression used to estimates allergen specific IgE antibodies and IgE antibody level by quartiles.</p> <p>Effect estimates shown for doubling of PFC concentration.</p> <p><b>Outcome:</b> Antibody titers</p> <p><b>Major Findings:</b> % Change <u>All</u> Measles=-0.1 (95% CI -13.8, 15.6) Mumps=-6.0 (95% CI -12.4, 0.9) Rubella=-2.5 (95% CI -9.1, 5.3)</p> <p><u>Seropositive</u> Measles=-3.4 (95% CI -16.7, 11.9) <b>Mumps= -6.6 (95% CI -11.7, -1.5)</b> <b>Rubella=-8.9 (95% CI -14.6, -2.9)</b></p>	<p><b>Major Limitations:</b></p> <p>Cross-sectional design limits causality interpretation.</p> <p>Receipt and/or timing of measles-mumps-rubella vaccination are not available.</p> <p>Other environmental contaminants, including other PFCs not controlled for.</p>

		<p><b>Outcome:</b> Allergic conditions  <b>Major Findings:</b>                  Asthma OR=1.28 (95% CI 0.81, 2.04)                  Wheeze OR=0.94 (95% CI 0.51, 1.73)                  Allergy OR=1.12 (95% CI 0.85, 1.47)  <b>Rhinitis OR=1.35 (95% CI 1.10, 1.66)</b></p> <p><b>Outcome:</b> Allergic sensitization  <b>Major Findings:</b>                  Any, Plants, Dust mites, Pets,                  Cockroach/shrimp, Rodents, Mold, Food:</p> <p>No findings were statistically significant, confidence intervals appeared wide and findings were both positive or negative depending on the type of allergen.</p> <p><b>Outcome:</b> Serum IgE Antibody Titer  <b>Major Findings:</b>  <b>%Change=10.5 (95% CI 0.17, 22)</b></p>	
--	--	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--

Reference and Study Design	Exposure Measures	Results	Comment
<p>(Wang, Rogan et al. 2014)</p> <p><b>Study Design:</b>                      Cross-sectional and prospective birth cohort.</p> <p><b>Location:</b>                      Central Taiwan</p> <p><b>Population:</b> Recruited from Taiwan Maternal and Infant Cohort Study (longitudinal birth cohort study of pregnant women and children); n=285 pregnant women in 3<sup>rd</sup> trimester, n=116 neonates.</p> <p><b>Outcome Definition:</b> Maternal (@ 3<sup>rd</sup> trimester) and cord serum neonatal thyroid</p>	<p><b>Exposure Assessment:</b>                      Maternal serum concentrations.</p> <p><b>Population-Level Exposure:</b>                      Maternal Median = 2.39 ng/mL</p>	<p><b>Stat Method:</b> Linear regression, covariates and confounders considered included maternal age, maternal education, previous live births, family income, maternal pregnancy BMI, and maternal fish consumption during pregnancy.</p> <p>Estimates calculated with and without log-transformation of thyroid hormones.</p> <p><b>Outcome:</b> Thyroid hormones  <b>Major Findings:</b>  <u>Maternal PFOA and maternal:</u>                      FT4: <math>\beta=-0.003</math> (95% -0.012, 0.005)                      TT4: <math>\beta=0.011</math> (95% CI -0.108, 0.130)                      TT3: <math>\beta=-0.000</math> (95% CI -0.002, 0.009)                      TSH: <math>\beta=0.011</math> (95% CI -0.057, 0.078)</p>	<p><b>Major Limitations:</b>                      Only one sample from mother and neonate was obtained, calls causal inference into question,</p> <p>Measurement of cord blood rather than infant blood may have been more informative, less affected by perturbations of birth,</p> <p>Sample size not sufficient for evaluation of clinical outcomes,</p> <p>Did not have measures of all possible factors that affect thyroid hormones (i.e., iodine)</p> <p>Some aspects of the study were cross sectional, therefore precluding causal inference.</p>

hormone status (TSH, FT4, TT4, T3)		<p>Maternal PFOA and cord:                  FT4: <math>\beta=-0.029</math> (95% -0.062, 0.004)                  TT4: <math>\beta=0.128</math> (95% CI -0.094, 0.350)                  TT3: <math>\beta=-0.001</math> (95% CI -0.004, 0.001)                  TSH: <math>\beta=-0.498</math> (95% CI -1.464, 0.468)</p>	<p><b>Funding Source:</b> National Health Research Institutes, Taiwan (grants EO-101-PP-05,EH-102-SP-02, EO-102-PP-05), the National Science Council, Taiwan (grant NSC101-2325-B-400-008), and in part by the National Institute of Environmental Health Sciences, National Institutes of Health (USA).</p>
------------------------------------	--	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Reference and Study Design	Exposure Measures	Results	Comment
<p>(Wang, Zhang et al. 2012)</p> <p><b>Study Design:</b> Cross-sectional</p> <p><b>Location:</b> Jiangsu High-Tech Fluorine Chemical Industrial Zone, Changshu City, Jiangsu Province, CN</p> <p><b>Population:</b> Employees at plant for greater than 2 years, n=55 (male) and nearby residents for at least 5 years, n=132.</p> <p><b>Outcome Definition:</b> serum lipid biomarkers and nine circulating miRNAs (endogenous, small noncoding RNAs. They play an important role in regulating gene expression by base-pairing to complementary sites on target mRNAs to block translation or trigger the degradation of target mRNAs.</p>	<p><b>Exposure Assessment:</b> Serum PFOA</p> <p><b>Population-Level Exposure:</b> Median: 284 ng/mL (residents) 1636 ng/mL (occupational cohort)</p>	<p><b>Stat Method:</b> Described correlations using Spearman non-parametric correlation coefficients. Also linear regression with control for age and BMI, smoking and drinking status.</p> <p>Also did a sensitivity analysis excluding older individuals (residents only) and combined younger (resident and workers). All outcomes and PFOA were natural log transformed.</p> <p><b>Outcome:</b> Serum lipids and liver enzymes</p> <p><b>Major findings:</b>  <u>Residents</u>                      Cholesterol: <math>\beta=-0.00</math>, p-value=0.85                      HDL: <math>\beta=0.02</math>, p-value=0.39                      LDL: <math>\beta=-0.00</math>, p-value=0.97                      HDL/LDL: <math>\beta=0.02</math>, p-value=0.57                      TG: <math>\beta=0.02</math>, p-value=0.73                      ALT: <math>\beta=-0.10</math>, p-value=0.05                      AST: <math>\beta=-0.04</math>, p-value=0.22</p> <p><u>Workers</u>                      Cholesterol: <math>\beta=0.02</math>, p-value=0.36  <b>HDL: <math>\beta=-0.07</math>, p-value=0.01</b>                      LDL: <math>\beta=0.03</math>, p-value=0.43  <b>HDL/LDL: <math>\beta=-0.09</math>, p-value=0.01</b>                      TG: <math>\beta=0.02</math>, p-value=0.73                      ALT: <math>\beta=0.04</math>, p-value=0.38  <b>AST: <math>\beta=-0.12</math>, p-value=0.02</b></p>	<p><b>Major Limitations:</b> Cross sectional design precludes causal inference.</p> <p>Healthy worker effect</p> <p>Small n.</p> <p>Volunteer bias.</p> <p>Age discrepancy in miRNA cohort.</p> <p>Self-reported weight and height,</p> <p>No info on socioeconomic data.</p> <p>No known covariates for miRNAs,</p> <p>No known exact pathological meanings of altered serum miRNAs</p> <p><b>Funding Source:</b> National Natural Science Foundation of China</p>

**Outcome:** Circulating miR-26b and miR-199a-3p

**Major Findings:**

miRNA	Residents	Workers	Fold change	P
miR-26b	4.05	3.11	1.9	<b>0.03</b>
miR-199a-3p	8.98	6.9	3.47	<b>0.02</b>

Other miRs were not statistically significant.

Reference and Study Design	Exposure Measures	Results	Comment
<p>(Webster, Venners et al. 2014)</p> <p><b>Study Design:</b> Prospective cohort study</p> <p><b>Location:</b> Vancouver, Canada</p> <p><b>Population:</b> Euthyroid pregnant women in early 2<sup>nd</sup> trimester, enrolled in the Chemicals, Health, and Pregnancy study, ≥ 19 years of age, n=152</p> <p><b>Outcome Definition:</b> <b>Repeated measures of</b> maternal thyroid hormones at 15 and 18 weeks gestation.</p>	<p><b>Exposure Assessment:</b> Serum concentrations</p> <p><b>Population-Level Exposure:</b> Median = 1.7 ng/mL</p>	<p><b>Stat Method:</b> Mixed effects linear regression models with random intercept for individual, Confounders and covariates considered include maternal age, ethnicity, education, household income, current stress levels, smoking, environmental tobacco smoke exposure, drug use, alcohol use, and use of iodized salt and prenatal vitamins containing iodine.</p> <p>PFCs and hormones not log transformed.</p> <p>Sensitivity analysis stratified by high v. normal TPOAb (thyroid peroxidase antibody levels, as marker of autoimmune hypothyroidism).</p> <p>Estimates presented for most adjusted models and an IQR increase.</p> <p><b>Outcome:</b> FT4 <b>Major Findings:</b> Normal TPOAb: <math>\beta=-0.03</math> (95% CI -0.3, 0.2) High TPOAb: <math>\beta=-0.4</math> (95% CI -1, 0.5)</p> <p><b>Outcome:</b> TSH <b>Major Findings:</b> Normal TPOAb: <math>\beta=0.07</math> (95% CI -0.1, 0.2) <b>High TPOAb: <math>\beta=0.7</math> (95% CI 0.09, 1)</b></p> <p><b>Outcome:</b> TT4 <b>Major Findings:</b> No associations found, estimates presented in supplemental material.</p>	<p><b>Major Limitations:</b> Small n, especially in high TPOAb group,  Sample unrepresentative of background population of Vancouver,  Use of questionnaires to determine iodine sufficiency and exposure to environmental tobacco smoke,  No control for serum binding protein levels or urinary/blood selenium,  Slightly outdated radioimmunoassay method,  Reverse causation may be a factor</p> <p><b>Note:</b> Associations found early in critical gestational period</p> <p><b>Funding Source:</b> Health Canada, BC Medical Services Foundation, BC Environmental and Occupational Health Research Network, UBC Centre for Health and Environment Research, Natural Sciences and Engineering Research Council, Michael Smith Foundation for Health Research, UBC Bridge Program, Interdisciplinary Women’s Reproductive Health Program</p>



Reference and Study Design	Exposure Measures	Results	Comment
<p>(Wen, Lin et al. 2013)</p> <p><b>Study Design:</b> Cross-sectional</p> <p><b>Location:</b> General U.S. population</p> <p><b>Population:</b> NHANES 2007-2008, and 2009-2010, adults &gt; 20 years of age, n=1.180</p> <p><b>Outcome Definition:</b> Serum concentrations of thyroid measures (TT3, TT4, FT4, thyroglobulin), subclinical hyperthyroidism was defined as TSH &lt; 0.24 mIU/L and subclinical hypothyroidism defined as TSH &gt; 5.43 mIU/L</p>	<p><b>Exposure Assessment:</b> Serum concentrations</p> <p><b>Population-Level Exposure:</b> Geometric mean = 4.15 ng/mL</p>	<p><b>Stat Method:</b> Linear and logistic regression, covariates and confounders considered included age, gender, race, alcohol consumption, smoking, and urinary iodine. Modeled separately for men and women.</p> <p>Outcomes were log transformed if improved model fit, PFOA was log transformed.</p> <p>PFCS were modeled separately and in composite model. Most adjusted (weighted) results shown below.</p> <p><b>Outcome:</b> Thyroid hormones</p> <p><b>Major Findings:</b></p> <p><u>TT4</u> Men: <math>\beta=0.000</math> (95% CI -0.280, 0.280) Women: <math>\beta=0.82</math> (95 % CI -0.369, 0.532 )</p> <p><u>Ln-FT4</u> Men: <math>\beta=-0.010</math> (95% CI -0.041, 0.022) Women: <math>\beta=-0.004</math> (95 % CI -0.047, 0.039 )</p> <p><u>TT3</u> Men: <math>\beta=0.775</math> (95% CI -3.048, 4.598) <b>Women: <math>\beta=6.628</math> (95 % CI 0.545, 12.712)</b></p> <p><u>ln-FT3</u> Men: <math>\beta=0.013</math> (95% CI -0.004, 0.031) Women: <math>\beta=0.016</math> (95 % CI -0.018, 0.051)</p> <p><u>Ln-TSH</u> Men: <math>\beta=0.004</math> (95% CI -0.081, 0.090) Women: <math>\beta=-0.030</math> (95 % CI -0.215, 0.154 )</p> <p><u>Ln-thyroglobulin</u> Men: <math>\beta=-0.096</math> (95% CI -0.258, 0.066) Women: <math>\beta=0.095</math> (95 % CI -0.111, 0.302)</p>	<p><b>Major Limitations:</b> Cross sectional design precludes causal inference,  Common physiology could confound,  No accounting for thyroid medications,  Data set limited to single time point measures (thyroid hormone levels vary in an individual).</p> <p><b>Funding Source:</b> unspec, authors employed by En Chu Kong Hospital (Wen LL, Lin CY), National Taiwan University Hospital (Lin LY, Su TC), National Taiwan University of Public Health (Chen PC) and Fu Jen Catholic University (Lin CY).</p>

	<p><b>Outcome:</b> Subclinical thyroid diseases</p> <p><b>Major Findings:</b>  <u>Hypothyroidism</u>                  Men: OR=1.29 (95% CI 0.40, 4.10)  <b>Women: OR=7.42 (95% CI 1.14, 48.12)</b></p> <p><u>Hyperthyroidism</u>  <b>Men: OR=0.38 (95% CI 0.16, 0.95)</b>                  Women: OR=0.99 (95% CI 0.13, 7.59)</p>	
--	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--

Reference and Study Design	Exposure Measures	Results	Comment												
<p>(Winquist and Steenland 2014)</p> <p><b>Study Design:</b> Retrospective cohort, prospective analyses in 2005-2006.</p> <p><b>Location:</b> WV and OH, USA</p> <p><b>Population:</b> Community member cohort (recruited from C8 Health Project participants (&gt;20 years of age)), n = 28,541 and plant workers in mid-Ohio River Valleys (recruited from a previous occupational mortality study cohort of people who worked at the chemical plant during 1948-2002), n = 3,713, n=32,254 total</p> <p><b>Outcome Definition:</b> Self-reported health professional diagnosis- Questionnaire of demographics, health-related behaviors, and lifetime personal medical history, completed 2008-2010 and 2010-2011.</p>	<p><b>Exposure Assessment:</b> Yearly estimated serum PFOA concentrations starting at birth of 1952, whichever came later. Estimates of yearly air and drinking water PFOA exposure using an environmental fate and transport model were developed. Additional information for community estimates includes residential history and drinking water consumption rates and sources. For workers an occupational exposure model was used, after work, they were decayed until they met the community exposure models.</p> <p><b>Population-Level Exposure:</b> Median 2005-06 = 26.1 ng/mL Median concentrations highest in late 1990s-early 2000s</p>	<p><b>Stat Method:</b> Cox proportional hazard models (survival analysis), stratified by birth year. Covariates and confounders considered include sex, race, education, smoking and alcohol use.</p> <p>Primary models considered patterns of hazard ratios across quintiles of each exposure metric. In tests for trend, natural log-transformed PFOA concentration estimates were used.</p> <p>Retrospective analyses used deciles to explore dose-response curve shape.</p> <p><b>Outcome:</b> Functional thyroid disease (n=2,323)</p> <p><b>Major Findings:</b> <u>Primary retrospective analysis:</u></p> <table border="1"> <thead> <tr> <th>Quintile</th> <th>HR</th> </tr> </thead> <tbody> <tr> <td>1</td> <td>1</td> </tr> <tr> <td>2</td> <td>1.21</td> </tr> <tr> <td>3</td> <td>1.12</td> </tr> <tr> <td>4</td> <td>1.27</td> </tr> <tr> <td>5</td> <td>1.28</td> </tr> </tbody> </table> <p>HR log µg/ml*yr = 1.03, p-value=0.09</p> <p><b>The trend was more pronounced among women (HR per log µg/ml*yr = 1.04, p-value=0.03), but was absent among men (HR per log µg/ml*yr = 1.01, p-value=0.85).</b></p>	Quintile	HR	1	1	2	1.21	3	1.12	4	1.27	5	1.28	<p><b>Major Limitations:</b> Healthy worker effect for worker cohort</p> <p>Population in study area changed over time, no way to identify and include all residents over exposure period.</p> <p>Potential bias if exposure and thyroid conditions were correlated with migration or participation in original C8 study,</p> <p>Possible changes in population susceptibility over time,</p> <p>Potential error in exposure estimates (would bias towards null),</p> <p>Exclusion of people who reported thyroid disease with no type specified,</p> <p>Potential impact of differential access to care (w/r/t thyroid diagnoses)</p> <p><b>Funding Source:</b> C8 Class Action Settlement between DuPont and Plaintiffs</p>
Quintile	HR														
1	1														
2	1.21														
3	1.12														
4	1.27														
5	1.28														

Medical records were reviewed to confirm diagnosis.

Functional thyroid disease defined as a report of goiter, Graves' disease, hyperthyroidism, Hashimoto's disease, hypothyroidism, thyroiditis not otherwise specified, or a thyroid function problem of unknown type. Hyperthyroidism defined as report of hyperthyroidism or Graves' disease. Hypothyroidism defined as report of hypothyroidism or Hashimoto's disease.

Yearly exposure metric:

Quintile	HR
1	1
2	1.23
3	1.24
4	1.10
5	1.28

**HR per log  $\mu\text{g/ml}\cdot\text{yr} = 1.03$ , p-value=0.04**

**The trend was more pronounced among women (HR per log  $\mu\text{g/ml}\cdot\text{yr} = 1.04$  p-value=0.008), and was absent among men.**

Prospective analysis, Bayesian calibration:

No clear associations with both sexes combined (smaller number of cases. There was a suggestion of an increasing hazard of function thyroid disease with increasing cumulative exposure among men (p-value=0.09).

**Outcome:** Hypothyroidism (n=1,655)

**Major Findings:**

A trend for increasing hazards with increasing exposure was suggested for both hypothyroidism in relation to cumulative exposure (although log-linear trend p-values were > 0.05).

For men considering the cumulative and yearly exposure metrics, and measured PFOA - HR per log  $\mu\text{g/ml}\cdot\text{yr} = 1.24$  P=0.021. And for prospective analyses.

**Outcome:** Hyperthyroidism (n=456)

**Major Findings:**

A trend for increasing hazards with increasing exposure was suggested for both. Log-linear trend p-value < 0.05, overall and for women.

Reference and Study Design	Exposure Measures	Results	Comment															
<p>(Winqvist and Steenland 2014)</p> <p><b>Study Design:</b> Longitudinal</p> <p><b>Location:</b> WV and OH, USA</p> <p><b>Population:</b> Community member cohort (recruited from C8 Health Project participants (&gt;20 years of age)), n = 28,541 and plant workers in mid-Ohio River Valleys (recruited from a previous occupational mortality study cohort of people who worked at the chemical plant during 1948-2002), n = 3,713, n=32,254 total</p> <p><b>Outcome Definition:</b> Self-reported health professional diagnosis- 2008-2011 Questionnaire completion for high blood pressure, high cholesterol, or heart disease.</p> <p>Questions include diagnosis of hypertension (not during pregnancy), hypercholesterolemia, coronary artery disease</p>	<p><b>Exposure Assessment:</b> Yearly estimated serum PFOA concentrations starting at birth of 1952, whichever came later. Estimates of yearly air and drinking water PFOA exposure using an environmental fate and transport model were developed. Additional information for community estimates includes residential history and drinking water consumption rates and sources. For workers an occupational exposure model was used, after work, they were decayed until they met the community exposure models.</p> <p><b>Population-Level Exposure:</b> Median measured in 2005-06: 26.1 ng/mL (24.2 community, 112.7 worker)</p>	<p><b>Stat Method:</b> Cox proportional hazard models (survival analysis), stratified by birth year. Covariates and confounders considered include sex, race, education, smoking and alcohol use, BMI, self-reported diabetes type 2, family history of coronary disease.</p> <p>Retrospective analyses started at the late of age 20 years or the age in 1952. Prospective analyses started at the participant's age 1 year after enrollment in the C8 Health Project (2005-2006).</p> <p>Primary exposure metric was a measure of cumulative PFOA (sum of all yearly serum concentration estimates). To look at short term effects, secondary analyses looked at yearly concentrations of PFOA estimates. Primary analyses considered the exposure by quintiles. Log of cumulative or yearly concentrations was used for a test of trend.</p> <p>All analyses performed overall and by age strata. Sensitivity analysis examining only community cohort.</p> <p><b>Outcome:</b> Hypertension</p> <p><b>Major Findings:</b> Retrospective analyses of both cumulative and yearly exposure metrics were similar and did not show clear evidence of association.</p> <p>Cumulative-</p> <table border="1" data-bbox="881 1166 1284 1328"> <thead> <tr> <th>Quintile</th> <th>HR</th> <th>95% CI</th> </tr> </thead> <tbody> <tr> <td>2</td> <td>1.10</td> <td>1.02, 1.19</td> </tr> <tr> <td>3</td> <td>1.10</td> <td>1.02, 1.18</td> </tr> <tr> <td>4</td> <td>1.05</td> <td>0.97, 1.12</td> </tr> <tr> <td>5</td> <td>0.98</td> <td>0.91, 1.06</td> </tr> </tbody> </table> <p>Age- and sex- stratified analyses found some evidence of hypertension with increasing exposure among females, 20 to 39 years and</p>	Quintile	HR	95% CI	2	1.10	1.02, 1.19	3	1.10	1.02, 1.18	4	1.05	0.97, 1.12	5	0.98	0.91, 1.06	<p><b>Major Limitations:</b> Survivor bias,  Hard to find decedents proxies (workers),  Healthy worker effect (workers)  Self-report bias (towards null)</p> <p><b>Funding Source:</b> C8 Class Action Settlement between DuPont and Plaintiffs</p>
Quintile	HR	95% CI																
2	1.10	1.02, 1.19																
3	1.10	1.02, 1.18																
4	1.05	0.97, 1.12																
5	0.98	0.91, 1.06																

males 40 to 59 but trends were not monotonic or statistically significant. Prospective analysis also did not show clear evidence.

**Outcome:**

Incident hypercholesterolemia with medication

**Major Findings:**

**Retrospective analyses showed elevated hazard.**

Cumulative-

Quintile	HR	95% CI
2	1.24	1.15, 1.33
3	1.17	1.09, 1.26
4	1.19	1.11, 1.27
5	1.19	1.11, 1.28

Test for trend p=0.005

Yearly exposure showed the same effect as cumulative (Test for trend p<0.001).

**The increased hazard was most pronounced among men 40-59 years of age (Test for trend p<0.001).**

Prospective analyses showed no evidence of a positive association.

**Outcome:** Coronary artery disease

**Major Findings:**

Retrospective analyses showed no clear association.

Quintile	HR	95% CI
2	1.26	1.10, 1.45
3	1.17	1.02, 1.35
4	0.99	0.86, 1.14
5	1.07	0.93, 1.23

Among males 20 to 39 years of age, there appeared to be higher hazards, but log linear test for trend not significant (P for trend = 0.64)

Prospective analyses also showed no evidence of association.

Reference and Study Design	Exposure Measures	Results	Comment																		
<p>(Yamaguchi, Arisawa et al. 2013)</p> <p><b>Study Design:</b> Cross-sectional</p> <p><b>Location:</b> Japan (15 prefectures)</p> <p><b>Population:</b> Participants in larger “Survey on the Accumulations of Dioxins and Other Chemical Compounds in Humans” project, ages 16-76, resided in area for at least 10 years with little relocation, n=608</p> <p><b>Outcome Definition:</b> Serum fatty acids and hepatic enzymes: <math>\gamma</math>-GTP (glutamyl transpeptidase), GOT (glutamic-oxaloacetic transaminase), GPT (glutamic-pyruvic transaminase), EPA (eicosapentaenoic acid), DHA (docosahexaenoic acid)</p>	<p><b>Exposure Assessment:</b> Serum concentrations</p> <p><b>Population-Level Exposure:</b> Median: 2.1 ng/mL IQR: 1.5-3.3 ng/mL</p>	<p><b>Stat Method:</b> Spearman rank correlations, covariates and confounders considered included effects of age, sex, BMI, regional block and smoking, and intake of alcoholic beverages.</p> <p>Most adjusted results presented when available.</p> <p><b>Outcome:</b> Liver enzymes and fatty acids</p> <p><b>Major Findings:</b></p> <table border="1" data-bbox="881 524 1239 808"> <thead> <tr> <th>Outcome</th> <th>r</th> <th>P</th> </tr> </thead> <tbody> <tr> <td>DHA</td> <td>0.12</td> <td>0.003</td> </tr> <tr> <td>EPA</td> <td>0.20</td> <td>&lt;0.0001</td> </tr> <tr> <td><math>\gamma</math>-GTP (GGT)</td> <td>0.06</td> <td>0.12</td> </tr> <tr> <td>GOT (AST)</td> <td>0.13</td> <td>0.002</td> </tr> <tr> <td>GPT (ALT)</td> <td>0.09</td> <td>0.04</td> </tr> </tbody> </table>	Outcome	r	P	DHA	0.12	0.003	EPA	0.20	<0.0001	$\gamma$ -GTP (GGT)	0.06	0.12	GOT (AST)	0.13	0.002	GPT (ALT)	0.09	0.04	<p><b>Major Limitations:</b> Cross sectional design precludes causal inference.</p> <p>Subjects engaged in fishing and farming may have been oversampled compared with gen pop</p> <p><b>Funding Source:</b> National Natural Science Foundation of China</p>
Outcome	r	P																			
DHA	0.12	0.003																			
EPA	0.20	<0.0001																			
$\gamma$ -GTP (GGT)	0.06	0.12																			
GOT (AST)	0.13	0.002																			
GPT (ALT)	0.09	0.04																			

Reference and Study Design	Exposure Measures	Results	Comment																									
<p>(Zeng, Qian et al. 2015)</p> <p><b>Study Design:</b> Cross-sectional</p> <p><b>Location:</b> Taipei, Taiwan</p> <p><b>Population:</b> Taiwanese children ages 12-15 years, n=225 From control group of Genetic and Biomarkers Study for Childhood Asthma</p> <p><b>Outcome Definition:</b> Serum lipids.</p> <p>LDL was calculated using the Friedewald formula for participants when TGs were lower than 400 mg/dl.</p>	<p><b>Exposure Assessment:</b> Serum concentrations</p> <p><b>Population-Level Exposure:</b> ng/mL Mean (boys,)=1.1 (+/- 1.4) Mean (girls)=0.92 (+/- 0.79)</p>	<p><b>Stat Method:</b> Linear regression models with continuous log transformed PFOA and as quartiles. Covariates and confounders considered include age, gender, BMI, regular exercise, parental education, and environmental tobacco smoke.</p> <p>Ordinal variable used to assess trends.</p> <p><b>Outcome:</b> Serum lipids</p> <p><b>Major Findings:</b></p> <table border="1" data-bbox="865 457 1400 678"> <thead> <tr> <th>Outcome</th> <th><math>\beta</math></th> <th colspan="2">95% CI</th> <th>P for trend</th> </tr> </thead> <tbody> <tr> <td><b>Total Cholesterol</b></td> <td><b>6.57</b></td> <td><b>2.72</b></td> <td><b>10.42</b></td> <td><b>0.004</b></td> </tr> <tr> <td>HDL</td> <td>-1.56</td> <td>-3.20</td> <td>0.08</td> <td>0.36</td> </tr> <tr> <td><b>LDL</b></td> <td><b>4.66</b></td> <td><b>1.67</b></td> <td><b>7.65</b></td> <td><b>0.002</b></td> </tr> <tr> <td><b>Triglycerides</b></td> <td><b>19.63</b></td> <td><b>14.82</b></td> <td><b>24.34</b></td> <td><b>0.01</b></td> </tr> </tbody> </table>	Outcome	$\beta$	95% CI		P for trend	<b>Total Cholesterol</b>	<b>6.57</b>	<b>2.72</b>	<b>10.42</b>	<b>0.004</b>	HDL	-1.56	-3.20	0.08	0.36	<b>LDL</b>	<b>4.66</b>	<b>1.67</b>	<b>7.65</b>	<b>0.002</b>	<b>Triglycerides</b>	<b>19.63</b>	<b>14.82</b>	<b>24.34</b>	<b>0.01</b>	<p><b>Major Limitations:</b> Cross sectional design precludes causal inference,  May be unmeasured confounders (dietary sources, etc) or pharmacokinetics.</p> <p><b>Funding Source:</b> National Natural Science Foundation of China</p>
Outcome	$\beta$	95% CI		P for trend																								
<b>Total Cholesterol</b>	<b>6.57</b>	<b>2.72</b>	<b>10.42</b>	<b>0.004</b>																								
HDL	-1.56	-3.20	0.08	0.36																								
<b>LDL</b>	<b>4.66</b>	<b>1.67</b>	<b>7.65</b>	<b>0.002</b>																								
<b>Triglycerides</b>	<b>19.63</b>	<b>14.82</b>	<b>24.34</b>	<b>0.01</b>																								



APPENDIX 5: Individual Tables for Toxicology Studies

## Appendix 5A. Studies that evaluated increased liver weight and provide serum PFOA data from end of dosing period

Note: An additional study (Macon et al, 2011) that includes this information is presented in Appendix 5B

Reference and Study Design	Results	Comment																																																								
<p><b>Lau et al. (2006).</b> Effects of perfluorooctanoic acid exposure during pregnancy in the mouse.</p> <p><b>NOTE:</b> A separate study of pharmacokinetics of PFOA in male and non-pregnant female mice and rats reported in this paper is not included in this table.</p> <p><b>Species and strain:</b> Timed pregnant CD-1 mice</p> <p><b>Test article and vehicle:</b> PFOA (&gt;98% pure; 98.9% linear, 1.1% branched isomers)</p> <p>Vehicle was NANOpure water.</p> <p><b>Route of exposure:</b> Oral gavage</p> <p><b>Exposure levels:</b> 0, 1, 3, 5, 10, 20, 40</p> <p><b>Exposure regimen:</b> GD 1-17</p> <p><b>Group size:</b> Not explicitly stated. Group numbers are reported with data in Results section.</p>	<p><b>Maternal body weight gain (GD 1-18)</b></p> <ul style="list-style-type: none"> <li>Data shown graphically.</li> <li>n = 9-57 dams per dose level.</li> <li>Dams were weighted daily on GD 1-18.</li> <li>Weight gain dramatically decreased during latter part of gestation at 20 mg/kg/day (stated significant on GD 8-18).</li> <li>Weight loss instead of gain during latter part of gestation at 40 mg/kg/day (weight effects stated significant on GD 5-18).</li> </ul> <p><b>Maternal liver weight (GD 18)</b></p> <ul style="list-style-type: none"> <li>Data for absolute liver weight shown graphically. Numerical data for liver weight (absolute, and relative to body weight with gravid uterus removed) provided by investigator.</li> <li>n = 9-45 dams per dose level.</li> <li>Absolute liver weight increased (p&lt;0.05) at all doses. Statistical evaluation of liver wt. relative to body wt. minus wt. of gravid uterus not provided by investigator.</li> <li>Absolute liver weight lower at 20 and 40 mg/kg/day than 10 mg/kg/day, but body weight also decreased at these doses.</li> </ul> <table border="1" data-bbox="693 727 1680 1015"> <thead> <tr> <th>Dose (mg/kg/day)</th> <th>Absolute liver weight (g)</th> <th colspan="2">Relative liver weight (% of body weight minus weight of gravid uterus)</th> </tr> </thead> <tbody> <tr> <td>0</td> <td>2.4±0.05</td> <td>7.3±0.14</td> <td>1</td> </tr> <tr> <td>1</td> <td>3.4±0.08*</td> <td>10.9±0.16</td> <td>1.49</td> </tr> <tr> <td>3</td> <td>4.2±0.15*</td> <td>12.9±0.41</td> <td>1.77</td> </tr> <tr> <td>5</td> <td>4.4±0.17*</td> <td>13.8±0.40</td> <td>1.89</td> </tr> <tr> <td>10</td> <td>5.1±0.24*</td> <td>15.9±0.52</td> <td>2.18</td> </tr> <tr> <td>20</td> <td>4.2±0.20*</td> <td>16.9±0.51</td> <td>2.32</td> </tr> <tr> <td>40</td> <td>4.0±0.16*</td> <td>18.9±0.63</td> <td>2.59</td> </tr> </tbody> </table> <p>*p&lt;0.05</p> <p><b>Maternal PFOA serum levels (GD 18).</b></p> <table border="1" data-bbox="647 1084 1295 1344"> <thead> <tr> <th>Dose (mg/kg/day)</th> <th>n</th> <th>Serum level (µg/ml)</th> </tr> </thead> <tbody> <tr> <td>0</td> <td>58</td> <td>0.51±0.12</td> </tr> <tr> <td>1</td> <td>6</td> <td>21.93±1.71</td> </tr> <tr> <td>3</td> <td>7</td> <td>40.5±1.89</td> </tr> <tr> <td>5</td> <td>33</td> <td>71.91±8.33</td> </tr> <tr> <td>10</td> <td>30</td> <td>116.12±16.18</td> </tr> <tr> <td>20</td> <td>54</td> <td>180.55±19.05</td> </tr> <tr> <td>40</td> <td>14</td> <td>271.14±19.15</td> </tr> </tbody> </table> <ul style="list-style-type: none"> <li>Shown graphically; numerical data provided by investigator.</li> <li>n = 6-58 per dose level.</li> </ul>	Dose (mg/kg/day)	Absolute liver weight (g)	Relative liver weight (% of body weight minus weight of gravid uterus)		0	2.4±0.05	7.3±0.14	1	1	3.4±0.08*	10.9±0.16	1.49	3	4.2±0.15*	12.9±0.41	1.77	5	4.4±0.17*	13.8±0.40	1.89	10	5.1±0.24*	15.9±0.52	2.18	20	4.2±0.20*	16.9±0.51	2.32	40	4.0±0.16*	18.9±0.63	2.59	Dose (mg/kg/day)	n	Serum level (µg/ml)	0	58	0.51±0.12	1	6	21.93±1.71	3	7	40.5±1.89	5	33	71.91±8.33	10	30	116.12±16.18	20	54	180.55±19.05	40	14	271.14±19.15	
Dose (mg/kg/day)	Absolute liver weight (g)	Relative liver weight (% of body weight minus weight of gravid uterus)																																																								
0	2.4±0.05	7.3±0.14	1																																																							
1	3.4±0.08*	10.9±0.16	1.49																																																							
3	4.2±0.15*	12.9±0.41	1.77																																																							
5	4.4±0.17*	13.8±0.40	1.89																																																							
10	5.1±0.24*	15.9±0.52	2.18																																																							
20	4.2±0.20*	16.9±0.51	2.32																																																							
40	4.0±0.16*	18.9±0.63	2.59																																																							
Dose (mg/kg/day)	n	Serum level (µg/ml)																																																								
0	58	0.51±0.12																																																								
1	6	21.93±1.71																																																								
3	7	40.5±1.89																																																								
5	33	71.91±8.33																																																								
10	30	116.12±16.18																																																								
20	54	180.55±19.05																																																								
40	14	271.14±19.15																																																								

Reference and Study Design	Results	Comment																																																
<p>Lau et al. (2006). (continued)</p>	<ul style="list-style-type: none"> <li>Increased in a dose-related fashion, but less than proportionally</li> </ul> <p><b>Reproductive outcomes</b></p> <p>Data presented in tabular form.</p> <ul style="list-style-type: none"> <li>Parameters examined include full litter resorptions, # of implants per live litter and per litter with full litter resorption, # live fetuses per litter, % prenatal loss, and fetal body weight.</li> <li>n = 9-45 dams per dose group</li> <li>Data in table below for parameters with statistically significant (p&lt;0.05) effects. No statistically significant effects for parameters now shown.</li> </ul> <table border="1" data-bbox="693 386 1731 740"> <thead> <tr> <th>Dose (mg/kg/day)</th> <th># of dams</th> <th>% full litter resorptions</th> <th># live fetuses per litter</th> <th>% prenatal loss per live litter</th> <th>Fetal body weight (g)</th> </tr> </thead> <tbody> <tr> <td>0</td> <td>45</td> <td>6.7</td> <td>12.5±0.4</td> <td>4.1±1.4</td> <td>1.05±0.02</td> </tr> <tr> <td>1</td> <td>17</td> <td>11.8</td> <td>13.0±0.4</td> <td>1.0±0.7</td> <td>0.98±0.03</td> </tr> <tr> <td>3</td> <td>17</td> <td>5.9</td> <td>10.8±0.9</td> <td>7.4±2.5</td> <td>1.03±0.04</td> </tr> <tr> <td>5</td> <td>27</td> <td>25.9*</td> <td>11.1±0.4</td> <td>2.4±0.8</td> <td>1.03±0.04*</td> </tr> <tr> <td>10</td> <td>26</td> <td>46.1*</td> <td>11.7±0.8</td> <td>7.7±3.3</td> <td>0.98±0.05</td> </tr> <tr> <td>20</td> <td>42</td> <td>88.1*</td> <td>7.2±2.0*</td> <td>25.9±11.7*</td> <td>0.86±0.11*</td> </tr> <tr> <td>40</td> <td>9</td> <td>100*</td> <td>---</td> <td>---</td> <td>----</td> </tr> </tbody> </table> <p>*p&lt;0.05</p> <ul style="list-style-type: none"> <li>Full litter resorptions increased at 5 mg/kg/day and above. NOAEL – 3 mg/kg/day.</li> <li>Number of live fetuses and fetal body weight decreased, % prenatal loss increased at 20 mg/kg/day. NOAEL – 10 mg/kg/day.</li> </ul> <p><b>Fetal teratology</b></p> <ul style="list-style-type: none"> <li>Data shown in tabular form.</li> <li>Extent of ossification assessed in sternbrae, caudal vertebrae, metacarpals, metatarsals, proximal phalanges of forelimb and hindlimb, calvari, supraoccipital, and hyoid. <ul style="list-style-type: none"> <li>Statistically significant (p&lt;0.05) reduction in ossification at one or more sites at all doses (1 mg/kg/day or above). No NOAEL identified.</li> <li>Reduced ossification effects at some sites. Do not increase in a dose-dependent fashion.</li> </ul> </li> <li>Tail defects significantly (p&lt;0.05) increased at 5, 10, and 20 mg/kg/day and limb defects at 5 and 20 mg/kg/day. NOAEL – 3 mg/kg/day.</li> <li>Microcardia significantly increased at 10 and 20 mg/kg/day. NOAEL – 5 mg/kg/day.</li> </ul>	Dose (mg/kg/day)	# of dams	% full litter resorptions	# live fetuses per litter	% prenatal loss per live litter	Fetal body weight (g)	0	45	6.7	12.5±0.4	4.1±1.4	1.05±0.02	1	17	11.8	13.0±0.4	1.0±0.7	0.98±0.03	3	17	5.9	10.8±0.9	7.4±2.5	1.03±0.04	5	27	25.9*	11.1±0.4	2.4±0.8	1.03±0.04*	10	26	46.1*	11.7±0.8	7.7±3.3	0.98±0.05	20	42	88.1*	7.2±2.0*	25.9±11.7*	0.86±0.11*	40	9	100*	---	---	----	
Dose (mg/kg/day)	# of dams	% full litter resorptions	# live fetuses per litter	% prenatal loss per live litter	Fetal body weight (g)																																													
0	45	6.7	12.5±0.4	4.1±1.4	1.05±0.02																																													
1	17	11.8	13.0±0.4	1.0±0.7	0.98±0.03																																													
3	17	5.9	10.8±0.9	7.4±2.5	1.03±0.04																																													
5	27	25.9*	11.1±0.4	2.4±0.8	1.03±0.04*																																													
10	26	46.1*	11.7±0.8	7.7±3.3	0.98±0.05																																													
20	42	88.1*	7.2±2.0*	25.9±11.7*	0.86±0.11*																																													
40	9	100*	---	---	----																																													

Reference and Study Design	Results	Comment
<p>Lau et al. (2006). (continued)</p>	<p><b><u>Neonatal survival</u></b> Data shown graphically for birth - PND 23. n = 8-22 litters per dose group. Stillbirth and neonatal mortality increased (p&lt;0.05) at 5 mg/kg/day and above. Effect most severe (&gt;50% stillbirth; &gt;70% neonatal mortality at 10 and 20 mg/kg/day.</p> <p><b><u>Offspring body weight</u></b></p> <ul style="list-style-type: none"> <li>• Birth – PND 23: Data shown graphically. <ul style="list-style-type: none"> <li>○ n = 7-30 litters per dose group.</li> <li>○ Body weight decreased (p&lt;0.05) at 3 mg/kg/day and higher. At PND 23, body weight 25-30% lower than controls at 3 mg/kg/day and higher. NOAEL – 1 mg/kg/day</li> </ul> </li> <li>• 6.5 – 60 weeks: Data shown in tabular form (male and female separately). <ul style="list-style-type: none"> <li>○ n = 4-11 litters per dose group.</li> <li>○ Significant (p&lt;0.05) dose-related effect at 6.5 weeks in males.</li> <li>○ Trend to higher body weights in treated than control at later time points.</li> </ul> </li> </ul> <p><b><u>Developmental landmarks</u></b></p> <ul style="list-style-type: none"> <li>• Data shown in tabular form. n=4-56 pups from 2-22 litters.</li> <li>• <i>Day of eye opening</i> – Dose-related delay at all doses 1 mg/kg/day and higher. Significant (p&lt;0.05) at 3 mg/kg/day and higher. Delayed by 3.1 days at 20 mg/kg/day.</li> <li>• <i>Day of vaginal opening</i> – Significant delay (p&lt;0.05) of 2.9 days at 20 mg/kg/day.</li> <li>• <i>Day of first estrus</i> – Significantly delayed at 5 and 20 mg/kg/day, but not 10 mg/kg/day</li> <li>• <i>Day of preputial separation</i> – Significantly accelerated compared to controls at 1 – 10 mg/kg/day, with greatest effect at 1 mg/kg/day (3.8 days). Significantly delayed at 20 mg/kg/day.</li> </ul>	

Reference and Study Design	Results										Comment																																																																															
<p><b>Loveless et al. (2006).</b> Comparative responses of rats and mice exposed to linear/branched, linear, or branched ammonium perfluorooctanoate (APFO)</p> <p><b>Species and strain:</b> Male rats and mice, approximately 8 weeks old, strain not stated.</p> <p><b>Test article and vehicle:</b> Linear/branched APFO, 77.6% linear. 97.99% pure. Linear APFO, purity not stated. Branched APFO, purity not stated.</p> <p>Vehicle was NANOpure water.</p> <p><b>Route of exposure:</b> Oral gavage</p> <p><b>Exposure levels:</b> 0, 0.3, 1, 3 or 1 mg/kg/day</p> <p><b>Exposure regimen:</b> 14 days</p> <p><b>Group size:</b> 10 per species per dose group.</p>	<p><b><u>RAT STUDY</u></b></p> <p><b><u>Hepatic endpoints</u></b></p> <table border="1" data-bbox="604 235 2217 690"> <thead> <tr> <th rowspan="2">Dose (mg/kg/day)</th> <th colspan="3">Linear/Branched</th> <th colspan="3">Linear</th> <th colspan="3">Branched</th> </tr> <tr> <th>Serum PFOA (µg/ml)</th> <th>Relative Liver Weight (g/100g)</th> <th>Peroxisomal beta-oxidation (palmitoyl CoA) (nM/min/mg protein)</th> <th>Serum PFOA (µg/ml)</th> <th>Relative Liver Weight (g/100g)</th> <th>Peroxisomal beta-oxidation (palmitoyl CoA) (nM/min/mg protein)</th> <th>Serum PFOA (µg/ml)</th> <th>Relative Liver Weight (g/100g)</th> <th>Peroxisomal beta-oxidation (palmitoyl CoA) (nM/min/mg protein)</th> </tr> </thead> <tbody> <tr> <td>0</td> <td>0.37±0.14</td> <td>3.43±0.40</td> <td>18.3±3.8</td> <td>0.39±0.51</td> <td>3.63±0.35</td> <td>15.7±3.6</td> <td>0.11±0.24</td> <td>3.38±0.29</td> <td>13.0±3.3</td> </tr> <tr> <td>0.3</td> <td>19±2.5</td> <td>3.63±0.23</td> <td>18.0±3.7</td> <td>20±3.2</td> <td>3.86±0.14</td> <td>16.0±3.1</td> <td>16±3.2</td> <td>3.58±0.27</td> <td>12.9±3.8</td> </tr> <tr> <td>1</td> <td>51±10</td> <td>3.94±0.20*</td> <td>27.0±4.3*</td> <td>65±11</td> <td>4.13±0.33*</td> <td>29.8±5.6*</td> <td>48±12</td> <td>3.91±0.33*</td> <td>14.4±3.1</td> </tr> <tr> <td>3</td> <td>106±10</td> <td>3.94±0.20*</td> <td>57.6±10.0</td> <td>137±18</td> <td>3.94±0.20*</td> <td>67.5±14.3*</td> <td>73±25</td> <td>3.94±0.20*</td> <td>17.4±3.5*</td> </tr> <tr> <td>10</td> <td>183±46</td> <td>5.67±0.52*</td> <td>82.2±18.1*</td> <td>206±65</td> <td>6.03±0.41*</td> <td>74.8±10.1*</td> <td>92±20</td> <td>5.77±0.75*</td> <td>28.7±8.0*</td> </tr> <tr> <td>30</td> <td>208±51</td> <td>6.82±0.56*</td> <td>84.7±16.3*</td> <td>223±77</td> <td>6.64±0.51*</td> <td>89.0±13.6*</td> <td>124±33</td> <td>6.37±0.70*</td> <td>37.6±12.2*</td> </tr> </tbody> </table> <p>*p&lt;0.05. n=10/group.</p> <ul style="list-style-type: none"> <li>Data shown in tabular form</li> <li>NOAEL for increased relative liver weight: 0.3 mg/kg/day; 16 µg/ml serum. LOAEL for increased relative liver weight: 1 mg/kg/day; 27 µg/ml serum.</li> <li>Linear/branched ratio data in linear branched/group shown in tabular form. Linear/branched ratio in serum increased with dose, suggesting preferential elimination of branched form</li> <li>The authors state that, when analyzed by serum levels, branched caused greater increase in liver weight than linear/branched and linear. Also, and peroxisomal beta-oxidation (palmitoyl Co-A oxidation; a marker of PPAR-alpha activity) lower in branched than in linear/branched and branched on a serum level basis., This indicates that PPAR-alpha independent increases in liver weight occurred. These data are shown graphically in the paper.</li> </ul> <p><b><u>Other Endpoints</u></b></p> <p><b><u>Mortality/clinical signs:</u></b> No mortality or clinical signs of toxicity during study.</p> <p><b><u>Body weight/body weight gain:</u></b> Data for body weight on day 0, 7, and 13, and for body weight gain on day 13; shown in tabular form. Body weight decreased (p&lt;0.05) compared to control on days 7 and 13 in linear/branched and linear 30 mg/kg/day groups. Body weight gain on days 0-13 decreased (p&lt;0.05) compared to control at 3 mg/kg/day in linear, 10 mg/kg/day in branched/linear, and 30 mg/kg/day in all treated groups.</p>										Dose (mg/kg/day)	Linear/Branched			Linear			Branched			Serum PFOA (µg/ml)	Relative Liver Weight (g/100g)	Peroxisomal beta-oxidation (palmitoyl CoA) (nM/min/mg protein)	Serum PFOA (µg/ml)	Relative Liver Weight (g/100g)	Peroxisomal beta-oxidation (palmitoyl CoA) (nM/min/mg protein)	Serum PFOA (µg/ml)	Relative Liver Weight (g/100g)	Peroxisomal beta-oxidation (palmitoyl CoA) (nM/min/mg protein)	0	0.37±0.14	3.43±0.40	18.3±3.8	0.39±0.51	3.63±0.35	15.7±3.6	0.11±0.24	3.38±0.29	13.0±3.3	0.3	19±2.5	3.63±0.23	18.0±3.7	20±3.2	3.86±0.14	16.0±3.1	16±3.2	3.58±0.27	12.9±3.8	1	51±10	3.94±0.20*	27.0±4.3*	65±11	4.13±0.33*	29.8±5.6*	48±12	3.91±0.33*	14.4±3.1	3	106±10	3.94±0.20*	57.6±10.0	137±18	3.94±0.20*	67.5±14.3*	73±25	3.94±0.20*	17.4±3.5*	10	183±46	5.67±0.52*	82.2±18.1*	206±65	6.03±0.41*	74.8±10.1*	92±20	5.77±0.75*	28.7±8.0*	30	208±51	6.82±0.56*	84.7±16.3*	223±77	6.64±0.51*	89.0±13.6*	124±33	6.37±0.70*	37.6±12.2*	<p>Data for parameters for hepatic effects and dosimetry are presented in detail.</p> <p>Data for other parameters are presented in summary form.</p>
Dose (mg/kg/day)	Linear/Branched			Linear			Branched																																																																																			
	Serum PFOA (µg/ml)	Relative Liver Weight (g/100g)	Peroxisomal beta-oxidation (palmitoyl CoA) (nM/min/mg protein)	Serum PFOA (µg/ml)	Relative Liver Weight (g/100g)	Peroxisomal beta-oxidation (palmitoyl CoA) (nM/min/mg protein)	Serum PFOA (µg/ml)	Relative Liver Weight (g/100g)	Peroxisomal beta-oxidation (palmitoyl CoA) (nM/min/mg protein)																																																																																	
0	0.37±0.14	3.43±0.40	18.3±3.8	0.39±0.51	3.63±0.35	15.7±3.6	0.11±0.24	3.38±0.29	13.0±3.3																																																																																	
0.3	19±2.5	3.63±0.23	18.0±3.7	20±3.2	3.86±0.14	16.0±3.1	16±3.2	3.58±0.27	12.9±3.8																																																																																	
1	51±10	3.94±0.20*	27.0±4.3*	65±11	4.13±0.33*	29.8±5.6*	48±12	3.91±0.33*	14.4±3.1																																																																																	
3	106±10	3.94±0.20*	57.6±10.0	137±18	3.94±0.20*	67.5±14.3*	73±25	3.94±0.20*	17.4±3.5*																																																																																	
10	183±46	5.67±0.52*	82.2±18.1*	206±65	6.03±0.41*	74.8±10.1*	92±20	5.77±0.75*	28.7±8.0*																																																																																	
30	208±51	6.82±0.56*	84.7±16.3*	223±77	6.64±0.51*	89.0±13.6*	124±33	6.37±0.70*	37.6±12.2*																																																																																	

Reference and Study Design	Results	Comment																																																																															
<p>Loveless et al. (2006). (continued)</p>	<p><u>Hematology:</u> Data not shown. Treatment related increases in acanthocytes in linear/branched and linear at 3, 10, and 30 mg/kg/day. Treatment related poikilocytes and schistocytes in linear/branched at 30 mg/kg/day, and linear at 3,10, and 30 mg/kg/day. Dose-related increases, but not present at high numbers.</p> <p><u>Serum lipids:</u> Data shown in tabular form. Cholesterol, HDL, Non-HDL, and triglycerides decreased by all 3 forms at multiple doses. Linear caused statistically significant (<math>p &lt; 0.05</math>) decreases on cholesterol, non-HDL, and triglycerides at lowest dose (0.3 mg/kg/day and above). All 3 forms caused statistically significant effects on one or more parameter at 1 mg/kg/day and above.</p> <p><b><u>MOUSE STUDY</u></b></p> <p><b><u>Hepatic endpoints</u></b></p> <table border="1" data-bbox="604 560 2265 941"> <thead> <tr> <th rowspan="2">Dose (mg/kg/day)</th> <th colspan="3">Linear/Branched</th> <th colspan="3">Linear</th> <th colspan="3">Branched</th> </tr> <tr> <th>Serum PFOA (<math>\mu\text{g/ml}</math>)</th> <th>Relative Liver Weight (g/100g)</th> <th>Peroxisomal beta-oxidation (nM/min/mg protein)</th> <th>Serum PFOA (<math>\mu\text{g/ml}</math>)</th> <th>Relative Liver Weight (g/100g)</th> <th>Peroxisomal beta-oxidation (nM/min/mg protein)</th> <th>Serum PFOA (<math>\mu\text{g/ml}</math>)</th> <th>Relative Liver Weight (g/100g)</th> <th>Peroxisomal beta-oxidation (nM/min/mg protein)</th> </tr> </thead> <tbody> <tr> <td>0</td> <td>0.04±0.02</td> <td>5.14±0.27</td> <td>17.9±5.7</td> <td>0.07±0.06</td> <td>5.52±0.24</td> <td>17.3±4.1</td> <td>0.02±0.03</td> <td>5.14±0.31</td> <td>18.2±4.3</td> </tr> <tr> <td>0.3</td> <td>10±1.4</td> <td>6.12±0.25</td> <td>34.4±7.4*</td> <td>13±2.4</td> <td>6.45±0.23*</td> <td>42.0±10.8*</td> <td>14±3.5</td> <td>6.12±0.34*</td> <td>24.2±3.7</td> </tr> <tr> <td>1</td> <td>27±5.0</td> <td>7.92±0.49</td> <td>48.8±8.9*</td> <td>32±5.2</td> <td>8.33±0.31*</td> <td>49.6±11.4*</td> <td>34±10</td> <td>7.85±0.85*</td> <td>36.9±10.2*</td> </tr> <tr> <td>3</td> <td>66±8.6</td> <td>10.72±0.63*</td> <td>47.1±7.1*</td> <td>69±10</td> <td>11.67±1.06*</td> <td>48.5±10.0*</td> <td>82±10</td> <td>11.94±0.83*</td> <td>44.5±8.5*</td> </tr> <tr> <td>10</td> <td>190±29</td> <td>16.27±1.05*</td> <td>31.6±7.4*</td> <td>225±68</td> <td>17.18±1.13*</td> <td>37.2±9.0*</td> <td>172±29</td> <td>17.71±1.81*</td> <td>42.5±4.4*</td> </tr> <tr> <td>30</td> <td>241±28</td> <td>18.28±1.57*</td> <td>30.7±8.2*</td> <td>259±34</td> <td>17.96±1.06*</td> <td>31.9±4.5*</td> <td>244±50</td> <td>21.01±1.40*</td> <td>35.4±9.7*</td> </tr> </tbody> </table> <p>*<math>p &lt; 0.05</math>.</p> <ul style="list-style-type: none"> <li>• LOAEL for increased relative liver weight: 0.3 mg/kg/day; serum PFOA 13 <math>\mu\text{g/ml}</math>, linear, 14 <math>\mu\text{g/ml}</math> branched.</li> <li>• No NOAEL identified.</li> <li>• Beta-oxidation similar in all 3 forms. Did not continue to increase with dose, although liver weight increase continued to increase with dose. Maximum beta-oxidation increase less than 3-fold.</li> </ul>	Dose (mg/kg/day)	Linear/Branched			Linear			Branched			Serum PFOA ( $\mu\text{g/ml}$ )	Relative Liver Weight (g/100g)	Peroxisomal beta-oxidation (nM/min/mg protein)	Serum PFOA ( $\mu\text{g/ml}$ )	Relative Liver Weight (g/100g)	Peroxisomal beta-oxidation (nM/min/mg protein)	Serum PFOA ( $\mu\text{g/ml}$ )	Relative Liver Weight (g/100g)	Peroxisomal beta-oxidation (nM/min/mg protein)	0	0.04±0.02	5.14±0.27	17.9±5.7	0.07±0.06	5.52±0.24	17.3±4.1	0.02±0.03	5.14±0.31	18.2±4.3	0.3	10±1.4	6.12±0.25	34.4±7.4*	13±2.4	6.45±0.23*	42.0±10.8*	14±3.5	6.12±0.34*	24.2±3.7	1	27±5.0	7.92±0.49	48.8±8.9*	32±5.2	8.33±0.31*	49.6±11.4*	34±10	7.85±0.85*	36.9±10.2*	3	66±8.6	10.72±0.63*	47.1±7.1*	69±10	11.67±1.06*	48.5±10.0*	82±10	11.94±0.83*	44.5±8.5*	10	190±29	16.27±1.05*	31.6±7.4*	225±68	17.18±1.13*	37.2±9.0*	172±29	17.71±1.81*	42.5±4.4*	30	241±28	18.28±1.57*	30.7±8.2*	259±34	17.96±1.06*	31.9±4.5*	244±50	21.01±1.40*	35.4±9.7*	
Dose (mg/kg/day)	Linear/Branched			Linear			Branched																																																																										
	Serum PFOA ( $\mu\text{g/ml}$ )	Relative Liver Weight (g/100g)	Peroxisomal beta-oxidation (nM/min/mg protein)	Serum PFOA ( $\mu\text{g/ml}$ )	Relative Liver Weight (g/100g)	Peroxisomal beta-oxidation (nM/min/mg protein)	Serum PFOA ( $\mu\text{g/ml}$ )	Relative Liver Weight (g/100g)	Peroxisomal beta-oxidation (nM/min/mg protein)																																																																								
0	0.04±0.02	5.14±0.27	17.9±5.7	0.07±0.06	5.52±0.24	17.3±4.1	0.02±0.03	5.14±0.31	18.2±4.3																																																																								
0.3	10±1.4	6.12±0.25	34.4±7.4*	13±2.4	6.45±0.23*	42.0±10.8*	14±3.5	6.12±0.34*	24.2±3.7																																																																								
1	27±5.0	7.92±0.49	48.8±8.9*	32±5.2	8.33±0.31*	49.6±11.4*	34±10	7.85±0.85*	36.9±10.2*																																																																								
3	66±8.6	10.72±0.63*	47.1±7.1*	69±10	11.67±1.06*	48.5±10.0*	82±10	11.94±0.83*	44.5±8.5*																																																																								
10	190±29	16.27±1.05*	31.6±7.4*	225±68	17.18±1.13*	37.2±9.0*	172±29	17.71±1.81*	42.5±4.4*																																																																								
30	241±28	18.28±1.57*	30.7±8.2*	259±34	17.96±1.06*	31.9±4.5*	244±50	21.01±1.40*	35.4±9.7*																																																																								

Reference and Study Design	Results	Comment
<p>Loveless et al. (2006). (continued)</p>	<p><b>Other Endpoints</b></p> <p><u>Mortality/clinical signs:</u> One mouse in 30 mg/kg/day linear group died suddenly of unknown cause. The incidence of enophthalmos and lethargy was significantly increased in 30 mg/kg/day linear group.</p> <p><u>Body weight/body weight gain:</u> Data for body weight on day 0, 7, and 13, and for body weight gain on day 13; shown in tabular form. Data were also analyzed on the basis of subtraction of liver weight, to account for liver weight gain. In summary, there was a dose-related decrease in body weight gain and/or loss of body weight (adjusted for liver weight) in all 3 forms. Linear/branched and linear affected body weight gain more than branched.</p> <p><u>Hematology:</u> Data not shown. Treatment related increases in acanthocytes in linear/branched and linear at 3, 10, and 30 mg/kg/day. Treatment related poiliocytes and schistocytes in linear/branched at 30 mg/kg/day, and linear at 3,10, and 30 mg/kg/day. Dose-related increases, but not present at high numbers.</p> <p><u>Serum lipids:</u> Data shown in tabular form. Cholesterol and HDL decreased at all doses in all treatment groups. Cholesterol significant (p&lt;0.05) at 3 and 30 mg/kg/day (except branched) for cholesterol. HDL significant at 3, 10, and 30 mg/kg/day for all treatment groups. Non-HDL generally not affected. Triglycerides significantly increased in linear /branched at 0.3, 1, 3, and 10 mg/kg/day.</p>	

Reference and Study Design	Results													Comment																																																																																																														
<p><b>Perkins et al. (2004).</b> 13-week dietary toxicity study of ammonium perfluorooctanoate (APFO) in male rats.</p> <p><b>Species and strain:</b> Males CR:CD BR rats, approximately 41 days old.</p> <p><b>Test article and vehicle:</b> Ammonium perfluorooctanoate (98% pure) in feed</p> <p><b>Route of exposure:</b> Dietary</p> <p><b>Exposure levels:</b> 0, 0 (pair fed with 100 ppm), 1, 10, 30, 100 ppm. Mean doses: 0, 0.06, 0.64, 1.94, 6.50 mg/kg/day. (Doses in mg/kg/day are provided for each time point).</p> <p><b>Exposure regimen:</b> 4, 7, and 13 weeks exposure, and 8 weeks post-exposure.</p> <p><b>Group size:</b> For each dose group; 15 per group for 4, 7, and 13 week exposure; 10 per group for 8 week recovery (week 22) sacrifice.</p>	<p><b>LIVER</b></p> <p><i>Liver weight relative to body weight (g/100 g) and brain weight (g/g) and PFOA dose (mg/kg/day) &amp; serum levels at weeks 4, 7, and 13</i></p> <table border="1" data-bbox="505 248 2279 641"> <thead> <tr> <th rowspan="2">Diet Conc. (ppm)</th> <th rowspan="2">Mean Dose (mg/kg/day)</th> <th colspan="4">Week 4</th> <th colspan="4">Week 7</th> <th colspan="4">Week 13</th> </tr> <tr> <th>Dose (mg/kg/day)</th> <th>PFOA serum level (µg/ml)</th> <th>Relative to body weight (g/100 g)</th> <th>Relative to brain weight (g/g)</th> <th>Dose (mg/kg/day)</th> <th>PFOA serum level (µg/ml)</th> <th>Relative to body weight (g/100 g)</th> <th>Relative to brain weight (g/g)</th> <th>Dose (mg/kg/day)</th> <th>PFOA serum level (µg/ml)</th> <th>Relative to body weight (g/100 g)</th> <th>Relative to brain weight (g/g)</th> </tr> </thead> <tbody> <tr> <td>0</td> <td>-</td> <td>--</td> <td>ND</td> <td>3.97±0.37</td> <td>7.88±0.94</td> <td>--</td> <td>ND</td> <td>3.75±0.29</td> <td>8.50±1.07</td> <td>--</td> <td>ND</td> <td>3.53±0.28</td> <td>9.03±1.20</td> </tr> <tr> <td>0-pair fed**</td> <td></td> <td>---</td> <td>ND</td> <td>4.07±0.27</td> <td>7.87±0.70</td> <td>--</td> <td>ND</td> <td>3.76±0.37</td> <td>8.12±1.14</td> <td>--</td> <td>ND</td> <td>3.24±0.23</td> <td>7.64±0.77</td> </tr> <tr> <td>1</td> <td>0.06</td> <td>0.07</td> <td>6.51±1.0</td> <td>3.73±0.23</td> <td>7.63±0.92</td> <td>0.06</td> <td>7.5±1.3</td> <td>3.64±0.33</td> <td>8.53±1.29</td> <td>0.05</td> <td>7.1±1.2</td> <td>3.24±0.30</td> <td>8.19±1.56</td> </tr> <tr> <td>10</td> <td>0.64</td> <td>0.71</td> <td>55±8.1</td> <td>4.49±0.32*</td> <td>8.77±1.13</td> <td>0.60</td> <td>46±16</td> <td>4.12±0.37</td> <td>9.33±1.10</td> <td>0.47</td> <td>41±13</td> <td>3.69±0.32</td> <td>9.41±1.33</td> </tr> <tr> <td>30</td> <td>1.94</td> <td>2.14</td> <td>104±14</td> <td>5.77±0.60*</td> <td>11.3±1.35*</td> <td>1.85</td> <td>87±28</td> <td>5.14±0.53*</td> <td>11.4±1.58*</td> <td>1.44</td> <td>70±16</td> <td>4.21±0.56*</td> <td>10.8±1.96</td> </tr> <tr> <td>100</td> <td>6.50</td> <td>7.39</td> <td>159±30</td> <td>6.73±0.49*</td> <td>12.5±1.10*</td> <td>6.21</td> <td>149±35</td> <td>6.06±0.72*</td> <td>13.3±1.52*</td> <td>4.97</td> <td>138±34</td> <td>5.50±0.84*</td> <td>12.6±2.88*</td> </tr> </tbody> </table> <p>Liver weight data: n=15 per data point. Serum data: n=8-10 per data point. *Increased compared to ad libitum controls at p&lt;0.05 using two-tailed test. ND: &lt;0.7 µg/ml. **Pair fed based on 100 ppm group.</p> <ul style="list-style-type: none"> <li>No effect on relative liver weight in recovery group sacrificed at Week 21. PFOA serum levels in recovery groups were 1.2 – 2.5 µg/ml.</li> <li>NOAEL for increased liver relative liver weight – 1 ppm (0.07 mg/kg/day; 6.51 µg/ml in serum (Week 4)).</li> <li>LOAEL for increased relative liver weight – 10 ppm (0.71 mg/kg/day; 55 µg/ml in serum (Week 4)).</li> <li>Serum levels increased with dose, but did not increase over time. Steady-state serum level was reached by Week 4.</li> <li>Relative liver weight increases were similar at all 3 time points.</li> </ul> <p><i>Liver histopathology</i> Data shown in tabular form. Minimal to slight hepatocellular hypertrophy in 10, 30, and 100 ppm groups at 4, 7, and 13 weeks. Severity increased with dose, but not with duration of exposure. It is stated that the histopathology of the livers in the recovery group (sacrificed at week 21 after 8 weeks of recovery) was similar to controls. The data are not shown.</p> <p><i>Palmitoyl CoA oxidase activity</i> <b>Discussed in detail in Mode of Action section.</b></p> <p><b>MORTALITY, CLINICAL OBSERVATIONS, BODY WEIGHT</b> Only mortality was one 100 ppm rat sacrificed during week 4 due to severe neck sores. No clinical signs observed. Body weight data shown in tabular form. Body weight affected only at 100 ppm (high dose). At 100 ppm, body weight decreased (p&lt;0.05) compared to ad libitum controls at all time points (weeks 1,4,7,10,13). Body weight gain during exposure period and recovery period decreased (p&lt;0.05) at 100 ppm.</p>													Diet Conc. (ppm)	Mean Dose (mg/kg/day)	Week 4				Week 7				Week 13				Dose (mg/kg/day)	PFOA serum level (µg/ml)	Relative to body weight (g/100 g)	Relative to brain weight (g/g)	Dose (mg/kg/day)	PFOA serum level (µg/ml)	Relative to body weight (g/100 g)	Relative to brain weight (g/g)	Dose (mg/kg/day)	PFOA serum level (µg/ml)	Relative to body weight (g/100 g)	Relative to brain weight (g/g)	0	-	--	ND	3.97±0.37	7.88±0.94	--	ND	3.75±0.29	8.50±1.07	--	ND	3.53±0.28	9.03±1.20	0-pair fed**		---	ND	4.07±0.27	7.87±0.70	--	ND	3.76±0.37	8.12±1.14	--	ND	3.24±0.23	7.64±0.77	1	0.06	0.07	6.51±1.0	3.73±0.23	7.63±0.92	0.06	7.5±1.3	3.64±0.33	8.53±1.29	0.05	7.1±1.2	3.24±0.30	8.19±1.56	10	0.64	0.71	55±8.1	4.49±0.32*	8.77±1.13	0.60	46±16	4.12±0.37	9.33±1.10	0.47	41±13	3.69±0.32	9.41±1.33	30	1.94	2.14	104±14	5.77±0.60*	11.3±1.35*	1.85	87±28	5.14±0.53*	11.4±1.58*	1.44	70±16	4.21±0.56*	10.8±1.96	100	6.50	7.39	159±30	6.73±0.49*	12.5±1.10*	6.21	149±35	6.06±0.72*	13.3±1.52*	4.97	138±34	5.50±0.84*	12.6±2.88*	<p>NOAEL for increased relative liver weight – 1 ppm (0.07 mg/kg/day; 6.51 µg/ml in serum; Week 4).</p> <p>LOAEL for increased relative liver weight – 10 ppm (0.71 mg/kg/day; 55 µg/ml in serum; Week 4).</p> <p>Serum levels increased with dose, but did not increase over time. Steady-state was apparently reached by Week 4.</p>
Diet Conc. (ppm)	Mean Dose (mg/kg/day)	Week 4				Week 7				Week 13																																																																																																																		
		Dose (mg/kg/day)	PFOA serum level (µg/ml)	Relative to body weight (g/100 g)	Relative to brain weight (g/g)	Dose (mg/kg/day)	PFOA serum level (µg/ml)	Relative to body weight (g/100 g)	Relative to brain weight (g/g)	Dose (mg/kg/day)	PFOA serum level (µg/ml)	Relative to body weight (g/100 g)	Relative to brain weight (g/g)																																																																																																															
0	-	--	ND	3.97±0.37	7.88±0.94	--	ND	3.75±0.29	8.50±1.07	--	ND	3.53±0.28	9.03±1.20																																																																																																															
0-pair fed**		---	ND	4.07±0.27	7.87±0.70	--	ND	3.76±0.37	8.12±1.14	--	ND	3.24±0.23	7.64±0.77																																																																																																															
1	0.06	0.07	6.51±1.0	3.73±0.23	7.63±0.92	0.06	7.5±1.3	3.64±0.33	8.53±1.29	0.05	7.1±1.2	3.24±0.30	8.19±1.56																																																																																																															
10	0.64	0.71	55±8.1	4.49±0.32*	8.77±1.13	0.60	46±16	4.12±0.37	9.33±1.10	0.47	41±13	3.69±0.32	9.41±1.33																																																																																																															
30	1.94	2.14	104±14	5.77±0.60*	11.3±1.35*	1.85	87±28	5.14±0.53*	11.4±1.58*	1.44	70±16	4.21±0.56*	10.8±1.96																																																																																																															
100	6.50	7.39	159±30	6.73±0.49*	12.5±1.10*	6.21	149±35	6.06±0.72*	13.3±1.52*	4.97	138±34	5.50±0.84*	12.6±2.88*																																																																																																															



Reference and Study Design	Results	Comment
<p>Perkins et al. (2004). (continued)</p>	<p><b><u>OTHER ORGANS</u></b></p> <p><i>Organ weight and histopathology</i> It is stated that organ weight, organ to body weight, organ to brain weight were assessed for brain, lungs, testes, and accessory sex organs, and that these organs were examined microscopically.</p> <p>Data for organ weights is not shown or discussed. It is stated that there was an increase in testis to body weight ratio in the 100 ppm recovery group that was not statistically significant. It is assumed that no effects were seen on these parameters for other organs or other treatment groups, although this is not stated.</p> <p>It is stated that histopathology of tissues from treated groups (other than liver) did not differ from controls.</p> <p><b><u>SERUM HORMONE LEVELS (ESTRADIOL, LUTEINIZING HORMONE, TESTOSTERONE)</u></b> Assessed at weeks, 4, 7, 13, and 21 (recovery). Data shown in tabular form. No statistically significant effects. For estradiol, most results were below detection level. More detectable levels in treated groups (and elevated levels at some timepoints) suggest that PFOA increased estradiol.</p>	

Reference and Study Design	Results	Comment																																							
<p><b>Six month oral capsule study in Cynomolgus monkeys.</b></p> <p><b>Citations:</b> Thomford (2001); Butenhoff et al. (2002); Butenhoff et al. (2004)</p> <p><b>Species and strain:</b> Male Cynomolgus monkeys, estimated age 3 – 9 years, mean 6 years.</p> <p><b>Test article and vehicle:</b> Ammonium perfluorooctanoate (95.2% pure; impurities included perfluorhexanoate, 0.73%; perfluoroheptanoate, 3.76%).</p> <p>Vehicle was gelatin capsule.</p> <p><b>Route of exposure:</b> Oral in capsule.</p> <p><b>Exposure levels:</b> 0, 3, 10, and 30/20 mg/kg/day (30 mg/kg/day suspended on Day 12, resumed at 20 mg/kg/day on Day 22 due to toxicity at higher level).</p> <p><b>Exposure regimen:</b> Daily for at least 26 weeks. Recovery animals observed for 13 weeks following 26 weeks dosing</p> <p><b>Group size:</b> Control – 4 plus 2 recovery. 3 mg/kg/day – 4 10 mg/kg/day – 4 plus 2 recovery 30/20 mg/kg/day - 6 (Note: some animals did not complete the study.)</p>	<p><b>Note: Results presented here focus primarily on hepatic effects, since this endpoint has been the focus of other evaluations and risk assessments based on this study. A summary of the entire study is presented in the text.</b></p> <p><b>Animals sacrificed or removed from study before end of dosing period</b></p> <ul style="list-style-type: none"> <li><b>Low dose (3 mg/kg/day) group:</b> In this group, 3 monkeys were dosed for the full 26 week study period. A monkey in this group (which entered the study on Day 17 to replace another monkey which died of an infection) was sacrificed in moribund condition on day 137, having lost 10% of its body weight in one week and showing other signs of toxicity, and this mortality was possibly treatment-related. The relative liver weight of this monkey (2.37%) was much higher than for the others in this dosing group, and was comparable to those in the high dose (30/20 mg/kg/day) group.</li> <li><b>High dose group (30/20 mg/kg/day):</b> In this group, 2 monkeys were dosed for the full 26 week study period. One monkey in this group was sacrificed in moribund condition on Day 29, having lost 12.5% of its body weight and showing other signs of toxicity, and this death was considered likely to be treatment-related. Dosing was stopped for 3 other monkeys on Days 43, 66, and 81 due to dramatic weight loss, and low or no food consumption and feces.</li> </ul> <p><b>Body weight</b></p> <ul style="list-style-type: none"> <li>Similar in the control, 3, and 10 mg/kg/day groups (19-20% during 26 wk study period).</li> <li>In high dose (30/20 mg/kg/day) group, one of 2 monkeys that completed the study had weight gain similar to controls (18%) and the other lost 5% of body weight.</li> </ul> <p><b>Relative liver weight, PFOA serum concentrations, and hepatic palmitoyl CoA</b></p> <table border="1" data-bbox="720 846 1994 1114"> <thead> <tr> <th rowspan="2">Dose (mg/kg/day)</th> <th rowspan="2">n</th> <th rowspan="2">Serum PFOA (µg/ml)<sup>a</sup></th> <th colspan="2">Relative Liver Weight</th> <th colspan="2">Palmitoyl Co-A</th> </tr> <tr> <th>% of body weight<sup>c</sup></th> <th>Comparison to control</th> <th>µmol/min/g liver<sup>e</sup></th> <th>Comparison to control</th> </tr> </thead> <tbody> <tr> <td>0</td> <td>4</td> <td>0.16±0.15</td> <td>1.53±0.08</td> <td>1</td> <td>0.53±0.12</td> <td>1</td> </tr> <tr> <td>3</td> <td>3 (4)<sup>d</sup></td> <td>72±47<sup>b</sup></td> <td>1.82±0.05* (1.96)<sup>d</sup></td> <td>1.19 (1.28)<sup>d</sup></td> <td>0.47±0.13</td> <td>0.89</td> </tr> <tr> <td>10</td> <td>4</td> <td>85±20</td> <td>1.87±0.06*</td> <td>1.23</td> <td>0.90±0.29</td> <td>1.70</td> </tr> <tr> <td>20/30</td> <td>2</td> <td>155±102</td> <td>2.41±0.05*</td> <td>1.58</td> <td>1.36±1.36</td> <td>2.60*</td> </tr> </tbody> </table> <p>*p&lt;0.05 compared to control. Data comes from tables in the three publications cited.  <sup>a</sup>From Butenhoff et al. (2004). Data from weeks 20, 22, 24, and 26.  <sup>b</sup>3 mg/kg/day data includes one measurement from monkey removed from study in moribund condition on Day 137.  <sup>c</sup>From Thomford (2001). Same data at 3 and 10 mg/kg/day is not stated to be statistically significant in Butenhoff et al. (2002).  <sup>d</sup>Includes data from monkey sacrificed in moribund condition on Day 137. Relative liver weight of this monkey was 2.37 % of body weight. <sup>e</sup>From Butenhoff et al. (2002).</p>	Dose (mg/kg/day)	n	Serum PFOA (µg/ml) <sup>a</sup>	Relative Liver Weight		Palmitoyl Co-A		% of body weight <sup>c</sup>	Comparison to control	µmol/min/g liver <sup>e</sup>	Comparison to control	0	4	0.16±0.15	1.53±0.08	1	0.53±0.12	1	3	3 (4) <sup>d</sup>	72±47 <sup>b</sup>	1.82±0.05* (1.96) <sup>d</sup>	1.19 (1.28) <sup>d</sup>	0.47±0.13	0.89	10	4	85±20	1.87±0.06*	1.23	0.90±0.29	1.70	20/30	2	155±102	2.41±0.05*	1.58	1.36±1.36	2.60*	<p>The results of this study are of limited use in risk assessment because of the small number of animals per group, the heterogeneity of the monkeys (e.g. widely different ages, potential for having been exposed to other chemicals in previous studies, etc.), possible treatment-related mortality in the low dose group, and because internal dose of PFOA (levels in serum and liver) did not differ in the low and mid-dose groups.</p> <p>Only two high dose monkeys completed the study, while 4 were sacrificed and/or removed due to toxicity. The 2 high dose animals that completed the study appeared to react very differently to PFOA. One monkey gained weight similarly to those in the control and lower dose groups, and its liver PFOA concentration was also similar to the low dose groups. The other monkey lost weight during the study and its PFOA liver concentration was about 4-fold higher than that of any other high dose monkey completing the study.</p> <p>Because of the potential mortality at the low dose, and the fact that the serum and liver PFOA levels did not differ the low and mid doses, the results of this study</p>
Dose (mg/kg/day)	n				Serum PFOA (µg/ml) <sup>a</sup>	Relative Liver Weight		Palmitoyl Co-A																																	
		% of body weight <sup>c</sup>	Comparison to control	µmol/min/g liver <sup>e</sup>		Comparison to control																																			
0	4	0.16±0.15	1.53±0.08	1	0.53±0.12	1																																			
3	3 (4) <sup>d</sup>	72±47 <sup>b</sup>	1.82±0.05* (1.96) <sup>d</sup>	1.19 (1.28) <sup>d</sup>	0.47±0.13	0.89																																			
10	4	85±20	1.87±0.06*	1.23	0.90±0.29	1.70																																			
20/30	2	155±102	2.41±0.05*	1.58	1.36±1.36	2.60*																																			

Reference and Study Design	Results	Comment
<p><b>Six month oral capsule study in Cynomolgus monkeys. (continued).</b></p> <p><b>Citations:</b> Thomford (2001); Butenhoff et al. (2002); Butenhoff et al. (2004)</p>	<p><b><u>Pathological observations</u></b> Discussed in text. In the 30/20 mg/kg/day monkey sacrificed in moribund condition, had liver lesions including hepatocellular degeneration and necrosis and other changes indicative of liver regeneration. The liver of the 3 mg/kg/day monkey sacrificed in moribund condition appeared normal, although this monkey had a highly elevated liver to body weight ratio. No other notable pathological findings were reported.</p> <p><b><u>Hepatic and non-hepatic clinical endpoints</u></b></p> <ul style="list-style-type: none"> <li>• Data for liver enzymes, serum lipid, bilirubin, glucose, thyroid hormones, and other hormones is shown in tabular form for before dosing began and weeks 5, 10, 14, and 27. Comparisons are made with baseline values and with controls at same timepoint. For comparisons with baseline values, data from monkeys remaining in the study are compared with data from all monkeys who began the study.</li> <li>• <i>3 and 10 mg/kg/day</i>: No effects on clinical parameters including hematology, clinical chemistry, and urinalysis except in 3 mg/kg/day monkey sacrificed moribund on Day 137. This monkey had increased plasma fibrinogen, and decreased lymphocytes, albumin, and cholesterol.</li> <li>• <i>30/20 mg/kg/day</i>: The 2 monkeys that completed the study had increased triglycerides, and decreased neutrophils, total protein, and albumin. The 3 monkeys removed from the study due to toxicity also had decreased neutrophils and albumin. Liver enzymes were extremely elevated (10-30 fold) in the monkey sacrificed moribund on Day 29 and the monkey removed from the study due to toxicity on Day 66.</li> <li>• Levels of several thyroid hormones appeared to be decreased in the two higher dose groups.</li> </ul> <p><b><u>Biochemical markers for subcellular fractions in liver</u></b></p> <ul style="list-style-type: none"> <li>• The data are shown in tabular form.</li> <li>• Peroxisomal oxidation (palmitoyl CoA oxidation) was increased in a dose dependent manner (shown in table above).</li> <li>• Activity of succinate dehydrogenase, a mitochondrial enzyme, was increased in treated groups.</li> <li>• There was no effect on acid phosphatase, a lysosomal marker, or glucose-6-phosphatase, a marker of endoplasmic reticulum.</li> </ul> <p><b><u>Liver PFOA concentrations</u></b> Shown in table and discussed in text. Concentrations were within a similar range (6.3 -18.8 ug/g) and did not increase with dose in the monkeys that completed the study and the 3 mg/kg/day monkey sacrificed in moribund condition, with the exception of one monkey in the 30/20 mg/kg/group (83.3 ug/g). The monkey in this group sacrificed in moribund condition in the high dose group had a very high concentration (154 ug/g).</p>	<p>are not informative as to the NOAEL for PFOA in this species of monkey.</p> <p>An additional major uncertainty is lack of information from female monkeys.</p>

## **Appendix 5B. Studies that evaluated mammary gland development in mice**

### **Notes:**

- **Tables include 9 publications on this endpoint. The tables are arranged in two groups:**  
**Appendix 5B-1: Studies of exposure to PFOA during the perinatal period (pregnant dams, and offspring during gestation and/or nursing) – 6 publications.**  
**Appendix 5B-2: Studies of exposure to PFOA during the peripubertal period – 3 publications. .**
- **Some of the publications include several separate studies.**
- **Many of the studies evaluated endpoints in addition to mammary gland development. Data on all endpoints are summarized in the tables.**

**Appendix 5B-1: Publications/studies of mammary gland development after perinatal (gestational and/or lactational) exposure to PFOA in mice**

Reference and Study Design	Results	Comment																																
<p><b>Albrecht et al. (2013).</b> A species difference in the peroxisome proliferator-activated receptor <math>\alpha</math>-dependent response to the developmental effects of perfluorooctanoic acid.</p> <p><b>Species and strain:</b> Sv/129 (obtained from NIH) wild type (WT), PPAR-alpha null (KO), and PPAR-alpha humanized (H) pregnant female mice and their offspring.</p> <p><b>Test article and vehicle:</b> PFOA (provided by DuPont Haskell Laboratories, purity not specified)</p> <p><b>Route of exposure:</b> Oral gavage</p> <p><b>Exposure levels:</b> 0 or 3 mg/kg/day. Preliminary studies reported in methods section used 0.6 and 1.0 mg/kg/day.</p> <p><b>Exposure regimen:</b> GD 1-17.</p> <p><b>Group size:</b> 5-8 per strain per dose group</p> <p><b>Timepoint for mammary gland (MG) evaluation:</b> Offspring on PND 20.</p> <p><b>Related studies:</b> Comparisons with Abbott et al. (2007)</p>	<p><b><u>MAMMARY GLAND DEVELOPMENT</u></b></p> <p>Whole mounts of MG from female pups on PND 20 were assessed. There were no significant differences in number of terminal end buds (TEB) or ductal length in control versus PFOA treated mice in any of the 3 strains.</p> <p>Effect of Prenatal PFOA Exposure on Mammary Gland Development in PND20 Female Offspring</p> <table border="1" data-bbox="540 448 1344 659"> <thead> <tr> <th>Genotype</th> <th>Treatment</th> <th>TEB/gland</th> <th>Ductal length (mm)</th> <th>N</th> </tr> </thead> <tbody> <tr> <td rowspan="2">Wild-type (WT)</td> <td>Control</td> <td>2.1±0.1</td> <td>2.4±0.3</td> <td>3</td> </tr> <tr> <td>PFOA</td> <td>2.2±0.2</td> <td>2.4±0.4</td> <td>4</td> </tr> <tr> <td rowspan="2"><i>Ppara</i>-null (KO)</td> <td>Control</td> <td>2.1±0.2</td> <td>2.5±0.1</td> <td>9</td> </tr> <tr> <td>PFOA</td> <td>2.6±0.6</td> <td>1.7±0.4</td> <td>3</td> </tr> <tr> <td rowspan="2"><i>hPPAR<math>\alpha</math></i> (H)</td> <td>Control</td> <td>2.1±0.3</td> <td>2.7±0.3</td> <td>4</td> </tr> <tr> <td>PFOA</td> <td>1.5±0.3</td> <td>2.6±0.2</td> <td>5</td> </tr> </tbody> </table> <p><i>Note.</i> Values represent the litter mean <math>\pm</math> SEM.</p> <p><b><u>OTHER ENDPOINTS</u></b></p> <p><b><u>Effect of PFOA on maternal and fetal reproductive outcomes on GD 18</u></b></p> <ul style="list-style-type: none"> <li>● Tabular data. N = 5-8 dams or litters per group. Significance evaluated at p&lt;0.05 level</li> <li>● No effect on maternal weight gain, gravid uterus weight, # of implantations per dam, # of resorptions per litter in any of the 3 strains of mice</li> <li>● No effect on number of fetuses per litter, fetus length or body weight, or number of live or dead fetuses per litter in any strain.</li> </ul> <p><b><u>Effect of PFOA on maternal liver on GD18</u></b></p> <ul style="list-style-type: none"> <li>● Tabular data. Absolute and relative maternal liver weight increased significantly and to a similar degree in all 3 strains. (photomicrographs and discussion in text; N = 5-8 dams per group. Significance evaluated at p&lt;0.05 level)</li> <li>● Hepatocellular hypertrophy in all 3 strains, with some differences in morphological features among the 3 strains. (n not provided)</li> <li>● Gene expression in maternal liver (Data presented in bar graphs. n not provided; significance at p&lt;0.05): Acox1 (PPAR alpha target gene) increased in WT, not KO or H Cyp4a10 (PPAR alpha target gene) increased in WT and H, but not KO Cyp2b10 (CAR target gene) and Cyp3a11 (PXR target gene) increased in all 3 strains.</li> </ul>	Genotype	Treatment	TEB/gland	Ductal length (mm)	N	Wild-type (WT)	Control	2.1±0.1	2.4±0.3	3	PFOA	2.2±0.2	2.4±0.4	4	<i>Ppara</i> -null (KO)	Control	2.1±0.2	2.5±0.1	9	PFOA	2.6±0.6	1.7±0.4	3	<i>hPPAR<math>\alpha</math></i> (H)	Control	2.1±0.3	2.7±0.3	4	PFOA	1.5±0.3	2.6±0.2	5	<ul style="list-style-type: none"> <li>● The authors conclude that the study confirms the PPAR alpha dependent postnatal lethality of PFOA previously reported by Abbott et al. (2007). They conclude that this effect occurs only in WT mice, but not in PPAR alpha null (KO) or humanized PPAR alpha (H) mice, and that this suggests a strain difference in developmental toxicity of PFOA.</li> <li>● They also conclude that PFOA did not affect MG development in WT, KO, or H mice at the single dose tested. However, there are several issues with the data and presentation of this study that are problematic and that limit the consideration of its results. <ul style="list-style-type: none"> <li>● The study used only one dose of PFOA, and it is unclear whether that dose was sufficient to cause developmental toxicity in the WT strain. For this reason, the basis for the conclusion that WT, but not H, mice are sensitive to developmental effects of PFOA is uncertain.</li> <li>● It is stated in the text that elevated PFOA levels (up to &gt; 1000 ng/ml) were found in liver and serum from some control fetuses, pups, and dams. However, no further information as to which groups of animals these samples came from, how many samples were elevated, or statistics for serum levels in the control samples is provided. Data from control animals with elevated PFOA exposures were not excluded from the comparisons of endpoints of toxicity in control and treated groups. Including the data from these control animals could have affected the results of the study, especially since serum levels in some of the treated groups were only a few fold higher than those in some of the controls.</li> <li>● The serum PFOA data for WT dams on PND 20 appear to be inconsistent within the paper. Maternal serum levels in WT dams on PND 20 are stated to range from 2066 – 6812 ng/ml. No statistical parameters (e.g. median, mean, S.D.) are provided numerically. However, the estimated serum level from the bar graph of maternal serum levels is 6700±3600 in WT (higher than what would be expected from the range provided in the text).</li> </ul> </li> </ul>
Genotype	Treatment	TEB/gland	Ductal length (mm)	N																														
Wild-type (WT)	Control	2.1±0.1	2.4±0.3	3																														
	PFOA	2.2±0.2	2.4±0.4	4																														
<i>Ppara</i> -null (KO)	Control	2.1±0.2	2.5±0.1	9																														
	PFOA	2.6±0.6	1.7±0.4	3																														
<i>hPPAR<math>\alpha</math></i> (H)	Control	2.1±0.3	2.7±0.3	4																														
	PFOA	1.5±0.3	2.6±0.2	5																														



Reference and Study Design	Results	Comment
<p><b>Albrecht et al. (2013). (continued)</b></p>	<p><b><u>Effect of PFOA on fetal liver on GD18</u></b></p> <ul style="list-style-type: none"> <li>● Relative liver weight increased in WT and H fetuses, but not KO (Data presented in bar graph. n not provided; p&lt;0.05).</li> <li>● Microscopic changes consistent with peroxisome proliferation in 2/5 of livers from WT fetuses.</li> <li>● No effects in other strains (n not provided).</li> </ul> <p>Gene expression in fetal liver (Data presented in bar graphs; n not provided; significance at p&lt;0.05):</p> <ul style="list-style-type: none"> <li>● Acox1 and Cyp4a10 (PPAR alpha target genes) increased in WT and H but not KO.</li> <li>● Cyp2b10 (CAR target gene) not changed in all 3 strains.</li> <li>● Cyp3a11 (PXR target gene) increased in H, but no effect in WT and KO.</li> </ul> <p><b><u>Effect of PFOA on reproductive and developmental parameters in offspring of dams allowed to deliver their litters</u></b></p> <ul style="list-style-type: none"> <li>● N = 8-14 dams and litters per group. Significance at p&lt;0.05</li> <li>● Day of parturition slightly but significantly increased by PFOA in H (numerical data).</li> <li>● No effect on number of pups per litter at birth (numerical data).</li> <li>● Percentage of male pups significantly increased by PFOA in H (numerical data).</li> <li>● Day of eye opening not affected by PFOA in any strain (bar graph).</li> <li>● Pup wt. gain through PND 20 not affected by PFOA in any strain (numerical data &amp; bar graph).</li> <li>● <b>At 3 mg/kg/day, post-natal lethality at PND 20 reported significantly increased in WT, but not KO or H (numerical data). This conclusion appears to be based on an invalid statistical comparison. See comments.</b></li> <li>● Text states that no post-natal lethality was seen in WT dosed with 0.6 or 1 mg/kg/day PFOA, but numerical data for this effect and serum levels at these doses are not provided.</li> </ul> <p><b><u>Effect of PFOA on pup liver on PND20</u></b></p> <ul style="list-style-type: none"> <li>● Pup liver weight on PND 20 increased in WT, but not KO or H (n not provided; bar graph).</li> <li>● Microscopic changes consistent with peroxisome proliferation in WT livers on PND 20 (n not stated). Equivocal evidence of centrilobular hypertrophy in 1/5 KO pup livers on PND 20. No definitive liver changes in H (n not stated).</li> <li>● Gene expression in fetal liver (Data presented in bar graphs. n not provided; significance at p&lt;0.05):</li> <li>● Acox1 (PPAR alpha target gene) increased in WT, not KO or H</li> <li>● Cyp4a10 (PPAR alpha target gene) increased in WT and to a lesser degree in KO, but not H</li> <li>● Cyp2b10 (CAR target gene) increased in all 3 strains.</li> <li>● Cyp3a11 (PXR target gene) increased in WT and H, but no effect in KO.</li> </ul>	<ul style="list-style-type: none"> <li>● The post-natal lethality in WT mice on PND 20 reported as statistically significant (p&lt;0.05) appears to be based on an inappropriate statistical comparison. Number of pups per litter on PND 20 in the control and PFOA-treated groups of WT mice were compared. However, this comparison does not appear to be valid because the control and PFOA treated litters had different numbers of pups on PND 0. This parameter should be evaluated by comparing number of pups in the same litter on PND 0 and PND 20 (i.e. percent mortality within the litter between PND 0 and PND 20). In WT pups, 96% of controls and 70% of PFOA-treated survived from PND 0 to PND 20. From the analysis presented, it is unclear whether post-natal lethality was actually significantly increased by PFOA in WT pups.</li> <li>● The authors note that PFOA serum levels in this study are lower than in the same strain of WT mice given comparable PFOA doses in Abbott et al. (2007). For example, the WT maternal serum PFOA levels on PND 20 are comparable to those in WT dams similarly dosed with lower levels of PFOA (0.3 – 1 mg/kg/day) in Abbott et al (2007). Although both studies used SV/129 mice, this study obtained them from NIH and Abbott et al. (2007) obtained them from Jackson Laboratories.</li> </ul> <p>The authors suggest that pharmacokinetic differences in the mice used may explain the differences in effects of PFOA in WT mice in the two studies. However, a close review of the data from the two studies indicates that Albrecht et al. (2013) did not observe developmental effects of PFOA in WT pups that were seen at similar or lower PFOA levels in WT mice by Abbott et al. (2007).</p> <p>Abbott et al. (2007) reported significantly increased post-natal lethality in WT pups exposed gestationally to 0.6 and 1 mg/kg/day PFOA. In both of these dose groups, pup survival to PND 22 was 43%. WT pup serum levels on PND 22 in the 0.6 and 1 mg/kg/day dose groups in Abbott et al. (2007) were 3810 and 9860 ng/ml (respectively). PFOA serum level in treated WT pups on PND 22</p>

Reference and Study Design	Results	Comment
<p>Albrecht et al. (2013). (continued)</p>	<p><b><u>PFOA LEVELS IN SERUM AND LIVERS FROM DAMS, FETUSES, AND PUPS</u></b></p> <ul style="list-style-type: none"> <li>● Dams – n=5 per strain on GD18 and PND 20. Fetuses and pups – n= 7-25 fetuses or pups from 3 – 7 litters on GD 18 and PND 20. It is not clear if this represents 7-25 fetuses/pups altogether at each time point or 7-25 pups per strain at each time point.</li> <li>● Text states that PFOA levels from <u>control</u> dams, fetuses, and pups ranged from &lt;5 to 1060 ng/ml in liver and from &lt;5 to 1370 ng/ml in serum. This is described as a “small cohort” of samples, and it is stated that concentrations in control samples “typically” were ND (&lt;5 ng/ml). However, the number/percentage of control samples with elevated levels (including how many from fetuses, pups, and dams), and data or statistics on the levels found in controls, are not provided numerically or in bar graphs. Additionally, the data on endpoints of toxicity from control animals with elevated PFOA levels were not excluded from the analysis (see comments).</li> <li>● Maternal serum levels in WT dams on PND 20 are stated to range from 2066 – 6812 ng/ml. No statistics (median, mean, S.D., etc.) are provided numerically. However, the estimated serum level from the bar graph of maternal serum level s is 6700±3600 in WT (higher than what would be expected from the range provided in the text). The WT maternal serum PFOA levels on PND 20 are comparable to those in WT dams similarly dosed with lower levels of PFOA (0.3 – 1 mg/kg/day) in Abbott et al (2007). See comments.</li> <li>● In dams, serum PFOA levels were lower in WT than in KO or H on GD 18, and were higher in WT than KO or H on PND 22 (shown in bar graph.).</li> <li>● In pups and fetuses, PFOA serum levels were higher in H than in KO or WT on GD 18, and were lower in H than in KO or WT on PND 22.</li> </ul> <p>Liver PFOA levels in dams, pups, and fetuses did not necessarily follow the same relative pattern among strains as serum PFOA.</p>	<p>in Albrecht et al. (2013; this study) are estimated as 10,000 ng/ml (presented in bar graph), yet post-natal mortality (70% survival to PND 20) was much lower than in Abbott et al. (2007) and may not be statistically significant (see above). Similarly, eye opening was significantly delayed in the 0.6 and 1 mg/kg/day WT pups in Abbott et al. (2007) but not in the treated pups with similar and higher PFOA serum levels in Albrecht et al. (2013).</p> <ul style="list-style-type: none"> <li>● In summary, this study is problematic for several reasons. The inclusion of data from controls with elevated PFOA exposures may have influenced the comparisons of effects in control and treated groups. Important data on serum levels is not presented or is presented inconsistently. It is unclear whether post-natal mortality actually was significantly increased in WT pups, and the delayed eye opening seen in WT pups in Abbott et al. (2007) was not observed. The differences in developmental effects in WT pups in Albrecht et al. (2013) versus Abbott et al. (2007) cannot be explained on the basis of pharmacokinetic differences in the two studies, since effects were seen at pup serum levels in Abbott et al. (2007) that are lower than the pup serum levels in Albrecht et al. (2013). For these reasons, the conclusion that developmental toxicity occurs in WT mice but not humanized PPAR-alpha mice, indicating that humans may be less sensitive to developmental toxicity of PFOA, is not clearly supported by this study.</li> </ul> <p>In this study, no effect on mammary gland development was reported in pups from the 3 strains on PND 20. The effects of PFOA on mammary gland development in SV/129 mice have not been evaluated in other studies. <b>It is possible that this strain may be less sensitive to this effect than the other strains in which it has been reported. However, the general issues with this study discussed above create uncertainty about its conclusions, including those related to mammary gland development.</b></p>



Reference and Study Design	Results	Comment																																								
<p><b>Macon et al (2011).</b> Prenatal perfluorooctanoic acid exposure in CD-1 mice: low-dose developmental effects and internal dosimetry.</p> <p><b>Species and strain:</b> Timed pregnant CD-1 mice and their offspring</p> <p><b>Test article and vehicle:</b> PFOA (ammonium salt, &gt;98% pure) in deionized water</p> <p><b>Route of exposure:</b> Oral gavage</p> <p><b>Full-gestation exposure study</b></p> <p><b>MG Assessment:</b> Female offspring</p> <p><b>Exposure levels:</b> 0, 0.3, 1.0, or 3.0 mg/kg/day</p> <p><b>Exposure regimen:</b> Gestational. GD 1-17.</p> <p><b>Group size:</b> 13 dams per treatment group. Litters equalized to 10 pups, with equal M &amp; F when possible.</p> <p><b>Timepoint(s) for mammary gland (MG) evaluation:</b> PND 7, PND 14, PND 28, PND 42, PND 63, and PND 84</p>	<p><b>General note:</b> The litter was the unit used for statistical analysis in this study. Thus, when multiple pups from the same litter were assessed at a given time point, the individual pup data were averaged to give a single data point for that litter.</p> <p><b>Full-gestation exposure study (GD 1-17)</b></p> <p><b>MG developmental scores in whole mounts (1-4 scale) from female offspring after exposure on GD 1-17</b></p> <table border="1" data-bbox="628 428 2021 740"> <thead> <tr> <th>Dose (mg/kg/day)</th> <th>PND 7 (n)</th> <th>PND 14 (n)</th> <th>PND 21 (n)</th> <th>PND 28 (n)</th> <th>PND 42 (n)</th> <th>PND 63 (n)</th> <th>PND 84 (n)</th> </tr> </thead> <tbody> <tr> <td>Control</td> <td>3.3 ± 0.2 (5)</td> <td>3.2 ± 0.3 (4)</td> <td>3.4 ± 0.3 (3)</td> <td>3.4 ± 0.3 (4)</td> <td>3.8 ± 0.1 (4)</td> <td>---</td> <td>4.0 ± 0.0 (2)</td> </tr> <tr> <td>0.3</td> <td>2.4 ± 0.4 (4)</td> <td>1.5 ± 0.2*** (6)</td> <td>1.9 ± 0.2** (5)</td> <td>2.8 ± 0.2 (6)</td> <td>2.8 ± 0.3* (5)</td> <td>2.4 ± 0.6 (3)</td> <td>2.4 ± 0.3* (3)</td> </tr> <tr> <td>1.0</td> <td>2.2 ± 0.3* (5)</td> <td>1.5 ± 0.1*** (6)</td> <td>1.3 ± 0.1*** (5)</td> <td>2.3 ± 0.3** (4)</td> <td>2.0 ± 0.3*** (6)</td> <td>2.9 ± 0.4 (5)</td> <td>2.2 ± 0.2** (4)</td> </tr> <tr> <td>3.0</td> <td>1.6 ± 0.2** (4)</td> <td>1.7 ± 0.3** (4)</td> <td>1.6 ± 0.4** (3)</td> <td>1.8 ± .2*** (6)</td> <td>2.8 ± 0.2 (4)</td> <td>1.8 ± 0.5 (2)</td> <td>2.9 ± 0.4 (2)</td> </tr> </tbody> </table> <p><sup>a</sup> Significance at PND 63 could not be determined due to absence of controls at this time point (because of low # of female pups in control group). * p≤0.05, ** p≤0.01, *** p≤0.001 as compared to controls.</p> <ul style="list-style-type: none"> <li>● MG development scores were decreased in all treated groups compared to controls at all time points.</li> <li>● MG development score decreases were significant (p&lt; 0.05, p &lt; 0.01, or p &lt; 0.001) at 4 or 5 of the 7 time points at each dose.</li> <li>● The authors state that the mammary glands from PFOA treated pups displayed histological characteristics of delayed epithelial growth, and that histological observations at PND 63 and PND 84 are indicative of substantially delayed MG development, although comparison to controls could not be made on PND 63. Terminal end buds persisted at PND 63 and 84 (9 and 12 weeks), while normally they differentiate into terminal structures starting at PND 63 and disappear by PND 84. At PND 84, epithelial branching did not fill the fat pads as completely as in the controls. The decreases were statistically significant at all doses on PND 14 and 21, at 1 and 3 mg/kg/day on PND 28, at 0.3 and 1 mg/kg/day on PND 42, and at 0.3 and 2.2 mg/kg/day on PND 84, while other decreases were not significantly significant, possibly due to the small numbers (n=2-6) for each data point.</li> <li>● The LOAEL for delayed MG development was 0.3 mg/kg/day, and a NOAEL was not identified.</li> </ul> <p><b>Other endpoints (full gestation exposure study)</b></p> <ul style="list-style-type: none"> <li>● <i>Body weight</i> - No effect in M or F pups (with or without liver weight subtracted) at any time point.</li> <li>● <i>Relative liver weight</i> – Increased (p&lt; 0.05, p &lt; 0.01, or p &lt; 0.001) at all doses in M &amp; F pups on PND 7, in 1 mg/kg/day F pups on PND 14, and in 3 mg/kg/day M &amp; F pups on PND 14, PND 21, and PND 28.</li> <li>● <i>Brain weight</i> – No effect on relative brain weight. Absolute brain weight decreased in 1 and 3 mg/kg/day M pups on PND 63 only (p&lt;0.05)</li> </ul>	Dose (mg/kg/day)	PND 7 (n)	PND 14 (n)	PND 21 (n)	PND 28 (n)	PND 42 (n)	PND 63 (n)	PND 84 (n)	Control	3.3 ± 0.2 (5)	3.2 ± 0.3 (4)	3.4 ± 0.3 (3)	3.4 ± 0.3 (4)	3.8 ± 0.1 (4)	---	4.0 ± 0.0 (2)	0.3	2.4 ± 0.4 (4)	1.5 ± 0.2*** (6)	1.9 ± 0.2** (5)	2.8 ± 0.2 (6)	2.8 ± 0.3* (5)	2.4 ± 0.6 (3)	2.4 ± 0.3* (3)	1.0	2.2 ± 0.3* (5)	1.5 ± 0.1*** (6)	1.3 ± 0.1*** (5)	2.3 ± 0.3** (4)	2.0 ± 0.3*** (6)	2.9 ± 0.4 (5)	2.2 ± 0.2** (4)	3.0	1.6 ± 0.2** (4)	1.7 ± 0.3** (4)	1.6 ± 0.4** (3)	1.8 ± .2*** (6)	2.8 ± 0.2 (4)	1.8 ± 0.5 (2)	2.9 ± 0.4 (2)	<p>In the <u>full gestation exposure study</u> (exposure on GD 1-7 to 0.3, 1.0, and 3 mg/kg/day), delayed MG development, as assessed by developmental score, occurred in female offspring the absence of effects on body weight. The LOAEL was 0.3 mg/kg/day and no NOAEL was identified. Delays were evident, and were statistically significant (with the exception of the 3 mg/kg/day dose group with n of only 2), at the end of the study on PND 84.</p> <p>In the <u>late gestation exposure study</u> (exposure on GD 10-17 to 0.01, 0.1, and 1 mg/kg/day), individual parameters of MG development were evaluated in addition to the overall developmental score used in the full gestation study and earlier studies from this laboratory (White et al., 2007, 2009, 2011). MG development, based on numerous endpoints, was assessed in female pups on PND 1, 4, 7, 14, and 21. The authors state that the mammary glands from the treated mice displayed aberrant morphology, with delays most evident on PND 21. Only PND 21 data are shown in tabular form and some PND 14 data are presented in the text, while data from other time points are not shown.</p> <p>On PND 21, the overall developmental score was significantly decreased in all dose groups compared to controls in a dose-related fashion. Other MG parameters were also decreased on</p>
Dose (mg/kg/day)	PND 7 (n)	PND 14 (n)	PND 21 (n)	PND 28 (n)	PND 42 (n)	PND 63 (n)	PND 84 (n)																																			
Control	3.3 ± 0.2 (5)	3.2 ± 0.3 (4)	3.4 ± 0.3 (3)	3.4 ± 0.3 (4)	3.8 ± 0.1 (4)	---	4.0 ± 0.0 (2)																																			
0.3	2.4 ± 0.4 (4)	1.5 ± 0.2*** (6)	1.9 ± 0.2** (5)	2.8 ± 0.2 (6)	2.8 ± 0.3* (5)	2.4 ± 0.6 (3)	2.4 ± 0.3* (3)																																			
1.0	2.2 ± 0.3* (5)	1.5 ± 0.1*** (6)	1.3 ± 0.1*** (5)	2.3 ± 0.3** (4)	2.0 ± 0.3*** (6)	2.9 ± 0.4 (5)	2.2 ± 0.2** (4)																																			
3.0	1.6 ± 0.2** (4)	1.7 ± 0.3** (4)	1.6 ± 0.4** (3)	1.8 ± .2*** (6)	2.8 ± 0.2 (4)	1.8 ± 0.5 (2)	2.9 ± 0.4 (2)																																			

Reference and Study Design	Results	Comment																																								
<p><b>Macon et al. (2011) (cont.)</b></p> <p><b><u>Late-gestation exposure study</u></b></p> <p><b>MG Assessment:</b> Female offspring</p> <p><b>Exposure levels:</b> 0, 0.01, 0.1, or 1.0 mg/kg/day</p> <p><b>Exposure regimen:</b> Gestational. GD 10-17.</p> <p><b>Group size:</b>  <i>Block 1:</i> 5 dams per treatment group.  <i>Block 2:</i> 8 dams per treatment group.            Pups pooled on PND 1 and redistributed to dams within treatment group. n=7-9 pups per dam, including 4-7 female pups per dam.</p> <p><b>Timepoint(s) for mammary gland (MG) evaluation:</b> Offspring – PND 1, PND 4, PND 7, PND 14, PND 21.</p> <p><b>Related studies:</b> Post et al. (2012)</p>	<p><b><u>Late-gestation exposure (GD 10-17) study</u></b></p> <p><b><u>MG development parameters in whole mounts from female offspring at PND 21 after exposure on GD 10-17</u></b></p> <table border="1" data-bbox="521 272 2134 467"> <thead> <tr> <th><i>Dose (mg/kg/day)</i></th> <th><i>Developmental score (1-4) (n)</i></th> <th><i>Longitudinal growth (µm) (n)</i></th> <th><i>Lateral growth (µm)<sup>a</sup> (n)</i></th> <th><i>Δ Longitudinal growth (µm)<sup>a</sup> (n)</i></th> <th><i>Δ Lateral growth (µm) (n)</i></th> <th><i># Terminal end buds(n)</i></th> <th><i># Terminal ends (n)</i></th> </tr> </thead> <tbody> <tr> <td><i>Control</i></td> <td>3.3 ± 0.3 (5)</td> <td>4321 ± 306 (5)</td> <td>5941 ± 280 (5)</td> <td>3394 ± 306 (5)</td> <td>4358 ± 280 (5)</td> <td>40 ± 4 (5)</td> <td>81 ± 12 (5)</td> </tr> <tr> <td><i>0.01</i></td> <td>2.2 ± 0.2* (4)</td> <td>3803 ± 386 (4)</td> <td>5420 ± 326 (4)</td> <td>3087 ± 386 (4)</td> <td>3899 ± 326 (4)</td> <td>33 ± 4 (4)</td> <td>61 ± 8 (4)</td> </tr> <tr> <td><i>0.1</i></td> <td>1.8 ± 0.3** (3)</td> <td>3615 ± 320 (3)</td> <td>4822 ± 672 (3)</td> <td>2370 ± 320 (3)</td> <td>3035 ± 672 (3)</td> <td>24 ± 4* (3)</td> <td>58 ± 4 (3)</td> </tr> <tr> <td><i>1.0</i></td> <td>1.6 ± 0.1*** (5)</td> <td>2775 ± 285** (5)</td> <td>4822 ± 313 (5)</td> <td>1553 ± 301** (5)</td> <td>3380 ± 313 (5)</td> <td>15 ± 2***(5)</td> <td>47 ± 11 (5)</td> </tr> </tbody> </table> <p><sup>a</sup> Change in lateral or longitudinal epithelial growth based on comparison to mean values on PND 1. Significant effects compared with controls, *<i>p</i> &lt; 0.05, **<i>p</i> &lt; 0.01, ***<i>p</i> &lt; 0.001.</p> <ul style="list-style-type: none"> <li>● At PND 14, longitudinal epithelial growth in the 0.1 and 1.0 mg/kg/day groups reduced compared with controls by 14.4% (<i>p</i> = 0.04) and 37.3% (<i>p</i> = 0.01), respectively, and the change in longitudinal growth from PNDs 1 to 14 was reduced by 27.4% (<i>p</i> = 0.005) and 56.5% (<i>p</i> = 0.002), respectively. Other PND 14 data not shown.</li> <li>● Developmental delays were most evident at PND 21. Numerical data presented in table. MG development scores in all treated groups were significantly lower than in controls (<i>p</i> &lt; 0.02; Table 1). Effects for developmental score and other endpoints (with the exception of change in lateral growth) occurred in a dose-related fashion.</li> <li>● LOAEL for delayed MG development was 0.01 mg/kg/day. No NOAEL was identified.</li> </ul> <p><b><u>Other endpoints (only female pups assessed) (late gestation exposure study)</u></b></p> <ul style="list-style-type: none"> <li>● <b><u>Body weight</u></b> - No effect (with or without liver weight subtracted) at any time point.</li> <li>● <b><u>Liver weight</u></b> – Absolute liver weight increased (<i>p</i>&lt;0.001) in 1 mg/mg/day group on PND 4 and PND 7. Relative liver weight increased (<i>p</i>&lt; 0.05, <i>p</i> &lt; 0.01, or <i>p</i> &lt; 0.001) in 1 mg/kg/day group on PND 4 – PND 14. No effect in 0.01 or 0.1 mg/kg/day groups.</li> <li>● <b><u>NOAEL for increased relative liver weight based on PFOA serum level</u></b> - In the 1 mg/kg/day group during the period when liver weight was increased, serum PFOA levels were 16,305 ng/ml on PND 1 and had decreased to 6084 ng/ml on PND 14. The NOAEL for increased relative liver weight was 2303 ng/ml, the highest serum level in the 0.1 mg/kg/day group, which occurred on PND 1. This is consistent with the serum level in the 1 mg/kg/day group on PND 21 (when liver weight was no longer increased), which was 2683 ng/ml.</li> </ul> <p><b><u>PFOA levels in serum, liver, and brain</u></b></p> <p>Numerical data are presented for serum, liver, and brain in M &amp; F pups in the full gestational (GD 1-17) study. Data from PND 7 (earliest time point assessed) shows that serum levels were similar in M&amp;F pups, with slightly higher values at all doses in males. Serum levels in the late gestational (GD 10-17) study are for combined M&amp;F pups on PND 1, and for F pups at other times. Serum data for late gestational study (exposure on PND 10-17) shown below.</p>	<i>Dose (mg/kg/day)</i>	<i>Developmental score (1-4) (n)</i>	<i>Longitudinal growth (µm) (n)</i>	<i>Lateral growth (µm)<sup>a</sup> (n)</i>	<i>Δ Longitudinal growth (µm)<sup>a</sup> (n)</i>	<i>Δ Lateral growth (µm) (n)</i>	<i># Terminal end buds(n)</i>	<i># Terminal ends (n)</i>	<i>Control</i>	3.3 ± 0.3 (5)	4321 ± 306 (5)	5941 ± 280 (5)	3394 ± 306 (5)	4358 ± 280 (5)	40 ± 4 (5)	81 ± 12 (5)	<i>0.01</i>	2.2 ± 0.2* (4)	3803 ± 386 (4)	5420 ± 326 (4)	3087 ± 386 (4)	3899 ± 326 (4)	33 ± 4 (4)	61 ± 8 (4)	<i>0.1</i>	1.8 ± 0.3** (3)	3615 ± 320 (3)	4822 ± 672 (3)	2370 ± 320 (3)	3035 ± 672 (3)	24 ± 4* (3)	58 ± 4 (3)	<i>1.0</i>	1.6 ± 0.1*** (5)	2775 ± 285** (5)	4822 ± 313 (5)	1553 ± 301** (5)	3380 ± 313 (5)	15 ± 2***(5)	47 ± 11 (5)	<p>PND 21 in all treated groups in a dose-related fashion, but were significant only for change in longitudinal growth and number of terminal end buds in the highest dose group (possibly due to the small <i>n</i> (3-5) at each dose.</p> <p>There were no effects on body weight, and liver weight was not affected at 0.01 or 0.1 mg/kg/day.</p> <p>Serum levels were highest in the treated pups on PND 1 and had decreased to 6-12% of the PND 1 levels by PND 21. The serum level on PND 1 in the 0.01 mg/kg/day group was 285 ng/ml.</p> <p>Serum levels in the dams were not measured but are expected to be similar to those in the pups. Serum levels in non-pregnant adult CD-1 mice exposed to 0.1 and 1 mg/kg/day for 8 days were 3200, and 31,000 ng/ml, from preliminary data of Das et al. (2010), and the serum level after dosing with 0.01 mg/kg/day for 8 days can be estimated at 320 ng/ml from these data. Earlier studies showed pup serum levels 2-fold or less higher than maternal serum levels at PND 1. Thus, levels in the dams at delivery would also be expected to be around 300 ng/L or less in the 0.01 mg/kg/day group.</p> <p><b>Summary:</b> Gestational exposure to ≥ 0.01 mg/kg/day PFOA caused dose-related delays in MG development in female offspring. MG development was delayed by doses that did not</p>
<i>Dose (mg/kg/day)</i>	<i>Developmental score (1-4) (n)</i>	<i>Longitudinal growth (µm) (n)</i>	<i>Lateral growth (µm)<sup>a</sup> (n)</i>	<i>Δ Longitudinal growth (µm)<sup>a</sup> (n)</i>	<i>Δ Lateral growth (µm) (n)</i>	<i># Terminal end buds(n)</i>	<i># Terminal ends (n)</i>																																			
<i>Control</i>	3.3 ± 0.3 (5)	4321 ± 306 (5)	5941 ± 280 (5)	3394 ± 306 (5)	4358 ± 280 (5)	40 ± 4 (5)	81 ± 12 (5)																																			
<i>0.01</i>	2.2 ± 0.2* (4)	3803 ± 386 (4)	5420 ± 326 (4)	3087 ± 386 (4)	3899 ± 326 (4)	33 ± 4 (4)	61 ± 8 (4)																																			
<i>0.1</i>	1.8 ± 0.3** (3)	3615 ± 320 (3)	4822 ± 672 (3)	2370 ± 320 (3)	3035 ± 672 (3)	24 ± 4* (3)	58 ± 4 (3)																																			
<i>1.0</i>	1.6 ± 0.1*** (5)	2775 ± 285** (5)	4822 ± 313 (5)	1553 ± 301** (5)	3380 ± 313 (5)	15 ± 2***(5)	47 ± 11 (5)																																			

Reference and Study Design	Results	Comment																																		
Macon et al. (2011) (cont.)	<b><i>PFOA serum levels on PND 1-21 in offspring exposed on GD 10-17 (late gestation exposure study)</i></b>						affect body weight or liver weight. The LOAEL for delayed MG development in the pups is a serum level of 285 ng/ml (measured) and is also estimated as about 300 ng/ml or lower in the dams, and no NOAEL was identified. This LOAEL is based on the serum level on PND 1, and the actual LOAEL may be lower, since effects occurred at later time points when serum levels had decreased.  These findings indicate that delayed mammary gland development is a more sensitive endpoint for PFOA's effects in female mouse pups than decreased body weight or increased liver weight.																													
	<table border="1"> <thead> <tr> <th><i>Serum (ng/ml)</i></th> <th><u>PND 1</u> (n)</th> <th><u>PND 4</u> (n)</th> <th><u>PND 7</u> (n)</th> <th><u>PND 14</u> (n)</th> <th><u>PND 21</u> (n)</th> </tr> </thead> <tbody> <tr> <td><i>Control</i></td> <td>22.6 ± 5.5 (4)</td> <td>8.6 ± 0.5 (2)</td> <td>7.8 ± 2.1 (5)</td> <td>7.8 ± 1.5 (8)</td> <td>4.1 ± 0.6 (7)</td> </tr> <tr> <td><i>0.01 mg/kg</i></td> <td>284.5 ± 21.0 (3)</td> <td>184.1 ± 12.1 (2)</td> <td>150.7 ± 20.9 (7)</td> <td>80.2 ± 13.9 (8)</td> <td>16.5 ± 2.1 (10)</td> </tr> <tr> <td><i>0.1 mg/kg</i></td> <td>2303.5 ± 114.1 (2)</td> <td>-</td> <td>1277.8 ± 122.6 (8)</td> <td>645.4 ± 114.2 (7)</td> <td>131.7 ± 24.5 (7)</td> </tr> <tr> <td><i>1.0 mg/kg</i></td> <td>16305.5 ± 873.5 (7)</td> <td>-</td> <td>11880.3 ± 1447.6 (11)</td> <td>6083.7 ± 662.6 (11)</td> <td>2025.1 ± 281.9 (11)</td> </tr> </tbody> </table>	<i>Serum (ng/ml)</i>	<u>PND 1</u> (n)	<u>PND 4</u> (n)	<u>PND 7</u> (n)	<u>PND 14</u> (n)		<u>PND 21</u> (n)	<i>Control</i>	22.6 ± 5.5 (4)	8.6 ± 0.5 (2)	7.8 ± 2.1 (5)	7.8 ± 1.5 (8)	4.1 ± 0.6 (7)	<i>0.01 mg/kg</i>	284.5 ± 21.0 (3)	184.1 ± 12.1 (2)	150.7 ± 20.9 (7)	80.2 ± 13.9 (8)	16.5 ± 2.1 (10)	<i>0.1 mg/kg</i>	2303.5 ± 114.1 (2)	-	1277.8 ± 122.6 (8)	645.4 ± 114.2 (7)	131.7 ± 24.5 (7)	<i>1.0 mg/kg</i>	16305.5 ± 873.5 (7)	-	11880.3 ± 1447.6 (11)	6083.7 ± 662.6 (11)	2025.1 ± 281.9 (11)				
	<i>Serum (ng/ml)</i>	<u>PND 1</u> (n)	<u>PND 4</u> (n)	<u>PND 7</u> (n)	<u>PND 14</u> (n)	<u>PND 21</u> (n)																														
	<i>Control</i>	22.6 ± 5.5 (4)	8.6 ± 0.5 (2)	7.8 ± 2.1 (5)	7.8 ± 1.5 (8)	4.1 ± 0.6 (7)																														
	<i>0.01 mg/kg</i>	284.5 ± 21.0 (3)	184.1 ± 12.1 (2)	150.7 ± 20.9 (7)	80.2 ± 13.9 (8)	16.5 ± 2.1 (10)																														
	<i>0.1 mg/kg</i>	2303.5 ± 114.1 (2)	-	1277.8 ± 122.6 (8)	645.4 ± 114.2 (7)	131.7 ± 24.5 (7)																														
	<i>1.0 mg/kg</i>	16305.5 ± 873.5 (7)	-	11880.3 ± 1447.6 (11)	6083.7 ± 662.6 (11)	2025.1 ± 281.9 (11)																														
<ul style="list-style-type: none"> <li>● Serum levels increased with dose and generally decreased over time.</li> </ul>																																				

Reference and Study Design	Results	Comment																																																
<p><b>Tucker et al. (2015).</b> The mammary gland is a sensitive pubertal target in CD-1 and C57Bl/6 mice following perinatal perfluorooctanoic acid (PFOA) exposure.</p> <p><b>Species and strain:</b> Timed pregnant CD-1 and C57Bl/6 mice and their offspring</p> <p><b>MG Assessment:</b> Female offspring</p> <p><b>Test article and vehicle:</b> PFOA (ammonium salt, &gt;98% pure) in deionized water</p> <p><b>Route of exposure:</b> Oral gavage</p> <p><b>Exposure levels:</b> 0, 0.01, 0.1, 0.3, or 1.0 mg/kg/day</p> <p><b>Exposure regimen:</b> Gestational. GD 1-17.</p> <p><b>Group size:</b> CD-1: 3 blocks of pregnant dams (n=97, 40, and 26) C57Bl/6: 41 pregnant dams</p> <p><b>Timepoint(s) for mammary gland (MG) evaluation:</b> CD-1: PND 21, PND 35, PND 56 C57Bl/6: PND 21 and PND 61</p>	<p><b><u>MG DEVELOPMENT</u></b></p> <p><b><u>MG development scores (1-4) in whole mounts from CD-1 and C57Bl/6 female offspring exposed on GD 1-17</u></b></p> <table border="1" data-bbox="559 282 2075 521"> <thead> <tr> <th></th> <th>Control (n)</th> <th>0.01 mg/kg (n)</th> <th>0.1 mg/kg (n)</th> <th>0.3 mg/kg (n)</th> <th>1.0 mg/kg (n)</th> </tr> </thead> <tbody> <tr> <td><b>CD-1</b></td> <td></td> <td></td> <td></td> <td></td> <td></td> </tr> <tr> <td>  PND 21</td> <td>2.9 ± 0.1 (19)</td> <td>2.4 ± 0.1 (22)</td> <td>2.3 ± 0.1 (22)<sup>***</sup></td> <td>2.0 ± 0.1 (21)<sup>****</sup></td> <td>1.7 ± 0.1 (21)<sup>****</sup></td> </tr> <tr> <td>  PND 35</td> <td>3.1 ± 0.1 (16)</td> <td>2.3 ± 0.2 (17)<sup>**</sup></td> <td>2.2 ± 0.2 (14)<sup>**</sup></td> <td>2.3 ± 0.1 (16)<sup>**</sup></td> <td>1.9 ± 0.2 (14)<sup>****</sup></td> </tr> <tr> <td>  PND 56</td> <td>3.3 ± 0.1 (9)</td> <td>2.3 ± 0.2 (13)<sup>**</sup></td> <td>2.5 ± 0.2 (8)<sup>*</sup></td> <td>2.2 ± 0.1 (10)<sup>**</sup></td> <td>1.9 ± 0.2 (9)<sup>****</sup></td> </tr> <tr> <td><b>C57Bl/6</b></td> <td></td> <td></td> <td></td> <td></td> <td></td> </tr> <tr> <td>  PND 21</td> <td>2.9 ± 0.2 (7)</td> <td>2.5 ± 0.4 (5)</td> <td>2.1 ± 0.7 (2)</td> <td>1.8 ± 0.3 (6)<sup>*</sup></td> <td>1.8 ± 0.2 (5)<sup>*</sup></td> </tr> <tr> <td>  PND 61</td> <td>2.8 ± 0.2 (10)</td> <td>2.2 ± 0.2 (5)</td> <td>2.6 ± 0.1 (3)</td> <td>2.1 ± 0.1 (10)<sup>*</sup></td> <td>1.7 ± 0.1 (8)<sup>****</sup></td> </tr> </tbody> </table> <p>*p≤0.05; **p≤0.01, ***p≤0.001, ****p≤0.0001. Means represent averages of individual pup scores.</p> <ul style="list-style-type: none"> <li>● Authors report that delayed MG development was apparent at lowest dose (0.01 mg/kg/day) in both strains.</li> <li>● MG development scores were lower than controls at all doses, including lowest (0.01 mg/kg/day) and timepoints in both strains.</li> <li>● Lack of significance in C57Bl/6 at lower doses may be due to lower PFOA serum levels and smaller n, as compared to CD-1.</li> <li>● Specific observations indicating delayed MG development at different time points in each strain are described in the text.</li> <li>● Delayed MG development persisted through early adulthood (end of study) in both strains.</li> </ul> <p><b><u>OTHER ENDPOINTS</u></b></p> <p><b><u>Body weight:</u></b> Assessed at same time points as MG development. No effect on absolute body weight. Body weight with liver weight subtracted decreased (p&lt;0.05) only in 1 mg/kg/day CD-1 on PND 21 and PND 35, but not PND 56.</p> <p><b><u>Liver weight:</u></b> Assessed at same time points as MG development. No effects on absolute liver weight. Relative liver weight increased (p&lt;0.05) on PND 21 only in 1 mg/kg/day CD-1.</p> <p><b><u>Pubertal events:</u></b> PFOA treatment had no effect on day of vaginal opening, body weight at vaginal opening, or day of first estrus in either strain.</p> <p><b><u>Serum estradiol and progesterone:</u></b> Assessed at same time points as MG development. PFOA treatment had no effect on hormone levels at any time point in either strain.</p>		Control (n)	0.01 mg/kg (n)	0.1 mg/kg (n)	0.3 mg/kg (n)	1.0 mg/kg (n)	<b>CD-1</b>						PND 21	2.9 ± 0.1 (19)	2.4 ± 0.1 (22)	2.3 ± 0.1 (22) <sup>***</sup>	2.0 ± 0.1 (21) <sup>****</sup>	1.7 ± 0.1 (21) <sup>****</sup>	PND 35	3.1 ± 0.1 (16)	2.3 ± 0.2 (17) <sup>**</sup>	2.2 ± 0.2 (14) <sup>**</sup>	2.3 ± 0.1 (16) <sup>**</sup>	1.9 ± 0.2 (14) <sup>****</sup>	PND 56	3.3 ± 0.1 (9)	2.3 ± 0.2 (13) <sup>**</sup>	2.5 ± 0.2 (8) <sup>*</sup>	2.2 ± 0.1 (10) <sup>**</sup>	1.9 ± 0.2 (9) <sup>****</sup>	<b>C57Bl/6</b>						PND 21	2.9 ± 0.2 (7)	2.5 ± 0.4 (5)	2.1 ± 0.7 (2)	1.8 ± 0.3 (6) <sup>*</sup>	1.8 ± 0.2 (5) <sup>*</sup>	PND 61	2.8 ± 0.2 (10)	2.2 ± 0.2 (5)	2.6 ± 0.1 (3)	2.1 ± 0.1 (10) <sup>*</sup>	1.7 ± 0.1 (8) <sup>****</sup>	<p>MG development was delayed on PND 21 until PND 56 or 61 in CD-1 and C57Bl/6 mice exposed to 0.01- 1 mg/kg/day PFOA on GD 1-17. No NOAEL for delayed MG development was identified in CD-1 mice. The results in CD-1 mice are consistent with delayed MG development after exposure to 0.01 mg/kg/day and higher doses on GD 10-17 (Macon et al., 2011). Lack of significant effects at lower doses in C57Bl/6 mice as compared to CD-1 mice may be due to the small number of mice per dose group and/or lower serum levels (faster excretion) in C57Bl/6.</p> <p>Serum PFOA levels were first measured on PND 21. After gestational exposure, PFOA serum levels in CD-1 mice were highest on PND 1 and decreased thereafter (Macon et al., 2011). Since the effects seen on PND 21 and later times could be the result of higher internal doses earlier in life, these serum data are not suitable as the basis for quantitative risk assessment.</p> <p><b><u>Summary:</u></b> Delayed MG development in both strains occurred in the absence of effects on body weight, liver weight, timing of pubertal events, and serum estradiol and progesterone. This suggests that MG development is a more sensitive endpoint for effects of PFOA than the other endpoints assessed.</p>
	Control (n)	0.01 mg/kg (n)	0.1 mg/kg (n)	0.3 mg/kg (n)	1.0 mg/kg (n)																																													
<b>CD-1</b>																																																		
PND 21	2.9 ± 0.1 (19)	2.4 ± 0.1 (22)	2.3 ± 0.1 (22) <sup>***</sup>	2.0 ± 0.1 (21) <sup>****</sup>	1.7 ± 0.1 (21) <sup>****</sup>																																													
PND 35	3.1 ± 0.1 (16)	2.3 ± 0.2 (17) <sup>**</sup>	2.2 ± 0.2 (14) <sup>**</sup>	2.3 ± 0.1 (16) <sup>**</sup>	1.9 ± 0.2 (14) <sup>****</sup>																																													
PND 56	3.3 ± 0.1 (9)	2.3 ± 0.2 (13) <sup>**</sup>	2.5 ± 0.2 (8) <sup>*</sup>	2.2 ± 0.1 (10) <sup>**</sup>	1.9 ± 0.2 (9) <sup>****</sup>																																													
<b>C57Bl/6</b>																																																		
PND 21	2.9 ± 0.2 (7)	2.5 ± 0.4 (5)	2.1 ± 0.7 (2)	1.8 ± 0.3 (6) <sup>*</sup>	1.8 ± 0.2 (5) <sup>*</sup>																																													
PND 61	2.8 ± 0.2 (10)	2.2 ± 0.2 (5)	2.6 ± 0.1 (3)	2.1 ± 0.1 (10) <sup>*</sup>	1.7 ± 0.1 (8) <sup>****</sup>																																													

Reference and Study Design	Results					Comment	
Tucker et al. (2015) (cont.)	<b><u>PFOA SERUM LEVELS (ng/ml)</u></b>						
		Control (n)	0.01 mg/kg (n)	0.1 mg/kg (n)	0.3 mg/kg (n)		1.0 mg/kg (n)
	CD-1						
	PND 21	<LOQ (6)	74.8 ± 16.9 (10)	457.3 ± 91.0 (9)	904.8 ± 131.5 (10) <sup>†</sup>		3119.0 ± 396.4 (5) <sup>***</sup>
	PND 35	<LOQ (11)	14.3 ± 2.3 (12)	61.7 ± 6.5 (9)	200.9 ± 32.2 (11) <sup>†</sup>		889.8 ± 117.5 (11) <sup>***</sup>
	PND 56	<LOQ (5)	< LOQ (5)	15.0 ± 5.0 (4)	46.2 ± 7.5 (6)		200.2 ± 21.1 (7) <sup>***</sup>
	C57Bl/6						
	PND 21	<LOQ (2)	26.1 ± 19.0 (2)	247.1 ± 11.4 (2)	891.3 ± 528.7 (3)		2141.67 ± 666.8 (2)
	PND 61	<LOQ (6)	<LOQ (2)	27.7 ± 10.4 (3) <sup>†</sup>	9.3 ± 2.2 (5)		22.0 ± 7.6 (5)
	<ul style="list-style-type: none"> <li>● Serum PFOA levels in both strains increased with dose and decreased over time.</li> <li>● Serum PFOA was below LOQ or very low (9-27 ng/L) at some doses and time points when MG development was significantly delayed.</li> <li>● Serum PFOA levels were lower in C57Bl/6 than CD-1 mice on PND 21, and generally lower at later time points (PND 56 in CD-1 versus PND 61 in C57Bl/6).</li> </ul>						



Reference and Study Design	Results	Comments																										
<p><b>White et al. (2007).</b> Gestational PFOA exposure of mice is associated with altered mammary gland development in dams and female offspring.</p> <p><b>Species and strain:</b> Timed pregnant CD-1 mice and their offspring</p> <p><b>Test article and vehicle:</b> PFOA (ammonium salt, &gt;98% pure) in deionized water</p> <p><b>Route of exposure:</b> Oral gavage</p> <p><b>Exposure levels:</b> 0 or 5 mg/kg/day</p> <p><b>Study 1</b> <b>MG assessment:</b> Dams</p> <p><b>Exposure regimen:</b> Gestational. GD 1-17</p> <p><b>Group size:</b> 5</p> <p><b>Timepoint(s) for mammary gland (MG) evaluation:</b> GD 18</p>	<p><b>Study 1</b> <b>MG development in dams on GD 18 after treatment on GD 1-17</b> Whole mounts were examined microscopically and scored on a scale of 1-4. Delay in 5 mg/kg/day group.</p> <table border="1" data-bbox="612 386 1131 483"> <thead> <tr> <th colspan="2"><i>MG Development Score (mean + SE)</i></th> </tr> <tr> <th>Control (n=4)</th> <th>5 mg/kg/day (n=3)</th> </tr> </thead> <tbody> <tr> <td>3.9±0.1</td> <td>2.0±0.6*</td> </tr> </tbody> </table> <p>*p&lt;0.015</p> <p><b>Study 2</b> <b>MG DEVELOPMENT (Study 2)</b> <b>Lactating dams on PND 10 or PND 20 after treatment during gestation (Study 2)</b></p> <p><i>MG development scores</i> All treated groups were dosed with 5 mg/kg/day on stated gestational days (GD). Whole mounts/H&amp;E slides were scored on a scale of 1-4. Numerical data shown only for whole mount scores. Representative H&amp;E slides from control and treated mice are shown.</p> <ul style="list-style-type: none"> <li>PND 10: MG development was delayed in all exposure groups (significant for GD 8-17 and 1-17).</li> <li>PND 20: MG in all PFOA-exposed groups resembled MG from PND 10 controls, indicating delayed development.</li> </ul> <table border="1" data-bbox="612 976 1438 1105"> <thead> <tr> <th colspan="5"><i>MG Development Score in Whole Mounts (mean ± SE)</i></th> </tr> <tr> <th></th> <th>Control</th> <th>GD 12-17</th> <th>GD 8-17</th> <th>GD 1-17</th> </tr> </thead> <tbody> <tr> <td>PND 10 (n=4-6)</td> <td>4.0±0.0</td> <td>3.7±0.1</td> <td>3.2±0.2*</td> <td>1.8±0.5**</td> </tr> <tr> <td>PND 20 (n=3-6)</td> <td>2.7±0.2</td> <td>2.8±0.2</td> <td>3.2±0.1</td> <td>3.3±0.2</td> </tr> </tbody> </table> <p>*p&lt;0.05; **p&lt;0.001</p> <ul style="list-style-type: none"> <li>Non-pregnant adult females dosed with PFOA for up to 17 days have no effects on MG (data not shown)</li> </ul> <p><i>Expression of milk proteins</i> Gene expression profiles of four milk protein genes (beta-casein, EGF, alpha-Lac, and LactoF) in maternal mammary gland tissue on PND 10 and 20 showed that expression of genes for all 4 proteins was significantly (p&lt;0.05 or p&lt;0.001) ↑ or ↓ in at least one exposure group (GD 12-17, 8-17, and 1-17) on PND 10 and/or PND 20. Some of the changes did not follow a consistent pattern.</p>	<i>MG Development Score (mean + SE)</i>		Control (n=4)	5 mg/kg/day (n=3)	3.9±0.1	2.0±0.6*	<i>MG Development Score in Whole Mounts (mean ± SE)</i>						Control	GD 12-17	GD 8-17	GD 1-17	PND 10 (n=4-6)	4.0±0.0	3.7±0.1	3.2±0.2*	1.8±0.5**	PND 20 (n=3-6)	2.7±0.2	2.8±0.2	3.2±0.1	3.3±0.2	<p><b>Study 1</b> The authors interpreted the delayed MG development in treated dams on PND 18 (prior to parturition) as indicating that the delayed MG development in dams at later time points in Study 2 was not due to a deficiency in stimulation of lactation due to decreased suckling ability of pups.</p> <p><b>Study 2</b> <b>Lactating dams on PND 10 and 20</b> <i>MG development in lactating dams</i> Delayed MG development in dams occurred in the absence of decreased maternal weight gain. Exposure during the second half of pregnancy was sufficient to cause this effect. MG development in non-pregnant females was not affected by similar exposures.</p> <p>On PND 10, normally the peak of lactation in rodents, MG from treated mice on PND 10 resembled those normally seen earlier in lactation. On PND 20, immediately prior to weaning, MG are normally involuted, but MG from PFOA-treated mice resembled PND 10 (peak of lactation) MG from controls. This suggests a delay of up to 10 days in MG differentiation due to PFOA exposure.</p> <p><i>Expression of milk proteins in lactating dams</i> The authors stated that the decrease in LactoF at PND 20, when a peak normally occurs, is consistent with the observed structural delays in mammary gland development seen at PND 20.</p> <p><i>Decreased pup body weight at birth</i> The authors state that this effect was not due to general maternal toxicity, since maternal body weight and reproductive parameters were not affected.</p> <p><i>MG development in female offspring</i> Delayed MG development occurred after exposure during the final 6 days of gestation. MG development was arrested between PND 10 and 20, although pups grew isometrically during this time period.</p>
<i>MG Development Score (mean + SE)</i>																												
Control (n=4)	5 mg/kg/day (n=3)																											
3.9±0.1	2.0±0.6*																											
<i>MG Development Score in Whole Mounts (mean ± SE)</i>																												
	Control	GD 12-17	GD 8-17	GD 1-17																								
PND 10 (n=4-6)	4.0±0.0	3.7±0.1	3.2±0.2*	1.8±0.5**																								
PND 20 (n=3-6)	2.7±0.2	2.8±0.2	3.2±0.1	3.3±0.2																								

Reference and Study Design	Results	Comments																				
<p><b>White et al. (2007) continued</b></p> <p><b>Study 2</b>  <b>MG assessment:</b>  Dams and female offspring</p> <p><b>Exposure regimen:</b>  Gestational.  GD 1-17; GD 8-17; or 12-17.  Controls dosed with water GD 1-17.</p> <p><b>White et al. (2007) (continued).</b></p> <p><b>Group size:</b>  14-16 dams  10 offspring per litter (litters equalized on PND 1)</p> <p><b>Timepoint(s) for mammary gland evaluation:</b>  PND 10 - Half of dams and litters  PND 20 - Half of dams and litters</p>	<p>LactoF expression was significantly (about 50%-80%) ↓ compared to controls in all 3 exposure duration groups on PND 20, the time point when a peak in this protein normally occurs. LactoF levels in the treated groups on PND 20 were similar to the controls on PND 10.</p> <p><b>Female Offspring on PND 10 or PND 20 (Study 2)</b>  Whole mounts were examined microscopically and scored on a scale of 1-4. All treated groups were prenatally exposed to 5 mg/kg/day on stated gestational days (GD).</p> <ul style="list-style-type: none"> <li>• MG development was delayed (p&lt;0.001) in all groups at both time points.</li> <li>• MG development was not correlated with body weight.</li> <li>• Virtually no MG development occurred in treated pups between PND 10 and 20, although relative body weight gain was not decreased in treated pups during this period.</li> <li>• PFOA serum levels in serum and liver decreased from PND 10 to PND 20, but MG development remained arrested.</li> </ul> <table border="1" data-bbox="612 597 1413 792"> <thead> <tr> <th colspan="5"><i>MG Development Score (mean ± SE)</i></th> </tr> <tr> <th></th> <th>Control</th> <th>GD 12-17</th> <th>GD 8-17</th> <th>GD 1-17</th> </tr> </thead> <tbody> <tr> <td>PND 10 (n=4-6 litters)</td> <td>3.1±0.2</td> <td>1.7±0.1*</td> <td>1.4±0.1*</td> <td>1.6±0.2*</td> </tr> <tr> <td>PND 20 (n=3-6 litters)</td> <td>3.3±0.2</td> <td>1.4±0.1*</td> <td>1.5±0.1*</td> <td>1.8±0.3*</td> </tr> </tbody> </table> <p>P&lt;0.001</p> <p><b>OTHER REPRODUCTIVE AND DEVELOPMENTAL PARAMETERS (Study 2)</b></p> <p><i>Maternal body weight gain</i> – No effect.</p> <p><i>Reproductive parameters</i> – No effect on number of implants, live fetuses, or % prenatal loss per live litter.</p> <p><i>Offspring body weight</i> – Significantly ↓ (p&lt;0.05; p&lt;0.01, or p&lt;0.001) in all treated exposure duration groups at all timepoints assessed (At birth [PND 1], PND 5, PND 10, and PND 20).</p> <p><b>PFOA LEVELS IN DAMS (BLOOD) AND OFFSPRING (BLOOD, LIVER)</b></p> <ul style="list-style-type: none"> <li>• PFOA was determined semiquantitatively in blood and quantitatively in liver (n=3-6 for each treatment duration group at each time point).</li> <li>• Dam blood - PND 10 and 20: ↑ with exposure duration; similar levels on PND 10 and 20; differences may have been masked by semiquantitative determination.</li> <li>• Offspring blood – PND 10 and 20: ↑ with exposure duration; ↓ between PND 10 and 20.</li> <li>• Offspring liver – PND 1, 10, and 20: ↑ with exposure duration; similar on PND 1 and 10, ↓ on PND 20.</li> <li>• Offspring liver:blood ratio: Levels in liver approximately 2 – 3 times higher than in blood in all treated groups at all time points.</li> </ul>	<i>MG Development Score (mean ± SE)</i>						Control	GD 12-17	GD 8-17	GD 1-17	PND 10 (n=4-6 litters)	3.1±0.2	1.7±0.1*	1.4±0.1*	1.6±0.2*	PND 20 (n=3-6 litters)	3.3±0.2	1.4±0.1*	1.5±0.1*	1.8±0.3*	
<i>MG Development Score (mean ± SE)</i>																						
	Control	GD 12-17	GD 8-17	GD 1-17																		
PND 10 (n=4-6 litters)	3.1±0.2	1.7±0.1*	1.4±0.1*	1.6±0.2*																		
PND 20 (n=3-6 litters)	3.3±0.2	1.4±0.1*	1.5±0.1*	1.8±0.3*																		



**White et al. (2009).** Effects of perfluorooctanoic acid on mouse mammary gland development and differentiation resulting from cross-foster and restricted gestational exposure

**Species and strain:**

Timed pregnant CD-1 mice and their offspring,

**Test article and vehicle:**

PFOA (ammonium salt, >98% pure; 98.9% straight chain, 1.1.% branched isomers) in deionized water

**Route of exposure:**

Oral gavage

**Early-life effects cross-foster study**

**MG assessment:** Dams and female offspring

**Exposure levels:** 0 and 5 mg/kg/day

**Exposure regimen:**

Gestational.  
GD 8-17.

Pups were cross-fostered at birth. Four groups of pups, with exposures to 0 or 5 mg/kg/day in utero (U), during lactation (L), or both (U, L), designated as follows: 0U/0L, 5U/5L, 5U/0L, and 0U/5L.

**Group size:**

56 per dose level on GD 8-17.  
10 pups per foster litters (M and F equal when possible).

**Timepoint(s) for mammary gland (MG) evaluation:**

PND 1, PND 3, PND 5, and PND 10

**EARLY-LIFE EFFECTS CROSS-FOSTER STUDY**

**MG development (Early effects cross foster study)**

Dams: Whole mounts assessed microscopically. Numerical data not shown.

- MG in treated dams nursing treated or untreated pups had profoundly altered differentiation on PND 1. The MG appeared immature, resembling normal late pregnancy MG. Deficits persisted until end of study (PND 10).
- MG in untreated dams nursing pups exposed in utero showed delayed MG morphology on PND 3-10. PFOA serum levels in these dams was about 2000 ng/ml on PND 3, presumably from exposure through maternal behavior such as grooming of pups and ingestion of waste excreted by pups.

Female offspring:

<i>MG development scores of whole mounts from female offspring exposed on GD 1-17</i>				
<i>Treatment group</i>	<i>PND 1</i>	<i>PND 3</i>	<i>PND 5</i>	<i>PND 10</i>
Control	3.3 ± 0.2	3.5 ± 0.2	3.0 ± 0.1	2.8 ± 0.2
5L	1.7 ± 0.4*	1.8 ± 0.2*	1.5 ± 0.1*	2.3 ± 0.2*
5U	1.9 ± 0.2*	1.9 ± 0.3*	2.0 ± 0.2*	1.4 ± 0.1*
5U/5L	1.5 ± 0.2*	1.7 ± 0.3*	1.1 ± 0.1*	1.5 ± 0.2*

\*p<0.05. n=4 litters, 3 pups per litter, per treatment group per timepoint.  
Scored on a 1-4 scale adjusted for stage of development and age.

- MG development was delayed on PND 1 (after less than 1 day of exposure in 5L group), and in the absence of effects on body weight or liver weight. See Comments for more detail.

**Other Effects (Body Weight and Relative Liver Weight) (Early effects cross foster study)**

Dams:

- No effect on body weight at any time point (PND 1-10).
- ↑ relative liver weight (p<0.05) at all time points (PND 1, 3, 5, 10) in treated dams (5U; 5U/5L).

Offspring:

- No effect on body weight on PND 1. ↓ body weight (p<0.05) in 5U/5L on PND 3, and in all treated groups (5U, 5L, 5U/5L) on PND 5 and PND 10.
- ↑ relative liver weight (p<0.05) PND 1 and PND 3 in pups exposed *in utero* (5U, 5U/5L) and in all treated groups (5U, 5L, 5U/5L) on PND 5 and PND 10. Relative liver weight not affected with lactation only exposure (5L group).

Offspring

MG development was delayed in female offspring after gestational and/or lactational exposure.

MG development delay in female offspring occurred at timepoints at which body weight was not decreased and/or relative liver weight was not increased, suggesting that MG development may be a more sensitive endpoint in offspring than decreased growth or increased relative liver weight.

MG development delay occurred as early as PND 1, including in PND 1 female offspring exposed only lactationally with less than 1 day of exposure and serum levels of ~2000 ng/ml.

MG development delay in female offspring persisted until PND 63 (9 weeks) after gestational and/or lactational exposure. At this time point, serum levels were <1000 ng/ml in treated groups, and as low as 350 ng/ml.

MG developmental deficits after gestational and/or lactational exposure persisted until age 18 months, a time point when PFOA had essentially been completed eliminated from the body.

Exposure on GD 15-17, or longer portions of gestation, caused MG development delay in female offspring on PND 29 and 32, and persistent changes in MG morphology at age 18 months.

<p><b>White et al. (2009) (continued).</b></p> <p><b><u>Late-life effects cross-foster study</u></b>  <b>Note:</b> This study is an additional component of Wolf et al. (2007).</p> <p><b>MG Assessment:</b> Female offspring only.</p> <p><b>Exposure levels:</b> 0, 3, 5 mg/kg/day</p> <p><b>Exposure regimen:</b>  Gestational.  GD 1-17.  Pups were cross-fostered at birth. Seven groups of pups, with exposures to 0, 3, or 5 mg/kg/day in utero (U), during lactation (L), or both (U, L), designated as follows: Control (0U/0L), 3U/3L, 5U/5L, 3U, 5U, 3L, and 5L.</p> <p><b>Group size:</b>  28-48 dams per dose level on GD 1-17.  10 pups per foster litter (M and F equal when possible).</p> <p><b>Timepoint(s) for mammary gland (MG) evaluation:</b>  Offspring - PND 22, PND 43, PND 63, and 18 months</p>	<p><b><u>LATE-LIFE EFFECTS CROSS-FOSTER STUDY</u></b></p> <p><b><u>MG development (Late-life effects cross foster study)</u></b></p> <table border="1" data-bbox="634 240 1725 527"> <thead> <tr> <th colspan="4"><i>MG development scores of whole mounts from female offspring exposed on GD 1-17</i></th> </tr> <tr> <th><i>Treatment group</i></th> <th><i>PND 22 (weaning)</i></th> <th><i>PND 42</i></th> <th><i>PND 63</i></th> </tr> </thead> <tbody> <tr> <td>Control (0U/0L)</td> <td>3.7 ± 0.1</td> <td>3.2 ± 0.2</td> <td>3.1 ± 0.2</td> </tr> <tr> <td>3L</td> <td>3.0 ± 0.2*</td> <td>2.5 ± 0.2*</td> <td>2.6 ± 0.2*</td> </tr> <tr> <td>5L</td> <td>2.1 ± 0.2*</td> <td>2.5 ± 0.1*</td> <td>2.4 ± 0.2*</td> </tr> <tr> <td>3U</td> <td>1.8 ± 0.2*</td> <td>2.2 ± 0.1*</td> <td>2.6 ± 0.2*</td> </tr> <tr> <td>5U</td> <td>2.1 ± 0.3*</td> <td>2.2 ± 0.1*</td> <td>1.9 ± 0.2*</td> </tr> <tr> <td>3U/3L</td> <td>1.8 ± 0.2*</td> <td>2.7 ± 0.1</td> <td>2.6 ± 0.3*</td> </tr> <tr> <td>5U/5L</td> <td>1.2 ± 0.2*</td> <td>1.9 ± 0.2*</td> <td>1.9 ± 0.2*</td> </tr> </tbody> </table> <p>*p&lt;0.05. n=9-18 per treatment group at each time point.  Scored on a 1-4 scale adjusted for stage of development and age.</p> <ul style="list-style-type: none"> <li>● MG development delayed until PND 63 (9 weeks of age) in all treatment groups. See Comments.</li> </ul> <p><b><u>MG development at 18 months:</u></b>  - MG examined both as whole mounts and as histological sections stained with H &amp; E; n= 5-12 per group. (Could not be assessed with scoring criteria used at earlier timepoints.)  - Epithelial density appeared reduced in treated animals.  - Higher densities of darkly staining foci in glands of treated animals. Mean # foci/gland: Control, 6.9; 3 mg/kg/day groups, 34.3; 5 mg/kg/day groups, 38.6. No statistical parameters presented.  - Foci appear due to hyperplasia of ductal epithelium, infiltration of inflammatory cells into ductal regions, increased stromal density surrounding the ducts, and/or inappropriate differentiation of ductal epithelium. Some ductal inflammation observed in controls.</p> <p><b><u>Other endpoints in female offspring (Late-life effects cross foster study; from Wolf et al., 2007)</u></b></p> <ul style="list-style-type: none"> <li>● ↓ body weight and/or body weight gain on PND 22 (weaning) in all groups except 3L (not significant at p&lt;0.05 in 3U). p&lt;0.05 or 0.001 in other groups.</li> <li>● ↓ body weight persisted to PND 85 in 5U and 5U/5L (p&lt;0.05).</li> <li>● ↓ survival until PND 22 (weaning) (65%) in 5U/5L (p&lt;0.001).</li> <li>● Delayed eye opening in 3U/3L, 5U, and 5U/5L (p&lt;0.05).</li> <li>● ↑ relative liver weight on PND 22 in all exposed groups (p&lt;0.001).</li> </ul>	<i>MG development scores of whole mounts from female offspring exposed on GD 1-17</i>				<i>Treatment group</i>	<i>PND 22 (weaning)</i>	<i>PND 42</i>	<i>PND 63</i>	Control (0U/0L)	3.7 ± 0.1	3.2 ± 0.2	3.1 ± 0.2	3L	3.0 ± 0.2*	2.5 ± 0.2*	2.6 ± 0.2*	5L	2.1 ± 0.2*	2.5 ± 0.1*	2.4 ± 0.2*	3U	1.8 ± 0.2*	2.2 ± 0.1*	2.6 ± 0.2*	5U	2.1 ± 0.3*	2.2 ± 0.1*	1.9 ± 0.2*	3U/3L	1.8 ± 0.2*	2.7 ± 0.1	2.6 ± 0.3*	5U/5L	1.2 ± 0.2*	1.9 ± 0.2*	1.9 ± 0.2*	<p><b><u>Dams</u></b>  MG development was profoundly delayed in treated dams on PND 1, and delays persisted until PND 10.</p> <p>MG development was also delayed beginning on PND 3 in untreated dams with exposure through nursing of treated pups. The exposure presumably was through maternal behavior and ingestion of excreted PFOA in pups' waste.</p>
<i>MG development scores of whole mounts from female offspring exposed on GD 1-17</i>																																						
<i>Treatment group</i>	<i>PND 22 (weaning)</i>	<i>PND 42</i>	<i>PND 63</i>																																			
Control (0U/0L)	3.7 ± 0.1	3.2 ± 0.2	3.1 ± 0.2																																			
3L	3.0 ± 0.2*	2.5 ± 0.2*	2.6 ± 0.2*																																			
5L	2.1 ± 0.2*	2.5 ± 0.1*	2.4 ± 0.2*																																			
3U	1.8 ± 0.2*	2.2 ± 0.1*	2.6 ± 0.2*																																			
5U	2.1 ± 0.3*	2.2 ± 0.1*	1.9 ± 0.2*																																			
3U/3L	1.8 ± 0.2*	2.7 ± 0.1	2.6 ± 0.3*																																			
5U/5L	1.2 ± 0.2*	1.9 ± 0.2*	1.9 ± 0.2*																																			

White et al. (2009) (continued).

**Restricted exposure study**

**Note:** This study is an additional component of Wolf et al. (2007).

**MG Assessment:** Female offspring

**Exposure levels:** 0, and 5 mg/kg/day

**Exposure regimen:**

Gestational.  
GD 7-17, GD 10-17, GD 13-17, or GD 15-17.

**Group size:**

12-14 dams per group.  
10 pups per litter (M and F equal when possible).

**Timepoint(s) for mammary gland (MG) evaluation:**

PND 29, PND 32, and 18 months

**Related studies:**

Wolf et al. (2007)

**RESTRICTED-EXPOSURE STUDY**

**MG development (restricted exposure study)**

<i>MG development scores of whole mounts from female offspring exposed to 0 or 5 mg/kg/day during gestation</i>		
<i>Treatment group</i>	<i>PND 29</i>	<i>PND 32</i>
Control	3.6 ± 0.1	3.6 ± 0.1
GD 7-17	2.1 ± 0.1*	2.2 ± 0.2*
GD 10-17	2.0 ± 0.2*	2.2 ± 0.2*
GD 13-17	2.2 ± 0.1*	2.5 ± 0.1*
GD 15-17	2.0 ± 0.2*	2.3 ± 0.3*

\*p<0.05. n=10-21 per treatment group at each time point.  
Scored on a 1-4 scale adjusted for stage of development and age.

- At 18 months, MG examined both as whole mounts and as histological sections stained with H & E; n= 4-11 per group. (Could not be assessed with scoring criteria used at earlier time points.)
- Higher densities of darkly staining foci in glands of treated animals. Mean # foci/gland: Control, 1.5; GD 15-17, 29.8; GD 13-17, 17.9; GD 10-17, 32.8; GD 7-17, 25.5. No statistical parameters presented.
- Foci appear due to hyperplasia of ductal epithelium, infiltration of inflammatory cells into ductal regions, increased stromal density surrounding the ducts, and/or inappropriate differentiation of ductal epithelium. Some ductal inflammation in controls.
- Peripheral localized increases in epithelial density in whole mounts from many treated animals.

**Other endpoints in female offspring (restricted exposure study; from Wolf et al., 2007)**

- No effect on pup survival to weaning.
- No effect on body weight at birth.
- ↓ body weight starting on PND 2 in longest exposed groups (GD 7-17, GD 10-17) and in all groups on PND 7-22 (p<0.05 or lower).
- No ↓ body weight after PND 29.
- Delayed eye opening in all groups, significant (p<0.01) in longest exposed (GD 7-17, GD 10-17)
- ↑ relative liver weight on PND 22 in all exposed groups (p<0.001).

**PFOA SERUM LEVELS**


- Data for 5 mg/kg/day dams from early-life exposure study, and 5 mg/kg/day offspring from early-life exposure and late-life exposure studies presented graphically together for comparison. (3 mg/kg/day data not shown).
- Levels in treated dams decreased from LD (lactation day) 1-10.
- Levels in control dams nursing treated pups increased from LD 1-5.
- Levels in gestationally exposed pups were higher than in dams on PND 1.
- Levels in gestationally exposed (5U and 5U/5L) pups decreased from PND 1-63, with 5U (no lactational exposure) decreasing more quickly.
- Levels in lactation-only group (5L) offspring stated to be ~2000 ng/ml on PND 1 in text. Levels in 5L increased from PND 1-10, and then decreased from PND 22-42. Levels in 5L were similar to 5U on PND 10-22.
- Levels in all offspring groups had decreased to <1000 ng/ml at PND 63.
- Data from restricted exposure study from Wolf et al. (2007) discussed in text, not shown.

Reference and Study Design	Results					Comments	
<p><b>White et al. (2011).</b> Gestational and chronic low-dose PFOA exposures and mammary gland growth and differentiation in three generations of CD-1 mice.</p> <p><b>Species and strain:</b> Timed pregnant CD-1 mice and their offspring</p> <p><b>MG assessment:</b> Dams and female offspring</p> <p><b>Test article and vehicle:</b> PFOA (ammonium salt, &gt;98% pure) in deionized water or drinking water</p> <p><b>Route of exposure:</b> Oral gavage and/or drinking water</p> <p><b>Exposure levels:</b> 0, 1, or 5 mg/kg/day and/or 5 ppb in drinking water</p> <p><b>Exposure regimen (see study design figure in 2<sup>nd</sup> column, below):</b> Gestational through PND 63. 5 groups as follows: - Control - GD 1-17: 1 mg/kg/day (P0 dams) - GD 1-17: 5 mg/kg/day (P0 dams) - 5 ppb in drinking water (P0 dams on GD 7-17 and continuing for P0 dams, F1, and F2 until end of study on F2 PND 63). - 1 mg/kg/day (P0 dams, GD 1-17) + 5 ppb in drinking water (P0 dams on GD 7-17 and continuing for P0 dams, F1, and F2 until end of study on F2 PND 63).</p>	<b><i>MG DEVELOPMENT and LACTATIONAL EFFECTS (P0 and F1 dams; F1 and F2 female offspring)</i></b>					<p>- In <b>P0 dams</b>, MG development was delayed in the absence of overt maternal toxicity (decreased body weight or effects on reproductive parameters), suggesting that MG development is a more sensitive endpoint.</p> <p>Higher MG development scores of whole mounts in all treated <b>P0 dams</b> and 5 mg/kg/day <b>F1 dams</b> on PND 22 is indicative of delayed MG development. In these treated dams, MG at PND 22, when MG involution is normally seen at weaning, resembled normal MG on PND 10, the peak of lactation. This is consistent with observations in MG from these animals in H&amp;E stained slides. Results are also consistent with White et al. (2007), but also occurred in this study after 34 days of exposure to 5 ppb in drinking water.</p> <p>- In the <b>F1 female pups</b>, MG development was significantly delayed in all dosed groups including 5 ug/L in drinking water at PND 22, 42, and 63. MG development was delayed in 5 ppb drinking water group in the absence of effects on body weight or relative liver weight at any timepoint, indicating that it is a more sensitive endpoint.</p> <p>The PFOA serum levels in the <b>F1 pups</b> exposed to 5 ppb in drinking water ranged from 21.3 ng/ml on PND 22 to 66.2 ng/ml on PND 63 (compared to 0.6 and 3.1 ng/ml, respectively, at these times in the controls). Thus the LOAEL for delayed mammary gland development in the F1 pups is 21.3 ng/ml (the level on PND 22), and no NOAEL was identified.</p> <p>- In the <b>F1 dams</b> that were bred at 7-8 weeks of age, MG development was significantly delayed in all treated groups on PND 10 and in the 1 mg/kg/day + 5 ppb drinking water group on PND 22. Maternal toxicity (effects on reproductive parameters) occurred only in the 5 mg/kg/day group. These MG development delays are consistent with the delayed MG development in the virgin F1 siblings up to PND 63, the latest time point assessed (see above).</p>	
	<b><i>MG Development Scores of Whole Mounts from Female Dams and Offspring (1-4 scale)**</i></b>						
	<i>Treatment group</i>	<i>PND 10</i>	<i>PND 22</i>	<i>PND 42</i>	<i>PND 63</i>		
	<b><i>P0 dams (1 or 5 mg/kg/day, P0 GD 1-17 and/or 5 ppb in drinking water, P0 GD 7- F1 PND 22)</i></b>						
	Control	-----	2.4 ± 0.2	-----	-----		
	5 ppb in dw	-----	3.4 ± 0.1*	-----	-----		
	1 mg/kg/day	-----	3.0 ± 0.2*	-----	-----		
	1 mg/kg/day + 5 ppb in dw	-----	3.2 ± 0.2*	-----	-----		
	5 mg/kg/day	-----	3.9 ± 0.1*	-----	-----		
	<i>*p&lt;0.05 compared with control; n=7-11 per group.</i>						
	<i>Stated to be consistent with observations from H&amp;E stained slides (data not shown)</i>						
	<b><i>F1 female offspring (1 or 5 mg/kg/day, P0 GD 1-17 and/or 5 ppb in drinking water, P0 GD 7- F1 PND 63)</i></b>						
	Control	-----	3.8 ± 0.1	3.8 ± 0.1	3.8 ± 0.2		
	5 ppb in dw	-----	2.5 ± 0.2*	3.3 ± 0.2*	2.6 ± 0.4*		
	1 mg/kg/day	-----	2.3 ± 0.2*	2.6 ± 0.4*	2.9 ± 0.2*		
	1 mg/kg/day + 5 ppb in dw	-----	2.2 ± 0.1*	2.2 ± 0.3*	2.0 ± 0.3**		
	5 mg/kg/day	-----	1.6 ± 0.1*	2.0 ± 0.3*	2.2 ± 0.2*		
	<i>*p&lt;0.05 compared with control; **p&lt;0.05 compared with 1 mg/kg/day. n=4-10 per group.</i>						
	<b><i>F1 dams (1 or 5 mg/kg/day, P0 GD 1-17 and/or 5 ppb in drinking water, P0 GD 7- F2 PND 22)</i></b>						
	Control	4.0 ± 0.1	2.1 ± 0.3	-----	-----		
5 ppb in dw	2.8 ± 0.5*	2.2 ± 0.2	-----	-----			
1 mg/kg/day	2.5 ± 0.2*	1.9 ± 0.4	-----	-----			
1 mg/kg/day + 5 ppb in dw	2.0 ± 0.2*	1.5 ± 0.2*	-----	-----			
5 mg/kg/day	2.5 ± 0.2*	3.2 ± 0.3*	-----	-----			
<i>*p&lt;0.05 compared with control; n=4-10 per group. Bred to F1 males at age 7-8 weeks (PND 49-56).</i>							
<i>Evaluation of H&amp;E stained slides showed compromised lactational morphology in all treated groups on PND 10. On PND 22, only 5 mg/kg/day group differed from controls &amp; did not show normal regression at weaning.</i>							
<b><i>F2 female offspring (1 or 5 mg/kg/day, P0 GD 1-17 and/or 5 ppb in drinking water, P0 GD 7- F2 PND 63)</i></b>							
Control	2.8 ± 0.1	3.1 ± 0.4	3.5 ± 0.2	3.4 ± 0.2			
5 ppb in dw	3.0 ± 0.2	1.9 ± 0.3	2.5 ± 0.4*	3.5 ± 0.2			
1 mg/kg/day	1.9 ± 0.3	2.3 ± 0.1	3.4 ± 0.2	2.4 ± 0.2*			
1 mg/kg/day + 5 ppb in dw	2.6 ± 0.2	2.3 ± 0.2	2.4 ± 0.2**	2.6 ± 0.5			
5 mg/kg/day	2.0 ± 0.2	2.0 ± 0.2	3.3 ± 0.4	2.6 ± 0.4			
<i>*p&lt;0.05 compared with control; **p&lt;0.05 compared with 1 mg/kg/day. n=4-8 per group.</i>							
<b><i>**PFOA exposure through drinking water was 50-100 ng/day in pregnant P0 dams and lower in F1 offspring.</i></b>							



<p><b>White et al. (2011) (cont.)</b></p> <p><b>Group size:</b>  P0 dams: 7-12 per treatment group  F1 offspring: 12-13 per litter  F1 dams: 7-10 per treatment group  F2 offspring: 10 per litter</p> <p><b>Timepoint(s) for mammary gland (MG) evaluation:</b></p> <p>F0 dams: PND 22  F1 offspring: PND 22, PND 42, PND 63  F1 dams: PND 10, PND 22  F2 offspring: PND 10, PND 22, PND 42, PND 63</p>	<p><b><u>Lactational challenge in F1 dams and F2 litters on PND 10</u></b></p> <table border="1" data-bbox="540 191 1521 386"> <thead> <tr> <th><u>Treatment group</u></th> <th><u>Milk produced in 30 min (g)</u></th> <th><u>Time to initiate (sec)</u></th> </tr> </thead> <tbody> <tr> <td>Control</td> <td>2.10 ± 0.20</td> <td>267 ± 38</td> </tr> <tr> <td>5 ppb in dw</td> <td>1.80 ± 0.35</td> <td>384 ± 55</td> </tr> <tr> <td>1 mg/kg/day</td> <td>2.08 ± 0.25</td> <td>307 ± 114</td> </tr> <tr> <td>1 mg/kg/day + 5 ppb in dw</td> <td>1.40 ± 0.44</td> <td>351 ± 86</td> </tr> <tr> <td>5 mg/kg/day</td> <td>1.73 ± 0.51</td> <td>279 ± 30</td> </tr> </tbody> </table> <p><i>n=7-10 litters per group; n=10 offspring per litter.</i></p> <ul style="list-style-type: none"> <li>● Dams were separated from offspring for three hours, then returned to their litters and allowed to nurse for 30 minutes. The time between reunion and initiation to nurse and the weight of the 10-pup litter were recorded before and after precisely 30 minutes of nursing, in order to estimate the volume of milk produced during the nursing period.</li> <li>● Although not statistically significant, milk volume was ↓ and time to initiate nursing was ↑ in all treated groups compared to controls. High variability limited power to detect statistically significant differences.</li> </ul> <p><b><u>OTHER ENDPOINTS (n=4-10 per treatment group)</u></b></p> <p><u>Maternal body weight gain</u> – No significant effect in P0 dams (data not shown for F1 dams).</p> <p><u>Reproductive parameters (P0 and F1 dams)</u></p> <ul style="list-style-type: none"> <li>● No significant ↓ in number of implants or live fetuses, or ↑ prenatal loss or postnatal survival except in 5 mg/kg/day group.</li> <li>● In 5 mg/kg/day group, ↓ in number of implants (F1) and live fetuses (P0, F1), and ↑ prenatal loss (P0) and postnatal survival (F1).</li> </ul> <p><u>Female offspring (F1 and F2) - body weight, body weight excluding liver weight, and relative liver weight:</u></p> <p><u>F1 offspring:</u> All parameters assessed on PND 22, PND 42, and PND 63:</p> <ul style="list-style-type: none"> <li>● ↓ Body weight, and body weight excluding liver weight - 5 mg/kg/day (compared to control) on PND 42 (<math>p&lt;0.05</math>).</li> <li>● ↓ Body weight in 1 mg/kg/day + 5 ppb in drinking water group compared to 1 mg/kg/day on PND 63 (<math>p&lt;0.05</math>).</li> <li>● ↑ Relative liver weight - 1 mg/kg/day on PND 22, and 5 mg/kg/day (compared to control) on PND 22 and PND 42 (<math>p&lt;0.05</math>).</li> </ul> <p><u>F2 offspring:</u> Body weight assessed on PND 1, PND 3, PND 5, PND 10, PND 14, PND 17 and PND 22); Body weight excluding liver weight, and relative liver weight assessed on PND 22, PND 42, and PND 63):</p> <ul style="list-style-type: none"> <li>● No consistent effects on body weight. ↓ Body weight only in 5 ppb in drinking water group on PND 1 (<math>p&lt;0.05</math>).</li> <li>● ↑ Body weight (or body weight excluding liver weight) ↑ at a few timepoints in 1 mg/kg/day (with or without 5 ppb in drinking water) groups (<math>p&lt;0.05</math>).</li> <li>● Relative liver weight was not affected.</li> </ul> <p><b><u>PFOA SERUM LEVELS</u></b></p> <ul style="list-style-type: none"> <li>● Serum levels assessed in P0 and F1 dams on PND 22; in F1 and F2 female offspring on PND 22, 42, and 63.</li> <li>● Serum levels in dams exposed only to 5 ppb in drinking water were 75-87 ng/mL. Serum levels in F1 and F2 offspring were 21–69 ng/ml.</li> </ul>	<u>Treatment group</u>	<u>Milk produced in 30 min (g)</u>	<u>Time to initiate (sec)</u>	Control	2.10 ± 0.20	267 ± 38	5 ppb in dw	1.80 ± 0.35	384 ± 55	1 mg/kg/day	2.08 ± 0.25	307 ± 114	1 mg/kg/day + 5 ppb in dw	1.40 ± 0.44	351 ± 86	5 mg/kg/day	1.73 ± 0.51	279 ± 30	<p>- In the lactational challenge experiment with <b>F1 dams and F2 litters</b> on PND 10, milk produced in 30 minutes was decreased, and time to initiate nursing behavior was increased, in all treated groups compared to controls. However, none of the changes were statistically significant, possibly due to high variability and the small number of animals assessed. Additionally, postnatal survival and body weight were not affected in the treated F2 offspring, suggesting that the ability of the F1 dams to provide nutritional support was not decreased. However, it is not known if there were deficits in lactational function that were compensated for by increased frequency or longer duration of nursing events, since these parameters were not assessed.</p> <p>- The <b>F2 pups</b> showed a trend toward delayed mammary gland development, with decreased scores in all treated groups compared to controls at all time points (PND 10, 22, 42, and 63) except for the 5 ug/L drinking water group on PND 63. However, decreases were statistically significant only on PND 42 in the 5 ppb drinking water group and the 1 mg/kg/day + 5 ppb drinking water groups, and on PND 63 in the 1 mg/kg/day group. Serum levels in F2 pups exposed to 5 ppb in drinking water were 26.6 to 68.5 ng/ml, similar to the F1 pups with the same exposure (see above). In the F2 pups which were the offspring of dams exposed during development to 1 mg/kg/day or 5 mg/kg/day, but not exposed later through drinking water, serum levels at the various time points (PND 22, 42, and 63) ranged from 0.4 ng/ml (below controls) to 7.8 ng/ml.</p> <p><u>Summary:</u> Chronic exposure to 5 ppb PFOA in drinking water caused delayed MG development in both P0 and F1 dams and F1 and F2 offspring. MG development was delayed by exposure to 5 ppb in drinking water at all timepoints in F1 offspring and on PND 42 in F2 offspring. Delayed MG development was a more sensitive endpoint than decreased body weight in dams and offspring, reproductive effects in dams, and increased liver weight in offspring. The LOAEL based on serum PFOA levels for delayed MG development in the F1 pups is 21.3 ng/ml (the level on PND 22). No NOAEL was identified in this study.</p>
<u>Treatment group</u>	<u>Milk produced in 30 min (g)</u>	<u>Time to initiate (sec)</u>																		
Control	2.10 ± 0.20	267 ± 38																		
5 ppb in dw	1.80 ± 0.35	384 ± 55																		
1 mg/kg/day	2.08 ± 0.25	307 ± 114																		
1 mg/kg/day + 5 ppb in dw	1.40 ± 0.44	351 ± 86																		
5 mg/kg/day	1.73 ± 0.51	279 ± 30																		

White et al. (2011) (cont.)



**White et al. (2011) study design and experimental timeline:** Bar color denotes dose: green, 0 mg PFOA/kg body weight/day; yellow, 1 mg PFOA/kg body weight/day; red, 5 mg PFOA/kg body weight /day; blue, 5 ppb PFOA in drinking water. Bar thickness denotes timing of treatment: thick bars denote on-going direct treatment, thin bars denote only group identity subsequent to treatment.

**Appendix 5B-2: Publications/studies of mammary gland development after peripubertal exposure to PFOA in mice**

Reference & Study Design	Results	Comment																																																							
<p><b>Yang et al. (2009).</b> Differential effects of peripubertal exposure to perfluorooctanoic acid on mammary gland development in C57Bl/6 and Balb/c mouse strains.</p> <p><b>Species and strain:</b> Female Balb/C and C57Bl/6 mice</p> <p><b>Test article and vehicle:</b> PFOA (ammonium salt, &gt;98% pure) in deionized water</p> <p><b>Route of exposure:</b> Oral gavage</p> <p><b>Exposure levels:</b> 0, 1, 5 or 10 mg/kg/day</p> <p><b>Exposure regimen:</b> Peripubertal. Starting at age 3 weeks for 4 weeks (5 days per week).</p> <p><b>Group size:</b> 5 per strain per dose group</p> <p><b>Timepoint for mammary gland (MG) evaluation:</b> Age 7 weeks</p> <p><b>Related studies:</b> Zhao et al. (2010). Zhao et al. (2012).</p>	<p><b>MAMMARY GLAND DEVELOPMENT</b></p> <p><b>MG development in whole mounts from female 7 week old Balb/C and C57BL/6 mice treated with PFOA for 4 weeks (SEE ALSO SUMMARY TABLE AND GRAPH OF ALL 3 STUDIES FROM THIS LAB)</b></p> <table border="1" data-bbox="518 363 2080 743"> <thead> <tr> <th>Treatment (mg/kg/day)</th> <th>PFOA serum level (ug/ml)<sup>a</sup></th> <th>Ductal Length (relative units)</th> <th># Terminal End Buds (TEBs)</th> <th># Stimulated Terminal Ducts (TDs)</th> </tr> </thead> <tbody> <tr> <td colspan="5"><b>Balb/c</b></td> </tr> <tr> <td>0</td> <td>--</td> <td>7.60 ± 0.94</td> <td>8.20 ± 1.92</td> <td>6.20 ± 2.39</td> </tr> <tr> <td>1</td> <td>29 ± 4</td> <td>7.28 ± 0.73</td> <td>6.00 ± 3.74</td> <td>3.80 ± 1.64</td> </tr> <tr> <td>5</td> <td>109 ± 12</td> <td>3.99 ± 0.36*</td> <td>3.99 ± 0.36*</td> <td>1.20 ± 1.30*</td> </tr> <tr> <td>10</td> <td>---</td> <td>3.40 ± 4.77*</td> <td>0.00 ± 0.00*</td> <td>0.00 ± 0.00*</td> </tr> <tr> <td colspan="5"><b>C57BL/6</b></td> </tr> <tr> <td>0</td> <td>---</td> <td>4.76 ± 1.19</td> <td>7.80 ± 2.39</td> <td>6.60 ± 2.88</td> </tr> <tr> <td>1</td> <td>26 ± 6</td> <td>4.06 ± 0.85</td> <td>10.40 ± 3.36</td> <td>9.80 ± 2.77</td> </tr> <tr> <td>5</td> <td>68 ± 10</td> <td>4.01 ± 0.71</td> <td>11.20 ± 1.30*</td> <td>16.60 ± 5.90*</td> </tr> <tr> <td>10</td> <td>96 ± 10</td> <td>0.30 ± 0.67*</td> <td>0.00 ± 0.00*</td> <td>0.00 ± 0.00*</td> </tr> </tbody> </table> <p><sup>a</sup> Not reported in this study. Reported in Zhao et al. (2012) in bar graph form. Levels estimated from bar graph. n = 5 per group. * p&lt;0.05 compared to control. n=5 per strain per dose group.</p> <ul style="list-style-type: none"> <li>● MG development was delayed at 1, 5, and 10 mg/kg/day, in a dose-related fashion in Balb/C strain (p&lt;0.05 at two highest doses).</li> <li>● A lower dose, 0.1 mg/kg/day, had no effect on MG development in Balb/C mice (data not shown).</li> <li>● In C57BL/6 strain, MG development was stimulated at 5 mg/kg/day and totally arrested at 10 mg/kg/day.</li> </ul> <p><b>MG epithelial cell proliferation in TEBs/stimulated TDs and ducts in 7 week old Balb/C and C57BL/6 mice treated with PFOA for 4 weeks</b></p> <ul style="list-style-type: none"> <li>● Assessed in 1 and 5 mg/kg/day groups as % Brdu positive cells after treatment with Brdu 2 hours before sacrifice.</li> <li>● Data shown graphically and discussed in text.</li> <li>● In Balb/C, ↓ % proliferating cells in TEBs/stimulated TDs at 1 and 5 mg/kg/day (dose-related) and ducts at 5 mg/kg/day.</li> <li>● In C57BL/6, % proliferating cells in TEBs/stimulated TDs and ducts at both doses. Since # of TEBs/stimulated TDs was ↑ at 5 mg/kg/day, results indicate overall ↑ in MG epithelial cell proliferation at this dose.</li> </ul>	Treatment (mg/kg/day)	PFOA serum level (ug/ml) <sup>a</sup>	Ductal Length (relative units)	# Terminal End Buds (TEBs)	# Stimulated Terminal Ducts (TDs)	<b>Balb/c</b>					0	--	7.60 ± 0.94	8.20 ± 1.92	6.20 ± 2.39	1	29 ± 4	7.28 ± 0.73	6.00 ± 3.74	3.80 ± 1.64	5	109 ± 12	3.99 ± 0.36*	3.99 ± 0.36*	1.20 ± 1.30*	10	---	3.40 ± 4.77*	0.00 ± 0.00*	0.00 ± 0.00*	<b>C57BL/6</b>					0	---	4.76 ± 1.19	7.80 ± 2.39	6.60 ± 2.88	1	26 ± 6	4.06 ± 0.85	10.40 ± 3.36	9.80 ± 2.77	5	68 ± 10	4.01 ± 0.71	11.20 ± 1.30*	16.60 ± 5.90*	10	96 ± 10	0.30 ± 0.67*	0.00 ± 0.00*	0.00 ± 0.00*	<p>After peripubertal exposure to PFOA, MG development was delayed at 1-10 mg/kg/day in Balb/C mice. In C57BL/6 mice, MG development was stimulated at 1 and 5 mg/kg/day and delayed at 10 mg/kg/day. The range of serum PFOA levels was similar in the two strains of mice within the dose ranges mentioned above.</p> <p>The dose-response curve for MG development in the C57Bl/6 mice was non-monotonic, and the change from a large stimulatory effect to a large inhibitory effect occurred within a relatively small range of serum PFOA levels (68 µg/ml to 96 µg/ml). .</p> <p><u>Uterine development</u> followed a similar pattern of delay/simulation as MG development in the two strains. However, in C57BL/6, stimulation of uterine development occurred at 1 mg/kg/day but not 5 mg/kg/day.</p> <p><u>Vaginal opening</u> was delayed at all doses in both strains.</p> <p><u>Liver weight</u> was increased at all doses in both strains.</p> <p>In this study, PFOA exposure was during the peripubertal period, while exposure was prenatal and/or neonatal in White et al., 2007, 2009, 2011; Macon et al., 2011; and Tucker et al., 2015.</p> <p>PFOA serum levels from this study are not reported in this publication, but are reported in Zhao et al. (2012).</p>
Treatment (mg/kg/day)	PFOA serum level (ug/ml) <sup>a</sup>	Ductal Length (relative units)	# Terminal End Buds (TEBs)	# Stimulated Terminal Ducts (TDs)																																																					
<b>Balb/c</b>																																																									
0	--	7.60 ± 0.94	8.20 ± 1.92	6.20 ± 2.39																																																					
1	29 ± 4	7.28 ± 0.73	6.00 ± 3.74	3.80 ± 1.64																																																					
5	109 ± 12	3.99 ± 0.36*	3.99 ± 0.36*	1.20 ± 1.30*																																																					
10	---	3.40 ± 4.77*	0.00 ± 0.00*	0.00 ± 0.00*																																																					
<b>C57BL/6</b>																																																									
0	---	4.76 ± 1.19	7.80 ± 2.39	6.60 ± 2.88																																																					
1	26 ± 6	4.06 ± 0.85	10.40 ± 3.36	9.80 ± 2.77																																																					
5	68 ± 10	4.01 ± 0.71	11.20 ± 1.30*	16.60 ± 5.90*																																																					
10	96 ± 10	0.30 ± 0.67*	0.00 ± 0.00*	0.00 ± 0.00*																																																					



Reference & Study Design	Results	Comment
Yang et al. (2009). (continued)	<p style="text-align: center;"><b><u>OTHER ENDPOINTS</u></b></p> <p><u>Body weight:</u></p> <ul style="list-style-type: none"> <li>● Numerical data provided.</li> <li>● Body weight was unaffected except for decreased body weight at 10 mg/kg/day of both strains on the final 2 days of dosing (Day 19 and 20).</li> </ul> <p><u>Liver weight and histology:</u></p> <ul style="list-style-type: none"> <li>● Numerical data provided for liver weight.</li> <li>● In both strains, dose-related increase in absolute and relative weight. Significant (<math>p &lt; 0.05</math>) compared to control at all doses. Principal change seen in histological examination was dose-related increase in hepatocellular hypertrophy.</li> </ul> <p><u>Uterine weight and histology:</u></p> <ul style="list-style-type: none"> <li>● Numerical data provided for uterine weight.</li> <li>● In Balb/C, dose-related decrease in absolute and relative weight. Significant (<math>p &lt; 0.05</math>) compared to control at all doses. Histological evaluation also showed decreased uterine development.</li> <li>● In C57BL/6, absolute and relative uterine weight (<math>p &lt; 0.05</math>) and histological development were increased at 1 mg/kg/day, no effect at 5 mg/kg/day, and delayed at 10 mg/kg/day.</li> <li>● Effects were not due to differences between groups in stage of estrus cycle at sacrifice.</li> </ul> <p><u>Day of vaginal opening</u></p> <ul style="list-style-type: none"> <li>● Numerical data provided.</li> <li>● Delayed in a dose-related manner at all doses in both strains.</li> <li>● In Balb/C, delayed (<math>p &lt; 0.05</math>) compared to control at 1 mg/kg/day and did not occur by Day 50 (end of study) in 5 and 10 mg/kg/day.</li> <li>● In C57BL/6, delayed (<math>p &lt; 0.05</math>) compared to control at 1 and 5 mg/kg/day and did not occur by Day 50 (end of study) in 10 mg/kg/day.</li> </ul>	

Reference & Study Design	Results	Comment																																																																						
<p><b>Zhao et al. (2012).</b> Perfluorooctanoic acid effects on ovaries mediate its inhibition of peripubertal mammary gland development in Balb/c and C57Bl/6 mice</p> <p><b>Species and strain:</b> Female Balb/C, C57Bl/6 Wild Type (WT), and C57Bl/6 PPAR-alpha null (KO) mice</p> <p><b>Test article and vehicle:</b> PFOA (ammonium salt, &gt;98% pure) in deionized water</p> <p><b>Route of exposure:</b> Oral gavage</p> <p><b>Exposure levels:</b> 0 or 2.5 mg/kg/day (Balb/C)</p> <p>0 or 7.5 mg/kg/day(C57BL/6 WT &amp; KO)</p> <p><b>PFOA exposure regimen:</b> Peripubertal. Starting at age 3 weeks for 4 weeks (5 days per week)).</p> <p>In study of effect of estradiol and progesterone, starting at age 3 weeks for 2 weeks. Estradiol and progesterone treatment during 2<sup>nd</sup> week of PFOA treatment.</p> <p><b>Group size:</b> 5-10</p> <p><b>Timepoint for MG evaluation:</b> 50 days (7 weeks). 356 days (5 weeks) for studies of effect of estradiol and progesterone.</p>	<p><b><u>MAMMARY GLAND DEVELOPMENT</u></b></p> <p><b><u>MG development in whole mounts from female 7 week old Balb/C, C57BL/6 WT, and C57BL/6 PPAR-null (KO) mice treated with PFOA for 4 weeks (SEE ALSO SUMMARY TABLE AND GRAPH OF 3 STUDIES FROM THIS LAB BELOW)</u></b></p> <table border="1" data-bbox="588 293 2050 797"> <thead> <tr> <th>Treatment (mg/kg/day)</th> <th>PFOA serum level (ng/ml)<sup>a</sup></th> <th>Ductal Length (relative units)</th> <th># Terminal End Buds (TEBs)</th> <th># Stimulated Terminal Ducts (TDs)</th> <th>Absolute MG Weight (g)</th> <th>Relative MG Weight (%)</th> </tr> </thead> <tbody> <tr> <td colspan="7"><b>Balb/c</b></td> </tr> <tr> <td>0</td> <td>--</td> <td>8.17 ± 1.08</td> <td>7.40 ± 1.14</td> <td>6.11 ± 2.52</td> <td>0.09±0.004</td> <td>0.51±0.04</td> </tr> <tr> <td>2.5</td> <td>51,000± 8000</td> <td>4.99 ± 0.67*</td> <td>3.25 ± 0.95*</td> <td>2.63 ± 1.41*</td> <td>0.11±0.024</td> <td>0.63±0.13</td> </tr> <tr> <td colspan="7"><b>C57BL/6 WT</b></td> </tr> <tr> <td>0</td> <td>--</td> <td>6.30 ± 0.96</td> <td>6.25 ± 2.06</td> <td>6.50 ± 2.89</td> <td>0.15±0.035</td> <td>0.77±0.18</td> </tr> <tr> <td>7.5</td> <td>93,000±11,000</td> <td>2.10 ± 1.98*</td> <td>1.00 ± 1.41*</td> <td>0.80 ± 1.31*</td> <td>0.11±0.026</td> <td>0.66±0.13</td> </tr> <tr> <td colspan="7"><b>C57BL/6 PPAR-null (KO)</b></td> </tr> <tr> <td>0</td> <td>--</td> <td>8.90 ± 1.04</td> <td>10.00 ± 4.36</td> <td>6.20 ± 1.64</td> <td>0.17±0.035</td> <td>0.88±0.21</td> </tr> <tr> <td>7.5</td> <td>38,000 ± 7000</td> <td>8.43 ± 1.08</td> <td>9.43 ± 1.90</td> <td>7.02 ± 2.16</td> <td>0.14±0.026</td> <td>0.78±0.11</td> </tr> </tbody> </table> <p>*p&lt;0.05 compared to control. n=5 per strain per dose group. <sup>a</sup> Levels estimated from bar graph. n = 5 per group.</p> <ul style="list-style-type: none"> <li>● Doses of PFOA (2.5 mg/kg/day in Balb/C mice and 7.5 mg/kg/day in WT and KO mice) were chosen because they were lower than the LOAELs for delayed MG development in Balb/C (5 mg/kg/day) and WT (10 mg/kg/day) strains in the previous study (Yang et al., 2009). The goal was to further study the delayed MG development caused by PFOA in these strains.</li> <li>● MG development was inhibited in Balb/C and WT mice, and was not affected in KO mice, by the PFOA doses used in this study..</li> </ul> <p>In <u>Balb/C mice</u>, the PFOA serum level and the MG development delay at 2.5 mg/kg/day were intermediate to the serum PFOA levels and MG development delays at 1 mg/kg/day and 5 mg/kg/day in this strain in Yang et al. (2009).</p> <p>In <u>WT mice</u>, the PFOA serum level (93,000±11,000 ng/ml) at 7.5 mg/kg/day in this study is very close to the PFOA serum level at 10 mg/kg/day (96,000±10,000 ng/ml) in the earlier study (Yang et al., 2009). MG development was delayed at both of these doses in these two studies. The serum level (68,000±10,000 ng/ml) at which MG development was reported to be greatly stimulated in Yang et al. (2009) is relatively close to the serum levels where MG development was delayed.</p> <p>In <u>KO mice</u>, PFOA (7.5 mg/kg/day) did not affect MG development. However, serum PFOA levels in KO mice (38,000 ± 7000 ng/ml) were much lower than the serum level where MG was inhibited in WT mice. It is stated that in KO mice treated with 10 mg/kg/day, the serum levels were similar to those at 7.5 mg/kg/day and there was no effect on MG development (data not shown). Because the serum levels in KO mice were lower than those in WT mice where MG development was delayed, no conclusions about PPAR-alpha dependence of delayed MG development can be made from these data.</p>	Treatment (mg/kg/day)	PFOA serum level (ng/ml) <sup>a</sup>	Ductal Length (relative units)	# Terminal End Buds (TEBs)	# Stimulated Terminal Ducts (TDs)	Absolute MG Weight (g)	Relative MG Weight (%)	<b>Balb/c</b>							0	--	8.17 ± 1.08	7.40 ± 1.14	6.11 ± 2.52	0.09±0.004	0.51±0.04	2.5	51,000± 8000	4.99 ± 0.67*	3.25 ± 0.95*	2.63 ± 1.41*	0.11±0.024	0.63±0.13	<b>C57BL/6 WT</b>							0	--	6.30 ± 0.96	6.25 ± 2.06	6.50 ± 2.89	0.15±0.035	0.77±0.18	7.5	93,000±11,000	2.10 ± 1.98*	1.00 ± 1.41*	0.80 ± 1.31*	0.11±0.026	0.66±0.13	<b>C57BL/6 PPAR-null (KO)</b>							0	--	8.90 ± 1.04	10.00 ± 4.36	6.20 ± 1.64	0.17±0.035	0.88±0.21	7.5	38,000 ± 7000	8.43 ± 1.08	9.43 ± 1.90	7.02 ± 2.16	0.14±0.026	0.78±0.11	<p>The purpose of this study was to evaluate effects on MG development from peripubertal exposure to doses lower than those that caused delayed MG development in Balb/C and C57Bl/6 WT mice in an earlier study (Yang et al., 2009). Effects in PPAR-alpha null mice were also studied.</p> <p>In Balb/C mice, inhibition of MG development occurred at 2.5 mg/kg/day, lower than the LOAEL of 5 mg/kg/day identified in Yang et al.(2009).</p> <p>In C57BL/6 WT mice, inhibition of MG development occurred at 7.5 mg/kg/day, lower than the LOAEL of 10 mg/kg/day identified in Yang et al. (2009). In Yang et al. (2009), 5 mg/kg/day was reported to stimulate MG development in this strain.</p> <p>In C57BL/6 PPAR alpha null (KO) mice, 7.5 mg/kg/day PFOA had no effect on MG development. Lack of inhibition of MG development in C57Bl/6 KO, as compared to the other two strains, in this study, may be due to kinetic factors unrelated to PPAR status. PFOA serum levels in KO mice were below the serum levels at which MG development was delayed in the other two strains of mice.</p>
Treatment (mg/kg/day)	PFOA serum level (ng/ml) <sup>a</sup>	Ductal Length (relative units)	# Terminal End Buds (TEBs)	# Stimulated Terminal Ducts (TDs)	Absolute MG Weight (g)	Relative MG Weight (%)																																																																		
<b>Balb/c</b>																																																																								
0	--	8.17 ± 1.08	7.40 ± 1.14	6.11 ± 2.52	0.09±0.004	0.51±0.04																																																																		
2.5	51,000± 8000	4.99 ± 0.67*	3.25 ± 0.95*	2.63 ± 1.41*	0.11±0.024	0.63±0.13																																																																		
<b>C57BL/6 WT</b>																																																																								
0	--	6.30 ± 0.96	6.25 ± 2.06	6.50 ± 2.89	0.15±0.035	0.77±0.18																																																																		
7.5	93,000±11,000	2.10 ± 1.98*	1.00 ± 1.41*	0.80 ± 1.31*	0.11±0.026	0.66±0.13																																																																		
<b>C57BL/6 PPAR-null (KO)</b>																																																																								
0	--	8.90 ± 1.04	10.00 ± 4.36	6.20 ± 1.64	0.17±0.035	0.88±0.21																																																																		
7.5	38,000 ± 7000	8.43 ± 1.08	9.43 ± 1.90	7.02 ± 2.16	0.14±0.026	0.78±0.11																																																																		

Reference & Study Design	Results	Comment
<p><b>Zhao et al. (2012). (continued)</b></p> <p><b>Related studies:</b> Yang et al. (2009). Zhao et al. (2010).</p>	<ul style="list-style-type: none"> <li>● PFOA had no effect on absolute or relative weight of mammary glands/fat pads. <ul style="list-style-type: none"> <li>● Absence of corpus lutea and uterine changes in Balb/C and WT stated to be indicative of absence of estrous cycling.</li> </ul> </li> </ul> <p><b><u>MG development in whole mounts from 5 week old Balb/C and C57BL/6 WT mice after 2 weeks of PFOA treatment, with or without estradiol and/or progesterone treatment during final week</u></b></p> <ul style="list-style-type: none"> <li>● Balb/C mice were dosed with PFOA at 2.5 mg/kg/day, and WT mice with 7.5 mg/kg/day, for 2 weeks. KO mice were not included in this component of the study.</li> <li>● During the second week, 5 mice from PFOA-treated groups in each strain were either not treated with hormones, or dosed with estrogen (0.1 ug/mouse), progesterone (0.1 mg/mouse), or both, by subcutaneous injection. Data on effects of hormones in controls (no PFOA treatment) are not shown.</li> </ul> <p>These doses of hormones were stated to be physiological levels of these hormones. n=5 per group. Mice were sacrificed 24 hours after last dose.</p> <ul style="list-style-type: none"> <li>● MG data are shown numerically for ductal length, number of TEBs, and absolute and relative mammary gland weight.</li> <li>● In mice from both strains that were not dosed with hormones, PFOA caused delayed MG development (decreased ductal length and number of TEBs), and there was no effect on MG weight. These results are consistent with the MG gland development delays at the same administered doses in these strains of mice in the first component of study (above). Serum PFOA levels were not measured in this second component of the study.</li> <li>● Hormone treatment (estradiol, progesterone, or both) prevented the delayed MG development caused by PFOA in both strains. Hormone treatment is stated to have no effect on MG development in mice not treated with PFOA (data not shown).</li> </ul> <p><b><u>Levels of growth factors, receptors, and cell proliferation marker in MG</u></b></p> <ul style="list-style-type: none"> <li>● MG levels of 2 growth factors (Areg and HGF alpha), two receptors (ER alpha and EGFR), and a cell proliferation marker (PCNA) were also assessed.</li> <li>● PFOA (in the absence of hormone treatment) decreased the levels of Areg, EGFR, and PCNA in both strains of mice compared to untreated control (n = 3 per group; data shown in bar graphs). Hormone treatment in mice dosed with PFOA (Balb/C and WT) increased the levels of these factors above those in untreated controls not given PFOA or hormones (p&lt;0.05 for all effects).</li> </ul> <p><b><u>OTHER ENDPOINTS (in 7 wk old mice after 4 wks of PFOA treatment (Balb/C - 7.5 mg/kg/day; WT &amp; KO - 2.5 mg/kg/day))</u></b></p> <p><b><u>Body weight:</u></b></p> <ul style="list-style-type: none"> <li>● PFOA treatment caused no significant effects except decrease (p&lt;0.05) in WT treated with 7.5 mg/kg/day during 4<sup>th</sup> (last) week of dosing (n=5 per group). Data shown graphically.</li> </ul>	<p>In Zhao et al. (2010), 5 mg/kg/day PFOA was reported to stimulate MG development similarly in KO and WT mice. The authors concluded that the stimulatory effect on MG development was PPAR alpha independent (Zhao et al., 2010). However, in Zhao et al. (2012) presented here, there was no effect on MG development in KO mice dosed with 7.5 mg/kg/day at a PFOA serum level of 38 ppb (Zhao et al., 2012). This serum level is within the range of PFOA serum levels (26 to 68 ppb) at which MG development was stimulated in WT mice (Yang et al., 2009).</p> <p>Considering these data together, a definitive conclusion about whether the stimulation is PPAR-dependent or independent cannot be made. There are no numerical data or concurrent comparisons with WT for the single data point where stimulation in KO mice was reported. Alternatively, the dose-response for stimulation of MG development may be very different in KO mice than WT mice.</p>

Reference & Study Design	Results	Comment
Zhao et al. (2012). (continued)	<p><b><u>Day of vaginal opening, presence of corpus lutea in ovary, and uterine histology:</u></b></p> <ul style="list-style-type: none"> <li>● Vaginal opening data presented numerically, other information presented in text. n=5 per group. <ul style="list-style-type: none"> <li>● PFOA treatment delayed vaginal opening in Balb/C and WT (p&lt;0.05), but not KO.</li> <li>● PFOA prevented development of corpus lutea present in Balb/C and WT, but had no effect in KO.</li> <li>● PFOA caused thinning of uterine myometrium and endometrium thinned Balb/C and WT; no changes in KO.</li> <li>● Absence of corpus lutea and uterine changes in Balb/C and WT stated to be indicative of absence of estrous cycling.</li> </ul> </li> </ul> <p><b><u>Levels of ovarian enzymes related to steroid hormone synthesis and PPAR alpha</u></b></p> <ul style="list-style-type: none"> <li>● PFOA treatment in both Balb/C and WT mice <u>decreased</u> (p&lt;0.05) levels of 4 ovarian enzymes related to synthesis of steroid hormones (StAR, CYP11A1, HSD3beta1, HSD17beta1) and had no effect on aromatase. PFOA did not affect these enzymes in KO mice (n=3 per group).</li> <li>● PFOA treatment did not affect ovarian PPAR alpha levels. Ovarian PPAR alpha was higher (p&lt;0.05) in Balb/C (1.00 ± 0.20) than WT (0.43 ± 0.19), and was not measured in KO mice. Units not stated.</li> </ul> <p><b><u>MG levels of ovarian growth factors, receptors, and cell proliferation marker in Balb/C, WT, and KO mice</u></b></p> <ul style="list-style-type: none"> <li>● Levels of 3 growth factors (Areg, IGF-I, HGF), 2 receptors (ERalpha, EGFR), and the cell proliferation marker PCNA were assessed in ovaries. (Data shown in bar graphs. n = 3 per group).</li> <li>● In Balb/C and WT mice, PFOA <u>decreased</u> 2 growth factors (Areg and HGF), <u>decreased</u> both receptors (ERalpha, EGFR), and <u>decreased</u> PCNA (p&lt;0.05) in Balb/C and WT mice. PFOA had no effect on IGF-I.</li> <li>● PFOA had <u>no effect</u> on any parameter in KO mice. <ul style="list-style-type: none"> <li>● These results are not consistent with the results in WT and KO mice dosed with 5 mg/kg/day PFOA for 4 weeks from Zhao et al. (2010). Ovarian levels of 3 growth factors (Areg, IGF-I, HGF), 2 receptors (ERalpha, EGFR), and 2 cell proliferation markers (cyclin D1, PCNA) were assessed (see above).</li> <li>● 5 mg/kg/day PFOA <u>increased</u> all 3 growth factors in KO mice and 2 growth factors in WT mice (1.5-2.7 fold, p&lt;0.05); <u>increased</u> both receptors in WT and KO mice, and <u>increased</u> both markers of cell proliferation) in both WT and KO mice</li> </ul> </li> </ul> <p><b><u>Estrogen and progesterone levels</u></b></p> <ul style="list-style-type: none"> <li>● It is not known if estrogen and progesterone levels were affected by PFOA treatment. The authors state that this could not be assessed due to insufficient numbers of animals in each stage of estrous. However, delayed vaginal opening, absence of corpus lutea, and abnormal uterine histology suggest abnormal ovarian function and decreased hormone levels.</li> </ul> <p><b><u>Kidney organic anion transporters (OATs):</u></b></p> <ul style="list-style-type: none"> <li>● Expression of 7 OATs was measured in kidneys from the three strains of mice (control and PFOA-treated).</li> <li>● In control &amp; PFOA-treated mice, levels of 3 OATs were higher in KO than Balb/C, &amp; 2 of these OATs were higher in WT than Balb/C.</li> <li>● PFOA treatment did not affect levels of OATs expression.</li> <li>● This endpoint is of interest in evaluation of strain differences in serum PFOA levels from same administered dose, but is not directly relevant to the evaluation of effects of PFOA on MG development.</li> </ul>	<p>Additionally, it is difficult to interpret the effects seen in Yang et al. (2009) and in this study in C57BL/6 WT mice because the dose-response between 5 and 7.5 mg/kg/day was not evaluated within the same study. The 5 and 10 mg/kg/day doses were not included along with 7.5 mg/kg/day dose in this study. The two doses and serum levels are close together (68 versus 93 µg/ml), yet opposite effects on MG development (stimulation versus strong inhibition) were reported at the lower versus higher dose. This implies that that a very steep dose-response curve exists for stimulation versus inhibition, and that there is a dose between 5 and 7.5 mg/kg/day and a serum level between 68 and 93 µg/ml where no effect occurs. These data cannot be validly interpreted in the absence of data at both doses from the same study.</p> <p>Similarly, it is difficult to interpret the opposite effects of PFOA at 5 versus 7.5 mg/kg/day on ovarian enzymes related to hormone synthesis, and MG growth factors, receptors, and markers of proliferation, since the data at each dose comes from a different study.</p>

Reference & Study Design	Results	Comment
	<p><b><u>SERUM PFOA LEVELS</u></b></p> <ul style="list-style-type: none"><li>● Serum PFOA levels from 3 studies (this study; Yang et al., 2009; and Zhao et al., 2010) are presented in this study. Numerical data are not shown and were estimated from the bar graph. n = 5 per group. These estimated numerical data are shown in the table on MG developmental effects above, and in the tables presenting the other two studies.</li><li>● Serum PFOA levels were not measured in the component of this study in which the effects of estradiol and progesterone given along with PFOA were studied.</li></ul>	

**SUPPLEMENTAL TABLE: Mammary gland development parameters and serum PFOA levels from female 7 week old Balb/C and C57BL/6 mice treated with PFOA for 4 weeks**

<u>Treatment</u> (mg/kg/day) <i>Balb/c</i>	<u>Citation</u> <sup>a</sup>	<u>Serum PFOA</u> <sup>b</sup> (µg/ml)	<u>Ductal Length</u> (relative units)	<u>% Control</u>	<u># Terminal End Buds</u> (TEBs)	<u>% Control</u>	<u># Stimulated Terminal Ducts</u> (TDs)	<u>% Control</u>
<b><i>Balb/C</i></b>								
0	1	--	7.60 ± 0.94	--	8.20 ± 1.92	--	6.20 ± 2.39	--
0	3	--	8.17 ± 1.08	--	7.40 ± 1.14	--	6.11 ± 2.52	--
1	1	29 ± 4	7.28 ± 0.73	96%	6.00 ± 3.74	73	3.80 ± 1.64	61
2.5	3	51 ± 8	4.99 ± 0.67*	61	3.25 ± 0.95*	44	2.63 ± 1.41*	43
5	1	109 ± 12	3.99 ± 0.36*	53%	3.99 ± 0.36*	49	1.20 ± 1.30*	19
10	1	---	3.40 ± 4.77*	45	0.00 ± 0.00*	0	0.00 ± 0.00*	0
<b><i>C57BL/6 Wild Type</i></b>								
0	1	--	4.76 ± 1.19	--	7.80 ± 2.39	--	6.60 ± 2.88	--
0	3	--	6.30 ± 0.96	--	6.25 ± 2.06	--	6.50 ± 2.89	--
1	1	26 ± 6	4.06 ± 0.85	85	10.40 ± 3.36	133	9.80 ± 2.77	148
5	1	68 ± 10	4.01 ± 0.71	84	11.20 ± 1.30*	144	16.60 ± 5.90*	252
7.5	3	93 ± 11	2.10 ± 1.98*	33	1.00 ± 1.41*	16	0.80 ± 1.31*	12
10	1	96 ± 10	0.30 ± 0.67*	6	0.00 ± 0.00*	0	0.00 ± 0.00*	0
<b><i>C57BL/6 PPAR-null (KO)</i></b>								
0	3	---	8.90 ± 1.04	---	10.00 ± 4.36	---	6.20 ± 1.64	---
5	2	28 ± 2	Terminal end buds and stimulated terminal ducts stated to be <b>INCREASED</b> . Numerical data not shown.					
7.5	3	38 ± 7	8.43 ± 1.08	95	9.43 ± 1.90	94	7.02 ± 2.16	113

<sup>a</sup> Citations are: 1. Yang et al. (2009); 2. Zhao et al. (2010); 3. Zhao et al. (2012).


<sup>b</sup> PFOA serum data from all 3 studies are presented in a bar graph in Zhao et al. (2012). Numerical values were extrapolated from the bar graph.

\*P<0.05 compared to control. n=5 per strain per dose group.

**Appendix 6: Outputs of Benchmark Dose Modeling for Mammary Gland Development Endpoints (Macon et al., 2011)**

**Appendix 6A: Benchmark Dose Modeling of Mammary Gland Developmental Score in Response to PFOA Using BMR of 10% Decrease Relative to Controls (Macon et al., 2011)**





14:10 05/04 2011

---

Hill Model. (Version: 2.15; Date: 10/28/2009)  
 Input Data File: C:/USEPA/EMCS212/Data/hil\_pfoa mammary\_opt.(d)  
 Graphot Plotting File: C:/USEPA/EMCS212/Data/hil\_pfoa mammary\_opt.plt  
 Wed May 04 14:10:58 2011

---

EMCS Model Run

---

The form of the response function is:

$$Y(\text{dose}) = \text{intercept} + v \cdot \text{dose}^n / (k^n + \text{dose}^n)$$

Dependent variable = dev\_score  
 Independent variable = seroed\_serum  
 rho is set to 0  
 Power parameter restricted to be greater than 1  
 A constant variance model is fit

Total number of dose groups = 4  
 Total number of records with missing values = 0  
 Maximum number of iterations = 250  
 Relative Function Convergence has been set to: 1e-008  
 Parameter Convergence has been set to: 1e-008

Default Initial Parameter Values

alpha = 0.331538  
 rho = 0 Specified  
 intercept = 3.3  
 v = -1.7  
 n = 1.59127  
 k = 202.323

Asymptotic Correlation Matrix of Parameter Estimates

( \*\*\* The model parameter(s) -rho -n  
 have been estimated at a boundary point, or have been  
 specified by the user,  
 and do not appear in the correlation matrix )

	alpha	intercept	v	k
alpha	1	-2.2e-011	-9.9e-008	6.4e-008
intercept	-2.2e-011	1	-0.74	-0.27
v	-9.9e-008	-0.74	1	-0.17
k	6.4e-008	-0.27	-0.17	1

Parameter Estimates

Interval	Variable	Estimate	Std. Err.	95.0% Wald Confidence	
Conf. Limit				Lower Conf. Limit	Upper
0.298673	alpha	0.178604	0.0612607	0.0585353	
3.68968	intercept	3.29993	0.189163	2.92818	
-1.18402	v	-1.67528	0.250648	-2.16654	
	n	1	NA		
332.058	k	141.808	97.0679	-48.4413	

NA - Indicates that this parameter has hit a bound implied by some inequality constraint and thus has no standard error.

Table of Data and Estimated Values of Interest

Dose	N	Obs Mean	Est Mean	Obs Std Dev	Est Std Dev	Scaled Res.
0	5	3.3	3.3	0.67	0.423	0.00565
261.7	4	2.2	2.21	0.4	0.423	-0.0597
2281	3	1.8	1.72	0.52	0.423	0.321
1.628e+004	5	1.6	1.64	0.22	0.423	-
0.282						

## Model Descriptions for likelihoods calculated

$$\text{Model A1: } Y_{ij} = \mu_0(i) + e(i,j) \\ \text{Var}(e(i,j)) = \sigma^2$$

$$\text{Model A2: } Y_{ij} = \mu_0(i) + e(i,j) \\ \text{Var}(e(i,j)) = \sigma(i)^2$$

$$\text{Model A3: } Y_{ij} = \mu_0(i) + e(i,j) \\ \text{Var}(e(i,j)) = \sigma^2$$

Model A3 uses any fixed variance parameters that were specified by the user

$$\text{Model R: } Y_i = \mu_0 + e(i) \\ \text{Var}(e(i)) = \sigma^2$$

## Likelihoods of Interest

Model	Log(Likelihood)	# Param's	AIC
A1	6.215023	5	-2.431646
A2	0.939248	8	-1.998497
A3	6.215023	5	-2.431646
fitted	6.141961	4	-4.283223
R	-4.983702	2	13.967403

## Explanation of Tests

- Test 1: Do responses and/or variances differ among Dose levels? (A2 vs. R)  
 Test 2: Are Variances Homogeneous? (A1 vs A2)  
 Test 3: Are variances adequately modeled? (A2 vs. A3)  
 Test 4: Does the Model for the Mean Fit? (A3 vs. fitted)  
 (Note: When  $\rho=0$  the results of Test 3 and Test 2 will be the same.)

## Tests of Interest

Test	$-2 \cdot \log(\text{Likelihood Ratio})$	Test df	p-value
Test 1	27.9659	6	<.0001
Test 2	5.5685	3	0.1347
Test 3	5.5685	3	0.1347
Test 4	0.14723	1	0.7007

The p-value for Test 1 is less than .05. There appears to be a difference between responses and/or variances among the dose levels. It seems appropriate to model the data.


The p-value for Test 2 is greater than .1. A homogeneous variance model appears to be appropriate here.

The p-value for Test 3 is greater than .1. The modeled variance appears to be appropriate here.

The p-value for Test 4 is greater than .1. The model chosen seems to adequately describe the data.

## Benchmark Dose Computation

Specified effect =	0.1
Risk Type =	Relative risk
Confidence level =	0.95
MMD =	34.7317
IHDR =	5.51541



11:43 05/04 2011

---

Polynomial Model. (Version: 2.16; Date: 05/26/2010)  
 Input Data File: C:/USEEPA/BMDS212/Data/ply\_pfoa mammary\_Opt.(d)  
 Graphlet Plotting File: C:/USEEPA/BMDS212/Data/ply\_pfoa mammary\_Opt.plt  
 Wed May 04 11:43:35 2011

---



---

#### BMDS Model Run

---

The form of the response function is:

$$Y(\text{dose}) = \text{beta}_0 + \text{beta}_1 \cdot \text{dose} + \text{beta}_2 \cdot \text{dose}^2 + \dots$$

Dependent variable = dev\_score  
 Independent variable = seroed\_log\_serum  
 rho is set to 0  
 Signs of the polynomial coefficients are not restricted  
 A constant variance model is fit

Total number of dose groups = 4  
 Total number of records with missing values = 0  
 Maximum number of iterations = 250  
 Relative Function Convergence has been set to: 1e-008  
 Parameter Convergence has been set to: 1e-008



Default Initial Parameter Values

alpha = 0.231538  
 rho = 0 Specified  
 beta\_0 = 3.30302  
 beta\_1 = -0.544614  
 beta\_2 = 0.032366

Asymptotic Correlation Matrix of Parameter Estimates

( \*\*\* The model parameter(s) -rho  
 have been estimated at a boundary point, or have been  
 specified by the user,  
 and do not appear in the correlation matrix )

	alpha	beta_0	beta_1	beta_2
alpha	1	3.7e-008	8.9e-008	-1e-007
beta_0	3.7e-008	1	-0.51	0.32
beta_1	8.9e-008	-0.51	1	-0.96
beta_2	-1e-007	0.32	-0.96	1

Parameter Estimates

Interval	Variable	Estimate	Std. Err.	95.0% Wald Confidence	
Conf. Limit				Lower Conf. Limit	Upper
0.296886	alpha	0.177536	0.0600942	0.0581851	
3.47089	beta_0	3.30304	0.188191	2.93319	
-0.6916905	beta_1	-0.541826	0.230176	-0.992962	
0.139975	beta_2	0.0320545	0.0550625	-0.075866	

Table of Data and Estimated Values of Interest

Dose	N	Obs Mean	Est Mean	Obs Std Dev	Est Std Dev	Scaled Res.
0	5	3.3	3.3	0.67	0.421	-0.0108
2.42	4	2.2	2.18	0.4	0.421	0.102
3.36	3	1.8	1.84	0.52	0.421	-0.178
4.21	5	1.6	1.59	0.22	0.421	0.0579

Model Descriptions for likelihoods calculated

Model A1:  $Y_{ij} = \mu_0(i) + \epsilon(i,j)$   
 $Var[\epsilon(i,j)] = \sigma^2$

Model A2:  $Y_{ij} = \mu_{0(i)} + \epsilon_{ij}$   
 $\text{Var}(\epsilon_{ij}) = \text{Sigma}(i)^2$

Model A3:  $Y_{ij} = \mu_{0(i)} + \epsilon_{ij}$   
 $\text{Var}(\epsilon_{ij}) = \text{Sigma}^2$

Model A3 uses any fixed variance parameters that were specified by the user

Model B:  $Y_i = \mu_0 + \epsilon(i)$   
 $\text{Var}(\epsilon(i)) = \text{Sigma}^2$

#### Likelihoods of Interest

Model	Log(Likelihood)	# Param's	AIC
A1	6.215823	5	-2.431646
A2	8.999248	8	-1.958497
A3	6.215823	5	-2.431646
Fitted	6.192967	4	-4.385934
B	-4.983702	2	13.307403

#### Explanation of Tests

- Test 1: Do responses and/or variances differ among Dose levels? (A2 vs. B)  
 Test 2: Are Variances Homogeneous? (A1 vs A2)  
 Test 3: Are variances adequately modeled? (A2 vs. A3)  
 Test 4: Does the Model for the Mean Fit? (A3 vs. fitted)  
 (Note: When rho=0 the results of Test 3 and Test 2 will be the same.)

#### Tests of Interest

Test	-2*log(Likelihood Ratio)	Test df	p-value
Test 1	27.9659	6	<.0001
Test 2	5.56685	3	0.1347
Test 3	5.56685	3	0.1347
Test 4	0.0457118	1	0.8307

The p-value for Test 1 is less than .05. There appears to be a difference between response and/or variances among the dose levels. It seems appropriate to model the data.

The p-value for Test 2 is greater than .1. A homogeneous variance model appears to be appropriate here.

The p-value for Test 3 is greater than .1. The modeled variance appears to be appropriate here.

The p-value for Test 4 is greater than .1. The model chosen seems to adequately describe the data.

#### Benchmark Dose Computation

Specified effect = 0.1

Risk Type = Relative risk


Confidence level = 0.95



EMD = 0.633144

EMDL = 0.387553

EMDL computation failed for one or more point on the EMDL curve.  
The EMDL curve will not be plotted



11:16 05/04/2011

---

Exponential Model. (Version: 1.7; Date: 12/10/2009)  
 Input Data File: C:\USER\FR\BMD53212\Data\exp\_pfoa\_summary\_Setting\_(d)  
 Output Plotting File:

Wed May 04 11:16:37 2011

---

**BMD5 Model Res**

---

The form of the response function by Model:

- Model 2:  $Y[dose] = a * \exp[sign * b * dose]$
- Model 3:  $Y[dose] = a * \exp[sign * (b * dose)^d]$
- Model 4:  $Y[dose] = a * [c - (c-1) * \exp[-b * dose]]$
- Model 5:  $Y[dose] = a * [c - (c-1) * \exp[-(b * dose)^d]]$

Note: Y(dose) is the median response for exposure = dose;  
 sign = +1 for increasing trend in data;  
 sign = -1 for decreasing trend.

- Model 2 is nested within Models 3 and 4.
- Model 3 is nested within Model 5.
- Model 4 is nested within Model 5.

Dependent variable = Calculated Median

Independent variable = zeroed log serum  
 Data are assumed to be distributed: lognormally  
 Variance Model: Log-scale variance =  $\exp(\ln\alpha)$   
 rho is set to 0.  
 A constant log-scale variance model is fit.

Total number of dose groups = 4  
 Total number of records with missing values = 0  
 Maximum number of iterations = 250  
 Relative Function Convergence has been set to: 1e-008  
 Parameter Convergence has been set to: 1e-008

MLE solution provided: Approximate

Initial Parameter Values

Variable	Model 2	Model 3	Model 4
lnalpha	-3.53767	-3.53767	-3.53767
rho (S)	0	0	0
a	1.41095	1.56597	3.39572
b	0.172782	-0.0106424	0.286517
c	--	--	0.233395
d	--	2	--

(S) = Specified

Parameter Estimates by Model

Variable	Model 2	Model 3	Model 4
lnalpha	-3.52095	-3.52095	-3.52186
rho	0	0	0
a	3.23432	3.23432	3.24152
b	0.172782	0.172782	0.195617
c	--	--	0.082423
d	--	1	--

Table of State From Input Data

Dose	N	Calc'd Median	Calc'd GSD
0	5	3.234	1.223

2.42	4	2.165	1.198
3.36	3	1.729	1.327
4.21	5	1.585	1.147

Estimated Values of Interest

Model	Dose	Est Median	Est QSD	Scaled Residual
2	0	3.234	1.188	-0.0205776
	2.42	2.129	1.188	0.05568
	3.36	1.81	1.188	-0.1176
	4.21	1.563	1.188	0.04216
3	0	3.234	1.188	-0.0205775
	2.42	2.129	1.188	0.05568
	3.36	1.81	1.188	-0.1176
	4.21	1.563	1.188	0.04216
4	0	3.242	1.188	-0.01413
	2.42	2.117	1.188	0.07966
	3.36	1.805	1.188	-0.1109
	4.21	1.569	1.188	0.03103
5	0	3.234	1.186	-4.18e-008
	2.42	2.165	1.186	-1.771e-008
	3.36	1.729	1.186	-1.37e-008
	4.21	1.585	1.186	-2.044e-009

Other models for which likelihoods are calculated:

Model A1:  $Y_{ij} = \mu_{(i)} + e_{(ij)}$   
 $Var(e_{(ij)}) = \sigma^2$

Model A2:  $Y_{ij} = \mu_{(i)} + e_{(ij)}$   
 $Var(e_{(ij)}) = \sigma_{(i)}^2$

Model A3:  $Y_{ij} = \mu_{(i)} + e_{(ij)}$   
 $Var(e_{(ij)}) = \exp(\alpha + \log(\mu_{(i)})) * \rho_{(i)}$

Model R:  $Y_{ij} = \mu + e_{(ij)}$   
 $Var(e_{(ij)}) = \sigma^2$

Likelihoods of Interest

Model	Log(Likelihood)	DF	AIC
A1	21.57016	5	-33.14031
A2	22.40331	8	-28.80662
A3	21.57016	5	-33.14031
R	9.975396	2	-15.95079
2	21.42811	3	-34.85623
3	21.42811	3	-34.85623
4	21.43241	4	-34.86491
5	21.57016	5	-33.14031

Additive constant for all log-likelihoods = -15.62. This constant added to the above values gives the log-likelihood including the term that does not depend on the model parameters.

Explanation of Tests

Test 1: Does response and/or variances differ among Dose levels? (A2 vs. R)  
 Test 2: Are Variances Homogeneous? (A2 vs. A1)  
 Test 3: Are variances adequately modeled? (A2 vs. A3)  
 Test 4: Does Model 2 fit the data? (A3 vs. 2)  
 Test 5a: Does Model 3 fit the data? (A3 vs 3)  
 Test 5b: Is Model 3 better than Model 2? (3 vs. 2)  
 Test 6a: Does Model 4 fit the data? (A3 vs 4)  
 Test 6b: Is Model 4 better than Model 2? (4 vs. 2)  
 Test 7a: Does Model 5 fit the data? (A3 vs 5)  
 Test 7b: Is Model 5 better than Model 3? (5 vs. 3)  
 Test 7c: Is Model 5 better than Model 4? (5 vs. 4)

## Tests of Interest

Test	$-2 \cdot \log(\text{Likelihood Ratio})$	D. F.	p-value
Test 1	24.86	6	0.0003631
Test 2	1.666	3	0.6445
Test 3	1.666	3	0.6445
Test 4	0.2841	2	0.8676
Test 5a	0.2841	2	0.8676
Test 5b	$7.105e-014$	0	N/A
Test 6a	0.2755	1	0.5997
Test 6b	0.008586	1	0.9262
Test 7a	$1.421e-014$	0	N/A
Test 7b	0.2841	2	0.8676
Test 7c	0.2755	1	0.5997

The p-value for Test 1 is less than .05. There appears to be a difference between response and/or variances among the dose levels, it seems appropriate to model the data.

The p-value for Test 2 is greater than .1. A homogeneous variance model appears to be appropriate here.

The p-value for Test 3 is greater than .1. The modeled variance appears to be appropriate here.

The p-value for Test 4 is greater than .1. Model 2 seems to adequately describe the data.

The p-value for Test 5a is greater than .1. Model 3 seems to adequately describe the data.

Degrees of freedom for Test 5b are less than or equal to 0. The Chi-Square test for fit is not valid.

The p-value for Test 6a is greater than .1. Model 4 seems to adequately describe the data.

The p-value for Test 6b is greater than .05. Model 4 does not seem to fit the data better than Model 2.

Degrees of freedom for Test 7a are less than or equal to 0. The Chi-Square test for fit is not valid.

The p-value for Test 7b is greater than .05. Model 5 does

not seem to fit the data better than Model 3.

The p-value for Test 7c is greater than .05. Model 5 does not seem to fit the data better than Model 4.

Benchmark Dose Computations:

Specified Effect = 0.100000


Risk Type = Relative deviation

Confidence Level = 0.950000

BMD and BMCL by Model

Model	BMD	BMCL
2	0.60979	0.489341
3	0.60919	0.489341
4	0.588417	0.286515
5	1.27833	0.239899





11:32 05/04/2011

---

Polynomial Model. (Version: 2.16; Date: 05/26/2010)  
 Input Data File: C:/USEPA/8085212/Data/lin\_pfoa\_summary\_Opt.(d)  
 Gnuplot Plotting File: C:/USEPA/8085212/Data/lin\_pfoa\_summary\_Opt.plt  
 Wed May 04 11:31:56 2011

---

EMD8 Model Run

---

The form of the response function is:

$$Y(\text{dose}) = \text{beta}_0 + \text{beta}_1 \cdot \text{dose} + \text{beta}_2 \cdot \text{dose}^2 + \dots$$

Dependent variable = dev\_score  
 Independent variable = zeroed\_log\_serum  
 rho is set to 0  
 Signs of the polynomial coefficients are not restricted  
 A constant variance model is fit

Total number of dose groups = 4  
 Total number of records with missing values = 0  
 Maximum number of iterations = 250  
 Relative Function Convergence has been set to: 1e-008  
 Parameter Convergence has been set to: 1e-008

Default Initial Parameter Values  
 alpha = 0.331538



```

rho = 0 Specified
beta_0 = 3.2622
beta_1 = -0.415294
    
```

Asymptotic Correlation Matrix of Parameter Estimates

[ \*\*\* The model parameter(s) -rho have been estimated at a boundary point, or have been specified by the user, and do not appear in the correlation matrix ]

	alpha	beta_0	beta_1
alpha	1	4.6e-010	7.7e-010
beta_0	4.6e-010	1	-0.82
beta_1	7.7e-010	-0.82	1

Parameter Estimates

Interval	Variable	Estimate	Std. Err.	95.0% Wald Confidence	
Conf. Limit				Lower Conf. Limit	Upper
0.302804	alpha	0.181075	0.0621061	0.0593451	
3.61982	beta_0	3.26695	0.180042	2.91407	
-0.29215	beta_1	-0.412597	0.0614538	-0.533945	

Table of Data and Estimated Values of Interest

Dose	N	Obs Mean	Est Mean	Obs Std Dev	Est Std Dev	Scaled Res.
0	5	3.3	3.27	0.67	0.426	0.174
2.42	4	2.2	2.27	0.4	0.426	-0.322
3.36	3	1.8	1.88	0.52	0.426	-0.328
4.21	5	1.6	1.53	0.32	0.426	0.368

Model Descriptions for likelihoods calculated

Model A1:  $Y_{ij} = \mu_0(i) + e_{ij}$   
 $Var(e_{ij}) = \sigma^2$

Model A2:  $Y_{ij} = \mu_0(i) + e_{ij}$   
 $Var(e_{ij}) = \sigma_0(i)^2$

Model A3:  $Y_{ij} = \mu_0(i) + e_{ij}$   
 $Var(e_{ij}) = \sigma^2$

Model A3 uses any fixed variance parameters that were specified by the user

Model A:  $Y_i = \mu_i + \epsilon(i)$   
 $\text{Var}(\epsilon(i)) = \sigma^2$

## Likelihoods of Interest

Model	Log{likelihood}	# Param's	AIC
A1	6.215823	5	-2.431646
A2	0.999248	8	-1.998497
A3	6.215823	5	-2.431646
fitted	6.025186	3	-6.050372
B	-4.983702	2	13.967403

## Explanation of Tests

- Test 1: Do responses and/or variances differ among Dose levels?  
 (A2 vs. B)  
 Test 2: Are Variances Homogeneous? (A1 vs A2)  
 Test 3: Are variances adequately modeled? (A2 vs. A3)  
 Test 4: Does the Model for the Mean Fit? (A3 vs. fitted)  
 (Note: When rho=0 the results of Test 3 and Test 2 will be the same.)

## Tests of Interest

Test	-2*log(Likelihood Ratio)	Test df	p-value
Test 1	27.9659	6	<.0001
Test 2	5.56685	3	0.1347
Test 3	5.56685	3	0.1347
Test 4	0.381274	2	0.8264

The p-value for Test 1 is less than .05. There appears to be a difference between response and/or variances among the dose levels. It seems appropriate to model the data.

The p-value for Test 2 is greater than .1. A homogeneous variance model appears to be appropriate here.

The p-value for Test 3 is greater than .1. The modeled variance appears to be appropriate here.


The p-value for Test 4 is greater than .1. The model chosen seems to adequately describe the data.

## Benchmark Dose Computation

Specified effect = 0.1  
 Risk Type = Relative risk  
 Confidence level = 0.95  
 BMD = 0.7918  
 BMDL = 0.673285

BMDL computation failed for one or more point on the BMDL curve.  
 The BMDL curve will not be plotted.

**Appendix 6B: Benchmark Dose Modeling of Number of Terminal Endbud in Response to PFOA Using BMR of 10% Decrease Relative to Controls (Macon et al., 2011)**




---

Hill Model. (Version: 2.15; Date: 10/28/2009)  
 Input Data File: C:/USEPA/BMDS212/Data/hill\_pfoa\_summary\_Opt.(d)  
 Output Plotting File: C:/USEPA/BMDS212/Data/hill\_pfoa\_summary\_Opt.plt  
 Wed May 04 14:30:47 2011

---

BMDS Model Run

---

The form of the response function is:

$$Y[\text{dose}] = \text{intercept} + v \cdot \text{dose}^n / (k^n + \text{dose}^n)$$

Dependent variable = buds  
 Independent variable = zeroed\_serum  
 rho is set to 0  
 Power parameter restricted to be greater than 1  
 A constant variance model is fit

Total number of dose groups = 4  
 Total number of records with missing values = 0  
 Maximum number of iterations = 250  
 Relative Function Convergence has been set to: 1e-008  
 Parameter Convergence has been set to: 1e-008

Default Initial Parameter Values

```

alpha =      52.8975
rho =         0   Specified
intercept =    40
gamma =      -25
n =      0.952636
k =      1495.53
    
```

Asymptotic Correlation Matrix of Parameter Estimates

( \*\*\* The model parameter(s) -rho -n have been estimated at a boundary point, or have been specified by the user, and do not appear in the correlation matrix )

	alpha	intercept	gamma	k
alpha	1	-3.2e-008	-4.5e-008	4.8e-008
intercept	-3.2e-008	1	-0.37	-0.57
gamma	-4.5e-008	-0.37	1	-0.35
k	4.8e-008	-0.57	-0.35	1

Parameter Estimates

Interval	Variable	Estimate	Std. Err.	95.0% Wald Confidence	
Conf. Limit				Lower Conf. Limit	Upper
69.7774	alpha	41.7264	14.312	13.6753	
44.8507	intercept	39.2559	2.85248	33.6692	
-17.144	gamma	-25.532	4.27964	-33.9199	
	n	1	NA		
3364.03	k	1169.31	1119.77	-1025.41	

NA - Indicates that this parameter has hit a bound implied by some inequality constraint and thus has no standard error.

Table of Data and Estimated Values of Interest

Dose	N	Obs Mean	Est Mean	Obs Std Dev	Est Std Dev	Scaled Res.
0	5	40	39.3	8.94	6.46	0.256
261.7	4	33	34.6	8	6.46	-0.493
2281	3	24	22.4	6.93	6.46	0.434
1.628e+004	5	15	15.4	4.47	6.46	-
0.152						

Model Descriptions for likelihoods calculated



Model A1:  $Y_{ij} = \mu_{(i)} + e_{(ij)}$   
 $Var[e_{(ij)}] = \sigma^2$

Model A2:  $Y_{ij} = \mu_{(i)} + e_{(ij)}$   
 $Var[e_{(ij)}] = \sigma_{(i)}^2$

Model A3:  $Y_{ij} = \mu_{(i)} + e_{(ij)}$   
 $Var[e_{(ij)}] = \sigma^2$   
 Model A3 uses any fixed variance parameters that were specified by the user

Model R:  $Y_i = \mu_i + e(i)$   
 $Var[e(i)] = \sigma^2$

Likelihoods of Interest

Model	Log(Likelihood)	# Param's	AIC
A1	-39.950786	5	89.901573
A2	-38.765686	8	93.531372
A3	-39.950786	5	89.901573
fitted	-40.214633	4	88.429266
R	-50.575581	2	105.191162

Explanation of Tests

- Test 1: Do responses and/or variances differ among Dose levels? (A2 vs. R)
  - Test 2: Are Variances Homogeneous? (A1 vs A2)
  - Test 3: Are variances adequately modeled? (A2 vs. A3)
  - Test 4: Does the Model for the Mean Fit? (A3 vs. fitted)
- [Note: When rho=0 the results of Test 3 and Test 2 will be the same.]

Tests of Interest

Test	-2*log(Likelihood Ratio)	Test df	p-value
Test 1	23.6198	6	0.0026134
Test 2	2.3702	3	0.4992
Test 3	2.3702	3	0.4992
Test 4	0.527693	1	0.4676

The p-value for Test 1 is less than .05. There appears to be a difference between response and/or variances among the dose levels. It seems appropriate to model the data.

The p-value for Test 2 is greater than .1. A homogeneous variance model appears to be appropriate here.

The p-value for Test 3 is greater than .1. The modeled variance appears to be appropriate here.


The p-value for Test 4 is greater than .1. The model chosen seems to adequately describe the data.

Benchmark Dose Computation

Specified effect = 0.1

Risk Type	=	Relative risk
Confidence level	=	0.95
EMD	=	212.474
EMDL	=	55.9134






---

Exponential Model. (Version: 1.7; Date: 12/10/2009)  
 Input Data File: C:\SRPA\EMD0212\Data\exp\_pfoa summary\_Setting.d  
 Gsplot Plotting File: Wed May 04 14:41:27 2011

---

EMD Model Run

---

The form of the response function by Model:  
 Model 2:  $Y[dose] = a * \exp[sign * b * dose]$   
 Model 3:  $Y[dose] = a * \exp[sign * (b * dose)^d]$   
 Model 4:  $Y[dose] = a * [c - (c-1) * \exp[-b * dose]]$   
 Model 5:  $Y[dose] = a * [c - (c-1) * \exp[-(b * dose)^d]]$

Note: Y[dose] is the median response for exposure = dose;  
 sign = +1 for increasing trend in data;  
 sign = -1 for decreasing trend.

Model 2 is nested within Models 3 and 4.  
 Model 3 is nested within Model 5.  
 Model 4 is nested within Model 5.

Dependent variable = buds  
 Independent variable = zeroed\_serum  
 Data are assumed to be distributed: normally

Variance Model:  $\exp(\ln\alpha + \rho \ln(V[\text{dose}]))$   
 $\rho$  is set to 0.  
 A constant variance model is fit.

Total number of dose groups = 4  
 Total number of records with missing values = 0  
 Maximum number of iterations = 250  
 Relative Function Convergence has been set to: 1e-008  
 Parameter Convergence has been set to: 1e-008

MLE solution provided: Exact

Initial Parameter Values

Variable Model 5	Model 2	Model 3	Model 4
$\ln\alpha$	3.70009	3.70009	3.70009
$\rho$	0	0	0
a	19.8825	19.8825	42
b	5.23786e-005	5.23786e-005	0.000229525
c	--	--	0.340136
d	--	1	--

(0) = Specified

Parameter Estimates by Model

Variable Model 5	Model 2	Model 3	Model 4
$\ln\alpha$	4.03627	4.03627	3.76287
$\rho$	0	0	0
a	35.4078	35.4078	38.36
b	5.87408e-005	5.87408e-005	0.000479266
c	--	--	0.395353
d	--	1	--

Table of Stats From Input Data

Dose	N	Obs Mean	Obs Std Dev
0	5	40	8.94
261.7	4	33	8
2281	3	24	6.93

1.628e+004 5 15 4.47

Estimated Values of Interest

Model	Dose	Est Mean	Est Std	Scaled Residual
2	0	35.41	7.524	1.365
	261.7	34.87	7.524	-0.4964
	2281	30.97	7.524	-1.604
	1.628e+004	13.61	7.524	0.4144
3	0	35.41	7.524	1.365
	261.7	34.87	7.524	-0.4964
	2281	30.97	7.524	-1.604
	1.628e+004	13.61	7.524	0.4144
4	0	38.36	6.563	0.5588
	261.7	35.63	6.563	-0.8002
	2281	22.94	6.563	0.2797
	1.628e+004	15.18	6.563	-0.05969
5	0	38.36	6.563	0.5588
	261.7	35.63	6.563	-0.8002
	2281	22.94	6.563	0.2797
	1.628e+004	15.18	6.563	-0.05969

Other models for which likelihoods are calculated:

- Model A1:  $T_{ij} = \mu_i + e_{ij}$   
 $Var(e_{ij}) = \sigma^2$
- Model A2:  $T_{ij} = \mu_i + e_{ij}$   
 $Var(e_{ij}) = \sigma_i^2$
- Model A3:  $T_{ij} = \mu_i + e_{ij}$   
 $Var(e_{ij}) = \exp[\alpha + \log(\mu_i)] * \rho$
- Model R:  $T_{ij} = \mu + e_{ij}$   
 $Var(e_{ij}) = \sigma^2$

Likelihoods of Interest

Model	Log(Likelihood)	DF	AIC
A1	-39.95079	5	89.90157
A2	-38.76569	8	93.53137
A3	-39.95079	5	89.90157
R	-50.57558	2	105.1512
<del>2</del>	-42.80832	3	<del>91.61664</del>
<del>3</del>	-42.80832	3	<del>91.61664</del>
<del>4</del>	-40.48439	4	<del>88.96877</del>
<del>5</del>	-40.48439	4	<del>88.96877</del>

Additive constant for all log-likelihoods = -15.62. This constant added to the above values gives the log-likelihood including the term that does not depend on the model parameters.

Explanation of Tests

- Test 1: Does response and/or variances differ among Dose levels? (A2 vs. B)
- Test 2: Are Variances Homogeneous? (A2 vs. A1)
- Test 3: Are variances adequately modeled? (A2 vs. A3)
- Test 4: Does Model 2 fit the data? (A3 vs. 2)
- Test 5a: Does Model 3 fit the data? (A3 vs 3)
- Test 5b: Is Model 3 better than Model 2? (3 vs. 2)
- Test 6a: Does Model 4 fit the data? (A3 vs 4)
- Test 6b: Is Model 4 better than Model 2? (4 vs. 2)
- Test 7a: Does Model 5 fit the data? (A3 vs 5)
- Test 7b: Is Model 5 better than Model 3? (5 vs. 3)
- Test 7c: Is Model 5 better than Model 4? (5 vs. 4)

## Tests of Interest

Test	$-2 \times \log(\text{Likelihood Ratio})$	D. F.	p-value
Test 1	23.62	6	0.0006134
Test 2	2.37	3	0.4992
Test 3	2.37	3	0.4992
Test 4	5.715	2	0.05741
Test 5a	5.715	2	0.05741
Test 5b	$-1.077e-011$	0	N/A
Test 6a	1.067	1	0.3016
Test 6b	4.648	1	0.03109
Test 7a	1.067	1	0.3016
Test 7b	4.648	1	0.03109
Test 7c	$1.421e-014$	0	N/A

The p-value for Test 1 is less than .05. There appears to be a difference between response and/or variances among the dose levels, it seems appropriate to model the data.

The p-value for Test 2 is greater than .1. A homogeneous variance model appears to be appropriate here.

The p-value for Test 3 is greater than .1. The modeled variance appears to be appropriate here.

The p-value for Test 4 is less than .1. Model 2 may not adequately describe the data; you may want to consider another model.

The p-value for Test 5a is less than .1. Model 3 may not adequately describe the data; you may want to consider another model.

Degrees of freedom for Test 5b are less than or equal to 0. The Chi-Square test for fit is not valid.

The p-value for Test 6a is greater than .1. Model 4 seems to adequately describe the data.

The p-value for Test 6b is less than .05. Model 4 appears to fit the data better than Model 2.

The p-value for Test 7a is greater than .1. Model 5 seems to adequately describe the data.

The p-value for Test 7b is less than .05. Model 5 appears to fit the data better than Model 3.

Degrees of freedom for Test 7c are less than or equal to 0.  
The Chi-Square test for fit is not valid.

Benchmark Done Computations:

Specified Effect = 0.100000


Risk Type = Relative deviation

Confidence Level = 0.950000

BMD and BMDG by Model

Model	BMD	BMDG
2	1793.65	1101.42
3	1793.65	1101.42
4	377.213	87.861
5	377.213	87.861





14:24 05/04 2011

---

Power Model. (Version: 2.16; Date: 10/29/2009)  
 Input Data File: C:/USKPA/EMD0212/Data/pow\_pfoa summary\_Opt.(d)  
 Output Plotting File: C:/USKPA/EMD0212/Data/pow\_pfoa summary\_Opt.plt  
 Wed May 04 14:24:01 2011

---

EMDS Model Run

---

The form of the response function is:

$$Y[\text{dose}] = \text{control} + \text{slope} * \text{dose}^{\text{power}}$$

Dependent variable = buds  
 Independent variable = seroed\_serum  
 rho is set to 0  
 The power is not restricted  
 A constant variance model is fit

Total number of dose groups = 4  
 Total number of records with missing values = 0  
 Maximum number of iterations = 250  
 Relative Function Convergence has been set to: 1e-008  
 Parameter Convergence has been set to: 1e-008



Default Initial Parameter Values

alpha = 52.8975  
 rho = 0 Specified  
 control = 40  
 slope = -1.24383  
 power = 0.309416

Asymptotic Correlation Matrix of Parameter Estimates

( \*\*\* The model parameter(s) -rho have been estimated at a boundary point, or have been specified by the user, and do not appear in the correlation matrix )

	alpha	control	slope	power
alpha	1	1.1e-009	-1.2e-009	-1.4e-009
control	1.1e-009	1	-0.61	-0.51
slope	-1.2e-009	-0.61	1	0.99
power	-1.4e-009	-0.51	0.99	1

Parameter Estimates

Interval	Variable	Estimate	Std. Err.	95.0% Wald Confidence	
Conf. Limit				Lower Conf. Limit	Upper
68.4239	alpha	41.0366	14.0754	13.4492	
45.6831	control	40.1466	2.62483	34.61	
1.54067	slope	-1.72177	1.67474	-5.0042	
0.468367	power	0.277549	0.0973577	0.0867315	

Table of Data and Estimated Values of Interest

Dose	N	Obs Mean	Est Mean	Obs Std Dev	Est Std Dev	Scaled Res.
0	5	40	40.1	8.94	6.41	-0.0512
261.7	4	33	32.1	8	6.41	0.289
2281	3	24	25.4	6.93	6.41	-0.385
1.628e+004	5	15	14.7	4.47	6.41	
0.0905						

Model Descriptions for likelihoods calculated

Model A1:  $Y_{ij} = \mu_{(i)} + e_{(ij)}$   
 $Var(e_{(ij)}) = \sigma^2$

Model A2:  $Y_{ij} = \mu_0(i) + \epsilon(i,j)$   
 $\text{Var}[\epsilon(i,j)] = \text{Sigma}(i)^2$

Model A3:  $Y_{ij} = \mu_0(i) + \epsilon(i,j)$   
 $\text{Var}[\epsilon(i,j)] = \text{Sigma}^2$

Model A3 uses any fixed variance parameters that were specified by the user.

Model R:  $Y_i = \mu_0 + \epsilon(i)$   
 $\text{Var}[\epsilon(i)] = \text{Sigma}^2$

#### Likelihoods of Interest

Model	Log(Likelihood)	# Param's	AIC
A1	-39.950786	5	89.901573
A2	-38.765686	8	93.531372
A3	-39.950786	5	89.901573
fitted	-40.072946	4	88.145893
R	-50.575581	2	105.151163

#### Explanation of Tests

Test 1: Do responses and/or variances differ among Dose levels?  
 (A2 vs. R)

Test 2: Are Variances Homogeneous? (A1 vs A3)

Test 3: Are variances adequately modeled? (A2 vs. A3)

Test 4: Does the Model for the Mean Fit? (A3 vs. fitted)

(Note: When rho=0 the results of Test 3 and Test 2 will be the same.)

#### Tests of Interest

Test	$-2 \cdot \log(\text{Likelihood Ratio})$	Test df	p-value
Test 1	23.6198	6	0.006134
Test 2	2.3702	3	0.4992
Test 3	2.3702	3	0.4992
Test 4	0.24432	1	0.6211

The p-value for Test 1 is less than .05. There appears to be a difference between response and/or variances among the dose levels. It seems appropriate to model the data.

The p-value for Test 2 is greater than .1. A homogeneous variance model appears to be appropriate here.

The p-value for Test 3 is greater than .1. The modeled variance appears to be appropriate here.

The p-value for Test 4 is greater than .1. The model chosen seems to adequately describe the data.

#### Benchmark Dose Computation


Specified effect = 0.1

Risk Type = Relative risk

Confidence level = 0.95

END = 21.1211

ENDL = 0.0759616



08:02 05/04/2011

---

Power Model. (Version: 2.16) Date: 10/28/2009  
 Input Data File: C:/USEPA/10003212/Data/pow\_pfos\_summary\_Opt.(d)  
 Gnuplot Plotting File: C:/USEPA/10003212/Data/pow\_pfos\_summary\_Opt.plt  
 Wed May 04 16:02:47 2011

---

BMDS Model Run

---

The form of the response function is:

$$Y(\text{dose}) = \text{control} + \text{slope} * \text{dose}^{\text{power}}$$

Dependent variable = buds

Independent variable = zeroed\_log\_serum

rho is set to 0

The power is restricted to be greater than or equal to 1

A constant variance model is fit

Total number of dose groups = 4

Total number of records with missing values = 0

Maximum number of iterations = 250

Relative Function Convergence has been set to: 1e-008

Parameter Convergence has been set to: 1e-008

Default Initial Parameter Values  
 alpha = 52.8975  
 rho = 0 Specified  
 control = 40  
 slope = -520.606  
 power = -2.11214

Asymptotic Correlation Matrix of Parameter Estimates

( \*\*\* The model parameter(s) -rho  
 have been estimated at a boundary point, or have been  
 specified by the user,  
 and do not appear in the correlation matrix )

	alpha	control	slope	power
alpha	1	4e-008	3.1e-008	4e-008
control	4e-008	1	-0.6	-0.52
slope	3.1e-008	-0.6	1	0.99
power	4e-008	-0.52	0.99	1

Parameter Estimates

Interval	Variable	Estimate	Std. Err.	95.0% Wald Confidence	
Conf. Limit				Lower Conf. Limit	Upper
67.8676	alpha	40.5843	13.9203	13.301	
45.5958	control	40.0806	2.81393	34.5654	
1.41038	slope	-1.08474	1.27305	-3.57987	
3.75282	power	2.18902	0.797466	0.626014	

Table of Data and Estimated Values of Interest

Case	N	Obs Mean	Est Mean	Obs Std Dev	Est Std Dev	Scaled Res.
0	5	40	40.1	8.94	6.37	-0.0283
2.42	4	33	32.6	8	6.37	0.134
3.36	3	24	24.7	6.93	6.37	-0.185
4.21	5	15	14.9	4.47	6.37	0.0519

Model Descriptions for likelihoods calculated

Model A1:  $Y_{ij} = \mu_{(i)} + \epsilon_{(ij)}$   
 $Var[\epsilon_{(ij)}] = \sigma^2$

Model A2:  $Y_{ij} = \mu_{(i)} + \epsilon_{(ij)}$



$$\text{Var}(e(i)) = \text{Sigma}(i)^2$$

Model A1:  $Y(i) = \mu(i) + e(i)$

$$\text{Var}(e(i)) = \text{Sigma}^2$$

Model A1 uses any fixed variance parameters that were specified by the user

Model B:  $Y_i = \mu_i + e(i)$

$$\text{Var}(e(i)) = \text{Sigma}^2$$

#### Likelihoods of Interest

Model	Log(Likelihood)	# Param's	AIC
A1	-39.950706	5	89.901573
A2	-38.765696	8	93.531372
A3	-39.950706	5	89.901573
fitted	-39.978739	4	87.957617
B	-50.975581	2	105.151162

#### Explanation of Tests

- Test 1: Do responses and/or variances differ among Dose levels? (A2 vs. B)  
 Test 2: Are Variances Homogeneous? (A1 vs A2)  
 Test 3: Are variances adequately modeled? (A2 vs. A3)  
 Test 4: Does the Model for the Mean Fit? (A3 vs. fitted)  
 (Note: When rho=0 the results of Test 3 and Test 2 will be the same.)

#### Tests of Interest

Test	-2*log(Likelihood Ratio)	Test df	p-value
Test 1	23.6198	6	0.0026134
Test 2	2.3702	3	0.4992
Test 3	2.3702	3	0.4992
Test 4	0.0559044	1	0.8131

The p-value for Test 1 is less than .05. There appears to be a difference between response and/or variances among the dose levels. It seems appropriate to model the data.

The p-value for Test 2 is greater than .1. A homogeneous variance model appears to be appropriate here.

The p-value for Test 3 is greater than .1. The modeled variance appears to be appropriate here.

The p-value for Test 4 is greater than .1. The model chosen seems to adequately describe the data.

#### Benchmark Dose Computation

Specified effect = 0.1


Risk Type = Relative risk

Confidence level = 0.95

BMD = 1.81676



REPL = 0.870604




---

Polynomial Model. (Version: 2-16; Date: 05/26/2010)  
 Input Data File: C:/USEPA/EMDS212/Data/ply\_pfoa\_memory\_Opt.d  
 Gnuplot Plotting File: C:/USEPA/EMDS212/Data/ply\_pfoa\_memory\_Opt.plt  
 Wed May 04 15:47:37 2011

---

EMDS Model Run

---

The form of the response function is:

$$Y[\text{dose}] = \text{beta}_0 + \text{beta}_1 \cdot \text{dose} + \text{beta}_2 \cdot \text{dose}^2 + \dots$$

Dependent variable = BUIS

Independent variable = zeroed\_log\_serum

rho is set to 0

Signs of the polynomial coefficients are not restricted

A constant variance model is fit

Total number of dose groups = 4


Total number of records with missing values = 0

Maximum number of iterations = 250

Relative Function Convergence has been set to: 1e-008

Parameter Convergence has been set to: 1e-008

Default Initial Parameter Values



```

=====
Polynomial Model. (Version: 2.16; Date: 05/26/2010)
Input Data File: C:/USEPA/BMDS212/Data/ply_pfoa mammary_Opt.(d)
Gnuplot Plotting File: C:/USEPA/BMDS212/Data/ply_pfoa mammary_Opt.plt
Wed May 04 15:47:37 2011
=====

```

BMDS Model Run

The form of the response function is:

$$Y[\text{dose}] = \text{beta}_0 + \text{beta}_1 \cdot \text{dose} + \text{beta}_2 \cdot \text{dose}^2 + \dots$$

Dependent variable = buds

Independent variable = zeroed\_log\_serum

rho is set to 0

Signs of the polynomial coefficients are not restricted

A constant variance model is fit

Total number of dose groups = 4

Total number of records with missing values = 0

Maximum number of iterations = 250

Relative Function Convergence has been set to: 1e-008

Parameter Convergence has been set to: 1e-008

Default Initial Parameter Values

```

alpha =      52.8975
rho =        0      Specified
beta_0 =     40.044
beta_1 =     0.912419
beta_2 =    -1.64299
    
```

Asymptotic Correlation Matrix of Parameter Estimates

( \*\*\* The model parameter(s) -rho  
 have been estimated at a boundary point, or have been  
 specified by the user,  
 and do not appear in the correlation matrix )

	alpha	beta_0	beta_1	beta_2
alpha	1	-1.5e-007	3.6e-007	-3.7e-007
beta_0	-1.5e-007	1	-0.51	0.32
beta_1	3.6e-007	-0.51	1	-0.96
beta_2	-3.7e-007	0.32	-0.96	1

Parameter Estimates

Interval Variable Conf. Limit	Estimate	Std. Err.	95.0% Wald Confidence	
			Lower Conf. Limit	Upper
57.8139 alpha	40.5522	13.9093	13.2905	
45.6043 beta_0	40.0297	2.84422	34.4552	
7.77126 beta_1	0.953024	3.47875	-5.86521	
-0.0164714 beta_2	-1.64752	0.832185	-3.27858	

Table of Data and Estimated Values of Interest

Dose	N	Obs Mean	Est Mean	Obs Std Dev	Est Std Dev	Scaled Res.
0	5	40	40	8.94	6.37	-0.0104
2.42	4	39	32.7	8	6.37	0.0981
3.36	3	24	24.6	6.93	6.37	-0.172
4.22	5	15	14.8	4.47	6.37	0.0559

Model Descriptions for likelihoods calculated

Model A1:  $Y_{ij} = \mu_0(i) + e(i,j)$   
 $Var(e(i,j)) = \sigma^2$

Model A2:  $Y_{ij} = \mu_0(i) + e(i,j)$   
 $Var(e(i,j)) = \sigma^2(i)^2$

Model A3:  $Y_{ij} = \mu_{ij} + e_{ij}$   
 $\text{Var}(e_{ij}) = \text{Sigma}^2$   
 Model A3 uses any fixed variance parameters that were specified by the user

Model R:  $Y_i = \mu_i + e_i$   
 $\text{Var}(e_i) = \text{Sigma}^2$

#### Likelihoods of Interest

Model	Log(Likelihood)	# Param's	AIC
A1	-39.950786	5	89.901573
A2	-38.765686	8	33.531372
A3	-39.950786	5	89.901573
fitted	-39.972016	4	87.944031
R	-50.575581	2	105.151168

#### Explanation of Tests

- Test 1: Do responses and/or variances differ among Dose levels? (A2 vs. R)  
 Test 2: Are Variances Homogeneous? (A1 vs A2)  
 Test 3: Are variances adequately modeled? (A2 vs. A3)  
 Test 4: Does the Model for the Mean Fit? (A3 vs. fitted)  
 (Note: When rho=0 the results of Test 3 and Test 2 will be the same.)

#### Tests of Interest

Test	$-2 \cdot \log(\text{Likelihood Ratio})$	Test df	p-value
Test 1	23.6198	6	0.0006134
Test 2	2.3702	3	0.4992
Test 3	2.3702	3	0.4992
Test 4	0.0424585	1	0.8367

The p-value for Test 1 is less than .05. There appears to be a difference between response and/or variances among the dose levels. It seems appropriate to model the data.

The p-value for Test 2 is greater than .1. A homogeneous variance model appears to be appropriate here.

The p-value for Test 3 is greater than .1. The modeled variance appears to be appropriate here.

The p-value for Test 4 is greater than .1. The model chosen seems to adequately describe the data.


#### Benchmark Dose Computation

Specified effect = 0.1  
 Risk Type = Relative risk  
 Confidence level = 0.95  
 BMD = 1.87458

BNCL = 0.811908

BNCL computation failed for one or more point on the BNCL curve.  
The BNCL curve will not be plotted





18:41 05/04 2011

---

Polynomial Model. (Version: 2.16; Date: 05/26/2010)  
 Input Data File: C:/USEPA/EMDC212/Data/lin\_pfoa\_mammary\_Opt.d  
 Graplot Plotting File: C:/USEPA/EMDC212/Data/lin\_pfoa\_mammary\_Opt.plt  
 Wed May 04 15:40:48 2011

---

EMDC Model Run

---

The form of the response function is:

$$Y(\text{dose}) = \text{beta}_0 + \text{beta}_1 \cdot \text{dose} + \text{beta}_2 \cdot \text{dose}^2 + \dots$$

Dependent variable = buds  
 Independent variable = zeroed\_log\_serum  
 rho is set to 0  
 Signs of the polynomial coefficients are not restricted  
 A constant variance model is fit

Total number of dose groups = 4  
 Total number of records with missing values = 0  
 Maximum number of iterations = 250  
 Relative Function Convergence has been set to: 1e-050  
 Parameter Convergence has been set to: 1e-050

Default Initial Parameter Values

```

alpha = 52.8975
rho = 0 Specified
beta_0 = 42.1163
beta_1 = -5.65218
    
```

Asymptotic Correlation Matrix of Parameter Estimates

( \*\*\* The model parameter(s) -rho  
 have been estimated at a boundary point, or have been  
 specified by the user,  
 and do not appear in the correlation matrix )

	alpha	beta_0	beta_1
alpha	1	-3.6e-008	-5.5e-010
beta_0	-3.6e-008	1	-0.82
beta_1	-5.5e-010	-0.82	1

Parameter Estimates

Interval	Variable	Estimate	Std. Err.	95.0% Wald Confidence	
Conf. Limit				Lower	Upper
83.4487	alpha	49.9017	17.1161	16.3547	
47.6315	beta_0	41.8335	2.98884	35.9755	
-3.68932	beta_1	-5.68904	1.02018	-7.68856	

Table of Data and Estimated Values of Interest

Case	N	Obs Mean	Est Mean	Obs Std Dev	Est Std Dev	Scaled Res.
0	5	40	41.8	8.94	7.06	-0.58
2.42	4	33	28.1	8	7.06	1.4
3.36	3	24	22.7	6.93	7.06	0.314
4.21	5	15	17.9	4.47	7.06	-0.912

Model Descriptions for likelihoods calculated

Model A1:  $Y_{ij} = \mu_{(i)} + \epsilon_{(ij)}$   
 $Var[\epsilon_{(ij)}] = \sigma^2$

Model A2:  $Y_{ij} = \mu_{(i)} + \epsilon_{(ij)}$   
 $Var[\epsilon_{(ij)}] = \sigma_{(i)}^2$

Model A3:  $Y_{ij} = \mu_{(i)} + \epsilon_{(ij)}$   
 $Var[\epsilon_{(ij)}] = \sigma^2$

Model A3 uses any fixed variance parameters that were specified by the user

Model R:  $Y_i = \mu + e(i)$   
 $\text{Var}\{e(i)\} = \text{Sigma}^2$

## Likelihoods of Interest

Model	Log(Likelihood)	# Param's	AIC
A1	-39.950786	5	89.901573
A2	-38.765686	8	93.531372
A3	-39.950786	5	89.901573
fitted	-41.735470	3	49.470940
R	-50.575581	2	105.731762

## Explanation of Tests

- Test 1: Do responses and/or variances differ among Dose levels?  
 (A2 vs. R)  
 Test 2: Are Variances Homogeneous? (A1 vs A2)  
 Test 3: Are variances adequately modeled? (A2 vs. A3)  
 Test 4: Does the Model for the Mean Fit? (A3 vs. fitted)  
 (Note: When rho=0 the results of Test 3 and Test 2 will be the same.)

## Tests of Interest

Test	$-2 \cdot \log(\text{Likelihood Ratio})$	Test df	p-value
Test 1	23.6198	6	0.0006134
Test 2	2.3702	3	0.4992
Test 3	2.3702	3	0.4992
Test 4	3.56937	2	0.1679

The p-value for Test 1 is less than .05. There appears to be a difference between response and/or variances among the dose levels. It seems appropriate to model the data.

The p-value for Test 2 is greater than .1. A homogeneous variance model appears to be appropriate here.

The p-value for Test 3 is greater than .1. The modeled variance appears to be appropriate here.


The p-value for Test 4 is greater than .1. The model chosen seems to adequately describe the data.

## Benchmark Dose Computation

Specified effect = 0.1  
 Risk Type = Relative risk  
 Confidence level = 0.95  
 BMD = 0.735335  
 BMDL = 0.610445

BMDL computation failed for one or more point on the BMDL curve.

The ~~MDL~~ curve will not be plotted




---

Exponential Model. (Version: 1.7; Date: 12/10/2009)  
 Input Data File: C:/USXPA/EMDS212/Data/exp\_pfoa mammary\_Setting.(4)  
 Gmplot Plotting File:

Wed May 04 15:16:09 2011

---

EMDS Model Run

---

The form of the response function by Model:

- Model 2:  $Y[dose] = a * \exp(sign * b * dose)$
- Model 3:  $Y[dose] = a * \exp(sign * (b + dose)^d)$
- Model 4:  $Y[dose] = a * [c - (c-1) * \exp(-b * dose)]$
- Model 5:  $Y[dose] = a * [c - (c-1) * \exp(-(b + dose)^d)]$

Note: Y[dose] is the median response for exposure = dose;  
 sign = +1 for increasing trend in data;  
 sign = -1 for decreasing trend.

- Model 2 is nested within Models 3 and 4.
- Model 3 is nested within Model 5.
- Model 4 is nested within Model 5.

Dependent variable = buds  
 Independent variable = zeroed log serum  
 Data are assumed to be distributed normally  
 Variance Model:  $\exp(\ln alpha + rho * \ln(Y[dose]))$   
 rho is set to 0.  
 A constant variance model is fit.



Total number of dose groups = 4  
 Total number of records with missing values = 0  
 Maximum number of iterations = 250  
 Relative Function Convergence has been set to: 1e-008  
 Parameter Convergence has been set to: 1e-008

NLS solution provided: Exact

Initial Parameter Values

Variable Model 5	Model 2	Model 3	Model 4
lnalpha	3.70009	3.70009	3.70009
rho(8)	0	0	0
a	15.5856	15.5856	42
b	0.216048	0.216048	0.19508
c	--	--	0.000357143
d	--	1	--

(8) = Specified

Parameter Estimates by Model

Variable Model 5	Model 2	Model 3	Model 4
lnalpha	4.02818	3.70014	4.02818
rho	0	0	0
a	41.4292	40.0112	41.4292
b	0.178366	0.236123	0.178366
c	--	--	0
d	--	2.92913	--

Table of Stats From Input Data

Dose	N	Obs Mean	Obs Std Dev
0	5	40	8.54
2.42	4	33	8
3.36	3	24	6.53
4.21	5	15	4.47

Estimated Values of Interest



Model	Dose	Est Mean	Est Std	Scaled Residual
2	0	41.43	7.494	-0.4265
	2.42	26.91	7.494	1.626
	3.36	22.75	7.494	0.2883
	4.21	19.55	7.494	-1.358
3	0	40.01	6.36	-0.003927
	2.42	32.95	6.36	0.01529
	3.36	24.08	6.36	-0.02269
	4.21	14.98	6.36	0.00852
4	0	41.43	7.494	-0.4265
	2.42	26.91	7.494	1.626
	3.36	22.75	7.494	0.2883
	4.21	19.55	7.494	-1.358
5	0	40	6.36	-1.514e-008
	2.42	33	6.36	8.575e-009
	3.36	24	6.36	3.174e-008
	4.21	15	6.36	-4.441e-008

Other models for which likelihoods are calculated:

$$\text{Model A1: } Y_{ij} = \mu_{(i)} + e_{(ij)}$$

$$\text{Var}(e_{(ij)}) = \text{Sigma}^2$$

$$\text{Model A2: } Y_{ij} = \mu_{(i)} + e_{(ij)}$$

$$\text{Var}(e_{(ij)}) = \text{Sigma}_{(i)}^2$$

$$\text{Model A3: } Y_{ij} = \mu_{(i)} + e_{(ij)}$$

$$\text{Var}(e_{(ij)}) = \exp[\alpha + \log(\text{mean}_{(i)}) * \rho]$$

$$\text{Model R: } Y_{ij} = \mu + e_{(ij)}$$

$$\text{Var}(e_{(ij)}) = \text{Sigma}^2$$

#### Likelihoods of Interest

Model	Log(Likelihood)	DF	AIC
A1	-39.95079	5	89.90157
A2	-38.76369	8	93.53137
A3	-39.95079	5	89.90157
R	-50.57558	2	105.1512
2	-42.73957	3	91.47914
3	-39.95121	4	91.90241
4	-42.73957	3	91.47914
5	-39.95079	5	89.90157

Additive constant for all log-likelihoods = -15.62. This constant added to the above values gives the log-likelihood including the term that does not depend on the model parameters.

#### Explanation of Tests

- Test 1: Does response and/or variances differ among Dose levels? (A2 vs. R)  
 Test 2: Are Variances Homogeneous? (A2 vs. A1)  
 Test 3: Are variances adequately modeled? (A2 vs. A3)  
 Test 4: Does Model 2 fit the data? (A3 vs. 2)

Test 5a: Does Model 3 fit the data? (A3 vs 3)  
 Test 5b: Is Model 3 better than Model 2? (3 vs. 2)  
 Test 6a: Does Model 4 fit the data? (A4 vs 4)  
 Test 6b: Is Model 4 better than Model 2? (4 vs. 2)  
 Test 7a: Does Model 5 fit the data? (A5 vs 5)  
 Test 7b: Is Model 5 better than Model 3? (5 vs. 3)  
 Test 7c: Is Model 5 better than Model 4? (5 vs. 4)

## Tests of Interest

Test	$-2 \cdot \log(\text{Likelihood Ratio})$	D. F.	p-value
Test 1	23.62	4	0.0006134
Test 2	2.37	3	0.4992
Test 3	2.37	3	0.4992
Test 4	5.578	2	0.0615
Test 5a	0.0008389	1	0.9769
Test 5b	5.577	1	0.0182
Test 6a	5.578	2	0.0615
Test 6b	0	0	N/A
Test 7a	0	0	N/A
Test 7b	0.0008389	1	0.9769
Test 7c	5.578	2	0.0615

The p-value for Test 1 is less than .05. There appears to be a difference between responses and/or variances among the dose levels, it seems appropriate to model the data.

The p-value for Test 2 is greater than .1. A homogeneous variance model appears to be appropriate here.

The p-value for Test 3 is greater than .1. The modeled variance appears to be appropriate here.

The p-value for Test 4 is less than .1. Model 2 may not adequately describe the data; you may want to consider another model.

The p-value for Test 5a is greater than .1. Model 3 seems to adequately describe the data.

The p-value for Test 5b is less than .05. Model 3 appears to fit the data better than Model 2.

The p-value for Test 6a is less than .1. Model 4 may not adequately describe the data; you may want to consider another model.

Degrees of freedom for Test 6b are less than or equal to 0. The Chi-Square test for fit is not valid.

Degrees of freedom for Test 7a are less than or equal to 0. The Chi-Square test for fit is not valid.

The p-value for Test 7b is greater than .05. Model 5 does not seem to fit the data better than Model 3.

The p-value for Test 7c is greater than .05. Model 5 does not seem to fit the data better than Model 4.

Benchmark Dose Computations:


Specified Effect = 0.100000

Risk Type = Absolute deviation

Confidence Level = 0.950000

BMD and BMDL by Model

<u>Model</u>	<u>BMD</u>	<u>BMDL</u>
2	0.0135489	0.00916543
3	0.547859	0.0955696
4	0.0135489	0.00827023
5	0.572901	0.095613



**APPENDIX 7: Benchmark dose analysis of relative liver weight in response to PFOA (linear/branched) using BMR of 10% increase relative to controls (Loveless et al., 2006).**

Model	Chi-sq p-value	AIC	BMD (µg/ml in serum)	BMDL (µg/ml in serum)
<b>Exponential (Models 4 and 5)</b>	<b>0.2636</b>	<b>2.12782</b>	<b>4.90419</b>	<b>4.46612</b>
Hill <sup>a</sup>	-	-	-	-
Linear <sup>b</sup>	-	-	-	-
Polynomial (2 <sup>nd</sup> deg)	0.03245 <sup>c</sup>	6.92134	5.31705	4.89558
<b>Polynomial (3<sup>rd</sup> deg) <sup>d</sup></b>	<b>0.4678</b>	<b>1.66669</b>	<b>4.68238</b>	<b>4.23604</b>

<sup>a</sup> The individual observations in these data have unequal variance in response. When modeled to account for the unequal variance, the Hill model fails (with or without restriction of the exponential function to > 1)

<sup>b</sup> Scaled residuals for one or more doses/serum concentrations for each of the four exponential models were > | 2 |. The fit of these models is considered inadequate for benchmark dose modeling.

<sup>c</sup> Note that the p-value is less than the value of 0.1 used by the BMDS software as a cut-off for determining goodness of fit by this test. However, the AIC value indicates a reasonable fit.

<sup>d</sup> The 3<sup>rd</sup> degree polynomial model over fits the data at the high doses (see graphic description). However, the fit at the lower doses (including the doses contributing most to the BMD and BMDL) appears appropriate

### **Summary**

Both the exponential models (models 4 and 5 give identical fits) and the 3<sup>rd</sup> degree polynomial model give acceptable fits to these data. The 3<sup>rd</sup> degree polynomial model over fits the data at the high dose, forcing a fit and resulting in a biologically unlikely fit in this area of the dose-response. However, the fit of the model at the lower doses (i.e., in the range of the BMD) is regular and biologically appropriate. It is unlikely that the forced fit at the high dose has any significant influence on the fit of the model at the BMD. Although this model gives a slightly better fit than the exponential models and also yields a slightly lower BMDL, the exponential models give a highly comparable fit and a similar BMDL. As neither model appears to have a claim to greater biological significance, it is recommended that the point-of-departure be derived as the average of the BMDLs for both of these models. **This yields an average BMDL of 4.35 µg/ml.**

```

=====
Exponential Model. (Version: 1.10; Date: 01/12/2015)
Input Data File: C:/BMDS2601_20150629/BMDS2601/Data/exp_Loveless 2006 - Mouose- rel
liver wt - linear-branched_Opt.(d)
Gnuplot Plotting File:
=====

```

Thu Mar 24 11:27:03 2016

BMDS Model Run

The form of the response function by Model:

```

Model 2: Y[dose] = a * exp(sign * b * dose)
Model 3: Y[dose] = a * exp(sign * (b * dose)^d)
Model 4: Y[dose] = a * [c-(c-1) * exp{-b * dose}]
Model 5: Y[dose] = a * [c-(c-1) * exp{-(b * dose)^d}]

```

Note: Y[dose] is the median response for exposure = dose;  
 sign = +1 for increasing trend in data;  
 sign = -1 for decreasing trend.

Model 2 is nested within Models 3 and 4.  
 Model 3 is nested within Model 5.  
 Model 4 is nested within Model 5.

Dependent variable = Mean  
 Independent variable = Dose  
 Data are assumed to be distributed: normally  
 Variance Model:  $\exp(\ln\alpha + \rho * \ln(Y[dose]))$   
 The variance is to be modeled as  $\text{Var}(i) = \exp(\ln\alpha + \log(\text{mean}(i)) * \rho)$

Total number of dose groups = 6  
 Total number of records with missing values = 0  
 Maximum number of iterations = 500  
 Relative Function Convergence has been set to: 1e-008  
 Parameter Convergence has been set to: 1e-008

MLE solution provided: Exact

Initial Parameter Values

Variable	Model 2	Model 3	Model 4	Model 5
lnalpha	-7.4076	-7.4076	-7.4076	-7.4076
rho	2.77531	2.77531	2.77531	2.77531
a	6.24624	6.24624	4.883	4.883
b	0.00485613	0.00485613	0.0101307	0.0101307
c	0 *	0 *	3.93078	3.93078
d	1 *	1	1 *	1

\* Indicates that this parameter has been specified

Parameter Estimates by Model

Variable	Model 2	Model 3	Model 4	Model 5
lnalpha	-0.912445	-0.912444	-7.45681	-7.45681
rho	0.694024	0.694024	2.79344	2.79344
a	6.58236	6.58236	5.13807	5.13807
b	0.00447289	0.00447289	0.00664742	0.00664742
c	--	--	4.11774	4.11774
d	--	1	--	1

-- Indicates that this parameter does not appear in model



Std. Err. Estimates by Model

Variable	Model 2	Model 3	Model 4	Model 5
lnalpha	0.192224	1.23391	0.893622	0.893622
rho	0.536418	0.536418	0.386543	0.386543
a	0.227146	0.227146	0.0668152	0.0668152
b	0.000208654	0.000208654	0.00066635	0.00066635
c	NA	NA	0.180148	0.180147
d	NA	NA	NA	NA

NA - Indicates that this parameter was specified (by the user or because of the model form) or has hit a bound implied by some inequality constraint and thus has no standard error.

Table of Stats From Input Data

Dose	N	Obs Mean	Obs Std Dev
0.04	10	5.14	0.27
10	10	6.12	0.25
27	10	7.92	0.49
66	10	10.72	0.63
190	10	16.27	1.05
241	10	18.28	1.57

Estimated Values of Interest

Model	Dose	Est Mean	Est Std	Scaled Residual
2	0.04	6.584	1.219	-3.746
	10	6.883	1.238	-1.951
	27	7.427	1.271	1.226
	66	8.843	1.35	4.397
	190	15.4	1.637	1.685
	241	19.34	1.771	-1.899
3	0.04	6.584	1.219	-3.746
	10	6.883	1.238	-1.951
	27	7.427	1.271	1.226
	66	8.843	1.35	4.397
	190	15.4	1.637	1.685
	241	19.34	1.771	-1.899
4	0.04	5.142	0.2366	-0.03107
	10	6.168	0.3051	-0.5007
	27	7.77	0.4211	1.127
	66	10.83	0.6694	-0.5063
	190	16.63	1.219	-0.9262
	241	17.93	1.354	0.8184
5	0.04	5.142	0.2366	-0.03107
	10	6.168	0.3051	-0.5007
	27	7.77	0.4211	1.127
	66	10.83	0.6694	-0.5063
	190	16.63	1.219	-0.9262
	241	17.93	1.354	0.8184

Other models for which likelihoods are calculated:

Model A1:  $Y_{ij} = \mu(i) + e(ij)$   
 $\text{Var}\{e(ij)\} = \sigma^2$

Model A2:  $Y_{ij} = \mu(i) + e(ij)$   
 $\text{Var}\{e(ij)\} = \sigma(i)^2$

Model A3:  $Y_{ij} = \mu(i) + e(ij)$   
 $\text{Var}\{e(ij)\} = \exp(\ln\alpha + \log(\text{mean}(i)) * \rho)$

Model R:  $Y_{ij} = \mu + e(i)$

$$\text{Var}\{e_{ij}\} = \text{Sigma}^2$$

Likelihoods of Interest			
Model	Log(likelihood)	DF	AIC
A1	-17.12125	7	48.2425
A2	6.872288	12	10.25542
A3	5.926418	8	4.147163
R	-126.9627	2	257.9255
2	-50.15017	4	108.3003
3	-50.15017	4	108.3003
4	3.936092	5	2.127815
5	3.936092	5	2.127815

Additive constant for all log-likelihoods = -55.14. This constant added to the above values gives the log-likelihood including the term that does not depend on the model parameters.

#### Explanation of Tests

Test 1: Does response and/or variances differ among Dose levels? (A2 vs. R)

Test 2: Are Variances Homogeneous? (A2 vs. A1)

Test 3: Are variances adequately modeled? (A2 vs. A3)

Test 4: Does Model 2 fit the data? (A3 vs. 2)

Test 5a: Does Model 3 fit the data? (A3 vs 3)

Test 5b: Is Model 3 better than Model 2? (3 vs. 2)

Test 6a: Does Model 4 fit the data? (A3 vs 4)

Test 6b: Is Model 4 better than Model 2? (4 vs. 2)

Test 7a: Does Model 5 fit the data? (A3 vs 5)

Test 7b: Is Model 5 better than Model 3? (5 vs. 3)

Test 7c: Is Model 5 better than Model 4? (5 vs. 4)

#### Tests of Interest

Test	-2*log(Likelihood Ratio)	D. F.	p-value
Test 1	267.7	10	< 0.0001
Test 2	47.99	5	< 0.0001
Test 3	1.892	4	0.7557
Test 4	112.2	4	< 0.0001
Test 5a	112.2	4	< 0.0001
Test 5b	-6.736e-012	0	N/A
Test 6a	3.981	3	0.2636
Test 6b	108.2	1	< 0.0001
Test 7a	3.981	3	0.2636
Test 7b	108.2	1	< 0.0001
Test 7c	-3.023e-012	0	N/A

The p-value for Test 1 is less than .05. There appears to be a difference between response and/or variances among the dose levels, it seems appropriate to model the data.

The p-value for Test 2 is less than .1. A non-homogeneous variance model appears to be appropriate.

The p-value for Test 3 is greater than .1. The modeled variance appears to be appropriate here.

The p-value for Test 4 is less than .1. Model 2 may not adequately describe the data; you may want to consider another model.

The p-value for Test 5a is less than .1. Model 3 may not adequately

describe the data; you may want to consider another model.

Degrees of freedom for Test 5b are less than or equal to 0. The Chi-Square test for fit is not valid.

The p-value for Test 6a is greater than .1. Model 4 seems to adequately describe the data.

The p-value for Test 6b is less than .05. Model 4 appears to fit the data better than Model 2.

The p-value for Test 7a is greater than .1. Model 5 seems to adequately describe the data.

The p-value for Test 7b is less than .05. Model 5 appears to fit the data better than Model 3.

Degrees of freedom for Test 7c are less than or equal to 0. The Chi-Square test for fit is not valid.

Benchmark Dose Computations:


Specified Effect = 0.100000

Risk Type = Relative deviation


Confidence Level = 0.950000

BMD and BMDL by Model

Model	BMD	BMDL
2	21.3084	19.7104
3	21.3084	19.7104
4	4.90419	4.46612
5	4.90419	4.46612



11:27 03/24 2016



11:26 03/24 2016

```

=====
Polynomial Model. (Version: 2.20; Date: 10/22/2014)
Input Data File: C:/BMDS2601_20150629/BMDS2601/Data/ply_Loveless 2006 - Mouse- rel
liver wt - linear-branched_Opt.(d)
Gnuplot Plotting File: C:/BMDS2601_20150629/BMDS2601/Data/ply_Loveless 2006 - Mouse-
rel liver wt - linear-branched_Opt.plt
Thu Mar 24 11:40:48 2016
=====

```

```

BMD5 Model Run
~~~~~

```

The form of the response function is:

$$Y[\text{dose}] = \text{beta}_0 + \text{beta}_1 \cdot \text{dose} + \text{beta}_2 \cdot \text{dose}^2 + \dots$$

Dependent variable = Mean  
 Independent variable = Dose  
 Signs of the polynomial coefficients are not restricted  
 The variance is to be modeled as  $\text{Var}(i) = \exp(\text{lalpha} + \log(\text{mean}(i))) * \text{rho}$

Total number of dose groups = 6  
 Total number of records with missing values = 0  
 Maximum number of iterations = 500  
 Relative Function Convergence has been set to: 1e-008  
 Parameter Convergence has been set to: 1e-008

```

Default Initial Parameter Values
lalpha = -0.323931
rho = 0
beta_0 = 5.38261
beta_1 = 0.0864747
beta_2 = -0.000141161

```

Asymptotic Correlation Matrix of Parameter Estimates

	lalpha	rho	beta_0	beta_1	beta_2
lalpha	1	-0.98	0.17	-0.25	0.24
rho	-0.98	1	-0.17	0.25	-0.24
beta_0	0.17	-0.17	1	-0.59	0.5
beta_1	-0.25	0.25	-0.59	1	-0.94
beta_2	0.24	-0.24	0.5	-0.94	1

Parameter Estimates

Variable	Estimate	Std. Err.	95.0% Wald Confidence Interval	
			Lower Conf. Limit	Upper Conf. Limit
lalpha	-7.55129	0.915261	-9.34516	-5.75741
rho	2.86927	0.39557	2.09396	3.64457
beta_0	5.175	0.0667518	5.04417	5.30584
beta_1	0.0983433	0.0042131	0.0900857	0.106601
beta_2	-0.000190851	1.99132e-005	-0.00022988	-0.000151822

Table of Data and Estimated Values of Interest

Dose	N	Obs Mean	Est Mean	Obs Std Dev	Est Std Dev	Scaled Res.
------	---	----------	----------	-------------	-------------	-------------



0.04	10	5.14	5.18	0.27	0.243	-0.508
10	10	6.12	6.14	0.25	0.31	-0.198
27	10	7.92	7.69	0.49	0.428	1.69
66	10	10.7	10.8	0.63	0.7	-0.517
190	10	16.3	17	1.05	1.33	-1.66
241	10	18.3	17.8	1.57	1.43	1.09

Model Descriptions for likelihoods calculated

Model A1:  $Y_{ij} = \mu(i) + e(ij)$   
 $\text{Var}\{e(ij)\} = \sigma^2$

Model A2:  $Y_{ij} = \mu(i) + e(ij)$   
 $\text{Var}\{e(ij)\} = \sigma(i)^2$

Model A3:  $Y_{ij} = \mu(i) + e(ij)$   
 $\text{Var}\{e(ij)\} = \exp(\alpha + \rho \cdot \ln(\mu(i)))$   
 Model A3 uses any fixed variance parameters that were specified by the user

Model R:  $Y_i = \mu + e(i)$   
 $\text{Var}\{e(i)\} = \sigma^2$

#### Likelihoods of Interest

Model	Log(likelihood)	# Param's	AIC
A1	-17.121248	7	48.242497
A2	6.872288	12	10.255424
A3	5.926418	8	4.147163
fitted	1.539332	5	6.921336
R	-126.962744	2	257.925488

#### Explanation of Tests

Test 1: Do responses and/or variances differ among Dose levels?  
 (A2 vs. R)  
 Test 2: Are Variances Homogeneous? (A1 vs A2)  
 Test 3: Are variances adequately modeled? (A2 vs. A3)  
 Test 4: Does the Model for the Mean Fit? (A3 vs. fitted)  
 (Note: When  $\rho=0$  the results of Test 3 and Test 2 will be the same.)

#### Tests of Interest

Test	$-2 \cdot \log(\text{Likelihood Ratio})$	Test df	p-value
Test 1	267.67	10	<.0001
Test 2	47.9871	5	<.0001
Test 3	1.89174	4	0.7557
Test 4	8.77417	3	0.03245

The p-value for Test 1 is less than .05. There appears to be a difference between response and/or variances among the dose levels. It seems appropriate to model the data.


The p-value for Test 2 is less than .1. A non-homogeneous variance model appears to be appropriate.

The p-value for Test 3 is greater than .1. The modeled variance appears to be appropriate here.

The p-value for Test 4 is less than .1. You may want to try a different model.

Benchmark Dose Computation

Specified effect = 0.1  
Risk Type = Relative deviation  
Confidence level = 0.95  
BMD = 5.31705  
BMDL = 4.89558



11:48 03/24 2016

```

=====
Polynomial Model. (Version: 2.20; Date: 10/22/2014)
Input Data File: C:/BMDS2601_20150629/BMDS2601/Data/ply_Loveless 2006 -
Mouose- rel liver wt - linear-branched_Opt.(d)
Gnuplot Plotting File: C:/BMDS2601_20150629/BMDS2601/Data/ply_Loveless 2006
- Mouose- rel liver wt - linear-branched_Opt.plt
Thu Mar 24 11:45:36 2016
=====

```

BMDS Model Run

The form of the response function is:

$$Y[\text{dose}] = \text{beta}_0 + \text{beta}_1 \cdot \text{dose} + \text{beta}_2 \cdot \text{dose}^2 + \dots$$

Dependent variable = Mean  
 Independent variable = Dose  
 Signs of the polynomial coefficients are not restricted  
 The variance is to be modeled as  $\text{Var}(i) = \exp(\text{lalpha} + \log(\text{mean}(i))) * \text{rho}$

Total number of dose groups = 6  
 Total number of records with missing values = 0  
 Maximum number of iterations = 500  
 Relative Function Convergence has been set to: 1e-008  
 Parameter Convergence has been set to: 1e-008

Default Initial Parameter Values

```

lalpha = -0.323931
rho = 0
beta_0 = 5.13303
beta_1 = 0.109803
beta_2 = -0.000421158
beta_3 = 7.96683e-007

```

Asymptotic Correlation Matrix of Parameter Estimates

	lalpha	rho	beta_0	beta_1	beta_2	
beta_3						
0.048	1	-0.98	0.012	-0.028	0.043	-
0.056	-0.98	1	-0.012	0.031	-0.05	
0.32	0.012	-0.012	1	-0.59	0.4	-
0.78	-0.028	0.031	-0.59	1	-0.88	
0.98	0.043	-0.05	0.4	-0.88	1	-
1	-0.048	0.056	-0.32	0.78	-0.98	

Parameter Estimates

Interval		95.0% Wald Confidence			
Variable	Estimate	Std. Err.	Lower Conf. Limit	Upper Conf. Limit	
lalpha	-7.33636	0.87882	-9.05882	-	
rho	2.72236	0.379829	1.97791	-	
beta_0	5.11878	0.0674735	4.98653	-	
beta_1	0.111381	0.00620885	0.0992116	-	
beta_2	-0.000444193	9.26512e-005	-0.000625786	-	
beta_3	8.69446e-007	3.09892e-007	2.62068e-007	1.47682e-006	

Table of Data and Estimated Values of Interest

Dose	N	Obs Mean	Est Mean	Obs Std Dev	Est Std Dev	Scaled Res.
0.04	10	5.14	5.12	0.27	0.236	0.225
10	10	6.12	6.19	0.25	0.305	-0.715
27	10	7.92	7.82	0.49	0.419	0.759
66	10	10.7	10.8	0.63	0.65	-0.316
190	10	16.3	16.2	1.05	1.13	0.17
241	10	18.3	18.3	1.57	1.34	-0.124

Model Descriptions for likelihoods calculated

Model A1:  $Y_{ij} = \mu(i) + e(ij)$   
 $\text{Var}\{e(ij)\} = \sigma^2$

Model A2:  $Y_{ij} = \mu(i) + e(ij)$   
 $\text{Var}\{e(ij)\} = \sigma(i)^2$

Model A3:  $Y_{ij} = \mu(i) + e(ij)$   
 $\text{Var}\{e(ij)\} = \exp(\text{lalpha} + \text{rho} \cdot \ln(\mu(i)))$   
 Model A3 uses any fixed variance parameters that were specified by the user

Model R:  $Y_i = \mu + e(i)$   
 $\text{Var}\{e(i)\} = \sigma^2$

Likelihoods of Interest

Model	Log(likelihood)	# Param's	AIC
A1	-17.121248	7	48.242497
A2	6.872288	12	10.255424
A3	5.926418	8	4.147163
fitted	5.166654	6	1.666693
R	-126.962744	2	257.925488

## Explanation of Tests

Test 1: Do responses and/or variances differ among Dose levels?  
(A2 vs. R)  
 Test 2: Are Variances Homogeneous? (A1 vs A2)  
 Test 3: Are variances adequately modeled? (A2 vs. A3)  
 Test 4: Does the Model for the Mean Fit? (A3 vs. fitted)  
 (Note: When rho=0 the results of Test 3 and Test 2 will be the same.)

## Tests of Interest

Test	-2*log(Likelihood Ratio)	Test df	p-value
Test 1	267.67	10	<.0001
Test 2	47.9871	5	<.0001
Test 3	1.89174	4	0.7557
Test 4	1.51953	2	0.4678

The p-value for Test 1 is less than .05. There appears to be a difference between response and/or variances among the dose levels. It seems appropriate to model the data.

The p-value for Test 2 is less than .1. A non-homogeneous variance model appears to be appropriate.


The p-value for Test 3 is greater than .1. The modeled variance appears to be appropriate here.

The p-value for Test 4 is greater than .1. The model chosen seems to adequately describe the data.

## Benchmark Dose Computation

Specified effect = 0.1  
 Risk Type = Relative deviation  
 Confidence level = 0.95  
 BMD = 4.68238  
 BMDL = 4.23604

BMDL computation failed for one or more point on the BMDL curve.  
 The BMDL curve will not be plotted.



11:45 03/24 2016



**APPENDIX 8: Benchmark dose analysis of testicular tumor data in response to PFOA using BMR of 5% tumor incidence (Butenhoff et al., 2012)**

Model	Chi-sq stat	Chi-sq p-value	AIC	BMD (mg/kg/d)	BMDL (mg/kg/d)	Cancer Potency Slope (mg/kg/d) <sup>-1</sup>	Dose at 1 x 10 <sup>-6</sup> risk (mg/kg/d)
<b>Gamma (power restricted to ≥ 1)</b>	<b>1.45</b>	<b>0.2292</b>	<b>62.6851</b>	<b>4.42913</b>	<b>2.50664</b>	<b>0.020</b>	<b>5.0 x 10<sup>-5</sup></b>
<b>Multistage (betas ≥ 0)</b>							
<b>Weibull (power restricted to ≥ 1)</b>							
<b>Quantal linear</b>							
Gamma (power unrestricted)	0.00	1.00	61.2908	4.42913	1.36483e-6		
Log-logistic (power unrestricted)	0.00	1.00	61.2908	1.95859	2.00091e-6		
Logistic	1.71	0.1905	63.6843	8.85708	6.49805		
<b>Log-logistic (slope restricted to ≤ 1)</b>	<b>1.42</b>	<b>0.2338</b>	<b>62.5526</b>	<b>4.02707</b>	<b>2.2101</b>	<b>0.023</b>	<b>4.3 x 10<sup>-5</sup></b>
Probit	1.68	0.1948	63.625	8.32341	5.95965		
Weibull (power unrestricted)	0.00	1.00	61.2908	1.97407	1.65976e-6		

**Summary**

The BMR of 0.05 (5%) was selected for consistency with the recommendations for selection of point-of-departure (POD) for cancer potency slope derivation in the USEPA (2005) Guidance for Carcinogen Risk Assessment. This value is close to the 4% response at the lowest dose in this data set. The Gamma model (power restricted to ≥ 1); Multistage model (betas ≥ 0); Weibull

model (power restricted to  $\geq 1$ ); and Quantal linear model all give good and essentially identical fits to this dataset and consequently yield identical BMDLs and cancer potency slopes. The Log-logistic model (slope restricted to  $\leq 1$ ) gives a closely comparable fit to these data and a similar BMDLs and cancer potency estimate. These models were selected as most appropriate for deriving a cancer potency slope from these data.

The Gamma model with power unrestricted; the Log-logistic model with power unrestricted; and the Weibull model with power unrestricted all fit the data exactly and yield very small BMDLs. However, despite their better fit of the data than the selected models, these models are not considered appropriate for derivation of a cancer potency slope from these data. This is because these models all assume a steep dose-response relationship at low doses which becomes much less steep at higher doses. The steepness of the dose-response at low doses (i.e., doses associated with a less than 5% response) leads to the very small BMDL values associated with these models. The steepness of the dose-response at low doses is a highly specific assumption which is not necessary and which is not dictated by any empirical or theoretical consideration. These models are therefore rejected.

The Gamma, power restricted to  $\geq 1$ , (and the other models giving essentially identical results) and the Log-logistic model (with slope restricted to  $\leq 1$ ) fit the data with very similar fits and yield very similar BMDLs. Additionally, none of these models has a form that is obviously more biologically accurate. For these reasons, it is appropriate to average their BMDLs. The average BMDL for these models is 2.36 mg/kg/day. For a 5% BMR, the corresponding linear (no threshold) cancer potency slope is 0.021 (mg/kg/day)<sup>-1</sup>, and the dose corresponding to a  $1 \times 10^{-6}$  risk is  $4.8 \times 10^{-5}$  mg/kg/day.

```

=====
Gamma Model. (Version: 2.16; Date: 2/28/2013)
Input Data File: C:/BMDS2601_20150629/BMDS2601/Data/gam_butenhoff testicular
tumors_Opt.(d)
Gnuplot Plotting File: C:/BMDS2601_20150629/BMDS2601/Data/gam_butenhoff testicular
tumors_Opt.plt
Tue Mar 01 13:55:34 2016
=====

```

```

BMDS_Model_Run
~~~~~

```

The form of the probability function is:

$P[\text{response}] = \text{background} + (1 - \text{background}) * \text{CumGamma}[\text{slope} * \text{dose}, \text{power}]$ ,  
 where CumGamma(.) is the cumulative Gamma distribution function

Dependent variable = Incidence  
 Independent variable = Dose  
 Power parameter is restricted as power >=1

Total number of observations = 3  
 Total number of records with missing values = 0  
 Maximum number of iterations = 500  
 Relative Function Convergence has been set to: 1e-008  
 Parameter Convergence has been set to: 1e-008

Default Initial (and Specified) Parameter Values

```

Background = 0.0196078
Slope = 0.0294212
Power = 1.3

```

Asymptotic Correlation Matrix of Parameter Estimates

( \*\*\* The model parameter(s) -Power  
 have been estimated at a boundary point, or have been specified by the user,  
 and do not appear in the correlation matrix )

	Background	Slope
Background	1	-0.58
Slope	-0.58	1

Parameter Estimates

Variable	Estimate	Std. Err.	95.0% Wald Confidence Interval	
			Lower Conf. Limit	Upper Conf. Limit
Background	0.00436511	0.0163662	-0.027712	0.0364423
Slope	0.0115809	0.00506549	0.0016527	0.0215091
Power	1	NA		

NA - Indicates that this parameter has hit a bound implied by some inequality constraint and thus has no standard error.

Analysis of Deviance Table

Model	Log(likelihood)	# Param's	Deviance	Test d.f.	P-value
Full model	-28.6454	3			
Fitted model	-29.3426	2	1.39438	1	0.2377
Reduced model	-33.983	1	10.6753	2	0.004807

AIC: 62.6851


Goodness of Fit					
Dose	Est._Prob.	Expected	Observed	Size	Scaled Residual
0.0000	0.0044	0.214	0.000	49.000	-0.463
1.3000	0.0192	0.962	2.000	50.000	1.068
14.2000	0.1553	7.767	7.000	50.000	-0.299

Chi^2 = 1.45      d.f. = 1      P-value = 0.2292

Benchmark Dose Computation

Specified effect = 0.05  
 Risk Type = Extra risk  
 Confidence level = 0.95  
 BMD = 4.42913  
 BMDL = 2.50664

Gamma Multi-Hit Model, with BMR of 5% Extra Risk for the BMD and 0.95 Lower Confidence Limit for the BMDL



13:55 03/01 2016

```

=====
Multistage Model. (Version: 3.4; Date: 05/02/2014)
Input Data File: C:/BMDS2601_20150629/BMDS2601/Data/mst_butenhoff testicular
tumors_Opt.(d)
Gnuplot Plotting File: C:/BMDS2601_20150629/BMDS2601/Data/mst_butenhoff testicular
tumors_Opt.plt

```

Tue Mar 01 14:29:06 2016

```

=====
BMDS_Model_Run
~~~~~

```

The form of the probability function is:

$$P[\text{response}] = \text{background} + (1-\text{background}) * [1 - \text{EXP}(-\text{beta1} * \text{dose}^{\text{beta2}})]$$

The parameter betas are restricted to be positive

Dependent variable = Incidence  
Independent variable = Dose

Total number of observations = 3  
Total number of records with missing values = 0  
Total number of parameters in model = 3  
Total number of specified parameters = 0  
Degree of polynomial = 2

Maximum number of iterations = 500  
Relative Function Convergence has been set to: 1e-008  
Parameter Convergence has been set to: 1e-008

```

Default Initial Parameter Values
Background = 0.0132945
Beta(1) = 0.0097738
Beta(2) = 0

```

Asymptotic Correlation Matrix of Parameter Estimates

( \*\*\* The model parameter(s) -Beta(2) have been estimated at a boundary point, or have been specified by the user, and do not appear in the correlation matrix )

	Background	Beta(1)
Background	1	-0.58
Beta(1)	-0.58	1

Parameter Estimates

Variable	Estimate	Std. Err.	95.0% Wald Confidence Interval	
			Lower Conf. Limit	Upper Conf. Limit
Background	0.00436512	0.0163652	-0.0277101	0.0364403
Beta(1)	0.0115808	0.00506553	0.00165257	0.0215091
Beta(2)	0	NA		

NA - Indicates that this parameter has hit a bound implied by some inequality constraint and thus has no standard error.

Analysis of Deviance Table

Model	Log(likelihood)	# Param's	Deviance	Test d.f.	P-value
-------	-----------------	-----------	----------	-----------	---------

Full model	-28.6454	3			
Fitted model	-29.3426	2	1.39438	1	0.2377
Reduced model	-33.983	1	10.6753	2	0.004807

AIC: 62.6851

Goodness of Fit

Dose	Est. Prob.	Expected	Observed	Size	Scaled Residual
0.0000	0.0044	0.214	0.000	49.000	-0.463
1.3000	0.0192	0.962	2.000	50.000	1.068
14.2000	0.1553	7.767	7.000	50.000	-0.299


Chi<sup>2</sup> = 1.45      d.f. = 1      P-value = 0.2292

Benchmark Dose Computation

Specified effect = 0.05  
 Risk Type = Extra risk  
 Confidence level = 0.95  
 BMD = 4.42916  
 BMDL = 2.50664  
 BMDU = 12.158

Taken together, (2.50664, 12.158 ) is a 90 % two-sided confidence interval for the BMD

Multistage Model, with BMR of 5% Extra Risk for the BMD and 0.95 Lower Confidence Limit for the BMDL



14:29 03/01 2016

```

=====
Weibull Model using Weibull Model (Version: 2.16; Date: 2/28/2013)
Input Data File: C:/BMDS2601_20150629/BMDS2601/Data/wei_butenhoff testicular
tumors_Opt.(d)
Gnuplot Plotting File: C:/BMDS2601_20150629/BMDS2601/Data/wei_butenhoff testicular
tumors_Opt.plt
Tue Mar 01 14:38:20 2016
=====

```

BMDS\_Model\_Run

The form of the probability function is:

$$P[\text{response}] = \text{background} + (1-\text{background}) * [1-\text{EXP}(-\text{slope} * \text{dose}^{\text{power}})]$$

Dependent variable = Incidence  
 Independent variable = Dose  
 Power parameter is restricted as power >= 1.000000

Total number of observations = 3  
 Total number of records with missing values = 0  
 Maximum number of iterations = 500  
 Relative Function Convergence has been set to: 1e-008  
 Parameter Convergence has been set to: 1e-008

Default Initial (and Specified) Parameter Values

Background = 0.0196078  
 Slope = 0.0103698  
 Power = 1

Asymptotic Correlation Matrix of Parameter Estimates

( \*\*\* The model parameter(s) -Power  
 have been estimated at a boundary point, or have been specified by the user,  
 and do not appear in the correlation matrix )

	Background	Slope
Background	1	-0.58
Slope	-0.58	1

Parameter Estimates

Variable	Estimate	Std. Err.	95.0% Wald Confidence Interval	
			Lower Conf. Limit	Upper Conf. Limit
Background	0.00436513	0.0163652	-0.0277102	0.0364404
Slope	0.0115809	0.00506554	0.00165257	0.0215091
Power	1	NA		

NA - Indicates that this parameter has hit a bound implied by some inequality constraint and thus has no standard error.

Analysis of Deviance Table

Model	Log(likelihood)	# Param's	Deviance	Test d.f.	P-value
Full model	-28.6454	3			
Fitted model	-29.3426	2	1.39438	1	0.2377



Reduced model -33.983 1 10.6753 2 0.004807

AIC: 62.6851

Goodness of Fit


Dose	Est. Prob.	Expected	Observed	Size	Scaled Residual
0.0000	0.0044	0.214	0.000	49.000	-0.463
1.3000	0.0192	0.962	2.000	50.000	1.068
14.2000	0.1553	7.767	7.000	50.000	-0.299

Chi^2 = 1.45 d.f. = 1 P-value = 0.2292

Benchmark Dose Computation

Specified effect = 0.05  
 Risk Type = Extra risk  
 Confidence level = 0.95  
 BMD = 4.42915  
 BMDL = 2.50664

Weibull Model, with BMR of 5% Extra Risk for the BMD and 0.95 Lower Confidence Limit for the BMDL



14:38 03/01 2016

```

=====
Weibull Model using Weibull Model (Version: 2.16; Date: 2/28/2013)
Input Data File: C:/BMDS2601_20150629/BMDS2601/Data/wei_butenhoff testicular
tumors_Opt.(d)
Gnuplot Plotting File: C:/BMDS2601_20150629/BMDS2601/Data/wei_butenhoff testicular
tumors_Opt.plt
Tue Mar 01 14:44:17 2016
=====

```

```

BMDS_Model_Run
~~~~~

```

The form of the probability function is:

$$P[\text{response}] = \text{background} + (1-\text{background}) * [1-\text{EXP}(-\text{slope} * \text{dose}^{\text{power}})]$$

Dependent variable = Incidence  
 Independent variable = Dose  
 Power parameter is not restricted

Total number of observations = 3  
 Total number of records with missing values = 0  
 Maximum number of iterations = 500  
 Relative Function Convergence has been set to: 1e-008  
 Parameter Convergence has been set to: 1e-008

```

Default Initial (and Specified) Parameter Values
Background = 0.0196078
Slope = 0.0214176
Power = 0.726632

```

Asymptotic Correlation Matrix of Parameter Estimates

( \*\*\* The model parameter(s) -Background  
 have been estimated at a boundary point, or have been specified by the user,  
 and do not appear in the correlation matrix )

	Slope	Power
Slope	1	-0.91
Power	-0.91	1

Parameter Estimates

Variable	Estimate	Std. Err.	95.0% Wald Confidence Interval	
			Lower Conf. Limit	Upper Conf. Limit
Background	0	NA		
Slope	0.0353681	0.0277941	-0.0191074	0.0898435
Power	0.546613	0.33544	-0.110837	1.20406

NA - Indicates that this parameter has hit a bound implied by some inequality constraint and thus has no standard error.

Warning: Likelihood for the fitted model larger than the Likelihood for the full model.

Analysis of Deviance Table

Model	Log(likelihood)	# Param's	Deviance	Test d.f.	P-value
Full model	-28.6454	3			
Fitted model	-28.6454	2	-7.10543e-015	1	-1
Reduced model	-33.983	1	10.6753	2	0.004807

AIC: 61.2908


Goodness of Fit

Dose	Est. Prob.	Expected	Observed	Size	Scaled Residual
0.0000	0.0000	0.000	0.000	49.000	0.000
1.3000	0.0400	2.000	2.000	50.000	0.000
14.2000	0.1400	7.000	7.000	50.000	-0.000

Chi<sup>2</sup> = 0.00      d.f. = 1      P-value = 1.0000

Benchmark Dose Computation

Specified effect = 0.05  
 Risk Type = Extra risk  
 Confidence level = 0.95  
 BMD = 1.97407  
 BMDL = 1.65976e-006



14:44 03/01 2016

```

=====
Gamma Model. (Version: 2.16; Date: 2/28/2013)
Input Data File: C:/BMDS2601_20150629/BMDS2601/Data/gam_butenhoff testicular
tumors_Opt.(d)
Gnuplot Plotting File: C:/BMDS2601_20150629/BMDS2601/Data/gam_butenhoff testicular
tumors_Opt.plt
Tue Mar 01 14:56:54 2016
=====

```

```

BMDS_Model_Run
~~~~~

```

The form of the probability function is:

$P[\text{response}] = \text{background} + (1 - \text{background}) * \text{CumGamma}[\text{slope} * \text{dose}, \text{power}]$ ,  
 where CumGamma(.) is the cumulative Gamma distribution function

Dependent variable = Incidence  
 Independent variable = Dose  
 Power parameter is not restricted

Total number of observations = 3  
 Total number of records with missing values = 0  
 Maximum number of iterations = 500  
 Relative Function Convergence has been set to: 1e-008  
 Parameter Convergence has been set to: 1e-008

```

Default Initial (and Specified) Parameter Values
Background = 0.0196078
Slope = 0.0294212
Power = 1.3

```

Asymptotic Correlation Matrix of Parameter Estimates

( \*\*\* The model parameter(s) -Background  
 have been estimated at a boundary point, or have been specified by the user,  
 and do not appear in the correlation matrix )

	Slope	Power
Slope	1	0.98
Power	0.98	1

Parameter Estimates

Variable	Estimate	Std. Err.	95.0% Wald Confidence Interval	
			Lower Conf. Limit	Upper Conf. Limit
Background	0	NA		
Slope	0.00135774	0.00399687	-0.00647598	0.00919146
Power	0.526497	0.333129	-0.126424	1.17942

NA - Indicates that this parameter has hit a bound implied by some inequality constraint and thus has no standard error.

Analysis of Deviance Table

Model	Log(likelihood)	# Param's	Deviance	Test d.f.	P-value
Full model	-28.6454	3			
Fitted model	-28.6454	2	1.66125e-010	1	1
Reduced model	-33.983	1	10.6753	2	0.004807


AIC: 61.2908

Goodness of Fit					
Dose	Est. Prob.	Expected	Observed	Size	Scaled Residual
0.0000	0.0000	0.000	0.000	49.000	0.000
1.3000	0.0400	2.000	2.000	50.000	0.000
14.2000	0.1400	7.000	7.000	50.000	0.000

Chi<sup>2</sup> = 0.00      d.f. = 1      P-value = 1.0000

Benchmark Dose Computation

Specified effect = 0.05  
 Risk Type = Extra risk  
 Confidence level = 0.95  
 BMD = 1.98737  
 BMDL = 1.36483e-006



14:56 03/01 2016

```

=====
      Logistic Model. (Version: 2.14; Date: 2/28/2013)
      Input Data File: C:/BMDS2601_20150629/BMDS2601/Data/lnl_butenhoff testicular
tumors_Opt.(d)
      Gnuplot Plotting File: C:/BMDS2601_20150629/BMDS2601/Data/lnl_butenhoff testicular
tumors_Opt.plt
      Tue Mar 01 15:00:41 2016
=====

```

BMDS\_Model\_Run

The form of the probability function is:

$$P[\text{response}] = \text{background} + (1 - \text{background}) / [1 + \text{EXP}(-\text{intercept} - \text{slope} * \text{Log}(\text{dose}))]$$

Dependent variable = Incidence  
 Independent variable = Dose  
 Slope parameter is restricted as slope >= 1

Total number of observations = 3  
 Total number of records with missing values = 0  
 Maximum number of iterations = 500  
 Relative Function Convergence has been set to: 1e-008  
 Parameter Convergence has been set to: 1e-008

User has chosen the log transformed model

Default Initial Parameter Values  
 background = 0  
 intercept = -4.17047  
 slope = 1

Asymptotic Correlation Matrix of Parameter Estimates

( \*\*\* The model parameter(s) -slope have been estimated at a boundary point, or have been specified by the user, and do not appear in the correlation matrix )

	background	intercept
background	1	-0.63
intercept	-0.63	1

Parameter Estimates

Variable	Estimate	Std. Err.	95.0% Wald Confidence Interval	
			Lower Conf. Limit	Upper Conf. Limit
background	0.00240787	0.0171729	-0.0312504	0.0360661
intercept	-4.33748	0.484279	-5.28665	-3.38831
slope	1	NA		

NA - Indicates that this parameter has hit a bound implied by some inequality constraint and thus has no standard error.

Analysis of Deviance Table

Model	Log(likelihood)	# Param's	Deviance	Test d.f.	P-value
Full model	-28.6454	3			
Fitted model	-29.2763	2	1.26188	1	0.2613
Reduced model	-33.983	1	10.6753	2	0.004807

AIC: 62.5526

Goodness of Fit


Dose	Est._Prob.	Expected	Observed	Size	Scaled Residual
0.0000	0.0024	0.118	0.000	49.000	-0.344
1.3000	0.0191	0.954	2.000	50.000	1.082
14.2000	0.1586	7.928	7.000	50.000	-0.359

Chi^2 = 1.42      d.f. = 1      P-value = 0.2338

Benchmark Dose Computation

Specified effect = 0.05  
 Risk Type = Extra risk  
 Confidence level = 0.95  
 BMD = 4.02707  
 BMDL = 2.2101





15:00 03/01 2016

```

=====
      Logistic Model. (Version: 2.14; Date: 2/28/2013)
      Input Data File: C:/BMDS2601_20150629/BMDS2601/Data/lnl_butenhoff testicular
tumors_Opt.(d)
      Gnuplot Plotting File: C:/BMDS2601_20150629/BMDS2601/Data/lnl_butenhoff testicular
tumors_Opt.plt
                                          Tue Mar 01 15:07:36 2016
=====

```

BMDS\_Model\_Run

The form of the probability function is:

$$P[\text{response}] = \text{background} + (1 - \text{background}) / [1 + \text{EXP}(-\text{intercept} - \text{slope} * \text{Log}(\text{dose}))]$$

Dependent variable = Incidence  
 Independent variable = Dose  
 Slope parameter is not restricted

Total number of observations = 3  
 Total number of records with missing values = 0  
 Maximum number of iterations = 500  
 Relative Function Convergence has been set to: 1e-008  
 Parameter Convergence has been set to: 1e-008

User has chosen the log transformed model

Default Initial Parameter Values

background = 0  
 intercept = -3.3276  
 slope = 0.569985

Asymptotic Correlation Matrix of Parameter Estimates

( \*\*\* The model parameter(s) -background  
 have been estimated at a boundary point, or have been specified by the user,  
 and do not appear in the correlation matrix )

	intercept	slope
intercept	1	-0.9
slope	-0.9	1

Parameter Estimates

Variable	Estimate	Std. Err.	95.0% Wald Confidence Interval	
			Lower Conf. Limit	Upper Conf. Limit
background	0	NA		
intercept	-3.3276	0.802128	-4.89974	-1.75546
slope	0.569985	0.346658	-0.109453	1.24942

NA - Indicates that this parameter has hit a bound implied by some inequality constraint and thus has no standard error.

Warning: Likelihood for the fitted model larger than the Likelihood for the full model.

Analysis of Deviance Table

Model	Log(likelihood)	# Param's	Deviance	Test d.f.	P-value
Full model	-28.6454	3			
Fitted model	-28.6454	2	-7.10543e-015	1	-1
Reduced model	-33.983	1	10.6753	2	0.004807

AIC: 61.2908


Goodness of Fit

Dose	Est._Prob.	Expected	Observed	Size	Scaled Residual
0.0000	0.0000	0.000	0.000	49.000	0.000
1.3000	0.0400	2.000	2.000	50.000	-0.000
14.2000	0.1400	7.000	7.000	50.000	-0.000

Chi^2 = 0.00      d.f. = 1      P-value = 1.0000

Benchmark Dose Computation

Specified effect = 0.05  
 Risk Type = Extra risk  
 Confidence level = 0.95  
 BMD = 1.95859  
 BMDL = 2.00091e-006



15:07 03/01 2016

```

=====
      Logistic Model. (Version: 2.14; Date: 2/28/2013)
      Input Data File: C:/BMDS2601_20150629/BMDS2601/Data/log_butenhoff testicular
tumors_Opt.(d)
      Gnuplot Plotting File: C:/BMDS2601_20150629/BMDS2601/Data/log_butenhoff testicular
tumors_Opt.plt
      Tue Mar 01 15:17:50 2016
=====
    
```

BMDS\_Model\_Run

The form of the probability function is:

$$P[\text{response}] = 1/[1+\text{EXP}(-\text{intercept}-\text{slope}*\text{dose})]$$

Dependent variable = Incidence  
 Independent variable = Dose  
 Slope parameter is not restricted

Total number of observations = 3  
 Total number of records with missing values = 0  
 Maximum number of iterations = 500  
 Relative Function Convergence has been set to: 1e-008  
 Parameter Convergence has been set to: 1e-008

```

Default Initial Parameter Values
      background =          0   Specified
      intercept =    -3.91633
    
```

slope = 0.156823

Asymptotic Correlation Matrix of Parameter Estimates

( \*\*\* The model parameter(s) -background have been estimated at a boundary point, or have been specified by the user, and do not appear in the correlation matrix )

	intercept	slope
intercept	1	-0.89
slope	-0.89	1

Parameter Estimates

Variable	Estimate	Std. Err.	95.0% Wald Confidence Interval	
			Lower Conf. Limit	Upper Conf. Limit
intercept	-4.0346	0.768353	-5.54055	-2.52866
slope	0.157289	0.0618536	0.0360579	0.27852

Analysis of Deviance Table

Model	Log(likelihood)	# Param's	Deviance	Test d.f.	P-value
Full model	-28.6454	3			
Fitted model	-29.8421	2	2.3935	1	0.1218
Reduced model	-33.983	1	10.6753	2	0.004807

AIC: 63.6843


Goodness of Fit

Dose	Est._Prob.	Expected	Observed	Size	Scaled Residual
0.0000	0.0174	0.852	0.000	49.000	-0.931
1.3000	0.0212	1.062	2.000	50.000	0.920
14.2000	0.1417	7.086	7.000	50.000	-0.035

Chi^2 = 1.71      d.f. = 1      P-value = 0.1905

Benchmark Dose Computation

Specified effect = 0.05  
 Risk Type = Extra risk  
 Confidence level = 0.95  
 BMD = 8.85708  
 BMDL = 6.49805



15:17 03/01 2016

```

=====
      Probit Model. (Version: 3.3; Date: 2/28/2013)
      Input Data File: C:/BMDS2601_20150629/BMDS2601/Data/pro_butenhoff testicular
tumors_Opt.(d)
      Gnuplot Plotting File: C:/BMDS2601_20150629/BMDS2601/Data/pro_butenhoff testicular
tumors_Opt.plt
                                          Tue Mar 01 15:22:19 2016
=====

```

BMDS\_Model\_Run

The form of the probability function is:

$$P[\text{response}] = \text{CumNorm}(\text{Intercept} + \text{Slope} * \text{Dose}),$$

where CumNorm(.) is the cumulative normal distribution function

Dependent variable = Incidence  
 Independent variable = Dose  
 Slope parameter is not restricted

Total number of observations = 3  
 Total number of records with missing values = 0  
 Maximum number of iterations = 500  
 Relative Function Convergence has been set to: 1e-008  
 Parameter Convergence has been set to: 1e-008

Default Initial (and Specified) Parameter Values

background = 0 Specified  
 intercept = -2.30551  
 slope = 0.089861

Asymptotic Correlation Matrix of Parameter Estimates

( \*\*\* The model parameter(s) -background  
 have been estimated at a boundary point, or have been specified by the user,  
 and do not appear in the correlation matrix )

	intercept	slope
intercept	1	-0.83
slope	-0.83	1

Parameter Estimates

Variable	Estimate	Std. Err.	95.0% Wald Confidence Interval	
			Lower Conf. Limit	Upper Conf. Limit
intercept	-2.12433	0.312226	-2.73628	-1.51238
slope	0.0742381	0.0273837	0.020567	0.127909

Analysis of Deviance Table

Model	Log(likelihood)	# Param's	Deviance	Test d.f.	P-value
Full model	-28.6454	3			
Fitted model	-29.8125	2	2.33427	1	0.1266
Reduced model	-33.983	1	10.6753	2	0.004807
AIC:	63.625				


Goodness of Fit

Dose	Est._Prob.	Expected	Observed	Size	Scaled Residual
0.0000	0.0168	0.824	0.000	49.000	-0.916
1.3000	0.0213	1.064	2.000	50.000	0.917
14.2000	0.1423	7.114	7.000	50.000	-0.046

Chi^2 = 1.68      d.f. = 1      P-value = 0.1948

Benchmark Dose Computation

Specified effect = 0.05  
 Risk Type = Extra risk  
 Confidence level = 0.95  
 BMD = 8.32341  
 BMDL = 5.95965



15:22 03/01 2016

```

=====
      Quantal Linear Model using Weibull Model (Version: 2.16; Date: 2/28/2013)
      Input Data File: C:/BMDS2601_20150629/BMDS2601/Data/qln_butenhoff testicular
tumors_Opt.(d)
      Gnuplot Plotting File: C:/BMDS2601_20150629/BMDS2601/Data/qln_butenhoff testicular
tumors_Opt.plt
  
```

Tue Mar 01 15:30:52 2016

BMDS\_Model\_Run

The form of the probability function is:

$$P[\text{response}] = \text{background} + (1-\text{background}) * [1-\text{EXP}(-\text{slope} * \text{dose})]$$

Dependent variable = Incidence  
 Independent variable = Dose

Total number of observations = 3  
 Total number of records with missing values = 0  
 Maximum number of iterations = 500  
 Relative Function Convergence has been set to: 1e-008  
 Parameter Convergence has been set to: 1e-008

Default Initial (and Specified) Parameter Values  
 Background = 0.0196078  
 Slope = 0.0103698



Power = 1 Specified

Asymptotic Correlation Matrix of Parameter Estimates

( \*\*\* The model parameter(s) -Power have been estimated at a boundary point, or have been specified by the user, and do not appear in the correlation matrix )

	Background	Slope
Background	1	-0.58
Slope	-0.58	1

Parameter Estimates

Variable	Estimate	Std. Err.	95.0% Wald Confidence Interval	
			Lower Conf. Limit	Upper Conf. Limit
Background	0.00436513	0.0163652	-0.0277102	0.0364404
Slope	0.0115809	0.00506554	0.00165257	0.0215091

Analysis of Deviance Table

Model	Log(likelihood)	# Param's	Deviance	Test d.f.	P-value
Full model	-28.6454	3			
Fitted model	-29.3426	2	1.39438	1	0.2377
Reduced model	-33.983	1	10.6753	2	0.004807

AIC: 62.6851


Goodness of Fit

Dose	Est._Prob.	Expected	Observed	Size	Scaled Residual
0.0000	0.0044	0.214	0.000	49.000	-0.463
1.3000	0.0192	0.962	2.000	50.000	1.068
14.2000	0.1553	7.767	7.000	50.000	-0.299

Chi^2 = 1.45      d.f. = 1      P-value = 0.2292

Benchmark Dose Computation

Specified effect = 0.05  
 Risk Type = Extra risk  
 Confidence level = 0.95  
 BMD = 4.42915  
 BMDL = 2.50664



15:30 03/01 2016